TOKEN	PREDICTED
Protein	O
Expression	O
in	O
the	O
Nucleus	O
Accumbens	O
of	O
Rats	O
Exposed	O
to	O
Developmental	O
Vitamin	O
D	O
Deficiency	O
Abstract	O
Introduction	O
Developmental	O
vitamin	O
D	O
(	O
DVD	O
)	O
deficiency	O
is	O
a	O
candidate	O
risk	O
factor	O
for	O
schizophrenia	O
.	O

Animal	O
models	O
have	O
confirmed	O
that	O
DVD	O
deficiency	O
is	O
associated	O
with	O
a	O
range	O
of	O
altered	O
genomic	O
,	O
proteomic	O
,	O
structural	O
and	O
behavioural	O
outcomes	O
in	O
the	O
rat	O
.	O

Because	O
the	O
nucleus	O
accumbens	O
has	O
been	O
implicated	O
in	O
neuropsychiatric	O
disorders	O
,	O
in	O
the	O
current	O
study	O
we	O
examined	O
protein	O
expression	O
in	O
this	O
region	O
in	O
adult	O
rats	O
exposed	O
to	O
DVD	O
deficiency	O
Methods	O
Female	O
Sprague	O
Dawley	O
rats	O
were	O
maintained	O
on	O
a	O
vitamin	O
D	O
deficient	O
diet	O
for	O
6	O
weeks	O
,	O
mated	O
and	O
allowed	O
to	O
give	O
birth	O
,	O
after	O
which	O
a	O
diet	O
containing	O
vitamin	O
D	O
was	O
reintroduced	O
.	O

Male	O
adult	O
offspring	O
(	O
n	O
=	O
8	O
)	O
were	O
compared	O
to	O
control	O
male	O
(	O
n	O
=	O
8	O
).	O

2	O
-	O
D	O
gel	O
electrophoresis	O
-	O
based	O
proteomics	O
and	O
mass	O
spectroscopy	O
were	O
used	O
to	O
investigate	O
differential	O
protein	O
expression	O
.	O

Results	O
There	O
were	O
35	O
spots	O
,	O
mapped	O
to	O
33	O
unique	O
proteins	O
,	O
which	O
were	O
significantly	O
different	O
between	O
the	O
two	O
groups	O
.	O

Of	O
these	O
,	O
22	O
were	O
down	O
-	O
regulated	O
and	O
13	O
up	O
-	O
regulated	O
.	O

The	O
fold	O
changes	O
were	O
uniformly	O
small	O
,	O
with	O
the	O
largest	O
FC	O
being	O
−	O
1	O
.	O
67	O
.	O

Within	O
the	O
significantly	O
different	O
spots	O
,	O
three	O
calcium	O
binding	O
proteins	O
(	O
calbindin1	O
,	O
calbindin2	O
and	O
hippocalcin	O
)	O
were	O
altered	O
.	O

Other	O
proteins	O
associated	O
with	O
DVD	O
deficiency	O
related	O
to	O
mitochondrial	O
function	O
,	O
and	O
the	O
dynamin	O
-	O
like	O
proteins	O
.	O

Conclusions	O
Developmental	O
vitamin	O
D	O
deficiency	O
was	O
associated	O
with	O
subtle	O
changes	O
in	O
protein	O
expression	O
in	O
the	O
nucleus	O
accumbens	O
.	O

Disruptions	O
in	O
pathways	O
related	O
to	O
calcium	O
-	O
binding	O
proteins	O
and	O
mitochondrial	O
function	O
may	O
underlie	O
some	O
of	O
the	O
behavioural	O
features	O
associated	O
with	O
animal	O
models	O
of	O
developmental	O
vitamin	O
D	O
deficiency	O
Introduction	O
Based	O
on	O
clues	O
from	O
epidemiology	O
,	O
we	O
have	O
proposed	O
that	O
low	O
prenatal	O
vitamin	O
D	O
may	O
be	O
a	O
risk	O
factor	O
for	O
later	O
development	O
of	O
schizophrenia	O
[	O
1	O
].	O

Many	O
studies	O
have	O
shown	O
that	O
those	O
born	O
in	O
winter	O
and	O
spring	O
have	O
a	O
significantly	O
increased	O
risk	O
of	O
developing	O
schizophrenia	O
[	O
2	O
],	O
and	O
that	O
those	O
born	O
at	O
higher	O
latitudes	O
are	O
also	O
at	O
increased	O
risk	O
of	O
schizophrenia	O
[	O
3	O
].	O

Given	O
that	O
vitamin	O
D	O
levels	O
in	O
the	O
population	O
fluctuate	O
across	O
the	O
seasons	O
and	O
decrease	O
across	O
higher	O
latitude	O
[	O
4	O
],	O
low	O
prenatal	O
vitamin	O
D	O
‘	O
fits	O
’	O
these	O
key	O
environmental	O
features	O
and	O
is	O
therefore	B
a	O
plausible	O
candidate	O
risk	O
factor	O
for	O
this	O
disease	O
.	O

In	O
order	O
to	O
explore	O
the	O
biological	O
plausibility	O
of	O
this	O
candidate	O
,	O
we	O
have	O
a	O
rat	O
model	O
that	O
we	O
call	O
the	O
Developmental	O
Vitamin	O
D	O
(	O
DVD	O
)	O
model	O
.	O

Rats	O
exposed	O
to	O
low	O
prenatal	O
vitamin	O
D	O
have	O
a	O
broad	O
range	O
of	O
neurobiological	O
outcomes	O
that	O
are	O
informative	O
for	O
schizophrenia	O
research	O
.	O

Briefly	O
,	O
DVD	O
-	O
deficient	O
neonates	O
had	O
larger	O
lateral	O
ventricles	O
,	O
increased	O
cellular	O
proliferation	O
and	O
reduced	O
apoptosis	O
,	O
altered	O
neurogenesis	O
,	O
reduced	O
density	O
of	O
neurotrophin	O
receptor	O
(	O
p75NTR	O
),	O
and	O
reduced	O
levels	O
of	O
nerve	O
growth	O
factor	O
(	O
NGF	O
)	O
and	O
glial	O
cell	O
line	O
-	O
derived	O
growth	O
factor	O
(	O
GDNF	O
)	O
compared	O
to	O
controls	O
[	O
5	O
]–[	O
7	O
].	O

As	O
adults	O
these	O
animals	O
had	O
larger	O
lateral	O
ventricles	O
and	O
reduced	O
NGF	O
expression	O
compared	O
to	O
controls	O
[	O
8	O
].	O

Behaviourally	O
,	O
adult	O
DVD	O
-	O
deficient	O
rats	O
were	O
more	O
active	O
than	O
controls	O
(	O
i	O
.	O
e	O
.	O

showing	O
“	O
hyperlocomotion	O
”)[	O
9	O
],[	O
10	O
].	O

5	O
)	O
DVD	O
-	O
deficient	O
rats	O
also	O
have	O
altered	O
attentional	O
processing	O
indicated	O
by	O
impaired	O
latent	O
inhibition	O
[	O
11	O
].	O

Some	O
of	O
the	O
most	O
robust	O
and	O
consistent	O
findings	O
in	O
the	O
DVD	O
model	O
have	O
emerged	O
in	O
behavioural	O
pharmacological	O
studies	O
.	O

For	O
example	O
,	O
we	O
have	O
shown	O
that	O
DVD	O
-	O
deficient	O
rats	O
have	O
enhanced	O
locomotion	O
in	O
response	O
to	O
the	O
psychomimetic	O
agents	O
such	O
as	O
NMDA	O
antagonist	O
MK	O
-	O
801	O
[	O
10	O
],[	O
12	O
].	O

The	O
DVD	O
adult	O
rat	O
is	O
also	O
more	O
sensitive	O
to	O
haloperidol	O
,	O
a	O
dopamine	O
(	O
DA	O
)	O
D2	O
receptor	O
antagonist	O
[	O
10	O
],	O
that	O
is	O
a	O
widely	O
used	O
antipsychotic	O
medication	O
used	O
to	O
treat	O
schizophrenia	O
.	O

Dysfunction	O
of	O
DA	O
signalling	O
has	O
been	O
strongly	O
implicated	O
in	O
the	O
pathogenesis	O
of	O
schizophrenia	O
[	O
13	O
].	O

Dopamine	O
projections	O
involve	O
a	O
range	O
of	O
cortical	O
and	O
subcortical	O
regions	O
,	O
however	O
its	O
role	O
in	O
the	O
nucleus	O
accumbens	O
has	O
been	O
of	O
particular	O
interest	O
with	O
respect	O
to	O
neuropsychiatric	O
disorders	O
[	O
14	O
]–[	O
16	O
].	O

In	O
the	O
nucleus	O
accumbens	O
,	O
dopamine	O
influences	O
the	O
integration	O
of	O
inputs	O
from	O
the	O
ventral	O
hippocampus	O
,	O
the	O
amygdala	O
,	O
and	O
the	O
prefrontal	O
cortex	O
.	O

Grace	O
and	O
colleagues	O
have	O
suggested	O
that	O
dopamine	O
may	O
modulate	O
a	O
range	O
of	O
limbic	O
and	O
cortical	O
functions	O
relevant	O
to	O
the	O
pathophysiology	O
of	O
schizophrenia	O
via	O
the	O
nucleus	O
accumbens	O
[	O
17	O
].	O

Previously	O
we	O
explored	O
the	O
genomic	O
and	O
proteomic	O
characteristics	O
of	O
frontal	O
cortex	O
and	O
the	O
hippocampus	O
in	O
the	O
adult	O
DVD	O
rat	O
[	O
18	O
],[	O
19	O
].	O

In	O
particular	O
,	O
a	O
proteomic	O
study	O
based	O
on	O
two	O
cortical	O
regions	O
of	O
DVD	O
-	O
deficient	O
rats	O
(	O
frontal	O
cortex	O
and	O
hippocampus	O
),	O
identified	O
36	O
dysregulated	O
proteins	O
.	O

These	O
proteins	O
are	O
associated	O
with	O
several	O
biological	O
pathways	O
including	O
oxidative	O
phosphorylation	O
,	O
cytoskeleton	O
maintenance	O
,	O
calcium	O
homeostasis	O
,	O
chaperoning	O
,	O
synaptic	O
plasticity	O
and	O
neurotransmission	O
.	O

A	O
computational	O
analysis	O
of	O
these	O
data	O
revealed	O
that	O
many	O
of	O
the	O
proteins	O
dysregulated	O
in	O
the	O
DVD	O
model	O
have	O
also	O
been	O
shown	O
to	O
be	O
altered	O
in	O
schizophrenia	O
post	O
-	O
mortem	O
brain	O
studies	O
[	O
18	O
].	O

In	O
order	O
to	O
further	O
explore	O
the	O
impact	O
of	O
DVD	O
on	O
brain	O
function	O
,	O
we	O
undertook	O
a	O
proteomic	O
study	O
of	O
the	O
nucleus	O
accumbens	O
.	O

Methods	O
To	O
obtain	O
vitamin	O
D3depletion	O
,	O
female	O
Sprague	O
-	O
Dawley	O
rats	O
(	O
Herston	O
Animal	O
Facility	O
,	O
Queensland	O
,	O
Australia	O
)	O
were	O
kept	O
on	O
a	O
vitamin	O
D	O
deficient	O
diet	O
(	O
Dyets	O
Inc	O
.,	O
PA	O
,	O
USA	O
).	O

Animals	O
were	O
housed	O
on	O
a	O
12	O
-	O
h	O
light	O
/	O
dark	O
cycle	O
(	O
lights	O
on	O
at	O
06	O
:	O
00	O
h	O
)	O
using	O
incandescent	O
lighting	O
,	O
to	O
avoid	O
ultraviolet	O
radiation	O
within	O
the	O
vitamin	O
D3action	O
spectrum	O
.	O

These	O
conditions	O
were	O
maintained	O
for	O
six	O
weeks	O
prior	O
to	O
mating	O
and	O
throughout	O
gestation	O
.	O

Control	O
animals	O
were	O
kept	O
under	O
similar	O
conditions	O
except	O
they	O
received	O
a	O
vitamin	O
D	O
replete	O
diet	O
(	O
Dyets	O
,	O
PA	O
,	O
USA	O
and	O
Specialty	O
Foods	O
,	O
WA	O
,	O
Australia	O
)	O
and	O
were	O
housed	O
under	O
standard	O
lighting	O
conditions	O
.	O

Dams	O
(	O
and	O
corresponding	O
litters	O
)	O
were	O
placed	O
under	O
control	O
conditions	O
for	O
the	O
remainder	O
of	O
the	O
experiment	O
.	O

The	O
male	O
pups	O
were	O
weaned	O
on	O
postnatal	O
day	O
21	O
and	O
housed	O
in	O
groups	O
of	O
3	O
–	O
6	O
.	O

Female	O
rats	O
were	O
not	O
used	O
in	O
these	O
experiments	O
,	O
because	O
the	O
estrous	O
cycle	O
can	O
introduce	O
variability	O
in	O
protein	O
expression	O
in	O
the	O
region	O
of	O
interest	O
[	O
20	O
],[	O
21	O
].	O

All	O
procedures	O
were	O
performed	O
with	O
approval	O
from	O
the	O
Queensland	O
University	O
Animal	O
Ethics	O
Committee	O
,	O
under	O
the	O
guidelines	O
of	O
the	O
National	O
Health	O
and	O
Medical	O
Research	O
Council	O
of	O
Australia	O
.	O

Sample	O
Preparation	O
Tissue	O
was	O
sampled	O
from	O
8	O
control	O
and	O
8	O
DVD	O
deficient	O
male	O
adult	O
offspring	O
.	O

These	O
animals	O
were	O
from	O
four	O
separate	O
litters	O
per	O
experimental	O
group	O
.	O

The	O
nucleus	O
accumbens	O
(	O
NAc	O
)	O
were	O
sampled	O
from	O
all	O
animals	O
according	O
to	O
boundaries	O
determined	O
from	O
a	O
standard	O
rat	O
brain	O
atlas	O
[	O
22	O
].	O

Sample	O
preparation	O
and	O
two	O
dimensional	O
gel	O
electrophoresis	O
(	O
2DE	O
)	O
methodology	O
was	O
performed	O
according	O
to	O
Alexander	O
-	O
Kaufman	O
et	O
al	O
[	O
23	O
].	O

Briefly	O
,	O
0	O
.	O
04	O
g	O
–	O
0	O
.	O
07	O
g	O
of	O
crude	O
fresh	O
frozen	O
NAc	O
tissue	O
was	O
placed	O
in	O
Buffer	O
1	O
(	O
7M	O
Urea	O
,	O
2M	O
Thiourea	O
,	O
1	O
%	O
C7bZO	O
,	O
40	O
mM	O
Tris	O
).	O

Sample	O
suspensions	O
were	O
sonicated	O
3	O
×	O
10	O
sec	O
at	O
40	O
%	O
intensity	O
and	O
centrifuged	O
at	O
14	O
,	O
000	O
×	O
g	O
for	O
20	O
min	O
at	O
15	O
°	O
C	O
.	O

The	O
supernatant	O
was	O
reduced	O
and	O
alkylated	O
in	O
5	O
mM	O
tributylphosphine	O
(	O
TBP	O
)	O
and	O
1M	O
acrylamide	O
monomer	O
at	O
room	O
temperature	O
for	O
2	O
hr	O
.	O

The	O
reaction	O
was	O
quenched	O
by	O
adding	O
10	O
mM	O
DTT	O
followed	O
by	O
20	O
mg	O
citric	O
acid	O
to	O
adjust	O
pH	O
to	O
approximately	O
pH	O
6	O
.	O
0	O
.	O

Samples	O
were	O
precipitated	O
using	O
5	O
volumes	O
of	O
room	O
temperature	O
acetone	O
for	O
10	O
min	O
and	O
centrifuged	O
at	O
3	O
,	O
500	O
×	O
g	O
for	O
15	O
min	O
at	O
15	O
°	O
C	O
.	O

The	O
pellet	O
was	O
air	O
dried	O
for	O
5	O
min	O
and	O
resuspended	O
in	O
Buffer	O
2	O
(	O
7M	O
urea	O
,	O
2M	O
thiourea	O
,	O
1	O
%	O
C7bZO	O
).	O

Two	O
Dimensional	O
Gel	O
Electrophoresis	O
Protein	O
concentration	O
was	O
determined	O
by	O
the	O
Bradford	O
method	O
[	O
24	O
].	O

The	O
8	O
DVD	O
deficient	O
and	O
8	O
control	O
sample	O
tissues	O
were	O
used	O
to	O
perform	O
duplicate	O
2DE	O
analyses	O
,	O
providing	O
a	O
total	O
of	O
16	O
gels	O
for	O
each	O
group	O
.	O

Pre	O
-	O
cast	O
immobilised	O
pH	O
gradient	O
strips	O
(	O
IPG	O
,	O
11	O
cm	O
,	O
pH	O
3	O
–	O
10	O
,	O
Proteome	O
Systems	O
,	O
North	O
Ryde	O
,	O
Australia	O
)	O
were	O
passively	O
rehydrated	O
in	O
200	O
µg	O
sample	O
protein	O
extract	O
for	O
6	O
hr	O
at	O
room	O
temperature	O
.	O

In	O
the	O
first	O
dimension	O
,	O
rehydrated	O
strips	O
were	O
focused	O
using	O
an	O
ElectrophoretIQ3	O
isoelectric	O
focusing	O
system	O
(	O
Proteome	O
Systems	O
)	O
for	O
a	O
total	O
of	O
120	O
kVh	O
.	O

IPG	O
strips	O
were	O
reduced	O
,	O
alkylated	O
and	O
detergent	O
exchanged	O
using	O
SDS	O
equilibration	O
buffer	O
(	O
Proteome	O
Systems	O
,	O
20	O
min	O
)	O
and	O
loaded	O
onto	O
pre	O
-	O
cast	O
SDS	O
-	O
PAGE	O
gels	O
(	O
GelChip	O
™	O
2D	O
,	O
6	O
–	O
15	O
%,	O
10	O
×	O
15	O
cm	O
;	O
Proteome	O
Systems	O
)	O
for	O
second	O
dimension	O
molecular	O
mass	O
separation	O
using	O
the	O
ElectrophoreticIQ3	O
system	O
(	O
50mA	O
/	O
gel	O
,	O
15	O
°	O
C	O
for	O
90	O
min	O
).	O

Image	O
acquisition	O
and	O
analysis	O
Gels	O
were	O
fixed	O
in	O
solution	O
containing	O
25	O
%	O
(	O
v	O
/	O
v	O
)	O
methanol	O
and	O
10	O
%	O
(	O
v	O
/	O
v	O
)	O
acetic	O
acid	O
for	O
1	O
hr	O
and	O
stained	O
using	O
colloidal	O
Coomassie	O
Blue	O
for	O
spot	O
visualization	O
.	O

Gels	O
were	O
scanned	O
using	O
a	O
transmissive	O
,	O
flatbed	O
scanner	O
(	O
UMAX	O
)	O
and	O
analyzed	O
using	O
Phoretix	O
2D	O
Expression	O
software	O
(	O
Nonlinear	O
Dynamics	O
,	O
Newcastle	O
-	O
upon	O
-	O
Tyne	O
,	O
UK	O
).	O

Following	O
background	O
subtraction	O
and	O
volume	O
normalization	O
of	O
all	O
gels	O
,	O
average	O
gels	O
were	O
created	O
for	O
each	O
group	O
to	O
assist	O
comparison	O
and	O
reduce	O
within	O
group	O
variations	O
.	O

Averaging	O
parameters	O
were	O
set	O
at	O
70	O
%,	O
therefore	O
for	O
a	O
protein	O
spot	O
to	O
appear	O
in	O
the	O
averaged	O
gel	O
it	O
must	O
be	O
present	O
in	O
70	O
%	O
of	O
all	O
gels	O
within	O
a	O
group	O
.	O

One	O
-	O
way	O
Analysis	O
of	O
Variance	O
(	O
ANOVA	O
)	O
statistical	O
tests	O
were	O
used	O
to	O
reveal	O
statistically	O
significant	O
protein	O
expression	O
differences	O
between	O
the	O
two	O
groups	O
(	O
p	O
<	O
0	O
.	O
05	O
).	O

Protein	O
spots	O
that	O
were	O
significantly	O
altered	O
were	O
excised	O
for	O
identification	O
by	O
mass	O
spectrometry	O
.	O

Mass	O
Spectrometry	O
Excised	O
spots	O
were	O
washed	O
in	O
50	O
mM	O
ammonium	O
bicarbonate	O
/	O
acetonitrile	O
(	O
60	O
∶	O
40	O
solution	O
)	O
for	O
1	O
hr	O
at	O
room	O
temperature	O
.	O

Spots	O
were	O
dried	O
in	O
a	O
Vacuum	O
Concentrator	O
(	O
Eppendorf	O
,	O
Hamburg	O
Germany	O
)	O
for	O
25	O
min	O
and	O
rehydrated	O
at	O
4	O
°	O
C	O
in	O
tryptic	O
digest	O
solution	O
(	O
10	O
ng	O
/	O
µl	O
porcine	O
sequencing	O
grade	O
trypsin	O
(	O
Promega	O
)	O
in	O
50	O
mM	O
NH4HCO3	O
)	O
for	O
1	O
h	O
.	O
Remaining	O
tryptic	O
digest	O
solution	O
was	O
removed	O
and	O
gel	O
pieces	O
suspended	O
overnight	O
at	O
37	O
°	O
C	O
in	O
50	O
mM	O
NH4HCO3	O
.	O

For	O
protein	O
identification	O
,	O
approximately	O
0	O
.	O
8	O
µl	O
of	O
the	O
peptide	O
mixture	O
was	O
spotted	O
onto	O
a	O
target	O
plate	O
and	O
covered	O
with	O
the	O
same	O
volume	O
of	O
matrix	O
solution	O
(	O
α	O
-	O
cyano	O
-	O
4	O
-	O
hydroxy	O
cinnamic	O
acid	O
(	O
Sigma	O
),	O
8	O
mg	O
/	O
ml	O
in	O
70	O
%	O
(	O
v	O
/	O
v	O
)	O
acetonitrile	O
/	O
1	O
%	O
(	O
v	O
/	O
v	O
)	O
formic	O
acid	O
)	O
and	O
allowed	O
to	O
air	O
dry	O
.	O

In	O
several	O
cases	O
,	O
peptides	O
were	O
concentrated	O
and	O
desalted	O
using	O
C18Perfect	O
Pure	O
Tips	O
(	O
Eppendorf	O
).	O

Tips	O
were	O
activated	O
with	O
acetonitrile	O
and	O
washed	O
with	O
5	O
×	O
10	O
µl	O
of	O
1	O
%	O
(	O
v	O
/	O
v	O
)	O
formic	O
acid	O
.	O

The	O
peptide	O
mixture	O
was	O
then	O
bound	O
and	O
aspirated	O
5	O
times	O
through	O
the	O
column	O
and	O
bound	O
peptides	O
washed	O
with	O
5	O
×	O
10	O
µl	O
of	O
1	O
%	O
formic	O
acid	O
.	O

Peptides	O
were	O
eluted	O
in	O
0	O
.	O
8	O
µl	O
of	O
matrix	O
solution	O
directly	O
onto	O
a	O
MALDI	O
-	O
TOF	O
target	O
plate	O
.	O

Peptide	O
mass	O
maps	O
of	O
tryptic	O
peptides	O
were	O
generated	O
by	O
matrix	O
assisted	O
laser	O
desorption	O
/	O
ionisation	O
time	O
-	O
of	O
-	O
flight	O
mass	O
spectrometry	O
(	O
MALDI	O
-	O
TOF	O
MS	O
)	O
using	O
an	O
Applied	O
Biosystems	O
Q	O
-	O
STAR	O
Pulsar	O
with	O
MALDI	O
source	O
(	O
APAF	O
,	O
University	O
of	O
Sydney	O
).	O

Mass	O
calibration	O
was	O
performed	O
using	O
trypsin	O
autolysis	O
peaks	O
,	O
2211	O
.	O
11	O
Da	O
and	O
842	O
.	O
51	O
Da	O
as	O
internal	O
standards	O
.	O

Database	O
searching	O
and	O
secondary	O
analyses	O
Data	O
generated	O
from	O
peptide	O
mass	O
mapping	O
(	O
PMM	O
)	O
of	O
each	O
spot	O
were	O
used	O
to	O
perform	O
searches	O
of	O
the	O
SWISS	O
-	O
PROT	O
,	O
NCBI	O
and	O
TrEMBL	O
databases	O
using	O
the	O
programs	O
Aldente	O
(	O
www	O
.	O
expasy	O
.	O
ch	O
)	O
and	O
MASCOT	O
(	O
www	O
.	O
matrixscience	O
.	O
com	O
).	O

Identifications	O
were	O
based	O
on	O
the	O
observed	O
pI	O
and	O
Mr	O
(	O
kDa	O
)	O
of	O
the	O
matched	O
protein	O
,	O
the	O
number	O
of	O
matching	O
peptide	O
masses	O
and	O
the	O
total	O
percentage	O
of	O
the	O
amino	O
acid	O
sequence	O
that	O
those	O
peptides	O
covered	O
,	O
in	O
comparison	O
to	O
other	O
database	O
entries	O
.	O

Generally	B
,	O
a	O
peptide	O
match	O
with	O
at	B
least	I
30	O
%	O
total	O
sequence	O
coverage	O
was	O
required	O
for	O
confidence	O
in	O
identification	O
,	O
but	O
very	O
low	O
and	O
high	O
mass	O
protein	O
,	O
and	O
those	O
resulting	O
from	O
protein	O
fragmentation	O
may	O
not	O
always	O
meet	O
the	O
criterion	O
.	O

For	O
searches	O
performed	O
using	O
MASCOT	O
,	O
E	O
-	O
value	O
and	O
Score	O
,	O
as	O
well	O
as	O
matching	O
peptides	O
and	O
sequence	O
coverage	O
,	O
were	O
used	O
to	O
determine	O
matches	O
.	O

Although	O
many	O
proteins	O
were	O
found	O
to	O
be	O
significantly	O
altered	O
in	O
DVD	O
-	O
deficient	O
adults	O
,	O
the	O
fold	O
-	O
change	O
level	O
was	O
insufficient	O
for	O
confirmation	O
analysis	O
by	O
western	O
blot	O
.	O

Bioinformatics	O
was	O
employed	O
as	O
secondary	O
analyses	O
.	O

Depending	O
of	O
the	O
size	O
of	O
the	O
fold	O
changes	O
,	O
we	O
planned	O
to	O
use	O
western	O
blot	O
and	O
/	O
or	O
bioinformatics	O
as	O
secondary	O
analyses	O
.	O

Significantly	O
dysregulated	O
proteins	O
were	O
examined	O
in	O
bioinformatic	O
pathways	O
analysis	O
(	O
Ingenuity	O
Pathway	O
Analysis	O
[	O
IPA	O
];	O
Ingenuity	O
Systems	O
,	O
Mountain	O
View	O
,	O
CA	O
).	O

This	O
manually	O
-	O
curated	O
database	O
builds	O
hypothetical	O
networks	O
based	O
on	O
the	O
candidate	O
proteins	O
and	O
other	O
potentially	O
associated	O
proteins	O
in	O
the	O
database	O
.	O

For	O
each	O
pathway	O
,	O
scores	O
are	O
calculated	O
as	O
the	O
negative	O
base	O
-	O
10	O
logarithm	O
of	O
the	O
P	O
value	O
,	O
indicating	O
the	O
likelihood	O
that	O
the	O
dysregulated	O
proteins	O
would	O
be	O
found	O
in	O
a	O
given	O
network	O
by	O
chance	O
.	O

Finally	O
,	O
proteomic	O
analyses	O
are	O
prone	B
to	O
Type	O
I	O
errors	O
.	O

While	O
we	O
did	O
not	O
adjust	O
the	O
p	O
value	O
for	O
the	O
number	O
of	O
comparisons	O
undertaken	O
,	O
we	O
report	O
the	O
false	O
discovery	O
rate	O
,	O
which	O
provides	O
an	O
estimate	O
of	O
the	O
proportion	O
of	O
significantly	O
different	O
proteins	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
that	O
may	O
be	O
truly	O
null	O
[	O
25	O
],[	O
26	O
].	O

Results	O
We	O
identified	O
637	O
spots	O
in	O
DVD	O
deplete	O
samples	O
and	O
655	O
spots	O
in	O
Control	O
samples	O
(	O
seeFigure	O
1for	O
a	O
representative	O
gel	O
).	O

These	O
spots	O
were	O
matched	O
,	O
normalized	O
and	O
quantified	O
.	O

For	O
each	O
animal	O
,	O
two	O
gels	O
were	O
averaged	O
.	O

There	O
were	O
35	O
spots	O
that	O
were	O
significantly	O
altered	O
between	O
the	O
two	O
groups	O
,	O
22	O
were	O
down	O
-	O
regulated	O
and	O
13	O
up	O
-	O
regulated	O
(	O
Table	O
1	O
).	O

These	O
spots	O
were	O
mapped	O
to	O
33	O
unique	O
proteins	O
.	O

The	O
fold	O
changes	O
were	O
uniformly	O
small	O
,	O
with	O
the	O
largest	O
FC	O
being	O
−	O
1	O
.	O
67	O
(	O
MEPD	O
).	O

Over	O
half	O
(	O
27	O
of	O
49	O
)	O
of	O
the	O
significantly	O
dysregulated	O
spots	O
that	O
were	O
identified	O
as	O
a	O
known	O
protein	O
had	O
a	O
fold	O
change	O
of	O
less	O
than	O
1	O
.	O
3	O
.	O

Based	O
on	O
a	O
False	O
Discovery	O
Rate	O
of	O
28	O
%,	O
we	O
predict	O
that	O
nine	O
of	O
these	O
spots	O
would	O
be	O
false	O
positives	O
.	O
10	O
.	O
1371	O
/	O
journal	O
.	O
pone	O
.	O
0002383	O
.	O
g001	O
Caption	O
(	O
FIG	O
):	O
FIGURE	O
1	O
Altered	O
proteins	O
in	O
the	O
nucleus	O
accumbens	O
in	O
adult	O
DVD	O
-	O
deficient	O
and	O
control	O
male	O
rats	O
.	O

Red	O
circles	O
indicate	O
increased	O
spots	O
,	O
blue	O
circles	O
indicate	O
spots	O
reduced	O
in	O
the	O
average	O
gel	O
in	O
DVD	O
animals	O
.	O
10	O
.	O
1371	O
/	O
journal	O
.	O
pone	O
.	O
0002383	O
.	O
t001	O
Caption	O
(	O
TABLE	O
-	O
WRAP	O
):	O
TABLE	O
1	O
Summary	O
of	O
differentially	O
expressed	O
protein	O
spots	O
in	O
nucleus	O
accumbens	O
tissue	O
from	O
adult	O
DVD	O
-	O
deficient	O
and	O
control	O
ratsFold	O
changep	O
valueProteinUniprot	O
Accession	O
NumberMowse	O
scoreMolecular	O
weightpH	O
Calcium	O
Binding	O
Proteins	O
1	O
.	O
140	O
.	O
031Calreticulin	O
CALRP18418114479664	O
.	O
33	O
-	O
1	O
.	O
250	O
.	O
050Calbindin	O
(	O
calretinin	O
)	O
CALB2P47728156313844	O
.	O
94	O
-	O
1	O
.	O
180	O
.	O
045Calbindin	O
CALB1P0717169299754	O
.	O
711	O
.	O
170	O
.	O
032Hippocalcin	O
HPCAP8407679224134	O
.	O
87	O
General	O
cellular	O
metabolism	O
proteins	O
1	O
.	O
470	O
.	O
026L	O
-	O
lactate	O
dehydrogenase	O
B	O
chain	O
LDHBP42123119365895	O
.	O
701	O
.	O
230	O
.	O
004Aldose	O
reductase	O
ALDRP07943154357746	O
.	O
26	O
-	O
1	O
.	O
110	O
.	O
014crystallin	O
,	O
mu	O
CRYMQ9QYU496335335	O
.	O
34	O
-	O
1	O
.	O
090	O
.	O
030Malate	O
dehydrogenase	O
,	O
cytoplasmic	O
MDHCO8898969364606	O
.	O
16	O
-	O
1	O
.	O
350	O
.	O
030Glycerol	O
-	O
3	O
-	O
phosphate	O
dehydrogenase	O
[	O
NAD	O
+],	O
cytoplasmic	O
GPDAO35077141374286	O
.	O
16	O
-	O
1	O
.	O
170	O
.	O
043Glutathione	O
S	O
-	O
transferase	O
P	O
GSTP1P0490678234246	O
.	O
89	O
Mitochondria	O
Proteins	O
-	O
1	O
.	O
540	O
.	O
041Hexokinase	O
1	O
HXK1P05708761023426	O
.	O
29	O
-	O
1	O
.	O
350	O
.	O
048Dynamin	O
1	O
-	O
like	O
protein	O
DNM1LO35303106838566	O
.	O
64	O
-	O
1	O
.	O
120	O
.	O
046Ubiquinol	O
-	O
cytochrome	O
-	O
c	O
reductase	O
complex	O
core	O
protein	O
1	O
,	O
UQCR1Q68FY0145528155	O
.	O
57	O
-	O
1	O
.	O
140	O
.	O
033Isocitrate	O
dehydrogenase	O
(	O
NAD	O
)	O
subunit	O
alpha	O
,	O
mitochondrial	O
IDH3AQ99NA5113395886	O
.	O
471	O
.	O
160	O
.	O
037IDH3AQ99NA5117	O
..-	O
1	O
.	O
370	O
.	O
011NADH	O
dehydrogenase	O
1	O
alpha	O
subcomplex	O
subunit	O
10	O
,	O
NDUAAQ561S0219404687	O
.	O
64	O
-	O
1	O
.	O
100	O
.	O
039Pyruvate	O
dehydrogenase	O
E1	O
component	O
subunit	O
beta	O
,	O
ODPBP4943295389576	O
.	O
20	O
-	O
1	O
.	O
180	O
.	O
033Voltage	O
-	O
dependent	O
anion	O
-	O
selective	O
channel	O
protein	O
2	O
VDAC2P8115559317267	O
.	O
44	O
Signal	O
transduction	O
and	O
MAP	O
-	O
related	O
proteins	O
-	O
1	O
.	O
280	O
.	O
007Mitogen	O
-	O
activated	O
protein	O
kinase	O
1	O
(	O
ERK	O
-	O
2	O
;	O
MAPK	O
2	O
)	O
MK01P6308657412496	O
.	O
50	O
-	O
1	O
.	O
240	O
.	O
009Serine	O
/	O
threonine	O
-	O
protein	O
phosphatase	O
2A	O
catalytic	O
subunit	O
beta	O
isoform	O
PP2ABP62716107355525	O
.	O
211	O
.	O
230	O
.	O
036Guanine	O
nucleotide	O
-	O
binding	O
protein	O
G	O
(	O
I	O
)/	O
G	O
(	O
S	O
)/	O
G	O
(	O
T	O
)	O
subunit	O
beta	O
1	O
GBB1P5431164373535	O
.	O
60	O
-	O
1	O
.	O
150	O
.	O
031Guanine	O
nucleotide	O
-	O
binding	O
protein	O
G	O
(	O
I	O
)/	O
G	O
(	O
S	O
)/	O
G	O
(	O
T	O
)	O
subunit	O
beta	O
2	O
GBB2P5431374373075	O
.	O
60	O
-	O
1	O
.	O
240	O
.	O
029Dynamin	O
1	O
DYN1P21575152958676	O
.	O
32	O
-	O
1	O
.	O
670	O
.	O
047Thimet	O
oligopeptidase	O
MEPDP24155112782645	O
.	O
54	O
-	O
1	O
.	O
220	O
.	O
006Dihydropyrimidinase	O
-	O
related	O
protein	O
2	O
(	O
DRP	O
-	O
2	O
;	O
CRMP	O
-	O
2	O
)	O
DPYL2P47942101622395	O
.	O
951	O
.	O
170	O
.	O
038DPYL2P4794253	O
..	O
1	O
.	O
240	O
.	O
007DPYL2P4794285	O
..-	O
1	O
.	O
210	O
.	O
024Syntaxin	O
-	O
binding	O
protein	O
1	O
STXB1P6176591675266	O
.	O
49	O
-	O
1	O
.	O
250	O
.	O
036Adenosylhomocysteinase	O
SAHHP1076093475076	O
.	O
071	O
.	O
310	O
.	O
013Ras	O
-	O
related	O
protein	O
Rab	O
-	O
3C	O
RAB3CP6282464258565	O
.	O
101	O
.	O
140	O
.	O
003Beta	O
-	O
synuclein	O
SYUBQ6375456144954	O
.	O
481	O
.	O
170	O
.	O
013Myosin	O
light	O
polypeptide	O
6	O
MYL6Q6411954169644	O
.	O
46	O
Proteins	O
not	O
otherwise	O
classified	O
1	O
.	O
480	O
.	O
011Eukaryotic	O
initiation	O
factor	O
4A	O
-	O
II	O
IF4A2Q5RKI190463735	O
.	O
331	O
.	O
190	O
.	O
001Glyceraldehyde	O
-	O
3	O
-	O
phosphate	O
dehydrogenase	O
G3PP0479778358058	O
.	O
14	O
-	O
1	O
.	O
150	O
.	O
047ADP	O
-	O
ribosylation	O
factor	O
1	O
ARF1P84079128206846	O
.	O
32	O
Ingenuity	O
Pathway	O
Analysis	O
identified	O
two	O
major	O
networks	O
;	O
(	O
a	O
)	O
Cellular	O
Movement	O
,	O
cellular	O
assembly	O
and	O
organization	O
,	O
cell	O
signaling	O
;	O
and	O
(	O
b	O
)	O
Protein	O
synthsis	O
,	O
RNA	O
Post	O
-	O
transcriptional	O
Modification	O
,	O
Cancer	O
.	O

These	O
pathways	O
had	O
scores	O
of	O
32	O
and	O
29	O
respectively	O
(	O
both	O
highly	O
significant	O
).	O
Figure	O
2shows	O
the	O
first	O
pathway	O
,	O
annotated	O
for	O
functions	O
related	O
to	O
calcium	O
buffering	O
.	O

Several	O
of	O
the	O
components	O
of	O
the	O
network	O
converge	O
on	O
MAPK1	O
,	O
a	O
MAP	O
kinase	O
that	O
serves	O
to	O
integrate	O
multiple	O
biochemical	O
signals	O
(	O
previously	O
known	O
as	O
ERK2	O
),	O
that	O
was	O
found	O
to	O
be	O
significantly	O
down	O
-	O
regulated	O
in	O
the	O
proteomics	O
study	O
.	O
10	O
.	O
1371	O
/	O
journal	O
.	O
pone	O
.	O
0002383	O
.	O
g002	O
Caption	O
(	O
FIG	O
):	O
FIGURE	O
2	O
Network	O
analysis	O
of	O
the	O
proteins	O
assembled	O
by	O
Ingenuity	O
Pathway	O
Analysis	O
.	O

Proteins	O
symbols	O
in	O
red	O
were	O
up	O
-	O
regulated	O
,	O
while	O
green	O
were	O
down	O
-	O
regulated	O
.	O

Hub	O
proteins	O
not	O
significantly	O
dysregulated	O
in	O
the	O
study	O
are	O
shown	O
as	O
clear	O
.	O

The	O
proteins	O
with	O
calcium	O
-	O
related	O
functions	O
are	O
annotated	O
(	O
Fx	O
).	O

Discussion	O
Developmental	O
vitamin	O
D	O
deficiency	O
is	O
associated	O
with	O
a	O
subtle	O
alteration	O
in	O
the	O
expression	O
of	O
protein	O
involved	O
in	O
functions	O
related	O
to	O
calcium	O
binding	O
proteins	O
,	O
and	O
mitochondrial	O
functioning	O
.	O

Calcium	O
binding	O
proteins	O
have	O
been	O
of	O
interest	O
to	O
schizophrenia	O
research	O
for	O
some	O
time	O
[	O
27	O
],	O
in	O
particular	O
with	O
respect	O
to	O
the	O
expression	O
in	O
cortical	O
GABAergic	O
interneurons	O
[	O
28	O
].	O

This	O
study	O
found	O
that	O
four	O
calcium	O
binding	O
proteins	O
were	O
significantly	O
altered	O
in	O
the	O
nucleus	O
accumbens	O
of	O
the	O
adult	O
DVD	O
-	O
deficient	O
rat	O
(	O
calbindin	O
,	O
calbindin2	O
,	O
hippocalcin	O
and	O
calreticulin	O
).	O

Calcium	O
binding	O
proteins	O
are	O
central	O
to	O
a	O
wide	O
range	O
of	O
cellular	O
functions	O
,	O
of	O
which	O
calcium	O
sequestration	O
and	O
buffering	O
are	O
particularly	O
important	O
for	O
neurons	O
.	O

Amongst	O
other	O
functions	O
,	O
it	O
is	O
thought	O
that	O
this	O
family	O
of	O
diffuse	O
cytoplasmic	O
proteins	O
provides	O
a	O
‘	O
sink	O
’	O
allowing	O
cells	O
to	O
rapidly	O
buffer	O
intracellular	O
calcium	O
after	O
actions	O
potentials	O
,	O
thus	B
allowing	O
the	O
cell	O
to	O
rapidly	O
repolarise	O
for	O
further	O
firing	O
.	O

Calbindin	O
is	O
strongly	O
induced	O
by	O
vitamin	O
D	O
[	O
29	O
],	O
and	O
thus	B
it	O
is	O
feasible	B
that	O
the	O
reduction	O
in	O
this	O
protein	O
may	O
be	O
a	O
consequence	O
of	O
the	O
early	O
life	O
reduction	O
in	O
vitamin	O
D	O
.	O
The	O
potential	O
links	O
between	O
vitamin	O
D	O
and	O
neuronal	O
calcium	O
binding	O
proteins	O
has	O
been	O
noted	O
in	O
a	O
recent	O
review	O
article	O
[	O
30	O
]	O
Two	O
members	O
of	O
the	O
dynamin	O
family	O
(	O
dynamin	O
1	O
and	O
dynamin	O
1	O
-	O
like	O
proteins	O
)	O
were	O
also	O
significantly	O
down	O
-	O
regulated	O
.	O

These	O
proteins	O
are	O
essential	O
for	O
clathrin	O
-	O
mediated	O
endocytosis	O
,	O
a	O
role	O
of	O
particular	O
importance	O
in	O
neurons	O
for	O
neurotransmitter	O
release	O
[	O
31	O
].	O

Apart	O
from	O
this	O
function	O
,	O
these	O
proteins	O
are	O
essential	O
for	O
the	O
insertion	O
of	O
dopamine	O
receptor	O
2	O
(	O
DRD2	O
)	O
into	O
the	O
nonsynaptic	O
membrane	O
of	O
dopaminergic	O
neurons	O
[	O
32	O
].	O

Syntaxin	O
-	O
binding	O
protein	O
1	O
was	O
also	O
significantly	O
down	O
-	O
regulated	O
in	O
the	O
DVD	O
-	O
deficient	O
rats	O
.	O

These	O
findings	O
suggest	O
that	O
proteins	O
involved	O
in	O
SNAP	O
and	O
SNARE	O
mediated	O
vesicle	O
release	O
may	O
be	O
disrupted	O
in	O
the	O
DVD	O
model	O
.	O

In	O
addition	O
,	O
six	O
mitochondrial	O
proteins	O
were	O
down	O
-	O
regulated	O
in	O
DVD	O
-	O
deficient	O
rats	O
(	O
NDUAA	O
,	O
UQCR1	O
,	O
ODPB	O
,	O
IDH3A	O
,	O
HKK1	O
,	O
VDAC2	O
).	O

These	O
findings	O
suggest	O
that	O
cellular	O
energics	O
may	O
be	O
altered	O
in	O
this	O
brain	O
region	O
in	O
the	O
DVD	O
-	O
deficient	O
rat	O
.	O

Curiously	O
,	O
it	O
has	O
recently	O
been	O
shown	O
that	O
dynamin	O
1	O
-	O
like	O
protein	O
is	O
also	O
important	O
for	O
mitochondrial	O
fission	O
and	O
general	O
morphology	O
[	O
33	O
].	O

It	O
is	O
known	O
that	O
down	O
-	O
regulation	O
of	O
calcium	O
binding	O
proteins	O
shift	O
essential	O
calcium	O
buffering	O
requirements	O
to	O
the	O
mitochondrial	O
compartment	O
,	O
which	O
,	O
in	O
turn	O
,	O
leads	O
to	O
compromised	O
mitochondrial	O
energy	O
production	O
[	O
34	O
].	O

With	O
respect	O
to	O
the	O
nucleus	O
accumbens	O
,	O
calcium	O
-	O
binding	O
proteins	O
such	O
as	O
calbindin	O
are	O
often	O
used	O
to	O
demarcate	O
discrete	O
neuroanatomical	O
boundaries	O
,	O
inferring	O
that	O
these	O
proteins	O
confer	O
selective	O
functional	O
properties	O
to	O
these	O
cells	O
[	O
35	O
].	O

Compromised	O
calcium	O
buffering	O
in	O
the	O
nucleus	O
accumbens	O
could	O
disrupt	O
adaptive	O
and	O
goal	O
-	O
directed	O
behaviors	O
.	O

In	O
the	O
core	O
region	O
of	O
the	O
nucleus	O
accumbens	O
,	O
neurons	O
have	O
dense	O
spines	O
,	O
which	O
may	O
reflect	O
the	O
degree	O
of	O
synaptic	O
plasticity	O
required	O
for	O
the	O
integrative	O
function	O
of	O
cells	O
in	O
this	O
region	O
[	O
36	O
].	O

Many	O
of	O
the	O
dopaminergic	O
cells	O
in	O
this	O
region	O
also	O
express	O
neuropeptides	O
such	O
as	O
bradykinan	O
,	O
neurotensin	O
and	O
substance	O
P	O
.	O
The	O
protein	O
with	O
the	O
greatest	O
fold	O
change	O
in	O
this	O
study	O
was	O
thimet	O
oligopeptidase	O
(	O
down	O
-	O
regulated	O
1	O
.	O
67	O
),	O
which	O
is	O
involved	O
in	O
the	O
degradation	O
of	O
these	O
small	O
proteins	O
[	O
37	O
].	O

Neuropeptides	O
such	O
as	O
neurotensin	O
can	O
indirectly	O
influence	O
dopaminergic	O
transmission	O
in	O
the	O
nucleus	O
accumbens	O
via	O
glutamate	O
and	O
GABA	O
-	O
ergic	O
mediated	O
processes	O
[	O
38	O
].	O

Thus	B
,	O
these	O
neuropeptides	O
are	O
of	O
interest	O
as	O
potential	O
targets	O
for	O
novel	O
antipsychotic	O
agents	O
[	O
39	O
],[	O
40	O
].	O

Curiously	O
,	O
it	O
has	O
been	O
shown	O
that	O
calcium	O
concentration	O
is	O
an	O
important	O
modulator	O
of	O
thimet	O
oligopeptidase	O
activity	O
[	O
41	O
],	O
thus	B
the	O
disruption	O
of	O
this	O
protein	O
may	O
also	O
be	O
down	O
-	O
stream	O
consequence	O
of	O
altered	O
calcium	O
buffering	O
.	O

With	O
respect	O
to	O
schizophrenia	O
,	O
several	O
of	O
proteins	O
identified	O
in	O
this	O
study	O
have	O
also	O
been	O
reported	O
to	O
be	O
disrupted	O
in	O
post	O
-	O
mortem	O
brain	O
tissue	O
from	O
patients	O
with	O
schizophrenia	O
.	O

A	O
range	O
of	O
studies	O
(	O
proteomics	O
,	O
genomics	O
,	O
gene	O
association	O
studies	O
)	O
have	O
linked	O
schizophrenia	O
with	O
alterations	O
in	O
malate	O
dehydrogenase	O
cytoplasmic	O
(	O
MDHC	O
,	O
now	O
known	O
as	O
malic	O
enzyme	O
2	O
)[	O
42	O
]–[	O
47	O
].	O

Similarly	O
,	O
mitogen	O
-	O
activated	O
protein	O
kinase	O
1	O
,	O
significantly	O
down	O
-	O
regulated	O
in	O
this	O
study	O
,	O
has	O
been	O
found	O
to	O
be	O
down	O
-	O
regulated	O
at	O
both	O
the	O
mRNA	O
and	O
protein	O
levels	O
in	O
post	O
-	O
mortem	O
schizophrenia	O
brain	O
tissue	O
(	O
thalamus	O
)[	O
48	O
]	O
Like	O
the	O
previous	O
proteomic	O
study	O
[	O
18	O
],	O
we	O
found	O
no	O
alterations	O
in	O
proteins	O
directly	O
associated	O
with	O
DA	O
signaling	O
.	O

This	O
suggests	O
that	O
baseline	O
DA	O
signaling	O
may	O
be	O
normal	O
in	O
this	O
model	O
and	O
abnormalities	O
only	O
become	O
unmasked	O
in	O
the	O
presence	O
of	O
drugs	O
that	O
alter	O
DA	O
/	O
glutamate	O
balance	O
in	O
the	O
brain	O
.	O

It	O
is	O
conceivable	B
that	O
a	O
slight	O
reduction	O
in	O
calcium	O
buffering	O
proteins	O
may	O
affect	O
the	O
ability	O
of	O
neurons	O
within	O
the	O
nucleus	O
accumbens	O
to	O
repolarise	O
in	O
response	O
to	O
psychomimetic	O
agents	O
.	O

Alternately	O
,	O
any	O
reduction	O
in	O
cellular	O
energetics	O
within	O
this	O
region	O
may	O
delay	O
the	O
integration	O
of	O
cortical	O
and	O
/	O
or	O
sub	O
-	O
cortical	O
inputs	O
.	O

Disappointingly	O
,	O
we	O
found	O
no	O
overlap	O
with	O
the	O
proteins	O
identified	O
in	O
the	O
current	O
study	O
versus	O
those	O
in	O
the	O
previous	O
publication	O
[	O
18	O
].	O

However	O
,	O
the	O
previous	O
study	O
was	O
based	O
on	O
cortical	O
and	O
hippocampal	O
tissue	O
from	O
adult	O
female	O
animals	O
,	O
whereas	O
the	O
current	O
study	O
was	O
based	O
on	O
tissue	O
from	O
the	O
nucleus	O
accumbens	O
in	O
adult	O
male	O
animals	O
.	O

Interpretation	O
of	O
the	O
current	O
study	O
is	O
also	O
limited	O
because	O
of	O
the	O
lack	O
of	O
immunoblot	O
confirmation	O
of	O
the	O
differentially	O
expressed	O
spots	O
.	O

The	O
small	O
fold	O
changes	O
found	O
in	O
the	O
study	O
,	O
while	O
statistically	O
significant	O
,	O
were	O
too	O
low	O
to	O
be	O
reliably	O
confirmed	O
via	O
immunoblot	O
[	O
49	O
].	O

Based	O
on	O
the	O
behavioural	O
findings	O
in	O
DVD	O
-	O
deficient	O
rats	O
,	O
there	O
is	O
a	O
case	O
to	O
explore	O
proteomic	O
dysregulation	O
in	O
rats	O
after	O
exposure	O
to	O
drugs	O
known	O
to	O
disrupt	O
dopaminergic	O
and	O
glutaminergic	O
pathways	O
.	O

For	O
example	O
,	O
we	O
have	O
shown	O
that	O
while	O
habituated	O
DVD	O
rats	O
have	O
normal	O
locomotion	O
activity	O
in	O
the	O
open	O
field	O
at	O
baseline	O
,	O
they	O
have	O
pronounced	O
hyperlocomotion	O
after	O
exposure	O
to	O
MK	O
-	O
801	O
[	O
10	O
],[	O
12	O
].	O

We	O
plan	O
to	O
explore	O
these	O
issues	O
in	O
future	O
experiments	O
.	O

In	O
conclusion	O
,	O
developmental	O
vitamin	O
D	O
deficiency	O
is	O
associated	O
with	O
subtle	O
changes	O
in	O
a	O
range	O
of	O
proteins	O
in	O
the	O
nucleus	O
accumbens	O
.	O

These	O
findings	O
suggest	O
that	O
pathways	O
involved	O
in	O
calcium	O
binding	O
and	O
mitochondrial	O
function	O
may	O
underpin	O
the	O
behavioural	O
features	O
associated	O
with	O
this	O
particular	O
animal	O
model	O
of	O
schizophrenia	O
.	O

Combined	O
with	O
other	O
experimental	O
findings	O
,	O
the	O
current	O
study	O
lends	O
further	O
credibility	O
to	O
the	O
notion	O
that	O
developmental	O
vitamin	O
D	O
deficiency	O
impacts	O
adversely	O
on	O
normal	O
brain	O
development	O
[	O
30	O
].	O

Mc	O
Grath	O
et	O
al	O
.	O

This	O
is	O
an	O
open	O
-	O
access	O
article	O
distributed	O
under	O
the	O
terms	O
of	O
the	O
Creative	O
Commons	O
Attribution	O
License	O
,	O
which	O
permits	O
unrestricted	O
use	O
,	O
distribution	O
,	O
and	O
reproduction	O
in	O
any	O
medium	O
,	O
provided	O
the	O
original	O
author	O
and	O
source	O
are	O
credited	O
.	O

PubMed	O
Central	O
:	O

Haematological	O
effects	O
of	O
multimicronutrient	O
supplementation	O
in	O
non	O
-	O
pregnant	O
Gambian	O
women	O
Abstract	O
Background	O
/	O
Objectives	O
:	O
The	O
use	O
of	O
multimicronutrient	O
(	O
MMN	O
)	O
supplementation	O
to	O
reduce	O
the	O
burden	O
of	O
anaemia	O
in	O
non	O
-	O
pregnant	O
women	O
of	O
reproductive	O
age	O
has	O
been	O
little	O
studied	O
,	O
particularly	O
in	O
Africa	O
.	O

The	O
objective	O
of	O
the	O
study	O
was	O
to	O
evaluate	O
haematological	O
outcomes	O
in	O
non	O
-	O
pregnant	O
,	O
rural	O
Gambian	O
women	O
of	O
reproductive	O
age	O
,	O
receiving	O
daily	O
MMN	O
supplements	O
for	O
one	O
-	O
year	O
.	O

Subjects	O
/	O
Methods	O
:	O
The	O
study	O
in	O
293	O
women	O
aged	O
from	O
17	O
to	O
45	O
years	O
old	O
was	O
nested	O
within	O
a	O
double	O
-	O
blind	O
,	O
randomised	O
placebo	O
-	O
controlled	O
trial	O
of	O
periconceptional	O
MMN	O
supplementation	O
[	O
ISRCTN	O
13687662	O
],	O
using	O
the	O
United	O
Nations	O
International	O
Multiple	O
Micronutrient	O
Preparation	O
(	O
UNIMMAP	O
),	O
received	O
daily	O
for	O
one	O
year	O
or	O
until	O
conception	O
.	O

Red	O
cell	O
parameters	O
and	O
free	O
erythrocyte	O
protoporphyrin	O
concentration	O
were	O
measured	O
at	O
baseline	O
and	O
after	O
12	O
-	O
months	O
in	O
those	O
women	O
who	O
did	O
not	O
conceive	O
.	O

Results	O
:	O
Anaemic	O
women	O
(	O
haemoglobin	O
concentration	O
<	O
12g	O
/	O
dL	O
)	O
were	O
more	O
likely	B
to	O
be	O
older	O
and	O
in	O
economic	O
deficit	O
at	O
baseline	O
.	O

Mean	O
change	O
in	O
haemoglobin	O
concentration	O
was	O
+	O
0	O
.	O
6	O
±	O
1	O
.	O
4g	O
/	O
dL	O
in	O
the	O
intervention	O
arm	O
and	O
−	O
0	O
.	O
2	O
±	O
1	O
.	O
2g	O
/	O
dL	O
in	O
the	O
placebo	O
arm	O
(	O
p	O
<	O
0	O
.	O
001	O
).	O

After	O
supplementation	O
with	O
MMN	O
the	O
relative	O
risk	O
of	O
anaemia	O
(<	O
12g	O
/	O
dL	O
)	O
was	O
0	O
.	O
59	O
(	O
0	O
.	O
46	O
,	O
0	O
.	O
76	O
)	O
compared	O
to	O
placebo	O
.	O

Anaemic	O
subjects	O
at	O
baseline	O
showed	O
an	O
increase	O
in	O
mean	O
haemoglobin	O
from	O
10	O
.	O
6g	O
/	O
dL	O
to	O
11	O
.	O
8g	O
/	O
L	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
after	O
MMN	O
supplementation	O
.	O

Conclusion	O
:	O
MMN	O
supplementation	O
should	O
be	O
considered	O
as	O
a	O
strategy	O
for	O
improving	O
the	O
micronutrient	O
and	O
haematological	O
status	O
of	O
non	O
-	O
pregnant	O
women	O
of	O
reproductive	O
age	O
.	O

INTRODUCTION	O
Many	O
women	O
in	O
low	O
-	O
income	O
countries	O
suffer	O
from	O
sub	O
-	O
optimal	O
micronutrition	O
as	B
a	O
consequence	B
of	O
eating	O
diets	O
which	O
are	O
often	B
low	O
in	O
animal	O
-	O
source	O
foods	O
and	O
which	O
do	O
not	O
meet	O
dynamic	O
micronutrient	O
requirements	O
throughout	O
the	O
reproductive	O
lifecycle	O
(	O
Bartley	O
et	O
al	O
2005	O
).	O

Although	O
iron	O
deficiency	O
is	O
the	O
commonest	O
cause	O
of	O
nutritional	O
morbidity	O
worldwide	O
(	O
Stoltzfus	O
2003	O
),	O
in	O
women	O
of	O
reproductive	O
age	O
concurrent	O
deficiencies	O
of	O
vitamins	O
A	O
,	O
C	O
,	O
B	O
and	O
folate	O
also	O
frequently	O
occur	O
and	O
all	O
contribute	O
to	O
an	O
increased	O
anaemia	O
risk	O
(	O
Huffman	O
SL	O
et	O
al	O
1998	O
).	O

The	O
prevention	O
of	O
multiple	O
micronutrient	O
deficiencies	O
as	O
a	O
strategy	O
to	O
reduce	O
the	O
risk	O
of	O
prenatal	O
anaemia	O
has	O
been	O
little	O
studied	O
and	O
attention	O
has	O
tended	O
to	O
focus	O
instead	O
on	O
iron	O
supplementation	O
during	O
pregnancy	O
,	O
with	O
conflicting	O
results	O
(	O
Reveiz	O
et	O
al	O
2007	O
)	O
.	O

There	O
are	O
few	O
large	O
intervention	O
trials	O
of	O
multiple	O
micronutrient	O
supplementation	O
in	O
non	O
-	O
pregnant	O
women	O
of	O
reproductive	O
age	O
and	O
none	O
have	O
been	O
conducted	O
in	O
Africa	O
.	O

In	O
The	O
Gambia	O
,	O
as	O
in	O
other	O
parts	O
of	O
sub	O
-	O
Saharan	O
Africa	O
,	O
seasonal	O
multiple	O
micronutrient	O
deficiencies	O
are	O
common	O
(	O
Bates	O
et	O
al	O
1984	O
,	O
Powers	O
and	O
Bates	O
1987	O
),	O
and	O
maternal	O
anaemia	O
and	O
its	O
sequelae	O
remain	O
frequent	O
problems	O
,	O
particularly	O
in	O
rural	O
areas	O
(	O
Powers	O
and	O
Bates	O
1987	O
,	O
Topley	O
1968	O
).	O

In	O
order	O
to	O
assess	O
the	O
effectiveness	O
of	O
MMN	O
supplementation	O
in	O
anaemia	O
prevention	O
in	O
rural	O
Gambian	O
women	O
,	O
we	O
analysed	O
a	O
sub	O
-	O
sample	O
of	O
participants	O
enrolled	O
as	O
part	O
of	O
a	O
large	O
MMN	O
,	O
placebo	O
-	O
controlled	O
supplementation	O
trial	O
.	O

MATERIALS	O
/	O
SUBJECTS	O
AND	O
METHODS	O
Study	O
design	O
and	O
intervention	O
The	O
current	O
study	O
was	O
nested	O
within	O
the	O
Periconceptional	O
Multimicronutrient	O
Supplementation	O
Trial	O
(	O
PMMST	O
)	O
[	O
ISRCTN	O
13687662	O
],	O
based	O
in	O
31	O
rural	O
Gambian	O
villages	O
of	O
Kiang	O
West	O
under	O
demographic	O
surveillance	O
by	O
the	O
UK	O
Medical	O
Research	O
Council	O
field	O
station	O
in	O
Keneba	O
and	O
which	O
ran	O
between	O
February	O
2005	O
and	O
June	O
2008	O
.	O

Between	O
March	O
and	O
July	O
2006	O
,	O
resident	O
females	O
aged	O
17	O
-	O
45y	O
were	O
identified	O
from	O
the	O
demographic	O
database	O
and	O
pre	O
-	O
randomised	O
to	O
receive	O
daily	O
supplementation	O
with	O
UNIMMAP	O
or	O
placebo	O
.	O

For	O
ease	O
of	O
administration	O
in	O
the	O
field	O
,	O
randomisation	O
was	O
to	O
one	O
of	O
four	O
colour	O
-	O
coded	O
groups	O
(	O
2	O
for	O
intervention	O
;	O
2	O
for	O
placebo	O
),	O
stratified	O
by	O
age	O
.	O

Researchers	O
were	O
blinded	O
to	O
subject	O
allocation	O
scheme	O
and	O
subjects	O
and	O
field	O
staff	O
knew	O
only	O
the	O
colour	O
-	O
coded	O
allocation	O
groups	O
.	O

UNIMMAP	O
is	O
a	O
balanced	O
preparation	O
of	O
15	O
vitamins	O
and	O
minerals	O
formulated	O
by	O
an	O
Expert	O
Committee	O
of	O
the	O
United	O
Nations	O
Children	O
'	O
s	O
Fund	O
,	O
World	O
Health	O
Organization	O
and	O
the	O
United	O
Nations	O
University	O
,	O
primarily	O
for	O
use	O
by	O
pregnant	O
and	O
lactating	O
women	O
.	O

The	O
composition	O
of	O
UNIMMAP	O
is	O
shown	O
inTable	O
1	O
(	O
UNICEF	O
/	O
WHO	O
/	O
UNU	O
1999	O
).	O

Eligible	O
females	O
were	O
invited	O
to	O
attend	O
a	O
recruitment	O
clinic	O
where	O
informed	O
consent	O
was	O
sought	O
in	O
writing	O
from	O
individuals	O
or	O
guardians	O
,	O
in	O
the	O
cases	O
of	O
girls	O
under	O
18	O
-	O
years	O
old	O
.	O

Consenting	O
non	O
-	O
pregnant	O
women	O
who	O
were	O
menstruating	O
,	O
not	O
breastfeeding	O
an	O
infant	O
,	O
not	O
using	O
contraception	O
or	O
not	O
severely	O
anaemic	O
(	O
haemoglobin	O
concentration	O
<	O
7g	O
/	O
dL	O
)	O
were	O
included	O
in	O
the	O
trial	O
.	O

Exclusions	O
were	O
referred	O
for	O
clinical	O
management	O
as	O
required	O
.	O

Women	O
received	O
30	O
tablets	O
according	O
to	O
their	O
allocated	O
intervention	O
group	O
and	O
were	O
instructed	O
to	O
take	O
one	O
tablet	O
daily	O
.	O

They	O
were	O
also	O
asked	O
to	O
attend	O
weekly	O
supplementation	O
clinics	O
held	O
in	O
their	O
own	O
villages	O
when	O
they	O
were	O
re	O
-	O
supplied	O
with	O
supplements	O
.	O

Compliance	O
with	O
supplementation	O
was	O
assessed	O
by	O
pill	O
counts	O
(	O
compliance	O
factor	O
=	O
ratio	O
of	O
the	O
number	O
of	O
tablets	O
apparently	O
consumed	O
/	O
number	O
of	O
days	O
enrolled	O
in	O
study	O
).	O

Information	O
on	O
morbidity	O
and	O
menstrual	O
patterns	O
was	O
also	O
recorded	O
at	O
these	O
visits	O
.	O

Subjects	O
were	O
asked	O
to	O
notify	O
fieldworkers	O
of	O
suspected	O
pregnancy	O
and	O
following	O
confirmation	O
of	O
pregnancy	O
by	O
study	O
midwives	O
,	O
women	O
were	O
instructed	O
to	O
stop	O
supplementation	O
and	O
no	O
further	O
supplements	O
were	O
issued	O
.	O

These	O
women	O
received	O
a	O
standard	O
antenatal	O
preparation	O
of	O
60mg	O
elemental	O
iron	O
and	O
250μg	O
of	O
folic	O
acid	O
daily	O
.	O

They	O
were	O
followed	O
in	O
the	O
antenatal	O
study	O
clinic	O
at	O
regular	O
intervals	O
until	O
delivery	O
.	O

Women	O
who	O
did	O
not	O
conceive	O
while	O
enrolled	O
in	O
PMMST	O
,	O
had	O
received	O
at	O
least	O
one	O
year	O
of	O
MMN	O
supplementation	O
or	O
placebo	O
and	O
were	O
still	O
resident	O
in	O
the	O
selected	O
villages	O
in	O
Kiang	O
West	O
,	O
were	O
eligible	O
for	O
inclusion	O
in	O
the	O
current	O
study	O
.	O

Data	O
collection	O
for	O
the	O
current	O
study	O
took	O
place	O
between	O
July	O
and	O
August	O
2007	O
.	O

Permission	O
for	O
this	O
study	O
was	O
obtained	O
from	O
the	O
London	O
School	O
of	O
Hygiene	O
and	O
Tropical	O
Medicine	O
Ethics	O
Committee	O
and	O
the	O
Gambian	O
Government	O
/	O
MRC	O
Joint	O
Ethics	O
Committee	O
.	O

The	O
parent	O
-	O
trial	O
was	O
subjected	O
to	O
the	O
scrutiny	O
of	O
an	O
independent	O
Data	O
Safety	O
and	O
Monitoring	O
Board	O
and	O
operated	O
under	O
the	O
auspices	O
of	O
Good	O
Clinical	O
Practice	O
guidelines	O
(	O
MRC	O
1999	O
).	O

MRC	O
Keneba	O
offers	O
free	O
primary	O
health	O
care	O
to	O
anyone	O
who	O
consults	O
,	O
in	O
collaboration	O
with	O
the	O
Gambian	O
Government	O
Lower	O
River	O
Divisional	O
Health	O
Team	O
.	O

Apart	O
from	O
the	O
structured	O
clinical	O
contacts	O
outlined	O
(	O
during	O
which	O
subjects	O
were	O
given	O
transport	O
and	O
a	O
meal	O
)	O
no	O
additional	O
benefits	O
were	O
provided	O
to	O
trial	O
participants	O
.	O

Study	O
location	O
and	O
population	O
Kiang	O
West	O
is	O
a	O
semi	O
-	O
arid	O
area	O
of	O
savannah	O
-	O
scrubland	O
with	O
a	O
rural	O
population	O
of	O
14	O
000	O
people	O
,	O
predominantly	O
of	O
the	O
Mandinka	O
tribe	O
.	O

HIV	O
status	O
was	O
not	O
assessed	O
during	O
this	O
study	O
but	O
national	O
sentinel	O
data	O
from	O
antenatal	O
clinics	O
indicates	O
a	O
HIV	O
prevalence	O
of	O
around	O
1	O
%	O
(	O
Schim	O
van	O
der	O
Loeff	O
et	O
al	O
2003	O
).	O

The	O
sub	O
-	O
sample	O
was	O
drawn	O
from	O
12	O
of	O
the	O
original	O
31	O
villages	O
,	O
chosen	O
on	O
the	O
grounds	O
of	O
their	O
larger	O
size	O
and	O
easier	O
accessibility	O
.	O

They	O
included	O
the	O
core	O
research	O
villages	O
of	O
the	O
Keneba	O
,	O
Kanton	O
Kunda	O
and	O
Manduar	O
and	O
9	O
of	O
the	O
villages	O
to	O
the	O
east	O
and	O
west	O
of	O
Keneba	O
.	O

This	O
provided	O
a	O
broad	O
yet	O
manageable	O
sample	O
frame	O
from	O
within	O
the	O
original	O
trial	O
cohort	O
,	O
given	O
the	O
logistical	O
constraints	O
under	O
which	O
the	O
current	O
study	O
was	O
carried	O
out	O
.	O

Consenting	O
subjects	O
who	O
were	O
present	O
in	O
the	O
village	O
on	O
an	O
allotted	O
day	O
were	O
recruited	O
.	O

Anthropometry	O
and	O
blood	O
samples	O
were	O
collected	O
from	O
participants	O
during	O
village	O
visits	O
Sample	O
size	O
Mean	O
recruitment	O
haemoglobin	O
for	O
the	O
PMMST	O
study	O
was	O
11	O
.	O
7	O
g	O
/	O
dL	O
,	O
(	O
SD	O
1	O
.	O
5	O
g	O
/	O
dL	O
)	O
for	O
a	O
population	O
of	O
1156	O
.	O

A	O
sample	O
of	O
150	O
for	O
each	O
trial	O
arm	O
was	O
required	O
in	O
order	O
to	O
detect	O
a	O
change	O
in	O
haemoglobin	O
of	O
0	O
.	O
5	O
g	O
/	O
dL	O
between	O
study	O
arms	O
with	O
5	O
%	O
significance	O
and	O
80	O
%	O
power	O
.	O

Data	O
and	O
sample	O
collection	O
Individual	O
informed	O
consent	O
was	O
obtained	O
in	O
the	O
local	O
language	O
by	O
Gambian	O
MRC	O
fieldworkers	O
.	O

A	O
thumbprint	O
was	O
requested	O
from	O
women	O
who	O
were	O
unable	O
to	O
write	O
.	O

An	O
information	O
sheet	O
in	O
English	O
was	O
provided	O
for	O
women	O
to	O
take	O
away	O
.	O

A	O
questionnaire	O
assessing	O
marital	O
status	O
and	O
socioeconomic	O
status	O
was	O
carried	O
out	O
.	O

Economic	O
situation	O
was	O
assessed	O
by	O
ownership	O
of	O
radio	O
and	O
/	O
or	O
bicycle	O
and	O
information	O
on	O
perceived	O
economic	O
status	O
.	O

Participants	O
were	O
asked	O
whether	O
they	O
considered	O
the	O
household	O
'	O
s	O
economic	O
situation	O
in	O
the	O
preceding	O
year	O
to	O
have	O
been	O
always	O
in	O
deficit	O
,	O
occasionally	O
deficit	O
,	O
balanced	O
or	O
surplus	O
.	O

A	O
household	O
was	O
categorised	O
as	O
in	O
‘	O
economic	O
deficit	O
’	O
if	O
the	O
subject	O
answered	O
either	O
always	O
deficit	O
or	O
occasionally	O
deficit	O
(	O
Hyder	O
et	O
al	O
2004	O
).	O

A	O
one	O
-	O
week	O
dietary	O
history	O
,	O
menstrual	O
and	O
medical	O
history	O
was	O
completed	O
for	O
each	O
subject	O
.	O

A	O
stool	O
sample	O
was	O
requested	O
and	O
sterile	O
universal	O
containers	O
provided	O
at	O
the	O
study	O
visit	O
following	O
the	O
trial	O
.	O

At	O
initial	O
recruitment	O
within	O
the	O
main	O
study	O
baseline	O
stool	O
samples	O
had	O
not	O
been	O
collected	O
.	O

Venous	O
blood	O
was	O
placed	O
in	O
EDTA	O
,	O
sedivette	O
and	O
serum	O
tubes	O
(	O
Sarstedt	O
Monovette	O
,	O
UK	O
).	O

Height	O
was	O
measured	O
to	O
the	O
nearest	O
cm	O
using	O
a	O
stadiometer	O
(	O
Seca	O
Leicester	O
,	O
UK	O
),	O
and	O
weight	O
to	O
the	O
nearest	O
100	O
g	O
using	O
an	O
electronic	O
scale	O
(	O
Tanita	O
,	O
USA	O
).	O

Mid	O
-	O
upper	O
arm	O
circumference	O
(	O
MUAC	O
)	O
was	O
measured	O
at	O
the	O
mid	O
-	O
point	O
of	O
the	O
left	O
arm	O
using	O
standard	O
tapes	O
(	O
TALC	O
,	O
UK	O
).	O

Data	O
were	O
double	O
entered	O
into	O
the	O
MRC	O
Keneba	O
database	O
(	O
MS	O
Access	O
,	O
Microsoft	O
,	O
USA	O
).	O

Laboratory	O
analysis	O
Haematological	O
analysis	O
included	O
haemoglobin	O
concentration	O
,	O
white	O
blood	O
cell	O
count	O
,	O
mean	O
cell	O
volume	O
(	O
MCV	O
),	O
mean	O
cell	O
haemoglobin	O
(	O
MCH	O
),	O
reticulocyte	O
count	O
(	O
Cel	O
-	O
Dyn	O
3700	O
Analyser	O
,	O
Abbott	O
Diagnostics	O
,	O
USA	O
and	O
Medonic	O
CA530	O
,	O
Clinical	O
Diagnostic	O
Solutions	O
,	O
Inc	O
.,	O
USA	O
),	O
and	O
zinc	O
protoporphyrin	O
concentration	O
(	O
ZnPP	O
)	O
(	O
AVIV	O
ZP	O
Hematofluorometer	O
Model	O
206	O
,	O
Analis	O
Scientific	O
Instruments	O
,	O
Belgium	O
).	O

The	O
erythrocyte	O
sedimentation	O
rate	O
(	O
ESR	O
)	O
(	O
Sarstedt	O
,	O
UK	O
)	O
and	O
C	O
-	O
reactive	O
protein	O
(	O
CRP	O
)	O
(	O
Vitros	O
system	O
250	O
,	O
Johnson	O
&	O
Johnson	O
,	O
USA	O
)	O
were	O
measured	O
.	O

Malaria	O
blood	O
films	O
were	O
prepared	O
and	O
stained	O
with	O
giemsa	O
stain	O
and	O
100	O
microscopic	O
fields	O
examined	O
to	O
determine	O
parasite	O
count	O
.	O

Wet	O
stool	O
samples	O
were	O
prepared	O
for	O
examination	O
by	O
light	O
microscopy	O
for	O
the	O
presence	O
of	O
helminths	O
.	O

Both	O
Cell	O
-	O
dyn	O
and	O
Medonic	O
CA530	O
analysers	O
were	O
used	O
for	O
processing	O
of	O
haematological	O
samples	O
due	O
to	O
a	O
technical	O
fault	O
with	O
the	O
Cell	O
-	O
dyn	O
machine	O
.	O

The	O
correlation	O
coefficient	O
between	O
the	O
results	O
for	O
the	O
two	O
machines	O
was	O
0	O
.	O
96	O
(	O
p	O
<	O
0	O
.	O
001	O
).	O

Statistical	O
analysis	O
Data	O
was	O
blinded	O
until	O
completion	O
of	O
the	O
analysis	O
,	O
which	O
was	O
performed	O
on	O
an	O
intention	O
-	O
to	O
-	O
treat	O
basis	O
.	O

Data	O
were	O
processed	O
and	O
analysed	O
using	O
SPSS	O
for	O
Windows	O
v15	O
.	O

Log	O
transformation	O
was	O
used	O
for	O
non	O
-	O
normal	O
distributions	O
.	O

Anaemia	O
was	O
defined	O
as	O
hemoglobin	O
concentration	O
less	O
than	O
12	O
g	O
/	O
dL	O
(	O
UNICEF	O
/	O
WHO	O
/	O
UNU	O
2001	O
).	O

Mean	O
haemoglobin	O
concentration	O
change	O
(	O
baseline	O
to	O
follow	O
-	O
up	O
)	O
was	O
compared	O
between	O
treatment	O
groups	O
with	O
analysis	O
of	O
covariance	O
.	O

Variables	O
which	O
did	O
not	O
require	O
adjustment	O
for	O
baseline	O
values	O
were	O
compared	O
using	O
an	O
independent	O
t	O
-	O
test	O
for	O
continuous	O
variables	O
,	O
Wilcoxon	O
ranksum	O
for	O
non	O
normally	O
distributed	O
variables	O
(	O
CRP	O
)	O
and	O
a	O
chi	O
-	O
squared	O
test	O
of	O
proportions	O
for	O
categorical	O
variables	O
.	O

The	O
odds	O
ratio	O
(	O
OR	O
)	O
and	O
relative	O
risk	O
(	O
RR	O
)	O
for	O
anaemia	O
in	O
relation	O
to	O
MMN	O
supplement	O
,	O
age	O
and	O
ESR	O
were	O
computed	O
using	O
logistic	O
regression	O
.	O

Differences	O
were	O
considered	O
significant	O
at	O
p	O
<	O
0	O
.	O
05	O
.	O

RESULTS	O
Of	O
1156	O
women	O
recruited	O
for	O
the	O
original	O
trial	O
421	O
were	O
considered	O
to	O
be	O
eligible	O
for	O
the	O
current	O
study	O
according	O
to	O
the	O
criteria	O
above	O
.	O

Of	O
these	O
293	O
subjects	O
were	O
identified	O
and	O
recruited	O
(	O
Figure	O
1	O
).	O

Subjects	O
who	O
could	O
not	O
be	O
traced	O
by	O
the	O
field	O
teams	O
or	O
who	O
did	O
not	O
attend	O
after	O
direct	O
invitation	O
were	O
not	O
recruited	O
(	O
n	O
=	O
128	O
).	O

Baseline	O
characteristics	O
of	O
recruited	O
(	O
n	O
=	O
293	O
)	O
and	O
non	O
-	O
recruited	O
(	O
n	O
=	O
128	O
)	O
women	O
are	O
summarised	O
inTable	O
2	O
.	O

Untraced	O
women	O
were	O
more	O
likely	B
to	O
be	O
nulliparous	O
,	O
to	O
have	O
lower	O
mean	O
anthropometric	O
indices	O
and	O
were	O
more	O
likely	B
to	O
have	O
received	O
formal	O
schooling	O
.	O

There	O
were	O
no	O
differences	O
in	O
haematological	O
parameters	O
.	O

Baseline	O
characteristics	O
of	O
the	O
intervention	O
and	O
placebo	O
groups	O
were	O
not	O
different	O
except	O
for	O
total	O
white	O
cell	O
concentration	O
at	O
baseline	O
(	O
Table	O
3	O
).	O

The	O
estimate	O
of	O
compliance	O
did	O
not	O
differ	O
between	O
treatment	O
groups	O
(	O
MMN	O
:	O
0	O
.	O
96	O
±	O
0	O
.	O
18	O
;	O
placebo	O
:	O
0	O
.	O
92	O
±	O
0	O
.	O
19	O
,	O
p	O
=	O
0	O
.	O
15	O
).	O

The	O
mean	O
time	O
of	O
follow	O
up	O
was	O
similar	O
in	O
both	O
groups	O
(	O
MMN	O
:	O
14	O
.	O
1	O
±	O
1	O
.	O
2	O
months	O
,	O
placebo	O
14	O
.	O
0	O
±	O
1	O
.	O
2	O
months	O
).	O

Baseline	O
predictors	O
of	O
anaemia	O
,	O
after	O
adjustment	O
(	O
Table	O
4	O
),	O
included	O
older	O
age	O
OR	O
=	O
2	O
.	O
01	O
(	O
1	O
.	O
16	O
,	O
3	O
.	O
48	O
)	O
and	O
economic	O
deficit	O
OR	O
=	O
1	O
.	O
98	O
(	O
1	O
.	O
21	O
,	O
3	O
.	O
25	O
).	O

Following	O
the	O
intervention	O
period	O
mean	O
haemoglobin	O
concentration	O
was	O
higher	O
in	O
women	O
receiving	O
micronutrients	O
(	O
MMN	O
:	O
12	O
.	O
3	O
±	O
1	O
.	O
1g	O
/	O
dL	O
,	O
placebo	O
:	O
11	O
.	O
5	O
±	O
1	O
.	O
4g	O
/	O
dL	O
)	O
with	O
a	O
mean	O
change	O
in	O
haemoglobin	O
concentration	O
of	O
+	O
0	O
.	O
6	O
±	O
1	O
.	O
4g	O
/	O
dL	O
(	O
MMN	O
)	O
and	O
−	O
0	O
.	O
2	O
±	O
1	O
.	O
2g	O
/	O
dL	O
(	O
placebo	O
)	O
(	O
p	O
<	O
0	O
.	O
001	O
).	O

The	O
increase	O
in	O
haemoglobin	O
concentration	O
in	O
the	O
intervention	O
group	O
relative	O
to	O
placebo	O
was	O
more	O
marked	O
in	O
women	O
who	O
were	O
anaemic	O
at	O
the	O
start	O
of	O
the	O
study	O
(	O
Figure	O
2	O
).	O

Although	O
age	O
and	O
economic	O
deficit	O
were	O
predictors	O
of	O
anaemia	O
at	O
baseline	O
,	O
in	O
a	O
sub	O
analysis	O
these	O
groups	O
did	O
not	O
respond	O
differently	O
to	O
supplementation	O
.	O
Table	O
3includes	O
the	O
haematological	O
findings	O
at	O
follow	O
up	O
.	O

Supplementation	O
was	O
associated	O
with	O
increased	O
haemoglobin	O
concentration	O
and	O
MCV	O
and	O
reduced	O
ZnPP	O
concentration	O
(	O
all	O
p	O
<	O
0	O
.	O
001	O
).	O

The	O
reduction	O
in	O
reticulocyte	O
count	O
was	O
marginally	O
significant	O
(	O
p	O
=	O
0	O
.	O
04	O
).	O

ESR	O
was	O
also	O
noted	O
to	O
be	O
lower	O
in	O
the	O
MMN	O
group	O
than	O
in	O
the	O
placebo	O
group	O
(	O
22	O
±	O
13	O
.	O
5mm	O
/	O
hr	O
versus	O
26	O
±	O
15	O
.	O
5mm	O
/	O
hr	O
,	O
p	O
=	O
0	O
.	O
02	O
).	O

Raised	O
ESR	O
values	O
(>	O
20mm	O
/	O
hr	O
)	O
were	O
less	O
frequent	O
in	O
supplemented	O
women	O
OR	O
0	O
.	O
71	O
(	O
0	O
.	O
55	O
,	O
0	O
.	O
91	O
).	O

There	O
were	O
no	O
differences	O
in	O
anthropometric	O
indices	O
(	O
BMI	O
,	O
weight	O
,	O
and	O
MUAC	O
)	O
between	O
the	O
two	O
groups	O
(	O
Table	O
3	O
).	O

No	O
subjects	O
had	O
malaria	O
parasitaemia	O
at	O
follow	O
-	O
up	O
.	O

Median	O
CRP	O
was	O
0	O
mg	O
/	O
L	O
for	O
both	O
groups	O
and	O
there	O
were	O
no	O
differences	O
in	O
proportion	O
of	O
women	O
with	O
a	O
raised	O
CRP	O
(>	O
10g	O
/	O
L	O
)	O
in	O
either	O
group	O
.	O

Only	O
one	O
stool	O
sample	O
showed	O
hookworm	O
infection	O
.	O

At	O
baseline	O
,	O
anaemia	O
prevalence	O
was	O
50	O
.	O
7	O
%	O
(	O
MMN	O
group	O
)	O
and	O
54	O
.	O
1	O
%	O
(	O
placebo	O
group	O
).	O

Following	O
supplementation	O
these	O
were	O
36	O
%	O
and	O
62	O
%	O
respectively	O
,	O
generating	O
RR	O
=	O
0	O
.	O
59	O
(	O
0	O
.	O
46	O
,	O
0	O
.	O
76	O
)	O
for	O
anaemia	O
in	O
the	O
MMN	O
group	O
.	O

Anaemia	O
was	O
less	O
frequent	O
in	O
the	O
MMN	O
group	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
and	O
more	O
frequent	O
in	O
older	O
women	O
(	O
p	O
=	O
0	O
.	O
01	O
)	O
and	O
there	O
was	O
no	O
significant	O
interaction	O
between	O
age	O
and	O
intervention	O
group	O
.	O

There	O
were	O
no	O
significant	O
differences	O
in	O
combined	O
or	O
system	O
-	O
specific	O
morbidity	O
profiles	O
between	O
study	O
groups	O
(	O
data	O
not	O
shown	O
).	O

DISCUSSION	O
To	B
our	I
knowledge	I
this	O
is	O
the	O
first	O
African	O
trial	O
to	O
evaluate	O
the	O
effect	O
of	O
multiple	O
micronutrient	O
supplementation	O
on	O
red	O
cell	O
parameters	O
and	O
iron	O
status	O
among	O
non	O
-	O
pregnant	O
women	O
of	O
reproductive	O
age	O
.	O

Twelve	O
months	O
of	O
daily	O
MMN	O
supplementation	O
significantly	O
improved	O
haemoglobin	O
concentration	O
in	O
this	O
group	O
of	O
women	O
.	O

The	O
associated	O
decrease	O
in	O
ZnPP	O
concentration	O
and	O
increased	O
MCV	O
in	O
supplemented	O
women	O
suggests	O
that	O
the	O
iron	O
content	O
of	O
the	O
supplements	O
underpinned	O
the	O
improved	O
haematological	O
profile	O
,	O
while	O
the	O
differences	O
in	O
reticulocyte	O
count	O
suggest	O
a	O
reduction	O
in	O
red	O
cell	O
turnover	O
among	O
MMN	O
supplemented	O
women	O
.	O

Anaemia	O
prevalence	O
was	O
almost	O
halved	O
in	O
supplemented	O
women	O
and	O
anaemic	O
women	O
showed	O
the	O
greatest	O
increase	O
in	O
haemoglobin	O
concentration	O
following	O
supplementation	O
(+	O
1	O
.	O
2g	O
/	O
dL	O
).	O

This	O
would	O
be	O
expected	O
as	B
subjects	O
who	O
are	O
iron	O
-	O
depleted	O
use	O
iron	O
more	O
effectively	O
than	O
those	O
who	O
are	O
iron	O
-	O
replete	O
(	O
Moriarty	O
-	O
Craige	O
et	O
al	O
2004	O
).	O

ESR	O
was	O
measured	O
in	O
this	O
study	O
.	O

ESR	O
is	O
a	O
non	O
-	O
specific	O
,	O
indirect	O
measurement	O
of	O
plasma	O
acute	O
-	O
phase	O
protein	O
and	O
systemic	O
inflammatory	O
status	O
that	O
is	O
known	O
to	O
correlate	O
with	O
haemoglobin	O
and	O
plasma	O
fibrinogen	O
concentrations	O
(	O
Kanfer	O
and	O
Nicol	O
1997	O
).	O

It	O
is	O
influenced	O
by	O
the	O
size	O
,	O
shape	O
,	O
and	O
number	O
of	O
erythrocytes	O
,	O
as	O
well	O
as	O
by	O
other	O
plasma	O
constituents	O
such	O
as	O
immunoglobulins	O
(	O
Brigden	O
1999	O
,	O
Gabay	O
and	O
Kushner	O
1999	O
).	O

Interpretation	O
of	O
the	O
effect	O
of	O
supplementation	O
on	O
ESR	O
is	O
complex	O
(	O
Breckenridge	O
and	O
Okpanachi	O
1976	O
)	O
but	O
the	O
reduction	O
in	O
ESR	O
following	O
supplementation	O
could	O
indicate	O
a	O
ameliorating	O
effect	O
of	O
MMN	O
on	O
systemic	O
inflammation	O
.	O

However	O
,	O
there	O
was	O
no	O
direct	O
evidence	O
that	O
CRP	O
concentration	O
was	O
affected	O
by	O
micronutrient	O
supplementation	O
.	O

More	O
detailed	O
studies	O
of	O
inflammatory	O
markers	O
and	O
MMN	O
supplementation	O
are	O
required	O
in	O
order	O
to	O
understand	O
their	O
roles	O
in	O
the	O
aetiology	O
of	O
anaemia	O
in	O
this	O
population	O
of	O
women	O
,	O
particularly	O
in	O
areas	O
of	O
high	O
malarial	O
endemicity	O
.	O

The	O
study	O
was	O
restricted	O
to	O
a	O
sub	O
-	O
sample	O
of	O
geographically	O
selected	O
villages	O
but	O
this	O
does	O
not	O
appear	O
to	O
have	O
biased	O
the	O
results	O
of	O
the	O
study	O
,	O
as	B
the	O
placebo	O
and	O
intervention	O
groups	O
were	O
comparable	O
at	O
baseline	O
.	O

The	O
high	O
compliance	O
,	O
regular	O
follow	O
-	O
up	O
and	O
long	O
duration	O
of	O
our	O
study	O
further	O
increases	O
confidence	O
in	O
the	O
findings	O
.	O

The	O
placebo	O
control	O
group	O
allowed	O
for	O
an	O
absolute	O
evaluation	O
of	O
the	O
effects	O
of	O
micronutrients	O
on	O
haematological	O
parameters	O
.	O

The	O
primary	O
analysis	O
was	O
powered	O
to	O
assess	O
changes	O
in	O
haemoglobin	O
concentration	O
,	O
which	O
limited	O
the	O
scope	O
of	O
this	O
study	O
to	O
the	O
functional	O
effect	O
of	O
MMN	O
supplementation	O
on	O
nutritional	O
anaemia	O
.	O

This	O
outcome	O
represented	B
a	O
simple	O
,	O
clinically	O
relevant	O
measure	O
of	O
composite	O
micronutrient	O
status	O
,	O
achievable	O
within	O
the	O
time	O
and	O
resource	O
constraints	O
under	O
which	O
the	O
nested	O
study	O
was	O
carried	O
out	O
.	O

However	O
an	O
analysis	O
of	O
the	O
effects	O
of	O
supplementation	O
on	O
broader	O
micronutrient	O
status	O
in	O
this	O
population	O
would	O
have	O
been	O
of	O
interest	O
and	O
is	O
a	O
specified	O
outcome	O
in	O
the	O
main	O
trial	O
,	O
which	O
will	O
be	O
reported	O
elsewhere	O
.	O

There	O
was	O
a	O
low	O
prevalence	O
of	O
malaria	O
parasitaemia	O
in	O
the	O
current	O
study	O
,	O
which	O
is	O
likely	B
to	O
have	O
been	O
a	O
consequence	B
of	O
cross	O
-	O
sectional	O
sampling	O
of	O
partially	O
immune	O
adults	O
early	O
in	O
the	O
wet	O
season	O
,	O
in	O
an	O
area	O
of	O
highly	O
seasonal	O
endemicity	O
.	O

Although	O
there	O
was	O
no	O
difference	O
in	O
the	O
rate	O
of	O
clinical	O
infection	O
diagnosis	O
between	O
the	O
two	O
arms	O
of	O
the	O
parent	O
trial	O
,	O
longitudinal	O
malaria	O
exposure	O
may	O
have	O
been	O
an	O
effect	O
modifier	O
or	O
confounding	O
variable	O
in	O
this	O
study	O
and	O
ought	O
to	O
be	O
assessed	O
formally	O
in	O
future	O
work	O
.	O

Iron	O
deficiency	O
is	O
an	O
important	O
risk	O
factor	O
for	O
increased	O
maternal	O
mortality	O
,	O
low	O
birth	O
weight	O
and	O
preterm	O
delivery	O
(	O
Brabin	O
et	O
al	O
2001	O
)	O
and	O
the	O
availability	O
of	O
calcium	O
,	O
iodine	O
,	O
folate	O
and	O
vitamins	O
A	O
and	O
D	O
may	O
modulate	O
fetal	O
development	O
(	O
Bartley	O
et	O
al	O
2005	O
).	O

In	O
order	O
to	O
achieve	O
Millennium	O
Development	O
Goals	O
,	O
new	O
strategies	O
to	O
address	O
nutritional	O
problems	O
in	O
women	O
of	O
reproductive	O
age	O
are	O
required	O
.	O

Several	O
recent	O
studies	O
in	O
poorer	O
countries	O
have	O
already	O
demonstrated	O
improved	O
parameters	O
of	O
fetal	O
growth	O
and	O
gestational	O
length	O
with	O
various	O
prenatal	O
MMN	O
supplementation	O
regimen	O
,	O
although	O
effects	O
have	O
been	O
inconsistent	O
and	O
the	O
mechanisms	O
of	O
action	O
are	O
unclear	O
(	O
Christian	O
et	O
al	O
2003	O
)	O
(	O
Kaestel	O
et	O
al	O
2005	O
)	O
(	O
Fawzi	O
et	O
al	O
2007	O
).	O

There	O
are	O
concerns	O
about	O
possible	O
detrimental	O
interactions	O
between	O
micronutrients	O
combined	O
within	O
a	O
single	O
supplement	O
but	O
experimental	O
data	O
are	O
sparse	O
and	O
the	O
potential	O
synergistic	O
and	O
positive	O
effects	O
of	O
particular	O
combinations	O
should	O
not	O
be	O
ignored	O
(	O
Sandstrom	O
2001	O
).	O

The	O
timing	O
of	O
supplementation	O
may	O
likewise	O
be	O
a	O
crucial	O
factor	O
(	O
Owens	O
and	O
Fall	O
2008	O
).	O

For	O
example	O
,	O
the	O
fact	O
that	O
prenatal	O
folate	O
supplementation	O
substantially	O
reduces	O
the	O
risk	O
of	O
neural	O
tube	O
defect	O
only	O
if	O
it	O
is	O
taken	O
preconceptually	O
is	O
well	O
known	O
but	O
improving	O
vitamin	O
A	O
status	O
before	O
pregnancy	O
has	O
also	O
been	O
shown	O
to	O
have	O
a	O
dramatic	O
and	O
as	O
yet	O
unexplained	O
effect	O
on	O
maternal	O
morbidity	O
and	O
mortality	O
(	O
West	O
et	O
al	O
1999	O
).	O

Optimising	O
the	O
pre	O
-	O
and	O
inter	O
-	O
pregnancy	O
micronutritional	O
status	O
of	O
women	O
,	O
particularly	O
in	O
low	O
resource	O
settings	O
could	O
be	O
extremely	O
beneficial	O
(	O
Allen	O
2000	O
,	O
Bartley	O
et	O
al	O
2005	O
,	O
Huffman	O
SL	O
et	O
al	O
1998	O
,	O
Owens	O
and	O
Fall	O
2008	O
)	O
and	O
may	O
lead	O
to	O
improved	O
subsequent	O
maternal	O
and	O
pregnancy	O
outcomes	O
.	O

Previous	O
studies	O
in	O
Mexico	O
and	O
Bangladesh	O
have	O
shown	O
no	O
additional	O
benefit	O
on	O
haematological	O
parameters	O
when	O
women	O
of	O
reproductive	O
age	O
and	O
adolescents	O
were	O
given	O
MMN	O
compared	O
to	O
iron	O
-	O
folate	O
supplements	O
(	O
Ahmed	O
et	O
al	O
2005	O
,	O
Moriarty	O
-	O
Craige	O
et	O
al	O
2004	O
).	O

The	O
duration	O
of	O
supplementation	O
in	O
these	O
studies	O
was	O
short	O
,	O
different	O
MMN	O
formulations	O
were	O
used	O
and	O
sample	O
sizes	O
were	O
smaller	O
than	O
in	O
the	O
present	O
study	O
.	O

Neither	O
trial	O
utilised	O
a	O
placebo	O
-	O
controlled	O
design	O
,	O
limiting	O
the	O
interpretation	O
of	O
the	O
study	O
results	O
.	O

The	O
present	O
study	O
achieved	O
a	O
greater	O
improvement	O
in	O
haemoglobin	O
concentration	O
and	O
a	O
greater	O
decline	O
in	O
the	O
prevalence	O
of	O
anaemia	O
compared	O
to	O
these	O
previous	O
reports	O
.	O

The	O
findings	O
from	O
the	O
Bangladesh	O
study	O
did	O
however	O
provide	O
additional	O
support	O
for	O
the	O
use	O
of	O
combinations	O
of	O
micronutrients	O
in	O
preference	O
to	O
iron	O
alone	O
,	O
as	B
the	O
prevalence	O
of	O
other	O
nutrient	O
deficiencies	O
including	O
folic	O
acid	O
,	O
riboflavin	O
and	O
vitamin	O
B12	O
,	O
A	O
and	O
C	O
were	O
also	O
decreased	O
in	O
addition	O
to	O
improved	O
values	O
for	O
haematological	O
parameters	O
(	O
Ahmed	O
et	O
al	O
2005	O
).	O

In	O
Indonesia	O
,	O
the	O
haemoglobin	O
concentration	O
of	O
adolescent	O
girls	O
improved	O
on	O
supplementation	O
with	O
combinations	O
of	O
iron	O
,	O
folic	O
acid	O
,	O
retinol	O
and	O
vitamin	O
C	O
,	O
over	O
placebo	O
but	O
did	O
not	O
respond	O
better	O
to	O
daily	O
rather	O
that	O
weekly	O
supplementation	O
,	O
although	O
serum	O
ferritin	O
increased	O
more	O
in	O
the	O
daily	O
supplemented	O
group	O
(	O
Angeles	O
-	O
Agdeppa	O
et	O
al	O
1997	O
).	O

The	O
intervention	O
period	O
was	O
only	O
3	O
-	O
months	O
,	O
compared	O
with	O
12	O
-	O
months	O
in	O
the	O
present	O
study	O
,	O
and	O
there	O
was	O
a	O
high	O
dropout	O
rate	O
.	O

A	O
study	O
of	O
Bangladeshi	O
adolescents	O
receiving	O
a	O
micronutrient	O
fortified	O
beverage	O
6d	O
/	O
week	O
reported	O
haematological	O
effects	O
which	O
were	O
of	O
a	O
similar	O
magnitude	O
to	O
those	O
in	O
the	O
current	O
study	O
(	O
Hyder	O
et	O
al	O
2007	O
).	O

An	O
increase	O
in	O
serum	O
retinol	O
and	O
improved	O
anthropometric	O
status	O
(	O
weight	O
,	O
height	O
,	O
BMI	O
)	O
in	O
supplemented	O
girls	O
was	O
also	O
recorded	O
(	O
Hyder	O
et	O
al	O
2007	O
),	O
indicating	O
the	O
potential	O
benefits	O
of	O
MMN	O
supplementation	O
for	O
a	O
risk	O
group	O
attempting	O
to	O
satisfy	O
increased	O
nutritional	O
requirements	O
for	O
pubertal	O
growth	O
while	O
commonly	O
manifesting	O
a	O
substantial	O
degree	O
of	O
undernutrition	O
.	O

It	O
has	O
frequently	O
been	O
suggested	O
that	O
adolescents	O
should	O
be	O
the	O
focus	O
of	O
targeted	O
intervention	O
strategies	O
which	O
aim	O
to	O
improve	O
reproductive	O
health	O
particularly	O
before	O
first	O
pregnancies	O
(	O
Leenstra	O
et	O
al	O
2007	O
).	O

Although	O
the	O
issue	O
of	O
supplementation	O
in	O
younger	O
women	O
is	O
critical	O
,	O
they	O
may	O
be	O
difficult	O
to	O
target	O
over	O
a	O
long	O
period	O
of	O
time	O
and	O
may	O
not	O
begin	O
their	O
reproductive	O
lives	O
proximal	O
to	O
the	O
supplementation	O
period	O
.	O

The	O
number	O
of	O
adolescents	O
in	O
the	O
present	O
study	O
was	O
small	O
(	O
n	O
=	O
23	O
)	O
and	O
conclusions	O
cannot	O
readily	O
be	O
drawn	O
concerning	O
the	O
haematological	O
responses	O
of	O
this	O
sub	O
-	O
group	O
.	O

By	O
contrast	O
,	O
subjects	O
were	O
generally	O
older	O
,	O
better	O
nourished	O
,	O
multiparous	O
and	O
poorly	O
educated	O
.	O

Two	O
-	O
thirds	O
of	O
untraced	O
women	O
were	O
nulliparous	O
compared	O
with	O
one	O
third	O
of	O
the	O
traced	O
women	O
,	O
characterising	O
a	O
group	O
of	O
younger	O
,	O
more	O
mobile	O
but	O
less	O
reproductively	O
-	O
active	O
women	O
,	O
akin	O
to	O
that	O
in	O
the	O
Bangladeshi	O
study	O
(	O
Hyder	O
et	O
al	O
2007	O
).	O

We	O
have	O
rather	O
shown	O
that	O
older	O
,	O
anaemic	O
multiparae	O
who	O
are	O
experiencing	O
recurrent	O
demands	O
of	O
pregnancy	O
and	O
lactation	O
under	O
seasonally	O
adverse	O
conditions	O
(	O
Anya	O
2004	O
,	O
Billewicz	O
and	O
McGregor	O
1981	O
)	O
clearly	O
benefit	O
from	O
MMN	O
supplementation	O
.	O

The	O
findings	O
of	O
this	O
study	O
provide	O
evidence	O
of	O
the	O
efficacy	O
of	O
MMN	O
supplementation	O
and	O
support	O
its	O
promotion	O
in	O
non	O
-	O
pregnant	O
women	O
as	B
a	O
means	O
of	O
optimising	O
haematological	O
and	O
micronutrient	O
status	O
in	O
between	O
pregnancies	O
,	O
especially	O
in	O
relation	O
to	O
iron	O
status	O
.	O

Community	O
antenatal	O
and	O
paediatric	O
clinics	O
,	O
which	O
often	O
already	O
serve	O
these	O
populations	O
,	O
can	O
readily	O
be	O
used	O
to	O
identify	O
those	O
at	O
particular	O
risk	O
on	O
finger	O
-	O
prick	O
testing	O
and	O
target	O
them	O
for	O
supplementation	O
.	O

There	O
is	O
now	O
a	O
small	O
but	O
growing	O
body	O
of	O
data	O
supporting	O
the	O
efficacy	O
of	O
prenatal	O
multi	O
-	O
micronutrients	O
in	O
improving	O
selected	O
perinatal	O
outcomes	O
of	O
women	O
and	O
babies	O
in	O
resource	O
-	O
poor	O
settings	O
.	O

Studies	O
specifically	O
utilising	O
UNIMMAP	O
benefit	O
from	O
and	O
contribute	O
to	O
datasets	O
based	O
on	O
a	O
uniform	O
and	O
targeted	O
intervention	O
,	O
facilitating	O
the	O
interpretation	O
and	O
reproducibility	O
of	O
their	O
results	O
.	O

Future	O
studies	O
should	O
compare	O
placebo	O
,	O
iron	O
-	O
folate	O
and	O
UNIMMAP	O
supplementation	O
in	O
order	O
to	O
assess	O
the	O
efficacy	O
and	O
effectiveness	O
of	O
pre	O
-	O
or	O
inter	O
-	O
pregnancy	O
supplementation	O
on	O
later	O
maternal	O
anaemia	O
and	O
pregnancy	O
outcome	O
,	O
as	O
well	O
as	O
the	O
impact	O
on	O
broader	O
micronutrient	O
status	O
and	O
other	O
functional	O
outcomes	O
in	O
this	O
vulnerable	O
group	O
.	O

PubMed	O
Central	O
:	O

Glucose	O
intolerance	O
and	O
gestational	O
diabetes	O
risk	O
in	O
relation	O
to	O
sleep	O
duration	O
and	O
snoring	O
during	O
pregnancy	O
:	O
a	O
pilot	O
study	O
Abstract	O
Background	O
Insufficient	O
sleep	O
and	O
poor	O
sleep	O
quality	O
,	O
considered	O
endemic	O
in	O
modern	O
society	O
,	O
are	O
associated	O
with	O
obesity	O
,	O
impaired	O
glucose	O
tolerance	O
and	O
diabetes	O
.	O

Little	O
,	O
however	O
,	O
is	O
known	O
about	O
the	O
consequences	O
of	O
insufficient	O
sleep	O
and	O
poor	O
sleep	O
quality	O
during	O
pregnancy	O
on	O
glucose	O
tolerance	O
and	O
gestational	O
diabetes	O
.	O

Methods	O
A	O
cohort	O
of	O
1	O
,	O
290	O
women	O
was	O
interviewed	O
during	O
early	O
pregnancy	O
.	O

We	O
collected	O
information	O
about	O
sleep	O
duration	O
and	O
snoring	O
during	O
early	O
pregnancy	O
.	O

Results	O
from	O
screening	O
and	O
diagnostic	O
testing	O
for	O
gestational	O
diabetes	O
mellitus	O
(	O
GDM	O
)	O
were	O
abstracted	O
from	O
medical	O
records	O
.	O

Generalized	O
linear	O
models	O
were	O
fitted	O
to	O
derive	O
relative	O
risk	O
(	O
RR	O
)	O
and	O
95	O
%	O
confidence	O
intervals	O
(	O
95	O
%	O
CIs	O
)	O
of	O
GDM	O
associated	O
with	O
sleep	O
duration	O
and	O
snoring	O
,	O
respectively	O
.	O

Results	O
After	O
adjusting	O
for	O
maternal	O
age	O
and	O
race	O
/	O
ethnicity	O
,	O
GDM	O
risk	O
was	O
increased	O
among	O
women	O
sleeping	O
≤	O
4	O
hours	O
compared	O
with	O
those	O
sleeping	O
9	O
hours	O
per	O
night	O
(	O
RR	O
=	O
5	O
.	O
56	O
;	O
95	O
%	O
CI	O
1	O
.	O
31	O
-	O
23	O
.	O
69	O
).	O

The	O
corresponding	O
RR	O
for	O
lean	O
women	O
(<	O
25	O
kg	O
/	O
m2	O
)	O
was	O
3	O
.	O
23	O
(	O
95	O
%	O
CI	O
0	O
.	O
34	O
-	O
30	O
.	O
41	O
)	O
and	O
9	O
.	O
83	O
(	O
95	O
%	O
CI	O
1	O
.	O
12	O
-	O
86	O
.	O
32	O
)	O
for	O
overweight	O
women	O
(≥	O
25	O
kg	O
/	O
m2	O
).	O

Overall	O
,	O
snoring	O
was	O
associated	O
with	O
a	O
1	O
.	O
86	O
-	O
fold	O
increased	O
risk	O
of	O
GDM	O
(	O
RR	O
=	O
1	O
.	O
86	O
;	O
95	O
%	O
CI	O
0	O
.	O
88	O
-	O
3	O
.	O
94	O
).	O

The	O
risk	O
of	O
GDM	O
was	O
particularly	O
elevated	O
among	O
overweight	O
women	O
who	O
snored	O
.	O

Compared	O
with	O
lean	O
women	O
who	O
did	O
not	O
snore	O
,	O
those	O
who	O
were	O
overweight	O
and	O
snored	O
had	O
a	O
6	O
.	O
9	O
-	O
fold	O
increased	O
risk	O
of	O
GDM	O
(	O
95	O
%	O
CI	O
2	O
.	O
87	O
-	O
16	O
.	O
6	O
).	O

Conclusions	O
These	O
preliminary	O
findings	O
suggest	O
associations	O
of	O
short	O
sleep	O
duration	O
and	O
snoring	O
with	O
glucose	O
intolerance	O
and	O
GDM	O
.	O

Though	O
consistent	O
with	O
studies	O
of	O
men	O
and	O
non	O
-	O
pregnant	O
women	O
,	O
larger	O
studies	O
that	O
include	O
objective	O
measures	O
of	O
sleep	O
duration	O
,	O
quality	O
and	O
apnea	O
are	O
needed	O
to	O
obtain	O
more	O
precise	O
estimates	O
of	O
observed	O
associations	O
.	O

Background	O
Insufficient	O
sleep	O
duration	O
and	O
poor	O
sleep	O
quality	O
are	O
considered	O
to	O
be	O
endemic	O
in	O
modern	O
society	O
.	O

Findings	O
from	O
epidemiological	O
and	O
animal	O
experimental	O
studies	O
indicate	O
that	O
chronic	O
partial	O
sleep	O
loss	O
is	O
associated	O
with	O
increased	O
risks	O
of	O
obesity	O
and	O
a	O
myriad	O
of	O
obesity	O
-	O
related	O
disorders	O
including	O
impaired	O
glucose	O
tolerance	O
,	O
hypertension	O
,	O
diabetes	O
,	O
metabolic	O
syndrome	O
,	O
coronary	O
heart	O
disease	O
,	O
stroke	O
and	O
premature	O
mortality	O
[	O
1	O
-	O
8	O
].	O

The	O
impact	O
of	O
short	O
sleep	O
duration	O
on	O
the	O
risk	O
of	O
diabetes	O
has	O
been	O
shown	O
in	O
several	O
epidemiological	O
studies	O
,	O
with	O
significant	O
increases	O
in	O
the	O
incidence	O
of	O
diabetes	O
among	O
individuals	O
who	O
report	O
habitual	O
short	O
sleep	O
duration	O
and	O
those	O
who	O
report	O
having	O
difficulty	O
maintaining	O
sleep	O
[	O
4	O
,	O
9	O
-	O
11	O
].	O

Moreover	O
,	O
accumulating	O
evidence	O
link	O
habitual	O
snoring	O
and	O
sleep	O
apnea	O
,	O
both	O
part	O
of	O
a	O
spectrum	O
of	O
sleep	O
-	O
related	O
breathing	O
disorders	O
,	O
with	O
cardiometabolic	O
abnormalities	O
that	O
include	O
hypertension	O
,	O
dyslipidemia	O
,	O
obesity	O
,	O
hyperglycemia	O
,	O
insulin	O
resistance	O
and	O
type	O
2	O
diabetes	O
[	O
2	O
,	O
7	O
,	O
12	O
-	O
15	O
].	O

Although	O
the	O
exact	O
mechanisms	O
underlying	O
these	O
associations	O
have	O
yet	O
to	O
be	O
fully	O
elucidated	O
,	O
evidence	O
from	O
experimental	O
studies	O
suggest	O
that	O
insufficient	O
sleep	O
and	O
sleep	O
fragmentation	O
result	O
in	O
metabolic	O
and	O
neuroendocrine	O
alterations	O
,	O
particularly	O
alterations	O
in	O
the	O
hypothalamic	O
-	O
pituitary	O
adrenal	O
(	O
HPA	O
)	O
axis	O
,	O
that	O
may	O
contribute	O
to	O
the	O
development	O
of	O
impaired	O
glucose	O
tolerance	O
,	O
insulin	O
resistance	O
and	O
type	O
2	O
diabetes	O
mellitus	O
[	O
16	O
-	O
20	O
].	O

Moreover	O
,	O
experimental	O
studies	O
in	O
humans	O
[	O
21	O
,	O
22	O
]	O
and	O
animals	O
[	O
23	O
,	O
24	O
]	O
have	O
demonstrated	O
that	O
intermittent	O
hypoxia	O
,	O
known	O
to	O
occur	O
in	O
sleep	O
apnea	O
,	O
exerts	O
adverse	O
effects	O
on	O
glucose	O
metabolism	O
.	O

Most	O
sleep	O
studies	O
,	O
however	O
,	O
have	O
excluded	O
pregnant	O
women	O
;	O
hence	B
very	O
little	O
is	O
known	O
about	O
how	O
insufficient	O
sleep	O
and	O
sleep	O
disordered	O
breathing	O
during	O
gestation	O
contribute	O
to	O
increased	O
risks	O
of	O
medical	O
complications	O
of	O
pregnancy	O
including	O
gestational	O
diabetes	O
mellitus	O
(	O
GDM	O
).	O

To	B
the	I
best	I
of	I
our	I
knowledge	I
no	O
one	O
has	O
evaluated	O
the	O
impact	O
of	O
sleep	O
duration	O
and	O
snoring	O
on	O
maternal	O
glucose	O
metabolism	O
in	O
pregnancy	O
.	O

In	O
this	O
pilot	O
study	O
,	O
we	O
assessed	O
associations	O
of	O
maternal	O
self	O
-	O
reported	O
sleep	O
duration	O
and	O
snoring	O
during	O
early	O
pregnancy	O
with	O
glucose	O
intolerance	O
and	O
a	O
diagnosis	O
of	O
GDM	O
later	O
in	O
pregnancy	O
.	O

We	O
analyzed	O
maternal	O
plasma	O
glucose	O
concentrations	O
1	O
hour	O
after	O
a	O
50	O
-	O
gram	O
oral	O
glucose	O
challenge	O
as	O
part	O
of	O
routine	O
mid	O
-	O
pregnancy	O
screening	O
for	O
GDM	O
.	O

We	O
hypothesized	O
that	O
maternal	O
habitual	O
short	O
sleep	O
duration	O
and	O
snoring	O
during	O
early	O
pregnancy	O
were	O
positively	O
associated	O
with	O
post	O
load	O
glucose	O
concentrations	O
later	O
in	O
pregnancy	O
and	O
with	O
an	O
increased	O
risk	O
of	O
clinically	O
diagnosed	O
GDM	O
.	O

Methods	O
Study	O
population	O
and	O
setting	O
This	O
preliminary	O
(	O
pilot	O
)	O
study	O
is	O
based	O
on	O
data	O
collected	O
from	O
a	O
cohort	O
of	O
women	O
attending	O
prenatal	O
care	O
clinics	O
affiliated	O
with	O
Swedish	O
Medical	O
Center	O
in	O
Seattle	O
,	O
Washington	O
.	O

The	O
cohort	O
study	O
was	O
designed	O
to	O
evaluate	O
the	O
influence	O
of	O
maternal	O
diet	O
,	O
physical	O
activity	O
and	O
the	O
other	O
life	O
style	O
factors	O
on	O
the	O
occurrence	O
of	O
preeclampsia	O
,	O
gestational	O
diabetes	O
mellitus	O
and	O
other	O
adverse	O
pregnancy	O
outcomes	O
.	O

Eligible	O
women	O
initiated	O
prenatal	O
care	O
before	O
20	O
weeks	O
gestation	O
,	O
were	O
18	O
years	O
of	O
age	O
or	O
older	O
,	O
could	O
speak	O
and	O
read	O
English	O
,	O
and	O
planned	O
to	O
carry	O
the	O
pregnancy	O
to	O
term	O
and	O
to	O
deliver	O
at	O
either	O
hospital	O
.	O

At	O
14	O
weeks	O
gestation	O
,	O
on	O
average	O
,	O
participants	O
reported	O
sociodemographic	O
,	O
behavioral	O
,	O
and	O
health	O
characteristics	O
in	O
a	O
structured	O
interview	O
.	O

After	O
delivery	O
,	O
study	O
personnel	O
abstracted	O
data	O
from	O
participants	O
'	O
hospital	O
labor	O
and	O
delivery	O
medical	O
records	O
and	O
clinic	O
records	O
.	O

Between	O
December	O
2003	O
and	O
July	O
2006	O
,	O
1	O
,	O
393	O
(	O
82	O
%)	O
of	O
1	O
,	O
685	O
approached	O
women	O
consented	O
to	O
participate	O
.	O

We	O
sequentially	O
excluded	O
12	O
women	O
with	O
early	O
pregnancy	O
losses	O
,	O
52	O
who	O
were	O
lost	O
to	O
follow	O
-	O
up	O
,	O
and	O
23	O
who	O
did	O
not	O
complete	O
the	O
interview	O
.	O

We	O
also	O
excluded	O
16	O
women	O
with	O
pre	O
-	O
gestational	O
diabetes	O
.	O

Thus	O
,	O
1	O
,	O
290	O
women	O
remained	O
for	O
analysis	O
.	O

All	O
study	O
procedures	O
were	O
approved	O
by	O
the	O
Institutional	O
Review	O
Board	O
of	O
Swedish	O
Medical	O
Center	O
.	O

All	O
participants	O
provided	O
written	O
informed	O
consent	O
.	O

Description	O
of	O
covariates	O
At	O
the	O
time	O
of	O
enrollment	O
in	O
the	O
study	O
,	O
a	O
45	O
to	O
60	O
-	O
minute	O
structured	O
questionnaire	O
was	O
administered	O
by	O
a	O
trained	O
interviewer	O
.	O

Information	O
on	O
medical	O
and	O
reproductive	O
histories	O
and	O
sociodemographic	O
and	O
lifestyle	O
characteristics	O
including	O
average	O
number	O
of	O
hours	O
of	O
sleep	O
before	O
and	O
during	O
early	O
pregnancy	O
was	O
collected	O
.	O

Maternal	O
average	O
nightly	O
sleep	O
duration	O
during	O
pregnancy	O
was	O
ascertained	O
by	O
asking	O
women	O
the	O
following	O
question	O
:	O
"	O
Since	O
becoming	O
pregnant	O
,	O
how	O
many	O
hours	O
per	O
night	O
do	O
you	O
sleep	O
?"	O

A	O
similar	O
question	O
was	O
asked	O
for	O
sleep	O
duration	O
before	O
pregnancy	O
.	O

Responses	O
were	O
recorded	O
as	O
integers	O
.	O

For	O
bivariate	O
analyses	O
,	O
we	O
classified	O
participants	O
into	O
4	O
sleep	O
duration	O
categories	O
:	O
≤	O
4	O
,	O
5	O
-	O
8	O
,	O
9	O
,	O
and	O
≥	O
10	O
hours	O
,	O
respectively	O
.	O

The	O
cut	O
-	O
points	O
were	O
based	O
on	O
categorizations	O
used	O
in	O
prior	O
research	O
[	O
4	O
,	O
11	O
].	O

Given	B
that	O
pregnant	O
women	O
,	O
particularly	O
those	O
in	O
the	O
first	O
trimester	O
,	O
are	O
known	O
to	O
require	O
30	O
-	O
45	O
more	O
minutes	O
of	O
sleep	O
per	O
night	O
than	O
their	O
non	O
-	O
pregnant	O
counterparts	O
[	O
25	O
-	O
27	O
],	O
we	O
a	O
priori	O
defined	O
those	O
women	O
who	O
reported	O
sleeping	O
9	O
hours	O
per	O
night	O
as	O
the	O
reference	O
group	O
.	O

Sleep	O
disordered	O
breathing	O
during	O
pregnancy	O
was	O
assessed	O
by	O
asking	O
women	O
about	O
the	O
frequency	O
of	O
snoring	O
during	O
the	O
index	O
pregnancy	O
.	O

Specifically	O
they	O
were	O
asked	O
"	O
Since	O
becoming	O
pregnant	O
,	O
when	O
you	O
are	O
asleep	O
,	O
to	O
the	O
best	O
of	O
your	O
knowledge	O
,	O
have	O
you	O
snored	O
?"	O

Responses	O
were	O
as	O
follows	O
:	O
(	O
i	O
)	O
all	O
of	O
the	O
time	O
,	O
(	O
ii	O
)	O
most	O
of	O
the	O
time	O
,	O
(	O
iii	O
)	O
some	O
of	O
the	O
time	O
,	O
(	O
iv	O
)	O
a	O
little	O
of	O
the	O
time	O
,	O
and	O
(	O
v	O
)	O
none	O
of	O
the	O
time	O
.	O

From	O
this	O
information	O
,	O
we	O
categorized	O
participants	O
as	O
snoring	O
if	O
their	O
reported	O
snoring	O
most	O
or	O
all	O
of	O
the	O
time	O
;	O
all	O
other	O
women	O
were	O
classified	O
as	O
non	O
-	O
snorers	O
.	O

Pre	O
-	O
pregnancy	O
weight	O
and	O
height	O
were	O
also	O
based	O
on	O
self	O
-	O
reports	O
made	O
during	O
the	O
interview	O
.	O

Pre	O
-	O
pregnancy	O
body	O
mass	O
index	O
(	O
BMI	O
)	O
was	O
calculated	O
as	O
weight	O
in	O
kilograms	O
divided	O
by	O
height	O
in	O
meters	O
squared	O
.	O

In	O
our	O
study	O
setting	O
,	O
according	O
to	O
the	O
recommendations	O
from	O
the	O
American	O
Diabetes	O
Association	O
(	O
ADA	O
)	O
[	O
25	O
],	O
all	O
pregnant	O
women	O
were	O
screened	O
at	O
24	O
-	O
28	O
weeks	O
gestation	O
using	O
a	O
50	O
gram	O
1	O
-	O
hour	O
oral	O
glucose	O
challenge	O
test	O
.	O

Those	O
patients	O
who	O
failed	O
this	O
screening	O
test	O
(	O
glucose	O
≥	O
140	O
mg	O
/	O
dl	O
)	O
were	O
then	O
followed	O
-	O
up	O
within	O
1	O
-	O
2	O
weeks	O
with	O
a	O
100	O
gram	O
,	O
3	O
-	O
hour	O
oral	O
glucose	O
tolerance	O
test	O
(	O
OGTT	O
).	O

We	O
abstracted	O
laboratory	O
results	O
from	O
participants	O
'	O
50	O
gram	O
1	O
-	O
hour	O
glucose	O
challenge	O
test	O
and	O
from	O
the	O
diagnostic	O
100	O
gram	O
3	O
-	O
hour	O
OGTT	O
.	O

Women	O
were	O
diagnosed	O
with	O
GDM	O
if	O
two	O
or	O
more	O
of	O
the	O
100	O
gram	O
OGTT	O
glucose	O
levels	O
exceeded	O
the	O
ADA	O
criteria	O
[	O
28	O
]	O
as	O
follows	O
:	O
fasting	O
≥	O
95	O
mg	O
/	O
dl	O
;	O
1	O
-	O
hour	O
≥	O
180	O
mg	O
/	O
dl	O
;	O
2	O
-	O
hour	O
≥	O
155	O
mg	O
/	O
dl	O
;	O
3	O
-	O
hour	O
≥	O
140	O
mg	O
/	O
dl	O
.	O

Statistical	O
analytical	O
methods	O
We	O
compared	O
the	O
frequency	O
distribution	O
of	O
sociodemographic	O
,	O
lifestyle	O
,	O
behavioral	O
and	O
medical	O
history	O
characteristics	O
of	O
participants	O
according	O
to	O
GDM	O
diagnosis	O
status	O
.	O

We	O
assessed	O
glucose	O
intolerance	O
by	O
analyzing	O
results	O
of	O
the	O
1	O
-	O
hour	O
oral	O
glucose	O
screening	O
test	O
results	O
.	O

Linear	O
regression	O
procedures	O
were	O
used	O
to	O
estimate	O
maternal	O
mean	O
1	O
-	O
hour	O
glucose	O
concentrations	O
while	O
adjusting	O
for	O
confounding	O
by	O
maternal	O
age	O
and	O
race	O
/	O
ethnicity	O
.	O

We	O
fitted	O
generalized	O
linear	O
models	O
,	O
using	O
a	O
log	O
-	O
link	O
function	O
,	O
to	O
derive	O
relative	O
risk	O
(	O
RR	O
)	O
and	O
95	O
%	O
confidence	O
intervals	O
(	O
95	O
%	O
CIs	O
)	O
[	O
29	O
,	O
30	O
]	O
of	O
the	O
associations	O
between	O
sleep	O
duration	O
and	O
snoring	O
variables	O
with	O
glucose	O
intolerance	O
and	O
GDM	O
risk	O
.	O

Separate	O
models	O
were	O
fitted	O
for	O
sleep	O
duration	O
and	O
snoring	O
.	O

We	O
evaluated	O
confounding	O
due	O
to	O
several	O
maternal	O
characteristics	O
.	O

We	O
selected	O
potential	O
confounders	O
from	O
a	O
list	O
of	O
variables	O
that	O
were	O
associated	O
with	O
sleep	O
duration	O
and	O
snoring	O
(	O
from	O
prior	O
studies	O
conducted	O
among	O
men	O
and	O
non	O
-	O
pregnant	O
women	O
)	O
and	O
that	O
met	O
criteria	O
for	O
confounding	O
based	O
on	O
a	O
review	O
of	O
the	O
literature	O
and	O
assessment	O
of	O
potential	O
causal	O
relationships	O
based	O
on	O
prior	O
knowledge	O
.	O

We	O
then	O
controlled	O
for	O
potential	O
confounders	O
that	O
changed	O
multivariable	O
RRs	O
by	O
more	O
than	O
10	O
%	O
relative	O
to	O
the	O
unadjusted	O
RR	O
[	O
31	O
].	O

On	O
the	O
basis	O
of	O
these	O
criteria	O
,	O
we	O
controlled	O
for	O
maternal	O
age	O
and	O
race	O
/	O
ethnicity	O
.	O

None	O
of	O
the	O
other	O
variables	O
listed	O
in	O
Table1were	O
found	O
to	O
be	O
confounders	O
.	O

Gestational	O
age	O
at	O
enrollment	O
or	O
interview	O
was	O
not	O
a	O
confounder	O
in	O
this	O
study	O
.	O

Given	B
that	O
this	O
is	O
the	O
first	O
study	O
to	O
be	O
conducted	O
among	O
pregnant	O
women	O
,	O
and	O
that	O
pre	O
-	O
pregnancy	O
BMI	O
may	O
reasonably	B
be	O
considered	O
a	O
confounder	O
or	O
a	O
covariate	O
along	O
the	O
causal	O
pathway	O
between	O
maternal	O
habitual	O
sleep	O
behaviors	O
and	O
GDM	O
,	O
we	O
were	O
careful	O
to	O
assess	O
the	O
potential	O
independent	O
contributions	O
of	O
the	O
sleep	O
variables	O
(	O
from	O
pre	O
-	O
pregnancy	O
BMI	O
).	O

The	O
distinction	O
is	O
important	O
because	O
adjustment	O
for	O
covariates	O
along	O
the	O
causal	O
pathway	O
may	O
spuriously	O
attenuate	O
estimates	O
of	O
association	O
.	O

Therefore	O
,	O
we	O
constructed	O
additional	O
models	O
that	O
simultaneously	O
adjusted	O
for	O
pre	O
-	O
pregnancy	O
BMI	O
.	O

We	O
also	O
reported	O
results	O
after	O
stratification	O
so	O
that	O
we	O
(	O
and	O
readers	O
)	O
could	O
assess	O
associations	O
(	O
even	O
with	O
a	O
fair	O
amount	O
of	O
statistical	O
imprecision	O
)	O
without	O
an	O
over	O
-	O
reliance	O
on	O
model	O
-	O
based	O
assumptions	O
.	O

In	O
keeping	O
with	O
prior	O
studies	O
that	O
sought	O
to	O
assess	O
the	O
extent	O
to	O
which	O
adiposity	O
modified	O
associations	O
between	O
sleep	O
disorders	O
and	O
abnormal	O
carbohydrate	O
metabolism	O
[	O
1	O
,	O
2	O
,	O
4	O
,	O
5	O
,	O
18	O
],	O
we	O
also	O
evaluated	O
the	O
joint	O
effect	O
of	O
pre	O
-	O
pregnancy	O
overweight	O
status	O
and	O
snoring	O
on	O
GDM	O
risk	O
.	O

For	O
these	O
analyses	O
,	O
we	O
classified	O
women	O
by	O
the	O
joint	O
distribution	O
of	O
pre	O
-	O
pregnancy	O
lean	O
or	O
overweight	O
status	O
(<	O
25	O
vs	O
.	O
≥	O
25	O
kg	O
/	O
m2	O
)	O
and	O
snoring	O
during	O
early	O
pregnancy	O
(	O
no	O
vs	O
.	O
yes	O
)	O
thus	O
resulting	O
in	O
the	O
following	O
categories	O
:	O
lean	O
and	O
non	O
-	O
snorer	O
(	O
the	O
reference	O
group	O
);	O
lean	O
and	O
snorer	O
;	O
overweight	O
and	O
non	O
-	O
snorer	O
;	O
and	O
overweight	O
and	O
snorer	O
.	O

All	O
analyses	O
were	O
performed	O
using	O
Stata	O
9	O
.	O
0	O
statistical	O
software	O
(	O
Stata	O
,	O
College	O
Station	O
,	O
TX	O
).	O

All	O
reported	O
p	O
-	O
values	O
are	O
two	O
-	O
tailed	O
.	O

Caption	O
(	O
TABLE	O
-	O
WRAP	O
):	O
TABLE	O
1	O
Sociodemographic	O
and	O
other	O
characteristics	O
of	O
the	O
study	O
subjects	O
,	O
Seattle	O
,	O
Washington	O
,	O
USA	O
2003	O
-	O
2006Gestational	O
Diabetes	O
MellitusEntire	O
Study	O
CohortN	O
=	O
1290NoN	O
=	O
1222YesN	O
=	O
68Characteristicsn	O
(%)	O
n	O
(%)	O
n	O
(%)	O
Maternal	O
age	O
at	O
Interview	O
(	O
years	O
)*	O
33	O
.	O
3	O
±	O
4	O
.	O
433	O
.	O
2	O
±	O
4	O
.	O
335	O
.	O
2	O
±	O
5	O
.	O
0	O
<	O
35	O
years772	O
(	O
59	O
.	O
8	O
)	O
746	O
(	O
61	O
.	O
0	O
)	O
26	O
(	O
38	O
.	O
2	O
)	O
≥	O
35	O
years518	O
(	O
40	O
.	O
2	O
)	O
476	O
(	O
39	O
.	O
0	O
)	O
42	O
(	O
61	O
.	O
8	O
)	O
Maternal	O
race	O
/	O
ethnicity	O
*	O
Non	O
-	O
Hispanic	O
White1133	O
(	O
87	O
.	O
8	O
)	O
1080	O
(	O
88	O
.	O
4	O
)	O
53	O
(	O
77	O
.	O
9	O
)	O
Other157	O
(	O
12	O
.	O
2	O
)	O
141	O
(	O
11	O
.	O
5	O
)	O
15	O
(	O
22	O
.	O
1	O
)	O
Medical	O
bill	O
payment	O
status	O
Insurance1239	O
(	O
96	O
.	O
1	O
)	O
1173	O
(	O
96	O
.	O
0	O
)	O
66	O
(	O
97	O
.	O
1	O
)	O
Medicaid26	O
(	O
2	O
.	O
0	O
)	O
24	O
(	O
2	O
.	O
0	O
)	O
2	O
(	O
2	O
.	O
9	O
)	O
unknown25	O
(	O
1	O
.	O
9	O
)	O
25	O
(	O
2	O
.	O
0	O
)	O
0	O
(	O
0	O
)	O
Nulliparous768	O
(	O
59	O
.	O
5	O
)	O
727	O
(	O
59	O
.	O
5	O
)	O
41	O
(	O
60	O
.	O
3	O
)≤	O
High	O
school	O
education37	O
(	O
2	O
.	O
9	O
)	O
33	O
(	O
2	O
.	O
7	O
)	O
4	O
(	O
5	O
.	O
9	O
)	O
Unmarried106	O
(	O
8	O
.	O
2	O
)	O
98	O
(	O
8	O
.	O
0	O
)	O
8	O
(	O
11	O
.	O
8	O
)	O
Smoked	O
during	O
pregnancy67	O
(	O
5	O
.	O
2	O
)	O
65	O
(	O
5	O
.	O
3	O
)	O
2	O
(	O
2	O
.	O
9	O
)	O
No	O
prenatal	O
vitamins32	O
(	O
2	O
.	O
5	O
)	O
30	O
(	O
2	O
.	O
5	O
)	O
2	O
(	O
2	O
.	O
9	O
)	O
Pre	O
-	O
pregnancy	O
body	O
mass	O
index	O
(	O
kg	O
/	O
m2	O
)*	O
23	O
.	O
5	O
±	O
4	O
.	O
523	O
.	O
3	O
±	O
4	O
.	O
426	O
.	O
6	O
±	O
6	O
.	O
3	O
Lean	O
(<	O
18	O
.	O
5	O
)	O
58	O
(	O
4	O
.	O
5	O
)	O
57	O
(	O
4	O
.	O
7	O
)	O
1	O
(	O
1	O
.	O
5	O
)	O
Normal	O
(	O
18	O
.	O
5	O
-	O
24	O
.	O
9	O
)	O
908	O
(	O
70	O
.	O
4	O
)	O
876	O
(	O
71	O
.	O
7	O
)	O
32	O
(	O
47	O
.	O
1	O
)	O
Overweight	O
(	O
25	O
-	O
29	O
.	O
9	O
)	O
229	O
(	O
17	O
.	O
7	O
)	O
208	O
(	O
17	O
.	O
0	O
)	O
21	O
(	O
30	O
.	O
9	O
)	O
Obese	O
(≥	O
30	O
)	O
95	O
(	O
7	O
.	O
4	O
)	O
81	O
(	O
6	O
.	O
6	O
)	O
14	O
(	O
20	O
.	O
4	O
)	O
Mean	O
±	O
standard	O
deviation	O
(	O
SD	O
).	O

*	O
P	O
-	O
value	O
<	O
0	O
.	O
05	O
from	O
Student	O
t	O
test	O
for	O
continuous	O
variable	O
or	O
from	O
Chi	O
-	O
Square	O
test	O
for	O
categorical	O
variables	O
.	O

Results	O
Approximately	O
5	O
.	O
3	O
%	O
of	O
the	O
study	O
cohort	O
developed	O
gestational	O
diabetes	O
mellitus	O
(	O
68	O
of	O
1	O
,	O
290	O
).	O

The	O
socio	O
-	O
demographic	O
characteristics	O
of	O
the	O
study	O
cohort	O
(	O
overall	O
and	O
by	O
GDM	O
status	O
),	O
are	O
presented	O
in	O
Table1	O
.	O

Overall	O
,	O
participants	O
included	O
in	O
this	O
analysis	O
tended	O
to	O
be	O
Caucasian	O
,	O
well	O
-	O
educated	O
,	O
and	O
married	O
.	O

GDM	O
cases	O
were	O
older	O
,	O
and	O
heavier	O
than	O
women	O
who	O
did	O
not	O
develop	O
the	O
disorder	O
.	O

Cases	O
were	O
less	O
likely	B
to	O
be	O
of	O
non	O
-	O
Hispanic	O
White	O
race	O
/	O
ethnicity	O
than	O
non	O
-	O
cases	O
.	O

A	O
curvilinear	O
relation	O
was	O
seen	O
across	O
levels	O
of	O
maternal	O
habitual	O
nightly	O
sleep	O
duration	O
in	O
early	O
pregnancy	O
for	O
maternal	O
mean	O
-	O
1	O
hour	O
plasma	O
glucose	O
concentration	O
after	O
a	O
50	O
-	O
gram	O
oral	O
glucose	O
challenge	O
during	O
weeks	O
24	O
-	O
28	O
gestation	O
(	O
Figure1	O
).	O

Maternal	O
mean	O
1	O
-	O
hour	O
plasma	O
glucose	O
concentrations	O
,	O
adjusted	O
for	O
age	O
and	O
race	O
/	O
ethnicity	O
,	O
were	O
highest	O
for	O
women	O
who	O
reported	O
habitual	O
sleep	O
duration	O
≤	O
4	O
hours	O
per	O
night	O
during	O
early	O
pregnancy	O
and	O
lowest	O
for	O
those	O
who	O
reported	O
sleeping	O
9	O
hours	O
per	O
night	O
on	O
average	O
.	O

Mean	O
glucose	O
concentrations	O
1	O
-	O
hour	O
after	O
a	O
50	O
-	O
gram	O
oral	O
glucose	O
challenge	O
were	O
16	O
.	O
3	O
mg	O
/	O
dl	O
higher	O
in	O
women	O
who	O
reported	O
sleeping	O
≤	O
4	O
hours	O
(	O
95	O
%	O
CI	O
1	O
.	O
1	O
-	O
31	O
.	O
6	O
,	O
p	O
=	O
0	O
.	O
04	O
),	O
2	O
.	O
3	O
mg	O
/	O
dl	O
higher	O
for	O
women	O
who	O
reported	O
sleeping	O
5	O
-	O
8	O
hours	O
(	O
95	O
%	O
CI	O
-	O
1	O
.	O
8	O
-	O
6	O
.	O
3	O
,	O
p	O
=	O
0	O
.	O
27	O
),	O
and	O
6	O
.	O
3	O
mg	O
/	O
dl	O
higher	O
for	O
women	O
who	O
reported	O
sleeping	O
≥	O
10	O
hours	O
(	O
95	O
%	O
CI	O
-	O
0	O
.	O
5	O
-	O
13	O
.	O
2	O
,	O
p	O
=	O
0	O
.	O
07	O
)	O
compared	O
with	O
those	O
who	O
reported	O
sleeping	O
9	O
hours	O
per	O
night	O
.	O

The	O
curvilinear	O
relationship	O
remained	O
evident	B
after	O
participants	O
were	O
stratified	O
on	O
the	O
basis	O
of	O
lean	O
(<	O
25	O
kg	O
/	O
m2	O
)	O
and	O
overweight	O
(≥	O
25	O
kg	O
/	O
m2	O
)	O
pre	O
-	O
pregnancy	O
status	O
(	O
Figure2a	O
).	O

As	O
can	O
be	O
seen	O
in	O
Figure2b	O
,	O
the	O
frequency	O
distribution	O
of	O
women	O
with	O
post	O
-	O
50	O
gram	O
1	O
-	O
hour	O
glucose	O
concentration	O
≥	O
140	O
mg	O
/	O
dl	O
(	O
i	O
.	O
e	O
.,	O
the	O
threshold	O
for	O
screen	O
positive	O
for	O
glucose	O
intolerance	O
)	O
also	O
had	O
a	O
curvilinear	O
pattern	O
.	O

Regardless	O
of	O
maternal	O
pre	O
-	O
pregnancy	O
overweight	O
status	O
,	O
both	O
short	O
and	O
long	O
sleep	O
durations	O
were	O
associated	O
with	O
higher	O
frequencies	O
of	O
elevated	O
plasma	O
glucose	O
concentrations	O
(	O
Figure2b	O
).	O

Compared	O
with	O
women	O
who	O
did	O
not	O
snore	O
during	O
pregnancy	O
,	O
the	O
adjusted	O
mean	O
1	O
-	O
hour	O
glucose	O
concentrations	O
were	O
noted	O
to	O
be	O
6	O
.	O
4	O
mg	O
/	O
dl	O
higher	O
among	O
those	O
women	O
who	O
snored	O
during	O
pregnancy	O
(	O
β	O
=	O
6	O
.	O
4	O
mg	O
/	O
dl	O
,	O
95	O
%	O
CI	O
0	O
.	O
32	O
-	O
12	O
.	O
5	O
,	O
p	O
=	O
0	O
.	O
04	O
).	O

Caption	O
(	O
FIG	O
):	O
FIGURE	O
1	O
Maternal	O
mean	O
plasma	O
glucose	O
concentrations	O
after	O
a	O
50	O
-	O
g	O
glucose	O
challenge	O
.	O

Means	O
are	O
adjusted	O
for	O
maternal	O
age	O
and	O
race	O
/	O
ethnicity	O
.	O

Error	O
bars	O
are	O
standard	O
errors	O
.	O

Caption	O
(	O
FIG	O
):	O
FIGURE	O
2	O
Maternal	O
mean	O
1	O
-	O
hour	O
plasma	O
glucose	O
concentrations	O
after	O
a	O
50	O
-	O
g	O
oral	O
glucose	O
challenge	O
.	O

(	O
a	O
).	O

Proportion	O
(%)	O
of	O
women	O
with	O
1	O
-	O
hour	O
glucose	O
concentrations	O
≥	O
140	O
mg	O
/	O
dl	O
(	O
b	O
).	O

Values	O
are	O
plotted	O
for	O
the	O
entire	O
cohort	O
(	O
black	O
),	O
lean	O
(	O
body	O
mass	O
index	O
<	O
25	O
kg	O
/	O
m2	O
,	O
blue	O
)	O
and	O
overweight	O
(	O
body	O
mass	O
index	O
≥	O
25	O
kg	O
/	O
m2	O
,	O
red	O
)	O
women	O
,	O
respectively	O
.	O

After	O
adjusting	O
for	O
maternal	O
age	O
and	O
race	O
/	O
ethnicity	O
,	O
women	O
who	O
reported	O
sleeping	O
≤	O
4	O
hours	O
per	O
night	O
during	O
early	O
pregnancy	O
had	O
a	O
5	O
.	O
56	O
-	O
fold	O
increased	O
risk	O
of	O
GDM	O
as	O
compared	O
with	O
those	O
women	O
who	O
reported	O
sleeping	O
9	O
hours	O
per	O
night	O
(	O
the	O
reference	O
group	O
)	O
(	O
RR	O
=	O
5	O
.	O
56	O
;	O
95	O
%	O
CI	O
1	O
.	O
31	O
-	O
23	O
.	O
69	O
).	O

The	O
positive	O
association	O
remained	O
,	O
though	O
was	O
attenuated	O
somewhat	O
,	O
after	O
further	O
adjustment	O
for	O
maternal	O
pre	O
-	O
pregnancy	O
BMI	O
(	O
RR	O
=	O
4	O
.	O
18	O
;	O
95	O
%	O
CI	O
0	O
.	O
94	O
-	O
18	O
.	O
60	O
).	O

We	O
also	O
noted	O
that	O
associations	O
between	O
short	O
sleep	O
duration	O
and	O
GDM	O
risk	O
were	O
particularly	O
pronounced	O
among	O
overweight	O
women	O
(	O
far	O
right	O
column	O
of	O
Table2	O
).	O

Given	B
the	O
suggestion	O
of	O
a	O
U	O
-	O
shaped	O
relation	O
between	O
sleep	O
duration	O
and	O
GDM	O
risk	O
(	O
with	O
elevated	O
risks	O
for	O
both	O
short	O
and	O
long	O
sleep	O
duration	O
),	O
and	O
given	B
suggestion	O
of	O
a	O
linear	O
trend	O
in	O
risk	O
of	O
GDM	O
for	O
sleep	O
duration	O
ranging	O
from	O
≤	O
4	O
to	O
5	O
-	O
8	O
hours	O
,	O
we	O
modeled	O
the	O
risk	O
of	O
GDM	O
in	O
relation	O
to	O
maternal	O
sleep	O
duration	O
as	O
a	O
continuous	O
variable	O
,	O
restricting	O
the	O
study	O
population	O
to	O
women	O
who	O
reported	O
sleeping	O
<	O
10	O
hours	O
.	O

In	O
this	O
subgroup	O
analysis	O
,	O
after	O
adjusting	O
for	O
maternal	O
age	O
and	O
race	O
/	O
ethnicity	O
,	O
a	O
1	O
-	O
hour	O
increase	O
in	O
nightly	O
sleep	O
was	O
associated	O
with	O
a	O
15	O
%	O
reduction	O
in	O
GDM	O
risk	O
(	O
RR	O
=	O
0	O
.	O
85	O
;	O
95	O
%	O
CI	O
0	O
.	O
69	O
-	O
1	O
.	O
05	O
);	O
though	O
this	O
association	O
was	O
not	O
statistically	O
significant	O
.	O

When	O
analyses	O
were	O
restricted	O
to	O
overweight	O
women	O
,	O
we	O
noted	O
that	O
the	O
GDM	O
risk	O
was	O
reduced	O
by	O
24	O
%	O
for	O
each	O
sleep	O
hour	O
increment	O
(	O
RR	O
=	O
0	O
.	O
76	O
;	O
95	O
%	O
CI	O
0	O
.	O
57	O
-	O
1	O
.	O
00	O
adjusted	O
for	O
maternal	O
age	O
and	O
race	O
/	O
ethnicity	O
),	O
but	O
again	O
the	O
association	O
was	O
not	O
statistically	O
significant	O
.	O

Reported	O
sleep	O
duration	O
before	O
pregnancy	O
was	O
highly	O
correlated	O
with	O
sleep	O
duration	O
during	O
pregnancy	O
(	O
ρ	O
=	O
0	O
.	O
92	O
,	O
p	O
<	O
0	O
.	O
002	O
).	O

Results	O
were	O
similar	O
when	O
analyses	O
were	O
repeated	O
using	O
maternal	O
nightly	O
sleep	O
duration	O
prior	O
to	O
pregnancy	O
(	O
data	O
not	O
shown	O
).	O

Caption	O
(	O
TABLE	O
-	O
WRAP	O
):	O
TABLE	O
2	O
Adjusted	O
risk	O
ratio	O
(	O
RR	O
)	O
and	O
95	O
%	O
confidence	O
intervals	O
(	O
CI	O
)	O
of	O
gestational	O
diabetes	O
mellitus	O
(	O
GDM	O
)	O
according	O
to	O
self	O
-	O
reported	O
sleep	O
duration	O
and	O
snoring	O
during	O
early	O
pregnancy	O
.	O
Gestational	O
Diabetes	O
Mellitus	O
*	O
All	O
*	O
Lean	O
*	O
Overweight	O
No	O
N	O
=	O
1222	O
(	O
n	O
)	O
Yes	O
N	O
=	O
68	O
(	O
n	O
)	O
1Adjusted	O
RR	O
(	O
95	O
%	O
CI	O
)	O
1Adjusted	O
RR	O
(	O
95	O
%	O
CI	O
)	O
1Adjusted	O
RR	O
(	O
95	O
%	O
CI	O
)	O
Sleep	O
duration	O
during	O
pregnancy	O
≤	O
4	O
hours1835	O
.	O
56	O
(	O
1	O
.	O
31	O
-	O
23	O
.	O
69	O
)	O
3	O
.	O
23	O
(	O
0	O
.	O
34	O
-	O
30	O
.	O
41	O
)	O
9	O
.	O
83	O
(	O
1	O
.	O
12	O
-	O
86	O
.	O
32	O
)	O
5	O
-	O
8	O
hours818521	O
.	O
99	O
(	O
0	O
.	O
89	O
-	O
4	O
.	O
47	O
)	O
1	O
.	O
28	O
(	O
0	O
.	O
47	O
-	O
3	O
.	O
43	O
)	O
3	O
.	O
47	O
(	O
0	O
.	O
79	O
-	O
15	O
.	O
22	O
)	O
9	O
hours25071	O
.	O
00	O
--	O
Reference	O
1	O
.	O
00	O
--	O
Reference1	O
.	O
00	O
--	O
Reference	O
≥	O
10	O
hours12961	O
.	O
82	O
(	O
0	O
.	O
60	O
-	O
5	O
.	O
57	O
)	O
1	O
.	O
39	O
(	O
0	O
.	O
32	O
-	O
5	O
.	O
98	O
)	O
2	O
.	O
56	O
(	O
0	O
.	O
40	O
-	O
16	O
.	O
43	O
)	O
Missing70Snore	O
during	O
pregnancy	O
No1112571	O
.	O
00	O
--	O
Reference	O
1	O
.	O
00	O
--	O
Reference1	O
.	O
00	O
--	O
Reference	O
Yes8091	O
.	O
86	O
(	O
0	O
.	O
88	O
-	O
3	O
.	O
94	O
)	O
Insufficient	O
data2	O
.	O
54	O
(	O
0	O
.	O
95	O
-	O
5	O
.	O
73	O
)	O
Missing302	O
*	O
All	O
refers	O
to	O
analysis	O
completed	O
on	O
the	O
entire	O
cohort	O
,	O
and	O
after	O
restriction	O
to	O
lean	O
(<	O
25	O
kg	O
/	O
m2	O
)	O
and	O
overweight	O
(≥	O
25	O
kg	O
/	O
m2	O
)	O
women	O
,	O
respectively	O
.	O

1RRs	O
and	O
95	O
%	O
CIs	O
are	O
adjusted	O
for	O
maternal	O
age	O
and	O
race	O
/	O
ethnicity	O
.	O

As	O
can	O
be	O
seen	O
from	O
the	O
bottom	O
panel	O
of	O
Table2	O
,	O
maternal	O
snoring	O
was	O
associated	O
with	O
a	O
statistically	O
non	O
-	O
significant	O
1	O
.	O
86	O
-	O
fold	O
increased	O
risk	O
of	O
GDM	O
(	O
RR	O
=	O
1	O
.	O
86	O
;	O
95	O
%	O
CI	O
0	O
.	O
88	O
-	O
3	O
.	O
94	O
).	O

An	O
elevated	O
risk	O
remained	O
after	O
adjustment	O
for	O
pre	O
-	O
pregnancy	O
BMI	O
(	O
RR	O
=	O
1	O
.	O
54	O
;	O
95	O
%	O
CI	O
0	O
.	O
71	O
-	O
3	O
.	O
35	O
).	O

The	O
risk	O
of	O
GDM	O
was	O
particularly	O
elevated	O
among	O
overweight	O
women	O
who	O
also	O
reported	O
snoring	O
during	O
pregnancy	O
.	O

Compared	O
with	O
lean	O
women	O
non	O
-	O
snorers	O
,	O
those	O
women	O
who	O
were	O
both	O
overweight	O
and	O
who	O
snored	O
had	O
a	O
statistically	O
significant	O
6	O
.	O
91	O
-	O
fold	O
increased	O
risk	O
of	O
GDM	O
(	O
RR	O
=	O
6	O
.	O
91	O
;	O
95	O
%	O
CI	O
2	O
.	O
87	O
-	O
16	O
.	O
6	O
)	O
(	O
Table3	O
).	O

Caption	O
(	O
TABLE	O
-	O
WRAP	O
):	O
TABLE	O
3	O
Adjusted	O
risk	O
ratio	O
(	O
RR	O
)	O
and	O
95	O
%	O
confidence	O
intervals	O
(	O
CI	O
)	O
of	O
gestational	O
diabetes	O
mellitus	O
(	O
GDM	O
)	O
according	O
to	O
self	O
-	O
reporting	O
snoring	O
during	O
early	O
and	O
pre	O
-	O
pregnancy	O
overweight	O
status	O
.	O
Gestational	O
Diabetes	O
MellitusNoN	O
=	O
1222	O
(	O
n	O
)	O
YesN	O
=	O
68	O
(	O
n	O
)	O
Unadjusted	O
RR	O
(	O
95	O
%	O
CI	O
)	O
1Adjusted	O
RR	O
(	O
95	O
%	O
CI	O
)	O
Overweight	O
&	O
Snore	O
StatusLean	O
&	O
Non	O
-	O
Snorer862311	O
.	O
00	O
--	O
Reference1	O
.	O
00	O
--	O
ReferenceLean	O
&	O
Snorer5110	O
.	O
55	O
(	O
0	O
.	O
07	O
-	O
4	O
.	O
07	O
)*	O
0	O
.	O
43	O
(	O
0	O
.	O
06	O
-	O
3	O
.	O
28	O
)*	O
Overweight	O
&	O
Non	O
-	O
Snorer250262	O
.	O
89	O
(	O
1	O
.	O
69	O
-	O
4	O
.	O
96	O
)	O
2	O
.	O
85	O
(	O
1	O
.	O
65	O
-	O
4	O
.	O
92	O
)	O
Overweight	O
&	O
Snorer2987	O
.	O
67	O
(	O
3	O
.	O
24	O
-	O
18	O
.	O
1	O
)	O
6	O
.	O
91	O
(	O
2	O
.	O
87	O
-	O
16	O
.	O
6	O
)	O
Missing302P	O
-	O
value	O
for	O
interaction0	O
.	O
160	O
.	O
13	O
1RRs	O
and	O
95	O
%	O
CIs	O
are	O
adjusted	O
for	O
maternal	O
age	O
and	O
race	O
/	O
ethnicity	O
*	O
The	O
data	O
are	O
insufficient	O
to	O
adequately	O
interpret	O
relative	O
risk	O
estimates	O
for	O
lean	O
snorers	O
Discussion	O
Using	O
sleep	O
duration	O
and	O
snoring	O
information	O
,	O
provided	O
in	O
early	O
pregnancy	O
,	O
we	O
were	O
able	O
to	O
detect	O
associations	O
between	O
sleep	O
characteristics	O
and	O
maternal	O
plasma	O
1	O
-	O
hour	O
glucose	O
concentrations	O
after	O
a	O
50	O
-	O
gram	O
oral	O
glucose	O
challenge	O
screening	O
test	O
later	O
in	O
pregnancy	O
.	O

Curvilinear	O
relations	O
were	O
observed	O
across	O
nocturnal	O
sleep	O
duration	O
categories	O
.	O

Additionally	O
,	O
glucose	O
concentrations	O
were	O
statistically	O
significantly	O
elevated	O
among	O
women	O
who	O
snored	O
during	O
pregnancy	O
;	O
and	O
the	O
relative	O
risk	O
of	O
GDM	O
among	O
overweight	O
women	O
who	O
snored	O
,	O
compared	O
to	O
their	O
non	O
-	O
snoring	O
and	O
lean	O
counterparts	O
was	O
6	O
.	O
91	O
(	O
95	O
%	O
CI	O
2	O
.	O
87	O
-	O
16	O
.	O
6	O
).	O

Collectively	O
,	O
the	O
findings	O
from	O
this	O
pilot	O
study	O
provides	O
evidence	O
consistent	O
with	O
the	O
notion	O
that	O
glucose	O
homeostasis	O
in	O
pregnancy	O
is	O
sensitive	O
to	O
maternal	O
habitual	O
short	O
sleep	O
duration	O
and	O
snoring	O
during	O
pregnancy	O
.	O

To	B
our	I
knowledge	I
,	O
this	O
is	O
the	O
first	O
examination	O
of	O
the	O
relation	O
between	O
plasma	O
glucose	O
concentrations	O
,	O
GDM	O
risk	O
and	O
sleep	O
parameters	O
(	O
i	O
.	O
e	O
.,	O
snoring	O
and	O
habitual	O
sleep	O
duration	O
)	O
during	O
pregnancy	O
.	O

A	O
large	O
literature	O
primarily	O
focused	O
on	O
men	O
and	O
non	O
-	O
pregnant	O
women	O
suggest	O
that	O
sleep	O
loss	O
adversely	O
affects	O
glucose	O
metabolism	O
and	O
increases	O
the	O
risk	O
of	O
type	O
2	O
diabetes	O
[	O
4	O
,	O
11	O
,	O
16	O
,	O
32	O
-	O
35	O
].	O

In	O
their	O
cross	O
sectional	O
study	O
of	O
740	O
Canadians	O
(	O
323	O
men	O
and	O
417	O
women	O
),	O
Chaput	O
et	O
al	O
noted	O
that	O
short	O
sleep	O
duration	O
(<	O
7	O
hours	O
)	O
was	O
associated	O
with	O
prevalent	O
type	O
2	O
diabetes	O
(	O
OR	O
=	O
1	O
.	O
58	O
;	O
95	O
%	O
CI	O
1	O
.	O
13	O
-	O
2	O
.	O
31	O
)	O
[	O
33	O
].	O

Ayas	O
et	O
al	O
,	O
in	O
their	O
study	O
of	O
70	O
,	O
026	O
US	O
nurses	O
,	O
followed	O
for	O
10	O
years	O
,	O
reported	O
that	O
individuals	O
who	O
slept	O
≤	O
5	O
hours	O
per	O
night	O
had	O
a	O
significantly	O
higher	O
risk	O
of	O
symptomatic	O
incident	O
diabetes	O
(	O
OR	O
=	O
1	O
.	O
34	O
;	O
95	O
%	O
CI	O
1	O
.	O
04	O
-	O
1	O
.	O
72	O
)	O
[	O
4	O
].	O

Analysis	O
of	O
data	O
from	O
the	O
Massachusetts	O
Male	O
Aging	O
Study	O
revealed	O
that	O
short	O
sleep	O
duration	O
at	O
baseline	O
(≤	O
5	O
or	O
6	O
hours	O
per	O
night	O
)	O
was	O
associated	O
with	O
elevated	O
risk	O
of	O
developing	O
incident	O
type	O
2	O
diabetes	O
after	O
adjustment	O
for	O
covariates	O
,	O
including	O
age	O
,	O
hypertension	O
,	O
smoking	O
,	O
self	O
-	O
rated	O
health	O
,	O
waist	O
circumference	O
,	O
education	O
,	O
total	O
testosterone	O
and	O
cortisol	O
[	O
11	O
].	O

Further	O
,	O
Gangwisch	O
et	O
al	O
,	O
in	O
their	O
analysis	O
of	O
data	O
from	O
the	O
first	O
National	O
Health	O
and	O
Nutrition	O
Examination	O
Survey	O
(	O
NHANES	O
I	O
)	O
noted	O
that	O
individuals	O
reporting	O
≤	O
5	O
hours	O
of	O
sleep	O
(	O
OR	O
=	O
1	O
.	O
47	O
;	O
95	O
%	O
CI	O
1	O
.	O
03	O
-	O
2	O
.	O
09	O
)	O
and	O
those	O
reporting	O
sleeping	O
≥	O
9	O
hours	O
(	O
OR	O
=	O
1	O
.	O
52	O
;	O
95	O
%	O
CI	O
1	O
.	O
06	O
-	O
2	O
.	O
18	O
)	O
had	O
increased	O
risks	O
of	O
developing	O
diabetes	O
as	O
compared	O
to	O
those	O
reporting	O
7	O
hours	O
of	O
sleep	O
[	O
34	O
].	O

Our	O
findings	O
of	O
elevated	O
risks	O
of	O
incident	O
GDM	O
among	O
women	O
reporting	O
both	O
long	O
and	O
short	O
sleep	O
durations	O
in	O
early	O
pregnancy	O
are	O
consistent	O
with	O
these	O
earlier	O
reports	O
from	O
men	O
and	O
non	O
pregnant	O
women	O
.	O

Our	O
observations	O
of	O
impaired	O
post	O
-	O
load	O
glucose	O
tolerance	O
and	O
increased	O
risk	O
of	O
GDM	O
among	O
women	O
who	O
snore	O
during	O
pregnancy	O
are	O
also	O
consistent	O
with	O
a	O
growing	O
body	O
of	O
epidemiological	O
evidence	O
that	O
documents	O
markers	O
of	O
the	O
severity	O
of	O
obstructive	O
sleep	O
apnea	O
(	O
OSA	O
)	O
and	O
increased	O
risk	O
of	O
type	O
2	O
diabetes	O
in	O
diverse	O
populations	O
of	O
men	O
and	O
non	O
-	O
pregnant	O
women	O
from	O
various	O
geographic	O
regions	O
[	O
32	O
,	O
36	O
-	O
38	O
].	O

In	O
a	O
cross	O
-	O
sectional	O
study	O
of	O
elderly	O
Danish	O
men	O
and	O
women	O
,	O
investigators	O
noted	O
that	O
self	O
-	O
reported	O
snoring	O
was	O
associated	O
with	O
abnormal	O
glucose	O
tolerance	O
test	O
results	O
after	O
control	O
for	O
confounding	O
factors	O
[	O
36	O
].	O

These	O
findings	O
were	O
subsequently	O
corroborated	O
and	O
extended	O
by	O
others	O
,	O
including	O
,	O
Al	O
-	O
Delaimy	O
et	O
al	O
[	O
32	O
]	O
who	O
reported	O
that	O
self	O
-	O
reported	O
regular	O
snoring	O
was	O
independently	O
associated	O
with	O
a	O
2	O
-	O
fold	O
increased	O
risk	O
(	O
RR	O
=	O
2	O
.	O
03	O
;	O
95	O
%	O
CI	O
1	O
.	O
71	O
-	O
2	O
.	O
40	O
)	O
of	O
developing	O
type	O
2	O
diabetes	O
over	O
a	O
10	O
-	O
year	O
follow	O
-	O
up	O
period	O
.	O

Lindberg	O
et	O
al	O
[	O
37	O
],	O
in	O
their	O
cross	O
sectional	O
study	O
of	O
6	O
,	O
799	O
Swedish	O
women	O
,	O
for	O
instance	O
,	O
reported	O
that	O
self	O
-	O
reported	O
snoring	O
and	O
excessive	O
daytime	O
sleepiness	O
was	O
an	O
independent	O
risk	O
factor	O
for	O
type	O
2	O
diabetes	O
(	O
OR	O
=	O
1	O
.	O
82	O
;	O
95	O
%	O
CI	O
0	O
.	O
97	O
-	O
3	O
.	O
43	O
).	O

In	O
a	O
population	O
-	O
based	O
Swedish	O
study	O
of	O
2	O
,	O
668	O
men	O
followed	O
for	O
10	O
-	O
years	O
,	O
investigators	O
reported	O
that	O
the	O
multivariable	O
adjusted	O
relative	O
risk	O
for	O
incident	O
type	O
2	O
diabetes	O
was	O
highest	O
for	O
obese	O
snorers	O
(	O
OR	O
=	O
7	O
.	O
0	O
;	O
95	O
%	O
CI	O
2	O
.	O
9	O
-	O
16	O
.	O
9	O
)	O
than	O
for	O
lean	O
non	O
-	O
snorers	O
[	O
38	O
].	O

In	O
our	O
study	O
we	O
found	O
that	O
the	O
adjusted	O
relative	O
risk	O
of	O
GDM	O
was	O
highest	O
among	O
overweight	O
mothers	O
who	O
snored	O
during	O
pregnancy	O
(	O
OR	O
=	O
6	O
.	O
91	O
;	O
95	O
%	O
CI	O
2	O
.	O
87	O
-	O
16	O
.	O
3	O
)	O
when	O
compared	O
with	O
lean	O
mothers	O
who	O
did	O
not	O
snore	O
.	O

In	O
summary	O
,	O
available	O
data	O
support	O
the	O
notion	O
that	O
habitual	O
snoring	O
may	O
be	O
a	O
risk	O
factor	O
for	O
abnormal	O
glucose	O
metabolism	O
.	O

Our	O
finding	O
extends	O
this	O
literature	O
by	O
adding	O
preliminary	O
evidence	O
that	O
links	O
snoring	O
with	O
pregnancy	O
-	O
related	O
impaired	O
glucose	O
tolerance	O
and	O
GDM	O
.	O

Our	O
present	O
pilot	O
study	O
has	O
several	O
important	O
strengths	O
.	O

First	O
,	O
our	O
determination	O
of	O
maternal	O
sleep	O
duration	O
and	O
snoring	O
was	O
based	O
on	O
reports	O
made	O
early	O
during	O
pregnancy	O
,	O
so	O
reporting	O
was	O
not	O
conditional	O
on	O
pregnancy	O
outcomes	O
or	O
on	O
signs	O
and	O
symptoms	O
of	O
GDM	O
.	O

Our	O
results	O
suggest	O
that	O
habitual	O
short	O
/	O
long	O
sleep	O
duration	O
and	O
snoring	O
precede	O
the	O
clinical	O
diagnosis	O
of	O
GDM	O
.	O

Second	O
,	O
the	O
high	O
follow	O
-	O
up	O
rate	O
(>	O
95	O
%)	O
minimized	O
possible	O
selection	O
bias	O
.	O

However	O
,	O
several	O
limitations	O
merit	O
discussion	O
and	O
consideration	O
.	O

Maternal	O
habitual	O
sleep	O
duration	O
and	O
snoring	O
was	O
obtained	O
from	O
self	O
-	O
report	O
,	O
and	O
thus	B
are	O
likely	B
susceptible	O
to	O
misclassification	O
.	O

Reported	O
sleep	O
duration	O
is	O
known	O
to	O
be	O
only	O
moderately	O
correlated	O
with	O
wrist	O
actigraph	O
-	O
measured	O
sleep	O
duration	O
(	O
ρ	O
=	O
0	O
.	O
47	O
),	O
and	O
reports	O
are	O
generally	B
longer	O
by	O
approximately	O
34	O
minutes	O
for	O
each	O
hour	O
of	O
objectively	O
measured	O
sleep	O
[	O
39	O
].	O

The	O
use	O
of	O
self	O
-	O
reported	O
snoring	O
as	O
a	O
tool	O
to	O
detect	O
sleep	O
disordered	O
breathing	O
is	O
well	B
established	I
.	O

Investigators	O
have	O
shown	O
that	O
self	O
-	O
reported	O
snoring	O
correlates	O
well	O
with	O
objective	O
findings	O
from	O
nocturnal	O
polysomnography	O
,	O
especially	O
in	O
frequent	O
snorers	O
[	O
40	O
].	O

Snoring	O
that	O
is	O
infrequent	O
or	O
non	O
-	O
habitual	O
has	O
not	O
been	O
shown	O
to	O
be	O
a	O
useful	O
screen	O
for	O
sleep	O
disordered	O
breathing	O
in	O
large	O
epidemiologic	O
studies	O
[	O
41	O
,	O
42	O
].	O

It	O
was	O
therefore	O
necessary	O
to	O
distinguish	O
frequent	O
snorers	O
from	O
infrequent	O
snorers	O
in	O
our	O
study	O
.	O

Our	O
pilot	O
study	O
was	O
also	O
limited	O
by	O
the	O
relatively	O
small	O
sample	O
of	O
GDM	O
cases	O
(	O
n	O
=	O
68	O
)	O
and	O
the	O
imprecision	O
of	O
relative	O
risk	O
estimates	O
which	O
were	O
reflected	O
by	O
their	O
wide	O
95	O
%	O
confidence	O
intervals	O
.	O

A	O
total	O
of	O
251	O
study	O
subjects	O
had	O
a	O
post	O
-	O
50	O
gram	O
1	O
-	O
hour	O
glucose	O
concentration	O
≥	O
140	O
mg	O
/	O
dl	O
and	O
thus	O
required	O
the	O
follow	O
-	O
up	O
diagnostic	O
100	O
-	O
gram	O
oral	O
glucose	O
tolerance	O
test	O
(	O
OGTT	O
).	O

Although	O
qualitative	O
results	O
(	O
i	O
.	O
e	O
.,	O
normal	O
/	O
abnormal	O
blood	O
glucose	O
concentrations	O
)	O
for	O
the	O
diagnostic	O
test	O
were	O
available	O
for	O
all	O
251	O
subjects	O
,	O
specific	O
glucose	O
concentrations	O
for	O
each	O
time	O
point	O
(	O
i	O
.	O
e	O
.,	O
fasting	O
;	O
1	O
-	O
hour	O
;	O
2	O
-	O
hour	O
;	O
and	O
3	O
-	O
hour	O
post	O
glucose	O
load	O
)	O
were	O
unavailable	O
for	O
approximately	O
44	O
%	O
of	O
subjects	O
.	O

Lastly	O
,	O
the	O
generalizability	O
of	O
our	O
study	O
may	O
be	O
limited	O
,	O
as	B
our	O
cohort	O
was	O
primarily	O
comprised	O
of	O
Non	O
-	O
Hispanic	O
White	O
and	O
well	O
-	O
educated	O
women	O
.	O

The	O
pathophysiological	O
mechanisms	O
underlying	O
these	O
consistently	B
observed	O
associations	O
of	O
short	O
sleep	O
duration	O
,	O
sleep	O
-	O
related	O
breathing	O
disorders	O
,	O
including	O
snoring	O
,	O
with	O
altered	O
glucose	O
metabolism	O
and	O
diabetes	O
are	O
likely	B
to	O
be	O
multifactorial	O
[	O
2	O
,	O
43	O
,	O
44	O
].	O

Notably	O
,	O
high	O
sympathetic	O
nervous	O
system	O
activity	O
,	O
intermittent	O
hypoxemia	O
,	O
dysregulation	O
of	O
the	O
HPA	O
axis	O
,	O
endothelial	O
dysfunction	O
and	O
alterations	O
in	O
cytokine	O
and	O
adipokine	O
synthesis	O
and	O
release	O
have	O
all	O
been	O
proposed	O
mechanisms	O
for	O
these	O
consistently	B
observed	O
epidemiological	O
observations	O
.	O

Sympathetic	O
hyperactivity	O
can	O
alter	O
glucose	O
homeostasis	O
and	O
induce	O
insulin	O
resistance	O
by	O
increasing	O
glycogen	O
breakdown	O
and	O
gluconeogenesis	O
.	O

Recently	O
,	O
investigators	O
reported	O
that	O
mild	O
sleep	O
restriction	O
induces	O
marked	O
reduction	O
in	O
basal	O
glucagon	O
concentrations	O
[	O
19	O
].	O

Furthermore	O
,	O
individuals	O
with	O
sleep	O
disorders	O
may	O
be	O
predisposed	O
to	O
insulin	O
resistance	O
and	O
glucose	O
intolerance	O
due	O
to	O
sleep	O
-	O
related	O
dysregulation	O
of	O
the	O
HPA	O
axis	O
with	O
consequent	O
elevations	O
in	O
serum	O
cortisol	O
[	O
16	O
,	O
45	O
].	O

In	O
a	O
community	O
dwelling	O
sample	O
of	O
2	O
,	O
751	O
middle	O
aged	O
men	O
and	O
women	O
,	O
Kumari	O
et	O
al	O
reported	O
that	O
short	O
sleep	O
duration	O
and	O
increased	O
sleep	O
disturbance	O
are	O
independently	O
associated	O
with	O
diurnal	O
slope	O
in	O
cortisol	O
secretion	O
[	O
45	O
].	O

Alternatively	O
,	O
cyclical	O
hypoxemia	O
with	O
re	O
-	O
oxygenation	O
,	O
similar	O
to	O
repeated	O
ischemia	O
-	O
reperfusion	O
damage	O
,	O
may	O
promote	O
the	O
formation	O
of	O
reactive	O
oxygen	O
species	O
that	O
may	O
then	O
elicit	O
the	O
release	O
of	O
pro	O
-	O
inflammatory	O
cytokines	O
including	O
interleukin	O
-	O
6	O
and	O
tumor	O
necrosis	O
factor	O
-	O
α	O
[	O
46	O
,	O
47	O
].	O

Investigators	O
have	O
shown	O
that	O
both	O
acute	O
total	O
and	O
short	O
-	O
term	O
partial	O
sleep	O
loss	O
results	O
in	O
elevated	O
C	O
-	O
reactive	O
protein	O
(	O
CRP	O
)	O
concentrations	O
[	O
48	O
].	O

Notably	O
,	O
investigators	O
have	O
reported	O
that	O
short	O
sleep	O
duration	O
and	O
other	O
parameters	O
of	O
sleep	O
disturbance	O
during	O
mid	O
and	O
late	O
pregnancy	O
are	O
associated	O
with	O
increased	O
systematic	O
inflammation	O
and	O
higher	O
stimulated	O
levels	O
of	O
IL	O
-	O
6	O
[	O
49	O
,	O
50	O
];	O
and	O
we	O
have	O
previously	O
reported	O
that	O
early	O
pregnancy	O
CRP	O
concentrations	O
are	O
predictive	O
of	O
incident	O
GDM	O
[	O
51	O
].	O

Collectively	O
,	O
these	O
data	O
suggest	O
that	O
sleep	O
disturbances	O
may	O
augment	O
pro	O
-	O
inflammatory	O
responses	O
that	O
may	O
then	O
contribute	O
to	O
altered	O
glucose	O
metabolism	O
.	O

Causal	O
biological	O
mechanisms	O
for	O
the	O
observed	O
positive	O
,	O
though	O
statistically	O
in	O
-	O
significant	O
association	O
between	O
long	O
sleep	O
duration	O
and	O
GDM	O
are	O
not	O
clear	O
.	O

Some	O
investigators	O
,	O
documenting	O
similar	O
positive	O
association	O
between	O
long	O
sleep	O
duration	O
and	O
type	O
2	O
diabetes	O
mellitus	O
speculate	O
that	O
the	O
association	O
may	O
be	O
due	O
in	O
part	O
to	O
residual	O
confounding	O
by	O
undiagnosed	O
health	O
conditions	O
,	O
co	O
-	O
morbid	O
depression	O
,	O
unemployment	O
,	O
or	O
poor	O
general	O
health	O
[	O
1	O
,	O
4	O
].	O

Despite	O
unclear	O
mechanisms	O
,	O
the	O
positive	O
relationship	O
between	O
later	O
pregnancy	O
hyperglycemia	O
and	O
GDM	O
risk	O
were	O
evident	B
among	O
women	O
who	O
reported	O
short	O
/	O
long	O
sleep	O
duration	O
and	O
snoring	O
in	O
our	O
cohort	O
.	O

The	O
risks	O
were	O
particularly	O
elevated	O
among	O
overweight	O
women	O
with	O
these	O
sleep	O
disorders	O
.	O

Conclusion	O
These	O
preliminary	O
findings	O
suggest	O
associations	O
of	O
short	O
sleep	O
duration	O
and	O
snoring	O
with	O
glucose	O
intolerance	O
and	O
GDM	O
.	O

Though	O
consistent	O
with	O
studies	O
of	O
men	O
and	O
non	O
-	O
pregnant	O
women	O
,	O
larger	O
prospective	O
studies	O
that	O
include	O
objective	O
measures	O
of	O
sleep	O
duration	O
,	O
sleep	O
quality	O
,	O
and	O
sleep	O
apnea	O
during	O
pregnancy	O
are	O
needed	O
to	O
confirm	O
our	O
findings	O
.	O

Enhanced	O
knowledge	O
of	O
possible	O
metabolic	O
consequences	O
of	O
sleep	O
disturbances	O
in	O
pregnancy	O
will	O
likely	B
have	O
important	O
clinical	O
implications	O
in	O
the	O
prevention	O
and	O
treatment	O
of	O
impaired	O
glucose	O
tolerance	O
and	O
GDM	O
among	O
pregnant	O
women	O
.	O

Competing	O
interests	O
The	O
authors	O
declare	O
that	O
they	O
have	O
no	O
competing	O
interests	O
.	O

Authors	O
'	O
contributions	O
CQ	O
and	O
MAW	O
had	O
full	O
access	O
to	O
all	O
the	O
data	O
in	O
the	O
study	O
and	O
take	O
responsibility	O
for	O
the	O
integrity	O
of	O
the	O
data	O
,	O
the	O
accuracy	O
of	O
the	O
data	O
analysis	O
,	O
and	O
the	O
decision	O
to	O
submit	O
for	O
publication	O
.	O

MAW	O
conceived	O
,	O
designed	O
and	O
obtained	O
funding	O
for	O
the	O
study	O
.	O

CQ	O
analyzed	O
the	O
data	O
.	O

CQ	O
and	O
MAW	O
drafted	O
the	O
manuscript	O
.	O

All	O
authors	O
interpreted	O
the	O
data	O
,	O
critically	O
revised	O
the	O
draft	O
for	O
important	O
intellectual	O
content	O
,	O
and	O
gave	O
final	O
approval	O
of	O
the	O
manuscript	O
to	O
be	O
published	O
.	O

Pre	O
-	O
publication	O
history	O
The	O
pre	O
-	O
publication	O
history	O
for	O
this	O
paper	O
can	O
be	O
accessed	O
here	O
:	O
http	O
://	O
www	O
.	O
biomedcentral	O
.	O
com	O
/	O
1472	O
-	O
6874	O
/	O
10	O
/	O
17	O
/	O
prepub	O
PubMed	O
Central	O
:	O

Management	O
and	O
follow	O
-	O
up	O
of	O
thyroid	O
cancer	O
in	O
pregnant	O
women	O
AbstractSUMMARY	O
Thyroid	O
cancer	O
,	O
the	O
most	O
common	O
endocrine	O
malignancy	O
,	O
is	O
often	O
detected	O
in	O
young	O
female	O
patients	O
.	O

Therefore	B
,	O
pregnancy	O
following	O
thyroid	O
cancer	O
is	O
not	O
infrequent	O
,	O
and	O
about	O
10	O
%	O
of	O
thyroid	O
cancers	O
occurring	O
during	O
the	O
reproductive	O
years	O
are	O
diagnosed	O
during	O
pregnancy	O
or	O
in	O
the	O
early	O
post	O
-	O
partum	O
period	O
.	O

Differentiated	O
thyroid	O
cancer	O
(	O
DTC	O
)	O
in	O
young	O
people	O
generally	B
has	O
an	O
excellent	O
prognosis	O
,	O
and	O
disease	O
-	O
free	O
survival	O
among	O
women	O
with	O
DTC	O
diagnosed	O
during	O
pregnancy	O
may	O
not	O
differ	O
from	O
that	O
in	O
age	O
-	O
matched	O
non	O
-	O
pregnant	O
women	O
with	O
similar	O
disease	O
.	O

However	O
,	O
thyroid	O
cancer	O
detected	O
during	O
pregnancy	O
may	O
cause	O
anxiety	O
about	O
the	O
optimal	O
timing	O
of	O
recommended	O
treatments	O
and	O
about	O
both	O
maternal	O
and	O
neonatal	O
morbidity	O
,	O
as	O
weel	O
as	O
pregnancy	O
following	O
a	O
diagnosis	O
of	O
thyroid	O
cancer	O
obviously	O
needs	O
both	O
maternal	O
and	O
foetal	O
management	O
.	O

The	O
main	O
objectives	O
in	O
clinical	O
monitoring	O
of	O
pregnant	O
thyroid	O
cancer	O
patients	O
are	O
:	O
1	O
)	O
to	O
reach	O
an	O
adequate	O
balance	O
of	O
maternal	O
calcium	O
and	O
thyroid	O
hormones	O
that	O
is	O
absolutely	O
required	O
by	O
the	O
foetal	O
central	O
nervous	O
system	O
for	O
normal	O
maturation	O
;	O
2	O
)	O
to	O
maintain	O
optimal	O
levels	O
of	O
maternal	O
thyroxin	O
to	O
avoid	O
possible	O
recurrence	O
or	O
spread	O
of	O
disease	O
;	O
and	O
3	O
)	O
to	O
perform	O
safe	O
follow	O
-	O
up	O
visits	O
for	O
the	O
mother	O
and	O
to	O
plan	O
further	O
therapy	O
when	O
needed	O
.	O

Data	O
from	O
a	O
review	O
of	O
the	O
literature	O
and	O
the	O
authors	O
'	O
own	O
experience	O
show	O
that	O
in	O
patients	O
undergoing	O
either	O
suppressive	O
or	O
substitutive	O
thyroxine	O
therapy	O
foetal	O
thyroid	O
growth	O
is	O
normal	O
at	O
ultrasound	O
study	O
,	O
newborn	O
thyroid	O
status	O
is	O
normal	O
,	O
and	O
the	O
incidence	O
of	O
maternal	O
morbidity	O
is	O
not	O
influenced	O
by	O
the	O
pregnancy	O
.	O

In	O
this	O
review	O
,	O
the	O
authors	O
underline	B
that	O
regular	O
adjustment	O
of	O
levo	O
-	O
thyroxine	O
and	O
calcium	O
therapy	O
is	O
of	O
outmost	O
importance	O
for	O
both	O
maternal	O
and	O
foetal	O
well	O
-	O
being	O
and	O
offer	O
some	O
insight	O
,	O
very	O
interesting	O
from	O
a	O
practical	O
point	O
of	O
view	O
,	O
to	O
provide	O
a	O
clear	O
and	O
simple	O
pathway	O
for	O
the	O
management	O
of	O
pregnancy	O
-	O
associated	O
thyroid	O
cancer	O
.	O

Introduction	O
Thyroid	O
cancer	O
,	O
the	O
most	O
common	O
endocrine	O
malignancy	O
,	O
is	O
often	O
detected	O
in	O
young	O
patients	O
and	O
is	O
more	O
frequently	O
diagnosed	O
in	O
women	O
.	O

The	O
median	O
age	O
at	O
diagnosis	O
is	O
low	O
,	O
below	O
40	O
years	O
in	O
most	O
populations	O
.	O

For	O
these	O
reasons	B
,	O
differentiated	O
thyroid	O
cancer	O
(	O
DTC	O
)	O
is	O
one	O
of	O
the	O
most	O
common	O
cancers	O
in	O
women	O
in	O
the	O
reproductive	O
age	O
.	O

Hence	B
,	O
thyroid	O
cancer	O
ranks	O
among	O
the	O
most	O
common	O
cancers	O
during	O
pregnancy	O
,	O
with	O
a	O
prevalence	O
of	O
3	O
.	O
6	O
-	O
14	O
per	O
100	O
,	O
000	O
live	O
births	O
,	O
mirroring	O
the	O
its	O
incidence1	O
-	O
4	O
.	O

Therefore	B
,	O
pregnancy	O
in	O
thyroid	O
cancer	O
patients	O
is	O
not	O
unusual	O
,	O
and	O
about	O
10	O
%	O
of	O
thyroid	O
cancers	O
occurring	O
during	O
reproductive	O
years	O
are	O
diagnosed	O
during	O
pregnancy	O
or	O
in	O
the	O
early	O
post	O
-	O
partum	O
period	O
.	O

Some	O
data	O
suggest	O
the	O
importance	O
of	O
growth	O
factors	O
(	O
mainly	B
TSH	O
,	O
but	O
also	O
HCG	O
)	O
in	O
growth	O
,	O
progression	O
and	O
spread	O
of	O
papillary	O
tumours	O
.	O

In	O
vitro	O
oestrogens	O
have	O
been	O
shown	O
to	O
down	O
-	O
regulate	O
the	O
NIS	O
(	O
sodium	O
iodide	O
symporter	O
)	O
gene	O
and	O
promote	O
the	O
production	O
of	O
thyroglobulin	O
(	O
HTG	O
),	O
increasing	O
HTG	O
-	O
gene	O
expression	O
via	O
oestrogen	O
receptors	O
present	O
in	O
thyroid	O
tissue	O
,	O
without	O
stimulating	O
rapid	O
cell	O
proliferation145	O
.	O

This	O
could	O
support	O
the	O
hypothesis	O
that	O
sex	O
hormones	O
and	O
,	O
therefore	B
,	O
menstrual	O
and	O
reproductive	O
events	O
,	O
may	O
modify	O
thyroid	O
cancer	O
risk	O
in	O
women6	O
,	O
although	O
these	O
associations	O
–	O
which	O
could	O
indicate	O
either	O
a	O
causal	O
link	O
or	O
a	O
surveillance	O
bias	O
–	O
may	O
reflect	O
an	O
aetiology	O
shared	O
by	O
both	O
the	O
above	O
-	O
mentioned	O
factors	O
and	O
by	O
thyroid	O
cancer	O
.	O

However	O
,	O
such	O
a	O
relation	O
has	O
not	O
yet	O
been	O
confirmed	O
.	O

The	O
diagnosis	O
of	O
a	O
tumour	O
during	O
pregnancy	O
obviously	O
causes	O
anxiety	O
about	O
the	O
optimal	O
timing	O
of	O
recommended	O
treatments	O
and	O
about	O
both	O
maternal	O
and	O
neonatal	O
morbidity	O
.	O

However	O
,	O
thyroid	O
cancer	O
in	O
young	O
people	O
has	O
generally	B
an	O
excellent	O
prognosis	O
,	O
and	O
survival	O
among	O
women	O
with	O
thyroid	O
cancer	O
diagnosed	O
during	O
pregnancy	O
may	O
not	O
differ	O
from	O
that	O
in	O
age	O
-	O
matched	O
non	O
-	O
pregnant	O
women	O
with	O
similar	O
disease	O
.	O

Pregnancy	O
is	O
a	O
special	O
situation	O
in	O
oncology	O
:	O
we	O
need	O
to	O
control	O
two	O
patients	O
at	O
the	O
same	O
time	O
,	O
and	O
both	O
are	O
vulnerable	O
.	O

In	O
addition	O
,	O
each	O
situation	O
must	O
be	O
considered	O
in	O
development	O
,	O
nothing	O
is	O
static	O
,	O
mainly	B
in	O
the	O
first	O
trimester	O
.	O

Finally	O
,	O
thyroid	O
cancer	O
patients	O
often	B
undergo	O
total	O
thyroidectomy	O
and	O
thus	B
need	O
adequate	O
supplementation	O
of	O
both	O
calcium	O
and	O
thyroxine	O
.	O

Thus	B
,	O
pregnancy	O
following	O
thyroid	O
cancer	O
needs	O
both	O
maternal	O
and	O
foetal	O
control	O
.	O

The	O
main	O
problems	O
are	O
:	O
i	O
)	O
to	O
reach	O
an	O
adequate	O
balance	O
of	O
maternal	O
thyroid	O
hormones	O
that	O
is	O
absolutely	O
required	O
by	O
the	O
foetal	O
central	O
nervous	O
system	O
for	O
normal	O
maturation7	O
,	O
ii	O
)	O
to	O
maintain	O
maternal	O
levels	O
of	O
l	O
-	O
thyroxin	O
to	O
avoid	O
possible	O
recurrence	O
or	O
spread	O
of	O
disease	O
,	O
and	O
iii	O
)	O
to	O
perform	O
safe	O
follow	O
-	O
up	O
controls	O
for	O
the	O
mother	O
and	O
to	O
plan	O
further	O
therapy	O
when	O
needed	O
.	O

Physiology	O
of	O
pregnancy	O
Thyroid	O
hormones	O
and	O
foetal	O
development	O
The	O
first	O
endocrine	O
structure	O
to	O
appear	O
during	O
embryonic	O
development	O
is	O
the	O
thyroid	O
gland	O
.	O

At	O
10	O
-	O
12	O
weeks	O
of	O
embryo	O
development	O
,	O
follicles	O
containing	O
colloid	O
become	O
visible	O
,	O
and	O
the	O
thyroid	O
is	O
able	O
to	O
incorporate	O
iodine	O
into	O
thyroid	O
hormones	O
.	O

Thyroid	O
hormones	O
are	O
major	O
factors	O
for	O
the	O
normal	O
development	O
of	O
foetal	O
brain	O
,	O
and	O
until	O
the	O
end	O
of	O
the	O
first	O
trimester	O
,	O
when	O
the	O
hypothalamic	O
-	O
pituitary	O
-	O
thyroid	O
axis	O
becomes	O
functional	O
,	O
the	O
foetal	O
brain	O
is	O
strictly	O
dependent	O
on	O
local	O
deiodination	O
of	O
maternal	O
thyroxine7	O
-	O
12	O
.	O

Thyroid	O
hormone	O
deficiency	O
may	O
cause	O
severe	O
neurologic	O
disorders	O
,	O
resulting	O
from	O
defects	O
in	O
neuronal	O
cell	O
differentiation	O
and	O
migration	O
,	O
axonal	O
and	O
dendritic	O
outgrowth	O
,	O
myelin	O
formation	O
and	O
synaptogenesis7913	O
.	O

The	O
offspring	O
of	O
women	O
with	O
a	O
serum	O
-	O
free	O
thyroxine	O
(	O
fT4	O
)	O
concentration	O
in	O
the	O
lowest	O
decile	O
of	O
the	O
reference	O
range	O
at	O
12	O
weeks	O
of	O
gestation	O
may	O
have	O
significant	O
delays	O
in	O
neurodevelopment	O
.	O

The	O
mother	O
is	O
the	O
only	O
source	O
of	O
foetal	O
thyroid	O
hormones	O
from	O
conception	O
to	O
approximately	O
13	O
weeks	O
of	O
gestation	O
,	O
when	O
foetal	O
thyroid	O
function	O
has	O
developed14	O
-	O
16	O
.	O

During	O
pregnancy	O
,	O
the	O
mother	O
'	O
s	O
thyroid	O
physiology	O
undergoes	O
many	O
well	O
-	O
defined	O
changes	O
,	O
leading	O
to	O
an	O
increase	O
in	O
thyroid	O
volume	O
which	O
is	O
often	B
associated	O
with	O
higher	O
urinary	O
iodine	O
excretion	O
.	O

It	O
is	O
also	O
associated	O
with	O
the	O
formation	O
of	O
new	O
thyroid	O
nodules	O
with	O
the	O
histological	O
features	O
of	O
nodular	O
hyperplasia	O
.	O

Very	O
early	O
in	O
pregnancy	O
,	O
the	O
increase	O
in	O
oestrogen	O
levels	O
causes	O
an	O
approximate	O
doubling	O
in	O
thyroxine	O
-	O
binding	O
globulin	O
(	O
TBG	O
)	O
that	O
can	O
lead	O
to	O
an	O
increases	O
in	O
total	O
T4	O
concentration	O
and	O
a	O
reduced	O
free	O
fraction	O
(	O
Table	O
I	O
).	O

In	O
healthy	O
women	O
,	O
the	O
final	O
effect	O
consists	O
of	O
a	O
significant	O
increase	O
in	O
the	O
total	O
thyroxine	O
pool	O
,	O
mainly	B
in	O
the	O
first	O
trimester17	O
-	O
19	O
.	O

This	O
increment	O
may	O
be	O
brought	O
about	O
largely	O
by	O
thyroid	O
stimulation	O
induced	O
by	O
human	O
chorionic	O
gonadotropin	O
(	O
HCG	O
)	O
through	O
its	O
structural	O
affinity	O
with	O
thyrotropin	O
(	O
TSH	O
).	O

It	O
can	O
be	O
observed	O
that	O
a	O
slight	O
increase	O
in	O
fT4	O
and	O
a	O
reduction	O
in	O
TSH	O
occur	O
between	O
the	O
9thand	O
12thweeks	O
of	O
gestation	O
;	O
subsequently	O
,	O
HCG	O
levels	O
decrease	O
and	O
TSH	O
reaches	O
normal	O
non	O
-	O
pregnant	O
levels	O
.	O

The	O
TSH	O
concentration	O
generally	B
lies	O
within	O
the	O
normal	O
range	O
after	O
the	O
16th	O
to	O
18th	O
week11171920	O
.	O

In	O
hypothyroid	O
or	O
thyroidectomized	O
pregnant	O
women	O
,	O
such	O
physiological	O
changes	O
obviously	O
cannot	O
occur	O
.	O

Both	O
during	O
suppressive	O
or	O
substitutive	O
therapy	O
,	O
L	O
-	O
T4	O
requirement	O
increases	O
very	O
early	O
during	O
pregnancy	O
,	O
reaching	O
a	O
plateau	O
after	O
16thto	O
20thweeks	O
of	O
gestation	O
,	O
with	O
a	O
required	O
L	O
-	O
T4	O
dosage	O
approximately	O
30	O
to	O
50	O
%	O
higher	O
than	O
that	O
administered	O
before	O
pregnancy	O
.	O

Caption	O
(	O
TABLE	O
-	O
WRAP	O
):	O
TABLE	O
I	O
.	O
Physiological	O
changes	O
in	O
thyroid	O
function	O
during	O
pregnancy	O
.	O
IncreaseDecreaseHCG	O
(	O
TSH	O
–	O
like	O
effect	O
)	O
TSHTBG	O
,	O
serum	O
total	O
T	O
4	O
and	O
T3	O
,	O
T3	O
and	O
T4	O
pool	O
sizeHTGType	O
III	O
5	O
-	O
deiodinase	O
,	O
iodine	O
clearance	O
,	O
T3	O
and	O
T4	O
degradationThyroid	O
volume	O
Besides	O
the	O
well	B
-	I
known	I
association	O
between	O
gestational	O
hypothyroidism	O
and	O
impaired	O
intellectual	O
and	O
cognitive	O
development	O
in	O
offspring	O
,	O
untreated	O
or	O
inadequately	O
treated	O
and	O
subclinical	O
hypothyroidism	O
is	O
associated	O
with	O
foetal	O
loss	O
,	O
anaemia	O
,	O
gestational	O
hypertension	O
and	O
preeclampsia	O
,	O
abruption	O
placentae	O
,	O
increased	O
risk	O
of	O
miscarriage	O
,	O
foetal	O
growth	O
retardation	O
,	O
perinatal	O
mortality	O
and	O
neonatal	O
morbidity91315	O
-	O
172122	O
.	O

Finally	O
,	O
for	O
thyroid	O
cancer	O
patients	O
,	O
hypothyroidism	O
can	O
rise	O
the	O
maternal	O
risk	O
of	O
recurrence	O
.	O

Thus	B
,	O
hypothyroidism	O
must	O
be	O
absolutely	O
avoided	O
in	O
all	O
pregnant	O
woman	O
,	O
especially	O
in	O
thyroid	O
cancer	O
patients	O
,	O
and	O
therefore	B
correct	O
supplementation	O
of	O
thyroxine	O
is	O
of	O
extreme	O
importance	O
.	O

Vitamin	O
D	O
requirement	O
during	O
pregnancy	O
Thyroidectomised	O
patients	O
often	B
need	O
calcium	O
and	O
D	O
vitamin	O
supplementation	O
,	O
and	O
the	O
treatment	O
needs	O
frequent	O
adjustment	O
during	O
the	O
pregnancy	O
to	O
prevent	O
maternal	O
and	O
neonatal	O
hypocalcemia	O
.	O

During	O
pregnancy	O
vitamin	O
D	O
and	O
calcium	O
metabolism	O
undergo	O
significant	O
changes	O
to	O
provide	O
the	O
calcium	O
needed	O
for	O
maternal	O
skeletal	O
preservation	O
and	O
foetal	O
skeletal	O
formation	O
.	O

Increased	O
intestinal	O
calcium	O
absorption	O
seems	O
to	O
be	O
the	O
primary	O
mechanism	O
for	O
obtaining	O
extra	O
calcium	O
in	O
physiological	O
pregnancy	O
,	O
but	O
frequent	O
nausea	O
and	O
vomiting	O
or	O
sometimes	O
diarrhea	O
reduce	O
the	O
amount	O
of	O
calcium	O
absorbed	O
by	O
the	O
mother23	O
.	O

Vitamin	O
D	O
does	O
not	O
occur	O
naturally	O
in	O
foods	O
.	O

Moreover	O
,	O
the	O
usual	O
recommendations	O
to	O
avoid	O
sun	O
exposure	O
reduces	O
dermal	O
synthesis	O
of	O
vitamin	O
D3Although	O
vitamin	O
D	O
is	O
undoubtedly	B
important	O
for	O
foetal	O
bone	O
development	O
,	O
we	O
know	O
that	O
it	O
plays	O
a	O
much	O
wider	O
role	O
in	O
health	O
and	O
disease	O
prevention	O
.	O

Not	O
really	O
a	O
vitamin	O
,	O
D3is	O
a	O
pro	O
-	O
prehormone	O
made	O
in	O
the	O
skin	O
in	O
response	O
to	O
ultraviolet	O
-	O
B	O
light	O
exposure	O
.	O

It	O
is	O
the	O
precursor	O
to	O
form	O
25	O
-	O
hydroxyvitamin	O
D3	O
[	O
25	O
(	O
OH	O
)	O
D3	O
],	O
a	O
prehormone	O
,	O
which	O
is	O
ultimately	O
converted	O
to	O
1	O
,	O
25	O
-	O
dihydroxyvitamin	O
D3	O
[	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
],	O
one	O
of	O
the	O
most	O
potent	O
steroid	O
hormones	O
known	O
.	O

1	O
,	O
25	O
(	O
OH	O
)	O
2D	O
may	O
interfere	O
with	O
many	O
functions	O
beyond	O
calcium	O
metabolism	O
,	O
such	O
as	O
foetal	O
"	O
imprinting	O
"	O
that	O
may	O
affect	O
neurodevelopment	O
,	O
immune	O
function	O
and	O
chronic	O
disease	O
susceptibility	O
later	O
in	O
life	O
,	O
as	O
well	O
as	O
soon	O
after	O
birth2425	O
.	O

The	O
active	O
metabolite	O
of	O
vitamin	O
D	O
,	O
1	O
,	O
25	O
-	O
dihydroxyvitamin	O
D	O
[	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D	O
]	O
increases	O
intestinal	O
calcium	O
absorption	O
and	O
decreases	O
renal	O
calcium	O
excretion	O
,	O
thus	O
increasing	O
the	O
pool	O
of	O
calcium	O
available	O
both	O
for	O
mother	O
and	O
foetus	O
.	O

Vitamin	O
D	O
and	O
calcium	O
deficiency	O
can	O
lead	O
to	O
maternal	O
anorexia	O
with	O
poor	O
weight	O
gain	O
,	O
and	O
impaired	O
bone	O
ossification	O
or	O
osteopenia	O
among	O
newborn	O
infant	O
..	O
Neonatal	O
hypocalcemia	O
with	O
seizures	O
is	O
not	O
uncommon	O
in	O
D	O
-	O
vitamin	O
deficient	O
mothers	O
.	O

Vitamin	O
D	O
is	O
likely	B
safe	O
during	O
pregnancy	O
and	O
breast	O
feeding	O
when	O
taken	O
by	O
mouth	O
in	O
recommended	O
amounts	O
,	O
that	O
is	O
10	O
mcg	O
(	O
400	O
USP	O
units	O
)	O
of	O
vitamin	O
D	O
daily	O
in	O
normal	O
pregnancy	O
.	O

but	O
sometimes	O
thyroidectomised	O
women	O
need	O
more	O
.	O

Dosage	O
in	O
excess	O
of	O
50	O
mcg	O
(	O
2000	O
units	O
)	O
per	O
day	O
are	O
not	O
recommended	O
,	O
thus	B
the	O
treatment	O
of	O
postsurgical	O
hypoparatithyroid	O
patient	O
calcium	O
supplementation	O
may	O
be	O
required	O
at	O
dosage	O
as	O
high	O
as	O
4	O
g	O
/	O
day	O
together	O
with	O
D	O
vitamin	O
.	O

The	O
range	O
between	O
therapeutic	O
and	O
toxic	O
doses	O
is	O
narrow	O
,	O
and	O
vitamin	O
D	O
toxicity	O
,	O
when	O
it	O
occurs	O
,	O
is	O
a	O
serious	O
problem	O
.	O

The	O
first	O
sign	O
is	O
a	O
rise	O
in	O
the	O
ratio	O
of	O
calcium	O
to	O
creatinine	O
in	O
the	O
urine	O
,	O
which	O
precedes	O
hypercalcemia	O
.	O

Hypervitaminosis	O
D	O
is	O
thought	O
to	O
be	O
associated	O
with	O
a	O
rare	O
infant	O
disease	O
with	O
supravalvular	O
aortic	O
stenosis	O
,	O
elfin	O
facies	O
and	O
mental	O
retardation	O
.	O

Thus	B
doses	O
of	O
D	O
vitamin	O
and	O
calcium	O
supplementation	O
,	O
which	O
may	O
differ	O
from	O
those	O
recommended	O
in	O
normal	O
pregnancy	O
,	O
need	O
to	O
be	O
carefully	O
tailored	O
in	O
thyroidectomised	O
patients	O
.	O

Thyroid	O
cancer	O
and	O
pregnancy	O
Treatment	O
and	O
follow	O
-	O
up	O
of	O
thyroid	O
cancer	O
in	O
pregnant	O
women	O
are	O
the	O
same	O
as	O
in	O
non	O
-	O
pregnant	O
patients	O
except	O
for	O
the	O
use	O
of	O
radioactive	O
iodine	O
.	O

There	O
are	O
some	O
differences	O
in	O
the	O
management	O
of	O
the	O
two	O
most	O
important	O
histotypes	O
:	O
DTC	O
(	O
differentiated	O
thyroid	O
cancer	O
:	O
follicular	O
and	O
papillary	O
cancer	O
)	O
and	O
MTC	O
(	O
medullary	O
thyroid	O
cancer	O
)	O
just	O
as	O
for	O
non	O
-	O
pregnant	O
patients	O
[	O
Boxes	O
1	O
-	O
2	O
].	O

Caption	O
(	O
BOXED	O
-	O
TEXT	O
)	O
Box	O
1	O
.	O

Differentiated	O
Thyroid	O
Cancer	O
(	O
DTC	O
)	O
–	O
cancer	O
arising	O
from	O
follicular	O
thyroid	O
cells	O
Mostly	B
diagnosed	O
in	O
young	O
people	O
,	O
DTC	O
usually	O
has	O
a	O
good	O
prognosis	O
with	O
an	O
overall	O
90	O
-	O
95	O
%	O
long	O
-	O
term	O
disease	O
-	O
free	O
survival	O
for	O
early	O
stage	O
or	O
low	O
risk	O
tumours	O
,	O
which	O
represent	B
the	O
vast	B
majority	B
of	O
tumours	O
diagnosed	O
below	O
40	O
-	O
45	O
years	O
of	O
age	O
.	O

According	O
to	O
the	O
current	O
staging	O
score	O
,	O
DTCs	O
of	O
any	O
dimension	O
,	O
even	O
with	O
nodal	O
invasion	O
,	O
for	O
patients	O
below	O
45	O
years	O
of	O
age	O
,	O
are	O
classified	O
as	O
Stage	O
I	O
tumours	O
,	O
and	O
usually	O
pregnant	O
patients	O
are	O
below	O
45	O
years	O
of	O
age	O
.	O

Genetic	O
alterations	O
activating	O
a	O
common	O
pathway	O
of	O
the	O
RET	O
-	O
RAS	O
-	O
BRAF	O
signalling	O
cascade	O
and	O
other	O
chromosomal	O
rearrangements	O
have	O
been	O
identified	O
in	O
most	B
DTC	O
.	O

The	O
existence	O
of	O
common	O
genomic	O
changes	O
between	O
DTC	O
and	O
anaplastic	O
carcinoma	O
may	O
provide	O
convincing	O
proof	B
of	O
the	O
multi	O
-	O
step	O
carcinogenesis	O
hypothesis	O
in	O
which	O
cancer	O
cells	O
are	O
produced	O
from	O
well	O
-	O
differentiated	O
benign	O
cells	O
by	O
transformation	O
caused	O
by	O
accumulating	O
damage	O
to	O
their	O
genome	O
Although	O
gene	O
expression	O
in	O
thyroid	O
cancer	O
reveals	O
highly	O
consistent	O
profiles	O
,	O
a	O
second	O
hypothesis	O
has	O
been	O
proposed	O
,	O
which	O
can	O
possibly	O
explain	B
other	O
"	O
non	O
-	O
RET	O
"	O
tumours	O
:	O
namely	O
foetal	O
cell	O
carcinogenesis	O
,	O
according	O
to	O
which	O
cancer	O
cells	O
are	O
derived	O
from	O
the	O
remnants	O
of	O
foetal	O
thyroid	O
cells	O
,	O
or	O
from	O
stem	O
cells	O
instead	O
of	O
differentiated	O
follicular	O
cells	O
.	O

Both	O
hypotheses	O
can	O
be	O
valid	O
and	O
coexist	O
,	O
and	O
the	O
second	O
(	O
foetal	O
-	O
cell	O
carcinogenesis	O
)	O
could	O
explain	B
some	O
cases	O
of	O
unusual	O
,	O
rapidly	O
growing	O
DTC	O
.	O

Both	O
hypotheses	O
would	O
suggest	O
a	O
higher	O
thyroid	O
neoplasm	O
proliferation	O
in	O
stimulated	O
thyroid	O
tissue	O
during	O
pregnancy	O
or	O
adolescence	O
,	O
though	O
even	O
in	O
growing	O
tissues	O
these	O
cancers	O
show	O
a	O
very	O
good	O
prognosis	O
.	O

The	O
best	O
treatment	O
for	O
nearly	B
all	I
identified	O
malignant	O
thyroid	O
neoplasm	O
is	O
surgery	O
.	O

The	O
aim	O
of	O
the	O
primary	O
treatment	O
is	O
an	O
adequate	O
excision	O
of	O
the	O
primary	O
tumour	O
and	O
any	O
loco	O
-	O
regional	O
extension	O
.	O

Considerable	O
controversy	O
still	O
exists	O
over	O
the	O
optimal	O
extent	O
of	O
primary	O
surgical	O
resection	O
.	O

According	O
to	O
the	O
extent	O
of	O
the	O
disease	O
,	O
hemithyroidectomy	O
or	O
radical	O
thyroidectomy	O
is	O
performed	O
.	O

As	B
nodal	O
spread	O
is	O
relatively	O
common	O
,	O
initial	O
surgical	O
exploration	O
should	O
include	O
careful	O
examination	O
of	O
the	O
central	O
compartment	O
nodes	O
(	O
paratracheal	O
and	O
tracheoesophageal	O
)	O
as	O
well	O
as	O
dissection	O
of	O
clinically	O
suspicious	O
nodes	O
for	O
frozen	O
section	O
examination	O
.	O

Nodes	O
in	O
the	O
jugular	O
chains	O
should	O
also	O
be	O
carefully	O
examined	O
with	O
US	O
before	O
surgery	O
and	O
,	O
when	O
suspicious	O
,	O
FNAB	O
should	O
be	O
obtained	O
.	O

If	O
nodal	O
involvement	O
is	O
confirmed	O
,	O
total	O
thyroidectomy	O
and	O
modified	O
radical	O
neck	O
dissection	O
are	O
indicated	O
.	O

Adjuvant	O
therapies	O
Thyroid	O
hormones	O
–	O
Endocrine	O
therapy	O
:	O
post	O
-	O
operative	O
oral	O
administration	O
of	O
supraphysiologic	O
oral	O
doses	O
of	O
levothyroxine	O
are	O
used	O
assuming	O
that	O
the	O
suppression	O
of	O
endogenous	O
production	O
of	O
TSH	O
deprives	O
TSH	O
-	O
dependent	O
DTC	O
cells	O
of	O
an	O
important	O
growth	O
-	O
promoting	O
influence	O
and	O
the	O
goal	O
for	O
basal	O
serum	O
TSH	O
should	O
be	O
in	O
the	O
0	O
.	O
1	O
to	O
0	O
.	O
4	O
mIU	O
/	O
L	O
range	O
.	O

When	O
radical	O
thyroidectomy	O
is	O
performed	O
,	O
the	O
second	O
most	O
frequently	O
used	O
post	O
-	O
operative	O
adjuvant	O
therapy	O
for	O
non	O
-	O
pregnant	O
patients	O
with	O
DTC	O
is	O
radioactive	O
iodine	O
(	O
RAI	O
,	O
I	O
-	O
131	O
)	O
administered	O
to	O
eradicate	O
persistent	O
neck	O
disease	O
or	O
distant	O
metastatic	O
lesions	O
.	O

This	O
adjunctive	O
therapy	O
is	O
supposed	B
to	O
destroy	O
occult	O
microscopic	O
carcinoma	O
within	O
the	O
thyroid	O
remnant	O
by	O
being	O
actively	O
trapped	O
both	O
by	O
normal	O
and	O
pathological	O
thyroid	O
cells	O
,	O
and	O
to	O
facilitate	O
follow	O
-	O
up	O
because	B
serum	O
thyroglobulin	O
(	O
HTG	O
)	O
measurements	O
are	O
more	O
reliable	O
after	O
the	O
destruction	O
of	O
residual	O
normal	O
thyroid	O
tissue	O
.	O

Follow	O
-	O
up	O
Follow	O
-	O
up	O
is	O
planned	O
according	O
to	O
the	O
stage	O
of	O
the	O
disease	O
and	O
to	O
the	O
extent	O
of	O
the	O
surgery	O
performed	O
.	O

All	O
patients	O
should	O
undergo	O
neck	O
ultrasound	O
and	O
serum	O
assay	O
for	O
HTG	O
,	O
HTG	O
antibodies	O
,	O
fT4	O
and	O
TSH	O
.	O

For	O
thyroidectomized	O
high	O
-	O
risk	O
,	O
non	O
-	O
pregnant	O
patients	O
,	O
I	O
-	O
131	O
scan	O
is	O
also	O
indicated	O
,	O
and	O
serum	O
HTG	O
measurements	O
–	O
performed	O
both	O
with	O
thyroxine	O
deprivation	O
or	O
under	O
rTSH	O
(	O
recombinant	O
human	O
TSH	O
)	O
stimulation	O
–	O
is	O
a	O
useful	O
and	O
reliable	O
marker	O
of	O
disease	O
progression	O
or	O
persistence	O
.	O

In	B
our	I
experience	I
,	O
the	O
best	O
follow	O
-	O
up	O
method	O
to	O
detect	O
loco	O
-	O
regional	O
recurrences	O
is	O
,	O
without	B
question	I
,	O
neck	O
sonography	O
,	O
followed	O
by	O
a	O
meticulous	O
physical	O
examination	O
by	O
experienced	O
personnel	O
and	O
,	O
when	O
indicated	O
,	O
ultrasound	O
-	O
guided	O
FNA	O
to	O
confirm	O
clinical	O
suspicion	O
of	O
neck	O
recurrence41	O
-	O
45	O
.	O

Caption	O
(	O
BOXED	O
-	O
TEXT	O
)	O
Box	O
2	O
.	O

Medullary	O
Thyroid	O
Cancer	O
(	O
MTC	O
)	O
–	O
cancer	O
arising	O
from	O
parafollicular	O
thyroid	O
cells	O
Medullary	O
carcinoma	O
of	O
the	O
thyroid	O
(	O
MTC	O
)	O
constitutes	O
approximately	O
5	O
-	O
10	O
%	O
of	O
thyroid	O
cancers	O
,	O
although	O
there	O
are	O
no	O
precise	O
figures	O
for	O
incidence	O
and	O
survival	O
rates	O
because	O
of	O
the	O
large	O
geographic	O
variations	O
,	O
mainly	B
due	O
to	O
its	O
familial	O
pattern	O
.	O

Although	O
uncommon	O
,	O
MTC	O
is	O
interesting	O
because	O
of	O
its	O
biochemical	O
and	O
genetic	O
features	O
and	O
clinical	O
association	O
,	O
both	O
in	O
autosomal	O
-	O
dominant	O
inherited	O
syndromes	O
with	O
incomplete	O
penetrance	O
(	O
MEN	O
IIA	O
and	O
IIB	O
),	O
and	O
in	O
the	O
non	O
-	O
MEN	O
forms	O
.	O

Familial	O
cases	O
account	B
for	I
about	O
30	O
%	O
of	O
MTCs	O
.	O

The	O
occurrence	O
of	O
MTC	O
in	O
both	O
sporadic	O
and	O
familial	O
forms	O
makes	O
the	O
clinical	O
approach	O
to	O
this	O
tumour	O
different	O
from	O
that	O
to	O
other	O
thyroid	O
tumours	O
.	O

First	O
,	O
patients	O
with	O
MTC	O
should	O
always	O
be	O
suspected	B
of	O
carrying	O
the	O
genetic	O
form	O
of	O
the	O
disease	O
.	O

Secondly	O
,	O
the	O
possible	O
presence	O
of	O
associated	O
conditions	O
,	O
such	O
as	O
pheochromocytoma	O
,	O
should	O
be	O
recognized	B
before	O
submitting	O
patients	O
to	O
thyroidectomy	O
.	O

Lastly	O
,	O
since	O
the	O
clinical	O
behaviour	O
of	O
MTC	O
is	O
extremely	O
variable	O
,	O
this	O
tumour	O
represents	O
a	O
true	B
therapeutic	O
challenge	O
.	O

MTC	O
arises	O
from	O
C	O
cells	O
secreting	O
calcitonin	O
,	O
a	O
32	O
-	O
amino	O
acid	O
peptide	O
.	O

Calcitonin	O
is	O
the	O
most	B
clinically	O
useful	O
biochemical	O
marker	O
for	O
these	O
tumours	O
,	O
and	O
C	O
cell	O
hyperplasia	O
represents	O
a	O
pre	O
-	O
cancerous	O
stage	O
.	O

These	O
neuroendocrine	O
cells	O
are	O
believed	O
to	O
be	O
of	O
neural	O
crest	O
origin	O
,	O
thus	B
having	O
a	O
separate	O
lineage	O
from	O
the	O
endoderm	O
-	O
derived	O
follicular	O
thyroid	O
cells	O
.	O

For	B
this	I
reason	I
,	O
in	O
addition	O
to	O
calcitonin	O
-	O
gene	O
products	O
,	O
such	O
as	O
calcitonin	O
CGRP	O
(	O
calcitonin	O
-	O
generelated	O
-	O
peptide	O
)	O
and	O
C	O
-	O
CAP	O
(	O
katacalcin	O
),	O
MTC	O
cells	O
express	O
several	O
other	O
biochemical	O
markers	O
that	O
reflect	O
the	O
features	O
of	O
diffuse	O
neuroendocrine	O
system	O
,	O
implicated	O
in	O
the	O
pathogenesis	O
of	O
the	O
symptoms	O
(	O
flushing	O
,	O
diarrhoea	O
,	O
carcinoid	O
syndrome	O
or	O
Cushing	O
'	O
s	O
syndrome	O
)	O
that	O
may	O
occur	O
in	O
patients	O
with	O
advanced	O
disease	O
.	O

These	O
cells	O
can	O
also	O
produce	O
prostaglandins	O
and	O
other	O
neuroendocrine	O
markers	O
such	O
as	O
chromogranin	O
A	O
,	O
sometimes	O
used	O
together	O
with	O
calcitonin	O
and	O
CEA	O
in	O
MTC	O
patients	O
during	O
follow	O
-	O
up	O
.	O

When	O
dealing	O
with	O
MTC	O
,	O
we	O
should	O
always	O
bear	O
in	O
mind	O
that	O
these	O
patients	O
may	O
be	O
the	O
index	O
-	O
case	O
for	O
one	O
of	O
the	O
familial	O
forms	O
of	O
the	O
disease	O
:	O
presymptomatic	O
screening	O
of	O
relatives	O
of	O
MTC	O
patients	O
enables	O
early	O
diagnosis	O
of	O
this	O
malignancy	O
.	O

Early	O
diagnosis	O
rather	O
than	O
more	O
extensive	O
surgery	O
may	O
improve	O
survival	O
and	O
reduce	O
recurrences	O
,	O
mostly	B
in	O
the	O
MEN	O
IIB	O
form	O
of	O
MTC	O
,	O
which	O
is	O
highly	O
aggressive	O
.	O

Biochemical	O
screening	O
of	O
familial	O
disease	O
consists	O
of	O
serum	O
calcitonin	O
evaluation	O
,	O
and	O
genetic	O
screening	O
of	O
individuals	O
with	O
a	O
RET	O
mutation	O
may	O
also	O
be	O
performed	O
.	O

In	O
inherited	O
forms	O
,	O
the	O
initial	O
germline	O
mutation	O
produces	O
multiple	O
foci	O
of	O
cells	O
–	O
the	O
so	O
-	O
called	O
C	O
-	O
cell	O
hyperplasia	O
–	O
that	O
are	O
susceptible	O
to	O
tumour	O
formation	O
,	O
and	O
each	O
MTC	O
is	O
the	O
result	O
of	O
a	O
second	O
cell	O
transformation	O
in	O
one	O
of	O
these	O
susceptible	O
clones	O
.	O

Primary	O
MTC	O
lesions	O
become	O
visible	O
at	O
echography	O
as	O
solid	O
masses	O
,	O
often	B
with	O
calcifications	O
.	O

Fine	O
needle	O
aspiration	O
shows	O
a	O
mixture	O
of	O
round	O
,	O
polyhedral	O
and	O
spindle	O
-	O
shaped	O
cells	O
that	O
may	O
seem	O
undifferentiated	O
,	O
and	O
look	O
like	O
a	O
variable	O
amount	O
of	O
extra	O
-	O
cellular	O
amyloid	O
.	O

MTCs	O
,	O
like	O
other	O
neuroendocrine	O
tumours	O
,	O
can	O
express	O
somatostatin	O
receptors	O
.	O

Follow	O
-	O
up	O
of	O
MTC	O
patients	O
suspected	O
for	O
recurrence	O
can	O
therefore	O
be	O
performed	O
by	O
using	O
the	O
somatostatin	O
analogue	O
octreotide	O
(	O
octreoscan	O
).	O

The	O
presence	O
of	O
somatostatin	O
receptors	O
provides	O
the	O
basis	O
for	O
treatment	O
with	O
longacting	O
analogues	O
of	O
somatostatin	O
or	O
with	O
Y	O
-	O
octreotide	O
(	O
DOTATOC	O
)	O
in	O
some	O
patients	O
.	O

MTC	O
is	O
somewhat	O
more	O
aggressive	O
than	O
papillary	O
or	O
follicular	O
carcinoma	O
.	O

It	O
locally	O
extends	O
into	O
lymph	O
nodes	O
and	O
into	O
the	O
surrounding	O
muscles	O
and	O
trachea	O
,	O
and	O
may	O
invade	O
lymphatic	O
and	O
blood	O
vessels	O
and	O
metastasize	O
in	O
lungs	O
,	O
bones	O
and	O
liver	O
.	O

Sporadic	O
MTC	O
tumours	O
are	O
often	B
monolateral	O
with	O
a	O
single	O
localization	O
,	O
while	O
familial	O
forms	O
are	O
mostly	B
bilateral	O
and	O
often	B
multifocal	O
or	O
diffuse	O
.	O

For	O
these	O
reasons	B
,	O
total	O
thyroidectomy	O
appears	O
to	O
be	O
the	O
appropriate	O
approach	O
to	O
MTC	O
.	O

Central	O
neck	O
and	O
upper	O
mediastinum	O
clearance	O
and	O
,	O
in	O
addition	O
,	O
mono	O
or	O
bilateral	O
node	O
dissection	O
(	O
depending	O
on	O
the	O
extent	O
of	O
nodal	O
involvement	O
)	O
is	O
also	O
advisable	O
.	O

The	O
most	O
appropriate	O
treatment	O
for	O
clinical	O
N0	O
tumours	O
is	O
still	O
a	O
matter	O
of	O
debate	O
,	O
but	O
most	O
surgeons	O
prefer	O
prophylactic	O
node	O
dissection	O
because	B
MTC	O
metastasize	O
in	O
regional	O
lymph	O
nodes	O
at	O
a	O
very	O
early	O
stage	O
.	O

Surgery	O
is	O
the	O
only	O
treatment	O
which	O
is	O
considered	O
potentially	O
curative	O
for	O
metastatic	O
or	O
recurrent	O
medullary	O
carcinoma	O
.	O

The	O
role	O
of	O
radiotherapy	O
is	O
controversial	O
as	B
MTC	O
is	O
generally	B
not	O
believed	O
to	O
be	O
radio	O
-	O
sensitive	O
.	O

Therapy	O
with	O
long	O
-	O
acting	O
somatostatin	O
analogues	O
has	O
been	O
tested	O
in	O
metastatic	O
disease	O
,	O
with	O
some	O
positive	O
benefots	O
in	O
most	O
patients	O
.	O

Radioactive	O
iodine	O
is	O
ineffective	O
because	O
I	O
-	O
131	O
uptake	O
by	O
MTC	O
cells	O
is	O
negligible	O
.	O

No	O
reliably	O
effective	O
chemotherapeutic	O
regimen	O
has	O
been	O
identified	O
.	O

New	O
drugs	O
with	O
anti	O
-	O
angiogenetic	O
,	O
anti	O
-	O
tyrosine	O
kinase	O
and	O
anti	O
-	O
VEGF	O
effects	O
are	O
currently	O
under	O
observation	O
.	O

In	O
conclusion	O
,	O
there	O
are	O
several	O
ways	O
to	O
expedite	O
the	O
diagnosis	O
of	O
MTC	O
and	O
to	O
follow	O
-	O
up	O
patients	O
after	O
surgery	O
:	O
biochemical	O
markers	O
(	O
e	O
.	O
g	O
.	O

CEA	O
,	O
calcitonin	O
,	O
katacalcin	O
,	O
chromogranin	O
-	O
A	O
according	O
to	O
tumour	O
staining	O
),	O
and	O
scanning	O
with	O
specific	O
ligands	O
such	O
as	O
octreotide	O
.	O

Furthermore	O
,	O
there	O
are	O
new	O
therapeutic	O
approaches	O
under	O
validation	O
for	O
advanced	O
or	O
recurrent	O
disease46	O
-	O
48	O
.	O

Thyroid	O
nodules	O
in	O
pregnancy	O
are	O
often	B
misdiagnosed	O
because	O
of	O
physiological	O
thyroid	O
increases	O
during	O
pregnancy	O
,	O
but	O
clinical	O
and	O
ultrasound	O
findings	O
are	O
sufficient	O
to	O
suspect	B
malignancy	O
.	O

Skilled	O
examiners	O
and	O
good	O
quality	O
images	O
with	O
grey	O
-	O
scale	O
and	O
power	O
Doppler	O
US	O
seem	O
more	O
reliable	O
than	O
other	O
techniques	O
in	O
detecting	O
and	O
differentiating	O
malignant	O
and	O
benign	O
solid	O
thyroid	O
nodules	O
,	O
especially	O
for	O
small	O
lesions	O
.	O

Even	O
during	O
pregnancy	O
,	O
US	O
guided	O
fine	O
-	O
needle	O
aspiration	O
biopsy	O
(	O
FNA	O
)	O
is	O
the	O
investigation	O
of	O
choice	O
,	O
thanks	O
to	O
its	O
reliability	O
and	O
safety1926	O
.	O

Papillary	O
thyroid	O
cancer	O
is	O
the	O
most	O
common	O
histological	O
type	O
detected	O
in	O
pregnant	O
women	O
,	O
and	O
in	O
most	O
series	O
90	O
%	O
to	O
95	O
%	O
of	O
thyroid	O
carcinoma	O
diagnosed	O
are	O
Stage	O
I	O
disease	O
,	O
with	O
the	O
majority	B
found	O
in	O
the	O
first	O
trimester	O
of	O
pregnancy	O
during	O
the	O
first	O
antenatal	O
visit	O
.	O

The	O
predominance	O
of	O
papillary	O
cancer	O
may	O
be	O
an	O
important	O
factor	O
favouring	B
localized	O
disease	O
,	O
as	B
these	O
cancers	O
metastasize	O
slowly	O
,	O
and	O
mostly	B
in	O
the	O
lymphatic	O
system	O
,	O
whereas	O
less	O
common	O
follicular	O
cancers	O
tend	O
to	O
spread	O
via	O
angio	O
-	O
invasion	O
with	O
a	O
higher	O
frequency	O
of	O
distant	O
metastasis	O
.	O

Although	O
thyroid	O
cancer	O
during	O
pregnancy	O
may	O
have	O
a	O
faster	O
growth2728since	O
hormonal	O
factors	O
(	O
mainly	B
HCG	O
)	O
may	O
accelerate	O
tumour	O
progression	O
,	O
the	O
real	O
impact	O
of	O
pregnancy	O
seems	O
to	O
be	O
minimal	O
.	O

In	O
fact	O
,	O
the	O
rates	O
of	O
recurrence	O
or	O
the	O
disease	O
-	O
free	O
period	O
do	O
not	O
differ	O
between	O
pregnant	O
and	O
non	O
-	O
pregnant	O
women	O
affected	O
by	O
the	O
same	O
disease22729	O
-	O
32	O
.	O

Hod	O
et	O
al	O
.	O

reported	O
a	O
single	O
case	O
of	O
accelerated	O
tumour	O
growth	O
during	O
pregnancy	O
,	O
but	O
this	O
would	O
appear	O
to	O
be	O
an	O
exception	O
rather	O
than	O
the	O
rule29	O
.	O

In	O
a	O
large	O
retrospective	O
study	O
on	O
595	O
pregnancy	O
-	O
associated	O
thyroid	O
cancers	O
,	O
Yasmeen	O
et	O
al	O
.	O

detected	O
no	O
difference	O
in	O
outcome	O
,	O
disease	O
-	O
free	O
survival	O
and	O
morbidity	O
when	O
compared	O
to	O
age	O
-	O
matched	O
non	O
-	O
pregnant	O
women2	O
.	O

Differently	O
from	O
what	O
is	O
observed	O
in	O
other	O
pregnancy	O
-	O
associated	O
cancers	O
,	O
no	O
metastasis	O
of	O
DTC	O
to	O
placenta	O
or	O
foetus	O
has	O
been	O
reported	O
.	O

An	O
association	O
between	O
thyroid	O
cancer	O
and	O
parity	O
or	O
full	O
-	O
term	O
pregnancy	O
has	O
been	O
assessed	O
in	O
many	O
studies	O
without	O
significant	O
or	O
conclusive	O
results6	O
.	O

During	O
pregnancy	O
,	O
cellular	O
immunity	O
undergoes	O
changes	O
,	O
as	O
reflected	O
by	O
a	O
decrease	O
in	O
T	O
-	O
cell	O
number	O
.	O

Pregnancyassociated	O
immune	O
tolerance	O
,	O
designed	O
for	O
foetal	O
survival	O
,	O
might	O
enhance	O
disease	O
progression	O
.	O

However	O
,	O
according	O
to	O
literature	O
data	O
and	O
our	O
own	O
experience	O
pregnancy	O
after	O
thyroid	O
cancer	O
has	O
been	O
shown	O
to	O
have	O
no	O
significant	O
effect	O
on	O
morbidity	O
,	O
disease	O
-	O
free	O
period	O
or	O
survival	O
time	O
.	O

Pregnant	O
women	O
with	O
thyroid	O
cancer	O
have	O
been	O
shown	O
to	O
have	O
favourable	O
outcomes	O
regardless	O
of	O
the	O
timing	O
of	O
diagnosis13233	O
.	O

Guidelines	B
for	O
evaluation	O
and	O
treatment	O
of	O
thyroid	O
cancer	O
must	O
consider	O
the	O
gestational	O
age	O
but	O
also	O
the	O
patients	O
'	O
desires	O
.	O

Detecting	O
a	O
thyroid	O
cancer	O
during	O
pregnancy	O
should	O
not	O
be	O
a	O
reason	O
for	O
termination	O
of	O
pregnancy	O
,	O
and	O
in	O
the	O
large	O
majority	B
of	O
cases	O
it	O
does	O
not	O
require	O
urgent	O
surgery4	O
.	O

The	O
problem	O
of	O
pregnancy	O
-	O
associated	O
thyroid	O
cancer	O
can	O
affect	O
three	O
groups	O
of	O
patients	O
:	O
New	O
diagnosis	O
Patients	O
with	O
no	O
prior	O
history	O
of	O
cancer	O
,	O
in	O
whom	O
a	O
malignant	O
thyroid	O
nodule	O
is	O
suspected	O
or	O
diagnosed	O
during	O
pregnancy	O
.	O

For	O
these	O
patients	O
,	O
surgery	O
could	O
be	O
safely	O
performed	O
during	O
the	O
mid	O
-	O
trimester	O
or	O
delayed	O
until	O
delivery	O
without	O
worsening	O
prognosis3034	O
.	O

Thyroidectomy	O
during	O
pregnancy	O
has	O
not	O
been	O
associated	O
with	O
adverse	O
maternal	O
or	O
neonatal	O
outcomes3536	O
.	O

There	O
are	O
no	O
indications	O
for	O
termination	O
of	O
pregnancy4	O
.	O

When	O
surgery	O
is	O
planned	O
during	O
pregnancy	O
,	O
it	O
is	O
important	O
to	O
consider	O
both	O
gestational	O
age	O
and	O
the	O
type	O
of	O
general	O
anaesthesia	O
.	O

Whenever	O
possible	O
,	O
the	O
operation	O
should	O
be	O
performed	O
during	O
the	O
second	O
trimester	O
or	O
after	O
delivery37	O
.	O

During	O
the	O
first	O
trimester	O
,	O
which	O
is	O
the	O
organogenesis	O
period	O
,	O
general	O
anaesthetic	O
agents	O
may	O
have	O
some	O
teratogenic	O
potential	O
or	O
may	O
increase	O
the	O
risk	O
of	O
miscarriage	O
.	O

In	O
the	O
third	O
trimester	O
,	O
surgery	O
may	O
induce	O
premature	O
labour	O
.	O

Physiological	O
changes	O
of	O
pregnancy	O
,	O
such	O
as	O
increased	O
heart	O
rate	O
and	O
blood	O
volume	O
,	O
may	O
complicate	O
general	O
anaesthesia	O
,	O
and	O
hypotension	O
caused	O
by	O
vena	O
cava	O
compression	O
of	O
the	O
uterus	O
during	O
a	O
long	O
period	O
in	O
the	O
supine	O
position	O
may	O
cause	O
foetal	O
hypoperfusion1	O
.	O

Postponing	O
surgery	O
to	O
at	B
least	I
6	O
-	O
7	O
months	O
after	O
diagnosis	O
of	O
DTC	O
in	O
the	O
first	O
trimester	O
does	O
not	O
adversely	O
affect	O
prognosis	O
;	O
on	O
the	O
other	O
hand	O
,	O
thyroidectomy	O
can	O
be	O
safely	O
performed	O
in	O
the	O
second	O
trimester	O
of	O
pregnancy	O
or	O
after	O
delivery15	O
.	O

Thyroxin	O
therapy	O
should	O
be	O
started	O
immediately	O
after	O
surgery	O
because	O
untreated	O
hypothyroidism	O
may	O
expose	O
the	O
mother	O
to	O
a	O
higher	O
risk	O
of	O
disease	O
recurrence	O
and	O
may	O
have	O
an	O
adverse	O
effect	O
on	O
cognitive	O
function	O
and	O
regular	O
growth	O
of	O
the	O
offspring	O
.	O

Regular	O
assessments	O
of	O
TSH	O
and	O
fT4	O
levels	O
every	O
6	O
/	O
8	O
weeks	O
during	O
pregnancy	O
and	O
breast	O
-	O
feeding	O
are	O
required	O
to	O
ensure	O
an	O
adequate	O
dose	O
of	O
levothyroxine	O
.	O

Follow	O
-	O
up	O
may	O
be	O
carried	O
out	O
on	O
a	O
regular	O
basis	O
with	O
ultrasound	O
techniques	O
and	O
thyroglobulin	O
assay	O
,	O
as	O
in	O
non	O
-	O
pregnant	O
women	O
.	O

Radioiodine	O
therapy	O
,	O
when	O
needed	O
,	O
can	O
be	O
safely	O
postponed	O
until	O
after	O
breast	O
-	O
feeding	O
.	O

"	O
Cured	O
"	O
patients	O
Pregnant	O
patients	O
with	O
a	O
history	O
of	O
previously	O
treated	O
DTC	O
with	O
no	O
evidence	O
of	O
recurrent	O
or	O
persistent	O
disease	O
by	O
imaging	O
and	O
by	O
thyroglobulin	O
measurement	O
.	O

Whether	O
women	O
treated	O
for	O
thyroid	O
cancer	O
should	O
become	O
pregnant	O
was	O
once	O
a	O
matter	O
of	O
concern	O
,	O
but	O
current	O
evidence	O
suggests	O
that	O
DTC	O
should	O
not	O
discourage	O
intended	O
pregnancy	O
,	O
with	O
the	O
usual	O
recommendation	O
to	O
postpone	O
it	O
to	O
at	B
least	I
6	O
months	O
after	O
radioiodine	O
therapy	O
.	O

In	O
spite	O
of	O
the	O
theoretical	O
proliferative	O
stimulation	O
caused	O
by	O
HCG	O
and	O
placental	O
growth	O
factors	O
,	O
published	O
data	O
indicate	O
that	O
there	O
is	O
no	O
evidence	O
that	O
thyroid	O
cancer	O
can	O
be	O
influenced	O
by	O
pregnancy	O
.	O

In	O
addition	O
,	O
follow	O
-	O
up	O
studies	O
have	O
shown	O
no	O
significant	O
increase	O
in	O
risk	O
.	O

Usually	O
,	O
patients	O
are	O
recommended	O
to	O
postpone	O
pregnancy	O
to	O
6	O
-	O
12	O
months	O
after	O
radioiodine	O
(	O
I	O
-	O
131	O
)	O
treatment	O
to	O
avoid	O
a	O
potentially	O
higher	O
risk	O
of	O
miscarriage	O
in	O
the	O
first	O
few	O
months	O
after	O
radioiodine	O
therapy	O
and	O
to	O
allow	O
time	O
enough	O
to	O
exclude	O
residual	O
disease	O
requiring	O
further	O
treatment41438	O
.	O

Miscarriages	O
or	O
premature	O
birth	O
have	O
raised	O
concern	O
about	O
the	O
use	O
of	O
radioactive	O
iodine	O
in	O
a	O
childbearing	O
age	O
due	O
to	O
the	O
known	O
mutagenic	O
effect	O
of	O
radiation	O
and	O
the	O
theoretical	O
possibility	O
that	O
it	O
may	O
affect	O
germ	O
cells	O
,	O
thereby	O
causing	O
genetic	O
damage	O
,	O
congenital	O
abnormalities	O
and	O
malignancy	O
in	O
offspring	O
.	O

Virtually	O
any	O
person	O
treated	O
with	O
any	O
dosage	O
of	O
I	O
-	O
131	O
is	O
at	O
potential	O
risk	O
,	O
but	O
experimental	O
evidence	O
in	O
animals	O
and	O
follow	O
-	O
up	O
studies	O
in	O
humans	O
has	O
failed	O
to	O
reveal	O
any	O
statistically	O
significant	O
effects	O
of	O
I	O
-	O
131	O
on	O
chromosomal	O
abnormalities	O
,	O
congenital	O
malformation	O
or	O
childhood	O
cancers	O
.	O

In	O
a	O
large	O
retrospective	O
study	O
,	O
Dottorini	O
et	O
al	O
.	O

evaluated	O
fertility	O
and	O
the	O
long	O
-	O
term	O
effects	O
of	O
I	O
-	O
131	O
therapy	O
in	O
815	O
women	O
.	O

Among	O
those	O
children	O
born	O
from	O
I	O
-	O
131	O
treated	O
women	O
,	O
the	O
authors	O
found	O
only	O
one	O
case	O
of	O
ventricular	O
septal	O
defect	O
and	O
patent	O
ductus	O
arteriosus223940	O
.	O

A	O
possible	O
increase	O
in	O
the	O
rate	O
of	O
miscarriages	O
has	O
been	O
reported	O
to	O
occur	O
in	O
the	O
early	O
period	O
after	O
therapy	O
,	O
but	O
it	O
remains	O
uncertain	O
whether	O
abortion	O
can	O
be	O
caused	O
either	O
by	O
I	O
-	O
131	O
itself	O
,	O
by	O
the	O
thyroid	O
autoimmunity	O
often	B
associated	O
with	O
disease	O
or	O
by	O
the	O
hypothyroid	O
-	O
hyperprolactinaemic	O
status	O
accompanying	O
I	O
-	O
131	O
therapy	O
.	O

At	O
present	O
,	O
consensus	B
has	O
been	O
reached	O
on	O
the	O
fact	O
that	O
radioiodine	O
treatment	O
of	O
DTC	O
does	O
not	O
affect	O
pregnancy	O
outcome	O
and	O
does	O
not	O
appear	O
to	O
be	O
associated	O
with	O
any	O
genetic	O
risk	O
,	O
with	O
the	O
usual	O
recommendation	O
to	O
delay	O
pregnancy	O
for	O
6	O
-	O
12	O
months	O
after	O
radioiodine	O
exposure	O
,	O
even	O
if	O
there	O
is	O
no	O
evidence	O
that	O
pregnancy	O
before	O
this	O
period	O
could	O
lead	O
to	O
a	O
less	O
favourable	O
outcome2238	O
.	O

Persistent	O
or	O
recurrent	O
disease	O
Pregnant	O
patients	O
with	O
the	O
evidence	O
of	O
persistent	O
disease	O
despite	O
therapy	O
.	O

Management	O
of	O
these	O
patients	O
and	O
providing	O
evidencebased	O
advice	O
are	O
obviously	O
extremely	O
difficult	O
tasks	O
.	O

Patients	O
with	O
active	O
DTC	O
can	O
be	O
reassured	B
that	O
,	O
as	O
mentioned	O
above	O
,	O
pregnancy	O
itself	O
does	O
not	O
appear	O
to	O
increase	O
disease	O
progression	O
,	O
and	O
therefore	B
a	O
gap	O
in	O
treatment	O
during	O
pregnancy	O
is	O
not	O
contraindicated	O
.	O

When	O
a	O
simple	O
increase	O
in	O
serum	O
Htg	O
levels	O
is	O
observed	O
,	O
further	O
therapy	O
is	O
not	O
necessary	O
.	O

For	O
patients	O
with	O
local	O
recurrent	O
disease	O
,	O
ultrasound	O
controls	O
by	O
skilled	O
hands	O
is	O
of	O
outmost	O
importance	O
,	O
both	O
to	O
help	O
surgeons	O
in	O
selecting	O
tissues	O
for	O
excision	O
and	O
to	O
perform	O
local	O
therapy	O
,	O
such	O
as	O
alcoholization	O
of	O
small	O
lesions	O
.	O

For	O
patients	O
with	O
advanced	O
disease	O
,	O
ultrasound	O
control	O
of	O
tissue	O
growth	O
can	O
help	O
in	O
therapeutic	O
decisions	O
,	O
such	O
as	O
timing	O
of	O
surgery	O
.	O

Whenever	O
possible	O
,	O
surgery	O
should	O
be	O
carried	O
out	O
during	O
the	O
second	O
trimester	O
or	O
after	O
delivery	O
,	O
as	O
for	O
newly	O
diagnosed	O
thyroid	O
cancer	O
.	O

For	O
any	O
patient	O
,	O
both	O
with	O
first	O
diagnosis	O
or	O
recurrent	O
disease	O
,	O
post	O
-	O
operative	O
therapy	O
for	O
DTC	O
is	O
based	O
on	O
the	O
administration	O
of	O
supraphysiologic	O
"	O
suppressive	O
"	O
oral	O
doses	O
of	O
levothyroxine	O
.	O

This	O
treatment	O
has	O
been	O
widely	O
used	O
for	O
more	O
than	O
40	O
years	O
,	O
with	O
the	O
assumption	O
that	O
suppression	O
of	O
endogenous	O
TSH	O
deprives	O
TSH	O
-	O
dependent	O
DTC	O
cells	O
of	O
the	O
most	O
important	O
growth	O
factor	O
.	O

Therefore	B
,	O
thyroxine	O
therapy	O
aims	O
at	O
suppressing	O
pituitary	O
secretion	O
of	O
TSH	O
,	O
as	B
indicated	O
by	O
serum	O
TSH	O
levels	O
below	O
0	O
.	O
05	O
mIU	O
/	O
L	O
.	O

In	O
univariate	O
analyses	O
,	O
thyroxine	O
therapy	O
apparently	O
helps	O
decrease	O
cancer	O
-	O
related	O
death	O
rates	O
among	O
patients	O
with	O
PTC	O
.	O

Many	O
series	O
have	O
reported	O
reduced	O
rates	O
of	O
tumour	O
recurrence	O
both	O
in	O
PTC	O
and	O
in	O
FTC	O
.	O

Doses	O
of	O
L	O
-	O
thyroxine	O
greater	O
than	O
150	O
/	O
200	O
μg	O
(	O
at	B
least	I
2	O
μg	O
/	O
kg	O
/	O
day	O
)	O
are	O
usually	O
needed	O
to	O
maintain	O
maternal	O
serum	O
-	O
free	O
thyroxin	O
concentrations	O
within	O
the	O
upper	O
third	O
of	O
the	O
reference	O
range	O
and	O
to	O
suppress	O
TSH	O
levels	O
.	O

Usually	O
the	O
dosage	O
needs	O
to	O
be	O
increased	O
as	O
early	O
as	O
during	O
the	O
fifth	O
week	O
of	O
gestation	O
,	O
and	O
fT4	O
TSH	O
monitoring	O
is	O
recommended	O
every	O
6	O
weeks	O
for	O
adequate	O
adjustment	O
of	O
dosage	O
.	O

After	O
delivery	O
,	O
thyroxine	O
dose	O
can	O
be	O
gradually	O
reduced	O
to	O
pre	O
-	O
pregnancy	O
levels	O
,	O
while	O
TSH	O
levels	O
should	O
be	O
constantly	O
monitored1015	O
.	O

Patients	O
with	O
MTC	O
whose	O
tumours	O
deriving	O
from	O
C	O
cells	O
are	O
not	O
TSH	O
-	O
dependent	O
do	O
not	O
require	O
suppressive	O
therapy	O
,	O
but	O
only	O
thyroxine	O
replacement	O
therapy	O
after	O
surgery	O
,	O
and	O
the	O
dosages	O
are	O
the	O
same	O
as	O
those	O
used	O
for	O
hypothyroidism	O
.	O

Pregnancy	O
status	O
requires	O
much	O
more	O
accuracy	O
in	O
assessing	O
levothyroxine	O
dosage	O
to	O
protect	O
the	O
foetus	O
from	O
maternal	O
hypothyroidism	O
because	O
,	O
as	O
mentioned	O
above	O
,	O
the	O
mother	O
is	O
the	O
only	O
source	O
of	O
thyroid	O
hormones	O
for	O
the	O
embryo	O
in	O
the	O
first	O
trimester	O
of	O
pregnancy	O
.	O

With	O
regards	O
to	O
pharmacokinetics	O
,	O
oral	O
dosing	O
produces	O
therapeutic	O
effects	O
within	O
3	O
-	O
5	O
days	O
.	O

Approximately	O
40	O
-	O
80	O
%	O
of	O
the	O
oral	O
dose	O
is	O
absorbed	O
,	O
with	O
peak	O
serum	O
levels	O
measured	O
within	O
2	O
-	O
4	O
hour	O
,	O
and	O
the	O
half	O
-	O
life	O
of	O
the	O
administered	O
dose	O
is	O
approximately	O
1	O
week	O
.	O

The	O
extent	O
of	O
absorption	O
is	O
increased	O
in	O
fasting	O
status	O
and	O
decreased	O
if	O
there	O
is	O
inadequate	O
intestinal	O
absorption	O
,	O
often	B
caused	O
by	O
other	O
drugs	O
,	O
such	O
as	O
ferrous	O
sulphate	O
.	O

Therefore	B
,	O
during	O
pregnancy	O
,	O
thyroxin	O
and	O
ferrous	O
sulphate	O
doses	O
should	O
be	O
spaced	O
by	O
at	B
least	I
4	O
hours	O
.	O

There	O
is	O
limited	O
but	O
still	O
important	O
placental	O
transfer	O
of	O
maternal	O
T4	O
to	O
the	O
foetus18	O
,	O
while	O
placental	O
type	O
III	O
deiodinase	O
catalyzes	O
the	O
conversion	O
of	O
T4	O
to	O
the	O
more	O
active	O
form	O
reverse	O
-	O
T3	O
,	O
which	O
crosses	O
the	O
placental	O
barrier	O
,	O
and	O
to	O
the	O
less	O
active	O
3	O
,	O
3	O
'-	O
diiodothyronine	O
(	O
T2	O
),	O
representing	B
a	O
homeostatic	O
mechanism	O
for	O
maintaining	O
T3production	O
in	O
the	O
placenta	O
when	O
maternal	O
serum	O
T4concentrations	O
are	O
modified18	O
.	O

Frequent	O
monitoring	O
and	O
adjustment	O
of	O
L	O
-	O
T4	O
dosages	O
are	O
very	O
important	O
because	B
of	O
large	O
fluctuations	O
of	O
T4	O
metabolism	O
during	O
pregnancy	O
;	O
calcium	O
and	O
D	O
vitamin	O
supplementation	O
,	O
often	B
indispensable	O
,	O
must	O
be	O
carefully	O
tailored2324	O
.	O

Conclusions	O
When	O
treating	O
thyroid	O
cancer	O
in	O
pregnancy	O
,	O
3	O
factors	O
should	O
be	O
considered	O
:	O
The	O
effect	O
of	O
cancer	O
on	O
pregnancy	O
:	O
No	O
metastasis	O
to	O
placenta	O
or	O
foetus	O
–	O
no	O
IUGR	O
.	O

Pregnancy	O
does	O
not	O
seem	O
to	O
be	O
compromised	O
by	O
thyroid	O
cancer	O
.	O

The	O
effect	O
of	O
pregnancy	O
on	O
cancer	O
:	O
In	O
vitro	O
accelerated	O
cell	O
growth	O
,	O
no	O
effect	O
seen	O
in	O
vivo	O
.	O

Survival	O
and	O
disease	O
-	O
free	O
intervals	O
identical	O
in	O
pregnant	O
and	O
non	O
-	O
pregnant	O
women	O
The	O
effects	O
of	O
management	O
modalities	O
on	O
pregnancy	O
outcome	O
:	O
No	O
I	O
-	O
131	O
,	O
tailored	O
therapy	O
.	O

Critical	O
monthly	O
adjustment	O
of	O
levothyroxine	O
therapy	O
:	O
maintain	O
fT4	O
in	O
the	O
upper	O
third	O
of	O
reference	O
range	O
.	O

PubMed	O
Central	O
:	O

In	O
Utero	O
Exposures	O
,	O
Infant	O
Growth	O
,	O
and	O
DNA	O
Methylation	O
of	O
Repetitive	O
Elements	O
and	O
Developmentally	O
Related	O
Genes	O
in	O
Human	O
Placenta	O
Abstract	O
Background	O
:	O
Fetal	O
programming	O
describes	O
the	O
theory	O
linking	O
environmental	O
conditions	O
during	O
embryonic	O
and	O
fetal	O
development	O
with	O
risk	O
of	O
diseases	O
later	O
in	O
life	O
.	O

Environmental	O
insults	O
in	O
utero	O
may	O
lead	O
to	O
changes	O
in	O
epigenetic	O
mechanisms	O
potentially	O
affecting	O
fetal	O
development	O
.	O

Objectives	O
:	O
We	O
examined	O
associations	O
between	O
in	O
utero	O
exposures	O
,	O
infant	O
growth	O
,	O
and	O
methylation	O
of	O
repetitive	O
elements	O
and	O
gene	O
-	O
associated	O
DNA	O
in	O
human	O
term	O
placenta	O
tissue	O
samples	O
.	O

Methods	O
:	O
Placental	O
tissues	O
and	O
associated	O
demographic	O
and	O
clinical	O
data	O
were	O
obtained	O
from	O
subjects	O
delivering	O
at	O
Women	O
and	O
Infants	O
Hospital	O
in	O
Providence	O
,	O
Rhode	O
Island	O
(	O
USA	O
).	O

Methylation	O
levels	O
of	O
long	O
interspersed	O
nuclear	O
element	O
-	O
1	O
(	O
LINE	O
-	O
1	O
)	O
and	O
the	O
Alu	O
element	O
AluYb8	O
were	O
determined	O
in	O
380	O
placental	O
samples	O
from	O
term	O
deliveries	O
using	O
bisulfite	O
pyrosequencing	O
.	O

Genomewide	O
DNA	O
methylation	O
profiles	O
were	O
obtained	O
in	O
a	O
subset	O
of	O
184	O
samples	O
using	O
the	O
Illumina	O
Infinium	O
HumanMethylation27	O
BeadArray	O
.	O

Multiple	O
linear	O
regression	O
,	O
model	O
-	O
based	O
clustering	O
methods	O
,	O
and	O
gene	O
set	O
enrichment	O
analysis	O
examined	O
the	O
association	O
between	O
birth	O
weight	O
percentile	O
,	O
demographic	O
variables	O
,	O
and	O
repetitive	O
element	O
methylation	O
and	O
gene	O
-	O
associated	O
CpG	O
locus	O
methylation	O
.	O

Results	O
:	O
LINE	O
-	O
1	O
and	O
AluYb8	O
methylation	O
levels	O
were	O
found	O
to	O
be	O
significantly	O
positively	O
associated	O
with	O
birth	O
weight	O
percentile	O
(	O
p	O
=	O
0	O
.	O
01	O
and	O
p	O
<	O
0	O
.	O
0001	O
,	O
respectively	O
)	O
and	O
were	O
found	O
to	O
differ	O
significantly	O
among	O
infants	O
exposed	O
to	O
tobacco	O
smoke	O
and	O
alcohol	O
.	O

Increased	O
placental	O
AluYb8	O
methylation	O
was	O
positively	O
associated	O
with	O
average	O
methylation	O
among	O
CpG	O
loci	O
found	O
in	O
polycomb	O
group	O
target	O
genes	O
;	O
developmentally	O
related	O
transcription	O
factor	O
binding	O
sites	O
were	O
overrepresented	O
for	O
differentially	O
methylated	O
loci	O
associated	O
with	O
both	O
elements	O
.	O

Conclusions	O
:	O
Our	O
results	O
suggest	O
that	O
repetitive	O
element	O
methylation	O
markers	O
,	O
most	O
notably	O
AluYb8	O
methylation	O
,	O
may	O
be	O
susceptible	O
to	O
epigenetic	O
alterations	O
resulting	O
from	O
the	O
intrauterine	O
environment	O
and	O
play	O
a	O
critical	O
role	O
in	O
mediating	O
placenta	O
function	O
,	O
and	O
may	O
ultimately	O
inform	O
on	O
the	O
developmental	O
basis	O
of	O
health	O
and	O
disease	O
.	O

The	O
importance	O
of	O
environmental	O
exposures	O
during	O
intrauterine	O
development	O
on	O
health	O
throughout	O
the	O
life	O
course	O
is	O
now	O
well	O
recognized	O
in	O
the	O
epidemiologic	O
literature	O
(	O
Barker	O
2004	O
).	O

The	O
molecular	O
mechanisms	O
that	O
underlie	O
these	O
observations	O
remain	O
unclear	O
,	O
although	O
recent	O
work	O
suggests	O
that	O
alterations	O
to	O
placental	O
function	O
may	O
lead	O
to	O
altered	O
fetal	O
development	O
and	O
programming	O
,	O
likely	B
playing	O
a	O
critical	O
role	O
in	O
mediating	O
these	O
associations	O
(	O
Higgins	O
et	O
al	O
.	O

2011	O
;	O
Lester	O
and	O
Padbury	O
2009	O
).	O

Throughout	O
in	O
utero	O
development	O
,	O
the	O
placenta	O
,	O
through	O
the	O
production	O
of	O
various	O
enzymes	O
and	O
hormones	O
,	O
plays	O
an	O
important	O
role	O
in	O
controlling	O
growth	O
and	O
development	O
through	O
the	O
transfer	O
of	O
nutrients	O
and	O
waste	O
and	O
in	O
protecting	O
the	O
fetus	O
from	O
many	O
xenobiotic	O
insults	O
(	O
Robins	O
et	O
al	O
.	O

2011	O
).	O

Recent	O
work	O
has	O
demonstrated	O
that	O
placental	O
genetic	O
and	O
epigenetic	O
profiles	O
may	O
possibly	O
serve	O
as	O
markers	O
(	O
Filiberto	O
et	O
al	O
.	O

2011	O
;	O
Sood	O
et	O
al	O
.	O

2006	O
)	O
of	O
the	O
intrauterine	O
and	O
extrauterine	O
environment	O
(	O
Nelissen	O
et	O
al	O
.	O

2011	O
).	O

DNA	O
methylation	O
is	O
a	O
key	O
mode	O
of	O
epigenetic	O
regulation	O
,	O
which	O
can	O
lead	O
to	O
silencing	O
of	O
genomic	O
regions	O
.	O

DNA	O
methylation	O
patterns	O
are	O
essential	O
for	O
the	O
growth	O
and	O
maintenance	O
of	O
tissue	O
-	O
specific	O
expression	O
profiles	O
in	O
different	O
cell	O
types	O
during	O
development	O
,	O
and	O
these	O
patterns	O
become	O
set	O
during	O
in	O
utero	O
development	O
(	O
Hajkova	O
et	O
al	O
.	O

2002	O
;	O
Jaenisch	O
1997	O
;	O
Rougier	O
et	O
al	O
.	O

1998	O
).	O

This	O
is	O
true	O
both	O
in	O
the	O
fetus	O
itself	O
and	O
in	O
the	O
placenta	O
,	O
where	O
changes	O
to	O
the	O
appropriate	O
methylation	O
patterning	O
have	O
been	O
linked	O
to	O
adverse	O
placental	O
morphology	O
and	O
birth	O
outcomes	O
(	O
Serman	O
et	O
al	O
.	O

2007	O
;	O
Sinclair	O
et	O
al	O
.	O

2007	O
).	O

Studies	O
examining	O
the	O
impact	O
of	O
environmental	O
exposures	O
on	O
DNA	O
methylation	O
have	O
often	B
focused	O
on	O
the	O
global	O
extent	O
of	O
5	O
-	O
methylcytosine	O
,	O
using	O
various	O
approaches	O
(	O
Einstein	O
et	O
al	O
.	O

2010	O
;	O
Pavanello	O
et	O
al	O
.	O

2009	O
),	O
including	O
the	O
examination	O
of	O
repetitive	O
elements	O
as	O
surrogate	O
markers	O
of	O
global	O
methylation	O
(	O
Choi	O
et	O
al	O
.	O

2009	O
;	O
Lupski	O
2010	O
;	O
Weisenberger	O
et	O
al	O
.	O

2005	O
).	O

These	O
DNA	O
repetitive	O
elements	O
are	O
made	O
up	O
of	O
interspersed	O
and	O
tandem	O
repeats	O
and	O
comprise	O
at	O
least	O
half	O
of	O
the	O
human	O
genome	O
(	O
Zamudio	O
and	O
Bourc	O
’	O
his	O
2010	O
).	O

Specifically	O
,	O
interspersed	O
repeats	O
are	O
composed	O
of	O
retrotransposable	O
elements	O
such	O
as	O
long	O
interspersed	O
nuclear	O
elements	O
(	O
LINEs	O
)	O
and	O
short	O
interspersed	O
nuclear	O
elements	O
(	O
SINEs	O
).	O

The	O
LINE	O
-	O
1	O
subclass	O
is	O
the	O
most	O
common	O
LINE	O
,	O
representing	O
about	O
20	O
%	O
of	O
the	O
total	O
human	O
genome	O
,	O
whereas	O
the	O
most	O
abundant	O
type	O
of	O
SINE	O
is	O
the	O
Alu	O
element	O
,	O
as	O
exemplified	O
by	O
AluYb8	O
;	O
together	O
LINE	O
and	O
Alu	O
sequences	O
make	O
up	O
nearly	O
one	O
-	O
third	O
of	O
the	O
genome	O
(	O
Choi	O
et	O
al	O
.	O

2009	O
;	O
Zamudio	O
and	O
Bourc	O
’	O
his	O
2010	O
).	O

The	O
methylation	O
status	O
of	O
these	O
elements	O
may	O
represent	O
a	O
passive	O
dosimeter	O
by	O
being	O
altered	O
by	O
various	O
exposures	O
,	O
although	O
differences	O
in	O
the	O
underlying	O
structure	O
of	O
these	O
elements	O
and	O
the	O
unclear	O
function	O
of	O
methylation	O
of	O
these	O
regions	O
suggest	O
that	O
their	O
alteration	O
and	O
their	O
potential	O
relevance	O
need	O
to	O
be	O
more	O
carefully	O
examined	O
.	O

Thus	O
,	O
in	O
this	O
study	O
we	O
examined	O
how	O
the	O
intrauterine	O
environment	O
is	O
related	O
to	O
the	O
methylation	O
status	O
of	O
LINE	O
-	O
1	O
and	O
Alu	O
regions	O
(	O
specifically	O
LINE	O
-	O
1	O
and	O
AluYb8	O
,	O
respectively	O
)	O
in	O
a	O
functionally	O
relevant	O
fetal	O
tissue	O
,	O
the	O
placenta	O
.	O

Further	O
,	O
we	O
aimed	O
to	O
explore	O
whether	O
alterations	O
to	O
the	O
methylation	O
of	O
these	O
regions	O
are	O
associated	O
with	O
methylation	O
of	O
gene	O
-	O
associated	O
loci	O
using	O
a	O
genomewide	O
bioinformatic	O
approach	O
,	O
in	O
order	O
to	O
provide	O
clues	O
about	O
the	O
potential	O
importance	O
of	O
these	O
alterations	O
.	O

Methods	O
Study	O
population	O
.	O

Residual	O
placental	O
tissues	O
were	O
obtained	O
from	O
479	O
patients	O
delivering	O
at	O
the	O
Women	O
and	O
Infants	O
Hospital	O
in	O
Providence	O
,	O
Rhode	O
Island	O
(	O
USA	O
),	O
from	O
September	O
2008	O
through	O
September	O
2009	O
.	O

This	O
hospital	O
performs	O
approximately	O
85	O
%	O
of	O
all	O
obstetrical	O
deliveries	O
in	O
Providence	O
County	O
(	O
the	O
largest	O
population	O
center	O
in	O
Rhode	O
Island	O
)	O
and	O
approximately	O
74	O
%	O
of	O
all	O
deliveries	O
in	O
Rhode	O
Island	O
.	O

Study	O
eligibility	O
criteria	O
for	O
mothers	O
included	O
healthy	O
mothers	O
ranging	O
from	O
18	O
to	O
40	O
years	O
of	O
age	O
,	O
with	O
no	O
history	O
of	O
gestational	O
diabetes	O
,	O
psychological	O
disorders	O
,	O
or	O
genetic	O
disorders	O
.	O

Eligibility	O
criteria	O
for	O
infants	O
included	O
viable	O
infants	O
of	O
term	O
births	O
(	O
born	O
>	O
37	O
weeks	O
of	O
gestation	O
)	O
with	O
no	O
known	O
genetic	O
disorders	O
or	O
life	O
-	O
threatening	O
illnesses	O
.	O

We	O
selected	O
infants	O
considered	O
small	O
for	O
gestational	O
age	O
(	O
SGA	O
;	O
<	O
10th	O
percentile	O
of	O
birth	O
weight	O
)	O
and	O
matched	O
non	O
-	O
SGA	O
infants	O
to	O
these	O
for	O
infant	O
sex	O
,	O
maternal	O
age	O
(±	O
3	O
years	O
),	O
and	O
gestational	O
age	O
(±	O
2	O
days	O
).	O

For	O
a	O
description	O
of	O
placental	O
tissue	O
use	O
,	O
DNA	O
extraction	O
,	O
and	O
DNA	O
purification	O
procedures	O
,	O
see	O
Supplemental	O
Material	O
,	O
Supplementary	O
Text	O
1	O
(	O
http	O
://	O
dx	O
.	O
doi	O
.	O
org	O
/	O
10	O
.	O
1289	O
/	O
ehp	O
.	O
1103927	O
).	O

All	O
procedures	O
were	O
approved	O
by	O
the	O
appropriate	O
institutional	O
review	O
boards	O
at	O
Women	O
and	O
Infants	O
Hospital	O
and	O
at	O
Brown	O
University	O
,	O
and	O
participants	O
were	O
exempted	O
from	O
informed	O
consent	O
requirements	O
.	O

Covariate	O
data	O
.	O

All	O
covariate	O
data	O
were	O
collected	O
from	O
a	O
structured	O
inpatient	O
medical	O
record	O
review	O
.	O

Birth	O
weight	O
percentile	O
was	O
calculated	O
using	O
the	O
Fenton	O
growth	O
chart	O
from	O
gestational	O
age	O
and	O
birth	O
weight	O
in	O
grams	O
(	O
Fenton	O
2003	O
),	O
allowing	O
us	O
to	O
account	O
for	O
gestational	O
age	O
in	O
our	O
birth	O
weight	O
metric	O
and	O
to	O
create	O
a	O
normalized	O
distribution	O
for	O
birth	O
weight	O
through	O
birth	O
weight	O
percentile	O
.	O

Birth	O
weight	O
percentile	O
was	O
stratified	O
into	O
three	O
clinically	O
meaningful	O
categories	O
to	O
create	O
birth	O
weight	O
status	O
:	O
SGA	O
babies	O
,	O
defined	O
as	O
babies	O
whose	O
birth	O
weight	O
lies	O
below	O
the	O
10th	O
percentile	O
for	O
that	O
gestational	O
age	O
;	O
appropriate	O
for	O
gestational	O
age	O
(	O
AGA	O
)	O
babies	O
,	O
defined	O
as	O
babies	O
whose	O
birth	O
weight	O
lies	O
above	O
the	O
10th	O
percentile	O
for	O
that	O
gestational	O
age	O
and	O
below	O
the	O
90th	O
percentile	O
for	O
that	O
gestational	O
age	O
;	O
and	O
large	O
for	O
gestational	O
age	O
(	O
LGA	O
)	O
babies	O
,	O
defined	O
as	O
babies	O
whose	O
birth	O
weight	O
lies	O
above	O
the	O
90th	O
percentile	O
for	O
that	O
gestational	O
age	O
.	O

DNA	O
methylation	O
analysis	O
.	O

Repetitive	O
element	O
DNA	O
methylation	O
was	O
determined	O
by	O
bisulfite	O
pyrosequencing	O
of	O
the	O
LINE	O
-	O
1	O
and	O
the	O
AluYb8	O
repetitive	O
elements	O
as	O
previously	O
described	O
(	O
Bollati	O
et	O
al	O
.	O

2007	O
;	O
Choi	O
et	O
al	O
.	O

2009	O
).	O

Methylation	O
extent	O
was	O
calculated	O
as	O
the	O
mean	O
LINE	O
-	O
1	O
methylation	O
of	O
four	O
positions	O
in	O
the	O
element	O
and	O
mean	O
AluYb8	O
methylation	O
of	O
five	O
positions	O
in	O
the	O
element	O
.	O

Pyrosequencing	O
of	O
these	O
repeat	O
elements	O
was	O
successful	O
in	O
380	O
samples	O
;	O
we	O
noted	O
no	O
significant	O
differences	O
in	O
the	O
demographics	O
or	O
clinical	O
characteristics	O
of	O
these	O
samples	O
compared	O
with	O
the	O
larger	O
population	O
.	O

To	O
examine	O
gene	O
-	O
related	O
CpG	O
methylation	O
on	O
a	O
subset	O
of	O
the	O
samples	O
(	O
n	O
=	O
184	O
),	O
methylation	O
was	O
measured	O
at	O
27	O
,	O
578	O
CpG	O
loci	O
using	O
the	O
Infinium	O
HumanMethylation27	O
BeadArray	O
(	O
Illumina	O
,	O
San	O
Diego	O
,	O
CA	O
).	O

The	O
microarrays	O
were	O
processed	O
at	O
the	O
University	O
of	O
California	O
–	O
San	O
Francisco	O
Institute	O
for	O
Human	O
Genetics	O
and	O
Genomics	O
Core	O
Facility	O
,	O
following	O
standard	O
protocols	O
.	O

The	O
methylation	O
status	O
for	O
each	O
individual	O
CpG	O
locus	O
was	O
calculated	O
as	O
the	O
ratio	O
of	O
fluorescent	O
signals	O
:	O
β	O
=	O
max	O
(	O
M	O
,	O
0	O
)/[	O
max	O
(	O
M	O
,	O
0	O
)	O
+	O
max	O
(	O
U	O
,	O
0	O
)	O
+	O
100	O
],	O
using	O
the	O
average	O
probe	O
intensity	O
for	O
the	O
methylated	O
(	O
M	O
)	O
and	O
unmethylated	O
(	O
U	O
)	O
alleles	O
.	O

Ratios	O
range	O
from	O
0	O
to	O
1	O
:	O
β	O
=	O
1	O
indicates	O
complete	O
methylation	O
and	O
β	O
=	O
0	O
represents	O
no	O
methylation	O
.	O

The	O
data	O
were	O
then	O
assembled	O
using	O
BeadStudio	O
methylation	O
software	O
(	O
version	O
1	O
.	O
9	O
.	O
0	O
;	O
Illumina	O
),	O
without	O
normalization	O
,	O
per	O
the	O
manufacturer	O
’	O
s	O
instructions	O
.	O

We	O
used	O
array	O
control	O
probes	O
to	O
assess	O
the	O
quality	O
of	O
our	O
samples	O
and	O
evaluate	O
potential	O
problems	O
such	O
as	O
poor	O
bisulfite	O
conversion	O
or	O
color	O
-	O
specific	O
issues	O
for	O
each	O
array	O
.	O

Mahalanobis	O
distance	O
was	O
used	O
to	O
screen	O
outliers	O
,	O
and	O
all	O
CpG	O
loci	O
on	O
X	O
and	O
Y	O
chromosomes	O
were	O
excluded	O
from	O
the	O
analysis	O
,	O
to	O
avoid	O
sex	O
-	O
specific	O
methylation	O
bias	O
,	O
leaving	O
a	O
final	O
26	O
,	O
486	O
autosomal	O
CpG	O
loci	O
representing	O
13	O
,	O
890	O
unique	O
genes	O
(	O
Poage	O
et	O
al	O
.	O

2011	O
).	O

We	O
and	O
others	O
have	O
previously	O
demonstrated	O
that	O
methylation	O
of	O
CpG	O
loci	O
detected	O
through	O
BeadArray	O
platforms	O
can	O
be	O
reliably	O
replicated	O
using	O
alternative	O
detection	O
techniques	O
including	O
pyrosequencing	O
,	O
MassARRAY	O
analysis	O
,	O
and	O
quantitative	O
methylation	O
-	O
specific	O
polymerase	O
chain	O
reaction	O
(	O
Ang	O
et	O
al	O
.	O

2010	O
;	O
Christensen	O
et	O
al	O
.	O

2010	O
;	O
Lin	O
et	O
al	O
.	O

2010	O
;	O
Marsit	O
et	O
al	O
.	O

2010	O
;	O
Poage	O
et	O
al	O
.	O

2010	O
,	O
2011	O
;	O
Wolff	O
et	O
al	O
.	O

2010	O
).	O

Statistical	O
methods	O
.	O

Univariate	O
associations	O
of	O
exposures	O
and	O
demographics	O
with	O
birth	O
weight	O
percentile	O
status	O
or	O
with	O
LINE	O
-	O
1	O
and	O
AluYb8	O
extent	O
were	O
examined	O
using	O
Kruskal	O
–	O
Wallis	O
tests	O
for	O
continuous	O
covariates	O
and	O
chi	O
-	O
square	O
tests	O
for	O
categorical	O
covariates	O
.	O

A	O
Pearson	O
correlation	O
was	O
used	O
to	O
examine	O
the	O
correlation	O
between	O
LINE	O
-	O
1	O
and	O
AluYb8	O
extents	O
.	O

Multiple	O
linear	O
regression	O
was	O
then	O
used	O
to	O
evaluate	O
the	O
association	O
between	O
LINE	O
-	O
1	O
or	O
AluYb8	O
methylation	O
levels	O
and	O
continuous	O
birth	O
weight	O
percentile	O
.	O

All	O
models	O
were	O
adjusted	O
for	O
infant	O
sex	O
and	O
maternal	O
age	O
,	O
body	O
mass	O
index	O
(	O
BMI	O
)	O
before	O
pregnancy	O
,	O
ethnicity	O
(	O
non	O
-	O
Caucasian	O
/	O
Caucasian	O
),	O
and	O
alcohol	O
,	O
tobacco	O
,	O
and	O
prenatal	O
vitamin	O
use	O
during	O
pregnancy	O
(	O
all	O
yes	O
/	O
no	O
).	O

To	O
check	O
the	O
linearity	O
assumption	O
for	O
the	O
regression	O
models	O
,	O
we	O
plotted	O
residuals	O
by	O
birth	O
weight	O
percentile	O
for	O
all	O
models	O
and	O
found	O
no	O
evidence	O
for	O
systematic	O
nonlinearity	O
.	O

To	O
examine	O
how	O
repetitive	O
element	O
methylation	O
was	O
related	O
to	O
gene	O
-	O
associated	O
methylation	O
,	O
we	O
restricted	O
our	O
analysis	O
to	O
placentas	O
for	O
which	O
we	O
had	O
both	O
repetitive	O
element	O
and	O
gene	O
-	O
associated	O
(	O
array	O
)	O
methylation	O
data	O
for	O
the	O
26	O
,	O
486	O
CpG	O
autosomal	O
loci	O
(	O
n	O
=	O
184	O
).	O

Using	O
a	O
data	O
-	O
driven	O
recursively	O
partitioned	O
mixture	O
model	O
(	O
RPMM	O
),	O
these	O
CpG	O
loci	O
were	O
clustered	O
into	O
16	O
methylation	O
classes	O
based	O
on	O
like	O
methylation	O
pattern	O
obtained	O
from	O
the	O
array	O
results	O
,	O
pruning	O
the	O
model	O
after	O
four	O
splits	O
to	O
maintain	O
power	O
(	O
Houseman	O
et	O
al	O
.	O

2008	O
).	O

For	O
each	O
subject	O
,	O
16	O
corresponding	O
aggregate	O
methylation	O
values	O
were	O
obtained	O
by	O
averaging	O
together	O
average	O
methylation	O
β	O
-	O
values	O
from	O
all	O
CpGs	O
within	O
each	O
class	O
.	O

RPMM	O
classes	O
were	O
labeled	O
using	O
a	O
series	O
of	O
numbers	O
,	O
ranging	O
from	O
1	O
to	O
16	O
(	O
with	O
class	O
1	O
having	O
the	O
lowest	O
methylation	O
level	O
and	O
class	O
16	O
having	O
the	O
highest	O
methylation	O
level	O
).	O

RPMM	O
was	O
selected	O
for	O
this	O
analysis	O
because	O
we	O
have	O
demonstrated	O
that	O
RPMM	O
provides	O
more	O
consistent	O
clustering	O
and	O
more	O
robustness	O
in	O
the	O
selection	O
of	O
the	O
number	O
of	O
classes	O
because	O
of	O
its	O
hierarchical	O
presentation	O
of	O
classes	O
,	O
compared	O
with	O
metric	O
hierarchical	O
clustering	O
,	O
for	O
this	O
data	O
set	O
[	O
see	O
Supplemental	O
Material	O
,	O
Supplementary	O
Text	O
2	O
(	O
http	O
://	O
dx	O
.	O
doi	O
.	O
org	O
/	O
10	O
.	O
1289	O
/	O
ehp	O
.	O
1103927	O
)].	O

An	O
alternative	O
,	O
attribute	O
-	O
driven	O
clustering	O
scheme	O
for	O
the	O
26	O
,	O
486	O
autosomal	O
CpG	O
loci	O
was	O
employed	O
by	O
grouping	O
CpGs	O
by	O
epigenetically	O
relevant	O
bioinformatic	O
attributes	O
:	O
CpG	O
island	O
(	O
CGI	O
)	O
status	O
(	O
Takai	O
and	O
Jones	O
2002	O
),	O
polycomb	O
group	O
(	O
PcG	O
)	O
target	O
status	O
of	O
the	O
associated	O
gene	O
[	O
i	O
.	O
e	O
.,	O
gene	O
was	O
described	O
as	O
a	O
PcG	O
target	O
in	O
at	O
least	O
one	O
ofBracken	O
et	O
al	O
.	O

(	O
2006	O
),	O
Lee	O
et	O
al	O
.	O

(	O
2006	O
),	O
Schlesinger	O
et	O
al	O
.	O

(	O
2007	O
),	O
and	O
/	O
orSquazzo	O
et	O
al	O
.	O

(	O
2006	O
)],	O
presence	O
within	O
1	O
kb	O
of	O
at	O
least	O
one	O
of	O
258	O
computationally	O
predicted	O
transcription	O
factor	O
binding	O
site	O
(	O
TFBS	O
)	O
sequences	O
obtained	O
from	O
the	O
tfbsConsSites	O
track	O
of	O
the	O
University	O
of	O
California	O
–	O
Santa	O
Cruz	O
(	O
UCSC	O
)	O
Genomes	O
Browser	O
site	O
(	O
TFBS	O
z	O
-	O
score	O
>	O
2	O
)	O
(	O
Kent	O
et	O
al	O
.	O

2002	O
),	O
and	O
localization	O
within	O
each	O
of	O
the	O
following	O
classes	O
of	O
repetitive	O
element	O
as	O
defined	O
by	O
the	O
Repeatmasker	O
track	O
of	O
Genomes	O
Browser	O
:	O
Alu	O
,	O
LINE	O
-	O
1	O
,	O
LINE	O
-	O
2	O
,	O
and	O
mammalian	O
wide	O
-	O
interspersed	O
repeat	O
elements	O
(	O
MIRs	O
).	O

This	O
bioinformatic	O
classification	O
resulted	O
in	O
41	O
distinct	O
bioinformatic	O
classes	O
containing	O
at	O
least	O
one	O
CpG	O
(	O
see	O
Supplemental	O
Material	O
,	O
Table	O
2	O
).	O

For	O
each	O
subject	O
,	O
41	O
corresponding	O
aggregate	O
methylation	O
values	O
were	O
obtained	O
by	O
averaging	O
together	O
average	O
β	O
-	O
values	O
from	O
all	O
CpGs	O
within	O
the	O
class	O
.	O

Caption	O
(	O
TABLE	O
-	O
WRAP	O
):	O
TABLE	O
1	O
Associations	O
between	O
infant	O
growth	O
and	O
repetitive	O
element	O
methylation	O
.	O
Covariate	O
(	O
n	O
=	O
380	O
)	O
Linear	O
regression	O
effect	O
estimate	O
(	O
95	O
%	O
CI	O
)	O
p	O
-	O
ValueMean	O
LINE	O
-	O
1	O
(	O
per	O
10	O
%)	O
9	O
.	O
7	O
(	O
2	O
.	O
9	O
,	O
16	O
.	O
6	O
)	O
0	O
.	O
01Infant	O
sex12	O
.	O
81	O
(	O
6	O
.	O
54	O
,	O
19	O
.	O
09	O
)<	O
0	O
.	O
0001White	O
maternal	O
ethnicity7	O
.	O
06	O
(	O
0	O
.	O
59	O
,	O
13	O
.	O
53	O
)	O
0	O
.	O
03Mean	O
AluYb8	O
(	O
per	O
10	O
%)	O
14	O
.	O
5	O
(	O
4	O
.	O
9	O
,	O
24	O
.	O
0	O
)<	O
0	O
.	O
0001Infant	O
sex12	O
.	O
05	O
(	O
5	O
.	O
76	O
,	O
18	O
.	O
33	O
)<	O
0	O
.	O
0001White	O
maternal	O
ethnicity6	O
.	O
91	O
(	O
0	O
.	O
46	O
,	O
13	O
.	O
36	O
)	O
0	O
.	O
04All	O
models	O
were	O
also	O
adjusted	O
for	O
maternal	O
age	O
,	O
BMI	O
before	O
pregnancy	O
,	O
tobacco	O
,	O
alcohol	O
,	O
and	O
prenatal	O
vitamin	O
use	O
during	O
pregnancy	O
.	O

Infant	O
sex	O
uses	O
female	O
sex	O
as	O
the	O
referent	O
.	O

Caption	O
(	O
TABLE	O
-	O
WRAP	O
):	O
TABLE	O
2	O
Repeat	O
element	O
methylation	O
markers	O
grouped	O
by	O
in	O
utero	O
exposures	O
.	O
Group	O
mean	O
±	O
SDExposure	O
n	O
LINE	O
-	O
1AluYb8Array	O
-	O
based	O
methylationSexMale19051	O
.	O
7	O
±	O
4	O
.	O
465	O
.	O
3	O
±	O
3	O
.	O
30	O
.	O
238	O
±	O
0	O
.	O
012Female19051	O
.	O
7	O
±	O
4	O
.	O
964	O
.	O
6	O
±	O
3	O
.	O
30	O
.	O
237	O
±	O
0	O
.	O
013	O
p	O
-	O
Value0	O
.	O
900	O
.	O
040	O
.	O
28Maternal	O
ethnicityCaucasian21751	O
.	O
4	O
±	O
4	O
.	O
564	O
.	O
9	O
±	O
3	O
.	O
30	O
.	O
239	O
±	O
0	O
.	O
013Non	O
-	O
Caucasian16352	O
.	O
0	O
±	O
4	O
.	O
865	O
.	O
1	O
±	O
3	O
.	O
30	O
.	O
236	O
±	O
0	O
.	O
011	O
p	O
-	O
Value0	O
.	O
210	O
.	O
470	O
.	O
17Maternal	O
tobacco	O
use	O
during	O
pregnancyYes3652	O
.	O
9	O
±	O
4	O
.	O
766	O
.	O
2	O
±	O
2	O
.	O
30	O
.	O
240	O
±	O
0	O
.	O
011No34351	O
.	O
6	O
±	O
4	O
.	O
664	O
.	O
8	O
±	O
3	O
.	O
40	O
.	O
237	O
±	O
0	O
.	O
012	O
p	O
-	O
Value0	O
.	O
10	O
<	O
0	O
.	O
010	O
.	O
31Maternal	O
alcohol	O
use	O
during	O
pregnancyYes355	O
.	O
0	O
±	O
1	O
.	O
066	O
.	O
0	O
±	O
3	O
.	O
40	O
.	O
230	O
±	O
0	O
.	O
001No37751	O
.	O
7	O
±	O
4	O
.	O
665	O
.	O
0	O
±	O
3	O
.	O
30	O
.	O
238	O
±	O
0	O
.	O
012	O
p	O
-	O
Value0	O
.	O
020	O
.	O
660	O
.	O
51Maternal	O
prenatal	O
vitamin	O
use	O
during	O
pregnancyYes31451	O
.	O
8	O
±	O
4	O
.	O
665	O
.	O
0	O
±	O
3	O
.	O
30	O
.	O
238	O
±	O
0	O
.	O
012No6651	O
.	O
3	O
±	O
4	O
.	O
764	O
.	O
6	O
±	O
3	O
.	O
40	O
.	O
238	O
±	O
0	O
.	O
014	O
p	O
-	O
Value0	O
.	O
500	O
.	O
290	O
.	O
80	O
p	O
-	O
Values	O
obtained	O
from	O
Kruskal	O
–	O
Wallis	O
tests	O
.	O

We	O
used	O
linear	O
regression	O
to	O
determine	O
the	O
association	O
between	O
methylation	O
of	O
LINE	O
-	O
1	O
or	O
AluYb8	O
and	O
the	O
aggregate	O
methylation	O
values	O
for	O
each	O
of	O
the	O
16	O
methylation	O
classes	O
determined	O
by	O
RPMM	O
and	O
the	O
41	O
bioinformatic	O
classes	O
.	O

Omnibus	O
tests	O
for	O
the	O
overall	O
association	O
between	O
each	O
repetitive	O
methylation	O
and	O
class	O
methylation	O
were	O
obtained	O
by	O
permutation	O
test	O
,	O
using	O
a	O
test	O
analogous	O
to	O
a	O
Kolmogorov	O
–	O
Smirnov	O
test	O
.	O

Specifically	O
,	O
a	O
test	O
statistic	O
was	O
constructed	O
as	O
the	O
maximum	O
absolute	O
t	O
-	O
statistic	O
for	O
the	O
appropriate	O
coefficient	O
from	O
the	O
regression	O
model	O
,	O
where	O
the	O
maximum	O
was	O
computed	O
over	O
the	O
16	O
or	O
41	O
individual	O
regression	O
models	O
.	O

The	O
corresponding	O
null	O
distribution	O
,	O
signifying	O
a	O
lack	O
of	O
association	O
between	O
repetitive	O
element	O
methylation	O
and	O
autosomal	O
CpG	O
methylation	O
,	O
was	O
obtained	O
by	O
randomly	O
permuting	O
each	O
repetitive	O
element	O
methylation	O
marker	O
with	O
respect	O
to	O
aggregate	O
methylation	O
values	O
of	O
the	O
RPMM	O
and	O
bioinformatic	O
classes	O
.	O

Ten	O
thousand	O
permutations	O
were	O
used	O
,	O
and	O
a	O
hypothesized	O
association	O
was	O
considered	O
significant	O
at	O
the	O
p	O
≤	O
0	O
.	O
05	O
level	O
.	O

To	O
clarify	O
the	O
TFBSs	O
overrepresented	O
among	O
loci	O
whose	O
methylation	O
was	O
associated	O
with	O
either	O
LINE	O
-	O
1	O
or	O
AluYb8	O
methylation	O
,	O
gene	O
set	O
enrichment	O
analysis	O
(	O
GSEA	O
)	O
(	O
Subramanian	O
et	O
al	O
.	O

2005	O
)	O
was	O
used	O
.	O

Across	O
binding	O
sites	O
of	O
transcription	O
factors	O
overrepresented	O
within	O
1	O
kb	O
of	O
loci	O
,	O
we	O
compared	O
the	O
distribution	O
of	O
statistics	O
representing	O
the	O
association	O
between	O
CpG	O
-	O
specific	O
average	O
β	O
-	O
value	O
and	O
each	O
repetitive	O
element	O
methylation	O
markers	O
.	O

All	O
statistical	O
analyses	O
were	O
performed	O
using	O
the	O
R	O
statistical	O
package	O
(	O
version	O
2	O
.	O
10	O
;	O
http	O
://	O
www	O
.	O
r	O
-	O
project	O
.	O
org	O
),	O
and	O
the	O
R	O
function	O
was	O
made	O
available	O
on	O
the	O
GSEA	O
website	O
,	O
using	O
permutation	O
tests	O
as	O
described	O
bySubramanian	O
et	O
al	O
.	O

(	O
2005	O
).	O

Results	O
Population	O
characteristics	O
.	O

The	O
characteristics	O
of	O
subjects	O
used	O
in	O
these	O
analyses	O
(	O
n	O
=	O
380	O
)	O
are	O
shown	O
in	O
Supplemental	O
Material	O
,	O
Table	O
1	O
(	O
http	O
://	O
dx	O
.	O
doi	O
.	O
org	O
/	O
10	O
.	O
1289	O
/	O
ehp	O
.	O
1103927	O
).	O

Because	O
subjects	O
were	O
selected	O
based	O
on	O
SGA	O
status	O
and	O
matched	O
to	O
non	O
-	O
SGA	O
infants	O
on	O
sex	O
,	O
gestational	O
age	O
,	O
and	O
maternal	O
age	O
,	O
we	O
observed	O
no	O
significant	O
differences	O
in	O
those	O
characteristics	O
among	O
birth	O
weight	O
groups	O
(	O
SGA	O
,	O
AGA	O
,	O
LGA	O
).	O

Significant	O
differences	O
were	O
noted	O
between	O
groups	O
for	O
maternal	O
ethnicity	O
and	O
maternal	O
tobacco	O
smoking	O
during	O
pregnancy	O
,	O
with	O
a	O
greater	O
proportion	O
of	O
non	O
-	O
Caucasian	O
infants	O
(	O
p	O
=	O
0	O
.	O
01	O
)	O
and	O
infants	O
with	O
exposure	O
to	O
tobacco	O
smoke	O
in	O
the	O
SGA	O
category	O
(	O
p	O
=	O
0	O
.	O
03	O
).	O

The	O
vast	O
majority	B
of	O
mothers	O
reported	O
prenatal	O
vitamin	O
use	O
;	O
only	O
three	O
subjects	O
reported	O
alcohol	O
consumption	O
during	O
pregnancy	O
.	O

DNA	O
methylation	O
and	O
infant	O
growth	O
.	O

Mean	O
LINE	O
-	O
1	O
and	O
AluYb8	O
methylation	O
levels	O
differed	O
significantly	O
by	O
birth	O
weight	O
status	O
[	O
see	O
Supplemental	O
Material	O
,	O
Table	O
1	O
(	O
http	O
://	O
dx	O
.	O
doi	O
.	O
org	O
/	O
10	O
.	O
1289	O
/	O
ehp	O
.	O
1103927	O
);	O
p	O
<	O
0	O
.	O
0001	O
].	O

Mean	O
LINE	O
-	O
1	O
and	O
AluYb8	O
methylation	O
levels	O
were	O
also	O
found	O
to	O
be	O
weakly	O
to	O
moderately	O
correlated	O
,	O
with	O
a	O
Pearson	O
correlation	O
of	O
0	O
.	O
29	O
[	O
95	O
%	O
confidence	O
interval	O
(	O
CI	O
):	O
0	O
.	O
20	O
,	O
0	O
.	O
38	O
].	O

To	O
examine	O
whether	O
“	O
global	O
methylation	O
”	O
represented	O
as	O
an	O
average	O
of	O
gene	O
-	O
associated	O
methylation	O
identified	O
in	O
a	O
genomewide	O
manner	O
was	O
associated	O
with	O
infant	O
growth	O
,	O
we	O
tested	O
for	O
an	O
association	O
between	O
birth	O
weight	O
percentile	O
and	O
mean	O
methylation	O
across	O
the	O
26	O
,	O
486	O
autosomal	O
loci	O
measured	O
using	O
the	O
Illumina	O
Infinium	O
array	O
in	O
a	O
subset	O
of	O
184	O
placenta	O
samples	O
.	O

Mean	O
methylation	O
across	O
the	O
26	O
,	O
486	O
autosomal	O
CpG	O
loci	O
was	O
not	O
significantly	O
associated	O
with	O
the	O
birth	O
weight	O
groups	O
(	O
see	O
Supplemental	O
Material	O
,	O
Table	O
1	O
).	O

There	O
were	O
no	O
significant	O
differences	O
in	O
the	O
distributions	O
of	O
the	O
demographic	O
characteristics	O
of	O
this	O
subsample	O
and	O
the	O
larger	O
population	O
examined	O
for	O
LINE	O
-	O
1	O
and	O
AluYb8	O
methylation	O
extent	O
(	O
data	O
not	O
shown	O
).	O

To	O
further	O
evaluate	O
the	O
association	O
between	O
infant	O
birth	O
weight	O
and	O
repetitive	O
element	O
methylation	O
identified	O
in	O
the	O
univariate	O
analyses	O
,	O
controlled	O
for	O
confounders	O
,	O
we	O
used	O
multiple	O
linear	O
regression	O
.	O

These	O
models	O
demonstrate	O
that	O
with	O
a	O
10	O
%	O
increase	O
in	O
LINE	O
-	O
1	O
mean	O
methylation	O
levels	O
,	O
birth	O
weight	O
percentile	O
significantly	O
increased	O
by	O
9	O
.	O
7	O
(	O
95	O
%	O
CI	O
:	O
2	O
.	O
9	O
,	O
16	O
.	O
6	O
),	O
and	O
with	O
a	O
10	O
%	O
increase	O
in	O
AluYb8	O
mean	O
methylation	O
levels	O
,	O
birth	O
weight	O
percentile	O
significantly	O
increased	O
by	O
14	O
.	O
5	O
(	O
95	O
%	O
CI	O
:	O
4	O
.	O
9	O
,	O
24	O
.	O
0	O
)	O
(	O
Table	O
1	O
).	O

Both	O
models	O
were	O
adjusted	O
for	O
infant	O
sex	O
and	O
maternal	O
age	O
,	O
BMI	O
,	O
ethnicity	O
,	O
and	O
tobacco	O
,	O
alcohol	O
and	O
prenatal	O
vitamin	O
use	O
during	O
pregnancy	O
.	O

Infant	O
sex	O
and	O
maternal	O
ethnicity	O
were	O
also	O
significant	O
predictors	O
of	O
birth	O
weight	O
percentile	O
(	O
Table	O
1	O
);	O
all	O
other	O
covariates	O
were	O
not	O
significant	O
.	O

DNA	O
methylation	O
and	O
in	O
utero	O
exposures	O
.	O

Table	O
2presents	O
the	O
results	O
of	O
our	O
exploration	O
of	O
the	O
differences	O
in	O
the	O
measures	O
of	O
DNA	O
methylation	O
by	O
various	O
in	O
utero	O
exposures	O
.	O

Only	O
AluYb8	O
methylation	O
levels	O
differed	O
by	O
infant	O
sex	O
(	O
p	O
=	O
0	O
.	O
04	O
),	O
with	O
male	O
infants	O
having	O
slightly	O
higher	O
mean	O
AluYb8	O
methylation	O
(	O
mean	O
±	O
SD	O
=	O
65	O
.	O
3	O
±	O
3	O
.	O
3	O
)	O
than	O
did	O
female	O
infants	O
(	O
64	O
.	O
6	O
±	O
3	O
.	O
3	O
).	O

Furthermore	O
,	O
we	O
found	O
that	O
mean	O
AluYb8	O
levels	O
differed	O
significantly	O
by	O
maternal	O
tobacco	O
use	O
during	O
pregnancy	O
(	O
p	O
<	O
0	O
.	O
01	O
),	O
whereas	O
mean	O
LINE	O
-	O
1	O
levels	O
significantly	O
differed	O
only	O
by	O
maternal	O
alcohol	O
use	O
during	O
pregnancy	O
(	O
p	O
=	O
0	O
.	O
02	O
;	O
Table	O
2	O
).	O

Array	O
-	O
based	O
mean	O
methylation	O
across	O
the	O
26	O
,	O
486	O
CpG	O
loci	O
did	O
not	O
differ	O
by	O
any	O
of	O
the	O
in	O
utero	O
exposures	O
explored	O
.	O

Relationships	O
between	O
repetitive	O
element	O
and	O
gene	O
associated	O
methylation	O
.	O

To	O
investigate	O
the	O
relationship	O
between	O
repeat	O
element	O
methylation	O
and	O
gene	O
-	O
associated	O
methylation	O
,	O
we	O
clustered	O
the	O
26	O
,	O
486	O
autosomal	O
CpG	O
loci	O
interrogated	O
on	O
the	O
Infinium	O
HumanMethylation27	O
BeadArray	O
into	O
16	O
methylation	O
classes	O
based	O
on	O
their	O
methylation	O
pattern	O
using	O
an	O
RPMM	O
[	O
for	O
the	O
heat	O
map	O
of	O
the	O
16	O
classes	O
,	O
see	O
Supplemental	O
Material	O
,	O
Figure	O
1	O
(	O
http	O
://	O
dx	O
.	O
doi	O
.	O
org	O
/	O
10	O
.	O
1289	O
/	O
ehp	O
.	O
1103927	O
)].	O

This	O
data	O
-	O
driven	O
clustering	O
allowed	O
us	O
to	O
define	O
stable	O
classes	O
of	O
CpG	O
loci	O
demonstrating	O
similar	O
patterns	O
of	O
methylation	O
,	O
which	O
we	O
used	O
to	O
examine	O
associations	O
between	O
methylation	O
of	O
these	O
classes	O
of	O
CpGs	O
and	O
LINE	O
-	O
1	O
or	O
AluYb8	O
methylation	O
.	O

By	O
clustering	O
,	O
we	O
hoped	O
to	O
uncover	O
biologically	O
meaningful	O
groups	O
of	O
CpG	O
loci	O
,	O
with	O
similar	O
methylation	O
patterns	O
,	O
which	O
may	O
share	O
biological	O
characteristics	O
such	O
as	O
comparable	O
functionality	O
in	O
certain	O
developmental	O
pathways	O
or	O
location	O
in	O
similar	O
genomic	O
regions	O
.	O

Caption	O
(	O
FIG	O
):	O
FIGURE	O
1	O
Association	O
of	O
LINE	O
-	O
1	O
(	O
A	O
)	O
and	O
AluYb8	O
(	O
B	O
)	O
methylation	O
with	O
mean	O
RPMM	O
class	O
methylation	O
.	O

The	O
colored	O
dots	O
indicate	O
the	O
degree	O
of	O
average	O
CpG	O
class	O
methylation	O
,	O
as	O
indicated	O
by	O
the	O
key	O
.	O

The	O
red	O
dashed	O
lines	O
represent	O
the	O
null	O
limits	O
for	O
the	O
permutation	O
distribution	O
of	O
regression	O
coefficient	O
t	O
-	O
statistics	O
(	O
t	O
-	O
stat	O
),	O
adjusted	O
for	O
multiple	O
comparisons	O
.	O

The	O
association	O
between	O
LINE	O
-	O
1	O
or	O
AluYb8	O
methylation	O
and	O
average	O
methylation	O
within	O
the	O
RPMM	O
-	O
derived	O
classes	O
for	O
each	O
of	O
the	O
184	O
individuals	O
in	O
the	O
study	O
is	O
presented	O
inFigure	O
1	O
.	O

There	O
was	O
an	O
overall	O
significant	O
relationship	O
between	O
AluYb8	O
methylation	O
and	O
RPMM	O
class	O
methylation	O
(	O
p	O
=	O
0	O
.	O
01	O
);	O
no	O
association	O
was	O
observed	O
between	O
LINE	O
-	O
1	O
and	O
RPMM	O
class	O
methylation	O
.	O

When	O
considering	O
class	O
-	O
specific	O
relationships	O
,	O
a	O
positive	O
association	O
was	O
noted	O
between	O
AluYb8	O
methylation	O
and	O
methylation	O
of	O
CpGs	O
encompassing	O
the	O
low	O
to	O
intermediately	O
methylated	O
class	O
9	O
(	O
Figure	O
1	O
).	O

Additionally	O
,	O
classes	O
7	O
,	O
11	O
,	O
and	O
12	O
were	O
marginally	O
positively	O
associated	O
with	O
AluYb8	O
methylation	O
levels	O
,	O
with	O
CpGs	O
exhibiting	O
low	O
to	O
intermediate	O
methylation	O
.	O

To	O
examine	O
similarities	O
in	O
the	O
genomic	O
context	O
of	O
the	O
CpGs	O
making	O
up	O
these	O
data	O
-	O
driven	O
RPMM	O
classes	O
,	O
we	O
examined	O
the	O
proportion	O
of	O
CpG	O
loci	O
associated	O
with	O
specific	O
DNA	O
sequence	O
features	O
within	O
each	O
class	O
,	O
including	O
location	O
within	O
a	O
repetitive	O
element	O
(	O
LINE	O
-	O
1	O
,	O
LINE	O
-	O
2	O
,	O
Alu	O
,	O
or	O
MIR	O
),	O
within	O
a	O
CGI	O
,	O
or	O
having	O
the	O
associated	O
gene	O
considered	O
a	O
PcG	O
protein	O
target	O
gene	O
(	O
Figure	O
2	O
).	O

As	O
expected	O
,	O
a	O
greater	O
proportion	O
of	O
CpGs	O
in	O
the	O
relatively	O
methylated	O
(	O
rightmost	O
)	O
classes	O
9	O
–	O
12	O
are	O
localized	O
in	O
repetitive	O
elements	O
(	O
Figure	O
2A	O
–	O
D	O
).	O

Conversely	O
,	O
a	O
high	O
proportion	O
of	O
CpGs	O
in	O
the	O
relatively	O
unmethylated	O
classes	O
1	O
–	O
6	O
and	O
8	O
are	O
in	O
CGIs	O
(	O
Figure	O
2E	O
).	O

There	O
was	O
also	O
interclass	O
variation	O
in	O
the	O
frequency	O
of	O
CpGs	O
association	O
with	O
PcG	O
target	O
genes	O
,	O
with	O
classes	O
7	O
and	O
9	O
in	O
particular	O
having	O
a	O
much	O
higher	O
proportion	O
than	O
the	O
others	O
(	O
Figure	O
2F	O
).	O

Class	O
9	O
,	O
which	O
was	O
associated	O
with	O
AluYb8	O
methylation	O
extent	O
,	O
contained	O
a	O
high	O
proportion	O
of	O
CpG	O
loci	O
located	O
within	O
CGIs	O
(	O
81	O
%)	O
and	O
whose	O
genes	O
are	O
considered	O
PcG	O
target	O
genes	O
(	O
32	O
%).	O

Caption	O
(	O
FIG	O
):	O
FIGURE	O
2	O
Frequency	O
of	O
sequence	O
features	O
associated	O
with	O
RPMM	O
class	O
CpG	O
loci	O
:	O
percentage	O
of	O
CpG	O
loci	O
found	O
in	O
LINE	O
-	O
1	O
(	O
A	O
),	O
LINE	O
-	O
2	O
(	O
B	O
),	O
Alu	O
(	O
C	O
),	O
and	O
MIR	O
(	O
D	O
),	O
within	O
a	O
CGI	O
(	O
E	O
),	O
or	O
having	O
the	O
associated	O
gene	O
considered	O
a	O
PcG	O
protein	O
target	O
gene	O
(	O
F	O
).	O

The	O
colored	O
dots	O
indicate	O
the	O
degree	O
of	O
average	O
class	O
methylation	O
.	O

Motivated	O
by	O
the	O
variation	O
in	O
sequence	O
features	O
(	O
bioinformatic	O
attributes	O
)	O
observed	O
between	O
RPMM	O
-	O
based	O
classes	O
,	O
we	O
next	O
performed	O
a	O
bioinformatically	O
informed	O
clustering	O
of	O
CpG	O
loci	O
into	O
classes	O
,	O
grouping	O
CpGs	O
according	O
to	O
their	O
sequence	O
context	O
:	O
presence	O
within	O
a	O
CGI	O
,	O
LINE	O
-	O
1	O
,	O
LINE	O
-	O
2	O
,	O
Alu	O
,	O
or	O
MIR	O
element	O
,	O
or	O
PcG	O
target	O
gene	O
and	O
proximity	O
(≤	O
1	O
,	O
000	O
bases	O
)	O
to	O
any	O
TFBS	O
.	O

This	O
resulted	O
in	O
41	O
distinct	O
bioinformatically	O
derived	O
classes	O
,	O
containing	O
at	O
least	O
one	O
CpG	O
,	O
based	O
on	O
bioinformatic	O
attributes	O
[	O
for	O
the	O
distribution	O
of	O
CpG	O
loci	O
by	O
bioinformatically	O
derived	O
class	O
,	O
see	O
Supplemental	O
Material	O
,	O
Table	O
2	O
(	O
http	O
://	O
dx	O
.	O
doi	O
.	O
org	O
/	O
10	O
.	O
1289	O
/	O
ehp	O
.	O
1103927	O
)].	O

The	O
association	O
between	O
LINE	O
-	O
1	O
and	O
AluYb8	O
repetitive	O
element	O
methylation	O
and	O
aggregate	O
methylation	O
values	O
of	O
the	O
autosomal	O
CpG	O
loci	O
within	O
each	O
of	O
the	O
41	O
bioinformatic	O
classes	O
is	O
depicted	O
inFigure	O
3	O
.	O

There	O
was	O
an	O
overall	O
significant	O
relationship	O
between	O
AluYb8	O
methylation	O
extent	O
and	O
bioinformatically	O
derived	O
CpG	O
class	O
methylation	O
(	O
p	O
<	O
0	O
.	O
0001	O
)	O
but	O
not	O
between	O
LINE	O
-	O
1	O
methylation	O
and	O
bioinformatically	O
derived	O
CpG	O
class	O
methylation	O
.	O

When	O
considering	O
class	O
-	O
specific	O
relationships	O
,	O
there	O
was	O
a	O
positive	O
association	O
between	O
AluYb8	O
methylation	O
levels	O
and	O
mean	O
methylation	O
across	O
loci	O
allocated	O
within	O
a	O
PcG	O
target	O
gene	O
and	O
LINE	O
-	O
2	O
element	O
and	O
proximal	O
to	O
a	O
TFBS	O
(	O
class	O
PcG	O
/	O
LINE	O
-	O
2	O
/	O
TFBS	O
)	O
and	O
loci	O
located	O
within	O
a	O
CGI	O
and	O
PcG	O
target	O
gene	O
and	O
proximal	O
to	O
a	O
TFBS	O
(	O
class	O
CpG	O
/	O
PcG	O
/	O
TFBS	O
).	O

Caption	O
(	O
FIG	O
):	O
FIGURE	O
3	O
Association	O
of	O
LINE	O
-	O
1	O
(	O
A	O
)	O
and	O
AluYb8	O
(	O
B	O
)	O
methylation	O
with	O
bioinformatically	O
derived	O
CpG	O
class	O
methylation	O
.	O

The	O
colored	O
dots	O
indicate	O
the	O
degree	O
of	O
average	O
class	O
methylation	O
.	O

The	O
red	O
dashed	O
lines	O
represent	O
the	O
null	O
limits	O
for	O
the	O
permutation	O
distribution	O
of	O
regression	O
coefficient	O
t	O
-	O
statistics	O
(	O
t	O
-	O
stat	O
),	O
adjusted	O
for	O
multiple	O
comparisons	O
.	O

GSEA	O
analysis	O
.	O

To	O
expand	O
on	O
the	O
bioinformatically	O
informed	O
analysis	O
,	O
which	O
suggested	O
that	O
methylation	O
of	O
CpG	O
loci	O
proximal	O
to	O
a	O
TFBS	O
were	O
associated	O
with	O
AluYb8	O
methylation	O
,	O
we	O
performed	O
a	O
GSEA	O
using	O
specific	O
TFBS	O
,	O
obtained	O
from	O
the	O
UCSC	O
Genomes	O
Browser	O
.	O

Specifically	O
,	O
each	O
of	O
the	O
26	O
,	O
486	O
autosomal	O
CpG	O
loci	O
are	O
simultaneously	O
evaluated	O
for	O
their	O
association	O
with	O
LINE	O
-	O
1	O
or	O
AluYb8	O
methylation	O
extent	O
and	O
the	O
genomic	O
locations	O
or	O
TFBS	O
that	O
are	O
overrepresented	O
within	O
1	O
kb	O
of	O
the	O
loci	O
[	O
for	O
the	O
GSEA	O
results	O
,	O
see	O
Supplemental	O
Material	O
,	O
Figure	O
2	O
(	O
http	O
://	O
dx	O
.	O
doi	O
.	O
org	O
/	O
10	O
.	O
1289	O
/	O
ehp	O
.	O
1103927	O
)].	O

Only	O
three	O
TFBS	O
genes	O
were	O
overrepresented	O
among	O
loci	O
whose	O
methylation	O
was	O
associated	O
with	O
LINE	O
-	O
1	O
methylation	O
:	O
MEF2	O
,	O
TBX1	O
,	O
and	O
POU2F1	O
.	O

For	O
those	O
overrepresented	O
among	O
loci	O
associated	O
with	O
AluYb8	O
methylation	O
,	O
there	O
were	O
a	O
number	O
of	O
developmentally	O
related	O
TFBS	O
genes	O
(	O
CUX1	O
,	O
CHX10	O
,	O
PAX4	O
,	O
PPARG	O
,	O
TAL1	O
/	O
ITF2	O
heterodimer	O
,	O
HAND1	O
,	O
MYOD	O
,	O
OCT	O
),	O
as	O
well	O
as	O
those	O
involved	O
in	O
cell	O
processes	O
(	O
ACTR3B	O
,	O
S8	O
),	O
gene	O
expression	O
(	O
NFE2L	O
),	O
lipid	O
/	O
sterol	O
homeostasis	O
(	O
NR3C1	O
),	O
and	O
immune	O
modulation	O
(	O
GATA1	O
).	O

Only	O
POU2F1	O
was	O
found	O
to	O
be	O
overrepresented	O
among	O
loci	O
associated	O
with	O
both	O
LINE	O
-	O
1	O
and	O
AluYb8	O
methylation	O
.	O

Discussion	O
In	O
this	O
study	O
,	O
we	O
have	O
identified	O
significant	O
associations	O
between	O
infant	O
growth	O
,	O
in	O
utero	O
exposures	O
,	O
and	O
repetitive	O
element	O
methylation	O
in	O
placental	O
tissue	O
.	O

Moreover	O
,	O
by	O
examining	O
the	O
relationship	O
between	O
repetitive	O
element	O
DNA	O
methylation	O
and	O
genomewide	O
(	O
array	O
)	O
gene	O
-	O
associated	O
methylation	O
,	O
this	O
work	O
suggests	O
potential	O
epigenetic	O
mechanisms	O
underlying	O
changes	O
to	O
placental	O
function	O
that	O
may	O
lead	O
to	O
altered	O
fetal	O
development	O
and	O
programming	O
.	O

In	O
addition	O
,	O
we	O
have	O
identified	O
particular	O
regions	O
of	O
the	O
genome	O
susceptible	O
to	O
alterations	O
by	O
the	O
intrauterine	O
environment	O
.	O

Overall	O
,	O
AluYb8	O
had	O
higher	O
DNA	O
methylation	O
levels	O
than	O
did	O
LINE	O
-	O
1	O
,	O
which	O
may	O
be	O
due	O
to	O
the	O
lower	O
degree	O
of	O
C	O
-	O
to	O
-	O
T	O
transition	O
mutations	O
owing	O
to	O
the	O
younger	O
age	O
of	O
AluYb8	O
elements	O
(	O
Choi	O
et	O
al	O
.	O

2009	O
).	O

AluYb8	O
levels	O
were	O
found	O
to	O
marginally	O
differ	O
by	O
infant	O
sex	O
,	O
which	O
is	O
consistent	O
with	O
the	O
previous	O
literature	O
in	O
that	O
repetitive	O
element	O
methylation	O
markers	O
in	O
blood	O
may	O
vary	O
by	O
sex	O
(	O
Cash	O
et	O
al	O
.	O

2011	O
;	O
Wilhelm	O
et	O
al	O
.	O

2010	O
).	O

We	O
found	O
that	O
birth	O
weight	O
percentile	O
levels	O
increased	O
by	O
about	O
10	O
and	O
15	O
points	O
,	O
respectively	O
,	O
with	O
a	O
10	O
%	O
increase	O
in	O
LINE	O
-	O
1	O
or	O
AluYb8	O
methylation	O
levels	O
,	O
suggesting	O
a	O
strong	O
association	O
of	O
repetitive	O
element	O
methylation	O
markers	O
with	O
fetal	O
growth	O
.	O

However	O
,	O
because	O
LINE	O
-	O
1	O
and	O
AluYb8	O
methylation	O
levels	O
have	O
a	O
moderate	O
correlation	O
,	O
it	O
is	O
possible	O
that	O
these	O
two	O
repetitive	O
element	O
methylation	O
markers	O
may	O
explain	O
both	O
similar	O
and	O
different	O
sources	O
of	O
variation	O
in	O
infant	O
growth	O
.	O

Our	O
analysis	O
of	O
the	O
relationship	O
between	O
the	O
extent	O
of	O
methylation	O
at	O
these	O
elements	O
and	O
genomewide	O
gene	O
-	O
associated	O
methylation	O
was	O
aimed	O
to	O
better	O
characterize	O
the	O
similarities	O
and	O
differences	O
in	O
the	O
potential	O
functional	O
importance	O
of	O
these	O
markers	O
.	O

The	O
approach	O
to	O
examining	O
the	O
relationship	O
between	O
repetitive	O
element	O
methylation	O
and	O
gene	O
-	O
associated	O
methylation	O
was	O
not	O
designed	O
to	O
assess	O
specific	O
loci	O
or	O
genes	O
associated	O
with	O
LINE	O
-	O
1	O
or	O
AluYb8	O
methylation	O
,	O
but	O
rather	O
to	O
evaluate	O
whether	O
methylation	O
of	O
particular	O
groups	O
of	O
CpG	O
loci	O
with	O
like	O
methylation	O
patterns	O
or	O
similar	O
bioinformatic	O
attributes	O
were	O
coordinately	O
associated	O
with	O
LINE	O
-	O
1	O
or	O
AluYb8	O
methylation	O
,	O
because	O
this	O
could	O
inform	O
on	O
the	O
process	O
responsible	O
for	O
the	O
variation	O
between	O
the	O
two	O
.	O

Based	O
on	O
our	O
data	O
-	O
driven	O
RPMM	O
approach	O
,	O
we	O
observed	O
that	O
AluYb8	O
methylation	O
was	O
significantly	O
and	O
positively	O
correlated	O
with	O
methylation	O
at	O
CpG	O
loci	O
in	O
an	O
intermediately	O
methylated	O
class	O
containing	O
loci	O
that	O
were	O
located	O
predominantly	O
within	O
CGIs	O
and	O
associated	O
with	O
PcG	O
target	O
genes	O
.	O

This	O
was	O
further	O
substantiated	O
in	O
our	O
bioinformatically	O
informed	O
classification	O
analysis	O
,	O
because	O
we	O
identified	O
a	O
significant	O
association	O
between	O
AluYb8	O
methylation	O
and	O
methylation	O
of	O
a	O
group	O
of	O
loci	O
defined	O
by	O
their	O
position	O
in	O
a	O
CGI	O
,	O
PcG	O
target	O
gene	O
,	O
and	O
a	O
TFBS	O
,	O
as	O
well	O
CpGs	O
defined	O
by	O
association	O
with	O
a	O
PcG	O
target	O
gene	O
and	O
LINE	O
-	O
2	O
element	O
and	O
proximal	O
to	O
a	O
TFBS	O
.	O

We	O
did	O
not	O
observe	O
an	O
overall	O
association	O
between	O
any	O
attribute	O
-	O
defined	O
gene	O
-	O
associated	O
class	O
methylation	O
and	O
LINE	O
-	O
1	O
methylation	O
levels	O
.	O

This	O
is	O
in	O
contrast	O
to	O
a	O
previous	O
study	O
involving	O
12	O
fetal	O
cord	O
blood	O
samples	O
,	O
which	O
reported	O
a	O
significant	O
correlation	O
between	O
LINE	O
-	O
1	O
methylation	O
and	O
methylation	O
of	O
specific	O
loci	O
residing	O
mostly	O
in	O
CGIs	O
(	O
Fryer	O
et	O
al	O
.	O

2011	O
).	O

This	O
disparity	O
may	O
reflect	O
tissue	O
-	O
specific	O
differences	O
in	O
these	O
relationships	O
,	O
as	O
well	O
as	O
the	O
larger	O
and	O
therefore	O
more	O
precise	O
nature	O
of	O
our	O
examination	O
.	O

PcG	O
targets	O
are	O
a	O
family	O
of	O
developmentally	O
related	O
genes	O
that	O
can	O
remodel	O
chromatin	O
and	O
are	O
responsible	O
for	O
silencing	O
HOX	O
genes	O
,	O
which	O
are	O
critical	O
in	O
embryonic	O
development	O
as	O
well	O
as	O
potentially	O
hundreds	O
of	O
other	O
genes	O
involved	O
in	O
cellular	O
differentiation	O
(	O
Kirmizis	O
et	O
al	O
.	O

2004	O
;	O
Simon	O
and	O
Kingston	O
2009	O
).	O

We	O
observed	O
that	O
increasing	O
AluYb8	O
methylation	O
was	O
associated	O
with	O
greater	O
extents	O
of	O
methylation	O
at	O
CpG	O
loci	O
located	O
in	O
a	O
PcG	O
target	O
,	O
and	O
thus	O
a	O
change	O
in	O
the	O
extent	O
of	O
methylation	O
of	O
AluYb8	O
may	O
represent	O
an	O
alteration	O
in	O
the	O
methylation	O
of	O
these	O
key	O
loci	O
important	O
in	O
tissue	O
development	O
and	O
differentiation	O
.	O

Both	O
bioinformatically	O
informed	O
CpG	O
classes	O
that	O
were	O
significantly	O
associated	O
with	O
AluYb8	O
methylation	O
contained	O
loci	O
that	O
are	O
proximal	O
to	O
TFBSs	O
.	O

Upon	O
further	O
exploration	O
through	O
GSEA	O
,	O
we	O
observed	O
an	O
overrepresentation	O
of	O
several	O
TFBSs	O
for	O
transcription	O
factors	O
critical	O
in	O
development	O
,	O
cellular	O
processes	O
,	O
immune	O
modulation	O
,	O
lipid	O
or	O
sterol	O
homeostasis	O
,	O
and	O
gene	O
expression	O
near	O
loci	O
associated	O
with	O
AluYb8	O
,	O
as	O
well	O
as	O
a	O
few	O
developmental	O
and	O
cellular	O
proliferation	O
pathways	O
for	O
LINE	O
-	O
1	O
.	O

Specifically	O
,	O
POU2F1	O
binding	O
sites	O
were	O
overrepresented	O
among	O
loci	O
associated	O
with	O
both	O
LINE	O
-	O
1	O
and	O
AluYb8	O
extent	O
.	O

This	O
transcription	O
factor	O
plays	O
a	O
role	O
in	O
the	O
control	O
of	O
a	O
wide	O
range	O
of	O
genes	O
,	O
including	O
small	O
nuclear	O
RNAs	O
,	O
immunoglobulins	O
,	O
histone	O
H2B	O
,	O
and	O
the	O
glucocorticoid	O
receptor	O
,	O
and	O
thus	O
has	O
a	O
central	O
role	O
in	O
controlling	O
various	O
functions	O
,	O
including	O
those	O
of	O
immunomodulation	O
and	O
steroid	O
homeostasis	O
in	O
the	O
placenta	O
(	O
Schonemann	O
et	O
al	O
.	O

1998	O
).	O

Taken	O
together	O
,	O
these	O
results	O
suggest	O
that	O
alterations	O
to	O
LINE	O
-	O
1	O
or	O
AluYb8	O
methylation	O
may	O
act	O
as	O
a	O
marker	O
for	O
key	O
changes	O
to	O
the	O
extent	O
of	O
methylation	O
at	O
loci	O
targeted	O
by	O
important	O
transcription	O
factors	O
for	O
normal	O
development	O
and	O
placenta	O
processes	O
necessary	O
for	O
appropriate	O
growth	O
.	O

When	O
looking	O
at	O
each	O
repetitive	O
element	O
methylation	O
marker	O
grouped	O
by	O
various	O
in	O
utero	O
exposures	O
,	O
we	O
found	O
that	O
mean	O
AluYb8	O
methylation	O
levels	O
were	O
significantly	O
different	O
by	O
maternal	O
tobacco	O
use	O
during	O
pregnancy	O
,	O
similar	O
to	O
results	O
from	O
another	O
group	O
that	O
found	O
significantly	O
different	O
levels	O
of	O
cytosine	O
methylation	O
by	O
smoking	O
status	O
(	O
Moore	O
et	O
al	O
.	O

2008	O
).	O

Furthermore	O
,	O
mean	O
LINE	O
-	O
1	O
methylation	O
levels	O
were	O
significantly	O
different	O
by	O
maternal	O
alcohol	O
use	O
during	O
pregnancy	O
;	O
however	O
,	O
limited	O
numbers	O
may	O
affect	O
our	O
precision	O
,	O
so	O
this	O
result	O
should	O
be	O
confirmed	O
in	O
further	O
analyses	O
.	O

This	O
study	O
was	O
limited	O
in	O
its	O
assessment	O
of	O
environmental	O
exposures	O
because	O
of	O
the	O
low	O
number	O
of	O
exposed	O
individuals	O
and	O
low	O
power	O
,	O
making	O
this	O
part	O
of	O
our	O
analysis	O
largely	O
exploratory	O
in	O
nature	O
.	O

However	O
,	O
it	O
will	O
be	O
increasingly	O
important	O
to	O
examine	O
,	O
in	O
larger	O
studies	O
,	O
how	O
additional	O
specific	O
exposures	O
,	O
such	O
as	O
lead	O
as	O
has	O
been	O
done	O
by	O
previous	O
researchers	O
(	O
Pilsner	O
et	O
al	O
.	O

2009	O
),	O
during	O
intrauterine	O
development	O
affect	O
these	O
epigenetic	O
markers	O
in	O
a	O
more	O
quantitative	O
way	O
.	O

Although	O
a	O
few	O
other	O
studies	O
have	O
correlated	O
array	O
-	O
based	O
methylation	O
levels	O
with	O
repetitive	O
element	O
methylation	O
markers	O
(	O
Fryer	O
et	O
al	O
.	O

2011	O
)	O
and	O
found	O
at	O
times	O
good	O
correlation	O
between	O
the	O
two	O
,	O
our	O
results	O
indicate	O
that	O
array	O
-	O
based	O
methylation	O
level	O
may	O
not	O
be	O
a	O
good	O
predictive	O
marker	O
of	O
repetitive	O
element	O
methylation	O
level	O
in	O
human	O
placenta	O
tissue	O
.	O

Array	O
-	O
based	O
mean	O
methylation	O
across	O
the	O
26	O
,	O
486	O
CpG	O
loci	O
was	O
not	O
found	O
to	O
be	O
associated	O
with	O
any	O
of	O
our	O
in	O
utero	O
exposures	O
,	O
contrasting	O
with	O
our	O
repetitive	O
element	O
methylation	O
markers	O
.	O

Additionally	O
,	O
LINE1	O
,	O
AluYb8	O
,	O
and	O
specific	O
array	O
-	O
based	O
methylation	O
loci	O
often	O
interrogate	O
different	O
genetic	O
regions	O
;	O
therefore	B
,	O
their	O
methylation	O
may	O
have	O
a	O
differential	O
genomic	O
impact	O
.	O

Furthermore	O
,	O
the	O
divergence	O
of	O
results	O
observed	O
between	O
LINE	O
-	O
1	O
and	O
AluYb8	O
reported	O
throughout	O
this	O
work	O
suggests	O
that	O
these	O
repetitive	O
element	O
methylation	O
markers	O
are	O
distinct	O
measures	O
and	O
may	O
not	O
represent	O
true	O
,	O
and	O
potentially	O
interchangeable	O
,	O
surrogates	O
of	O
“	O
global	O
”	O
methylation	O
.	O

Although	O
we	O
found	O
that	O
these	O
repetitive	O
element	O
indicators	O
are	O
weakly	O
to	O
moderately	O
correlated	O
,	O
they	O
have	O
their	O
own	O
unique	O
distributions	O
of	O
methylation	O
values	O
,	O
consistent	O
with	O
previous	O
comparisons	O
between	O
LINE	O
-	O
1	O
and	O
Alu	O
methylation	O
in	O
normal	O
blood	O
(	O
Jintaridth	O
and	O
Mutirangura	O
2010	O
).	O

In	O
addition	O
,	O
it	O
is	O
believed	O
that	O
genomic	O
location	O
and	O
sequence	O
context	O
play	O
a	O
crucial	O
role	O
in	O
the	O
maintenance	O
or	O
loss	O
of	O
DNA	O
methylation	O
in	O
these	O
regions	O
.	O

For	O
example	O
,	O
research	O
has	O
suggested	O
that	O
Alu	O
sequences	O
often	O
flank	O
CGIs	O
(	O
Graff	O
et	O
al	O
.	O

1997	O
)	O
and	O
therefore	B
may	O
play	O
a	O
distinct	O
role	O
in	O
both	O
repetitive	O
element	O
and	O
gene	O
-	O
directed	O
methylation	O
.	O

Differences	O
between	O
these	O
markers	O
can	O
most	B
likely	B
be	I
explained	I
by	O
the	O
unequal	O
distributions	O
of	O
these	O
sequences	O
throughout	O
the	O
genome	O
,	O
owing	O
in	O
some	O
part	O
to	O
the	O
evolutionary	O
age	O
of	O
these	O
two	O
retrotransposable	O
elements	O
(	O
Zamudio	O
and	O
Bourc	O
’	O
his	O
2010	O
).	O

This	O
may	O
therefore	B
be	O
affecting	O
the	O
number	O
of	O
these	O
elements	O
in	O
the	O
genome	O
and	O
the	O
functional	O
relevance	O
of	O
their	O
methylation	O
,	O
particularly	O
in	O
the	O
placenta	O
.	O

As	O
our	O
results	O
suggest	O
,	O
distinct	O
mechanisms	O
and	O
selective	O
pressures	O
are	O
likely	B
responsible	O
for	O
their	O
alteration	O
.	O

The	O
strengths	O
of	O
this	O
study	O
include	O
the	O
large	O
sample	O
size	O
,	O
population	O
-	O
based	O
ascertainment	O
of	O
placenta	O
samples	O
,	O
quantitative	O
assessment	O
of	O
LINE	O
-	O
1	O
and	O
AluYb8	O
methylation	O
,	O
and	O
the	O
use	O
of	O
a	O
well	O
-	O
established	O
,	O
high	O
-	O
density	O
methylation	O
array	O
for	O
methylation	O
profiling	O
.	O

Modest	O
limitations	O
of	O
this	O
study	O
include	O
the	O
use	O
of	O
data	O
from	O
medical	O
records	O
,	O
which	O
may	O
have	O
reduced	O
the	O
quality	O
of	O
covariate	O
data	O
used	O
in	O
this	O
study	O
.	O

This	O
may	O
have	O
been	O
especially	O
relevant	O
in	O
our	O
measurement	O
of	O
maternal	O
tobacco	O
,	O
alcohol	O
,	O
and	O
prenatal	O
vitamin	O
use	O
and	O
could	O
have	O
potentially	O
introduced	O
a	O
bias	O
toward	O
the	O
null	O
.	O

Additionally	O
,	O
because	O
Rhode	O
Island	O
is	O
a	O
small	O
state	O
representing	O
a	O
small	O
geographic	O
area	O
,	O
recruiting	O
participants	O
from	O
this	O
state	O
may	O
affect	O
the	O
generalizability	O
of	O
our	O
findings	O
;	O
however	O
,	O
because	O
the	O
Women	O
and	O
Infants	O
Hospital	O
performs	O
>	O
85	O
%	O
of	O
all	O
obstetrical	O
deliveries	O
in	O
Providence	O
County	O
(	O
the	O
largest	O
population	O
center	O
in	O
Rhode	O
Island	O
),	O
we	O
believe	O
this	O
limitation	O
is	O
compensated	O
for	O
to	O
some	O
extent	O
by	O
the	O
lack	O
of	O
ascertainment	O
bias	O
in	O
this	O
population	O
-	O
based	O
study	O
.	O

Conclusions	O
Overall	O
,	O
we	O
have	O
demonstrated	O
that	O
altered	O
methylation	O
of	O
repetitive	O
elements	O
in	O
the	O
placenta	O
is	O
associated	O
with	O
birth	O
outcome	O
and	O
with	O
specific	O
environmental	O
exposures	O
encountered	O
by	O
the	O
fetus	O
.	O

Of	O
course	O
,	O
birth	O
weight	O
is	O
likely	B
a	O
proxy	O
for	O
a	O
complex	O
interplay	O
of	O
underlying	O
etiologic	O
mechanisms	O
and	O
environmental	O
factors	O
that	O
overall	O
contribute	O
to	O
infant	O
health	O
at	O
birth	O
and	O
beyond	O
.	O

Our	O
data	O
also	O
suggest	O
that	O
these	O
alterations	O
may	O
reflect	O
underlying	O
functional	O
epigenetic	O
alterations	O
to	O
genes	O
important	O
in	O
placental	O
growth	O
and	O
development	O
.	O

Confirmation	O
and	O
expansion	O
of	O
these	O
findings	O
in	O
additional	O
populations	O
,	O
with	O
additional	O
environmental	O
data	O
and	O
more	O
comprehensive	O
methylation	O
profiles	O
as	O
well	O
as	O
studies	O
of	O
the	O
mechanism	O
of	O
these	O
alterations	O
,	O
will	O
provide	O
additional	O
valuable	O
insights	O
into	O
the	O
epigenetic	O
mechanisms	O
controlling	O
fetal	O
growth	O
.	O

These	O
data	O
also	O
further	O
the	O
hypothesis	O
that	O
the	O
intrauterine	O
environment	O
acting	O
through	O
epigenetic	O
alteration	O
of	O
the	O
placenta	O
is	O
a	O
key	O
mechanism	O
to	O
explain	O
the	O
developmental	O
origins	O
of	O
health	O
and	O
disease	O
and	O
suggest	O
that	O
enhanced	O
examinations	O
of	O
the	O
importance	O
of	O
placental	O
epigenetic	O
variation	O
in	O
health	O
outcomes	O
should	O
be	O
undertaken	O
.	O

Supplemental	O
Material	O
Caption	O
(	O
MEDIA	O
)	O
Click	O
here	O
for	O
additional	O
data	O
file	O
.	O

PubMed	O
Central	O
:	O

Acute	O
stridor	O
and	O
wheeze	O
as	O
an	O
initial	O
manifestation	O
of	O
hypocalcemia	O
in	O
an	O
infant	O
Sir	O
,	O
A	O
4	O
-	O
month	O
-	O
old	O
male	O
infant	O
who	O
was	O
delivered	O
at	O
term	O
with	O
a	O
normal	O
birth	O
weight	O
and	O
uneventful	O
neonatal	O
period	O
was	O
brought	O
with	O
history	O
of	O
cough	O
and	O
noisy	O
breathing	O
of	O
1	O
-	O
day	O
duration	O
.	O

The	O
baby	O
had	O
been	O
on	O
cow	O
'	O
s	O
milk	O
since	O
birth	O
.	O

On	O
examination	O
,	O
the	O
infant	O
was	O
afebrile	O
,	O
alert	O
and	O
interacting	O
with	O
his	O
mother	O
.	O

The	O
heart	O
rate	O
was	O
130	O
/	O
min	O
,	O
respiratory	O
rate	O
was	O
36	O
/	O
min	O
and	O
oxygen	O
saturation	O
was	O
98	O
%	O
in	O
room	O
air	O
.	O

Stridor	O
was	O
present	O
while	O
crying	O
and	O
the	O
infant	O
had	O
a	O
barking	O
cough	O
and	O
occasional	O
wheeze	O
.	O

Other	O
systems	O
were	O
normal	O
.	O

Investigations	O
revealed	O
normal	O
hemoglobin	O
,	O
total	O
and	O
differential	O
counts	O
and	O
normal	O
c	O
-	O
reactive	O
protein	O
.	O

Chest	O
and	O
soft	O
tissue	O
neck	O
X	O
-	O
ray	O
were	O
normal	O
.	O

The	O
child	O
was	O
treated	O
with	O
nebulized	O
adrenaline	O
followed	O
by	O
salbutamol	O
.	O

While	O
on	O
treatment	O
,	O
child	O
had	O
an	O
episode	O
of	O
multifocal	O
clonic	O
movements	O
involving	O
all	O
four	O
limbs	O
lasting	O
for	O
2	O
minutes	O
.	O

Blood	O
sugar	O
checked	O
at	O
that	O
time	O
was	O
normal	O
.	O

Serum	O
calcium	O
was	O
7	O
.	O
5	O
mg	O
/	O
dl	O
.	O

In	O
view	O
of	O
hypocalcemia	O
,	O
the	O
child	O
was	O
treated	O
with	O
2	O
ml	O
/	O
kg	O
of	O
10	O
%	O
calcium	O
gluconate	O
followed	O
by	O
maintenance	O
calcium	O
,	O
following	O
which	O
the	O
stridor	O
disappeared	O
and	O
there	O
were	O
no	O
further	O
seizures	O
.	O

Cranial	O
ultrasound	O
was	O
done	O
following	O
the	O
seizures	O
and	O
was	O
reported	O
as	O
normal	O
.	O

Serum	O
vitamin	O
D3	O
level	O
was	O
found	O
to	O
be	O
low	O
(	O
4	O
.	O
7	O
ng	O
/	O
ml	O
).	O

There	O
was	O
no	O
evidence	O
of	O
rickets	O
both	O
clinically	O
and	O
radiologically	O
.	O

The	O
child	O
was	O
treated	O
with	O
600	O
,	O
000	O
IU	O
of	O
oral	O
vitamin	O
D	O
and	O
discharged	O
on	O
maintenance	O
doses	O
of	O
calcium	O
gluconate	O
and	O
800	O
IU	O
of	O
oral	O
vitamin	O
D	O
daily	O
for	O
3	O
months	O
.	O

Hypocalcemia	O
is	O
common	O
in	O
preterm	O
infants	O
,	O
infants	O
born	O
to	O
gestational	O
diabetic	O
mothers	O
and	O
infants	O
on	O
cow	O
'	O
s	O
milk	O
.	O

Hypocalcemia	O
has	O
also	O
been	O
shown	O
to	O
occur	O
in	O
exclusively	O
breast	O
fed	O
babies	O
not	O
exposed	O
to	O
sunlight	O
and	O
in	O
infants	O
whose	O
mothers	O
are	O
deficient	O
in	O
vitamin	O
D	O
.[	O
1	O
]	O
Symptoms	O
of	O
hypocalcemia	O
in	O
children	O
include	O
lethargy	O
,	O
recurrent	O
respiratory	O
tract	O
infections	O
,	O
focal	O
clonic	O
seizures	O
,	O
jitteriness	O
,	O
carpopedal	O
spasm	O
and	O
rarely	O
stridor	O
due	O
to	O
laryngospasm	O
.	O

Stridor	O
occurring	O
as	O
a	O
consequence	O
of	O
nutritional	O
rickets	O
is	O
reported	O
in	O
literature	O
.	O

[	O
2	O
]	O
Hypocalcemic	O
laryngospasm	O
causing	O
stridor	O
and	O
tetany	O
in	O
a	O
child	O
with	O
renal	O
dysplasia	O
has	O
also	O
been	O
described	O
.	O

[	O
3	O
]	O
A	O
fatal	O
case	O
of	O
biphasic	O
wheezing	O
in	O
an	O
infant	O
attributed	O
to	O
hypocalcemia	O
has	O
been	O
described	O
in	O
literature	O
.	O

[	O
4	O
]	O
Vitamin	O
D	O
by	O
itself	O
has	O
been	O
shown	O
to	O
have	O
beneficial	O
effects	O
in	O
children	O
who	O
wheeze	O
by	O
up	O
regulating	O
antimicrobial	O
proteins	O
or	O
through	O
multiple	O
immune	O
effects	O
.	O

Higher	O
prenatal	O
vitamin	O
D	O
levels	O
are	O
shown	O
to	O
have	O
a	O
protective	O
role	O
against	O
wheezing	O
in	O
young	O
children	O
in	O
epidemiological	O
studies	O
.	O

[	O
5	O
]	O
The	O
above	O
observations	O
highlight	O
the	O
fact	O
that	O
vitamin	O
D	O
has	O
a	O
key	O
role	O
to	O
play	O
in	O
the	O
pathogenesis	O
of	O
wheezing	O
/	O
asthma	O
.	O

The	O
infant	O
reported	O
here	O
was	O
managed	O
as	O
a	O
case	O
of	O
acute	O
laryngotracheobronchitis	O
initially	O
as	O
there	O
was	O
no	O
evidence	O
of	O
rickets	O
and	O
the	O
diagnosis	O
of	O
hypocalcemia	O
was	O
made	O
only	O
after	O
he	O
had	O
convulsions	O
.	O

This	O
case	O
report	O
highlights	O
the	O
importance	O
of	O
measuring	O
serum	O
calcium	O
levels	O
in	O
infants	O
with	O
acute	O
stridor	O
and	O
or	O
wheeze	O
.	O

Management	O
consists	O
of	O
correcting	O
hypocalcemia	O
and	O
determining	O
the	O
cause	O
of	O
hypocalcemia	O
and	O
treating	O
it	O
.	O

Prompt	O
resolution	O
of	O
symptoms	O
on	O
correction	O
of	O
hypocalcemia	O
as	O
had	O
happened	O
in	O
our	O
case	O
has	O
also	O
been	O
reported	O
in	O
literature	O
.	O

[	O
6	O
]	O
While	O
treating	O
young	O
infants	O
with	O
acute	O
stridor	O
and	O
or	O
wheeze	O
,	O
it	O
would	O
be	O
prudent	O
to	O
consider	O
hypocalcemia	O
especially	O
when	O
one	O
or	O
several	O
risk	O
factors	O
are	O
present	O
.	O

Treatment	O
with	O
calcium	O
usually	O
reverses	O
the	O
symptoms	O
rapidly	O
.	O

Vitamin	O
D	O
therapy	O
may	O
be	O
of	O
benefit	O
in	O
wheezing	O
children	O
.	O

PubMed	O
Central	O
:	O

A	O
low	O
protein	O
diet	O
during	O
pregnancy	O
provokes	O
a	O
lasting	O
shift	O
of	O
hepatic	O
expression	O
of	O
genes	O
related	O
to	O
cell	O
cycle	O
throughout	O
ontogenesis	O
in	O
a	O
porcine	O
model	O
Abstract	O
Background	O
In	O
rodent	O
models	O
and	O
in	O
humans	O
the	O
impact	O
of	O
gestational	O
diets	O
on	O
the	O
offspring	O
'	O
s	O
phenotype	O
was	O
shown	O
experimentally	O
and	O
epidemiologically	O
.	O

Adverse	O
environmental	O
conditions	O
during	O
fetal	O
development	O
provoke	O
an	O
intrauterine	O
adaptive	O
response	O
termed	O
'	O
fetal	O
programming	O
',	O
which	O
may	O
lead	O
to	O
both	O
persistently	O
biased	O
responsiveness	O
to	O
extrinsic	O
factors	O
and	O
permanent	O
consequences	O
for	O
the	O
organismal	O
phenotype	O
.	O

This	O
leads	O
to	O
the	O
hypothesis	O
that	O
the	O
offspring	O
'	O
s	O
transcriptome	O
exhibits	O
short	O
-	O
term	O
and	O
long	O
-	O
term	O
changes	O
,	O
depending	O
on	O
the	O
maternal	O
diet	O
.	O

In	O
order	O
to	O
contribute	O
to	O
a	O
comprehensive	O
inventory	O
of	O
genes	O
and	O
functional	O
networks	O
that	O
are	O
targets	O
of	O
nutritional	O
programming	O
initiated	O
during	O
fetal	O
life	O
,	O
we	O
applied	O
whole	O
-	O
genome	O
microarrays	O
for	O
expression	O
profiling	O
in	O
a	O
longitudinal	O
experimental	O
design	O
covering	O
prenatal	O
,	O
perinatal	O
,	O
juvenile	O
,	O
and	O
adult	O
ontogenetic	O
stages	O
in	O
a	O
porcine	O
model	O
.	O

Pregnant	O
sows	O
were	O
fed	O
either	O
a	O
gestational	O
low	O
protein	O
diet	O
(	O
LP	O
,	O
6	O
%	O
CP	O
)	O
or	O
an	O
adequate	O
protein	O
diet	O
(	O
AP	O
,	O
12	O
%	O
CP	O
).	O

All	O
offspring	O
was	O
nursed	O
by	O
foster	O
sows	O
receiving	O
standard	O
diets	O
.	O

After	O
weaning	O
,	O
all	O
offspring	O
was	O
fed	O
standard	O
diets	O
ad	O
libitum	O
.	O

Results	O
Analyses	O
of	O
the	O
hepatic	O
gene	O
expression	O
of	O
the	O
offspring	O
at	O
prenatal	O
(	O
94	O
dies	O
post	O
conceptionem	O
,	O
dpc	O
)	O
and	O
postnatal	O
stages	O
(	O
1	O
,	O
28	O
,	O
188	O
dies	O
post	O
natum	O
,	O
dpn	O
)	O
included	O
comparisons	O
between	O
dietary	O
groups	O
within	O
stages	O
as	O
well	O
as	O
comparisons	O
between	O
ontogenetic	O
stages	O
within	O
diets	O
to	O
separate	O
diet	O
-	O
specific	O
transcriptional	O
changes	O
and	O
maturation	O
processes	O
.	O

We	O
observed	O
differential	O
expression	O
of	O
genes	O
related	O
to	O
lipid	O
metabolism	O
(	O
e	O
.	O
g	O
.	O

Fatty	O
acid	O
metabolism	O
,	O
Biosynthesis	O
of	O
steroids	O
,	O
Synthesis	O
and	O
degradation	O
of	O
ketone	O
bodies	O
,	O
FA	O
elongation	O
in	O
mitochondria	O
,	O
Bile	O
acid	O
synthesis	O
)	O
and	O
cell	O
cycle	O
regulation	O
(	O
e	O
.	O
g	O
.	O

Mitotic	O
roles	O
of	O
PLK	O
,	O
G1	O
/	O
S	O
checkpoint	O
regulation	O
,	O
G2	O
/	O
M	O
DNA	O
damage	O
checkpoint	O
regulation	O
).	O

Notably	O
,	O
at	O
stage	O
1	O
dpn	O
no	O
regulation	O
of	O
a	O
distinct	O
pathway	O
was	O
found	O
in	O
LP	O
offspring	O
.	O

Conclusions	O
The	O
transcriptomic	O
modulations	O
point	O
to	O
persistent	O
functional	O
demand	O
on	O
the	O
liver	O
towards	O
cell	O
proliferation	O
in	O
the	O
LP	O
group	O
but	O
not	O
in	O
the	O
AP	O
group	O
at	O
identical	O
nutritional	O
conditions	O
during	O
postnatal	O
life	O
due	O
to	O
divergent	O
'	O
programming	O
'	O
of	O
the	O
genome	O
.	O

Together	O
with	O
the	O
observation	O
that	O
the	O
offspring	O
of	O
both	O
groups	O
did	O
not	O
differ	O
in	O
body	O
weight	O
but	O
in	O
body	O
composition	O
and	O
fat	O
content	O
,	O
the	O
data	O
indicate	O
that	O
the	O
activity	O
of	O
various	O
genes	O
led	O
to	O
diverse	O
partitioning	O
of	O
nutrients	O
among	O
peripheral	O
and	O
visceral	O
organs	O
and	O
tissues	O
.	O

Background	O
Pregnancy	O
and	O
fetal	O
development	O
are	O
periods	O
of	O
rapid	O
growth	O
and	O
cell	O
differentiation	O
when	O
mother	O
and	O
offspring	O
are	O
vulnerable	O
to	O
changes	O
in	O
dietary	O
supply	O
.	O

Adverse	O
environmental	O
conditions	O
during	O
fetal	O
development	O
provoke	O
an	O
intrauterine	O
adaptive	O
response	O
termed	O
'	O
fetal	O
programming	O
',	O
which	O
may	O
lead	O
to	O
both	O
persistently	O
biased	O
responsiveness	O
to	O
extrinsic	O
factors	O
and	O
permanent	O
consequences	O
for	O
the	O
organismal	O
phenotype	O
[	O
1	O
-	O
6	O
].	O

Due	O
to	O
developmental	O
plasticity	O
,	O
environmental	O
factors	O
induce	O
altered	O
expression	O
of	O
the	O
genome	O
and	O
ultimately	O
modify	O
the	O
offspring	O
'	O
s	O
phenotype	O
[	O
7	O
].	O

In	O
various	O
human	O
and	O
animal	O
studies	O
a	O
gestational	O
low	O
protein	O
intake	O
during	O
pregnancy	O
was	O
accompanied	O
by	O
low	O
birth	O
weight	O
offspring	O
,	O
which	O
was	O
subsequently	O
predisposed	O
for	O
metabolic	O
disorders	O
and	O
alterations	O
in	O
body	O
composition	O
[	O
6	O
,	O
8	O
-	O
10	O
].	O

Interestingly	O
,	O
epidemiological	O
studies	O
in	O
women	O
showed	O
that	O
maternal	O
malnutrition	O
during	O
pregnancy	O
can	O
result	O
in	O
fetal	O
growth	O
retardation	O
[	O
11	O
,	O
12	O
].	O

In	O
order	O
to	O
contribute	O
to	O
a	O
comprehensive	O
inventory	O
of	O
genes	O
and	O
functional	O
networks	O
that	O
are	O
targets	O
of	O
nutritional	O
programming	O
initiated	O
during	O
fetal	O
life	O
,	O
we	O
applied	O
whole	O
-	O
genome	O
microarrays	O
for	O
expression	O
profiling	O
in	O
a	O
longitudinal	O
experimental	O
design	O
covering	O
prenatal	O
,	O
perinatal	O
,	O
juvenile	O
and	O
adult	O
ontogenetic	O
stages	O
in	O
a	O
porcine	O
model	O
.	O

On	O
an	O
isoenergetic	O
basis	O
,	O
pregnant	O
sows	O
were	O
fed	O
either	O
a	O
gestational	O
low	O
protein	O
diet	O
(	O
LP	O
,	O
6	O
%	O
CP	O
)	O
or	O
an	O
adequate	O
protein	O
diet	O
(	O
AP	O
,	O
12	O
%	O
CP	O
)	O
to	O
investigate	O
the	O
effects	O
on	O
hepatic	O
gene	O
expression	O
in	O
their	O
fetuses	O
and	O
offspring	O
.	O

The	O
experiment	O
comprises	O
a	O
valuable	O
model	O
especially	O
for	O
'	O
fetal	O
'	O
programming	O
,	O
because	O
cross	O
-	O
fostering	O
enabled	O
assessment	O
of	O
solely	O
the	O
nutritional	O
effects	O
during	O
gestation	O
.	O

Moreover	O
,	O
due	O
to	O
the	O
similarity	O
in	O
metabolism	O
,	O
physiology	O
,	O
anatomy	O
and	O
genome	O
the	O
study	O
is	O
also	O
a	O
beneficial	O
model	O
for	O
nutritional	O
programming	O
in	O
humans	O
[	O
13	O
,	O
14	O
].	O

Thus	O
the	O
experimental	O
data	O
will	O
complement	O
previous	O
findings	O
from	O
rodent	O
models	O
and	O
epidemiological	O
human	O
data	O
.	O

In	O
particular	O
,	O
the	O
low	O
protein	O
diet	O
provides	O
a	O
model	O
for	O
prenatal	O
dietary	O
undersupply	O
and	O
exposure	O
to	O
famine	O
that	O
regrettably	O
still	O
burdens	O
a	O
considerable	O
proportion	O
of	O
the	O
human	O
population	O
.	O

In	O
our	O
experiment	O
the	O
porcine	O
offspring	O
,	O
which	O
was	O
exposed	O
to	O
an	O
undersupply	O
of	O
protein	O
during	O
fetal	O
development	O
but	O
had	O
appropriate	O
postnatal	O
dietary	O
conditions	O
,	O
was	O
able	O
to	O
broadly	O
adapt	O
in	O
terms	O
of	O
their	O
body	O
weight	O
.	O

In	O
fact	O
,	O
newborns	O
from	O
sows	O
that	O
received	O
a	O
low	O
protein	O
supply	O
during	O
gestation	O
had	O
a	O
significantly	O
lower	O
birth	O
weight	O
,	O
a	O
lower	O
body	O
fat	O
content	O
,	O
reduced	O
size	O
and	O
number	O
of	O
adipocytes	O
and	O
muscle	O
fibres	O
than	O
newborns	O
of	O
the	O
control	O
group	O
.	O

At	O
weaning	O
(	O
28	O
dpn	O
)	O
offspring	O
of	O
the	O
LP	O
group	O
showed	O
slight	O
but	O
significant	O
higher	O
fat	O
content	O
and	O
adipocyte	O
size	O
,	O
and	O
still	O
lower	O
muscle	O
fibre	O
numbers	O
.	O

But	O
neither	O
body	O
weight	O
at	O
weaning	O
nor	O
body	O
weight	O
at	O
188	O
dpn	O
differed	O
significantly	O
among	O
offspring	O
of	O
the	O
LP	O
and	O
the	O
AP	O
group	O
,	O
whereas	O
visceral	O
and	O
subcutaneous	O
fat	O
content	O
remained	O
higher	O
in	O
LP	O
than	O
in	O
AP	O
during	O
postnatal	O
life	O
[	O
15	O
-	O
17	O
].	O

Here	O
the	O
focus	O
is	O
on	O
the	O
hepatic	O
transcriptomic	O
response	O
.	O

We	O
present	O
that	O
the	O
hepatic	O
expression	O
profiles	O
showed	O
considerable	O
modulation	O
during	O
prenatal	O
and	O
postnatal	O
stages	O
,	O
i	O
.	O
e	O
.	O

in	O
acute	O
and	O
delayed	O
response	O
to	O
the	O
nutritional	O
stimulus	O
.	O

Nutritional	O
fetal	O
programming	O
becomes	O
apparent	O
as	O
an	O
altered	O
hepatic	O
expression	O
of	O
genes	O
related	O
to	O
cell	O
cycle	O
and	O
cell	O
maintenance	O
,	O
and	O
lipid	O
,	O
ketone	O
body	O
,	O
and	O
amino	O
acid	O
metabolism	O
,	O
indicating	O
different	O
functional	O
demands	O
and	O
replies	O
of	O
the	O
liver	O
in	O
both	O
experimental	O
groups	O
under	O
identical	O
nutritional	O
conditions	O
post	O
natum	O
.	O

Results	O
We	O
performed	O
a	O
longitudinal	O
holistic	O
study	O
of	O
the	O
hepatic	O
transcriptome	O
of	O
offspring	O
of	O
dams	O
fed	O
either	O
an	O
experimental	O
low	O
protein	O
diet	O
(	O
LP	O
)	O
or	O
an	O
adequate	O
protein	O
diet	O
(	O
AP	O
)	O
throughout	O
gestation	O
,	O
in	O
order	O
to	O
obtain	O
a	O
comprehensive	O
picture	O
of	O
genes	O
and	O
functional	O
networks	O
that	O
are	O
sensitive	O
to	O
fetal	O
nutritional	O
programming	O
using	O
a	O
porcine	O
model	O
.	O

We	O
investigated	O
the	O
offspring	O
'	O
s	O
hepatic	O
gene	O
expression	O
at	O
94	O
dpc	O
,	O
1	O
dpn	O
,	O
28	O
dpn	O
and	O
188	O
dpn	O
by	O
24	O
k	O
-	O
microarray	O
analysis	O
.	O

In	O
total	O
we	O
found	O
12	O
,	O
650	O
probe	O
-	O
sets	O
expressed	O
at	O
stage	O
94	O
dpc	O
(	O
1	O
dpn	O
:	O
12	O
,	O
005	O
;	O
28	O
dpn	O
:	O
12	O
,	O
307	O
;	O
188	O
dpn	O
:	O
11	O
,	O
784	O
)	O
according	O
to	O
MAS5	O
analysis	O
.	O

Further	O
filtering	O
based	O
on	O
the	O
variability	O
of	O
expression	O
of	O
probe	O
-	O
sets	O
revealed	O
7	O
,	O
937	O
probe	O
-	O
sets	O
for	O
further	O
analysis	O
at	O
stage	O
94	O
dpc	O
(	O
1	O
dpn	O
:	O
9	O
,	O
099	O
;	O
28	O
dpn	O
:	O
8	O
,	O
250	O
;	O
188	O
dpn	O
:	O
8	O
,	O
943	O
).	O

These	O
probe	O
-	O
sets	O
represent	O
5	O
,	O
887	O
genes	O
at	O
stage	O
94	O
dpc	O
(	O
1	O
dpn	O
:	O
6	O
,	O
965	O
;	O
28	O
dpn	O
:	O
6	O
,	O
387	O
;	O
188	O
dpn	O
:	O
6	O
,	O
958	O
),	O
according	O
to	O
the	O
recent	O
annotation	O
[	O
18	O
].	O

In	O
order	O
to	O
identify	O
molecular	O
pathways	O
affected	O
by	O
the	O
gestational	O
diets	O
we	O
first	O
analysed	O
differential	O
expression	O
between	O
the	O
dietary	O
groups	O
within	O
each	O
stage	O
separately	O
.	O

The	O
different	O
dietary	O
exposure	O
of	O
the	O
offspring	O
during	O
prenatal	O
development	O
can	O
be	O
expected	O
to	O
cause	O
slight	O
shifts	O
of	O
the	O
developmental	O
age	O
of	O
the	O
offspring	O
that	O
may	O
be	O
reflected	O
by	O
subtle	O
changes	O
of	O
the	O
transcriptome	O
and	O
could	O
hamper	O
the	O
identification	O
of	O
direct	O
effects	O
of	O
the	O
gestational	O
diets	O
on	O
the	O
hepatic	O
expression	O
.	O

Secondly	O
,	O
we	O
analysed	O
the	O
differences	O
among	O
both	O
experimental	O
groups	O
regarding	O
the	O
more	O
long	O
-	O
term	O
and	O
more	O
pronounced	O
changes	O
of	O
expression	O
patterns	O
between	O
the	O
adjacent	O
stages	O
.	O

In	O
total	O
we	O
found	O
13	O
,	O
357	O
probe	O
-	O
sets	O
expressed	O
within	O
94	O
dpc	O
and	O
1	O
dpn	O
(	O
1	O
dpn	O
and	O
28	O
dpn	O
:	O
13	O
,	O
259	O
;	O
28	O
dpn	O
and	O
188	O
dpn	O
:	O
12	O
,	O
637	O
)	O
according	O
to	O
MAS5	O
analysis	O
(	O
Table1	O
).	O

After	O
the	O
filtering	O
steps	O
described	O
above	O
,	O
10	O
,	O
293	O
probe	O
-	O
sets	O
were	O
detected	O
within	O
94	O
dpc	O
and	O
1	O
dpn	O
(	O
1	O
dpn	O
and	O
28	O
dpn	O
:	O
10	O
,	O
317	O
;	O
28	O
dpn	O
and	O
188	O
dpn	O
:	O
8	O
,	O
892	O
).	O

These	O
probe	O
-	O
sets	O
represent	O
7	O
,	O
697	O
genes	O
within	O
94	O
dpc	O
and	O
1	O
dpn	O
(	O
1	O
dpn	O
and	O
28	O
dpn	O
:	O
7	O
,	O
758	O
;	O
28	O
dpn	O
and	O
188	O
dpn	O
:	O
6	O
,	O
879	O
).	O

Notably	O
,	O
q	O
-	O
values	O
between	O
ontogenetic	O
stages	O
within	O
diet	O
were	O
remarkable	O
lower	O
(	O
q	O
≤	O
0	O
.	O
05	O
)	O
than	O
between	O
diets	O
within	O
stage	O
(	O
q	O
≤	O
0	O
.	O
25	O
).	O

Caption	O
(	O
TABLE	O
-	O
WRAP	O
):	O
TABLE	O
1	O
No	O
.	O

of	O
expressed	O
probe	O
-	O
sets	O
,	O
filtered	O
probe	O
-	O
sets	O
,	O
and	O
regulated	O
probe	O
-	O
sets	O
of	O
LP	O
and	O
AP	O
offspring	O
at	O
distinct	O
developmental	O
stages	O
and	O
periodsNo	O
.	O

of	O
expressed	O
probe	O
-	O
setsNo	O
.	O

of	O
filtered	O
probe	O
-	O
setsNo	O
.	O

of	O
total	O
regulated	O
probe	O
-	O
setsNo	O
.	O

of	O
regulated	O
probe	O
-	O
sets	O
private	O
to	O
LP	O
offspringNo	O
.	O

of	O
regulated	O
probe	O
-	O
sets	O
private	O
to	O
AP	O
offspringNo	O
.	O

of	O
commonly	O
regulated	O
probe	O
-	O
sets	O
of	O
LP	O
and	O
AP	O
offspring	O
(	O
intersection	O
)	O
94	O
dpc	O
12	O
,	O
6507	O
,	O
9371	O
,	O
001	O
(	O
541	O
up	O
,	O
460	O
down	O
)	O
1	O
dpn	O
12	O
,	O
0059	O
,	O
0991	O
(	O
0	O
up	O
,	O
1	O
down	O
)	O
28	O
dpn	O
12	O
,	O
3078	O
,	O
250483	O
(	O
214	O
up	O
,	O
269	O
down	O
)	O
188	O
dpn	O
11	O
,	O
7848	O
,	O
9432	O
,	O
084	O
(	O
952	O
up	O
,	O
1	O
,	O
132	O
down	O
)	O
developmental	O
period	O
1	O
13	O
,	O
35710	O
,	O
2938	O
,	O
166	O
(	O
3	O
,	O
731	O
up	O
,	O
4	O
,	O
435	O
down	O
)	O
1	O
,	O
042	O
(	O
384	O
up	O
,	O
658	O
down	O
)	O
1	O
,	O
034	O
(	O
503	O
up	O
,	O
531	O
down	O
)	O
6	O
,	O
090	O
(	O
2	O
,	O
844	O
up	O
,	O
3	O
,	O
246	O
down	O
)	O
developmental	O
period	O
2	O
13	O
,	O
35910	O
,	O
3178	O
,	O
329	O
(	O
4	O
,	O
118	O
up	O
,	O
4	O
,	O
211	O
down	O
)	O
881	O
(	O
423	O
up	O
,	O
458	O
down	O
)	O
991	O
(	O
448	O
up	O
,	O
543	O
down	O
)	O
6	O
,	O
457	O
(	O
3	O
,	O
247	O
up	O
,	O
3	O
,	O
210	O
down	O
)	O
developmental	O
period	O
3	O
12	O
,	O
6378	O
,	O
8926	O
,	O
612	O
(	O
2	O
,	O
810	O
up	O
,	O
3	O
,	O
803	O
down	O
)	O
1	O
,	O
959	O
(	O
834	O
up	O
,	O
1	O
,	O
125	O
down	O
)	O
1	O
,	O
549	O
(	O
697	O
up	O
,	O
852	O
down	O
)	O
3	O
,	O
104	O
(	O
1	O
,	O
279	O
up	O
,	O
1	O
,	O
825	O
down	O
)	O
Developmental	O
period	O
1	O
indicates	O
the	O
comparisons	O
between	O
stages	O
94	O
dpc	O
and	O
1	O
dpn	O
;	O
Developmental	O
period	O
2	O
indicates	O
the	O
comparisons	O
between	O
stages	O
1	O
dpc	O
and	O
28	O
dpn	O
;	O
Developmental	O
period	O
3	O
indicates	O
the	O
comparisons	O
between	O
stages	O
28	O
dpc	O
and	O
188	O
dpn	O
;	O
'	O
Up	O
'	O
indicates	O
higher	O
expression	O
values	O
of	O
later	O
stages	O
,	O
'	O
down	O
'	O
indicates	O
lower	O
expression	O
values	O
at	O
later	O
stages	O
.	O

Comparisons	O
between	O
LP	O
and	O
AP	O
within	O
stages	O
Expression	O
of	O
mRNA	O
was	O
compared	O
in	O
LP	O
and	O
AP	O
offspring	O
within	O
each	O
ontogenetic	O
stage	O
(	O
Figure1	O
).	O

At	O
stage	O
94	O
dpc	O
1	O
,	O
001	O
probe	O
-	O
sets	O
differed	O
significantly	O
between	O
LP	O
and	O
AP	O
fetuses	O
(	O
541	O
LP	O
≻	O
AP	O
).	O

Ingenuity	O
Pathway	O
Analysis	O
indicates	O
enrichment	O
of	O
molecular	O
routes	O
related	O
to	O
genetic	O
information	O
and	O
nucleic	O
acid	O
processing	O
and	O
cell	O
cycle	O
that	O
were	O
found	O
to	O
be	O
diminished	O
,	O
whereas	O
the	O
'	O
Wnt	O
signaling	O
'	O
was	O
found	O
to	O
be	O
increased	O
in	O
LP	O
offspring	O
(	O
Table2	O
).	O

In	O
perinatal	O
piglets	O
(	O
stage	O
1	O
dpn	O
)	O
1	O
probe	O
-	O
set	O
differed	O
between	O
LP	O
offspring	O
and	O
AP	O
offspring	O
(	O
0	O
increased	O
).	O

Therefore	O
,	O
no	O
significant	O
regulated	O
metabolic	O
pathway	O
was	O
determined	O
.	O

Caption	O
(	O
FIG	O
):	O
FIGURE	O
1	O
Number	O
of	O
regulated	O
probe	O
-	O
sets	O
in	O
liver	O
tissue	O
.	O

The	O
numbers	O
at	O
the	O
horizontal	O
arrows	O
indicate	O
the	O
quantity	O
of	O
probe	O
-	O
sets	O
significantly	O
regulated	O
between	O
the	O
adjacent	O
ontogenetic	O
stages	O
in	O
either	O
AP	O
or	O
LP	O
offspring	O
,	O
whereas	O
the	O
numbers	O
in	O
the	O
intersections	O
indicate	O
the	O
quantity	O
of	O
probe	O
-	O
sets	O
commonly	O
regulated	O
between	O
stages	O
in	O
AP	O
and	O
LP	O
offspring	O
.	O

The	O
numbers	O
at	O
vertical	O
arrows	O
are	O
the	O
number	O
of	O
probe	O
-	O
sets	O
differentially	O
expressed	O
between	O
AP	O
and	O
LP	O
offspring	O
at	O
the	O
same	O
ontogenetic	O
stage	O
.	O

(	O
Arrows	O
between	O
boxes	O
show	O
direction	O
of	O
the	O
comparison	O
;	O
small	O
arrows	O
indicate	O
up	O
and	O
down	O
regulation	O
,	O
respectively	O
).	O

Caption	O
(	O
TABLE	O
-	O
WRAP	O
):	O
TABLE	O
2	O
Significantly	O
regulated	O
transcripts	O
of	O
metabolic	O
pathways	O
in	O
liver	O
tissue	O
within	O
different	O
ontogenetic	O
stages	O
(	O
Ingenuity	O
Pathway	O
Analysis	O
).	O
Ontogenetic	O
stageRegulated	O
pathwayDirection	O
of	O
regulation	O
P	O
valueNo	O
.	O

of	O
regulated	O
genesGenes	O
involved	O
in	O
pathway94	O
dpcWnt	O
signalingup1	O
.	O
20	O
*	O
E	O
-	O
29ACVR1	O
,	O
CSNK1G3	O
,	O
FZD4	O
,	O
FZD6	O
,	O
MAP3K7	O
,	O
MMP7	O
,	O
TCF4	O
,	O
TCF7L2	O
,	O
WNT5AMitotic	O
roles	O
of	O
Polo	O
-	O
like	O
kinasedown5	O
.	O
15	O
*	O
E	O
-	O
811CCNB1	O
,	O
CCNB2	O
,	O
CDC23	O
,	O
CDC25B	O
,	O
CDK1	O
,	O
FZR1	O
,	O
SP90AA1	O
,	O
KIF11	O
,	O
PLK1	O
,	O
PPP2R1B	O
,	O
PTTG1G1	O
/	O
S	O
checkpoint	O
regulationdown2	O
.	O
76	O
*	O
E	O
-	O
58CCND2	O
,	O
CCND3	O
,	O
CCNE1	O
,	O
CDK4	O
,	O
E2F1	O
,	O
E2F4	O
,	O
RB1	O
,	O
TFDP1G2	O
/	O
M	O
DNA	O
damage	O
checkpoint	O
regulationdown1	O
.	O
53	O
*	O
E	O
-	O
35CCNB1	O
,	O
CCNB2	O
,	O
CDC25B	O
,	O
CDK1	O
,	O
PLK11	O
dpn	O
-----	O
28	O
dpnComplement	O
systemup2	O
.	O
07	O
*	O
E	O
-	O
55C4B	O
,	O
C5	O
,	O
C6	O
,	O
C9	O
,	O
CD55G1	O
/	O
S	O
checkpoint	O
regulationdown2	O
.	O
49	O
*	O
E	O
-	O
23CDKN1B	O
,	O
HDAC11	O
,	O
TGFB3188	O
dpnVEGF	O
signalingup2	O
.	O
80	O
*	O
E	O
-	O
412ACTA2	O
,	O
AKT3	O
,	O
BCL2	O
,	O
EIF2B1	O
,	O
KDR	O
,	O
MAPK1	O
,	O
MRAS	O
,	O
PIK3R3	O
,	O
PRKCB	O
,	O
RRAS2	O
,	O
VCL	O
,	O
VEGFCmTOR	O
signalingup6	O
.	O
29	O
*	O
E	O
-	O
313AKT3	O
,	O
EIF3B	O
,	O
EIF4B	O
,	O
MAPK1	O
,	O
MRAS	O
,	O
PIK3R3	O
,	O
PPP2CB	O
,	O
PRKAB2	O
,	O
PRKCB	O
,	O
RHOJ	O
,	O
RRAS2	O
,	O
TSC1	O
,	O
VEGFCSynthesis	O
and	O
degradation	O
of	O
ketone	O
bodiesup1	O
.	O
18	O
*	O
E	O
-	O
34ACAA1	O
,	O
BDH1	O
,	O
HADHA	O
,	O
HADHBBile	O
acid	O
synthesisup3	O
.	O
33	O
*	O
E	O
-	O
37ACAA1	O
,	O
ADH5	O
,	O
ADHFE1	O
,	O
ALDH7A1	O
,	O
HADHA	O
,	O
HADHB	O
,	O
LIPAFatty	O
acid	O
elongation	O
in	O
mitochondriaup4	O
.	O
81	O
*	O
E	O
-	O
34ACAA1	O
,	O
AUH	O
,	O
HADHA	O
,	O
HADHBGlucocorticoid	O
receptor	O
signalingup3	O
.	O
99	O
*	O
E	O
-	O
217AKT3	O
,	O
BCL2	O
,	O
CCL2	O
,	O
GTF2A2	O
,	O
GTF2B	O
,	O
GTF2E2	O
,	O
HSP90AB1	O
,	O
HSPA1B	O
,	O
IL1RN	O
,	O
MAPK1	O
,	O
MRAS	O
,	O
NCOR1	O
,	O
PBX1	O
,	O
PIK3R3	O
,	O
RRAS2	O
,	O
TAF4	O
,	O
VCAM1Val	O
,	O
Leu	O
,	O
Ile	O
degradationup8	O
.	O
32	O
*	O
E	O
-	O
38ACAA1	O
,	O
ACAD10	O
,	O
ALDH7A1	O
,	O
AUH	O
,	O
BCKDHB	O
,	O
HADHA	O
,	O
HADHB	O
,	O
HIBADHBiosynthesis	O
of	O
steroidsdown7	O
.	O
65	O
*	O
E	O
-	O
35CYP24A1	O
,	O
CYP7B1	O
,	O
DHCR7	O
,	O
FDFT1	O
,	O
MVD	O
The	O
comparison	O
between	O
the	O
dietary	O
gestational	O
protein	O
diets	O
(	O
LP	O
vs	O
.	O
AP	O
)	O
is	O
shown	O
in	O
dependence	O
of	O
the	O
regulatory	O
direction	O
(	O
up	O
or	O
down	O
).	O

In	O
juvenile	O
piglets	O
(	O
stage	O
28	O
dpn	O
)	O
483	O
probe	O
-	O
sets	O
differed	O
between	O
LP	O
and	O
AP	O
offspring	O
.	O

The	O
expression	O
of	O
214	O
probe	O
-	O
sets	O
was	O
increased	O
in	O
the	O
LP	O
offspring	O
compared	O
with	O
AP	O
offspring	O
.	O

Genes	O
associated	O
with	O
the	O
'	O
complement	O
system	O
'	O
showed	O
increased	O
mRNA	O
expression	O
levels	O
,	O
whereas	O
the	O
canonical	O
pathway	O
'	O
G1	O
/	O
S	O
checkpoint	O
regulation	O
'	O
was	O
found	O
to	O
be	O
decreased	O
in	O
LP	O
offspring	O
.	O

At	O
adult	O
age	O
(	O
stage	O
188	O
dpn	O
)	O
2	O
,	O
084	O
probe	O
-	O
sets	O
were	O
significantly	O
different	O
between	O
LP	O
and	O
AP	O
offspring	O
.	O

Of	O
these	O
,	O
952	O
probe	O
-	O
sets	O
showed	O
higher	O
expression	O
and	O
1	O
,	O
132	O
probe	O
-	O
sets	O
showed	O
lower	O
expression	O
in	O
LP	O
than	O
in	O
AP	O
offspring	O
.	O

The	O
mRNA	O
expression	O
levels	O
of	O
genes	O
associated	O
with	O
metabolic	O
processing	O
of	O
ketones	O
,	O
fatty	O
acids	O
,	O
bile	O
acids	O
,	O
and	O
hydrophobic	O
amino	O
acids	O
(	O
Val	O
,	O
Ile	O
,	O
Leu	O
)	O
as	O
well	O
as	O
'	O
mTOR	O
signaling	O
',	O
'	O
VEGF	O
signaling	O
',	O
and	O
'	O
glucocorticoid	O
receptor	O
signaling	O
',	O
were	O
increased	O
in	O
LP	O
offspring	O
at	O
stage	O
188	O
dpn	O
,	O
whereas	O
'	O
biosynthesis	O
of	O
steroids	O
'	O
was	O
found	O
to	O
be	O
diminished	O
.	O

No	O
genes	O
were	O
found	O
consistently	O
differentially	O
expressed	O
between	O
the	O
groups	O
along	O
all	O
examined	O
stages	O
.	O

However	O
,	O
at	O
94	O
dpc	O
and	O
188	O
dpn	O
179	O
probe	O
-	O
sets	O
were	O
differentially	O
regulated	O
in	O
both	O
stages	O
between	O
LP	O
and	O
AP	O
.	O

Differences	O
of	O
longitudinal	O
ontogenetic	O
regulation	O
among	O
LP	O
and	O
AP	O
offspring	O
Considering	O
two	O
adjacent	O
ontogenetic	O
stages	O
within	O
one	O
treatment	O
group	O
,	O
significantly	O
regulated	O
transcripts	O
were	O
determined	O
.	O

The	O
resulting	O
gene	O
lists	O
were	O
compared	O
between	O
LP	O
and	O
AP	O
offspring	O
at	O
the	O
corresponding	O
ontogenetic	O
periods	O
.	O

The	O
intersection	O
of	O
commonly	O
regulated	O
genes	O
between	O
those	O
comparisons	O
was	O
discarded	O
because	O
regulation	O
of	O
these	O
genes	O
was	O
likely	B
due	O
to	O
physiologically	O
developmental	O
processes	O
.	O

Consequently	O
,	O
only	O
genes	O
whose	O
regulation	O
between	O
two	O
consecutive	O
ontogenetic	O
stages	O
(	O
period	O
I	O
:	O
94dpc	O
-	O
1dpn	O
;	O
period	O
II	O
:	O
1dpn	O
-	O
28dpn	O
;	O
period	O
III	O
:	O
28dpn	O
-	O
188dpn	O
)	O
was	O
private	O
to	O
either	O
the	O
LP	O
or	O
the	O
AP	O
group	O
were	O
analysed	O
(	O
Table1	O
).	O

These	O
genes	O
display	O
diet	O
-	O
dependent	O
longitudinal	O
transcriptomic	O
regulation	O
(	O
Figure1	O
).	O

Thus	O
,	O
genes	O
and	O
pathways	O
identified	O
as	O
regulated	O
in	O
one	O
offspring	O
group	O
were	O
either	O
unregulated	O
or	O
showed	O
an	O
opposite	O
direction	O
of	O
regulation	O
in	O
the	O
corresponding	O
ontogenetic	O
period	O
within	O
the	O
other	O
dietary	O
group	O
.	O

Between	O
fetal	O
and	O
perinatal	O
stages	O
(	O
period	O
I	O
),	O
there	O
were	O
1	O
,	O
034	O
(	O
503	O
1	O
dpn	O
≻	O
94	O
dpc	O
)	O
probe	O
-	O
sets	O
showing	O
levels	O
and	O
directions	O
of	O
regulation	O
in	O
the	O
AP	O
group	O
that	O
were	O
different	O
from	O
the	O
LP	O
group	O
.	O

Genes	O
associated	O
with	O
'	O
AMPK	O
signaling	O
'	O
were	O
found	O
to	O
be	O
increased	O
at	O
stage	O
1	O
dpn	O
,	O
while	O
expression	O
of	O
genes	O
associated	O
with	O
'	O
G2	O
/	O
M	O
DNA	O
damage	O
checkpoint	O
regulation	O
',	O
'	O
mitotic	O
roles	O
of	O
Polo	O
-	O
like	O
kinase	O
'	O
and	O
'	O
pyrimidine	O
metabolism	O
'	O
were	O
decreased	O
(	O
Table3	O
).	O

In	O
LP	O
offspring	O
1	O
,	O
042	O
probe	O
-	O
sets	O
showed	O
ontogenetic	O
regulation	O
(	O
384	O
1	O
dpn	O
≻	O
94	O
dpc	O
)	O
during	O
the	O
corresponding	O
time	O
period	O
that	O
was	O
group	O
-	O
specific	O
.	O

The	O
mRNA	O
expression	O
level	O
of	O
genes	O
associated	O
with	O
cell	O
cycle	O
,	O
mitosis	O
,	O
and	O
metabolism	O
of	O
purines	O
and	O
pyrimidines	O
was	O
increased	O
in	O
LP	O
offspring	O
.	O

Furthermore	O
,	O
genes	O
participating	O
in	O
'	O
Wnt	O
signaling	O
'	O
were	O
found	O
to	O
be	O
decreased	O
in	O
LP	O
perinatal	O
piglets	O
.	O

Caption	O
(	O
TABLE	O
-	O
WRAP	O
):	O
TABLE	O
3	O
Significantly	O
regulated	O
transcripts	O
of	O
metabolic	O
pathways	O
in	O
liver	O
tissue	O
between	O
two	O
ontogenetic	O
stages	O
within	O
one	O
dietary	O
group	O
(	O
Ingenuity	O
Pathway	O
Analysis	O
)	O
Ontogenetic	O
comparisonDietRegulated	O
pathwayDirection	O
of	O
regulation	O
P	O
valueNo	O
.	O

of	O
regulated	O
genesGenes	O
involved	O
in	O
pathway94	O
dpc	O
vs	O
.	O
1	O
dpn	O
AP	O
AMPK	O
signalingup6	O
.	O
96	O
*	O
E	O
-	O
38AKT2	O
,	O
INSR	O
,	O
PIK3C2A	O
,	O
PIK3R1	O
,	O
PPM1B	O
,	O
PRKAA1	O
,	O
PRKACB	O
,	O
RAC1	O
AP	O
Mitotic	O
roles	O
of	O
Polo	O
-	O
like	O
kinasedown3	O
.	O
25	O
*	O
E	O
-	O
47CCNB1	O
,	O
CCNB2	O
,	O
CDC25B	O
,	O
CHEK2	O
,	O
KIF11	O
,	O
PLK4	O
,	O
PTTG1	O
AP	O
Pyrimidine	O
metabolismdown2	O
.	O
52	O
*	O
E	O
-	O
310CAD	O
,	O
DCTD	O
,	O
DKC1	O
,	O
POLQ	O
,	O
POLR3E	O
,	O
POLR3K	O
,	O
RFC5	O
,	O
RRM1	O
,	O
TYMS	O
,	O
UCK2	O
AP	O
G2	O
/	O
M	O
DNA	O
damage	O
checkpoint	O
regulationdown2	O
.	O
04	O
*	O
E	O
-	O
46CCNB1	O
,	O
CCNB2	O
,	O
CDC25B	O
,	O
CHEK2	O
,	O
UBC	O
,	O
YWHAE	O
LP	O
Purine	O
metabolismup9	O
.	O
20	O
*	O
E	O
-	O
312DDX39	O
,	O
PNPT1	O
,	O
POLA2	O
,	O
POLE2	O
,	O
POLR1B	O
,	O
POLR1C	O
,	O
POLR2I	O
,	O
RFC3	O
,	O
RRM2	O
,	O
RRM2B	O
,	O
RUVBL1	O
,	O
RUVBL2	O
LP	O
Pyrimidine	O
metabolismup6	O
.	O
15	O
*	O
E	O
-	O
714CTPS	O
,	O
PNPT1	O
,	O
POLA2	O
,	O
POLE2	O
,	O
POLR1B	O
,	O
POLR1C	O
,	O
POLR2I	O
,	O
PUS1	O
,	O
RFC3	O
,	O
RRM2	O
,	O
RRM2B	O
,	O
TXNRD1	O
,	O
TYMS	O
,	O
UCK2	O
LP	O
Mitotic	O
roles	O
of	O
Polo	O
-	O
like	O
kinaseup7	O
.	O
55	O
*	O
E	O
-	O
57ANAPC4	O
,	O
CDC27	O
,	O
CDK1	O
,	O
ESPL1	O
,	O
FZR1	O
,	O
PPP2R1B	O
,	O
PTTG1	O
LP	O
G2	O
/	O
M	O
DNA	O
damage	O
checkpoint	O
regulationup3	O
.	O
09	O
*	O
E	O
-	O
23CDK1	O
,	O
CHEK1	O
,	O
YWHAZ	O
LP	O
Wnt	O
signalingdown4	O
.	O
02	O
*	O
E	O
-	O
29AKT3	O
,	O
FZD5	O
,	O
MMP7	O
,	O
NLK	O
,	O
SOX4	O
,	O
TCF3	O
,	O
TCF4	O
,	O
TCF7L2	O
,	O
WNT5A1	O
dpn	O
vs	O
.	O
28	O
dpn	O
AP	O
AMPK	O
signalingup4	O
.	O
26	O
*	O
E	O
-	O
38AK1	O
,	O
CPT1A	O
,	O
EIF4EBP1	O
,	O
HMGCR	O
,	O
MAPK14	O
,	O
NOS3	O
,	O
PRKAA2	O
,	O
PRKAB2	O
AP	O
mTOR	O
signalingup1	O
.	O
89	O
*	O
E	O
-	O
27EIF3F	O
,	O
EIF3G	O
,	O
EIF4EBP1	O
,	O
FNBP1	O
,	O
GNB1L	O
,	O
PRKAA2	O
,	O
PRKAB2	O
AP	O
Val	O
,	O
Leu	O
,	O
Ile	O
degradationdown6	O
.	O
40	O
*	O
E	O
-	O
36ACAD8	O
,	O
ACADL	O
,	O
ACADSB	O
,	O
BCAT1	O
,	O
DBT	O
,	O
MCCC2	O
LP	O
Val	O
,	O
Leu	O
,	O
Ile	O
degradationup7	O
.	O
12	O
*	O
E	O
-	O
811ACADSB	O
,	O
ACAT1	O
,	O
ACAT2	O
,	O
ALDH1A1	O
,	O
AUH	O
,	O
BCKDHB	O
,	O
GCDH	O
,	O
HMGCL	O
,	O
HMGCS1	O
,	O
MCCC2	O
,	O
MCEE	O
LP	O
Fatty	O
acid	O
metabolismup3	O
.	O
23	O
*	O
E	O
-	O
38ACADSB	O
,	O
ACAT1	O
,	O
ACAT2	O
,	O
ALDH1A1	O
,	O
AUH	O
,	O
CYP51A1	O
,	O
GCDH	O
,	O
PECI	O
LP	O
Synthesis	O
and	O
degradation	O
of	O
ketone	O
bodiesup1	O
.	O
76	O
*	O
E	O
-	O
65ACAT1	O
,	O
ACAT2	O
,	O
BDH2	O
,	O
HMGCL	O
,	O
HMGCS1	O
LP	O
Biosynthesis	O
of	O
steroidsup3	O
.	O
27	O
*	O
E	O
-	O
45CYP24A1	O
,	O
FDPS	O
,	O
HMGCR	O
,	O
IDI1	O
,	O
SC5DL	O
LP	O
Glucocorticoid	O
receptor	O
signalingup3	O
.	O
57	O
*	O
E	O
-	O
312CDKN1C	O
,	O
CXCL3	O
,	O
IL10	O
,	O
MAP3K1	O
,	O
NCOA2	O
,	O
NFKBIB	O
,	O
NR3C1	O
,	O
POLR2B	O
,	O
PRKACB	O
,	O
RRAS2	O
,	O
SLPI	O
,	O
SMARCA4	O
LP	O
G1	O
/	O
S	O
checkpoint	O
regulationdown2	O
.	O
22	O
*	O
E	O
-	O
24CCNE1	O
,	O
CDC25A	O
,	O
CDKN1A	O
,	O
E2F328	O
dpn	O
vs	O
.	O
188	O
dpn	O
AP	O
AMPK	O
signalingup1	O
.	O
50	O
*	O
E	O
-	O
310INSR	O
,	O
MAPK12	O
,	O
PPAT	O
,	O
PPM1A	O
,	O
PPP2CA	O
,	O
PPP2R3A	O
,	O
PRKAA2	O
,	O
SMARCA2	O
,	O
SRC	O
,	O
STK11	O
AP	O
Fatty	O
acid	O
metabolismup1	O
.	O
28	O
*	O
E	O
-	O
28ACADSB	O
,	O
ALDH1A1	O
,	O
CYP1B1	O
,	O
CYP2D6	O
,	O
CYP3A4	O
,	O
CYP4A11	O
,	O
CYP4B1	O
,	O
PECI	O
AP	O
Mitotic	O
roles	O
of	O
Polo	O
-	O
like	O
kinasedown8	O
.	O
33	O
*	O
E	O
-	O
37ANAPC5	O
,	O
CDK1	O
,	O
PLK1	O
,	O
PLK2	O
,	O
PPP2R1B	O
,	O
SLK	O
,	O
WEE1	O
AP	O
VEGF	O
signalingdown7	O
.	O
3	O
*	O
E	O
-	O
39AKT3	O
,	O
BCL2	O
,	O
KDR	O
,	O
NOS3	O
,	O
PRKCB	O
,	O
RAC2	O
,	O
RRAS	O
,	O
VCL	O
,	O
VEGFC	O
LP	O
Val	O
,	O
Leu	O
,	O
Ile	O
degradationup1	O
.	O
07	O
*	O
E	O
-	O
27ACAA1	O
,	O
ACAT1	O
,	O
ALDH1B1	O
,	O
AUH	O
,	O
ECH1	O
,	O
IVD	O
,	O
IWS1	O
LP	O
Fatty	O
acid	O
elongation	O
in	O
mitochondriaup2	O
.	O
05	O
*	O
E	O
-	O
23ACAA1	O
,	O
AUH	O
,	O
ECH1	O
LP	O
mTOR	O
signalingup2	O
.	O
65	O
*	O
E	O
-	O
210AKT3	O
,	O
DDIT4	O
,	O
EIF4B	O
,	O
EIF4G3	O
,	O
PPP2R1B	O
,	O
PRKAB2	O
,	O
PRKAG1	O
,	O
PRKAG2	O
,	O
TSC1	O
,	O
VEGFA	O
LP	O
Actin	O
cytoskeleton	O
signalingdown7	O
.	O
99	O
*	O
E	O
-	O
524ACTB	O
,	O
ACTR2	O
,	O
ARPC4	O
,	O
ARPC1A	O
,	O
CD14	O
,	O
CFL1	O
,	O
F2R	O
,	O
FGD1	O
,	O
LBP	O
,	O
MAP2K1	O
,	O
MYH9	O
,	O
NCKAP1	O
,	O
PAK2	O
,	O
PIK3C3	O
,	O
PIK3C2A	O
,	O
PIK3R4	O
,	O
PIKFYVE	O
,	O
PPP1R12A	O
,	O
RDX	O
,	O
ROCK1	O
,	O
ROCK2	O
,	O
TMSB4X	O
,	O
TMSL3	O
,	O
WASF1	O
LP	O
RhoA	O
signalingdow5	O
.	O
05	O
*	O
E	O
-	O
3n12ACTB	O
,	O
ACTR2	O
,	O
ARHGAP1	O
,	O
ARPC4	O
,	O
ARPC1A	O
,	O
CFL1	O
,	O
PIKFYVE	O
,	O
PPP1R12A	O
,	O
RDX	O
,	O
ROCK1	O
,	O
ROCK2	O
,	O
WASF1	O
LP	O
Rac	O
signalingdown4	O
.	O
34	O
*	O
E	O
-	O
312ACTR2	O
,	O
ARPC4	O
,	O
ARPC1A	O
,	O
CFL1	O
,	O
MAP2K1	O
,	O
NCKAP1	O
,	O
PAK2	O
,	O
PIK3C3	O
,	O
PIK3C2A	O
,	O
PIK3R4	O
,	O
PIKFYVE	O
,	O
WASF1	O
LP	O
Complement	O
systemdown2	O
.	O
17	O
*	O
E	O
-	O
25C2	O
,	O
C7	O
,	O
C9	O
,	O
CFB	O
,	O
MBL2	O
The	O
comparison	O
between	O
the	O
dietary	O
gestational	O
protein	O
diets	O
(	O
LP	O
vs	O
.	O
AP	O
)	O
is	O
shown	O
in	O
dependence	O
of	O
the	O
regulatory	O
direction	O
(	O
up	O
or	O
down	O
).	O

Comparing	O
perinatal	O
and	O
juvenile	O
piglets	O
(	O
period	O
II	O
)	O
991	O
probe	O
-	O
sets	O
were	O
regulated	O
in	O
a	O
different	O
manner	O
in	O
AP	O
offspring	O
and	O
in	O
LP	O
offspring	O
.	O

Of	O
these	O
,	O
448	O
probe	O
-	O
sets	O
were	O
up	O
-	O
regulated	O
and	O
543	O
probe	O
-	O
sets	O
showed	O
lower	O
expression	O
at	O
a	O
higher	O
age	O
.	O

Expression	O
values	O
of	O
genes	O
participating	O
in	O
'	O
AMPK	O
signaling	O
'	O
and	O
'	O
mTOR	O
signaling	O
'	O
were	O
increased	O
,	O
whereas	O
genes	O
associated	O
with	O
the	O
'	O
degradation	O
of	O
valine	O
,	O
leucine	O
and	O
isoleucine	O
'	O
were	O
decreased	O
in	O
AP	O
offspring	O
.	O

In	O
the	O
same	O
period	O
881	O
probe	O
-	O
sets	O
exhibited	O
ontogenetic	O
regulation	O
that	O
was	O
specific	O
to	O
LP	O
offspring	O
.	O

Of	O
these	O
,	O
423	O
probe	O
-	O
sets	O
showed	O
an	O
increased	O
mRNA	O
expression	O
.	O

Genes	O
involved	O
in	O
'	O
fatty	O
acid	O
metabolism	O
',	O
'	O
biosynthesis	O
of	O
steroids	O
',	O
'	O
synthesis	O
and	O
degradation	O
of	O
ketone	O
bodies	O
',	O
'	O
glucocorticoid	O
receptor	O
signaling	O
'	O
as	O
well	O
as	O
the	O
'	O
degradation	O
of	O
valine	O
,	O
leucine	O
and	O
isoleucine	O
'	O
were	O
found	O
to	O
be	O
up	O
-	O
regulated	O
in	O
LP	O
offspring	O
,	O
while	O
genes	O
associated	O
with	O
'	O
G1	O
/	O
S	O
checkpoint	O
regulation	O
'	O
were	O
down	O
-	O
regulated	O
.	O

When	O
juvenile	O
and	O
young	O
adult	O
pigs	O
(	O
period	O
III	O
)	O
are	O
compared	O
,	O
1	O
,	O
549	O
probe	O
-	O
sets	O
differed	O
significantly	O
(	O
697	O
188	O
dpn	O
≻	O
28	O
dpn	O
)	O
in	O
AP	O
offspring	O
.	O

Genes	O
participating	O
in	O
'	O
AMPK	O
signaling	O
'	O
and	O
'	O
fatty	O
acid	O
metabolism	O
'	O
were	O
found	O
to	O
be	O
up	O
-	O
regulated	O
while	O
genes	O
associated	O
with	O
'	O
mitotic	O
roles	O
of	O
Polo	O
-	O
like	O
kinase	O
'	O
and	O
'	O
VEGF	O
signaling	O
'	O
were	O
found	O
to	O
be	O
down	O
-	O
regulated	O
in	O
AP	O
offspring	O
.	O

In	O
LP	O
offspring	O
1	O
,	O
959	O
probe	O
-	O
sets	O
were	O
differently	O
expressed	O
(	O
834	O
188	O
dpn	O
≻	O
28	O
dpn	O
).	O

In	O
LP	O
offspring	O
,	O
genes	O
involved	O
in	O
'	O
mTOR	O
signaling	O
',	O
'	O
fatty	O
acid	O
elongation	O
in	O
mitochondria	O
'	O
as	O
well	O
as	O
the	O
'	O
degradation	O
of	O
valine	O
,	O
leucine	O
and	O
isoleucine	O
'	O
were	O
up	O
regulated	O
.	O

Furthermore	O
,	O
genes	O
involved	O
in	O
'	O
actin	O
cytoskeleton	O
signaling	O
',	O
'	O
RhoA	O
signaling	O
',	O
'	O
Rac	O
signaling	O
'	O
and	O
'	O
complement	O
system	O
'	O
were	O
found	O
to	O
be	O
down	O
-	O
regulated	O
.	O

Figure2gives	O
a	O
comprehensive	O
overview	O
of	O
the	O
pathways	O
found	O
regulated	O
between	O
stages	O
and	O
diets	O
.	O

For	O
all	O
genes	O
exemplarily	O
analysed	O
,	O
qRT	O
-	O
PCR	O
confirmed	O
the	O
direction	O
of	O
differential	O
regulation	O
as	O
obtained	O
by	O
microarray	O
analysis	O
.	O

In	O
90	O
%	O
of	O
the	O
genes	O
that	O
we	O
validated	O
by	O
qRT	O
-	O
PCR	O
,	O
significant	O
expression	O
differences	O
in	O
mRNA	O
levels	O
between	O
the	O
treatment	O
groups	O
were	O
identified	O
by	O
both	O
qRT	O
-	O
PCR	O
and	O
microarray	O
analysis	O
(	O
Table4	O
).	O

Correlations	O
between	O
expression	O
values	O
of	O
microarray	O
and	O
qRT	O
-	O
PCR	O
of	O
positive	O
validated	O
transcripts	O
ranged	O
between	O
0	O
.	O
47	O
and	O
0	O
.	O
86	O
and	O
were	O
highly	O
significant	O
.	O

This	O
suggests	O
that	O
our	O
microarray	O
data	O
are	O
reliable	O
.	O

Caption	O
(	O
FIG	O
):	O
FIGURE	O
2	O
Regulated	O
pathways	O
in	O
liver	O
tissue	O
between	O
ontogenetic	O
stages	O
and	O
diets	O
.	O

Listed	O
pathways	O
between	O
AP	O
stages	O
(	O
white	O
boxes	O
)	O
indicate	O
the	O
appropriate	O
ontogenetic	O
development	O
,	O
which	O
does	O
not	O
take	O
place	O
in	O
the	O
LP	O
offspring	O
(	O
black	O
boxes	O
)	O
at	O
the	O
corresponding	O
developmental	O
period	O
.	O

Pathways	O
between	O
the	O
LP	O
stages	O
indicate	O
processes	O
and	O
metabolic	O
regulation	O
,	O
which	O
occur	O
in	O
the	O
LP	O
offspring	O
but	O
not	O
in	O
the	O
AP	O
offspring	O
in	O
the	O
corresponding	O
developmental	O
period	O
.	O

The	O
differences	O
in	O
gene	O
regulation	O
dependent	O
on	O
diet	O
and	O
ontogenetic	O
stage	O
indicate	O
fetal	O
programming	O
in	O
terms	O
of	O
developmental	O
and	O
metabolic	O
disorders	O
(	O
arrows	O
between	O
boxes	O
show	O
direction	O
of	O
the	O
comparison	O
;	O
small	O
arrows	O
indicate	O
up	O
and	O
down	O
regulation	O
,	O
respectively	O
;	O
PLK	O
,	O
Polo	O
-	O
like	O
kinase	O
;	O
VEGF	O
,	O
Vascular	O
endothelial	O
growth	O
factor	O
,	O
mTOR	O
,	O
mammalian	O
target	O
of	O
rapamycin	O
;	O
AMPK	O
,	O
AMP	O
-	O
activated	O
protein	O
kinase	O
;	O
RhoA	O
,	O
Ras	O
homolog	O
gene	O
family	O
,	O
member	O
A	O
;	O
Rac	O
,	O
Ras	O
-	O
related	O
C3	O
botulinum	O
toxin	O
substrate	O
;	O
FA	O
,	O
Fatty	O
acid	O
)	O
Caption	O
(	O
TABLE	O
-	O
WRAP	O
):	O
TABLE	O
4	O
Comparison	O
of	O
microarray	O
data	O
and	O
qRT	O
-	O
PCR	O
of	O
selected	O
transcriptsGene	O
nameMicroarrayqRT	O
-	O
PCR	O
#	O
Correlation	O
##	O
p	O
-	O
valueFCRegulationp	O
-	O
valueFCRegulationExpr	O
.	O

values94	O
dpc	O
CCND20	O
.	O
022	O
-	O
1	O
.	O
25down0	O
.	O
0001	O
-	O
1	O
.	O
83down0	O
.	O
47	O
*	O
NCAPG0	O
.	O
019	O
-	O
1	O
.	O
73down0	O
.	O
003	O
-	O
1	O
.	O
58down0	O
.	O
47	O
*	O
MGMT0	O
.	O
031	O
+	O
1	O
.	O
12up0	O
.	O
011	O
+	O
1	O
.	O
32up0	O
.	O
53	O
**	O
GADD45B0	O
.	O
669	O
-	O
1	O
.	O
08n	O
.	O
r	O
.	O
0	O
.	O
522	O
+	O
1	O
.	O
17n	O
.	O
r0	O
.	O
68	O
***	O
1	O
dpn	O
SDHB0	O
.	O
0006	O
-	O
1	O
.	O
19down0	O
.	O
028	O
-	O
1	O
.	O
30down0	O
.	O
71	O
***	O
CCND20	O
.	O
711	O
-	O
1	O
.	O
06n	O
.	O
r	O
.	O
0	O
.	O
651	O
-	O
1	O
.	O
09n	O
.	O
r	O
.	O
0	O
.	O
46	O
*	O
PPARGC1A0	O
.	O
745	O
-	O
1	O
.	O
03n	O
.	O
r	O
.	O
0	O
.	O
761	O
-	O
1	O
.	O
04n	O
.	O
r	O
.	O
0	O
.	O
67	O
***	O
188	O
dpn	O
PRKAA10	O
.	O
0004	O
-	O
1	O
.	O
68down0	O
.	O
027	O
-	O
1	O
.	O
40down0	O
.	O
77	O
***	O
PRKAA20	O
.	O
009	O
-	O
1	O
.	O
36down0	O
.	O
095	O
-	O
1	O
.	O
25down0	O
.	O
10PPARGC1A0	O
.	O
126	O
-	O
1	O
.	O
35n	O
.	O
r	O
.	O
0	O
.	O
105	O
-	O
1	O
.	O
36n	O
.	O
r	O
.	O
0	O
.	O
86	O
***	O
CCND2	O
-	O
cyclin	O
D2	O
;	O
NCAPG	O
-	O
non	O
-	O
SMC	O
condensin	O
I	O
complex	O
,	O
subunit	O
G	O
;	O
MGMT	O
-	O
O	O
-	O
6	O
-	O
methylguanine	O
-	O
DNA	O
methyltransferase	O
;	O
GADD45B	O
-	O
growth	O
arrest	O
and	O
DNA	O
-	O
damage	O
-	O
inducible	O
,	O
β	O
;	O
SDHB	O
-	O
succinate	O
dehydrogenase	O
complex	O
,	O
subunit	O
B	O
,	O
iron	O
sulfur	O
(	O
Ip	O
);	O
PPARGC1A	O
-	O
Peroxisome	O
proliferator	O
activated	O
receptor	O
γ	O
coactivator	O
-	O
1	O
α	O
;	O
PRKAA1	O
-	O
5	O
'-	O
AMP	O
-	O
activated	O
protein	O
kinase	O
,	O
catalytic	O
α	O
1	O
chain	O
;	O
PRKAA2	O
-	O
5	O
'-	O
AMP	O
-	O
activated	O
protein	O
kinase	O
,	O
catalytic	O
α	O
2	O
chain	O
*	O
calculated	O
by	O
factorial	O
normalisation	O
on	O
RPL10	O
expression	O
values	O
;	O
**	O
p	O
-	O
value	O
of	O
pamn	O
'	O
rho	O
;	O
n	O
.	O
r	O
.	O

-	O
not	O
regulated	O
Discussion	O
We	O
applied	O
whole	O
-	O
genome	O
microarrays	O
to	O
evaluate	O
hepatic	O
gene	O
expression	O
profiles	O
of	O
offspring	O
from	O
sows	O
fed	O
either	O
an	O
isocaloric	O
maternal	O
low	O
protein	O
or	O
adequate	O
protein	O
diet	O
throughout	O
their	O
pregnancy	O
.	O

In	O
order	O
to	O
investigate	O
transcriptional	O
features	O
of	O
developmental	O
nutritional	O
programming	O
we	O
conducted	O
a	O
longitudinal	O
experimental	O
design	O
covering	O
prenatal	O
,	O
perinatal	O
,	O
juvenile	O
and	O
adult	O
ontogenetic	O
stages	O
in	O
a	O
porcine	O
model	O
.	O

The	O
comparisons	O
of	O
the	O
relative	O
mRNA	O
abundances	O
depending	O
on	O
dietary	O
group	O
and	O
ontogenetic	O
stages	O
provide	O
an	O
overall	O
view	O
of	O
the	O
developmental	O
plasticity	O
of	O
the	O
liver	O
.	O

At	O
the	O
prenatal	O
stage	O
mRNA	O
expression	O
profiles	O
were	O
extensively	O
altered	O
between	O
the	O
dietary	O
groups	O
.	O

At	O
this	O
time	O
point	O
the	O
fetuses	O
were	O
subjected	O
to	O
a	O
serious	O
nutritional	O
deficiency	O
that	O
requires	O
an	O
acute	O
transcriptomic	O
response	O
.	O

Following	O
in	O
utero	O
exposure	O
to	O
a	O
gestational	O
low	O
protein	O
diet	O
at	O
1	O
dpn	O
we	O
could	O
not	O
find	O
significant	O
regulatory	O
changes	O
of	O
genes	O
of	O
any	O
molecular	O
route	O
in	O
porcine	O
perinatal	O
liver	O
.	O

At	O
this	O
stage	O
the	O
animals	O
experienced	O
a	O
kind	O
of	O
release	O
from	O
metabolic	O
burden	O
after	O
cross	O
-	O
fostering	O
and	O
suckling	O
.	O

Obviously	O
,	O
this	O
initiates	O
an	O
immediate	O
recovery	O
of	O
the	O
activity	O
of	O
genes	O
to	O
'	O
normal	O
level	O
'	O
reflected	O
by	O
similar	O
expression	O
pattern	O
in	O
LP	O
and	O
AP	O
piglets	O
.	O

However	O
,	O
at	O
the	O
whole	O
-	O
body	O
level	O
adverse	O
consequences	O
of	O
restricted	O
intrauterine	O
supply	O
were	O
observed	O
[	O
15	O
].	O

In	O
juvenile	O
LP	O
offspring	O
,	O
mRNA	O
expression	O
profiles	O
were	O
moderately	O
altered	O
compared	O
to	O
AP	O
offspring	O
.	O

However	O
,	O
the	O
number	O
of	O
differentially	O
expressed	O
probe	O
-	O
sets	O
increased	O
extensively	O
at	O
adult	O
stage	O
.	O

The	O
observed	O
transcriptional	O
postnatal	O
regulations	O
were	O
delayed	O
long	O
-	O
term	O
effects	O
of	O
the	O
prenatal	O
nutritional	O
supply	O
.	O

Due	O
to	O
the	O
normal	O
dietary	O
conditions	O
at	O
juvenile	O
and	O
adult	O
stages	O
the	O
alterations	O
found	O
here	O
can	O
be	O
regarded	O
as	O
fetal	O
nutritional	O
programming	O
.	O

Our	O
model	O
indicates	O
that	O
gestational	O
LP	O
diets	O
affected	O
the	O
hepatic	O
expression	O
profiles	O
in	O
an	O
acute	O
,	O
short	O
-	O
term	O
as	O
well	O
as	O
in	O
a	O
delayed	O
,	O
long	O
-	O
term	O
manner	O
in	O
LP	O
offspring	O
.	O

Due	O
to	O
the	O
LP	O
diet	O
a	O
number	O
of	O
molecular	O
routes	O
related	O
to	O
cell	O
cycle	O
and	O
cellular	O
turnover	O
,	O
response	O
to	O
stimuli	O
,	O
as	O
well	O
as	O
energy	O
-,	O
lipid	O
-	O
and	O
amino	O
acid	O
metabolic	O
pathways	O
are	O
shifted	O
on	O
the	O
transcriptional	O
level	O
in	O
the	O
liver	O
at	O
prenatal	O
stages	O
under	O
the	O
direct	O
influence	O
of	O
limited	O
protein	O
and	O
/	O
or	O
amino	O
acid	O
supply	O
,	O
but	O
also	O
postnatal	O
.	O

The	O
effect	O
is	O
characterised	O
by	O
a	O
programming	O
of	O
the	O
genome	O
that	O
leads	O
to	O
different	O
responsiveness	O
and	O
adaptability	O
of	O
the	O
gene	O
expression	O
machinery	O
to	O
chronic	O
and	O
acute	O
environmental	O
stimuli	O
,	O
i	O
.	O
e	O
.	O

nutritional	O
supply	O
.	O

Together	O
with	O
the	O
observation	O
that	O
the	O
offspring	O
of	O
both	O
groups	O
did	O
not	O
differ	O
in	O
bodyweight	O
but	O
in	O
body	O
composition	O
and	O
fat	O
content	O
[	O
17	O
],	O
the	O
data	O
indicate	O
that	O
the	O
activity	O
of	O
different	O
genes	O
led	O
to	O
different	O
partitioning	O
of	O
nutrients	O
among	O
peripheral	O
and	O
visceral	O
organs	O
and	O
tissues	O
.	O

Transcriptional	O
excursions	O
regarding	O
cell	O
maintenance	O
and	O
proliferation	O
Mammalian	O
cell	O
division	O
is	O
precisely	O
regulated	O
by	O
variate	O
factors	O
and	O
functional	O
networks	O
.	O

Therefore	O
,	O
cell	O
division	O
is	O
synchronous	O
with	O
cell	O
growth	O
[	O
19	O
,	O
20	O
].	O

Eukaryotic	O
cells	O
evolved	O
elaborate	O
mechanisms	O
to	O
verify	O
the	O
fidelity	O
of	O
cell	O
division	O
.	O

Therefore	O
,	O
a	O
cell	O
cycle	O
control	O
system	O
can	O
arrest	O
the	O
cycle	O
at	O
certain	O
checkpoints	O
.	O

Key	O
components	O
in	O
terms	O
of	O
cell	O
cycle	O
regulation	O
are	O
cyclins	O
.	O

Cyclin	O
levels	O
undergo	O
an	O
oscillation	O
of	O
synthesis	O
and	O
degradation	O
in	O
each	O
cell	O
cycle	O
and	O
fall	O
at	O
a	O
proper	O
developmental	O
time	O
point	O
to	O
exit	O
the	O
cell	O
cycle	O
[	O
21	O
,	O
22	O
].	O

Therefore	B
,	O
the	O
transcriptional	O
control	O
of	O
cyclins	O
provides	O
an	O
additional	O
level	O
of	O
growth	O
regulation	O
.	O

Mitotic	O
cyclins	O
interact	O
with	O
Polo	O
-	O
like	O
kinases	O
(	O
PLK	O
),	O
an	O
evolutionary	O
conserved	O
family	O
of	O
essential	O
cell	O
cycle	O
regulators	O
,	O
which	O
are	O
required	O
at	O
several	O
key	O
points	O
within	O
mitosis	O
,	O
including	O
entry	O
into	O
and	O
exit	O
from	O
mitosis	O
[	O
23	O
,	O
24	O
].	O

It	O
has	O
been	O
shown	O
that	O
fetal	O
growth	O
retardation	O
is	O
accompanied	O
by	O
alterations	O
in	O
cell	O
cycle	O
regulating	O
molecules	O
at	O
both	O
transcriptome	O
[	O
25	O
]	O
and	O
proteome	O
level	O
[	O
26	O
].	O

However	O
,	O
longitudinal	O
studies	O
focussed	O
on	O
diet	O
-	O
dependent	O
alterations	O
of	O
cell	O
cycle	O
regulators	O
are	O
scarce	O
.	O

The	O
porcine	O
expression	O
patterns	O
in	O
this	O
study	O
showed	O
a	O
decreased	O
mRNA	O
expression	O
of	O
genes	O
associated	O
with	O
the	O
control	O
of	O
mitosis	O
and	O
cell	O
cycle	O
checkpoint	O
regulation	O
at	O
stage	O
94	O
dpc	O
in	O
LP	O
fetuses	O
.	O

These	O
regulations	O
may	O
indicate	O
an	O
impaired	O
fetal	O
growth	O
performance	O
due	O
to	O
the	O
gestational	O
low	O
protein	O
diet	O
.	O

Therefore	B
,	O
the	O
down	O
-	O
regulation	O
of	O
cell	O
cycle	O
regulating	O
pathways	O
might	O
lead	O
to	O
a	O
lengthened	O
cell	O
cycle	O
in	O
LP	O
fetuses	O
and	O
offspring	O
[	O
27	O
]	O
and	O
cumulate	O
in	O
growth	O
retardation	O
in	O
LP	O
fetuses	O
.	O

In	O
AP	O
fetuses	O
,	O
cell	O
cycle	O
parameters	O
were	O
found	O
to	O
be	O
decreased	O
in	O
expression	O
within	O
developmental	O
period	O
I	O
,	O
which	O
indicates	O
a	O
terminated	O
fetal	O
growth	O
.	O

In	O
contrast	O
,	O
LP	O
fetuses	O
showed	O
an	O
increased	O
expression	O
of	O
transcripts	O
associated	O
with	O
cell	O
division	O
within	O
the	O
corresponding	O
developmental	O
period	O
.	O

Obviously	O
,	O
the	O
increased	O
mRNA	O
expression	O
of	O
genes	O
related	O
to	O
cell	O
cycle	O
regulators	O
within	O
developmental	O
period	O
I	O
in	O
LP	O
offspring	O
accounts	O
for	O
compensatory	O
regulations	O
regarding	O
the	O
lowered	O
fetal	O
weight	O
due	O
to	O
the	O
gestational	O
diet	O
.	O

Within	O
developmental	O
period	O
III	O
,	O
AP	O
offspring	O
showed	O
a	O
decreased	O
expression	O
of	O
genes	O
associated	O
with	O
Polo	O
-	O
like	O
kinases	O
,	O
which	O
is	O
in	O
line	O
with	O
the	O
assumption	O
that	O
LP	O
pigs	O
have	O
not	O
terminated	O
their	O
growth	O
at	O
stage	O
188	O
dpn	O
;	O
in	O
particular	O
their	O
liver	O
has	O
not	O
attained	O
a	O
steady	O
-	O
state	O
and	O
that	O
there	O
is	O
persistent	O
functional	O
demand	O
towards	O
cell	O
proliferation	O
potentially	O
to	O
respond	O
to	O
an	O
elevated	O
metabolic	O
burden	O
,	O
including	O
a	O
higher	O
turn	O
over	O
of	O
lipids	O
and	O
ketone	O
bodies	O
.	O

The	O
expression	O
level	O
of	O
NCAPG	O
(	O
non	O
-	O
structural	O
maintenance	O
of	O
chromosomes	O
(	O
SMC	O
)	O
condensin	O
I	O
complex	O
subunit	O
G	O
)	O
was	O
highlighted	O
as	O
strongly	O
associated	O
with	O
fetal	O
growth	O
retardation	O
[	O
28	O
,	O
29	O
].	O

According	O
to	O
recent	O
studies	O
NCAPG	O
is	O
important	O
during	O
mitotic	O
cell	O
division	O
.	O

Due	O
to	O
the	O
gestational	O
low	O
protein	O
diet	O
NCAPG	O
was	O
found	O
to	O
be	O
down	O
-	O
regulated	O
in	O
LP	O
fetuses	O
compared	O
to	O
AP	O
fetuses	O
,	O
which	O
reflects	O
the	O
organismal	O
effort	O
to	O
counteract	O
the	O
growth	O
retarding	O
processes	O
in	O
LP	O
fetuses	O
.	O

Beside	O
pathways	O
related	O
to	O
the	O
control	O
of	O
growth	O
and	O
cell	O
deviation	O
,	O
the	O
diet	O
-	O
dependent	O
expression	O
patterns	O
showed	O
regulation	O
in	O
genes	O
associated	O
with	O
biosynthesis	O
,	O
degradation	O
and	O
salvage	O
of	O
nucleotides	O
('	O
purine	O
and	O
pyrimidine	O
metabolism	O
')	O
as	O
well	O
as	O
cell	O
motility	O
and	O
cytokinesis	O
('	O
actin	O
cytoskeleton	O
signaling	O
',	O
'	O
Rac	O
signaling	O
',	O
'	O
RhoA	O
signaling	O
').	O

These	O
expression	O
patterns	O
suggest	O
a	O
dietary	O
effect	O
on	O
cellular	O
turn	O
-	O
over	O
,	O
which	O
might	O
be	O
increased	O
at	O
early	O
stages	O
but	O
decreased	O
at	O
adult	O
stage	O
in	O
LP	O
offspring	O
.	O

Therefore	B
,	O
a	O
diet	O
-	O
dependent	O
tissue	O
remodelling	O
might	O
take	O
place	O
in	O
LP	O
offspring	O
as	O
observed	O
previously	O
[	O
30	O
].	O

The	O
'	O
mTOR	O
signaling	O
'	O
acts	O
as	O
an	O
important	O
nutrient	O
sensing	O
pathway	O
that	O
controls	O
protein	O
synthesis	O
in	O
mammalian	O
cells	O
at	O
the	O
level	O
of	O
translation	O
[	O
31	O
].	O

Upstream	O
signaling	O
events	O
of	O
'	O
mTOR	O
signaling	O
'	O
include	O
alterations	O
in	O
amino	O
acid	O
availability	O
,	O
abundance	O
of	O
hormones	O
,	O
AMP	O
and	O
growth	O
factors	O
[	O
32	O
].	O

Thus	B
,	O
'	O
mTOR	O
signaling	O
'	O
is	O
involved	O
in	O
regulating	O
individual	O
cell	O
growth	O
,	O
growth	O
performance	O
,	O
and	O
developmental	O
processes	O
[	O
33	O
,	O
34	O
].	O

An	O
increase	O
of	O
'	O
mTOR	O
signaling	O
'	O
within	O
developmental	O
period	O
II	O
was	O
observed	O
in	O
AP	O
offspring	O
,	O
but	O
not	O
in	O
the	O
LP	O
group	O
.	O

This	O
may	O
account	O
for	O
improper	O
protein	O
synthesis	O
[	O
35	O
]	O
in	O
LP	O
offspring	O
.	O

However	O
,	O
at	O
adult	O
stage	O
a	O
diet	O
-	O
dependent	O
up	O
-	O
regulation	O
of	O
'	O
mTOR	O
signaling	O
'	O
in	O
LP	O
offspring	O
suggests	O
a	O
transcriptional	O
priority	O
for	O
cellular	O
growth	O
and	O
proliferation	O
.	O

Therefore	B
,	O
'	O
mTOR	O
signaling	O
'	O
might	O
be	O
involved	O
in	O
compensatory	O
growth	O
processes	O
at	O
adult	O
stage	O
in	O
LP	O
offspring	O
.	O

Another	O
signaling	O
pathway	O
identified	O
to	O
be	O
regulated	O
in	O
a	O
diet	O
-	O
dependent	O
manner	O
is	O
the	O
'	O
VEGF	O
(	O
vascular	O
endothelial	O
growth	O
factor	O
)	O
signaling	O
'	O
pathway	O
,	O
which	O
is	O
known	O
from	O
gene	O
deletion	O
studies	O
to	O
be	O
essential	O
in	O
developmental	O
processes	O
[	O
36	O
,	O
37	O
].	O

Therefore	B
,	O
the	O
transcriptional	O
up	O
-	O
regulation	O
of	O
'	O
VEGF	O
signaling	O
'	O
reflects	O
the	O
effort	O
on	O
cell	O
maintenance	O
and	O
angiogenic	O
growth	O
in	O
LP	O
offspring	O
at	O
stage	O
188	O
dpn	O
.	O

Obviously	O
,	O
hepatic	O
ontogenetic	O
growth	O
is	O
not	O
finished	O
at	O
adult	O
stage	O
in	O
LP	O
offspring	O
in	O
contrast	O
to	O
AP	O
offspring	O
.	O

Furthermore	O
,	O
the	O
dietary	O
modifications	O
led	O
to	O
regulation	O
of	O
the	O
'	O
Wnt	O
signaling	O
'	O
pathway	O
,	O
which	O
is	O
involved	O
in	O
various	O
aspects	O
of	O
embryogenesis	O
,	O
including	O
cell	O
differentiation	O
and	O
cell	O
proliferation	O
[	O
38	O
].	O

Therefore	B
,	O
the	O
observed	O
mRNA	O
expression	O
patterns	O
might	O
contribute	O
to	O
an	O
impaired	O
developmental	O
growth	O
in	O
LP	O
offspring	O
.	O

Regarding	O
the	O
LP	O
model	O
used	O
in	O
rodents	O
,	O
it	O
has	O
been	O
suggested	O
that	O
the	O
maternal	O
LP	O
diet	O
had	O
an	O
impact	O
on	O
'	O
insulin	O
signaling	O
'	O
as	O
well	O
as	O
on	O
'	O
IGF1	O
signaling	O
'	O
and	O
its	O
binding	O
proteins	O
[	O
30	O
,	O
39	O
-	O
43	O
].	O

However	O
,	O
in	O
this	O
study	O
no	O
regulation	O
of	O
both	O
'	O
insulin	O
signaling	O
'	O
and	O
'	O
IGF1	O
signaling	O
'	O
was	O
observed	O
in	O
liver	O
tissue	O
of	O
LP	O
porcine	O
offspring	O
,	O
possibly	O
due	O
to	O
maturation	O
-,	O
species	O
-,	O
tissue	O
-,	O
sex	O
-	O
and	O
time	O
-	O
dependent	O
regulations	O
.	O

Transcriptional	O
excursions	O
regarding	O
lipid	O
-,	O
energy	O
-	O
and	O
N	O
-	O
metabolism	O
During	O
postnatal	O
development	O
a	O
remarkable	O
number	O
of	O
diet	O
-	O
and	O
stage	O
-	O
dependent	O
transcriptionally	O
regulated	O
pathways	O
were	O
related	O
to	O
lipid	O
metabolism	O
,	O
including	O
'	O
fatty	O
acid	O
metabolism	O
',	O
'	O
fatty	O
acid	O
elongation	O
in	O
mitochondria	O
',	O
'	O
synthesis	O
and	O
degradation	O
of	O
ketone	O
bodies	O
',	O
'	O
bile	O
acid	O
synthesis	O
'	O
and	O
'	O
biosynthesis	O
of	O
steroids	O
'.	O

These	O
findings	O
suggest	O
that	O
pathways	O
associated	O
to	O
lipid	O
metabolism	O
are	O
part	O
of	O
postnatal	O
adaptive	O
responses	O
to	O
the	O
prenatal	O
nutritional	O
environment	O
in	O
LP	O
offspring	O
.	O

Consistent	O
with	O
these	O
observations	O
,	O
genes	O
associated	O
with	O
lipid	O
metabolism	O
were	O
found	O
to	O
be	O
altered	O
at	O
pre	O
-	O
and	O
postnatal	O
stages	O
in	O
rodents	O
,	O
where	O
the	O
LP	O
model	O
was	O
studied	O
intensively	O
[	O
44	O
-	O
49	O
].	O

Furthermore	O
,	O
the	O
transcriptional	O
adaptations	O
may	O
have	O
consequences	O
for	O
the	O
offspring	O
'	O
s	O
phenotype	O
,	O
including	O
alterations	O
of	O
plasma	O
parameters	O
[	O
44	O
-	O
46	O
,	O
50	O
],	O
hepatic	O
histology	O
[	O
46	O
]	O
and	O
body	O
composition	O
[	O
47	O
].	O

According	O
to	O
the	O
longitudinal	O
study	O
design	O
the	O
'	O
AMPK	O
(	O
AMP	O
-	O
dependent	O
activated	O
kinase	O
)	O
signaling	O
'	O
was	O
found	O
to	O
be	O
regulated	O
throughout	O
ontogenesis	O
in	O
AP	O
offspring	O
only	O
.	O

'	O
AMPK	O
signaling	O
'	O
is	O
a	O
metabolic	O
pathway	O
which	O
is	O
involved	O
in	O
the	O
regulation	O
of	O
the	O
lipid	O
and	O
energy	O
metabolism	O
in	O
mammalian	O
cells	O
[	O
51	O
-	O
56	O
].	O

In	O
particular	O
,	O
the	O
cellular	O
energy	O
sensor	O
AMPK	O
is	O
essential	O
for	O
a	O
proper	O
mitochondrial	O
activity	O
and	O
metabolic	O
health	O
citeTowler2007	O
.	O

Therefore	B
,	O
the	O
up	O
-	O
regulation	O
of	O
'	O
AMPK	O
signaling	O
'	O
in	O
developmental	O
periods	O
I	O
,	O
II	O
and	O
III	O
in	O
AP	O
offspring	O
accounts	O
for	O
metabolic	O
health	O
in	O
AP	O
offspring	O
,	O
but	O
not	O
in	O
LP	O
offspring	O
.	O

On	O
the	O
one	O
hand	O
,	O
this	O
matter	O
may	O
be	O
related	O
to	O
mitochondrial	O
impairments	O
which	O
may	O
happen	O
due	O
to	O
the	O
LP	O
diet	O
,	O
as	O
has	O
been	O
suggested	O
previously	O
[	O
57	O
,	O
58	O
].	O

On	O
the	O
other	O
hand	O
,	O
it	O
might	O
be	O
associated	O
to	O
the	O
transcriptional	O
excursions	O
within	O
the	O
lipid	O
metabolism	O
in	O
LP	O
offspring	O
.	O

Moreover	O
,	O
the	O
expression	O
of	O
the	O
catalytic	O
subunits	O
of	O
AMPK	O
,	O
PRKAA1	O
and	O
PRKAA2	O
was	O
found	O
to	O
be	O
decreased	O
in	O
LP	O
offspring	O
compared	O
to	O
AP	O
offspring	O
at	O
stage	O
188	O
dpn	O
,	O
which	O
may	O
contribute	O
to	O
an	O
imbalanced	O
cellular	O
metabolism	O
.	O

Taken	O
together	O
,	O
the	O
observed	O
regulations	O
were	O
seen	O
as	O
a	O
clue	O
for	O
impairments	O
in	O
energy	O
metabolism	O
in	O
LP	O
offspring	O
during	O
ontogenesis	O
.	O

Furthermore	O
,	O
the	O
diet	O
-	O
dependent	O
transcriptional	O
excursions	O
revealed	O
an	O
impact	O
on	O
N	O
-	O
metabolism	O
.	O

In	O
particular	O
,	O
the	O
degradation	O
of	O
essential	O
,	O
branch	O
-	O
chained	O
amino	O
acids	O
like	O
valine	O
,	O
leucine	O
and	O
isoleucine	O
was	O
found	O
to	O
be	O
regulated	O
,	O
which	O
may	O
illustrate	O
the	O
LP	O
offspring	O
'	O
s	O
efforts	O
to	O
mimic	O
prenatal	O
experiences	O
in	O
terms	O
of	O
dietary	O
supply	O
during	O
postnatal	O
development	O
in	O
the	O
face	O
of	O
richer	O
conditions	O
.	O

Although	O
essential	O
amino	O
acids	O
are	O
needed	O
for	O
growth	O
,	O
anabolic	O
and	O
developmental	O
processes	O
,	O
transcriptional	O
levels	O
of	O
genes	O
leading	O
to	O
degradation	O
of	O
those	O
dietary	O
valuable	O
compounds	O
is	O
forced	O
during	O
postnatal	O
development	O
in	O
LP	O
offspring	O
.	O

Transcriptional	O
excursions	O
regarding	O
stress	O
and	O
immune	O
response	O
The	O
biological	O
effect	O
of	O
glucocorticoids	O
is	O
modulated	O
by	O
glucocorticoid	O
receptors	O
.	O

By	O
means	O
of	O
succeeding	O
direct	O
and	O
indirect	O
interactions	O
of	O
downstream	O
target	O
genes	O
,	O
mRNA	O
expression	O
regarding	O
metabolic	O
,	O
behavioural	O
,	O
cardiovascular	O
and	O
immune	O
functions	O
is	O
modulated	O
.	O

In	O
rodents	O
,	O
many	O
studies	O
reported	O
an	O
impact	O
of	O
maternal	O
low	O
protein	O
diets	O
on	O
expression	O
and	O
affinity	O
of	O
the	O
glucocorticoid	O
receptor	O
and	O
its	O
signaling	O
molecules	O
[	O
8	O
,	O
48	O
,	O
59	O
-	O
61	O
].	O

Consistently	B
,	O
in	O
porcine	O
offspring	O
a	O
diet	O
-	O
dependent	O
regulation	O
of	O
'	O
glucocorticoid	O
receptor	O
signaling	O
'	O
was	O
also	O
found	O
.	O

Therefore	B
,	O
expression	O
profiles	O
at	O
weaning	O
and	O
adult	O
stages	O
point	O
to	O
an	O
alarm	O
alert	O
(	O
activated	O
defence	O
)	O
in	O
LP	O
offspring	O
.	O

Furthermore	O
,	O
genes	O
associated	O
with	O
the	O
complement	O
system	O
were	O
found	O
to	O
be	O
regulated	O
in	O
a	O
diet	O
-	O
dependent	O
manner	O
at	O
stage	O
28	O
dpn	O
.	O

Obviously	O
,	O
at	B
least	I
a	O
part	O
of	O
the	O
innate	O
immune	O
system	O
is	O
impaired	O
when	O
LP	O
offspring	O
is	O
faced	O
with	O
a	O
pre	O
-	O
biotical	O
stress	O
like	O
weaning	O
.	O

Consistent	O
with	O
this	O
finding	O
,	O
expression	O
of	O
genes	O
associated	O
with	O
an	O
impaired	O
immunity	O
were	O
found	O
to	O
be	O
altered	O
in	O
offspring	O
of	O
protein	O
malnourished	O
dams	O
[	O
62	O
,	O
63	O
].	O

Conclusions	O
In	O
conclusion	O
,	O
the	O
longitudinal	O
survey	O
of	O
the	O
hepatic	O
transcriptomic	O
response	O
in	O
offspring	O
of	O
dams	O
fed	O
either	O
a	O
gestational	O
low	O
protein	O
diet	O
(	O
LP	O
,	O
6	O
%	O
CP	O
)	O
or	O
an	O
adequate	O
protein	O
diet	O
(	O
AP	O
,	O
12	O
%	O
CP	O
)	O
at	O
prenatal	O
(	O
94	O
dpc	O
),	O
perinatal	O
(	O
1	O
dpn	O
),	O
juvenile	O
(	O
28	O
dpn	O
),	O
and	O
adult	O
(	O
188	O
dpn	O
)	O
ontogenetic	O
stages	O
revealed	O
acute	O
short	O
-	O
term	O
and	O
delayed	O
long	O
-	O
term	O
modulations	O
.	O

The	O
changes	O
in	O
gene	O
expression	O
were	O
not	O
persistent	O
in	O
terms	O
of	O
consistent	O
differential	O
expression	O
of	O
genes	O
at	O
all	O
stages	O
.	O

However	O
,	O
genes	O
related	O
to	O
cell	O
cycle	O
and	O
cellular	O
turnover	O
were	O
differentially	O
expressed	O
at	O
all	O
stages	O
except	O
stage	O
1	O
dpn	O
.	O

This	O
stage	O
appeared	O
as	O
a	O
phase	O
of	O
recovery	O
of	O
the	O
activity	O
of	O
genes	O
.	O

Differential	O
expression	O
of	O
genes	O
related	O
to	O
lipid	O
,	O
ketone	O
body	O
,	O
and	O
amino	O
acid	O
metabolism	O
indicate	O
that	O
the	O
offspring	O
of	O
both	O
groups	O
uses	O
different	O
metabolic	O
directions	O
in	O
response	O
to	O
identical	O
nutritional	O
condition	O
during	O
postnatal	O
life	O
.	O

Methods	O
Animals	O
and	O
sample	O
collection	O
Animal	O
care	O
and	O
tissue	O
collection	O
processes	O
followed	O
the	O
guidelines	O
of	O
the	O
German	O
Law	O
of	O
Animal	O
Protection	O
and	O
the	O
experimental	O
protocol	O
was	O
approved	O
by	O
the	O
Animal	O
Care	O
Committee	O
of	O
the	O
State	O
Mecklenburg	O
-	O
Vorpommern	O
(	O
Landesamt	O
für	O
Landwirtschaft	O
,	O
Lebensmittelsicherheit	O
und	O
Fischerei	O
,	O
Mecklenburg	O
-	O
Vorpommern	O
,	O
Germany	O
;	O
LVL	O
MV	O
/	O
TSD	O
/	O
7221	O
.	O
3	O
-	O
1	O
.	O
1	O
-	O
006	O
/	O
04	O
;	O
LALLF	O
M	O
-	O
V	O
/	O
TSD	O
/	O
7221	O
.	O
3	O
-	O
1	O
.	O
2	O
-	O
05	O
/	O
06	O
;	O
LALLF	O
M	O
-	O
V	O
/	O
TSD	O
/	O
7221	O
.	O
3	O
-	O
1	O
.	O
2	O
-	O
013	O
/	O
06	O
).	O

The	O
animal	O
experiment	O
was	O
performed	O
as	O
described	O
[	O
15	O
].	O

Briefly	O
,	O
at	O
insemination	O
German	O
Landrace	O
primiparous	O
sows	O
(	O
n	O
=	O
42	O
)	O
were	O
randomly	O
assigned	O
to	O
either	O
a	O
low	O
protein	O
diet	O
(	O
LP	O
)	O
with	O
6	O
%	O
(	O
w	O
/	O
w	O
)	O
crude	O
protein	O
or	O
an	O
adequate	O
protein	O
diet	O
(	O
AP	O
)	O
containing	O
12	O
%	O
crude	O
protein	O
.	O

Diets	O
were	O
formulated	O
to	O
be	O
isocaloric	O
(	O
13	O
.	O
6	O
MJ	O
ME	O
/	O
kg	O
on	O
average	O
)	O
[	O
15	O
].	O

Tissue	O
sampling	O
included	O
offspring	O
of	O
these	O
sows	O
at	O
one	O
prenatal	O
(	O
94	O
dpc	O
)	O
and	O
three	O
postnatal	O
(	O
1	O
,	O
28	O
,	O
188	O
dpn	O
)	O
time	O
points	O
(	O
Figure3	O
).	O

Caption	O
(	O
FIG	O
):	O
FIGURE	O
3	O
Experimental	O
design	O
.	O

At	O
94	O
dpc	O
of	O
gestation	O
,	O
a	O
subset	O
of	O
eight	O
sows	O
per	O
dietary	O
group	O
was	O
subjected	O
to	O
Caesarean	O
section	O
(	O
EXP1	O
).	O

Sows	O
were	O
anaesthetised	O
as	O
described	O
[	O
15	O
].	O

This	O
experiment	O
was	O
performed	O
over	O
5	O
replicates	O
.	O

Eight	O
viable	O
fetuses	O
per	O
sow	O
were	O
collected	O
starting	O
at	O
the	O
tip	O
of	O
the	O
left	O
uterus	O
horn	O
and	O
alternating	O
between	O
left	O
and	O
right	O
horn	O
.	O

Fetuses	O
were	O
killed	O
by	O
i	O
.	O
v	O
.	O

injection	O
of	O
T61	O
in	O
the	O
V	O
.	O
cava	O
cranialis	O
and	O
liver	O
samples	O
were	O
immediately	O
collected	O
(	O
approximately	O
500	O
mg	O
),	O
frozen	O
in	O
liquid	O
nitrogen	O
,	O
and	O
stored	O
at	O
-	O
80	O
°	O
C	O
until	O
analysis	O
.	O

Fetuses	O
originated	O
from	O
litters	O
of	O
at	O
least	O
11	O
viable	O
piglets	O
.	O

Fetuses	O
of	O
LP	O
-	O
fed	O
dams	O
showed	O
a	O
numerically	O
lowered	O
weight	O
compared	O
to	O
AP	O
fetuses	O
at	O
94	O
dpc	O
(	O
LP	O
:	O
661	O
±	O
115	O
g	O
,	O
and	O
AP	O
:	O
711	O
±	O
118	O
g	O
,	O
respectively	O
;	O
P	O
=	O
0	O
.	O
12	O
;	O
n	O
=	O
32	O
).	O

The	O
smallest	O
and	O
the	O
heaviest	O
fetus	O
within	O
one	O
litter	O
were	O
selected	O
for	O
transcriptome	O
analysis	O
.	O

In	O
the	O
second	O
experiment	O
(	O
EXP2	O
)	O
offspring	O
selected	O
for	O
the	O
postnatal	O
time	O
points	O
was	O
born	O
to	O
primiparous	O
sows	O
after	O
prostaglandin	O
induction	O
of	O
parturition	O
as	O
described	O
[	O
15	O
]	O
and	O
farrowed	O
after	O
mean	O
pregnancy	O
duration	O
of	O
115	O
days	O
.	O

This	O
experiment	O
was	O
conducted	O
over	O
8	O
replicates	O
and	O
offspring	O
of	O
a	O
subset	O
of	O
4	O
sows	O
(	O
2	O
per	O
diet	O
per	O
replicate	O
)	O
with	O
a	O
minimum	O
of	O
11	O
live	O
born	O
piglets	O
(	O
median	O
litter	O
size	O
=	O
13	O
)	O
were	O
used	O
.	O

At	O
birth	O
10	O
piglets	O
in	O
each	O
litter	O
were	O
distributed	O
over	O
three	O
time	O
points	O
(	O
1	O
,	O
28	O
,	O
188	O
dpn	O
).	O

For	O
the	O
microarray	O
analyses	O
,	O
8	O
sib	O
pairs	O
(	O
light	O
and	O
heavy	O
piglet	O
from	O
one	O
litter	O
)	O
which	O
were	O
balanced	O
for	O
sex	O
(	O
all	O
stages	O
)	O
and	O
discordant	O
for	O
weight	O
(	O
light	O
and	O
heavy	O
piglet	O
;	O
stages	O
94	O
dpc	O
and	O
1	O
dpn	O
only	O
)	O
were	O
chosen	O
per	O
stage	O
and	O
diet	O
.	O

Mean	O
birth	O
weights	O
of	O
LP	O
newborn	O
piglets	O
used	O
for	O
microarray	O
analyses	O
were	O
numerically	O
lower	O
than	O
birth	O
weights	O
of	O
AP	O
offspring	O
(	O
LP	O
:	O
1	O
.	O
21	O
±	O
0	O
.	O
30	O
kg	O
,	O
AP	O
:	O
1	O
.	O
36	O
±	O
0	O
.	O
31	O
kg	O
,	O
P	O
=	O
0	O
.	O
08	O
,	O
n	O
=	O
32	O
).	O

Including	O
all	O
piglets	O
derived	O
from	O
the	O
complete	O
experiment	O
,	O
LP	O
offspring	O
was	O
growth	O
-	O
restricted	O
compared	O
to	O
AP	O
offspring	O
,	O
but	O
litter	O
size	O
did	O
not	O
differ	O
[	O
15	O
].	O

Thirty	O
-	O
six	O
hours	O
after	O
birth	O
,	O
the	O
lightest	O
and	O
the	O
heaviest	O
piglet	O
within	O
one	O
litter	O
were	O
killed	O
by	O
i	O
.	O
m	O
.	O

injection	O
of	O
1	O
.	O
25	O
mg	O
propionyl	O
-	O
promazine	O
(	O
0	O
.	O
2	O
ml	O
Combelen	O
,	O
Bayer	O
AG	O
,	O
Leverkusen	O
,	O
Germany	O
)	O
and	O
50	O
mg	O
ketamine	O
(	O
Ursotamin	O
,	O
Serumwerk	O
Bernburg	O
AG	O
,	O
Germany	O
).	O

Samples	O
were	O
immediately	O
collected	O
from	O
lobus	O
sinister	O
hepaticus	O
(	O
approximately	O
500	O
mg	O
),	O
frozen	O
in	O
liquid	O
nitrogen	O
,	O
and	O
stored	O
at	O
-	O
80	O
°	O
C	O
until	O
analysis	O
.	O

The	O
remaining	O
piglets	O
were	O
cross	O
-	O
fostered	O
to	O
non	O
-	O
experimental	O
sows	O
of	O
2ndto	O
4thparities	O
,	O
which	O
were	O
on	O
the	O
AP	O
diet	O
during	O
gestation	O
.	O

All	O
sows	O
were	O
fed	O
AP	O
lactation	O
diets	O
.	O

Litter	O
size	O
during	O
suckling	O
was	O
standardised	O
to	O
11	O
piglets	O
per	O
sow	O
.	O

Male	O
piglets	O
were	O
castrated	O
at	O
d	O
4	O
of	O
age	O
.	O

From	O
weaning	O
(	O
28	O
dpn	O
)	O
to	O
slaughter	O
(	O
188	O
dpn	O
),	O
all	O
piglets	O
were	O
individually	O
reared	O
.	O

They	O
had	O
free	O
access	O
to	O
standard	O
diets	O
formulated	O
for	O
post	O
-	O
weaning	O
(	O
d	O
29	O
to	O
d	O
76	O
),	O
growing	O
(	O
d	O
77	O
to	O
d	O
105	O
)	O
and	O
finishing	O
periods	O
[	O
64	O
].	O

At	O
28	O
dpn	O
and	O
188	O
dpn	O
of	O
age	O
,	O
pigs	O
were	O
weighed	O
after	O
an	O
overnight	O
fast	O
and	O
killed	O
by	O
electronarcosis	O
followed	O
by	O
exsanguination	O
in	O
the	O
experimental	O
slaughterhouse	O
of	O
FBN	O
.	O

Among	O
the	O
animals	O
used	O
for	O
the	O
microarray	O
expression	O
analysis	O
,	O
weaners	O
of	O
the	O
LP	O
group	O
showed	O
numerically	O
but	O
not	O
significantly	O
lower	O
body	O
weight	O
than	O
the	O
AP	O
group	O
,	O
(	O
LP	O
:	O
7	O
.	O
24	O
±	O
1	O
.	O
56	O
kg	O
,	O
AP	O
:	O
7	O
.	O
59	O
±	O
2	O
.	O
14	O
kg	O
,	O
P	O
=	O
0	O
.	O
30	O
,	O
n	O
=	O
32	O
).	O

At	O
188	O
dpn	O
the	O
body	O
weight	O
was	O
slightly	O
but	O
significantly	O
reduced	O
in	O
LP	O
compared	O
to	O
AP	O
(	O
LP	O
:	O
123	O
.	O
19	O
±	O
9	O
.	O
15	O
kg	O
,	O
AP	O
:	O
131	O
.	O
55	O
±	O
15	O
.	O
11	O
kg	O
,	O
P	O
-	O
0	O
.	O
03	O
;	O
n	O
-	O
32	O
).	O

For	O
all	O
animals	O
of	O
the	O
experiment	O
no	O
significant	O
differences	O
in	O
body	O
weight	O
were	O
observed	O
at	O
28	O
and	O
188	O
dpn	O
[	O
15	O
,	O
16	O
].	O

Liver	O
tissue	O
was	O
immediately	O
collected	O
from	O
lobus	O
sinister	O
hepaticus	O
,	O
frozen	O
in	O
liquid	O
nitrogen	O
,	O
and	O
stored	O
at	O
-	O
80	O
°	O
C	O
until	O
use	O
for	O
RNA	O
isolation	O
.	O

RNA	O
isolation	O
,	O
target	O
preparation	O
and	O
hybridisation	O
According	O
to	O
the	O
manufacturer	O
'	O
s	O
protocol	O
total	O
RNA	O
from	O
individual	O
liver	O
samples	O
was	O
isolated	O
using	O
Tri	O
-	O
Reagent	O
(	O
Sigma	O
-	O
Aldrich	O
,	O
Taufkirchen	O
,	O
Germany	O
).	O

After	O
DNase	O
treatment	O
a	O
column	O
-	O
based	O
purification	O
using	O
the	O
RNeasy	O
Mini	O
Kit	O
(	O
Qiagen	O
,	O
Hilden	O
,	O
Germany	O
)	O
was	O
done	O
.	O

The	O
RNA	O
samples	O
were	O
visualised	O
on	O
1	O
%	O
agarose	O
gels	O
containing	O
ethidium	O
bromide	O
to	O
check	O
RNA	O
integrity	O
.	O

RNA	O
was	O
quantified	O
by	O
spectrometry	O
with	O
a	O
NanoDrop	O
ND	O
-	O
1000	O
spectrophotometer	O
(	O
PEQLAB	O
,	O
Erlangen	O
,	O
Germany	O
).	O

To	O
ensure	O
the	O
absence	O
of	O
a	O
DNA	O
contamination	O
within	O
the	O
isolated	O
RNA	O
a	O
PCR	O
amplification	O
with	O
the	O
porcine	O
glyceraldehyde	O
-	O
3	O
-	O
phosphate	O
dehydrogenase	O
(	O
GAPDH	O
)	O
gene	O
was	O
done	O
(	O
Forward	O
primer	O
:	O
aagcagggatgatgttctgg	O
;	O
Reverse	O
primer	O
:	O
atgcctcctgtaccaccaac	O
).	O

All	O
RNA	O
samples	O
were	O
stored	O
at	O
-	O
80	O
°	O
C	O
until	O
downstream	O
analysis	O
was	O
performed	O
.	O

For	O
the	O
microarray	O
experiments	O
individual	O
biotin	O
-	O
labeled	O
cRNA	O
was	O
synthesised	O
by	O
the	O
Gene	O
Chip	O
3	O
'	O
Express	O
Kit	O
(	O
Affymetrix	O
,	O
Santa	O
Clara	O
,	O
CA	O
,	O
USA	O
).	O

The	O
cRNA	O
was	O
fragmented	O
(≈	O
100	O
bp	O
)	O
and	O
hybridised	O
on	O
Affymetrix	O
GeneChip	O
®	O
porcine	O
Genome	O
Array	O
.	O

After	O
staining	O
and	O
washing	O
steps	O
the	O
arrays	O
were	O
scanned	O
(	O
Affymetrix	O
,	O
Santa	O
Clara	O
,	O
CA	O
,	O
USA	O
).	O

Data	O
analysis	O
The	O
bioinformatic	O
analysis	O
was	O
done	O
in	O
R	O
[	O
65	O
].	O

Firstly	O
,	O
a	O
quality	O
control	O
was	O
performed	O
.	O

At	O
94	O
dpc	O
15	O
AP	O
-	O
samples	O
met	O
the	O
appropriate	O
quality	O
control	O
criteria	O
(	O
94	O
dpc	O
-	O
LP	O
:	O
16	O
;	O
1	O
dpn	O
-	O
AP	O
:	O
15	O
;	O
1	O
dpn	O
-	O
LP	O
:	O
14	O
;	O
28	O
dpn	O
-	O
AP	O
:	O
14	O
;	O
28	O
dpn	O
-	O
LP	O
:	O
15	O
;	O
188	O
dpn	O
-	O
AP	O
:	O
16	O
;	O
188	O
dpn	O
-	O
LP	O
:	O
16	O
samples	O
).	O

Samples	O
were	O
GC	O
-	O
RMA	O
normalised	O
(	O
Log2	O
).	O

The	O
MAS5	O
algorithm	O
was	O
used	O
to	O
skip	O
those	O
transcripts	O
which	O
were	O
expressed	O
in	O
less	O
than	O
50	O
%	O
of	O
the	O
animals	O
within	O
one	O
dietary	O
group	O
per	O
stage	O
.	O

For	O
a	O
second	O
filtering	O
step	O
standard	O
deviations	O
were	O
calculated	O
for	O
each	O
probe	O
-	O
set	O
over	O
all	O
subsets	O
of	O
arrays	O
of	O
the	O
particular	O
comparisons	O
.	O

Probe	O
-	O
sets	O
with	O
a	O
low	O
standard	O
deviation	O
(	O
s	O
≤	O
0	O
.	O
25	O
)	O
were	O
discarded	O
,	O
because	O
such	O
transcripts	O
are	O
not	O
likely	B
to	O
be	O
regulated	O
.	O

Relative	O
changes	O
in	O
mRNA	O
levels	O
were	O
determined	O
using	O
a	O
mixed	O
model	O
analysis	O
,	O
including	O
effects	O
of	O
dietary	O
treatment	O
,	O
sex	O
,	O
mother	O
,	O
birth	O
weight	O
and	O
interaction	O
between	O
diet	O
and	O
sex	O
(	O
vijkl	O
=	O
dieti	O
+	O
sexj	O
+	O
motherk	O
(	O
dieti	O
)	O
+	O
weightl	O
+	O
(	O
dietxsex	O
)	O
ij	O
+	O
errorijkl	O
).	O

P	O
-	O
values	O
(	O
significance	O
set	O
at	O
P	O
≤	O
0	O
.	O
05	O
)	O
for	O
each	O
stage	O
were	O
converted	O
to	O
a	O
set	O
of	O
q	O
-	O
values	O
(	O
q	O
≤	O
0	O
.	O
25	O
)	O
using	O
the	O
algorithm	O
proposed	O
by	O
Storey	O
and	O
Tibshirani	O
[	O
66	O
].	O

In	O
general	O
,	O
results	O
are	O
given	O
for	O
the	O
comparisons	O
in	O
the	O
direction	O
of	O
LP	O
vs	O
.	O
AP	O
;	O
thus	O
'	O
up	O
-	O
regulation	O
'	O
or	O
'	O
increased	O
expression	O
'	O
indicates	O
higher	O
expression	O
in	O
LP	O
than	O
in	O
AP	O
.	O

Analysis	O
of	O
the	O
pathways	O
involved	O
was	O
carried	O
out	O
using	O
Ingenuity	O
Pathway	O
Analysis	O
[	O
67	O
].	O

The	O
up	O
-	O
to	O
-	O
date	O
annotation	O
of	O
Affymetrix	O
probe	O
-	O
sets	O
to	O
EnsEMBL	O
Sscofa	O
9	O
(	O
20	O
,	O
439	O
of	O
23	O
,	O
935	O
annotated	O
probe	O
-	O
sets	O
)	O
was	O
used	O
[	O
18	O
].	O

All	O
the	O
microarray	O
data	O
is	O
MIAME	O
compliant	O
and	O
the	O
raw	O
data	O
has	O
been	O
deposited	O
in	O
a	O
MIAME	O
compliant	O
database	O
,	O
the	O
National	O
Center	O
for	O
Biotechnology	O
Information	O
Gene	O
Expression	O
Omnibushttp	O
://	O
www	O
.	O
ncbi	O
.	O
nlm	O
.	O
nih	O
.	O
gov	O
/	O
geo	O
(	O
accession	O
numbers	O
:	O
GSE25482	O
and	O
GSE31191	O
).	O

Pathway	O
analysis	O
Gene	O
lists	O
from	O
microarray	O
results	O
were	O
submitted	O
to	O
the	O
manually	O
curated	O
database	O
'	O
Ingenuity	O
Pathways	O
Analysis	O
'	O
to	O
elucidate	O
putative	O
pathways	O
associated	O
with	O
an	O
altered	O
gene	O
expression	O
in	O
porcine	O
liver	O
.	O

The	O
focus	O
was	O
on	O
those	O
canonical	O
pathways	O
which	O
came	O
up	O
at	O
least	O
once	O
within	O
the	O
top	O
ten	O
regulated	O
pathways	O
within	O
one	O
single	O
analysis	O
.	O

It	O
should	O
be	O
noted	O
here	O
that	O
the	O
interactions	O
presented	O
in	O
the	O
networks	O
are	O
not	O
specific	O
for	O
porcine	O
liver	O
tissue	O
,	O
as	O
the	O
database	O
contains	O
literature	O
from	O
many	O
different	O
research	O
areas	O
.	O

Quantitative	O
real	O
-	O
time	O
RT	O
-	O
PCR	O
First	O
-	O
strand	O
cDNA	O
was	O
synthesized	O
from	O
2	O
μg	O
of	O
total	O
RNA	O
(	O
n	O
=	O
14	O
per	O
diet	O
and	O
stage	O
)	O
using	O
random	O
primers	O
and	O
oligo	O
d	O
(	O
T	O
)	O
13VN	O
in	O
the	O
presence	O
of	O
Superscript	O
III	O
reverse	O
transcriptase	O
(	O
Invitrogen	O
,	O
Karlsruhe	O
,	O
Germany	O
).	O

In	O
order	O
to	O
survey	O
expression	O
of	O
the	O
liver	O
tissue	O
samples	O
,	O
total	O
transcript	O
levels	O
of	O
selected	O
target	O
and	O
reference	O
genes	O
(	O
Table5	O
)	O
were	O
quantified	O
by	O
real	O
-	O
time	O
quantitative	O
PCR	O
(	O
qPCR	O
)	O
performed	O
on	O
a	O
LightCycler	O
®	O
480	O
system	O
using	O
the	O
LightCycler	O
480	O
SYBR	O
Green	O
I	O
Master	O
(	O
Roche	O
,	O
Mannheim	O
,	O
Germany	O
).	O

The	O
amplification	O
was	O
conducted	O
in	O
duplicate	O
according	O
to	O
manufacturer	O
'	O
s	O
instructions	O
using	O
10	O
μM	O
of	O
each	O
primer	O
.	O

Reactions	O
were	O
performed	O
in	O
a	O
final	O
volume	O
of	O
10	O
μl	O
using	O
5	O
.	O
0	O
μl	O
of	O
LightCycler	O
480	O
SYBR	O
Green	O
I	O
Master	O
(	O
Roche	O
),	O
2	O
.	O
0	O
μl	O
of	O
Aqua	O
dest	O
.,	O
10	O
μM	O
(	O
0	O
.	O
5	O
μl	O
)	O
of	O
each	O
primer	O
(	O
Table5	O
)	O
and	O
40	O
ng	O
(	O
2	O
μl	O
)	O
cDNA	O
.	O

The	O
temperature	O
profiles	O
comprised	O
an	O
initial	O
denaturation	O
step	O
at	O
95	O
°	O
C	O
for	O
10	O
min	O
and	O
40	O
cycles	O
consisting	O
of	O
denaturation	O
at	O
95	O
°	O
C	O
for	O
15	O
s	O
,	O
annealing	O
at	O
60	O
°	O
C	O
for	O
10	O
s	O
and	O
extension	O
/	O
fluorescence	O
acquisition	O
at	O
72	O
°	O
C	O
for	O
15	O
s	O
.	O
For	O
all	O
the	O
assays	O
threshold	O
cycles	O
were	O
converted	O
to	O
copy	O
numbers	O
using	O
a	O
standard	O
curve	O
generated	O
by	O
amplifying	O
serial	O
dilutions	O
of	O
an	O
external	O
PCR	O
standard	O
(	O
107	O
-	O
102copies	O
).	O

At	O
the	O
completion	O
of	O
the	O
amplification	O
protocol	O
,	O
all	O
samples	O
were	O
subjected	O
to	O
melting	O
curve	O
analyses	O
and	O
gel	O
electrophoresis	O
to	O
verify	O
the	O
absence	O
of	O
any	O
non	O
-	O
specific	O
product	O
.	O

To	O
account	O
for	O
variation	O
in	O
RNA	O
input	O
and	O
efficiency	O
of	O
reverse	O
transcription	O
the	O
calculated	O
mRNA	O
copy	O
numbers	O
were	O
normalized	O
by	O
dividing	O
with	O
a	O
normalization	O
factor	O
derived	O
from	O
the	O
expression	O
of	O
the	O
reference	O
gene	O
.	O

In	O
total	O
,	O
28	O
individual	O
liver	O
mRNA	O
samples	O
were	O
analyzed	O
in	O
duplicate	O
per	O
stage	O
.	O

Data	O
were	O
analyzed	O
using	O
the	O
PROC	O
MIXED	O
,	O
including	O
effects	O
of	O
diet	O
,	O
sex	O
,	O
mother	O
,	O
birth	O
weight	O
and	O
interaction	O
between	O
diet	O
and	O
sex	O
(	O
SAS	O
version	O
9	O
.	O
1	O
;	O
SAS	O
Institute	O
,	O
Cary	O
,	O
NC	O
).	O

Differences	O
were	O
considered	O
significant	O
at	O
P	O
≤	O
0	O
.	O
05	O
.	O

Caption	O
(	O
TABLE	O
-	O
WRAP	O
):	O
TABLE	O
5	O
Primer	O
used	O
to	O
verify	O
microarray	O
experiments	O
in	O
liver	O
tissue	O
by	O
qRT	O
-	O
PCRGene	O
nameProbe	O
-	O
set	O
IDSequence	O
5	O
'	O
-	O
3	O
'	O
T	O
(°	O
C	O
)	O
Size	O
(	O
bp	O
)	O
CCND2Ssc	O
.	O
15749	O
.	O
1	O
.	O
S1_atFor	O
AGGAGCAGATTGAGGTCGTG86185Rev	O
CAACCAGAGAGAAGGAAGGAGANCAPGSsc	O
.	O
28512	O
.	O
1	O
.	O
S1_atFor	O
CTTGTAGATTTGACGAGACCA60156Rev	O
GGCTTTAGTATAGACCCGAACMGMTSsc	O
.	O
19639	O
.	O
1	O
.	O
A1_atFor	O
GCAACTACTCGGGAGGAATG88171Rev	O
CTGCGAACGCTCAGTCTTGGADD45BSsc	O
.	O
14764	O
.	O
1	O
.	O
A1_atFor	O
GGACTTAGACTTTGGGACTTG60140Rev	O
GTAAGCCTCCCATCTCTCTTSDHBSsc	O
.	O
8939	O
.	O
1	O
.	O
S1_atFor	O
GCAGGACCCGTTCTCTCTGT60170Rev	O
GGTTACAGTCACGTTAGGTTGGPPARGC1ASsc	O
.	O
16864	O
.	O
1	O
.	O
S1_atFor	O
GTAAATCTGCGGGATGATGG60208Rev	O
TGGTGGAAGCAGGATCAAAGPRKAA1Ssc	O
.	O
8107	O
.	O
1	O
.	O
A1_atFor	O
TTGTTAATTTCATAAACTTTGCTTC60193Rev	O
GTGCAGCCTTGACATACTCPRKAA2Ssc	O
.	O
16257	O
.	O
1	O
.	O
S1_atFor	O
TCTGTAATTCTGTTTTGCCTACGA60168Rev	O
AGCAAGAAGGTGATGCCAAGRPL10	O
*	O
Ssc	O
.	O
9130	O
.	O
1	O
.	O
A1_atFor	O
CTGTGTTCGTCTTTTCTTCC60199Rev	O
TCATCCACTTTTGCCTTCT	O
CCND2	O
-	O
cyclin	O
D2	O
;	O
NCAPG	O
-	O
non	O
-	O
SMC	O
condensin	O
I	O
complex	O
,	O
subunit	O
G	O
;	O
MGMT	O
-	O
O	O
-	O
6	O
-	O
methylguanine	O
-	O
DNA	O
methyltransferase	O
;	O
GADD45B	O
-	O
growth	O
arrest	O
and	O
DNA	O
-	O
damage	O
-	O
inducible	O
,	O
β	O
;	O
SDHB	O
-	O
succinate	O
dehydrogenase	O
complex	O
,	O
subunit	O
B	O
,	O
iron	O
sulfur	O
(	O
Ip	O
);	O
PPARGC1A	O
-	O
Peroxisome	O
proliferator	O
activated	O
receptor	O
γ	O
coactivator	O
-	O
1	O
α	O
;	O
PRKAA1	O
-	O
5	O
'-	O
AMP	O
-	O
activated	O
protein	O
kinase	O
,	O
catalytic	O
α	O
1	O
chain	O
;	O
PRKAA2	O
-	O
5	O
'-	O
AMP	O
-	O
activated	O
protein	O
kinase	O
,	O
catalytic	O
α	O
2	O
chain	O
;	O
RPL10	O
-	O
Ribosomal	O
protein	O
10	O
;	O
*	O
house	O
keeping	O
gene	O
.	O

Competing	O
interests	O
The	O
authors	O
declare	O
that	O
they	O
have	O
no	O
competing	O
interests	O
.	O

Authors	O
'	O
contributions	O
Conceived	O
and	O
designed	O
the	O
experiments	O
:	O
KW	O
CCM	O
SP	O
.	O

Performed	O
the	O
experiments	O
:	O
MO	O
EM	O
CCM	O
SP	O
KW	O
.	O

Analyzed	O
the	O
data	O
:	O
MO	O
EM	O
SP	O
KW	O
.	O

Contributed	O
reagents	O
/	O
materials	O
/	O
analysis	O
tools	O
:	O
CCM	O
KW	O
SP	O
EM	O
.	O

Wrote	O
the	O
paper	O
:	O
MO	O
KW	O
.	O

All	O
authors	O
read	O
and	O
approved	O
the	O
final	O
manuscript	O
.	O

PubMed	O
Central	O
:	O

Preventive	O
Treatments	O
of	O
Iron	O
Deficiency	O
Anaemia	O
in	O
Pregnancy	O
:	O
A	O
Review	O
of	O
Their	O
Effectiveness	O
and	O
Implications	O
for	O
Health	O
System	O
Strengthening	O
Abstract	O
Objectives	O
.	O

We	O
conducted	O
a	O
review	O
of	O
effectiveness	O
of	O
preventive	O
treatments	O
of	O
iron	O
deficiency	O
anaemia	O
in	O
pregnancy	O
in	O
developing	O
countries	O
and	O
highlighted	O
their	O
constraints	O
as	O
well	O
as	O
interventions	O
required	O
to	O
strengthen	O
the	O
health	O
services	O
.	O

Methods	O
.	O

Literature	O
from	O
Pubmed	O
(	O
MEDLINE	O
),	O
AJOL	O
,	O
Google	O
Scholar	O
,	O
and	O
Cochrane	O
database	O
was	O
reviewed	O
.	O

Results	O
.	O

Evidence	O
-	O
based	O
preventive	O
treatment	O
options	O
for	O
iron	O
deficiency	O
anaemia	O
in	O
pregnancy	O
include	O
prophylaxis	O
iron	O
supplements	O
and	O
food	O
fortification	O
with	O
iron	O
.	O

Evidence	O
abounds	O
on	O
their	O
effectiveness	O
in	O
reducing	O
the	O
prevalence	O
of	O
iron	O
deficiency	O
anaemia	O
in	O
pregnancy	O
.	O

However	O
,	O
these	O
prospects	O
are	O
threatened	O
by	O
side	O
effects	O
of	O
iron	O
supplements	O
,	O
low	O
utilization	O
of	O
maternal	O
health	O
service	O
in	O
developing	O
countries	O
,	O
partial	O
implementation	O
of	O
preventive	O
treatments	O
,	O
and	O
weak	O
infrastructure	O
and	O
political	O
commitment	O
to	O
implement	O
mass	O
fortification	O
of	O
local	O
staple	O
foods	O
by	O
national	O
governments	O
.	O

Conclusion	O
.	O

Sustainability	O
of	O
effectiveness	O
of	O
preventive	O
treatments	O
of	O
iron	O
deficiency	O
anaemia	O
in	O
pregnancy	O
could	O
be	O
achieved	O
if	O
the	O
identified	O
threats	O
are	O
adequately	O
addressed	O
.	O

1	O
.	O

Introduction	O
Iron	O
deficiency	O
anaemia	O
is	O
defined	O
as	O
anaemia	O
accompanied	O
by	O
depleted	O
iron	O
stores	O
and	O
signs	O
of	O
a	O
compromised	O
supply	O
of	O
iron	O
to	O
the	O
tissues	O
[	O
1	O
].	O

There	O
is	O
variation	O
in	O
haemoglobin	O
levels	O
during	O
pregnancy	O
;	O
at	O
the	O
beginning	O
of	O
a	O
pregnancy	O
,	O
there	O
is	O
a	O
normal	O
reduction	O
in	O
haemoglobin	O
level	O
followed	O
by	O
a	O
slight	O
rise	O
towards	O
the	O
end	O
of	O
pregnancy	O
[	O
2	O
].	O

The	O
initial	O
reduction	O
has	O
been	O
explained	B
to	O
result	O
from	O
increased	O
red	O
cell	O
mass	O
and	O
demands	O
of	O
the	O
fetus	O
which	O
exceeds	O
iron	O
intake	O
with	O
consequent	O
reduction	O
in	O
iron	O
stores	O
of	O
the	O
woman	O
'	O
s	O
body	O
[	O
2	O
].	O

Thus	B
,	O
the	O
World	O
Health	O
Organization	O
has	O
defined	B
anaemia	O
in	O
pregnancy	O
as	B
a	O
haemoglobin	O
value	O
below	O
11	O
g	O
/	O
dL	O
[	O
1	O
,	O
3	O
].	O

There	O
are	O
two	O
known	O
factors	O
which	O
contribute	O
to	O
development	O
of	O
iron	O
deficiency	O
anaemia	O
(	O
IDA	O
)	O
in	O
pregnancy	O
;	O
the	O
first	O
is	O
the	O
woman	O
'	O
s	O
iron	O
stores	O
at	O
the	O
time	O
of	O
conception	O
and	O
the	O
second	O
is	O
the	O
amount	O
of	O
iron	O
absorbed	O
during	O
gestation	O
.	O

The	O
fact	O
that	O
anaemia	O
frequently	O
does	O
occur	O
in	O
pregnancy	O
among	O
women	O
in	O
developing	O
countries	O
is	O
an	O
indication	O
that	O
preexisting	O
iron	O
stores	O
are	O
often	B
inadequate	O
and	O
physiological	O
adaptations	O
to	O
pregnancy	O
are	O
insufficient	O
to	O
meet	O
the	O
increased	O
requirements	O
[	O
4	O
].	O

Hence	B
,	O
iron	O
supplementation	O
in	O
pregnancy	O
has	O
become	O
a	O
standard	O
and	O
routine	O
practice	O
as	B
a	O
preventive	O
treatment	O
for	O
iron	O
deficiency	O
anaemia	O
in	O
pregnancy	O
in	O
developing	O
countries	O
.	O

In	O
view	O
of	O
the	O
foregoing	O
,	O
a	O
review	O
of	O
effectiveness	O
of	O
preventive	O
treatments	O
of	O
iron	O
deficiency	O
anaemia	O
in	O
pregnancy	O
was	O
conducted	O
;	O
furthermore	O
,	O
constraints	O
were	O
highlighted	O
and	O
suggestions	O
for	O
improvement	O
were	O
provided	O
.	O

2	O
.	O

Methods	O
We	O
conducted	O
a	O
review	O
of	O
literature	O
on	O
evidence	O
-	O
based	O
preventive	O
treatments	O
of	O
iron	O
deficiency	O
anaemia	O
in	O
pregnancy	O
with	O
particular	O
reference	O
to	O
developing	O
countries	O
.	O

The	O
following	O
search	O
terms	O
were	O
used	O
:	O
prevalence	O
,	O
burden	O
,	O
iron	O
deficiency	O
,	O
anaemia	O
in	O
pregnancy	O
,	O
preventive	O
treatments	O
,	O
and	O
developing	O
countries	O
.	O

Cross	O
-	O
sectional	O
,	O
observational	O
,	O
and	O
randomized	O
control	O
trials	O
'	O
literature	O
on	O
the	O
subject	O
published	O
between	O
2000	O
and	O
2011	O
served	O
as	O
the	O
main	O
sources	O
of	O
information	O
.	O

These	O
works	O
of	O
literature	O
were	O
obtained	O
from	O
the	O
commonly	O
used	O
medical	O
databases	O
such	O
as	O
PubMed	O
(	O
Medline	O
),	O
AJOL	O
,	O
and	O
Google	O
Scholar	O
;	O
in	O
addition	O
,	O
Cochrane	O
Library	O
was	O
used	O
as	O
source	O
for	O
systematic	O
reviews	O
on	O
the	O
subject	O
matter	O
.	O

The	O
search	O
generated	O
27	O
related	O
articles	O
in	O
the	O
following	O
categories	O
:	O
prevalence	O
—	O
2	O
,	O
treatments	O
—	O
8	O
,	O
reviews	O
—	O
6	O
,	O
interventions	O
/	O
trials	O
—	O
6	O
,	O
dosage	O
—	O
1	O
,	O
and	O
technical	O
reports	O
—	O
4	O
.	O

This	O
paper	O
was	O
limited	O
to	O
the	O
six	O
randomised	O
and	O
quasi	O
-	O
randomised	O
trials	O
(	O
listed	O
inTable	O
1	O
)	O
on	O
preventive	O
treatments	O
of	O
iron	O
deficiency	O
anaemia	O
in	O
pregnancy	O
,	O
which	O
met	O
at	O
least	O
one	O
of	O
the	O
following	O
inclusion	O
criteria	O
:	O
(	O
i	O
)	O
comparison	O
between	O
daily	O
routine	O
oral	O
supplementation	O
with	O
iron	O
or	O
ironfolic	O
acid	O
and	O
no	O
supplementation	O
/	O
placebo	O
;	O
(	O
ii	O
)	O
comparison	O
between	O
daily	O
routine	O
oral	O
supplementation	O
with	O
iron	O
or	O
ironfolic	O
acid	O
and	O
routine	O
-	O
intermittent	O
(	O
weekly	O
and	O
twice	O
weekly	O
)	O
regimens	O
;	O
(	O
iii	O
)	O
comparison	O
between	O
intermittent	O
oral	O
iron	O
or	O
ironfolic	O
acid	O
supplementation	O
and	O
no	O
supplementation	O
/	O
placebo	O
;	O
(	O
iv	O
)	O
comparison	O
between	O
intravenous	O
route	O
versus	O
oral	O
route	O
of	O
iron	O
supplementation	O
;	O
(	O
v	O
)	O
comparison	O
between	O
food	O
fortification	O
with	O
iron	O
and	O
no	O
fortification	O
/	O
placebo	O
.	O

3	O
.	O

Results	O
3	O
.	O
1	O
.	O

Prevalence	O
and	O
Burden	O
of	O
Iron	O
Deficiency	O
Anaemia	O
in	O
Pregnancy	O
in	O
Developing	O
Countries	O
Worldwide	O
,	O
anemia	O
affects	O
over	O
two	O
billion	O
people	O
and	O
the	O
World	O
Health	O
Organization	O
(	O
WHO	O
)	O
has	O
estimated	O
that	O
half	O
of	O
these	O
are	O
due	O
to	O
iron	O
deficiency	O
[	O
5	O
,	O
6	O
].	O

Iron	O
deficiency	O
is	O
not	O
only	O
the	O
most	O
prevalent	O
but	O
also	O
the	O
most	O
neglected	O
nutrient	O
deficiency	O
in	O
the	O
world	O
,	O
particularly	O
among	O
pregnant	O
women	O
and	O
children	O
in	O
developing	O
countries	O
[	O
7	O
].	O

Presently	O
,	O
over	O
40	O
million	O
pregnant	O
women	O
suffer	O
from	O
iron	O
deficiency	O
(	O
ID	O
)	O
and	O
its	O
consequences	O
in	O
developing	O
countries	O
[	O
8	O
].	O

Iron	O
deficiency	O
is	O
the	O
most	O
common	O
cause	O
of	O
anaemia	O
in	O
pregnancy	O
[	O
2	O
].	O

Iron	O
deficiency	O
anaemia	O
accounts	O
for	O
75	O
–	O
95	O
%	O
of	O
cases	O
of	O
anaemia	O
in	O
pregnancy	O
[	O
9	O
].	O

Iron	O
-	O
deficiency	O
anaemia	O
,	O
the	O
late	O
manifestation	O
of	O
chronic	O
iron	O
deficiency	O
,	O
is	O
thought	O
to	O
be	O
the	O
most	O
common	O
nutrient	O
deficiency	O
among	O
pregnant	O
women	O
[	O
10	O
].	O

Studies	O
conducted	O
on	O
pregnant	O
women	O
in	O
Zimbabwe	O
,	O
China	O
,	O
India	O
,	O
and	O
Mexico	O
from	O
1996	O
to	O
2008	O
indicated	O
that	O
between	O
43	O
%	O
and	O
73	O
%	O
of	O
the	O
women	O
were	O
iron	O
deficient	O
(	O
usually	O
diagnosed	O
as	O
a	O
low	O
-	O
ferritin	O
concentration	O
);	O
out	O
of	O
these	O
,	O
7	O
%	O
to	O
33	O
%	O
had	O
IDA	O
[	O
4	O
].	O

Among	O
pregnant	O
women	O
,	O
IDA	O
has	O
been	O
associated	O
with	O
increased	O
risks	O
of	O
low	O
birth	O
weight	O
,	O
prematurity	O
,	O
and	O
maternal	O
morbidity	O
[	O
11	O
].	O

UNICEF	O
has	O
reported	O
deaths	O
of	O
an	O
estimated	O
50	O
,	O
000	O
young	O
women	O
per	O
year	O
globally	O
in	O
pregnancy	O
and	O
childbirth	O
due	O
to	O
severe	O
iron	O
deficiency	O
anemia	O
[	O
12	O
].	O

The	O
high	O
frequency	O
of	O
iron	O
deficiency	O
anaemia	O
in	O
the	O
developing	O
countries	O
has	O
substantial	O
health	O
and	O
economic	O
cost	O
implications	O
.	O

An	O
analysis	O
of	O
10	O
developing	O
countries	O
reported	O
$	O
0	O
.	O
32	O
per	O
head	O
or	O
0	O
.	O
57	O
%	O
of	O
gross	O
domestic	O
product	O
as	O
a	O
median	O
value	O
of	O
physical	O
productivity	O
loss	O
per	O
year	O
resulting	O
from	O
iron	O
deficiency	O
[	O
13	O
].	O

3	O
.	O
2	O
.	O

Evidence	O
-	O
Based	O
Preventive	O
Treatment	O
Options	O
3	O
.	O
2	O
.	O
1	O
.	O

Prophylaxis	O
Iron	O
Supplements	O
The	O
high	O
physiological	O
requirement	O
for	O
iron	O
in	O
pregnancy	O
is	O
difficult	O
to	O
meet	O
with	O
most	O
diets	O
;	O
this	O
is	O
so	O
especially	O
in	O
developing	O
countries	O
where	O
food	O
requirement	O
is	O
a	O
problem	O
.	O

During	O
pregnancy	O
,	O
iron	O
requirements	O
are	O
not	O
uniform	O
[	O
14	O
].	O

In	O
the	O
first	O
trimester	O
,	O
daily	O
needs	O
decrease	O
due	O
to	O
the	O
absence	O
of	O
menstruation	O
;	O
thereby	O
saving	O
about	O
0	O
.	O
56	O
mg	O
of	O
iron	O
per	O
day	O
,	O
or	O
160	O
mg	O
for	O
the	O
pregnancy	O
[	O
15	O
].	O

In	O
the	O
second	O
trimester	O
,	O
blood	O
volume	O
increases	O
by	O
45	O
%	O
with	O
an	O
increase	O
in	O
plasma	O
volume	O
of	O
50	O
%;	O
red	O
cell	O
mass	O
is	O
raised	O
by	O
35	O
%	O
which	O
amounts	O
to	O
about	O
450	O
mg	O
of	O
iron	O
in	O
a	O
55	O
kg	O
woman	O
[	O
4	O
].	O

Fetal	O
demands	O
for	O
iron	O
are	O
maximal	O
during	O
the	O
third	O
trimester	O
and	O
these	O
are	O
estimated	O
at	O
about	O
270	O
mg	O
in	O
a	O
3	O
kg	O
fetus	O
[	O
16	O
].	O

Therefore	B
,	O
an	O
average	O
daily	O
dose	O
of	O
4	O
–	O
6	O
mg	O
of	O
iron	O
is	O
required	O
in	O
the	O
second	O
and	O
third	O
trimesters	O
of	O
pregnancy	O
[	O
14	O
].	O

Overall	O
,	O
a	O
woman	O
requires	O
about	O
2	O
–	O
2	O
.	O
8	O
mg	O
of	O
iron	O
per	O
day	O
during	O
pregnancy	O
[	O
17	O
].	O

But	O
she	O
will	O
need	O
to	O
consume	O
much	O
more	O
to	O
obtain	O
this	O
daily	O
requirement	O
(	O
i	O
.	O
e	O
.,	O
between	O
20	O
and	O
48	O
mg	O
of	O
dietary	O
iron	O
)	O
[	O
18	O
].	O

However	O
,	O
literature	O
has	O
presented	O
different	O
views	O
on	O
iron	O
requirements	O
during	O
pregnancy	O
ranging	O
from	O
450	O
to	O
1	O
,	O
150	O
mg	O
with	O
a	O
median	O
of	O
790	O
mg	O
[	O
14	O
,	O
19	O
–	O
21	O
].	O

Since	O
these	O
requirements	O
are	O
difficult	O
to	O
meet	O
through	O
an	O
ordinary	O
diet	O
,	O
especially	O
in	O
developing	O
countries	O
where	O
most	O
diets	O
do	O
not	O
contain	O
adequate	O
bioavailable	O
iron	O
,	O
routine	O
iron	O
supplementation	O
in	O
pregnancy	O
has	O
been	O
found	O
to	O
be	O
of	O
immense	O
benefit	O
[	O
14	O
,	O
19	O
–	O
21	O
].	O

Iron	O
deficiency	O
in	O
nonpregnant	O
populations	O
can	O
be	O
measured	O
quite	O
precisely	O
using	O
laboratory	O
tests	O
such	O
as	O
serum	O
ferritin	O
,	O
serum	O
iron	O
,	O
transferrin	O
,	O
transferrin	O
saturation	O
,	O
and	O
transferrin	O
receptors	O
[	O
7	O
].	O

However	O
,	O
there	O
is	O
a	O
limitation	O
to	O
the	O
use	O
of	O
some	O
of	O
these	O
biochemical	O
indicators	O
of	O
iron	O
status	O
in	O
certain	O
settings	O
and	O
conditions	O
;	O
thus	B
,	O
necessitating	O
caution	O
in	O
their	O
interpretations	O
.	O

For	O
example	O
,	O
serum	O
ferritin	O
level	O
,	O
being	O
an	O
acute	O
-	O
phase	O
protein	O
,	O
is	O
raised	O
in	O
associated	O
underlying	O
infections	O
and	O
long	O
-	O
term	O
diseases	O
;	O
it	O
can	O
therefore	B
give	O
a	O
false	O
normal	O
or	O
high	O
level	O
in	O
a	O
state	O
of	O
iron	O
deficiency	O
.	O

Whereas	O
in	O
pregnancy	O
,	O
serum	O
ferritin	O
levels	O
decline	O
even	O
in	O
women	O
ingesting	O
daily	O
supplements	O
of	O
iron	O
[	O
22	O
–	O
24	O
].	O

There	O
are	O
different	O
forms	O
of	O
preventive	O
treatment	O
of	O
iron	O
deficiency	O
anaemia	O
in	O
pregnancy	O
.	O

Iron	O
supplements	O
can	O
be	O
given	O
by	O
mouth	O
and	O
parenteral	O
route	O
as	O
intramuscular	O
and	O
intravenous	O
injections	O
;	O
in	O
addition	O
,	O
it	O
can	O
be	O
administered	O
as	O
blood	O
transfusion	O
and	O
recombinant	O
erythropoietin	O
with	O
iron	O
.	O

The	O
first	O
choice	O
in	O
the	O
prophylaxis	O
of	O
iron	O
deficiency	O
anaemia	O
for	O
almost	B
all	I
women	O
is	O
oral	O
iron	O
replacement	O
because	O
of	O
its	O
effectiveness	O
,	O
safety	O
,	O
and	O
low	O
cost	O
[	O
25	O
].	O

Oral	O
iron	O
,	O
either	O
as	O
iron	O
sulphate	O
or	O
fumarate	O
,	O
is	O
the	O
most	O
commonly	O
used	O
preventive	O
treatment	O
for	O
iron	O
deficiency	O
and	O
iron	O
deficiency	O
anaemia	O
in	O
pregnancy	O
.	O

Direct	O
iron	O
supplementation	O
has	O
been	O
extensively	O
used	O
in	O
most	O
developing	O
countries	O
as	B
an	O
intervention	O
to	O
prevent	O
iron	O
deficiency	O
and	O
consequently	B
anaemia	O
during	O
pregnancy	O
[	O
7	O
].	O

Thus	B
,	O
preventive	O
treatment	O
with	O
iron	O
supplements	O
has	O
always	O
been	O
given	O
in	O
combination	O
with	O
folic	O
acid	O
and	O
this	O
has	O
been	O
included	O
as	O
part	O
of	O
routine	O
antenatal	O
care	O
provided	O
to	O
pregnant	O
women	O
at	O
every	O
visit	O
in	O
developing	O
countries	O
[	O
26	O
].	O

The	O
rationale	O
for	O
this	O
combination	O
is	O
to	O
meet	O
increased	O
folic	O
acid	O
requirements	O
in	O
pregnancy	O
brought	O
about	O
by	O
the	O
rapidly	O
dividing	O
cells	O
in	O
the	O
fetus	O
and	O
elevated	O
urinary	O
losses	O
[	O
7	O
].	O

The	O
International	O
Nutritional	O
Anaemia	O
Consultative	O
Group	O
had	O
recommended	O
a	O
daily	O
dose	O
of	O
60	O
mg	O
of	O
iron	O
for	O
pregnant	O
nonanaemic	O
women	O
,	O
if	O
supplementation	O
for	O
more	O
than	O
six	O
months	O
is	O
possible	O
before	O
delivery	O
[	O
27	O
].	O

An	O
increased	O
daily	O
dose	O
of	O
120	O
mg	O
of	O
iron	O
is	O
further	O
suggested	O
if	O
the	O
duration	O
of	O
supplementation	O
in	O
pregnant	O
nonanaemic	O
women	O
is	O
shorter	O
or	O
where	O
the	O
prevalence	O
of	O
iron	O
deficiency	O
in	O
women	O
is	O
high	O
or	O
in	O
settings	O
where	O
pregnant	O
women	O
are	O
generally	O
anaemic	O
[	O
27	O
].	O

This	O
supplement	O
should	O
include	O
400	O
μ	O
g	O
of	O
folic	O
acid	O
or	O
lower	O
doses	O
,	O
if	O
this	O
amount	O
is	O
not	O
available	O
[	O
7	O
].	O

3	O
.	O
2	O
.	O
2	O
.	O

Food	O
Fortification	O
with	O
Iron	O
Iron	O
fortification	O
involves	O
the	O
addition	O
of	O
iron	O
,	O
usually	O
with	O
folic	O
acid	O
,	O
to	O
an	O
appropriate	O
food	O
vehicle	O
that	O
is	O
made	O
available	O
to	O
the	O
population	O
at	O
large	O
.	O

Food	O
fortification	O
with	O
iron	O
has	O
thus	B
become	O
a	O
promising	B
approach	O
for	O
preventing	O
iron	O
deficiency	O
anaemia	O
in	O
pregnancy	O
in	O
developing	O
countries	O
.	O

Iron	O
fortification	O
of	O
foods	O
might	O
be	O
particularly	O
useful	O
and	O
cost	O
effective	O
in	O
settings	O
where	O
the	O
logistics	O
of	O
oral	O
iron	O
supplementation	O
among	O
pregnant	O
women	O
are	O
highly	O
challenging	O
.	O

In	O
addition	O
,	O
it	O
is	O
found	O
very	O
useful	O
in	O
developing	O
countries	O
where	O
the	O
rate	O
of	O
compliance	O
with	O
preventive	O
treatment	O
of	O
iron	O
is	O
poor	O
[	O
4	O
].	O

To	O
this	O
end	O
,	O
a	O
variety	O
of	O
food	O
items	O
such	O
as	O
cereal	O
flour	O
(	O
maize	O
or	O
wheat	O
),	O
salt	O
,	O
beverage	O
,	O
milk	O
,	O
sugar	O
,	O
noodles	O
,	O
rice	O
,	O
and	O
fish	O
sauce	O
had	O
been	O
fortified	O
with	O
iron	O
and	O
used	O
successfully	O
as	B
dietary	O
supplements	O
to	O
boost	O
iron	O
stores	O
,	O
and	O
hence	B
improve	O
haemoglobin	O
levels	O
in	O
the	O
population	O
[	O
28	O
–	O
31	O
].	O

Elemental	O
iron	O
powders	O
are	O
the	O
most	O
widely	O
used	O
iron	O
compound	O
in	O
fortification	O
programmes	O
since	O
about	O
50	O
years	O
[	O
32	O
].	O

3	O
.	O
3	O
.	O

A	O
Review	O
of	O
Effectiveness	O
of	O
Preventive	O
Treatments	O
of	O
Iron	O
Deficiency	O
Anaemia	O
in	O
Pregnancy	O
3	O
.	O
3	O
.	O
1	O
.	O

Prophylaxis	O
Iron	O
Supplements	O
The	O
overall	O
impact	O
of	O
interventions	O
on	O
iron	O
supplementation	O
under	O
field	O
conditions	O
has	O
been	O
limited	O
and	O
its	O
effectiveness	O
questioned	O
[	O
33	O
].	O

These	O
concerns	O
had	O
been	O
attributed	O
to	O
inadequate	O
infrastructure	O
and	O
poor	O
compliance	O
with	O
preventive	O
treatment	O
,	O
among	O
others	O
[	O
34	O
].	O

Furthermore	O
,	O
the	O
effectiveness	O
of	O
this	O
intervention	O
has	O
been	O
evaluated	O
mostly	B
in	O
terms	O
of	O
improvement	O
in	O
haemoglobin	O
concentration	O
,	O
rather	O
than	O
maternal	O
or	O
infant	O
health	O
[	O
35	O
].	O

For	O
example	O
,	O
a	O
randomized	O
controlled	O
trial	O
among	O
pregnant	O
women	O
in	O
Switzerland	O
showed	O
that	O
the	O
parenteral	O
route	O
of	O
iron	O
prophylaxis	O
of	O
anaemia	O
has	O
no	O
clinically	O
significant	O
benefit	O
over	O
oral	O
route	O
as	B
there	O
was	O
no	O
significant	O
difference	O
in	O
maternal	O
outcomes	O
and	O
serious	O
adverse	O
events	O
between	O
the	O
two	O
groups	O
[	O
25	O
].	O

A	O
Cochrane	O
review	O
of	O
a	O
randomized	O
control	O
trial	O
conducted	O
in	O
Pakistan	O
reported	O
that	O
daily	O
iron	O
treatment	O
is	O
better	O
than	O
intermittent	O
iron	O
supplementation	O
in	O
increasing	O
haemoglobin	O
level	O
at	O
delivery	O
among	O
pregnant	O
women	O
in	O
developing	O
countries	O
[	O
2	O
].	O

Findings	O
from	O
other	O
studies	O
on	O
routine	O
daily	O
or	O
weekly	O
antenatal	O
iron	O
or	O
iron	O
plus	O
folic	O
acid	O
supplementation	O
showed	O
that	O
it	O
may	O
be	O
of	O
benefit	O
,	O
especially	O
where	O
pregestational	O
iron	O
deficiency	O
and	O
anaemia	O
are	O
prevalent	O
[	O
7	O
].	O

A	O
recently	O
published	O
randomized	O
study	O
found	O
no	O
difference	O
in	O
most	O
pregnancy	O
outcomes	O
between	O
daily	O
and	O
twice	O
weekly	O
iron	O
supplementation	O
regimens	O
,	O
though	O
the	O
daily	O
regimen	O
was	O
found	O
to	O
be	O
more	O
effective	O
than	O
twice	O
weekly	O
regimen	O
in	O
preventing	O
Hb	O
decrement	O
at	O
near	O
term	O
[	O
8	O
].	O

The	O
timing	O
and	O
dosage	O
of	O
oral	O
iron	O
are	O
also	O
controversial	O
as	B
most	O
studies	O
have	O
focused	O
on	O
preventive	O
treatment	O
from	O
midpregnancy	O
,	O
at	O
or	O
before	O
20	O
weeks	O
gestation	O
[	O
4	O
].	O

Some	O
researchers	O
,	O
on	O
the	O
other	O
hand	O
,	O
believe	O
that	O
both	O
daily	O
and	O
weekly	O
iron	O
supplementation	O
are	O
relatively	O
unsuccessful	O
in	O
the	O
reduction	O
of	O
prevalence	O
of	O
anemia	O
in	O
pregnancy	O
.	O

They	O
opined	O
that	O
sufficient	O
attention	O
should	O
be	O
paid	O
to	O
adolescent	O
girls	O
and	O
women	O
of	O
reproductive	O
age	O
long	O
before	O
pregnancy	O
and	O
suggested	O
intermittent	O
low	O
-	O
dose	O
iron	O
supplements	O
and	O
in	O
some	O
cases	O
,	O
combined	O
with	O
necessary	O
micronutrients	O
[	O
36	O
,	O
37	O
].	O

Apart	O
from	O
its	O
effectiveness	O
,	O
it	O
was	O
argued	O
that	O
intermittent	O
supplementation	O
is	O
more	O
physiological	O
by	O
avoiding	O
mucosal	O
absorption	O
block	O
and	O
excessive	O
pooling	O
of	O
intestinal	O
iron	O
with	O
associated	O
oxidative	O
stress	O
;	O
furthermore	O
,	O
it	O
has	O
logistic	O
advantages	O
of	O
distribution	O
particularly	O
in	O
areas	O
of	O
limited	O
supply	O
and	O
many	O
of	O
the	O
gastrointestinal	O
side	O
effects	O
of	O
daily	O
iron	O
are	O
avoided	O
[	O
4	O
].	O

Experiences	O
on	O
parenteral	O
iron	O
use	O
are	O
predominantly	O
,	O
but	O
not	O
exclusively	O
,	O
from	O
the	O
developed	O
world	O
as	B
reports	O
of	O
its	O
prophylactic	O
use	O
in	O
pregnancy	O
are	O
scant	O
;	O
this	O
may	O
be	O
related	O
to	O
concerns	O
about	O
adverse	O
reactions	O
associated	O
with	O
its	O
use	O
in	O
parenteral	O
form	O
.	O

However	O
,	O
intravenous	O
iron	O
sucrose	O
in	O
particular	O
has	O
been	O
used	O
in	O
several	O
recent	O
studies	O
and	O
might	O
be	O
highly	O
beneficial	O
in	O
refractory	O
patients	O
or	O
those	O
intolerant	O
of	O
oral	O
iron	O
formulations	O
[	O
4	O
].	O

Though	O
,	O
because	B
of	O
its	O
immediate	O
bioavailability	O
,	O
it	O
may	O
result	O
in	O
a	O
more	O
rapid	O
rise	O
in	O
haemoglobin	O
level	O
in	O
anaemic	O
patients	O
compared	O
with	O
oral	O
iron	O
;	O
but	O
it	O
probably	B
does	O
not	O
confer	O
an	O
advantage	O
in	O
preventing	O
anaemia	O
in	O
pregnancy	O
[	O
25	O
,	O
38	O
].	O

The	O
WHO	O
technical	O
working	O
group	O
on	O
the	O
prevention	O
and	O
the	O
treatment	O
of	O
severe	O
anaemia	O
has	O
documented	O
that	O
parenteral	O
iron	O
therapy	O
produces	O
a	O
rapid	O
and	O
complete	O
correction	O
of	O
iron	O
deficiency	O
,	O
including	O
replacement	O
of	O
iron	O
stores	O
;	O
thereby	O
producing	O
a	O
more	O
rapid	O
erythropoietic	O
response	O
than	O
oral	O
iron	O
replacement	O
[	O
39	O
].	O

However	O
,	O
its	O
use	O
should	O
be	O
limited	O
to	O
a	O
selected	O
group	O
of	O
patients	O
who	O
are	O
unable	O
to	O
tolerate	O
oral	O
iron	O
and	O
in	O
whom	O
oral	O
iron	O
therapy	O
fails	O
due	O
to	O
noncompliance	O
.	O

It	O
is	O
also	O
indicated	O
in	O
pregnant	O
women	O
whose	O
hemoglobin	O
level	O
is	O
required	O
to	O
be	O
restored	O
rapidly	O
such	O
as	O
those	O
who	O
present	O
too	O
close	O
to	O
term	O
and	O
those	O
who	O
have	O
severe	O
anemia	O
[	O
40	O
].	O

3	O
.	O
3	O
.	O
2	O
.	O

Food	O
Fortification	O
with	O
Iron	O
Food	O
fortification	O
with	O
iron	O
has	O
also	O
been	O
shown	O
to	O
be	O
an	O
equally	O
effective	O
strategy	O
of	O
boosting	O
haemoglobin	O
level	O
in	O
the	O
population	O
,	O
including	O
pregnant	O
women	O
.	O

Asibey	O
-	O
Berko	O
et	O
al	O
.	O

in	O
2007	O
recorded	O
19	O
.	O
5	O
%	O
significant	O
increase	O
in	O
the	O
prevalence	O
of	O
anaemia	O
among	O
rural	O
Ghanaian	O
women	O
,	O
who	O
were	O
not	O
exposed	O
to	O
iron	O
-	O
fortified	O
salt	O
[	O
29	O
].	O

It	O
was	O
also	O
shown	O
that	O
iron	O
fortification	O
of	O
sugar	O
(	O
with	O
mean	O
intake	O
of	O
4	O
mg	O
/	O
day	O
)	O
in	O
nonpregnant	O
Guatemalan	O
women	O
over	O
three	O
years	O
resulted	O
in	O
a	O
substantial	O
increase	O
in	O
iron	O
stores	O
,	O
with	O
reserves	O
still	O
increasing	O
by	O
about	O
40	O
mg	O
/	O
year	O
after	O
the	O
third	O
year	O
[	O
41	O
].	O

Furthermore	O
,	O
two	O
Vietnamese	O
studies	O
showed	O
similar	O
improvements	O
in	O
iron	O
stores	O
following	O
ingestion	O
of	O
ironfortified	O
fish	O
sauce	O
for	O
six	O
to	O
12	O
months	O
[	O
42	O
,	O
43	O
].	O

Comparable	O
results	O
were	O
documented	O
with	O
dietary	O
supplements	O
containing	O
iron	O
and	O
ironfortified	O
milk	O
[	O
30	O
,	O
31	O
].	O

3	O
.	O
4	O
.	O

Constraints	O
to	O
Successful	O
Preventive	O
Treatments	O
of	O
Iron	O
Deficiency	O
Anaemia	O
in	O
Pregnancy	O
3	O
.	O
4	O
.	O
1	O
.	O

Side	O
Effects	O
of	O
Iron	O
Supplements	O
Gastrointestinal	O
distress	O
is	O
commonly	O
observed	O
in	O
women	O
consuming	O
high	O
levels	O
of	O
supplemental	O
iron	O
on	O
an	O
empty	O
stomach	O
[	O
7	O
].	O

Thus	B
,	O
occurrence	O
of	O
gastrointestinal	O
symptoms	O
is	O
usually	O
considered	O
as	B
a	O
critical	O
adverse	O
effect	O
on	O
which	O
a	O
tolerable	O
upper	O
intake	O
level	O
for	O
iron	O
is	O
based	O
for	O
an	O
individual	O
.	O

High	O
dose	O
of	O
oral	O
iron	O
supplements	O
is	O
commonly	O
associated	O
with	O
gastrointestinal	O
effects	O
such	O
as	O
constipation	O
,	O
nausea	O
,	O
vomiting	O
,	O
and	O
diarrhea	O
;	O
the	O
frequency	O
and	O
severity	O
of	O
which	O
vary	O
according	O
to	O
the	O
amount	O
of	O
elemental	O
iron	O
released	O
into	O
the	O
stomach	O
.	O

In	O
addition	O
,	O
elevation	O
of	O
“	O
free	O
iron	O
”	O
in	O
the	O
plasma	O
and	O
hence	B
lipid	O
peroxidation	O
which	O
is	O
indicative	O
of	O
oxidative	O
stress	O
has	O
been	O
reported	O
[	O
44	O
–	O
46	O
].	O

Intramuscular	O
or	O
intravenous	O
iron	O
is	O
thought	O
to	O
be	O
associated	O
with	O
allergic	O
reactions	O
and	O
anaphylactic	O
shock	O
;	O
furthermore	O
,	O
parenteral	O
iron	O
is	O
thought	O
to	O
predispose	O
to	O
venous	O
thrombosis	O
and	O
occasionally	O
cardiac	O
arrest	O
and	O
death	O
[	O
2	O
].	O

Parenteral	O
iron	O
sucrose	O
complex	O
is	O
known	O
to	O
have	O
several	O
advantages	O
because	O
of	O
its	O
low	O
-	O
allergenic	O
properties	O
and	O
consequently	B
,	O
an	O
extremely	O
low	O
incidence	O
of	O
severe	O
side	O
effects	O
such	O
as	O
anaphylactic	O
reactions	O
[	O
47	O
,	O
48	O
];	O
however	O
,	O
its	O
use	O
requires	O
caution	O
as	B
it	O
may	O
not	O
be	O
completely	O
devoid	O
of	O
side	O
effect	O
.	O

Other	O
disadvantages	O
of	O
intravenous	O
iron	O
supplementation	O
include	O
cost	O
and	O
invasiveness	O
of	O
the	O
procedure	O
.	O

However	O
,	O
it	O
is	O
argued	O
that	O
cost	O
benefit	O
of	O
intravenous	O
iron	O
prophylaxis	O
may	O
be	O
large	O
taking	O
into	O
consideration	O
the	O
opportunity	O
costs	O
of	O
erythropoiesis	O
-	O
stimulating	O
agents	O
,	O
blood	O
transfusions	O
,	O
and	O
hospitalization	O
[	O
25	O
].	O

3	O
.	O
4	O
.	O
2	O
.	O

Low	O
Utilization	O
of	O
Maternal	O
Health	O
Service	O
in	O
Developing	O
Countries	O
It	O
is	O
well	B
established	I
that	O
antenatal	O
care	O
provides	O
pregnant	O
women	O
with	O
opportunities	O
to	O
receive	O
cost	O
-	O
effective	O
interventions	O
which	O
are	O
beneficial	O
to	O
mother	O
and	O
child	O
;	O
these	O
interventions	O
include	O
preventive	O
treatments	O
of	O
iron	O
deficiency	O
anemia	O
.	O

However	O
,	O
the	O
potentials	O
of	O
antenatal	O
service	O
have	O
not	O
been	O
maximally	O
utilized	O
in	O
developing	O
countries	O
.	O

This	O
is	O
because	O
these	O
settings	O
are	O
characterized	O
by	O
poor	O
maternal	O
health	O
service	O
indicators	O
such	O
as	O
nonutilization	O
of	O
service	O
or	O
delayed	O
antenatal	O
visit	O
.	O

For	O
example	O
,	O
researchers	O
have	O
reported	O
a	O
common	O
occurrence	O
of	O
unbooked	O
pregnancies	O
[	O
49	O
,	O
50	O
]	O
and	O
a	O
wide	O
range	O
(	O
60	O
%	O
to	O
90	O
%)	O
of	O
antenatal	O
care	O
utilization	O
rates	O
(	O
i	O
.	O
e	O
.,	O
antenatal	O
care	O
clinic	O
attendance	O
of	O
at	O
least	O
once	O
during	O
most	O
recent	O
pregnancy	O
)	O
[	O
51	O
–	O
53	O
].	O

In	O
addition	O
,	O
for	O
certain	O
reasons	O
,	O
a	O
substantial	O
proportion	O
(	O
20	O
%	O
to	O
80	O
%)	O
of	O
pregnant	O
women	O
in	O
these	O
settings	O
make	O
their	O
first	O
antenatal	O
visit	O
in	O
their	O
third	O
trimester	O
[	O
54	O
–	O
56	O
].	O

3	O
.	O
4	O
.	O
3	O
.	O

Partial	O
Implementation	O
of	O
Preventive	O
Treatments	O
The	O
success	O
of	O
routine	O
iron	O
and	O
folate	O
supplementation	O
,	O
especially	O
in	O
areas	O
with	O
a	O
high	O
prevalence	O
of	O
anemia	O
,	O
recommended	O
as	O
a	O
component	O
of	O
antenatal	O
care	O
package	O
for	O
all	O
pregnant	O
women	O
by	O
the	O
World	O
Health	O
Organization	O
is	O
threatened	O
by	O
the	O
practice	O
of	O
partial	O
implementation	O
of	O
preventive	O
treatments	O
of	O
health	O
workers	O
.	O

Researchers	O
have	O
persistently	B
reported	O
noncompliance	O
with	O
this	O
recommendation	O
at	O
a	O
given	O
antenatal	O
visit	O
.	O

Van	O
Eijk	O
et	O
al	O
.	O

in	O
2006	O
reported	O
that	O
53	O
%	O
and	O
44	O
%	O
of	O
pregnant	O
women	O
received	O
iron	O
and	O
folate	O
supplementation	O
,	O
respectively	O
,	O
during	O
last	O
pregnancy	O
[	O
54	O
].	O

Other	O
studies	O
reported	O
36	O
–	O
54	O
%	O
iron	O
supplementation	O
[	O
51	O
,	O
55	O
].	O

3	O
.	O
4	O
.	O
4	O
.	O

Weak	O
Infrastructure	O
and	O
Political	O
Commitment	O
The	O
efforts	O
of	O
World	O
Food	O
Programme	O
(	O
WFP	O
)	O
in	O
overcoming	O
micronutrient	O
deficiencies	O
in	O
nutritionally	O
-	O
vulnerable	O
groups	O
and	O
low	O
-	O
income	O
food	O
-	O
deficit	O
countries	O
continue	O
to	O
be	O
thwarted	O
by	O
challenges	O
such	O
as	O
technical	O
and	O
managerial	O
capacity	O
constraints	O
,	O
the	O
need	O
for	O
systematic	O
compliance	O
with	O
procurement	O
specifications	O
and	O
quality	O
control	O
,	O
clearer	O
policies	O
on	O
micronutrient	O
content	O
labeling	O
,	O
and	O
the	O
need	O
for	O
cash	O
resources	O
to	O
support	O
many	O
aspects	O
associated	O
with	O
local	O
processing	O
and	O
fortification	O
activities	O
[	O
57	O
].	O

3	O
.	O
5	O
.	O

Recommendations	O
The	O
World	O
Health	O
Organization	O
has	O
recommended	O
that	O
weekly	O
iron	O
and	O
folic	O
acid	O
supplementation	O
should	O
be	O
considered	O
as	B
a	O
strategy	O
for	O
prevention	O
of	O
iron	O
deficiency	O
in	O
population	O
groups	O
.	O

This	O
is	O
particularly	O
so	O
where	O
the	O
prevalence	O
of	O
anemia	O
is	O
above	O
20	O
%	O
among	O
women	O
of	O
reproductive	O
age	O
[	O
58	O
].	O

Since	O
iron	O
tablets	O
induce	O
a	O
high	O
concentration	O
of	O
free	O
radicals	O
in	O
the	O
intestinal	O
milieu	O
,	O
which	O
may	O
damage	O
the	O
intestinal	O
epithelium	O
,	O
the	O
minimal	O
essential	O
iron	O
dose	O
is	O
to	O
be	O
recommended	O
[	O
59	O
].	O

Therefore	B
,	O
there	O
is	O
a	O
need	O
to	O
establish	O
effective	O
and	O
safe	O
doses	O
of	O
supplemental	O
iron	O
with	O
folic	O
acid	O
either	O
as	O
daily	O
or	O
weekly	O
supplementation	O
;	O
this	O
should	O
take	O
into	O
consideration	O
nutritional	O
and	O
haematological	O
status	O
of	O
women	O
in	O
developing	O
countries	O
.	O

Though	O
compliance	O
with	O
weekly	O
dosage	O
may	O
be	O
better	O
than	O
daily	O
regimen	O
because	O
of	O
reduced	O
side	O
effects	O
,	O
it	O
is	O
desirable	O
to	O
conduct	O
further	O
field	O
randomized	O
controlled	O
trials	O
in	O
order	O
to	O
establish	O
the	O
efficacy	O
of	O
weekly	O
supplementation	O
compared	O
to	O
daily	O
regimen	O
.	O

Alternatively	O
,	O
an	O
equally	O
effective	O
,	O
safe	O
,	O
and	O
affordable	O
iron	O
compound	O
with	O
little	O
or	O
no	O
side	O
effect	O
can	O
be	O
developed	O
for	O
use	O
especially	O
in	O
public	O
health	O
antenatal	O
supplementation	O
programmes	O
.	O

To	O
this	O
end	O
,	O
we	O
recommend	O
a	O
cue	O
to	O
be	O
taken	O
from	O
new	O
approaches	O
to	O
iron	O
fortification	O
technology	O
development	O
whereby	O
iron	O
-	O
mediated	O
undesirable	O
taste	O
and	O
appearance	O
are	O
prevented	O
while	O
its	O
stability	O
and	O
bioavailability	O
are	O
preserved	O
[	O
60	O
].	O

While	O
this	O
approach	O
is	O
being	O
pursued	O
,	O
we	O
recommend	O
that	O
appropriate	O
measures	O
be	O
taken	O
to	O
strengthen	O
the	O
existing	O
health	O
systems	O
in	O
dealing	O
with	O
gastro	O
-	O
intestinal	O
and	O
life	O
-	O
threatening	O
side	O
effects	O
of	O
iron	O
supplements	O
.	O

Thus	B
,	O
clinical	O
skills	O
of	O
local	O
health	O
staff	O
could	O
be	O
improved	O
through	O
targeted	O
trainings	O
such	O
as	O
the	O
WHO	O
training	O
on	O
Life	O
Saving	O
Skills	O
[	O
61	O
]	O
for	O
health	O
workers	O
.	O

Though	O
the	O
training	O
lays	O
emphasis	O
on	O
core	O
midwifery	O
skills	O
,	O
it	O
could	O
be	O
expanded	O
to	O
include	O
cardiopulmonary	O
resuscitation	O
of	O
mothers	O
;	O
furthermore	O
,	O
local	O
health	O
staff	O
should	O
be	O
provided	O
with	O
appropriate	O
state	O
-	O
of	O
-	O
art	O
equipment	O
to	O
work	O
with	O
.	O

Although	O
,	O
laboratories	O
at	O
the	O
health	O
facilities	O
in	O
developing	O
countries	O
usually	O
lack	O
the	O
capacity	O
to	O
conduct	O
quality	O
blood	O
test	O
,	O
they	O
could	O
be	O
strengthened	O
to	O
provide	O
reliable	O
estimations	O
of	O
red	O
blood	O
cell	O
indices	O
such	O
as	O
haemoglobin	O
,	O
haematocrit	O
,	O
mean	O
cell	O
volume	O
,	O
mean	O
cell	O
haemoglobin	O
,	O
and	O
mean	O
cell	O
haemoglobin	O
concentration	O
.	O

Where	O
possible	O
,	O
estimation	O
of	O
serum	O
ferritin	O
level	O
is	O
desirable	O
to	O
adjust	O
the	O
dose	O
of	O
iron	O
supplements	O
[	O
62	O
].	O

With	O
respect	O
to	O
partial	O
implementation	O
of	O
preventive	O
treatment	O
,	O
local	O
health	O
staff	O
should	O
be	O
encouraged	O
on	O
adherence	O
to	O
the	O
guidelines	O
on	O
antenatal	O
care	O
package	O
at	O
any	O
given	O
antenatal	O
visit	O
so	O
that	O
partial	O
implementation	O
of	O
preventive	O
treatments	O
is	O
minimized	O
.	O

Mass	O
fortification	O
programme	O
of	O
common	O
local	O
staple	O
foods	O
with	O
iron	O
and	O
folic	O
acid	O
is	O
a	O
long	O
-	O
term	O
goal	O
,	O
which	O
national	O
governments	O
in	O
developing	O
countries	O
should	O
consider	O
as	B
a	O
strategy	O
aimed	O
at	O
reducing	O
the	O
prevalence	O
of	O
iron	O
deficiency	O
anaemia	O
in	O
the	O
general	O
population	O
.	O

Since	O
iron	O
deficiency	O
anaemia	O
in	O
pregnancy	O
is	O
determined	O
by	O
preexisting	O
body	O
iron	O
stores	O
,	O
among	O
other	O
factors	O
,	O
we	O
recommend	O
that	O
the	O
mass	O
fortification	O
programme	O
should	O
be	O
located	O
and	O
implemented	O
within	O
the	O
context	O
of	O
reproductive	O
health	O
services	O
.	O

4	O
.	O

Conclusions	O
Iron	O
deficiency	O
remains	O
the	O
most	O
important	O
cause	O
of	O
anaemia	O
in	O
pregnancy	O
in	O
developing	O
countries	O
.	O

Hence	B
,	O
its	O
contribution	O
to	O
increased	O
risks	O
of	O
low	O
birth	O
weight	O
,	O
prematurity	O
,	O
and	O
maternal	O
morbidity	O
cannot	O
be	O
underscored	O
.	O

Prophylaxis	O
iron	O
supplement	O
and	O
food	O
fortification	O
with	O
iron	O
have	O
the	O
prospects	O
of	O
improving	O
maternal	O
and	O
child	O
health	O
,	O
except	O
for	O
the	O
identified	O
constraints	O
.	O

Sustained	O
advocacy	O
in	O
tackling	O
micronutrient	O
deficiencies	O
at	O
national	O
and	O
international	O
policy	O
levels	O
is	O
also	O
a	O
prerequisite	O
to	O
the	O
attainment	O
of	O
Millennium	O
Development	O
Goals	O
4	O
and	O
5	O
.	O

PubMed	O
Central	O
:	O

High	O
Prevalence	O
of	O
Vitamin	O
D	O
Deficiency	O
in	O
Pregnant	O
Women	O
:	O
A	O
National	O
Cross	O
-	O
Sectional	O
Survey	O
Abstract	O
An	O
increasing	O
number	O
of	O
studies	O
suggest	O
that	O
vitamin	O
D	O
deficiency	O
during	O
pregnancy	O
is	O
associated	O
with	O
multiple	O
adverse	O
health	O
outcomes	O
in	O
mothers	O
,	O
neonates	O
and	O
children	O
.	O

There	O
are	O
no	O
representative	O
country	O
data	O
available	O
on	O
vitamin	O
D	O
status	O
of	O
pregnant	O
women	O
in	O
Europe	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
estimate	O
the	O
prevalence	O
of	O
vitamin	O
D	O
deficiency	O
among	O
Belgian	O
pregnant	O
women	O
and	O
to	O
assess	O
the	O
determinants	O
of	O
vitamin	O
D	O
status	O
in	O
the	O
first	O
and	O
third	O
trimester	O
of	O
pregnancy	O
.	O

The	O
women	O
were	O
selected	O
via	O
a	O
multi	O
-	O
stage	O
proportionate	O
-	O
to	O
-	O
size	O
sampling	O
design	O
.	O

Blood	O
samples	O
were	O
collected	O
and	O
a	O
questionnaire	O
was	O
completed	O
face	O
-	O
to	O
-	O
face	O
.	O

55	O
obstetric	O
clinics	O
were	O
randomly	O
selected	O
and	O
1311	O
pregnant	O
women	O
participated	O
in	O
the	O
study	O
.	O

The	O
median	O
serum	O
25	O
-	O
hydroxyvitamin	O
D	O
[	O
25	O
-(	O
OH	O
)	O
D	O
]	O
concentration	O
was	O
significantly	O
lower	O
in	O
the	O
first	O
trimester	O
(	O
20	O
.	O
4	O
ng	O
/	O
ml	O
)	O
than	O
in	O
third	O
trimester	O
(	O
22	O
.	O
7	O
ng	O
/	O
ml	O
).	O

Of	O
all	O
women	O
,	O
74	O
.	O
1	O
%	O
(	O
95	O
%	O
CI	O
=	O
71	O
.	O
8	O
–	O
76	O
.	O
5	O
%)	O
were	O
vitamin	O
D	O
insufficient	O
(	O
25	O
-(	O
OH	O
)	O
D	O
<	O
30	O
ng	O
/	O
ml	O
),	O
44	O
.	O
6	O
%	O
(	O
95	O
%	O
CI	O
=	O
41	O
.	O
9	O
–	O
47	O
.	O
3	O
%)	O
were	O
vitamin	O
D	O
deficient	O
(	O
25	O
-(	O
OH	O
)	O
D	O
<	O
20	O
ng	O
/	O
ml	O
),	O
while	O
12	O
.	O
1	O
%	O
(	O
95	O
%	O
CI	O
=	O
10	O
.	O
3	O
–	O
13	O
.	O
8	O
%)	O
were	O
severely	O
vitamin	O
D	O
deficient	O
(	O
25	O
-(	O
OH	O
)	O
D	O
<	O
10	O
ng	O
/	O
ml	O
).	O

Of	O
all	O
women	O
included	O
,	O
62	O
.	O
0	O
%	O
reported	O
taking	O
vitamin	O
D	O
-	O
containing	O
multivitamins	O
,	O
of	O
which	O
only	O
24	O
.	O
2	O
%	O
started	O
taking	O
those	O
before	O
pregnancy	O
.	O

The	O
risk	O
of	O
vitamin	O
D	O
deficiency	O
(	O
25	O
-(	O
OH	O
)	O
D	O
<	O
20	O
ng	O
/	O
ml	O
)	O
was	O
significantly	O
higher	O
for	O
less	O
educated	O
women	O
and	O
women	O
who	O
reported	O
not	O
going	O
on	O
holidays	O
to	O
sunny	O
climates	O
.	O

The	O
risk	O
of	O
severe	O
vitamin	O
D	O
deficiency	O
(	O
25	O
-(	O
OH	O
)	O
D	O
<	O
10	O
ng	O
/	O
ml	O
)	O
decreased	O
for	O
women	O
who	O
reported	O
alcohol	O
consumption	O
during	O
pregnancy	O
,	O
decreased	O
with	O
more	O
frequent	O
use	O
of	O
sunscreen	O
lotion	O
and	O
increased	O
for	O
smokers	O
and	O
women	O
who	O
reported	O
preference	O
for	O
shadow	O
.	O

In	O
conclusion	O
,	O
vitamin	O
D	O
deficiency	O
is	O
highly	O
prevalent	O
among	O
pregnant	O
women	O
in	O
Belgium	O
and	O
this	O
raises	O
concerns	O
about	O
the	O
health	O
consequences	O
for	O
the	O
mother	O
and	O
the	O
offspring	O
.	O

A	O
targeted	O
screening	O
strategy	O
to	O
detect	O
and	O
treat	O
women	O
at	O
high	O
risk	O
of	O
severe	O
vitamin	O
D	O
deficiency	O
is	O
needed	O
in	O
Belgium	O
and	O
in	O
Europe	O
.	O

Introduction	O
Vitamin	O
D	O
status	O
is	O
a	O
well	B
-	I
known	I
determinant	O
of	O
bone	O
health	O
[	O
1	O
],[	O
2	O
].	O

Vitamin	O
D	O
deficiency	O
increases	O
the	O
risk	O
of	O
osteoporosis	O
[	O
3	O
]	O
and	O
fractures	O
[	O
4	O
],	O
while	O
in	O
its	O
most	O
severe	O
form	O
it	O
causes	O
rickets	O
in	O
children	O
[	O
5	O
]	O
and	O
osteomalacia	O
in	O
adults	O
[	O
6	O
].	O

The	O
ubiquitous	O
presence	O
of	O
vitamin	O
D	O
receptors	O
in	O
most	O
tissues	O
,	O
including	O
the	O
placenta	O
,	O
suggests	O
that	O
vitamin	O
D	O
may	O
have	O
other	O
roles	O
as	O
well	O
.	O

Adequate	O
vitamin	O
D	O
intake	O
is	O
associated	O
with	O
a	O
lower	O
risk	O
of	O
cancer	O
[	O
7	O
],[	O
8	O
],[	O
9	O
],[	O
10	O
],[	O
11	O
],	O
cardiovascular	O
diseases	O
[	O
12	O
],	O
autoimmune	O
diseases	O
[	O
13	O
],	O
neurological	O
disorders	O
[	O
14	O
]	O
and	O
diabetes	O
[	O
15	O
].	O

In	O
addition	O
,	O
an	O
increasing	O
number	O
of	O
studies	O
suggest	O
that	O
vitamin	O
D	O
deficiency	O
during	O
pregnancy	O
is	O
associated	O
with	O
multiple	O
adverse	O
health	O
outcomes	O
in	O
mothers	O
(	O
gestational	O
diabetes	O
and	O
pre	O
-	O
eclampsia	O
),	O
in	O
neonates	O
(	O
wheezing	O
)	O
and	O
children	O
(	O
low	O
bone	O
mineral	O
density	O
,	O
type	O
-	O
1	O
diabetes	O
,	O
eczema	O
)[	O
16	O
]–[	O
22	O
].	O

However	O
there	O
is	O
so	O
far	O
no	O
conclusive	O
evidence	O
about	O
the	O
causality	O
of	O
these	O
relationships	O
,	O
as	O
no	O
randomised	O
controlled	O
trials	O
of	O
vitamin	O
D	O
supplementation	O
with	O
an	O
appropriate	O
assessment	O
of	O
a	O
variety	O
of	O
health	O
outcomes	O
have	O
been	O
carried	O
out	O
to	O
date	O
[	O
21	O
].	O

Humans	O
get	O
vitamin	O
D	O
(	O
cholecalciferol	O
)	O
from	O
exposure	O
to	O
sunlight	O
,	O
diet	O
and	O
dietary	O
supplements	O
.	O

As	O
few	O
food	O
items	O
contain	O
or	O
are	O
fortified	O
with	O
vitamin	O
D	O
(	O
such	O
as	O
liver	O
,	O
fatty	O
fish	O
,	O
eggs	O
,	O
milk	O
and	O
dairy	O
products	O
,	O
soy	O
milk	O
,	O
butter	O
,	O
margarines	O
),	O
the	O
skin	O
synthesis	O
of	O
vitamin	O
D	O
induced	O
by	O
ultraviolet	O
B	O
radiation	O
(	O
UVB	O
)	O
is	O
the	O
main	O
determinant	O
of	O
vitamin	O
D	O
status	O
in	O
the	O
population	O
[	O
23	O
].	O

Vitamin	O
D	O
once	O
synthesized	O
in	O
the	O
skin	O
is	O
metabolized	O
into	O
25	O
-	O
dihydroxyvitamin	O
D	O
[	O
25	O
-(	O
OH	O
)	O
D	O
]	O
in	O
the	O
liver	O
.	O

Due	O
to	O
its	O
longer	O
half	O
-	O
life	O
,	O
25	O
-(	O
OH	O
)	O
D	O
is	O
considered	O
the	O
best	O
bio	O
-	O
marker	O
of	O
vitamin	O
D	O
status	O
.	O

25	O
-(	O
OH	O
)	O
D	O
is	O
then	O
metabolized	O
in	O
the	O
kidney	O
by	O
the	O
1	O
-	O
α	O
hydroxylase	O
to	O
the	O
active	O
steroid	O
hormone	O
1	O
,	O
25	O
-	O
dihydroxyvitamin	O
D	O
[	O
1	O
,	O
25	O
-(	O
OH	O
)	O
2D	O
].	O

Several	O
modifications	O
of	O
vitamin	O
D	O
metabolism	O
occur	O
during	O
pregnancy	O
.	O

The	O
expression	O
of	O
1	O
-	O
α	O
hydroxylase	O
is	O
increased	O
in	O
the	O
kidney	O
and	O
placenta	O
and	O
the	O
concentration	O
of	O
serum	O
1	O
,	O
25	O
-(	O
OH	O
)	O
2D	O
increases	O
in	O
normal	O
pregnancy	O
from	O
the	O
first	O
to	O
the	O
third	O
trimester	O
.	O

The	O
role	O
of	O
1	O
,	O
25	O
-(	O
OH	O
)	O
2D	O
during	O
pregnancy	O
to	O
increase	O
intestinal	O
calcium	O
absorption	O
is	O
since	B
long	B
acknowledged	I
[	O
24	O
].	O

The	O
cut	O
-	O
off	O
points	O
used	O
to	O
define	O
vitamin	O
D	O
insufficiency	O
and	O
deficiency	O
are	O
not	O
well	O
established	O
and	O
remain	O
controversial	O
.	O

Nevertheless	O
there	O
is	O
a	O
consensus	B
to	O
consider	O
serum	O
25	O
-(	O
OH	O
)	O
D	O
below	O
20	O
ng	O
/	O
ml	O
as	O
inadequately	O
low	O
[	O
25	O
],	O
and	O
some	O
evidence	O
suggests	O
that	O
values	O
higher	O
than	O
30	O
ng	O
/	O
ml	O
may	O
be	O
associated	O
with	O
better	O
health	O
outcomes	O
in	O
the	O
adult	O
population	O
.[	O
26	O
],[	O
27	O
].	O

The	O
uncertainty	O
concerning	O
the	O
optimal	O
serum	O
25	O
-(	O
OH	O
)	O
D	O
concentration	O
in	O
pregnant	O
women	O
is	O
even	O
higher	O
.	O

As	O
long	O
as	O
the	O
proposed	O
values	O
are	O
not	O
validated	O
in	O
clinical	O
trials	O
the	O
controversy	O
will	O
remain	O
[	O
28	O
].	O

There	O
is	O
a	O
growing	O
concern	O
about	O
the	O
health	O
consequences	O
of	O
the	O
high	O
prevalence	O
of	O
vitamin	O
D	O
deficiency	O
worldwide	O
among	O
the	O
general	O
population	O
,	O
including	O
pregnant	O
women	O
.	O

The	O
adequacy	O
of	O
the	O
current	O
vitamin	O
D	O
dietary	O
recommendations	O
to	O
reach	O
an	O
optimal	O
vitamin	O
D	O
status	O
during	O
pregnancy	O
has	O
been	O
questioned	O
[	O
24	O
].	O

Although	O
previous	O
small	O
surveys	O
suggest	O
that	O
vitamin	O
D	O
deficiency	O
among	O
pregnant	O
women	O
is	O
common	O
in	O
Europe	O
[	O
29	O
],[	O
30	O
],	O
there	O
are	O
no	O
reliable	O
country	O
-	O
wide	O
estimates	O
of	O
vitamin	O
D	O
status	O
of	O
pregnant	O
women	O
in	O
European	O
countries	O
.	O

Therefore	B
the	O
aim	O
of	O
this	O
study	O
was	O
to	O
carry	O
out	O
the	O
first	O
national	O
representative	O
random	O
sample	O
survey	O
on	O
vitamin	O
D	O
status	O
in	O
pregnant	O
women	O
in	O
a	O
European	O
country	O
and	O
to	O
assess	O
the	O
determinants	O
of	O
vitamin	O
D	O
status	O
in	O
the	O
first	O
and	O
third	O
trimester	O
of	O
pregnancy	O
.	O

Methods	O
Ethics	O
Statement	O
This	O
study	O
was	O
conducted	O
according	O
to	O
the	O
guidelines	O
laid	O
down	O
in	O
the	O
Declaration	O
of	O
Helsinki	O
and	O
all	O
procedures	O
involving	O
human	O
subjects	O
were	O
approved	O
by	O
the	O
medical	O
ethical	O
committee	O
of	O
the	O
Erasme	O
hospital	O
in	O
Brussels	O
.	O

The	O
subjects	O
provided	O
written	O
consent	O
for	O
participation	O
in	O
the	O
study	O
.	O

Sampling	O
The	O
target	O
population	O
of	O
the	O
survey	O
comprised	O
all	O
pregnant	O
women	O
in	O
Belgium	O
during	O
the	O
first	O
and	O
the	O
third	O
trimester	O
of	O
pregnancy	O
in	O
the	O
period	O
from	O
September	O
2010	O
to	O
June	O
2011	O
.	O

The	O
women	O
were	O
selected	O
according	O
to	O
a	O
multi	O
-	O
stage	O
proportionate	O
-	O
to	O
-	O
size	O
stratified	O
sampling	O
design	O
as	O
recommended	O
for	O
studies	O
assessing	O
iodine	O
deficiency	O
[	O
31	O
].	O

The	O
country	O
was	O
divided	O
into	O
two	O
regions	O
.	O

In	O
each	O
region	O
the	O
obstetric	O
clinics	O
were	O
ordered	O
by	O
province	O
and	O
size	O
based	O
on	O
the	O
number	O
of	O
deliveries	O
during	O
the	O
past	O
year	O
and	O
60	O
clusters	O
of	O
4	O
clinics	O
were	O
selected	O
per	O
region	O
using	O
systematic	O
sampling	O
in	O
order	O
to	O
have	O
enough	O
replacement	O
clinics	O
in	O
case	O
some	O
refused	O
to	O
participate	O
.	O

Out	O
of	O
these	O
60	O
clusters	O
,	O
30	O
clusters	O
were	O
randomly	O
selected	O
and	O
within	O
each	O
cluster	O
the	O
first	O
clinic	O
was	O
invited	O
to	O
participate	O
.	O

In	O
each	O
clinic	O
all	O
gynaecologist	O
-	O
obstetricians	O
were	O
invited	O
to	O
participate	O
in	O
order	O
to	O
level	O
out	O
a	O
possible	O
gynaecologist	O
effect	O
.	O

The	O
aim	O
was	O
to	O
include	O
22	O
women	O
in	O
each	O
cluster	O
of	O
which	O
11	O
in	O
the	O
first	O
trimester	O
and	O
11	O
in	O
the	O
third	O
trimester	O
of	O
pregnancy	O
.	O

Data	O
Collection	O
Blood	O
samples	O
were	O
collected	O
from	O
the	O
antecubital	O
vein	O
and	O
a	O
general	O
questionnaire	O
about	O
socio	O
-	O
demographic	O
and	O
socio	O
-	O
economic	O
characteristics	O
,	O
smoking	O
and	O
alcohol	O
consumption	O
during	O
pregnancy	O
and	O
during	O
the	O
4	O
weeks	O
prior	O
to	O
the	O
interview	O
,	O
diseases	O
and	O
medication	O
and	O
use	O
of	O
food	O
supplements	O
was	O
completed	O
in	O
a	O
face	O
-	O
to	O
-	O
face	O
interview	O
conducted	O
by	O
the	O
study	O
nurse	O
.	O

Women	O
from	O
Algeria	O
,	O
Egypt	O
,	O
Libya	O
,	O
Morocco	O
,	O
Sudan	O
,	O
Tunisia	O
,	O
and	O
Western	O
Sahara	O
were	O
considered	O
of	O
North	O
African	O
descent	O
.	O

For	O
all	O
women	O
included	O
in	O
the	O
study	O
,	O
body	O
mass	O
index	O
(	O
BMI	O
)	O
was	O
obtained	O
from	O
weight	O
and	O
height	O
recorded	O
by	O
the	O
gynaecologist	O
during	O
the	O
first	O
prenatal	O
consultation	O
in	O
the	O
beginning	O
of	O
the	O
first	O
trimester	O
of	O
pregnancy	O
.	O

First	O
trimester	O
BMI	O
was	O
used	O
as	O
a	O
proxy	O
for	O
prepregnancy	O
BMI	O
for	O
both	O
first	O
and	O
third	O
trimester	O
pregnant	O
women	O
.	O

Analysis	O
of	O
Samples	O
Approximately	O
5	O
ml	O
whole	O
blood	O
was	O
collected	O
by	O
venipuncture	O
in	O
a	O
non	O
-	O
heparinized	O
tube	O
.	O

Serum	O
aliquots	O
were	O
then	O
stored	O
at	O
–	O
80C	O
for	O
further	O
analysis	O
.	O

Serum	O
25	O
-	O
hydroxyvitamin	O
D	O
(	O
25	O
-(	O
OH	O
)	O
D	O
)	O
concentrations	O
were	O
measured	O
by	O
radioimmunoassay	O
(	O
Diasorin	O
,	O
Stillwater	O
,	O
MN	O
,	O
USA	O
).	O

Statistical	O
Analyses	O
The	O
statistical	O
analyses	O
were	O
carried	O
out	O
using	O
STATA	O
10	O
.	O
1	O
(	O
StataCorp	O
,	O
Texas	O
,	O
USA	O
).	O

As	O
serum	O
25	O
-(	O
OH	O
)	O
D	O
is	O
not	O
normally	O
distributed	O
,	O
non	O
-	O
parametric	O
methods	O
were	O
used	O
.	O

The	O
median	O
was	O
used	O
as	O
the	O
measure	O
of	O
central	O
tendency	O
.	O

Differences	O
between	O
regions	O
,	O
trimesters	O
and	O
age	O
groups	O
were	O
explored	O
using	O
two	O
-	O
sample	O
Wilcoxon	O
rank	O
-	O
sum	O
test	O
or	O
Kruskal	O
-	O
Wallis	O
equality	O
-	O
of	O
-	O
populations	O
rank	O
test	O
.	O

The	O
odds	O
of	O
having	O
a	O
serum	O
25	O
-(	O
OH	O
)	O
D	O
concentration	O
lower	O
than	O
20	O
ng	O
/	O
ml	O
(	O
vitamin	O
D	O
deficiency	O
)	O
versus	O
a	O
non	O
deficient	O
vitamin	O
D	O
status	O
were	O
estimated	O
through	O
multiple	O
logistic	O
regressions	O
while	O
entering	O
the	O
following	O
variables	O
as	O
predictors	O
in	O
the	O
model	O
:	O
season	O
,	O
age	O
,	O
trimester	O
of	O
pregnancy	O
,	O
region	O
,	O
BMI	O
,	O
smoking	O
behaviour	O
,	O
alcohol	O
consumption	O
,	O
use	O
of	O
vitamin	O
D	O
-	O
containing	O
food	O
supplements	O
,	O
fish	O
consumption	O
,	O
milk	O
and	O
dairy	O
product	O
consumption	O
,	O
education	O
level	O
,	O
ethnicity	O
,	O
parity	O
,	O
exposure	O
to	O
sunlight	O
during	O
weekdays	O
,	O
exposure	O
to	O
sunlight	O
during	O
weekend	O
days	O
,	O
use	O
of	O
sunscreen	O
lotion	O
,	O
use	O
of	O
solarium	O
,	O
shadow	O
or	O
sun	O
preference	O
and	O
sometimes	O
going	O
on	O
holidays	O
to	O
sunny	O
climates	O
(	O
yes	O
/	O
no	O
question	O
).	O

In	O
addition	O
the	O
odds	O
of	O
having	O
a	O
serum	O
25	O
-(	O
OH	O
)	O
D	O
concentration	O
lower	O
than	O
10	O
ng	O
/	O
ml	O
(	O
severe	O
vitamin	O
D	O
deficiency	O
)	O
versus	O
a	O
non	O
severe	O
deficient	O
vitamin	O
D	O
status	O
were	O
estimated	O
through	O
multiple	O
logistic	O
regressions	O
while	O
entering	O
the	O
same	O
predictors	O
in	O
the	O
model	O
.	O

Results	O
Among	O
the	O
1311	O
pregnant	O
women	O
participating	O
in	O
the	O
survey	O
,	O
there	O
were	O
271	O
from	O
Brussels	O
,	O
597	O
from	O
Flanders	O
and	O
437	O
from	O
Wallonia	O
(	O
Figure	O
1	O
;	O
Table	O
1	O
).	O

For	O
6	O
women	O
information	O
on	O
the	O
age	O
was	O
missing	O
.	O

The	O
mean	O
age	O
of	O
women	O
was	O
similar	O
in	O
all	O
three	O
regions	O
.	O

For	O
1307	O
women	O
a	O
general	O
questionnaire	O
was	O
available	O
.	O

For	O
1	O
hospital	O
(	O
n	O
=	O
23	O
women	O
)	O
certain	O
questions	O
(	O
mainly	O
nationality	O
,	O
ethnicity	O
,	O
education	O
level	O
)	O
needed	O
to	O
be	O
omitted	O
from	O
the	O
questionnaire	O
upon	O
decision	O
of	O
the	O
ethical	O
committee	O
of	O
this	O
particular	O
hospital	O
.	O
10	O
.	O
1371	O
/	O
journal	O
.	O
pone	O
.	O
0043868	O
.	O
g001	O
Caption	O
(	O
FIG	O
):	O
FIGURE	O
1	O
Geographical	O
distribution	O
of	O
the	O
55	O
hospitals	O
visited	O
in	O
Belgium	O
and	O
the	O
number	O
of	O
pregnant	O
women	O
(	O
n	O
=	O
1311	O
)	O
investigated	O
by	O
site	O
(	O
national	O
survey	O
on	O
vitamin	O
D	O
status	O
of	O
pregnant	O
women	O
Belgium	O
2010	O
–	O
2011	O
).	O
10	O
.	O
1371	O
/	O
journal	O
.	O
pone	O
.	O
0043868	O
.	O
t001	O
Caption	O
(	O
TABLE	O
-	O
WRAP	O
):	O
TABLE	O
1	O
Number	O
of	O
pregnant	O
women	O
by	O
region	O
,	O
trimester	O
and	O
age	O
(	O
national	O
survey	O
on	O
vitamin	O
D	O
status	O
among	O
pregnant	O
women	O
Belgium	O
,	O
2010	O
–	O
2011	O
).	O
RegionsBrussels	O
**	O
Flanders	O
**	O
WalloniaAge	O
(	O
years	O
)	O
1sttrimester3rdtrimester1sttrimester3rdtrimester1sttrimester3rdtrimester15	O
–	O
20721110211721	O
–	O
2534277751567326	O
–	O
304139108149765831	O
–	O
3534536975494536	O
–	O
4014142319132441	O
–	O
45231332Total132138289307218219	O
6	O
missing	O
data	O
for	O
age	O
.	O

1	O
pregnant	O
woman	O
from	O
2ndtrimester	O
.	O

The	O
characteristics	O
of	O
the	O
pregnant	O
women	O
included	O
in	O
the	O
study	O
are	O
shown	O
inTable	O
2	O
.	O

More	O
than	O
50	O
%	O
of	O
the	O
women	O
included	O
had	O
a	O
lower	O
education	O
level	O
,	O
which	O
means	O
only	O
completion	O
of	O
secondary	O
school	O
or	O
even	O
lower	O
education	O
.	O

More	O
than	O
20	O
%	O
of	O
the	O
women	O
in	O
the	O
sample	O
were	O
from	O
non	O
-	O
Caucasian	O
origin	O
.	O

Of	O
all	O
women	O
included	O
,	O
15	O
%	O
smoked	O
during	O
pregnancy	O
and	O
12	O
%	O
reported	O
having	O
drunk	O
alcohol	O
during	O
pregnancy	O
(	O
Table	O
2	O
).	O
10	O
.	O
1371	O
/	O
journal	O
.	O
pone	O
.	O
0043868	O
.	O
t002	O
Caption	O
(	O
TABLE	O
-	O
WRAP	O
):	O
TABLE	O
2	O
Characteristics	O
of	O
the	O
pregnant	O
women	O
included	O
in	O
the	O
study	O
(	O
n	O
=	O
1311	O
)	O
(	O
Belgian	O
national	O
survey	O
on	O
vitamin	O
D	O
status	O
in	O
pregnant	O
women	O
,	O
2010	O
–	O
2011	O
).	O
CharacteristicNMean	O
age28	O
.	O
5	O
±	O
5	O
.	O
11305Mean	O
BMI	O
*(	O
kg	O
/	O
m2	O
)	O
24	O
.	O
4	O
±	O
5	O
.	O
11290	O
%	O
Underweight5	O
.	O
6673	O
%	O
Healthy	O
weight59	O
.	O
20763	O
%	O
Overweight22	O
.	O
09285	O
%	O
Obese13	O
.	O
10169	O
Ethnicity	O
%	O
White	O
/	O
Caucasian73	O
.	O
61965	O
%	O
Asiatic2	O
.	O
5233	O
%	O
African	O
(	O
Black	O
)	O
4	O
.	O
8864	O
%	O
North	O
African13	O
.	O
42176	O
%	O
Hispanic0	O
.	O
9212	O
%	O
Not	O
known4	O
.	O
6561	O
Education	O
level	O
%	O
Secondary	O
education	O
or	O
lower54	O
.	O
54715	O
%	O
Higher	O
education27	O
.	O
23357	O
%	O
University	O
or	O
higher14	O
.	O
87195	O
%	O
Other	O
education0	O
.	O
233	O
%	O
No	O
diploma0	O
.	O
699	O
%	O
Not	O
known2	O
.	O
4432	O
Smoking	O
%	O
Yes16	O
.	O
78220	O
%	O
Of	O
which	O
during	O
past	O
4	O
wks15	O
.	O
41202	O
%	O
No82	O
.	O
911087	O
%	O
Not	O
known0	O
.	O
314	O
Drinking	O
alcohol	O
%	O
Yes20	O
.	O
37267	O
%	O
Of	O
which	O
during	O
past	O
4	O
wks11	O
.	O
51151	O
%	O
No78	O
.	O
491029	O
%	O
Not	O
known1	O
.	O
1415	O
First	O
trimester	O
BMI	O
used	O
as	O
a	O
proxy	O
for	O
prepregnancy	O
BMI	O
.	O

Of	O
all	O
pregnant	O
women	O
included	O
,	O
640	O
were	O
in	O
the	O
first	O
,	O
666	O
were	O
in	O
the	O
third	O
and	O
2	O
were	O
in	O
the	O
second	O
trimester	O
of	O
pregnancy	O
.	O

For	O
3	O
women	O
information	O
on	O
the	O
trimester	O
was	O
missing	O
.	O

For	O
41	O
.	O
7	O
%	O
of	O
the	O
women	O
this	O
was	O
their	O
first	O
pregnancy	O
(	O
unknown	O
for	O
0	O
.	O
4	O
%	O
of	O
the	O
women	O
),	O
while	O
for	O
45	O
.	O
6	O
%	O
of	O
the	O
women	O
this	O
would	O
be	O
their	O
first	O
child	O
(	O
status	O
not	O
known	O
for	O
1	O
.	O
4	O
%	O
of	O
the	O
women	O
).	O

More	O
or	O
less	O
4	O
%	O
of	O
the	O
women	O
within	O
the	O
sample	O
had	O
had	O
a	O
miscarriage	O
before	O
at	O
least	O
once	O
.	O

For	O
77	O
.	O
6	O
%	O
of	O
the	O
women	O
their	O
pregnancy	O
was	O
planned	O
(	O
unknown	O
for	O
3	O
.	O
3	O
%	O
of	O
the	O
women	O
).	O

The	O
median	O
serum	O
25	O
-(	O
OH	O
)	O
D	O
concentration	O
in	O
pregnant	O
women	O
was	O
21	O
.	O
2	O
ng	O
/	O
mL	O
.	O

The	O
median	O
25	O
-(	O
OH	O
)	O
D	O
concentration	O
was	O
significantly	O
higher	O
in	O
the	O
first	O
trimester	O
than	O
in	O
the	O
third	O
trimester	O
:	O
20	O
.	O
4	O
ng	O
/	O
mL	O
and	O
22	O
.	O
7	O
ng	O
/	O
mL	O
respectively	O
.	O

Differences	O
in	O
25	O
-(	O
OH	O
)	O
D	O
concentration	O
among	O
both	O
regions	O
were	O
not	O
significant	O
.	O

Of	O
all	O
women	O
,	O
74	O
.	O
1	O
%	O
(	O
95	O
%	O
CI	O
=	O
71	O
.	O
8	O
–	O
76	O
.	O
5	O
%)	O
were	O
vitamin	O
D	O
insufficient	O
(	O
25	O
-(	O
OH	O
)	O
D	O
concentration	O
<	O
30	O
ng	O
/	O
ml	O
)	O
and	O
44	O
.	O
6	O
%	O
(	O
95	O
%	O
CI	O
=	O
41	O
.	O
9	O
–	O
47	O
.	O
3	O
%)	O
of	O
the	O
pregnant	O
women	O
were	O
vitamin	O
D	O
deficient	O
(	O
25	O
-(	O
OH	O
)	O
D	O
concentration	O
<	O
20	O
ng	O
/	O
ml	O
),	O
while	O
12	O
.	O
1	O
%	O
(	O
95	O
%	O
CI	O
=	O
10	O
.	O
3	O
–	O
13	O
.	O
8	O
%)	O
of	O
the	O
women	O
were	O
severely	O
vitamin	O
D	O
deficient	O
(	O
25	O
-(	O
OH	O
)	O
D	O
concentration	O
<	O
10	O
ng	O
/	O
ml	O
).	O

The	O
percentage	O
of	O
women	O
with	O
vitamin	O
D	O
insufficiency	O
and	O
deficiency	O
was	O
higher	O
in	O
the	O
first	O
than	O
in	O
the	O
third	O
trimester	O
of	O
pregnancy	O
but	O
the	O
prevalence	O
of	O
severe	O
vitamin	O
D	O
deficiency	O
was	O
higher	O
in	O
the	O
third	O
trimester	O
(	O
Table	O
3	O
).	O
10	O
.	O
1371	O
/	O
journal	O
.	O
pone	O
.	O
0043868	O
.	O
t003	O
Caption	O
(	O
TABLE	O
-	O
WRAP	O
):	O
TABLE	O
3	O
Serum	O
25	O
-(	O
OH	O
)	O
D	O
concentration	O
in	O
pregnant	O
women	O
(	O
n	O
=	O
1311	O
)	O
(	O
Belgian	O
national	O
survey	O
on	O
vitamin	O
D	O
status	O
in	O
pregnant	O
women	O
,	O
2010	O
–	O
2011	O
).	O
All	O
womenWalloniaFlanders1sttrimester3rdtrimesterN1300453633633665Age28	O
.	O
5	O
±	O
5	O
.	O
127	O
.	O
9	O
±	O
5	O
.	O
528	O
.	O
8	O
±	O
4	O
.	O
728	O
.	O
3	O
±	O
5	O
.	O
128	O
.	O
8	O
±	O
5	O
.	O
1Gestational	O
weeks22	O
.	O
2	O
±	O
12	O
.	O
522	O
.	O
1	O
±	O
12	O
.	O
822	O
.	O
4	O
±	O
12	O
.	O
39	O
.	O
9	O
±	O
2	O
.	O
834	O
.	O
1	O
±	O
3	O
.	O
625	O
-(	O
OH	O
)	O
D	O
(	O
ng	O
/	O
ml	O
)	O
Median21	O
.	O
220	O
.	O
922	O
.	O
320	O
.	O
422	O
.	O
7	O
*	O
IQR13	O
.	O
8	O
–	O
30	O
.	O
013	O
.	O
5	O
–	O
29	O
.	O
114	O
.	O
6	O
–	O
30	O
.	O
613	O
.	O
6	O
–	O
26	O
.	O
714	O
.	O
3	O
–	O
34	O
.	O
195	O
%	O
CI20	O
.	O
5	O
–	O
22	O
.	O
219	O
.	O
8	O
–	O
22	O
.	O
321	O
.	O
2	O
–	O
23	O
.	O
219	O
.	O
3	O
–	O
21	O
.	O
121	O
.	O
6	O
–	O
24	O
.	O
4	O
%	O
<	O
10	O
ng	O
/	O
ml12	O
.	O
112	O
.	O
310	O
.	O
911	O
.	O
612	O
.	O
6	O
%	O
<	O
20	O
ng	O
/	O
ml44	O
.	O
645	O
.	O
742	O
.	O
347	O
.	O
042	O
.	O
3	O
%	O
<	O
30	O
ng	O
/	O
ml74	O
.	O
176	O
.	O
372	O
.	O
582	O
.	O
266	O
.	O
7	O
Different	O
from	O
first	O
trimester	O
pregnant	O
women	O
,	O
p	O
<	O
0	O
.	O
001	O
.	O

For	O
both	O
first	O
and	O
third	O
trimester	O
women	O
there	O
was	O
a	O
clear	O
seasonal	O
trend	O
in	O
the	O
mean	O
serum	O
25	O
-(	O
OH	O
)	O
D	O
concentrations	O
with	O
lowest	O
concentrations	O
in	O
winter	O
and	O
highest	O
during	O
spring	O
and	O
summer	O
,	O
while	O
decreasing	O
again	O
in	O
autumn	O
.	O

Women	O
of	O
other	O
ethnic	O
origins	O
were	O
vitamin	O
D	O
deficient	O
(	O
25	O
-(	O
OH	O
)	O
D	O
concentration	O
<	O
20	O
ng	O
/	O
ml	O
)	O
all	O
year	O
round	O
,	O
except	O
during	O
summer	O
for	O
third	O
trimester	O
women	O
(	O
Figure	O
2	O
).	O
10	O
.	O
1371	O
/	O
journal	O
.	O
pone	O
.	O
0043868	O
.	O
g002	O
Caption	O
(	O
FIG	O
):	O
FIGURE	O
2	O
Serum	O
25	O
-(	O
OH	O
)	O
D	O
concentrations	O
over	O
the	O
different	O
seasons	O
,	O
by	O
trimester	O
of	O
pregnancy	O
and	O
ethnicity	O
(	O
national	O
survey	O
on	O
vitamin	O
D	O
status	O
among	O
pregnant	O
women	O
in	O
Belgium	O
,	O
2010	O
–	O
2011	O
).	O

Of	O
all	O
women	O
included	O
,	O
76	O
.	O
2	O
%	O
reported	O
taking	O
at	O
least	O
1	O
multivitamin	O
during	O
pregnancy	O
.	O

For	O
62	O
.	O
0	O
%	O
of	O
them	O
the	O
multivitamin	O
contained	O
vitamin	O
D	O
.	O
In	O
the	O
first	O
and	O
third	O
trimester	O
of	O
pregnancy	O
the	O
percentage	O
of	O
women	O
taking	O
a	O
multivitamin	O
containing	O
vitamin	O
D	O
was	O
52	O
.	O
6	O
%	O
and	O
72	O
.	O
3	O
%	O
respectively	O
.	O

Only	O
24	O
.	O
2	O
%	O
of	O
all	O
pregnant	O
women	O
started	O
taking	O
multivitamins	O
before	O
pregnancy	O
,	O
while	O
46	O
.	O
6	O
%	O
of	O
these	O
women	O
started	O
taking	O
multivitamins	O
within	O
the	O
first	O
trimester	O
of	O
pregnancy	O
.	O

The	O
risk	O
of	O
vitamin	O
D	O
deficiency	O
(	O
25	O
-(	O
OH	O
)	O
D	O
<	O
20	O
ng	O
/	O
ml	O
)	O
increased	O
significantly	O
with	O
BMI	O
and	O
was	O
significantly	O
higher	O
for	O
women	O
who	O
reported	O
not	O
taking	O
vitamin	O
D	O
-	O
containing	O
multivitamins	O
(	O
Table	O
4	O
).	O

In	O
addition	O
the	O
risk	O
of	O
vitamin	O
D	O
deficiency	O
was	O
threefold	O
higher	O
among	O
women	O
of	O
Asiatic	O
descent	O
,	O
six	O
fold	O
higher	O
for	O
North	O
African	O
women	O
and	O
five	O
fold	O
higher	O
for	O
women	O
of	O
Hispanic	O
descent	O
compared	O
to	O
Caucasians	O
.	O

The	O
risk	O
of	O
vitamin	O
D	O
insufficiency	O
was	O
significantly	O
lower	O
for	O
more	O
educated	O
women	O
and	O
for	O
persons	O
reporting	O
going	O
on	O
holidays	O
to	O
sunny	O
climates	O
.	O

In	O
addition	O
the	O
risk	O
of	O
vitamin	O
D	O
deficiency	O
was	O
significantly	O
lower	O
in	O
summer	O
,	O
spring	O
and	O
autumn	O
compared	O
to	O
winter	O
(	O
Table	O
4	O
).	O
10	O
.	O
1371	O
/	O
journal	O
.	O
pone	O
.	O
0043868	O
.	O
t004	O
Caption	O
(	O
TABLE	O
-	O
WRAP	O
):	O
TABLE	O
4	O
Risk	O
of	O
vitamin	O
D	O
deficiency	O
during	O
pregnancy	O
in	O
Belgium	O
(	O
25	O
-(	O
OH	O
)	O
D	O
<	O
20	O
ng	O
/	O
ml	O
)	O
(	O
n	O
=	O
1100	O
),	O
results	O
of	O
multiple	O
logistic	O
regressions	O
.	O
N	O
of	O
subjectsN	O
of	O
deficient	O
casesOR	O
[	O
95	O
%	O
Conf	O
Interval	O
]	O
p	O
Season	O
Winter4702781	O
.	O
000Spring3841270	O
.	O
2340	O
.	O
1650	O
.	O
332	O
<	O
0	O
.	O
001Summer93120	O
.	O
1000	O
.	O
0490	O
.	O
203	O
<	O
0	O
.	O
001Autumn3511660	O
.	O
5500	O
.	O
3910	O
.	O
7750	O
.	O
001BMI	O
*	O
1	O
.	O
0511	O
.	O
0221	O
.	O
080	O
<	O
0	O
.	O
001	O
Smoking	O
yes2191181	O
.	O
000no10784650	O
.	O
7010	O
.	O
4801	O
.	O
0250	O
.	O
067	O
Use	O
of	O
multivitamins	O
containing	O
vitamin	O
D	O
no4893171	O
.	O
000yes8092660	O
.	O
2240	O
.	O
1680	O
.	O
300	O
<	O
0	O
.	O
001	O
Ethnicity	O
Caucasian	O
,	O
white9553691	O
.	O
000Asiatic33192	O
.	O
8231	O
.	O
2356	O
.	O
4540	O
.	O
014African	O
(	O
black	O
)	O
64341	O
.	O
3090	O
.	O
6942	O
.	O
4680	O
.	O
406North	O
African1741306	O
.	O
0483	O
.	O
8139	O
.	O
595	O
<	O
0	O
.	O
001Hispanic1275	O
.	O
3051	O
.	O
54918	O
.	O
1670	O
.	O
008	O
Education	O
level	O
Secondary	O
education	O
or	O
less7194131	O
.	O
000High	O
school3531080	O
.	O
4880	O
.	O
3490	O
.	O
681	O
<	O
0	O
.	O
001University195520	O
.	O
5090	O
.	O
3310	O
.	O
7830	O
.	O
002	O
Frequency	O
of	O
fish	O
consumption	O
(	O
non	O
-	O
fatty	O
fish	O
)	O
Never2261171	O
.	O
000Less	O
than	O
once	O
a	O
month225900	O
.	O
5640	O
.	O
3540	O
.	O
8970	O
.	O
0161	O
–	O
3	O
days	O
a	O
month5052160	O
.	O
8390	O
.	O
5641	O
.	O
2480	O
.	O
3861	O
day	O
per	O
week2701240	O
.	O
7940	O
.	O
5061	O
.	O
2480	O
.	O
3182	O
–	O
4	O
days	O
a	O
week	O
or	O
more	O
frequent69350	O
.	O
5620	O
.	O
2891	O
.	O
0950	O
.	O
090	O
Sometimes	O
going	O
on	O
holidays	O
to	O
sunny	O
climates	O
Yes8823661	O
.	O
000No4082151	O
.	O
7031	O
.	O
2482	O
.	O
3240	O
.	O
001	O
First	O
trimester	O
BMI	O
used	O
as	O
a	O
proxy	O
for	O
prepregnancy	O
BMI	O
.	O

OR	O
Odds	O
ratio	O
.	O

BMI	O
Body	O
mass	O
index	O
.	O

The	O
risk	O
of	O
severe	O
vitamin	O
D	O
deficiency	O
(	O
25	O
-(	O
OH	O
)	O
D	O
<	O
10	O
ng	O
/	O
ml	O
)	O
was	O
significantly	O
lower	O
among	O
third	O
than	O
first	O
trimester	O
pregnant	O
women	O
(	O
Table	O
5	O
).	O

In	O
addition	O
risk	O
of	O
severe	O
vitamin	O
D	O
deficiency	O
increased	O
for	O
women	O
who	O
reported	O
not	O
taking	O
vitamin	O
D	O
containing	O
multivitamins	O
,	O
who	O
were	O
of	O
non	O
Caucasian	O
origin	O
and	O
who	O
reported	O
smoking	O
during	O
pregnancy	O
.	O

On	O
the	O
other	O
hand	O
risk	O
of	O
severe	O
vitamin	O
D	O
deficiency	O
decreased	O
for	O
women	O
who	O
reported	O
alcohol	O
consumption	O
during	O
pregnancy	O
.	O

Interestingly	O
,	O
risk	O
of	O
severe	O
vitamin	O
D	O
deficiency	O
decreased	O
with	O
more	O
frequent	O
use	O
of	O
sunscreen	O
lotion	O
and	O
increased	O
for	O
women	O
who	O
reported	O
preference	O
for	O
shadow	O
(	O
Table	O
5	O
).	O

Exposure	O
to	O
the	O
sun	O
during	O
week	O
and	O
weekend	O
days	O
,	O
and	O
consumption	O
of	O
milk	O
and	O
dairy	O
products	O
were	O
not	O
associated	O
with	O
either	O
severe	O
or	O
normal	O
vitamin	O
D	O
deficiency	O
.	O
10	O
.	O
1371	O
/	O
journal	O
.	O
pone	O
.	O
0043868	O
.	O
t005	O
Caption	O
(	O
TABLE	O
-	O
WRAP	O
):	O
TABLE	O
5	O
Risk	O
of	O
severe	O
vitamin	O
D	O
deficiency	O
during	O
pregnancy	O
in	O
Belgium	O
(	O
25	O
-(	O
OH	O
)	O
D	O
<	O
10	O
ng	O
/	O
ml	O
)	O
(	O
n	O
=	O
1121	O
),	O
results	O
of	O
multiple	O
logistic	O
regressions	O
.	O
N	O
of	O
subjectsN	O
of	O
severe	O
deficient	O
casesOR	O
[	O
95	O
%	O
Conf	O
Interval	O
]	O
p	O
Trimester	O
of	O
pregnancy	O
first	O
trimester633741	O
.	O
000third	O
trimester665841	O
.	O
7511	O
.	O
1282	O
.	O
7190	O
.	O
013	O
Season	O
Winter470891	O
.	O
000Spring384350	O
.	O
2830	O
.	O
1680	O
.	O
477	O
<	O
0	O
.	O
001Summer930Autumn351340	O
.	O
3240	O
.	O
1910	O
.	O
551	O
<	O
0	O
.	O
001	O
Smoking	O
Yes219331	O
.	O
000No10781250	O
.	O
4630	O
.	O
2680	O
.	O
8010	O
.	O
006	O
Alcohol	O
consumption	O
Yes264131	O
.	O
000No10221432	O
.	O
3701	O
.	O
1624	O
.	O
8340	O
.	O
018	O
Use	O
of	O
multivitamins	O
containing	O
vitamin	O
D	O
No4891151	O
.	O
000Yes809430	O
.	O
1210	O
.	O
0750	O
.	O
193	O
<	O
0	O
.	O
001	O
Ethnicity	O
Caucasian	O
,	O
white955691	O
.	O
000Asiatic3396	O
.	O
6562	O
.	O
41318	O
.	O
359	O
<	O
0	O
.	O
001African	O
,	O
black64132	O
.	O
6051	O
.	O
1515	O
.	O
8960	O
.	O
022African	O
,	O
north174638	O
.	O
1744	O
.	O
71214	O
.	O
177	O
<	O
0	O
.	O
001	O
Frequency	O
fatty	O
fish	O
consumption	O
Never192181	O
.	O
000Less	O
than	O
once	O
a	O
month188242	O
.	O
2051	O
.	O
0104	O
.	O
8160	O
.	O
0471	O
–	O
3	O
days	O
a	O
month498591	O
.	O
4810	O
.	O
7552	O
.	O
9040	O
.	O
2541	O
day	O
per	O
week291351	O
.	O
3910	O
.	O
6712	O
.	O
8850	O
.	O
3752	O
–	O
4	O
days	O
a	O
week	O
or	O
more	O
frequent128221	O
.	O
5130	O
.	O
6593	O
.	O
4720	O
.	O
328	O
Use	O
of	O
sunscreen	O
lotion	O
Yes	O
,	O
much	O
of	O
the	O
time644361	O
.	O
000Yes	O
,	O
sometimes281342	O
.	O
0871	O
.	O
1713	O
.	O
7220	O
.	O
013No368883	O
.	O
2631	O
.	O
9355	O
.	O
504	O
<	O
0	O
.	O
001	O
Preference	O
sun	O
/	O
shadow	O
Sun476531	O
.	O
000Shadow497701	O
.	O
9831	O
.	O
2253	O
.	O
2100	O
.	O
005Does	O
not	O
matter321351	O
.	O
2060	O
.	O
6912	O
.	O
1040	O
.	O
510	O
OR	O
Odds	O
ratio	O
.	O

Discussion	O
Despite	O
the	O
fact	O
that	O
more	O
than	O
60	O
%	O
of	O
the	O
pregnant	O
women	O
reported	O
taking	O
multivitamins	O
containing	O
vitamin	O
D	O
during	O
pregnancy	O
,	O
nearly	O
45	O
%	O
of	O
the	O
women	O
were	O
vitamin	O
D	O
deficient	O
(	O
25	O
-(	O
OH	O
)	O
D	O
<	O
20	O
ng	O
/	O
ml	O
).	O

The	O
prevalence	O
of	O
severe	O
vitamin	O
D	O
deficiency	O
was	O
12	O
%	O
during	O
the	O
first	O
trimester	O
and	O
was	O
slightly	O
higher	O
,	O
13	O
%,	O
during	O
the	O
third	O
trimester	O
of	O
pregnancy	O
.	O

A	O
previous	O
small	O
study	O
in	O
Brussels	O
suggested	O
that	O
the	O
prevalence	O
of	O
vitamin	O
D	O
deficiency	O
was	O
high	O
among	O
the	O
adult	O
population	O
and	O
that	O
immigrants	O
were	O
at	O
greater	O
risk	O
of	O
vitamin	O
D	O
deficiency	O
[	O
32	O
].	O

Other	O
small	O
-	O
scale	O
studies	O
in	O
Belgium	O
showed	O
a	O
high	O
prevalence	O
of	O
vitamin	O
D	O
deficiency	O
among	O
Belgian	O
postmenopausal	O
osteoporotic	O
women	O
[	O
33	O
]	O
and	O
elderly	O
[	O
34	O
].	O

However	O
,	O
the	O
present	O
study	O
is	O
the	O
first	O
national	O
survey	O
on	O
vitamin	O
D	O
status	O
among	O
pregnant	O
women	O
in	O
Belgium	O
.	O

The	O
high	O
prevalence	O
of	O
vitamin	O
D	O
deficiency	O
in	O
Belgium	O
stems	O
from	O
the	O
fact	O
that	O
the	O
contribution	O
of	O
dietary	O
sources	O
to	O
the	O
vitamin	O
D	O
status	O
is	O
negligible	O
as	O
was	O
shown	O
by	O
the	O
Flemish	O
food	O
consumption	O
survey	O
among	O
preschoolers	O
which	O
estimated	O
the	O
mean	O
vitamin	O
D	O
intake	O
at	O
only	O
2	O
µg	O
/	O
day	O
[	O
35	O
].	O

The	O
prevalence	O
of	O
vitamin	O
deficiency	O
(	O
25	O
-(	O
OH	O
)	O
D	O
<	O
20	O
ng	O
/	O
ml	O
)	O
is	O
high	O
in	O
many	O
European	O
countries	O
[	O
36	O
]–[	O
43	O
]	O
and	O
some	O
studies	O
suggest	O
that	O
pregnant	O
women	O
in	O
Europe	O
are	O
also	O
at	O
high	O
risk	O
of	O
vitamin	O
D	O
deficiency	O
[	O
29	O
],[	O
30	O
].	O

Similarly	O
as	O
in	O
our	O
pregnant	O
women	O
population	O
,	O
in	O
the	O
adult	O
population	O
the	O
risk	O
of	O
vitamin	O
D	O
deficiency	O
was	O
higher	O
in	O
winter	O
than	O
in	O
summer	O
and	O
increased	O
with	O
BMI	O
[	O
36	O
],[	O
37	O
],[	O
44	O
],[	O
45	O
],[	O
46	O
].	O

The	O
variations	O
of	O
25	O
-(	O
OH	O
)	O
D	O
concentration	O
with	O
seasons	O
reflect	O
the	O
changes	O
in	O
UVB	O
exposure	O
,	O
one	O
of	O
the	O
main	O
determinants	O
of	O
vitamin	O
D	O
status	O
in	O
many	O
European	O
countries	O
.	O

The	O
association	O
of	O
vitamin	O
D	O
status	O
with	O
BMI	O
has	O
been	O
attributed	O
to	O
an	O
excessive	O
storage	O
of	O
vitamin	O
D	O
in	O
fat	O
tissue	O
decreasing	O
thereby	O
serum	O
concentrations	O
[	O
47	O
].	O

Ethnicity	O
was	O
also	O
a	O
major	O
determinant	O
of	O
vitamin	O
D	O
status	O
in	O
the	O
present	O
study	O
,	O
as	O
previously	O
reported	O
in	O
the	O
adult	O
population	O
[	O
32	O
]	O
and	O
in	O
pregnant	O
women	O
[	O
29	O
],[	O
48	O
],[	O
49	O
].	O

In	O
Belgium	O
,	O
pregnant	O
women	O
of	O
different	O
ethnic	O
origins	O
had	O
substantially	O
lower	O
vitamin	O
D	O
concentrations	O
than	O
Caucasian	O
women	O
and	O
were	O
vitamin	O
D	O
deficient	O
all	O
year	O
long	O
except	O
during	O
summer	O
for	O
third	O
trimester	O
women	O
.	O

In	O
addition	O
education	O
level	O
was	O
associated	O
with	O
vitamin	O
D	O
status	O
in	O
our	O
pregnant	O
women	O
population	O
.	O

Smoking	O
increased	O
the	O
risk	O
of	O
both	O
vitamin	O
D	O
deficiency	O
and	O
severe	O
vitamin	O
D	O
deficiency	O
;	O
the	O
mechanism	O
for	O
this	O
appears	O
to	O
be	O
unclear	O
[	O
50	O
].	O

Interestingly	O
the	O
risk	O
for	O
severe	O
vitamin	O
D	O
deficiency	O
was	O
lower	O
among	O
women	O
who	O
reported	O
alcohol	O
consumption	O
during	O
pregnancy	O
.	O

The	O
latter	O
has	O
been	O
found	O
also	O
among	O
Korean	O
men	O
[	O
51	O
].	O

Variables	O
influencing	O
the	O
formation	O
of	O
previtamin	O
D3	O
in	O
the	O
skin	O
include	O
skin	O
pigmentation	O
and	O
intensity	O
of	O
the	O
solar	O
UV	O
light	O
[	O
52	O
]–[	O
55	O
].	O

In	O
summer	O
,	O
light	O
-	O
skinned	O
people	O
who	O
spend	O
at	O
least	O
15	O
minutes	O
outside	O
during	O
the	O
day	O
with	O
their	O
hands	O
and	O
face	O
exposed	O
will	O
have	O
adequate	O
vitamin	O
D	O
levels	O
.	O

Sunscreen	O
lotions	O
prevent	O
UV	O
radiation	O
from	O
reaching	O
the	O
skin	O
and	O
might	O
therefore	B
reduce	O
the	O
skin	O
’	O
s	O
vitamin	O
D	O
production	O
[	O
56	O
].	O

However	O
,	O
another	O
study	O
found	O
this	O
effect	O
to	O
be	O
only	O
minor	O
[	O
57	O
].	O

In	O
Belgium	O
,	O
pregnant	O
women	O
who	O
reported	O
going	O
on	O
holidays	O
to	O
sunny	O
climates	O
had	O
a	O
lower	O
risk	O
of	O
vitamin	O
D	O
deficiency	O
and	O
women	O
who	O
reported	O
using	O
sunscreen	O
lotion	O
had	O
a	O
lower	O
risk	O
of	O
severe	O
vitamin	O
D	O
deficiency	O
.	O

The	O
latter	O
is	O
possibly	O
due	O
to	O
the	O
fact	O
that	O
women	O
using	O
sunscreen	O
lotion	O
are	O
more	O
often	O
exposed	O
to	O
the	O
sun	O
.	O

Women	O
who	O
reported	O
a	O
preference	O
for	O
shadow	O
had	O
a	O
higher	O
risk	O
of	O
severe	O
vitamin	O
D	O
deficiency	O
in	O
our	O
study	O
.	O

The	O
adequate	O
intake	O
of	O
vitamin	O
D	O
during	O
pregnancy	O
and	O
lactation	O
is	O
unknown	O
,	O
although	O
it	O
appears	O
to	O
be	O
greater	O
than	O
the	O
current	O
dietary	O
recommendations	O
of	O
400	O
IU	O
/	O
d	O
or	O
10	O
µg	O
/	O
d	O
[	O
58	O
].	O

Some	O
studies	O
suggest	O
that	O
the	O
dietary	O
requirement	O
during	O
pregnancy	O
and	O
lactation	O
may	O
be	O
as	O
high	O
as	O
6000	O
IU	O
/	O
d	O
[	O
59	O
]	O
and	O
recognize	O
that	O
at	B
least	I
1500	O
–	O
2000	O
IU	O
/	O
d	O
of	O
vitamin	O
D	O
may	O
be	O
needed	O
in	O
order	O
to	O
maintain	O
a	O
blood	O
level	O
of	O
25	O
(	O
OH	O
)	O
D	O
above	O
30	O
ng	O
/	O
ml	O
[	O
24	O
].	O

As	O
those	O
authors	O
recognize	O
that	O
the	O
evidence	O
to	O
propose	O
such	O
intakes	O
is	O
scarce	O
and	O
as	O
long	O
as	O
the	O
health	O
benefits	O
of	O
having	O
serum	O
25	O
(	O
OH	O
)	O
D	O
levels	O
higher	O
than	O
30	O
ng	O
/	O
ml	O
are	O
not	O
clearly	O
established	O
particularly	O
in	O
pregnant	O
women	O
,	O
the	O
Belgian	O
Superior	O
Health	O
council	O
still	O
recommends	O
a	O
vitamin	O
D	O
supplement	O
of	O
20	O
µg	O
/	O
day	O
or	O
800	O
IU	O
during	O
pregnancy	O
[	O
58	O
].	O

However	O
,	O
the	O
vitamin	O
D	O
content	O
of	O
multivitamins	O
for	O
pregnant	O
women	O
in	O
Belgium	O
is	O
only	O
400	O
IU	O
indicating	O
even	O
this	O
recommendation	O
is	O
not	O
followed	O
as	O
pregnant	O
women	O
only	O
take	O
one	O
multivitamin	O
pill	O
a	O
day	O
.	O

In	O
the	O
absence	O
of	O
survey	O
data	O
from	O
other	O
European	O
countries	O
,	O
we	O
suspect	B
that	O
the	O
prevalence	O
of	O
vitamin	O
D	O
deficiency	O
in	O
Belgium	O
likely	B
reflects	O
the	O
situation	O
in	O
other	O
Western	O
European	O
countries	O
.	O

This	O
assumption	O
is	O
based	O
on	O
the	O
fact	O
that	O
the	O
main	O
risk	O
factors	O
associated	O
with	O
vitamin	O
D	O
deficiency	O
(	O
sun	O
exposure	O
and	O
/	O
or	O
ethnicity	O
)	O
are	O
common	O
to	O
many	O
European	O
countries	O
.	O

In	O
addition	O
to	O
the	O
uncertainty	O
concerning	O
the	O
optimal	O
vitamin	O
D	O
intakes	O
preventing	O
vitamin	O
D	O
deficiency	O
,	O
there	O
exists	O
also	O
a	O
lack	O
of	O
recommendations	O
to	O
treat	O
vitamin	O
D	O
deficient	O
pregnant	O
women	O
.	O

Even	O
in	O
the	O
last	O
published	O
guidelines	O
the	O
treatment	O
of	O
vitamin	O
D	O
deficient	O
women	O
is	O
not	O
specifically	O
discussed	O
[	O
24	O
].	O

The	O
uncovering	O
of	O
the	O
magnitude	O
of	O
vitamin	O
D	O
deficiency	O
in	O
pregnant	O
women	O
in	O
Belgium	O
(	O
and	O
Western	O
Europe	O
)	O
should	O
be	O
translated	O
into	O
new	O
research	O
in	O
order	O
to	O
fill	O
the	O
huge	O
knowledge	O
gap	O
concerning	O
the	O
adequate	O
amount	O
of	O
vitamin	O
D	O
to	O
prevent	O
and	O
treat	O
vitamin	O
D	O
deficient	O
pregnant	O
women	O
.	O

In	O
addition	O
,	O
an	O
increasing	O
number	O
of	O
studies	O
suggest	O
that	O
gestational	O
vitamin	O
D	O
deficiency	O
is	O
associated	O
with	O
multiple	O
adverse	O
health	O
outcomes	O
in	O
mothers	O
and	O
children	O
[	O
16	O
]–[	O
22	O
].	O

Therefore	B
,	O
there	O
is	O
an	O
urgent	O
need	O
of	O
randomised	O
controlled	O
trials	O
of	O
vitamin	O
D	O
supplementation	O
to	O
investigate	O
the	O
maternal	O
and	O
neonatal	O
health	O
benefits	O
of	O
correcting	O
vitamin	O
D	O
deficiency	O
during	O
pregnancy	O
[	O
24	O
].	O

Given	O
the	O
high	O
prevalence	O
of	O
vitamin	O
D	O
deficiency	O
in	O
pregnant	O
women	O
in	O
Belgium	O
and	O
probably	B
in	O
many	O
European	O
countries	O
,	O
a	O
vitamin	O
D	O
nutrition	O
policy	O
is	O
needed	O
at	O
the	O
country	O
and	O
European	O
level	O
.	O

The	O
current	O
vitamin	O
D	O
recommendations	O
for	O
pregnant	O
women	O
are	O
clearly	O
insufficient	O
to	O
prevent	O
and	O
even	O
more	O
to	O
treat	O
vitamin	O
D	O
deficient	O
pregnant	O
women	O
.	O

Until	O
the	O
adequate	O
treatment	O
of	O
vitamin	O
D	O
deficient	O
pregnant	O
women	O
is	O
established	O
,	O
a	O
safe	O
approach	O
may	O
be	O
to	O
correct	O
vitamin	O
D	O
deficiency	O
by	O
targeting	O
pregnant	O
women	O
at	O
high	O
risk	O
of	O
severe	O
vitamin	O
D	O
deficiency	O
.	O

In	O
addition	O
the	O
current	O
vitamin	O
D	O
content	O
of	O
multivitamins	O
for	O
pregnancy	O
,	O
400	O
IU	O
,	O
do	O
not	O
even	O
comply	O
with	O
the	O
current	O
Belgian	O
recommendations	O
of	O
800	O
IU	O
per	O
day	O
,	O
therefore	B
a	O
prudent	O
step	O
should	O
at	B
least	I
be	O
to	O
increase	O
the	O
vitamin	O
D	O
content	O
in	O
multivitamins	O
for	O
pregnant	O
women	O
to	O
800	O
IU	O
.	O

In	O
conclusion	O
,	O
despite	O
that	O
more	O
than	O
60	O
%	O
of	O
the	O
pregnant	O
women	O
reported	O
taking	O
multivitamins	O
containing	O
vitamin	O
D	O
,	O
vitamin	O
D	O
deficiency	O
is	O
highly	O
prevalent	O
among	O
pregnant	O
women	O
in	O
Belgium	O
and	O
up	O
to	O
12	O
%	O
of	O
pregnant	O
women	O
are	O
severely	O
vitamin	O
D	O
deficient	O
.	O

A	O
targeted	O
screening	O
strategy	O
to	O
detect	O
and	O
treat	O
women	O
at	O
high	O
risk	O
of	O
severe	O
vitamin	O
D	O
deficiency	O
is	O
clearly	O
needed	O
in	O
Belgium	O
and	O
in	O
other	O
European	O
countries	O
.	O

While	O
several	O
observational	O
studies	O
point	O
to	O
correlations	O
between	O
vitamin	O
D	O
insufficiency	O
and	O
maternal	O
and	O
neonatal	O
ill	O
health	O
,	O
experimental	O
evidence	O
from	O
supplementation	O
clinical	O
trials	O
is	O
needed	O
to	O
inform	O
health	O
policy	O
.	O

PubMed	O
Central	O
:	O

Characterization	O
of	O
Two	O
ENU	O
-	O
Induced	O
Mutations	O
Affecting	O
Mouse	O
Skeletal	O
Morphology	O
Abstract	O
Using	O
the	O
N	O
-	O
ethyl	O
-	O
N	O
-	O
nitrosourea	O
(	O
ENU	O
)	O
mutagenesis	O
screen	O
,	O
we	O
have	O
identified	O
two	O
skeletal	O
morphology	O
mutants	O
,	O
Skm1	O
and	O
Skm2	O
.	O

Positional	O
cloning	O
and	O
candidate	O
gene	O
sequencing	O
localized	O
the	O
causative	O
point	O
mutations	O
within	O
the	O
genes	O
coding	O
for	O
natriuretic	O
peptide	O
receptor	O
C	O
(	O
NPR	O
-	O
C	O
)	O
and	O
filamin	O
b	O
(	O
FLNB	O
),	O
respectively	O
.	O

Mice	O
that	O
carry	O
a	O
mutation	O
in	O
Npr3	O
exhibit	O
a	O
skeletal	O
overgrowth	O
phenotype	O
,	O
resulting	O
in	O
an	O
elongated	O
body	O
and	O
kyphosis	O
.	O

Skm2	O
mice	O
,	O
carrying	O
a	O
mutation	O
in	O
Flnb	O
,	O
present	O
with	O
scoliosis	O
and	O
lordosis	O
.	O

These	O
mutant	O
mice	O
will	O
serve	O
as	O
useful	O
models	O
for	O
the	O
study	O
of	O
vertebral	O
malformations	O
.	O

Vertebral	O
malformations	O
that	O
cause	O
kyphosis	O
or	O
scoliosis	O
are	O
an	O
important	O
health	O
problem	O
that	O
can	O
result	O
in	O
disability	O
and	O
suffering	O
attributable	B
to	O
both	O
physical	O
pain	O
and	O
psychological	O
distress	O
from	O
the	O
disfigurement	O
.	O

Congenital	O
spine	O
deformities	O
occur	O
with	O
an	O
approximate	O
frequency	O
of	O
0	O
.	O
5	O
–	O
1	O
per	O
1000	O
live	O
births	O
(	O
Sparrow	O
et	O
al	O
.	O

2011	O
)	O
and	O
may	O
arise	O
sporadically	O
or	O
as	O
the	O
result	O
of	O
an	O
underlying	O
heritable	O
abnormality	O
in	O
genes	O
that	O
contribute	O
to	O
vertebral	O
development	O
.	O

Although	O
there	O
is	O
evidence	O
that	O
the	O
embryonic	O
environment	O
,	O
including	O
oxygen	O
tension	O
,	O
exposure	O
to	O
teratogens	O
,	O
and	O
prenatal	O
vitamin	O
deficiencies	O
,	O
can	O
all	O
contribute	O
to	O
congenital	O
defects	O
(	O
Hensinger	O
2009	O
),	O
the	O
genetic	O
contribution	O
to	O
the	O
pathogenesis	O
of	O
vertebral	O
malformation	O
syndromes	O
is	O
less	O
understood	O
.	O

This	O
is	O
largely	O
attributable	B
to	O
the	O
fact	O
that	O
,	O
in	O
humans	O
,	O
vertebral	O
malformation	O
syndromes	O
often	B
represent	B
a	O
sporadic	O
occurrence	O
within	O
a	O
family	O
and	O
traditional	O
linkage	O
analysis	O
to	O
identify	O
the	O
chromosomal	O
regions	O
responsible	O
for	O
these	O
defects	O
is	O
often	O
not	O
possible	O
.	O

As	O
a	O
result	O
,	O
the	O
genetic	O
etiology	O
of	O
many	O
congenital	O
vertebral	O
malformation	O
syndromes	O
remains	O
unknown	O
.	O

However	O
,	O
familial	O
occurrences	O
(	O
Miller	O
et	O
al	O
.	O

2006	O
;	O
Wynne	O
-	O
Davies	O
1975	O
)	O
and	O
twin	O
studies	O
(	O
Kesling	O
and	O
Reinker	O
1997	O
)	O
have	O
shown	O
that	O
the	O
cause	O
of	O
spinal	O
deformities	O
,	O
including	O
scoliosis	O
and	O
kyphosis	O
,	O
can	O
have	O
a	O
genetic	O
component	O
.	O

Using	O
model	O
organisms	O
and	O
using	O
a	O
phenotype	O
-	O
driven	O
approach	O
to	O
identify	O
causal	O
genes	O
underlying	O
spinal	O
deformities	O
can	O
overcome	O
some	O
of	O
the	O
limitations	O
to	O
studying	O
the	O
genetic	O
basis	O
of	O
these	O
syndromes	O
.	O

Mouse	O
models	O
have	O
contributed	O
greatly	O
to	O
our	O
understanding	O
of	O
molecular	O
embryonic	O
development	O
,	O
including	O
vertebral	O
formation	O
and	O
segmentation	O
(	O
Sparrow	O
et	O
al	O
.	O

2011	O
),	O
and	O
the	O
use	O
of	O
forward	O
genetics	O
screens	O
has	O
been	O
shown	O
to	O
be	O
a	O
valuable	O
tool	O
for	O
the	O
discovery	O
of	O
mutations	O
that	O
are	O
important	O
during	O
skeletogenesis	O
in	O
the	O
mouse	O
(	O
Mohan	O
et	O
al	O
.	O

2008	O
).	O

N	O
-	O
ethyl	O
-	O
N	O
-	O
nitrosourea	O
(	O
ENU	O
)	O
is	O
a	O
chemical	O
mutagen	O
that	O
introduces	O
random	O
point	O
mutations	O
into	O
the	O
mouse	O
genome	O
that	O
,	O
together	O
with	O
positional	O
cloning	O
or	O
exome	O
sequencing	O
,	O
permits	B
the	O
identification	O
of	O
phenotype	O
–	O
genotype	O
relationships	O
in	O
an	O
unbiased	O
manner	O
(	O
Probst	O
and	O
Justice	O
2010	O
).	O

In	O
this	O
article	O
,	O
we	O
report	O
the	O
identification	O
of	O
two	O
mutations	O
affecting	O
skeletal	O
morphology	O
,	O
skeletal	O
morphology	O
1	O
(	O
skm1	O
)	O
and	O
skeletal	O
morphology	O
2	O
(	O
Skm2	O
),	O
in	O
a	O
recessive	O
ENU	O
mutagenesis	O
screen	O
for	O
infectious	O
disease	O
susceptibility	O
.	O

Homozygous	O
Skm1	O
mice	O
show	O
kyphosis	O
or	O
an	O
elongated	O
torso	O
and	O
homozygous	O
Skm2	O
mice	O
exhibit	O
shortened	O
stature	O
,	O
scoliosis	O
,	O
and	O
lordosis	O
.	O

We	O
show	O
that	O
Skm1	O
and	O
Skm2	O
mice	O
carry	O
a	O
missense	O
mutation	O
in	O
the	O
Npr3	O
and	O
Flnb	O
genes	O
,	O
respectively	O
.	O

These	O
mutants	O
provide	B
important	O
tools	O
for	O
the	O
study	O
of	O
skeletal	O
malformation	O
disorders	O
that	O
result	O
from	O
the	O
loss	O
of	O
a	O
functional	O
Npr3	O
or	O
Flnb	O
gene	O
.	O

Materials	O
and	O
Methods	O
Mice	O
The	O
129S1	O
/	O
SvImJ	O
(	O
129S1	O
)	O
males	O
,	O
129X1	O
/	O
SvJ	O
(	O
129X1	O
)	O
females	O
,	O
and	O
DBA	O
/	O
2J	O
mice	O
were	O
purchased	O
from	O
the	O
Jackson	O
Laboratory	O
(	O
Bar	O
Harbor	O
,	O
ME	O
)	O
at	O
age	O
6	O
wk	O
.	O

Mice	O
were	O
housed	O
at	O
the	O
McGill	O
University	O
Life	O
Sciences	O
Centre	O
Animal	O
Facility	O
in	O
accordance	O
with	O
the	O
guidelines	O
specified	O
by	O
the	O
Canadian	O
Council	O
on	O
Animal	O
Care	O
.	O

The	O
Animal	O
Use	O
Protocol	O
was	O
approved	O
by	O
the	O
McGill	O
University	O
Animal	O
Care	O
Committee	O
.	O

ENU	O
mutagenesis	O
Male	O
129S1	O
mice	O
received	O
one	O
intraperitoneal	O
injection	O
of	O
ENU	O
at	O
a	O
dose	O
of	O
150	O
mg	O
/	O
kg	O
at	O
age	O
8	O
–	O
12	O
wk	O
.	O

Infertility	O
of	O
the	O
mutagenized	O
mice	O
was	O
confirmed	O
after	O
treatment	O
and	O
mice	O
were	O
allowed	O
8	O
–	O
12	O
wk	O
to	O
recover	O
fertility	O
and	O
then	O
were	O
bred	O
to	O
129X1	O
females	O
.	O

Mice	O
were	O
outcrossed	O
to	O
DBA	O
/	O
2J	O
at	O
the	O
first	O
generation	O
(	O
G1	O
)	O
to	O
facilitate	O
mapping	O
using	O
a	O
panel	O
of	O
markers	O
polymorphic	O
between	O
129S1	O
and	O
DBA	O
/	O
2J	O
strains	O
,	O
and	O
second	O
generation	O
(	O
G2	O
)	O
progeny	O
were	O
backcrossed	O
to	O
G1	O
mice	O
to	O
generate	O
homozygosity	O
.	O

Mice	O
with	O
visible	O
abnormalities	O
in	O
the	O
third	O
generation	O
(	O
G3	O
)	O
were	O
kept	O
for	O
further	O
analysis	O
.	O

Genotyping	O
/	O
mapping	O
DNA	O
was	O
isolated	O
from	O
tail	O
biopsy	O
specimens	O
using	O
overnight	O
digestion	O
in	O
a	O
lysis	O
buffer	O
containing	O
proteinase	O
K	O
(	O
10	O
nM	O
Tris	O
,	O
2	O
mM	O
EDTA	O
,	O
0	O
.	O
5	O
%	O
SDS	O
,	O
0	O
.	O
4	O
M	O
NaCl	O
,	O
and	O
0	O
.	O
2	O
mg	O
/	O
ml	O
proteinase	O
K	O
),	O
followed	O
by	O
a	O
phenol	O
/	O
chloroform	O
extraction	O
.	O

The	O
genome	O
scan	O
was	O
conducted	O
using	O
an	O
Illumina	O
Mouse	O
Medium	O
density	O
SNP	O
panel	O
(	O
Genetic	O
Analysis	O
Facility	O
,	O
Centre	O
for	O
Applied	O
Genomics	O
,	O
Hospital	O
for	O
Sick	O
Children	O
,	O
Toronto	O
,	O
ON	O
).	O

Chromosome	O
distances	O
were	O
established	O
using	O
NCBI	O
build	O
37	O
.	O
1	O
.	O

Genetic	O
analysis	O
J	O
/	O
QTL	O
software	O
(	O
http	O
://	O
churchill	O
.	O
jax	O
.	O
org	O
/	O
software	O
/	O
jqtl	O
.	O
shtml	O
)	O
was	O
used	O
to	O
calculate	O
LOD	O
scores	O
for	O
the	O
whole	O
-	O
genome	O
SNP	O
analysis	O
.	O

The	O
software	O
assembled	O
a	O
genetic	O
map	O
from	O
the	O
SNP	O
data	O
using	O
the	O
settings	O
of	O
binary	O
model	O
,	O
expectation	O
-	O
maximum	O
algorithm	O
,	O
and	O
1000	O
permutations	O
.	O

Sequence	O
analysis	O
Exons	O
of	O
candidate	O
genes	O
were	O
sequenced	O
for	O
wild	O
-	O
type	O
and	O
mutant	O
mice	O
,	O
as	O
well	O
as	O
parental	O
controls	O
,	O
at	O
the	O
McGill	O
University	O
and	O
Génome	O
Québec	O
Innovation	O
Centre	O
.	O

X	O
-	O
ray	O
measurement	O
Mice	O
(	O
age	O
approximately	O
7	O
wk	O
)	O
were	O
anesthetized	O
using	O
a	O
combination	O
of	O
100	O
mg	O
/	O
kg	O
ketamine	O
HCl	O
,	O
10	O
mg	O
/	O
kg	O
xyaline	O
HCl	O
,	O
and	O
3	O
mg	O
/	O
kg	O
acepromazine	O
administered	O
by	O
subcutaneous	O
injection	O
and	O
radiographs	O
were	O
performed	O
using	O
a	O
Faxitron	O
(	O
Hewlett	O
Packard	O
,	O
Palo	O
Alto	O
,	O
CA	O
).	O

Results	O
Identification	O
of	O
the	O
Skm	O
mutants	O
During	O
our	O
ENU	O
mutagenesis	O
screen	O
for	O
infectious	O
disease	O
susceptibility	O
,	O
we	O
identified	O
two	O
mutations	O
that	O
contribute	O
to	O
skeletal	O
malformations	O
in	O
mice	O
.	O

In	O
our	O
pipeline	O
,	O
ENU	O
-	O
mutagenized	O
mice	O
were	O
bred	O
to	O
homozygosity	O
in	O
a	O
three	O
-	O
generation	O
breeding	O
scheme	O
(	O
Figure	O
1A	O
),	O
and	O
although	O
G3	O
progeny	O
were	O
to	O
be	O
screened	O
for	O
susceptibility	O
to	O
bacterial	O
infection	O
,	O
mice	O
were	O
initially	O
examined	O
for	O
gross	O
morphological	O
defects	O
.	O

Here	O
,	O
we	O
report	O
the	O
identification	O
of	O
two	O
pedigrees	O
based	O
on	O
their	O
skeletal	O
disfigurement	O
,	O
Skm1	O
and	O
Skm2	O
.	O

Caption	O
(	O
FIG	O
):	O
FIGURE	O
1	O
N	O
-	O
ethyl	O
-	O
N	O
-	O
nitrosourea	O
(	O
ENU	O
)	O
breeding	O
scheme	O
and	O
visible	O
morphology	O
of	O
skeletal	O
morphology	O
mutants	O
(	O
Skm	O
).	O

(	O
A	O
)	O
Schematic	O
representation	O
of	O
the	O
breeding	O
scheme	O
used	O
during	O
the	O
identification	O
of	O
deviant	O
pedigrees	O
.	O

129S1	O
male	O
G0	O
mutagenized	O
mice	O
were	O
crossed	O
to	O
129X1	O
females	O
and	O
the	O
resulting	O
G1	O
males	O
were	O
outcrossed	O
to	O
DBA	O
/	O
2J	O
females	O
to	O
generate	O
G2	O
progeny	O
.	O

Visible	O
skeletal	O
malformations	O
in	O
Skm1	O
(	O
B	O
)	O
mice	O
and	O
Skm2	O
(	O
C	O
)	O
mice	O
.	O

(	O
B	O
)	O
Skm1	O
mice	O
show	O
kyphotic	O
spines	O
and	O
kinked	O
tails	O
(	O
left	O
)	O
and	O
elongated	O
bodies	O
(	O
right	O
).	O

(	O
C	O
)	O
Skm2	O
mice	O
exhibit	O
severe	O
scoliosis	O
and	O
lordosis	O
.	O

Skm1	O
homozygous	O
mutant	O
mice	O
were	O
born	O
with	O
expected	O
Mendelian	O
frequency	O
and	O
were	O
easily	O
distinguished	O
from	O
their	O
wild	O
-	O
type	O
littermates	O
at	O
weaning	O
.	O

Skm1	O
mice	O
were	O
visibly	O
leaner	O
than	O
their	O
littermate	O
controls	O
and	O
presented	O
with	O
either	O
an	O
elongated	O
body	O
or	O
a	O
thoracolumbar	O
kyphosis	O
and	O
a	O
kinked	O
tail	O
(	O
Figure	O
1B	O
).	O

Skm2	O
mice	O
presented	O
a	O
more	O
severe	O
phenotype	O
and	O
were	O
readily	O
identified	O
after	O
birth	O
by	O
a	O
shortened	O
stature	O
,	O
abnormal	O
gait	O
,	O
and	O
severe	O
scoliosis	O
and	O
lordosis	O
(	O
Figure	O
1C	O
).	O

In	O
addition	O
,	O
Skm2	O
mutants	O
were	O
dehydrated	O
and	O
presented	O
with	O
tachypnea	O
,	O
likely	B
as	O
a	O
consequence	B
of	O
thoracic	O
deformities	O
.	O

At	O
weaning	O
,	O
only	O
eight	O
Skm2	O
mutants	O
out	O
of	O
84	O
progeny	O
were	O
identified	O
(	O
9	O
.	O
5	O
%	O
ratio	O
),	O
suggesting	O
embryonic	O
or	O
perinatal	O
mortality	O
.	O

Positional	O
cloning	O
of	O
the	O
Skm	O
mutants	O
The	O
Skm	O
mutations	O
originally	O
generated	O
on	O
a	O
129S1	O
background	O
were	O
segregated	O
on	O
a	O
mixed	O
genetic	O
background	O
of	O
129S1	O
,	O
129X1	O
,	O
and	O
DBA	O
/	O
2J	O
.	O

For	O
mapping	O
,	O
a	O
total	O
of	O
six	O
mice	O
for	O
each	O
of	O
the	O
visible	O
phenotypes	O
were	O
used	O
in	O
a	O
SNP	O
panel	O
with	O
708	O
markers	O
polymorphic	O
between	O
129	O
and	O
DBA	O
/	O
2J	O
strains	O
across	O
the	O
entire	O
genome	O
.	O

The	O
Skm1	O
mutants	O
generated	O
a	O
significant	O
linkage	O
(	O
LOD	O
score	O
=	O
3	O
.	O
612	O
)	O
at	O
chromosome	O
15	O
at	O
marker	O
rs13482455	O
(	O
16	O
.	O
73	O
Mb	O
)	O
(	O
Figure	O
2A	O
,	O
top	O
panel	O
).	O

The	O
region	O
of	O
the	O
mutation	O
was	O
localized	O
to	O
a	O
22	O
.	O
6	O
Mb	O
interval	O
on	O
chromosome	O
15	O
(	O
Figure	O
2B	O
,	O
left	O
panel	O
)	O
containing	O
180	O
known	B
genes	O
.	O

Candidate	O
genes	O
were	O
prioritized	O
based	B
on	I
reported	O
phenotypes	O
and	O
natriuretic	O
peptide	O
receptor	O
C	O
(	O
Npr3	O
)	O
was	O
selected	O
for	O
sequencing	O
based	B
on	I
the	O
existence	O
of	O
seven	O
known	B
alleles	O
(	O
spontaneous	O
and	O
generated	O
)	O
with	O
phenotypes	O
similar	O
to	O
those	O
of	O
the	O
Skm1	O
mice	O
.	O

Sequencing	O
of	O
genomic	O
DNA	O
revealed	O
a	O
T	O
-	O
to	O
-	O
A	O
transversion	O
at	O
nucleotide	O
position	O
1151	O
,	O
causing	O
a	O
mutation	O
from	O
an	O
isoleucine	O
residue	O
to	O
an	O
asparagine	O
residue	O
(	O
I384N	O
)	O
(	O
Figure	O
3A	O
,	O
left	O
panel	O
).	O

The	O
mutation	O
underlying	O
the	O
Skm1	O
phenotype	O
occurred	O
at	O
a	O
residue	O
that	O
is	O
highly	O
conserved	O
across	O
species	O
(	O
Figure	O
3B	O
,	O
upper	O
panel	O
)	O
and	O
mouse	O
strains	O
(	O
data	O
not	O
shown	O
).	O

This	O
mutation	O
occurs	O
within	O
the	O
membrane	O
proximal	O
region	O
of	O
the	O
extracellular	O
domain	O
of	O
the	O
receptor	O
,	O
which	O
is	O
important	O
for	O
ligand	O
binding	O
(	O
Figure	O
3C	O
,	O
upper	O
panel	O
).	O

Caption	O
(	O
FIG	O
):	O
FIGURE	O
2	O
Mapping	O
of	O
the	O
mutant	O
pedigrees	O
.	O

(	O
A	O
)	O
Genome	O
-	O
wide	O
linkage	O
analysis	O
of	O
the	O
visible	O
mutants	O
(	O
Skm1	O
,	O
left	O
panel	O
;	O
Skm2	O
,	O
right	O
panel	O
)	O
was	O
conducted	O
with	O
12	O
animals	O
(	O
6	O
mutant	O
and	O
6	O
normal	O
)	O
using	O
polymorphic	O
markers	O
informative	O
for	O
the	O
129S1	O
and	O
DBA	O
/	O
2J	O
parents	O
.	O

LOD	O
scores	O
above	O
the	O
threshold	O
line	O
were	O
considered	O
significant	O
.	O

(	O
B	O
)	O
Haplotype	O
analysis	O
of	O
the	O
proximal	O
region	O
of	O
chromosome	O
15	O
for	O
Skm1	O
(	O
left	O
panel	O
)	O
and	O
of	O
chromosome	O
14	O
for	O
Skm2	O
(	O
right	O
panel	O
).	O

Positions	O
of	O
the	O
markers	O
(	O
Mb	O
)	O
are	O
relative	O
to	O
the	O
centromere	O
.	O

Caption	O
(	O
FIG	O
):	O
FIGURE	O
3	O
Identification	O
of	O
mutations	O
underlying	O
skeletal	O
morphology	O
mutant	O
1	O
(	O
Skm1	O
)	O
and	O
skeletal	O
morphology	O
mutant	O
2	O
(	O
Skm2	O
).	O

(	O
A	O
)	O
Genomic	O
DNA	O
sequence	O
chromatograms	O
from	O
normal	O
(	O
upper	O
)	O
and	O
mutant	O
(	O
lower	O
)	O
Skm1	O
and	O
Skm2	O
mice	O
(	O
left	O
panel	O
and	O
right	O
panel	O
,	O
respectively	O
).	O

The	O
location	O
of	O
the	O
mutation	O
is	O
indicated	O
by	O
the	O
arrowhead	O
.	O

(	O
B	O
)	O
Alignment	O
of	O
the	O
amino	O
acid	O
sequence	O
for	O
NPR3	O
(	O
top	O
)	O
and	O
FLNB	O
(	O
bottom	O
)	O
orthologs	O
.	O

The	O
location	O
of	O
the	O
mutation	O
is	O
indicated	O
by	O
shading	O
.	O

(	O
C	O
)	O
Schematic	O
representation	O
of	O
NPR3	O
(	O
top	O
)	O
and	O
FLNB	O
(	O
bottom	O
).	O
The	O
arrows	O
indicate	O
location	O
of	O
Skm	O
mutations	O
(	O
black	O
)	O
and	O
other	O
reported	O
mutations	O
(	O
gray	O
).	O

NPR3	O
contains	O
an	O
extracellular	O
domain	O
(	O
ECD	O
),	O
transmembrane	O
(	O
TM	O
)	O
domain	O
,	O
and	O
cytoplasmic	O
domain	O
(	O
CD	O
).	O

FLNB	O
comprises	O
an	O
actin	O
-	O
binding	O
domain	O
(	O
ABD	O
)	O
containing	O
two	O
calponin	O
homology	O
(	O
CH	O
)	O
domains	O
at	O
the	O
amino	O
terminus	O
,	O
followed	O
by	O
24	O
filamin	O
repeat	O
domains	O
that	O
are	O
separated	O
by	O
two	O
hinge	O
(	O
1H	O
-	O
2	O
)	O
regions	O
.	O

The	O
Skm2	O
mutants	O
generated	O
a	O
significant	O
linkage	O
(	O
LOD	O
score	O
=	O
3	O
.	O
612	O
)	O
at	O
chromosome	O
14	O
at	O
marker	O
rs3687889	O
(	O
19	O
.	O
69	O
Mb	O
)	O
(	O
Figure	O
2A	O
,	O
bottom	O
panel	O
).	O

Genotyping	O
of	O
120	O
mice	O
,	O
including	O
10	O
mice	O
with	O
a	O
deviant	O
phenotype	O
,	O
confined	B
the	O
mutation	O
to	O
a	O
region	O
of	O
24	O
.	O
6	O
Mb	O
on	O
chromosome	O
14	O
(	O
Figure	O
2B	O
,	O
right	O
panel	O
),	O
containing	O
394	O
known	B
/	O
predicted	O
genes	O
and	O
3	O
genes	O
with	O
the	O
associated	O
mouse	O
phenotype	O
of	O
kyphosis	O
[	O
Ataxin	O
7	O
,	O
Topoisomerase	O
(	O
DNA	O
)	O
II	O
beta	O
,	O
and	O
Filamin	O
b	O
].	O

DNA	O
sequence	O
analysis	O
of	O
Flnb	O
revealed	O
a	O
T	O
-	O
to	O
-	O
C	O
transition	O
at	O
nucleotide	O
position	O
481	O
converting	O
a	O
serine	O
residue	O
to	O
a	O
proline	O
residue	O
(	O
S96P	O
),	O
resulting	O
in	O
a	O
missense	O
mutation	O
(	O
Figure	O
3A	O
,	O
right	O
panel	O
)	O
within	O
the	O
actin	O
-	O
binding	O
domain	O
of	O
FLNB	O
(	O
Figure	O
3C	O
,	O
bottom	O
panel	O
).	O

All	O
mice	O
that	O
carry	O
the	O
mutation	O
display	O
the	O
skeletal	O
phenotype	O
(	O
data	O
not	O
shown	O
).	O

In	O
this	O
case	O
also	O
,	O
the	O
mutation	O
occurred	O
at	O
a	O
residue	O
highly	O
conserved	O
across	O
species	O
(	O
Figure	O
3B	O
,	O
bottom	O
panel	O
)	O
and	O
mouse	O
strains	O
(	O
data	O
not	O
shown	O
).	O

Examination	O
of	O
the	O
skeletal	O
abnormalities	O
To	O
further	O
characterize	O
the	O
skeletal	O
abnormalities	O
,	O
we	O
performed	O
radiography	O
on	O
wild	O
-	O
type	O
and	O
mutant	O
mice	O
aged	O
6	O
wk	O
.	O

Skm1	O
mice	O
were	O
thin	O
and	O
exhibited	O
a	O
marked	O
thoracolumbar	O
kyphosis	O
(	O
Figure	O
4	O
,	O
C	O
and	O
D	O
)	O
compared	O
to	O
wild	O
-	O
type	O
littermates	O
(	O
Figure	O
4	O
,	O
A	O
and	O
B	O
).	O

Skm1	O
mice	O
also	O
exhibited	O
arachnodactyly	O
characterized	O
by	O
elongated	O
phalanges	O
(	O
Figure	O
5	O
,	O
B	O
and	O
D	O
),	O
compared	O
to	O
wild	O
-	O
type	O
littermates	O
(	O
Figure	O
5	O
,	O
A	O
and	O
C	O
),	O
and	O
kinked	O
tail	O
(	O
Figure	O
5B	O
),	O
attributable	B
to	O
either	O
the	O
presence	O
of	O
hemivertebrae	O
or	O
fused	O
vertebrae	O
in	O
the	O
tail	O
region	O
(	O
Figure	O
5E	O
).	O

Skm2	O
mice	O
exhibited	O
abnormal	O
skeleton	O
morphology	O
,	O
with	O
severe	O
scoliosis	O
(	O
the	O
convexity	O
of	O
the	O
curve	O
pointing	O
to	O
the	O
left	O
)	O
and	O
lordosis	O
(	O
Figure	O
4	O
,	O
E	O
and	O
F	O
).	O

In	O
addition	O
,	O
the	O
mutant	O
mice	O
showed	O
an	O
abnormal	O
thoracic	O
cage	O
with	O
less	O
ribs	O
,	O
a	O
malformed	O
sternum	O
,	O
and	O
fusion	O
of	O
several	O
vertebrae	O
.	O

Caption	O
(	O
FIG	O
):	O
FIGURE	O
4	O
Skeletal	O
abnormalities	O
in	O
skeletal	O
morphology	O
mutant	O
(	O
Skm	O
)	O
mice	O
.	O

Radiographs	O
of	O
normal	O
(	O
A	O
,	O
B	O
),	O
Skm1	O
(	O
C	O
,	O
D	O
),	O
and	O
Skm2	O
(	O
E	O
,	O
F	O
)	O
mice	O
in	O
lateral	O
and	O
supine	O
positions	O
.	O

Skm1	O
mice	O
in	O
the	O
lateral	O
position	O
showing	O
kyphosis	O
(	O
C	O
)	O
and	O
in	O
the	O
supine	O
position	O
showing	O
elongated	O
body	O
(	O
D	O
).	O

Skm2	O
mice	O
in	O
the	O
supine	O
(	O
E	O
)	O
and	O
lateral	O
(	O
F	O
)	O
positions	O
.	O

Scoliotic	O
and	O
lordotic	O
curvatures	O
of	O
the	O
vertebral	O
columns	O
are	O
indicated	O
by	O
arrowhead	O
relative	O
to	O
wild	O
-	O
type	O
littermates	O
.	O

Caption	O
(	O
FIG	O
):	O
FIGURE	O
5	O
Arachnodactyly	O
and	O
kinked	O
tail	O
in	O
skeletal	O
morphology	O
mutant	O
1	O
(	O
Skm1	O
).	O

Radiographs	O
of	O
normal	O
(	O
A	O
–	O
C	O
)	O
and	O
Skm1	O
(	O
B	O
–	O
D	O
)	O
manus	O
(	O
A	O
,	O
B	O
)	O
and	O
pes	O
(	O
C	O
,	O
D	O
).	O

Phalanges	O
are	O
indicated	O
by	O
arrowheads	O
.	O

(	O
E	O
)	O
Radiograph	O
of	O
the	O
tail	O
of	O
Skm1	O
.	O

The	O
hemivertebrae	O
and	O
fused	O
vertebrae	O
are	O
indicated	O
by	O
arrowheads	O
.	O

Discussion	O
Using	O
a	O
large	O
-	O
scale	O
ENU	O
mutagenesis	O
screen	O
,	O
we	O
have	O
identified	O
two	O
novel	O
mutations	O
,	O
Skm1	O
and	O
Skm2	O
,	O
that	O
result	O
in	O
congenital	O
spinal	O
deformities	O
in	O
mice	O
.	O

The	O
genes	O
underlying	O
these	O
new	O
ENU	O
-	O
derived	O
mutants	O
have	O
previously	O
been	O
associated	O
with	O
skeletal	O
abnormalities	O
in	O
both	O
mice	O
and	O
humans	O
,	O
and	O
thus	B
serve	O
as	B
excellent	O
tools	O
for	O
the	O
study	O
of	O
the	O
human	O
skeleton	O
and	O
its	O
development	O
.	O

The	O
Skm1	O
mutation	O
lies	O
within	O
the	O
Npr3	O
gene	O
coding	O
for	O
natriuretic	O
peptide	O
receptor	O
C	O
(	O
NPR	O
-	O
C	O
).	O

Natriuretic	O
peptides	O
(	O
NP	O
),	O
which	O
are	O
important	O
in	O
cardiovascular	O
homeostasis	O
through	O
the	O
maintenance	O
of	O
blood	O
pressure	O
and	O
extracellular	O
fluid	O
volume	O
,	O
comprise	O
three	O
structurally	O
related	O
molecules	O
:	O
atrial	O
NP	O
,	O
brain	O
NP	O
,	O
and	O
C	O
-	O
type	O
NP	O
(	O
Potter	O
2011	O
).	O

Osteocrin	O
,	O
a	O
bone	O
-	O
secreted	O
protein	O
important	O
in	O
osteoblast	O
regulation	O
,	O
shows	O
homology	O
to	O
the	O
NP	O
family	O
and	O
can	O
also	O
bind	O
to	O
NPR	O
-	O
C	O
(	O
Moffatt	O
et	O
al	O
.	O

2007	O
).	O

NPR	O
-	O
C	O
acts	O
as	O
a	O
clearance	O
receptor	O
for	O
these	O
peptides	O
through	O
an	O
endocytic	O
mechanism	O
that	O
involves	O
recycling	O
of	O
the	O
receptor	O
at	O
the	O
cellular	O
membrane	O
(	O
Rubattu	O
et	O
al	O
.	O

2010	O
).	O

Mice	O
with	O
a	O
mutation	O
in	O
Npr3	O
,	O
or	O
Npr3	O
knockout	O
mice	O
,	O
all	O
exhibit	O
the	O
same	O
skeletal	O
-	O
overgrowth	O
phenotype	O
,	O
resulting	O
in	O
an	O
elongated	O
body	O
and	O
thoracic	O
kyphosis	O
(	O
Jaubert	O
et	O
al	O
.	O

1999	O
).	O

Similarly	O
,	O
Skm1	O
mice	O
also	O
exhibit	O
these	O
skeletal	O
phenotypes	O
.	O

The	O
Skm1	O
mutation	O
occurs	O
within	O
the	O
membrane	O
proximal	O
region	O
of	O
the	O
extracellular	O
domain	O
of	O
Npr3	O
,	O
suggesting	O
that	O
ligand	O
binding	O
may	O
be	O
altered	O
in	O
these	O
mice	O
.	O

A	O
mutation	O
in	O
this	O
domain	O
would	O
prevent	O
clearance	O
of	O
the	O
NPs	O
and	O
result	O
in	O
their	O
accumulation	O
.	O

Transgenic	O
mice	O
that	O
overexpress	O
the	O
brain	O
NP	O
or	O
C	O
-	O
type	O
NP	O
ligand	O
exhibit	O
elongated	O
bones	O
and	O
skeletal	O
overgrowth	O
(	O
Suda	O
et	O
al	O
.	O

1998	O
;	O
Yasoda	O
et	O
al	O
.	O

2004	O
).	O

In	O
addition	O
,	O
mice	O
that	O
overexpress	O
osteocrin	O
have	O
elongated	O
bones	O
and	O
exhibit	O
a	O
kyphosis	O
phenotype	O
(	O
Moffatt	O
et	O
al	O
.	O

2007	O
).	O

Together	O
,	O
these	O
data	O
suggest	O
that	O
an	O
accumulation	O
of	O
NPR	O
-	O
C	O
ligands	O
in	O
the	O
Skm1	O
mice	O
may	O
contribute	O
to	O
the	O
skeletal	O
phenotype	O
.	O

More	O
recently	O
,	O
using	O
a	O
genome	O
-	O
wide	O
analysis	O
,	O
NPR3	O
was	O
shown	O
to	O
be	O
associated	O
with	O
overall	O
body	O
height	O
and	O
trunk	O
length	O
in	O
humans	O
(	O
Soranzo	O
et	O
al	O
.	O

2009	O
).	O

Whether	O
the	O
I384N	O
mutation	O
observed	O
in	O
the	O
Skm1	O
mice	O
correlates	O
to	O
a	O
SNP	O
in	O
human	O
patients	O
with	O
kyphosis	O
or	O
in	O
a	O
subset	O
of	O
individuals	O
with	O
increased	O
torso	O
length	O
remains	O
to	O
be	O
determined	O
.	O

The	O
gene	O
underlying	O
the	O
mutation	O
in	O
Skm2	O
mice	O
,	O
Flnb	O
,	O
encodes	O
filamin	O
B	O
,	O
a	O
member	O
of	O
a	O
family	O
of	O
cytoplasmic	O
proteins	O
including	O
filamin	O
A	O
and	O
filamin	O
C	O
.	O
These	O
proteins	O
provide	O
a	O
scaffold	O
for	O
the	O
cytoskeletal	O
network	O
by	O
crosslinking	O
actin	O
to	O
the	O
cytoskeleton	O
,	O
thereby	O
regulating	O
intracellular	O
signaling	O
and	O
protein	O
trafficking	O
(	O
Stossel	O
et	O
al	O
.	O

2001	O
).	O

The	O
Skm2	O
mutation	O
lies	O
within	O
a	O
highly	O
conserved	O
hydrophobic	O
region	O
in	O
the	O
actin	O
-	O
binding	O
site	O
2	O
(	O
ABS2	O
),	O
which	O
corresponds	O
to	O
the	O
last	O
α	O
-	O
helix	O
of	O
the	O
calponin	O
homology	O
domain	O
1	O
,	O
and	O
is	O
critical	O
for	O
the	O
binding	O
of	O
F	O
-	O
actin	O
(	O
van	O
der	O
Flier	O
and	O
Sonnenberg	O
2001	O
).	O

Mice	O
that	O
lack	O
functional	O
Flnb	O
have	O
been	O
generated	O
that	O
exhibit	O
impaired	O
development	O
of	O
the	O
microvascular	O
and	O
skeletal	O
systems	O
,	O
including	O
lack	O
of	O
invertebral	O
discs	O
and	O
kyphotic	O
and	O
scoliotic	O
spines	O
(	O
Farrington	O
-	O
Rock	O
et	O
al	O
.	O

2008	O
;	O
Lu	O
et	O
al	O
.	O

2007	O
;	O
Zhou	O
et	O
al	O
.	O

2007	O
).	O

The	O
mutation	O
in	O
Skm2	O
(	O
S96P	O
)	O
recapitulates	O
the	O
phenotype	O
observed	O
in	O
the	O
knockout	O
mice	O
,	O
suggesting	O
that	O
this	O
residue	O
is	O
critical	O
for	O
the	O
function	O
of	O
FLNB	O
.	O

Interestingly	O
,	O
Flnb	O
knockout	O
is	O
associated	O
with	O
embryonic	O
lethality	O
beginning	O
at	O
E11	O
.	O
5	O
and	O
<	O
3	O
%	O
of	O
Flnb	O
−/−	O
survive	O
to	O
birth	O
,	O
with	O
all	O
mice	O
being	O
killed	O
by	O
4	O
weeks	O
of	O
age	O
because	O
of	O
impaired	O
movement	O
and	O
reduced	O
body	O
weight	O
(	O
Zhou	O
et	O
al	O
.	O

2007	O
).	O

Although	O
Skm2	O
mice	O
are	O
viable	O
,	O
the	O
occurrence	O
of	O
the	O
mutant	O
phenotype	O
(	O
eight	O
mutants	O
in	O
84	O
pups	O
)	O
suggests	O
that	O
there	O
may	O
be	O
some	O
embryonic	O
lethality	O
in	O
the	O
Skm2	O
mice	O
as	O
well	O
.	O

Mutations	O
in	O
human	O
FLNB	O
have	O
been	O
found	O
in	O
various	O
skeletal	O
disorders	O
with	O
vertebral	O
abnormalities	O
,	O
including	O
spondylocarpotarsal	O
synostosis	O
,	O
boomerang	O
dysplasia	O
,	O
Larsen	O
syndrome	O
,	O
and	O
atelosteogenesis	O
III	O
.	O

These	O
disorders	O
are	O
characterized	O
by	O
vertebral	O
fusions	O
,	O
abnormal	O
spinal	O
segmentation	O
,	O
and	O
skeletogenesis	O
(	O
Krakow	O
et	O
al	O
.	O

2004	O
).	O

Consistent	O
with	O
the	O
Flnb	O
knockout	O
mice	O
,	O
the	O
Skm2	O
phenotype	O
resembles	O
that	O
seen	O
in	O
human	O
vertebral	O
malformation	O
syndromes	O
involving	O
this	O
gene	O
.	O

To	B
our	I
knowledge	I
,	O
this	O
is	O
the	O
first	O
chemically	O
induced	O
allele	O
of	O
Flnb	O
that	O
has	O
been	O
reported	O
.	O

Our	O
findings	O
emphasize	O
the	O
utility	O
of	O
ENU	O
mutagenesis	O
for	O
the	O
identification	O
of	O
genes	O
important	O
in	O
spinal	O
formation	O
.	O

Comparisons	O
of	O
mouse	O
phenotypes	O
with	O
clinical	O
descriptions	O
will	O
facilitate	O
a	O
better	O
understanding	O
of	O
the	O
genetic	O
component	O
of	O
vertebral	O
malformations	O
.	O

PubMed	O
Central	O
:	O

PA01	O
.	O
78	O
.	O

Ayurvedic	O
diet	O
in	O
pregnancy	O
Abstract	O
Purpose	O
:	O
The	O
fast	O
changing	O
life	O
style	O
of	O
the	O
modern	O
era	O
has	O
caused	O
increase	O
in	O
the	O
pregnancy	O
complications	O
,	O
anamolies	O
etc	O
.	O

due	O
to	O
the	O
change	O
in	O
the	O
diet	O
of	O
pregnant	O
women	O
.	O

Ayurveda	O
has	O
focused	O
on	O
this	O
concept	O
&	O
have	O
explained	O
it	O
very	O
effectively	O
.	O

The	O
diet	O
of	O
pregnant	O
woman	O
is	O
not	O
only	O
explained	O
according	O
to	O
the	O
need	O
of	O
the	O
mother	O
but	O
also	O
by	O
the	O
fetus	O
,	O
which	O
is	O
advised	O
month	O
wise	O
(	O
masanumasik	O
patya	O
).	O

Thus	B
,	O
it	O
is	O
very	O
necessary	O
to	O
promote	O
the	O
pregnant	O
women	O
to	O
take	O
proper	O
diet	O
i	O
.	O
e	O
.	O

masanumasik	O
patya	O
which	O
will	O
lead	O
to	O
healthly	O
&	O
safe	O
motherhood	O
along	O
with	O
its	O
outcome	O
.	O

Method	O
:	O
Masanumasik	O
patya	O
of	O
Ayurveda	O
,	O
as	O
the	O
name	O
suggest	O
,	O
is	O
advised	O
according	O
to	O
the	O
month	O
&	O
by	O
the	O
need	O
of	O
fetal	O
development	O
.	O

During	O
pregnancy	O
.	O

Various	O
symptoms	O
are	O
faced	O
by	O
woman	O
like	O
in	O
first	O
trimester	O
,	O
nausea	O
,	O
vomiting	O
is	O
seen	O
very	O
comman	O
.	O

Thus	B
,	O
patya	O
advised	O
is	O
madhura	O
,	O
shita	O
,	O
drava	O
(	O
liquid	O
),	O
which	O
will	O
prevent	O
dehydration	O
&	O
supply	O
required	O
nourishment	O
.	O

In	O
second	O
trimester	O
,	O
development	O
of	O
muscles	O
,	O
organs	O
occurs	O
,	O
so	O
the	O
diet	O
rich	O
in	O
proteins	O
is	O
advised	O
.	O

In	O
third	O
trimester	O
retention	O
of	O
water	O
,	O
constipation	O
is	O
seen	O
&	O
finally	O
preparation	O
of	O
genital	O
tract	O
for	O
delivery	O
is	O
needed	O
.	O

So	O
patyas	O
prescribed	O
are	O
diuretics	O
.	O

Mild	O
laxatives	O
and	O
basti	O
,	O
which	O
will	O
smoothen	O
genital	O
tract	O
.	O

According	O
to	O
Ayurvedic	O
diets	O
,	O
the	O
junk	O
&	O
fast	O
food	O
which	O
is	O
prevalent	O
now	O
is	O
not	O
benificial	O
for	O
mother	O
&	O
fetus	O
is	O
also	O
described	O
.	O

Result	O
:	O
As	O
mentioned	O
above	O
,	O
the	O
diet	O
of	O
pregnant	O
woman	O
according	O
to	O
month	O
is	O
proved	B
to	O
se	O
helpful	O
for	O
mother	O
&	O
fetus	O
.	O

Also	O
the	O
present	O
diet	O
substances	O
causes	O
complication	O
.	O

Thus	B
Masanumasik	O
patya	O
is	O
the	O
need	O
of	O
the	O
hour	O
.	O

Conclusion	O
:	O
It	O
is	O
therefore	B
clear	O
that	O
the	O
diet	O
of	O
pregnant	O
woman	O
according	O
to	O
Ayurveda	O
will	O
prevent	O
many	O
complications	O
of	O
pregnancy	O
,	O
which	O
will	O
lead	O
to	O
healthy	O
pregnancy	O
&	O
healthy	O
fetus	O
&	O
finally	O
good	O
outcome	O
.	O

PubMed	O
Central	O
:	O

Once	O
Upon	O
a	O
Mine	O
:	O
The	O
Legacy	O
of	O
Uranium	O
on	O
the	O
Navajo	O
Nation	O
On	O
a	O
low	O
,	O
windswept	O
rise	O
at	O
the	O
southeastern	O
edge	O
of	O
the	O
Navajo	O
Nation	O
,	O
Jackie	O
Bell	O
-	O
Jefferson	O
prepares	O
to	O
move	O
her	O
family	O
from	O
their	O
home	O
for	O
a	O
temporary	O
stay	O
that	O
could	O
last	O
up	O
to	O
seven	O
years	O
.	O

A	O
mound	O
of	O
uranium	O
-	O
laden	O
waste	O
the	O
size	O
of	O
several	O
football	O
fields	O
,	O
covered	O
with	O
a	O
thin	O
veneer	O
of	O
gravel	O
,	O
dominates	O
the	O
view	O
from	O
her	O
front	O
door	O
.	O

After	O
many	O
years	O
of	O
living	O
next	O
to	O
the	O
contamination	O
and	O
a	O
litany	O
of	O
health	O
problems	O
she	O
believes	O
it	O
caused	O
,	O
Bell	O
-	O
Jefferson	O
and	O
several	O
other	O
local	O
families	O
will	O
have	O
to	O
vacate	O
their	O
homes	O
for	O
a	O
third	O
round	O
of	O
cleanup	O
efforts	O
by	O
the	O
U	O
.	O
S	O
.	O
Environmental	O
Protection	O
Agency	O
(	O
EPA	O
).	O

Decades	O
of	O
uranium	O
mining	O
have	O
dotted	O
the	O
landscape	O
across	O
the	O
Navajo	O
Nation	O
with	O
piles	O
of	O
contaminated	O
mine	O
waste	O
.	O

The	O
EPA	O
has	O
mapped	O
521	O
abandoned	O
uranium	O
mines	O
on	O
the	O
reservation	O
,	O
ranging	O
from	O
small	O
holes	O
dug	O
by	O
a	O
single	O
prospector	O
into	O
the	O
side	O
of	O
a	O
mesa	O
to	O
large	O
commercial	O
mining	O
operations	O
.	O
1The	O
Navajo	O
people	O
did	O
not	O
have	O
a	O
word	O
for	O
“	O
radioactivity	O
”	O
when	O
mining	O
outfits	O
looking	O
for	O
vanadium2and	O
uranium3began	O
moving	O
onto	O
their	O
land	O
in	O
the	O
1940s	O
,	O
and	O
they	O
did	O
not	B
understand	I
that	O
radiation	O
could	O
be	O
dangerous	O
.	O

They	O
were	O
not	O
told	O
that	O
the	O
men	O
who	O
worked	O
in	O
the	O
mines	O
were	O
breathing	O
carcinogenic	O
radon	O
gas	O
and	O
showering	O
in	O
radioactive	O
water	O
,	O
nor	O
that	O
the	O
women	O
washing	O
their	O
husbands	O
’	O
work	O
clothes	O
could	O
spread	O
radionuclides	O
to	O
the	O
rest	O
of	O
the	O
family	O
’	O
s	O
laundry	O
.	O

Bell	O
-	O
Jefferson	O
and	O
her	O
brother	O
Peterson	O
Bell	O
played	O
in	O
and	O
around	O
the	O
mines	O
,	O
splashing	O
and	O
swimming	O
in	O
pools	O
of	O
radioactive	O
water	O
that	O
had	O
been	O
pumped	O
out	O
of	O
the	O
mines	O
and	O
then	O
collected	O
on	O
their	O
property	O
.	O

The	O
contaminated	O
water	O
looked	O
and	O
tasted	O
perfectly	O
clean	O
.	O

Families	O
used	O
it	O
for	O
cooking	O
,	O
drinking	O
,	O
and	O
cleaning	O
.	O

Hogans	O
and	O
corrals	O
were	O
built	O
with	O
mine	O
wastes	O
,	O
as	O
were	O
roads	O
.	O

All	O
that	O
changed	O
on	O
16	O
July	O
1979	O
.	O

Just	O
about	O
a	O
mile	O
and	O
a	O
half	O
from	O
Bell	O
-	O
Jefferson	O
’	O
s	O
home	O
,	O
a	O
dam	O
broke	O
at	O
the	O
United	O
Nuclear	O
Corporation	O
mill	O
,	O
where	O
workers	O
processed	O
ore	O
from	O
the	O
nearby	O
Northeast	O
Church	O
Rock	O
uranium	O
mine	O
.	O

The	O
spill	O
dumped	O
94	O
million	O
gallons	O
of	O
mill	O
process	O
effluent	O
and	O
1	O
,	O
100	O
tons	O
of	O
tailings	O
—	O
an	O
acidic	O
,	O
radioactive	O
sludge	O
—	O
into	O
a	O
large	O
arroyo	O
that	O
emptied	O
into	O
the	O
Puerco	O
River	O
.	O
4	O
The	O
Church	O
Rock	O
spill	O
occurred	O
less	O
than	O
four	O
months	O
after	O
the	O
partial	O
meltdown	O
of	O
the	O
Three	O
Mile	O
Island	O
nuclear	O
reactor	O
,	O
and	O
it	O
released	O
three	O
times	O
as	O
much	O
radiation	O
,	O
making	O
it	O
the	O
biggest	O
nuclear	O
spill	O
in	O
U	O
.	O
S	O
.	O
history	O
,	O
yet	O
it	O
received	O
only	O
a	O
tiny	O
fraction	O
of	O
the	O
news	O
coverage	O
.	O
5Declared	O
a	O
Superfund	O
site	O
in	O
1983	O
,	O
the	O
heaps	O
of	O
waste	O
around	O
the	O
mill	O
still	O
cause	O
radiation	O
survey	O
instruments	O
to	O
squeal	O
from	O
the	O
invisible	O
uranium	O
atoms	O
that	O
remain	O
active	O
30	O
years	O
later	O
.	O
6	O
“	O
This	O
area	O
used	O
to	O
be	O
my	O
playground	O
,”	O
Bell	O
-	O
Jefferson	O
says	O
.	O

“	O
Now	O
it	O
’	O
s	O
just	O
a	O
huge	O
wound	O
.”	O
For	O
the	O
Bells	O
and	O
other	O
Diné	O
(	O
the	O
term	O
by	O
which	O
many	O
Navajo	O
people	O
refer	O
to	O
themselves	O
),	O
the	O
Church	O
Rock	O
spill	O
was	O
a	O
turning	O
point	O
.	O

When	O
corporate	O
and	O
government	O
officials	O
appeared	O
in	O
the	O
spill	O
’	O
s	O
aftermath	O
and	O
began	O
inquiring	O
into	O
exposure	O
to	O
the	O
slurry	O
and	O
potential	O
health	O
problems	O
,	O
the	O
Navajo	O
people	O
finally	O
learned	O
the	O
truth	O
—	O
far	O
from	O
being	O
harmless	O
,	O
these	O
uranium	O
mines	O
were	O
poisoning	O
people	O
,	O
and	O
researchers	O
say	O
they	O
will	O
continue	O
to	O
do	O
so	O
for	O
decades	O
to	O
come	O
.	O

Canaries	O
in	O
the	O
Uranium	O
Mines	O
The	O
arrival	O
of	O
prospectors	O
signified	O
the	O
Navajo	O
Nation	O
’	O
s	O
entrance	O
into	O
the	O
modern	O
wage	O
economy	O
.	O
7Some	O
welcomed	O
the	O
potential	O
income	O
.	O

In	O
1995	O
former	O
uranium	O
miner	O
George	O
Tutt	O
recollected	O
,	O
“	O
We	O
were	O
blessed	O
,	O
we	O
thought	O
.	O

Railroad	O
jobs	O
were	O
available	O
only	O
far	O
off	O
like	O
Denver	O
.	O

…	O
But	O
for	O
mining	O
,	O
one	O
can	O
just	O
walk	O
to	O
it	O
in	O
the	O
canyon	O
.	O

We	O
thought	O
we	O
were	O
very	O
fortunate	O
,	O
but	O
we	O
were	O
not	O
told	O
,	O
‘	O
Later	O
on	O
this	O
will	O
affect	O
you	O
in	O
this	O
way	O
.’”	O
7	O
Yet	O
researchers	O
had	O
noted	O
as	O
early	O
as	O
1879	O
that	O
uranium	O
miners	O
in	O
Europe	O
showed	O
significantly	O
elevated	O
levels	O
of	O
lung	O
cancer	O
.	O
8By	O
the	O
1930s	O
,	O
they	O
suspected	B
radiation	O
as	O
the	O
culprit	O
.	O
9As	O
early	O
as	O
1951	O
,	O
government	O
scientists	O
had	O
begun	O
to	O
work	O
out	O
what	O
made	O
uranium	O
so	O
deadly	O
.	O

The	O
answer	O
,	O
as	O
it	O
turned	O
out	O
,	O
wasn	O
’	O
t	O
uranium	O
itself	O
but	O
its	O
decay	O
products	O
,	O
including	O
radium	O
,	O
10thorium	O
,	O
11and	O
radon	O
.	O
12	O
Radon	O
is	O
a	O
gas	O
,	O
but	O
with	O
a	O
half	O
-	O
life	O
of	O
four	O
days	O
,	O
it	O
rapidly	O
decays	O
into	O
solid	O
products	O
,	O
explains	O
Doug	O
Brugge	O
,	O
a	O
professor	O
of	O
public	O
health	O
at	O
Tufts	O
University	O
.	O
13	O
“	O
Being	O
solids	O
,	O
these	O
are	O
going	O
to	O
want	O
to	O
stick	O
to	O
things	O
like	O
your	O
lungs	O
,”	O
Brugge	O
says	O
.	O

“	O
Both	O
radon	O
and	O
its	O
daughter	O
products	O
emit	O
alpha	O
particles	O
,	O
and	O
this	O
is	O
a	O
very	O
effective	O
way	O
to	O
cause	O
damage	O
that	O
can	O
lead	O
to	O
cancer	O
.”	O
In	O
just	O
over	O
a	O
decade	O
,	O
Navajo	O
miners	O
were	O
being	O
diagnosed	O
with	O
lung	O
cancer	O
,	O
14a	O
relatively	O
rare	O
disease	O
in	O
this	O
largely	O
nonsmoking	O
population	O
.	O
15Beginning	O
in	O
1950	O
,	O
workers	O
with	O
the	O
U	O
.	O
S	O
.	O
Public	O
Health	O
Service	O
led	O
by	O
Duncan	O
Holaday	O
and	O
Victor	O
Archer	O
began	O
following	O
uranium	O
miners	O
in	O
the	O
Southwest	O
,	O
both	O
Navajo	O
and	O
white	O
,	O
to	O
measure	O
their	O
exposures	O
and	O
assess	O
their	O
specific	O
cancer	O
risks	O
.	O

To	O
get	O
access	O
to	O
the	O
workers	O
,	O
the	O
researchers	O
had	O
to	O
strike	O
a	O
Faustian	O
bargain	O
with	O
the	O
mining	O
companies	O
:	O
They	O
could	O
not	O
inform	O
the	O
miners	O
of	O
the	O
potential	O
health	O
hazards	O
of	O
their	O
work	O
.	O
2Seeing	O
it	O
as	O
the	O
only	O
way	O
to	O
convince	O
government	O
regulators	O
to	O
improve	O
safety	O
in	O
the	O
mines	O
,	O
the	O
researchers	O
accepted	O
.	O
16By	O
1965	O
,	O
the	O
investigators	O
reported	O
an	O
association	O
between	O
cumulative	O
exposure	O
to	O
uranium	O
and	O
lung	O
cancer	O
among	O
white	O
miners	O
and	O
had	O
definitively	O
identified	O
the	O
cause	O
as	B
radiation	O
exposure	O
.	O
17	O
In	O
1984	O
another	O
team	O
published	O
results	O
of	O
a	O
case	O
–	O
control	O
study	O
that	O
further	O
implicated	O
uranium	O
mining	O
as	B
a	O
cause	O
of	O
lung	O
cancer	O
in	O
Navajo	O
men	O
.	O

The	O
team	O
analyzed	O
96	O
confirmed	O
cancer	O
cases	O
from	O
the	O
New	O
Mexico	O
Tumor	O
Registry	O
,	O
32	O
lung	O
cancer	O
cases	O
and	O
64	O
cases	O
of	O
other	O
cancers	O
.	O

Of	O
the	O
32	O
Navajo	O
men	O
who	O
developed	O
lung	O
cancer	O
,	O
72	O
%	O
had	O
worked	O
as	O
uranium	O
miners	O
,	O
compared	O
with	O
none	O
of	O
the	O
controls	O
.	O

Furthermore	O
,	O
the	O
median	O
age	O
of	O
miners	O
with	O
lung	O
cancer	O
was	O
44	O
years	O
,	O
compared	O
with	O
63	O
years	O
for	O
nonminers	O
with	O
other	O
cancers	O
.	O
18Decades	O
after	O
their	O
exposure	O
ended	O
,	O
standardized	O
mortality	O
ratios	O
and	O
relative	O
risks	O
for	O
lung	O
cancer	O
and	O
other	O
respiratory	O
problems	O
were	O
still	O
nearly	O
four	O
times	O
higher	O
in	O
Navajo	O
miners	O
than	O
in	O
nonminers	O
.	O
19	O
Community	O
Exposure	O
to	O
Uranium	O
Getting	O
the	O
ore	O
out	O
of	O
the	O
ground	O
was	O
only	O
the	O
first	O
step	O
in	O
a	O
long	O
process	O
.	O

Miners	O
then	O
transported	O
the	O
ore	O
to	O
a	O
mill	O
,	O
where	O
it	O
was	O
crushed	O
and	O
soaked	O
in	O
sulfuric	O
acid	O
to	O
extract	O
the	O
uranium	O
.	O
20More	O
chemicals	O
were	O
added	O
to	O
precipitate	O
out	O
the	O
uranium	O
,	O
leaving	O
behind	O
a	O
radioactive	O
slurry	O
.	O

This	O
slurry	O
was	O
frequently	O
stored	O
in	O
large	O
,	O
unlined	O
ponds	O
,	O
says	O
Chris	O
Shuey	O
,	O
an	O
environmental	O
health	O
specialist	O
with	O
the	O
Southwest	O
Research	O
and	O
Information	O
Center	O
in	O
Albuquerque	O
,	O
who	O
has	O
spent	O
the	O
last	O
three	O
decades	O
working	O
with	O
Navajo	O
communities	O
affected	O
by	O
uranium	O
mining	O
and	O
milling	O
.	O

Mining	O
in	O
the	O
area	O
had	O
mostly	O
ceased	O
by	O
the	O
mid	O
-	O
1960s	O
.	O

Today	O
,	O
after	O
decades	O
of	O
inactivity	O
,	O
the	O
uranium	O
from	O
these	O
ponds	O
,	O
waste	O
and	O
tailings	O
piles	O
,	O
and	O
the	O
mines	O
themselves	O
is	O
still	O
present	O
in	O
highly	O
chemically	O
soluble	O
forms6	O
,	O
21that	O
have	O
been	O
leaching	O
into	O
the	O
area	O
’	O
s	O
drinking	O
water	O
,	O
according	O
to	O
water	O
testing	O
by	O
the	O
EPA	O
and	O
the	O
Army	O
Corps	O
of	O
Engineers	O
.	O
22	O
In	O
a	O
small	O
,	O
one	O
-	O
story	O
adobe	O
building	O
tucked	O
into	O
the	O
far	O
edge	O
of	O
the	O
University	O
of	O
New	O
Mexico	O
campus	O
,	O
Johnnye	O
Lewis	O
,	O
a	O
professor	O
of	O
toxicology	O
,	O
has	O
spent	O
more	O
than	O
a	O
decade	O
studying	O
mining	O
-	O
related	O
health	O
effects	O
in	O
the	O
Navajo	O
people	O
.	O

In	O
2000	O
she	O
received	O
an	O
environmental	O
justice	O
grant	O
from	O
the	O
National	O
Institute	O
of	O
Environmental	O
Health	O
Sciences	O
to	O
collect	O
clinical	O
and	O
survey	O
data	O
from	O
people	O
living	O
on	O
the	O
Eastern	O
Navajo	O
Nation	O
.	O

The	O
DiNEH	O
(	O
Diné	O
Network	O
for	O
Environmental	O
Health	O
)	O
Project	O
was	O
originally	O
started	O
to	O
address	O
community	O
concerns	O
about	O
the	O
high	O
rate	O
of	O
kidney	O
disease	O
in	O
this	O
population	O
,	O
which	O
some	O
community	O
leaders	O
and	O
health	O
professionals	O
suspected	B
was	O
related	O
to	O
drinking	O
contaminated	O
water	O
.	O

Lewis	O
and	O
colleagues	O
surveyed	O
1	O
,	O
304	O
residents	O
,	O
obtaining	O
basic	O
demographic	O
information	O
,	O
mapping	O
the	O
locations	O
of	O
their	O
homes	O
,	O
and	O
taking	O
samples	O
from	O
the	O
wells	O
where	O
they	O
obtained	O
their	O
drinking	O
water	O
.	O

Of	O
these	O
,	O
267	O
provided	O
blood	O
and	O
urine	O
samples	O
so	O
the	O
researchers	O
could	O
look	O
for	O
markers	O
of	O
biological	O
damage	O
.	O
23The	O
average	O
age	O
of	O
study	O
participants	O
was	O
51	O
.	O
5	O
years	O
.	O

The	O
data	O
the	O
team	O
amassed	O
over	O
the	O
last	O
13	O
years	O
suggests	O
that	O
health	O
problems	O
from	O
these	O
mines	O
in	O
fact	O
aren	O
’	O
t	O
limited	O
to	O
the	O
miners	O
who	O
worked	O
in	O
them	O
but	O
also	O
extend	O
to	O
those	O
exposed	O
through	O
drinking	O
water	O
or	O
simply	O
living	O
near	O
a	O
mine	O
.	O

“	O
We	O
’	O
re	O
still	O
analyzing	O
data	O
—	O
it	O
generated	O
just	O
an	O
enormous	O
amount	O
of	O
data	O
,”	O
Lewis	O
says	O
.	O

“	O
But	O
what	O
we	O
will	O
end	O
up	O
with	O
is	O
that	O
we	O
now	O
will	O
be	O
able	O
to	O
study	O
three	O
successive	O
generations	O
of	O
Navajos	O
that	O
have	O
been	O
exposed	O
.”	O
Although	O
the	O
literature	O
on	O
chronic	O
low	O
-	O
level	O
uranium	O
exposure	O
is	O
still	O
quite	O
small	O
,	O
by	O
2003	O
researchers	O
knew	O
that	O
the	O
dangers	O
these	O
exposures	O
posed	O
were	O
due	O
not	O
to	O
uranium	O
’	O
s	O
radioactivity	O
but	O
to	O
its	O
chemical	O
toxicity	O
.	O
24Both	O
animal25and	O
human26studies	O
have	O
found	O
uranium	O
to	O
be	O
primarily	B
toxic	O
to	O
the	O
kidneys	O
.	O

One	O
such	O
study	O
,	O
led	O
by	O
Maria	O
Limson	O
-	O
Zamora	O
,	O
head	O
of	O
Health	O
Canada	O
’	O
s	O
Bioassay	O
Section	O
,	O
compared	O
biomarkers	O
of	O
kidney	O
function	O
in	O
the	O
urine	O
of	O
Canadians	O
chronically	O
exposed	O
to	O
high	O
(	O
2	O
–	O
780	O
µg	O
/	O
L	O
)	O
or	O
low	O
(	O
0	O
.	O
02	O
µg	O
/	O
L	O
)	O
levels	O
of	O
uranium	O
in	O
their	O
drinking	O
water	O
.	O

The	O
investigators	O
found	O
signs	O
of	O
kidney	O
damage	O
that	O
increased	O
with	O
higher	O
daily	O
intake	O
of	O
uranium	O
in	O
the	O
drinking	O
water	O
.	O
27	O
Uranium	O
appears	O
to	O
exert	O
its	O
chemical	O
effects	O
on	O
the	O
kidney	O
’	O
s	O
proximal	O
tubules	O
.	O
28Arsenic	O
and	O
cadmium	O
—	O
which	O
,	O
along	O
with	O
other	O
potentially	O
hazardous	O
metals	O
,	O
are	O
sometimes	O
found	O
in	O
uranium	O
tailings29	O
—	O
create	O
similar	O
signatures	O
of	O
metal	O
damage	O
in	O
the	O
kidneys	O
.	O
30	O
Lewis	O
’	O
s	O
early	O
data	O
from	O
the	O
DiNEH	O
Project	O
suggest	O
that	O
self	O
-	O
reported	O
kidney	O
disease	O
,	O
hypertension	O
,	O
and	O
autoimmune	O
diseases	O
were	O
more	O
prevalent	O
among	O
people	O
who	O
lived	O
closer	O
to	O
mine	O
waste	O
sites	O
.	O
31Her	O
colleague	O
at	O
the	O
University	O
of	O
New	O
Mexico	O
,	O
immunologist	O
Ester	O
Erdei	O
,	O
believes	O
the	O
increase	O
in	O
hypertension	O
and	O
autoimmune	O
diseases	O
might	O
be	O
connected	O
to	O
consumption	O
of	O
contaminated	O
water	O
.	O

A	O
growing	O
body	O
of	O
evidence	O
links	O
hypertension	O
,	O
32heart	O
disease	O
,	O
33and	O
autoimmune	O
diseases34to	O
markers	O
of	O
inflammation	O
such	O
as	O
C	O
-	O
reactive	O
protein	O
and	O
assorted	O
chemokines	O
.	O
35Erdei	O
hypothesizes	O
that	O
uranium	O
exposure	O
might	O
contribute	O
to	O
these	O
diseases	O
through	O
effects	O
on	O
inflammation	O
.	O

She	O
recently	O
presented	O
findings	O
showing	O
an	O
association	O
between	O
increased	O
levels	O
of	O
activated	O
T	O
cells	O
in	O
DiNEH	O
Project	O
participants	O
and	O
greater	O
residential	O
proximity	O
to	O
mine	O
waste	O
sites	O
.	O
36	O
“	O
If	O
we	O
see	O
any	O
of	O
these	O
activated	O
T	O
cells	O
,	O
we	O
know	O
that	O
the	O
immune	O
system	O
is	O
highly	O
reacting	O
to	O
something	O
,”	O
Erdei	O
says	O
.	O

“	O
We	O
didn	O
’	O
t	O
know	O
what	O
it	O
is	O
.	O

This	O
is	O
the	O
next	O
step	O
to	O
find	O
out	O
how	O
it	O
’	O
s	O
really	O
happening	O
on	O
the	O
molecular	O
level	O
.”	O
Uranium	O
’	O
s	O
Toxic	O
Legacy	O
Human	O
and	O
animal	O
studies	O
elsewhere	O
have	O
indicated	O
the	O
health	O
legacy	O
of	O
uranium	O
exposure	O
may	O
extend	O
to	O
the	O
children	O
of	O
exposed	O
parents	O
.	O

A	O
study	O
of	O
266	O
cases	O
and	O
matched	O
controls	O
among	O
Navajo	O
births	O
over	O
18	O
years	O
suggested	O
that	O
children	O
of	O
women	O
who	O
lived	O
near	O
abandoned	O
uranium	O
sites	O
were	O
1	O
.	O
83	O
times	O
more	O
likely	B
to	O
have	O
1	O
of	O
33	O
selected	O
defects	O
.	O

Among	O
these	O
were	O
defects	O
thought	O
to	O
be	O
connected	O
to	O
radiation	O
exposure	O
(	O
e	O
.	O
g	O
.,	O
chromosomal	O
disorders	O
,	O
single	O
gene	O
mutations	O
)	O
as	O
well	O
as	O
distinctly	O
nonrelated	O
defects	O
(	O
e	O
.	O
g	O
.,	O
deaths	O
due	O
to	O
obstetrical	O
complications	O
).	O

On	O
the	O
other	O
hand	O
,	O
these	O
outcomes	O
also	O
were	O
twice	O
as	O
common	O
among	O
children	O
whose	O
mothers	O
worked	O
at	O
an	O
electronics	O
assembly	O
plant	O
as	O
in	O
other	O
children	O
.	O
37	O
Animal	O
studies	O
suggest	O
potential	O
reproductive	O
implications	O
of	O
exposure	O
.	O

A	O
study	O
in	O
rats	O
exposed	O
to	O
uranium	O
found	O
the	O
offspring	O
had	O
a	O
higher	O
body	O
burden	O
of	O
uranium	O
than	O
the	O
dams	O
.	O

These	O
offspring	O
also	O
had	O
higher	O
rates	O
of	O
physiological	O
changes	O
,	O
including	O
atypical	O
sperm	O
formation	O
.	O
38And	O
a	O
mouse	O
study	O
produced	O
evidence	O
that	O
uranium	O
in	O
drinking	O
water	O
caused	O
estrogenic	O
activity	O
even	O
at	O
levels	O
below	O
the	O
EPA	O
safe	O
drinking	O
water	O
level	O
of	O
30	O
µg	O
/	O
L	O
.	O
39	O
To	O
look	O
more	O
closely	O
at	O
the	O
effects	O
of	O
uranium	O
exposure	O
on	O
human	O
reproduction	O
and	O
development	O
,	O
Lewis	O
has	O
recently	O
begun	O
recruiting	O
up	O
to	O
1	O
,	O
500	O
pregnant	O
women	O
to	O
participate	O
in	O
the	O
Navajo	O
Birth	O
Cohort	O
Study	O
.	O
40Besides	O
tracking	O
birth	O
outcomes	O
and	O
infant	O
development	O
,	O
pharmacologist	O
Laurie	O
Hudson	O
of	O
the	O
University	O
of	O
New	O
Mexico	O
is	O
looking	O
at	O
molecular	O
changes	O
that	O
may	O
be	O
induced	O
by	O
exposure	O
to	O
uranium	O
waste	O
.	O

Arsenic	O
is	O
chemically	O
very	O
similar	O
to	O
zinc	O
and	O
can	O
replace	O
zinc	O
in	O
proteins	O
that	O
are	O
important	O
in	O
DNA	O
repair	O
.	O
41	O
“	O
Arsenic	O
goes	O
in	O
and	O
kicks	O
zinc	O
out	O
,	O
but	O
the	O
arsenic	O
doesn	O
’	O
t	O
replace	O
the	O
function	O
of	O
zinc	O
.	O

So	O
the	O
proteins	O
become	O
incapacitated	O
,”	O
Hudson	O
says	O
.	O

This	O
creates	O
a	O
hat	O
trick	O
of	O
DNA	O
damage	O
:	O
Uranium	O
’	O
s	O
radioactive42and	O
chemical43properties	O
both	O
can	O
harm	O
DNA	O
,	O
and	O
the	O
presence	O
of	O
arsenic	O
may	O
prevent	O
cells	O
from	O
repairing	O
the	O
damage	O
.	O

Animal	O
and	O
cell	O
culture	O
studies	O
have	O
suggested	O
a	O
potential	O
solution	O
:	O
zinc	O
supplementation	O
.	O
44Hudson	O
and	O
Lewis	O
want	O
to	O
see	O
if	O
zinc	O
supplementation	O
may	O
prevent	O
arsenic	O
from	O
damaging	O
DNA	O
repair	O
enzymes	O
in	O
women	O
enrolled	O
in	O
the	O
Navajo	O
Birth	O
Cohort	O
Study	O
,	O
and	O
they	O
have	O
identified	O
an	O
easy	O
way	O
to	O
do	O
this	O
.	O

Prenatal	O
vitamins	O
,	O
which	O
contain	O
zinc	O
,	O
are	O
generally	B
obtained	O
via	O
a	O
prescription	O
through	O
the	O
Indian	O
Health	O
Service	O
.	O

Researchers	O
can	O
determine	O
which	O
women	O
are	O
taking	O
their	O
vitamins	O
by	O
who	O
refills	O
their	O
prescription	O
.	O

Women	O
who	O
don	O
’	O
t	O
take	O
vitamins	O
will	O
serve	O
as	O
the	O
control	O
group	O
.	O

The	O
investigators	O
will	O
have	O
information	O
on	O
the	O
women	O
’	O
s	O
environmental	O
exposures	O
and	O
their	O
body	O
burden	O
of	O
metals	O
,	O
so	O
they	O
can	O
start	O
to	O
zero	O
in	O
on	O
how	O
arsenic	O
and	O
uranium	O
exposures	O
affect	O
protein	O
function	O
and	O
whether	O
zinc	O
supplementation	O
provides	O
any	O
protection	O
.	O

The	O
findings	O
will	O
provide	O
a	O
concrete	O
way	O
for	O
the	O
researchers	O
to	O
give	O
back	O
to	O
the	O
community	O
.	O

“	O
We	O
’	O
ve	O
pretty	O
much	O
been	O
clear	O
from	O
the	O
beginning	O
that	O
if	O
we	O
see	O
something	O
that	O
’	O
s	O
wrong	O
,	O
we	O
’	O
re	O
not	O
going	O
to	O
let	O
it	O
stick	O
around	O
just	O
to	O
preserve	O
the	O
data	O
,”	O
Lewis	O
says	O
.	O

“	O
We	O
’	O
re	O
going	O
to	O
make	O
sure	O
people	O
know	O
their	O
risks	O
and	O
can	O
take	O
action	O
.”	O
PubMed	O
Central	O
:	O

Nutritional	O
knowledge	O
as	O
a	O
determinant	O
of	O
vitamin	O
and	O
mineral	O
supplementation	O
during	O
pregnancy	O
Abstract	O
Background	O
Pregnancy	O
is	O
a	O
critical	O
period	O
for	O
both	O
woman	O
and	O
baby	O
from	O
a	O
nutritional	O
perspective	O
.	O

Nutritional	O
education	O
is	O
considered	O
an	O
important	O
tool	O
for	O
promoting	O
a	O
healthy	O
lifestyle	O
,	O
but	O
has	O
not	O
been	O
studied	O
as	O
a	O
determinant	O
for	O
maternal	O
use	O
of	O
supplements	O
during	O
pregnancy	O
,	O
especially	O
in	O
Romania	O
,	O
where	O
evidence	O
about	O
pregnancy	O
and	O
nutrition	O
is	O
scarce	O
.	O

This	O
study	O
aimed	O
to	O
evaluate	O
the	O
relationship	O
between	O
nutritional	O
knowledge	O
and	O
the	O
use	O
of	O
folic	O
acid	O
,	O
iron	O
and	O
multivitamin	O
supplements	O
during	O
pregnancy	O
and	O
to	O
assess	O
the	O
influence	O
of	O
socio	O
-	O
demographic	O
factors	O
and	O
prenatal	O
care	O
.	O

Methods	O
We	O
conducted	O
a	O
cross	O
-	O
sectional	O
study	O
on	O
a	O
sample	O
of	O
400	O
pregnant	O
women	O
admitted	O
to	O
the	O
Cuza	O
-	O
Vodă	O
Obstetrics	O
and	O
Gynaecology	O
Clinical	O
Hospital	O
in	O
Iaşi	O
,	O
Romania	O
,	O
during	O
August	O
-	O
September	O
2010	O
.	O

We	O
collected	O
self	O
-	O
reported	O
data	O
regarding	O
socio	O
-	O
demographic	O
characteristics	O
,	O
number	O
of	O
prenatal	O
check	O
-	O
ups	O
and	O
the	O
use	O
of	O
folic	O
acid	O
,	O
iron	O
and	O
multivitamin	O
supplements	O
during	O
pregnancy	O
.	O

We	O
assessed	O
nutritional	O
knowledge	O
using	O
a	O
standardized	O
questionnaire	O
divided	O
into	O
three	O
sections	O
:	O
general	O
nutritional	O
recommendations	O
for	O
pregnant	O
women	O
;	O
the	O
roles	O
of	O
nutrients	O
;	O
and	O
sources	O
of	O
nutrients	O
.	O

We	O
used	O
logistic	O
regression	O
to	O
analyse	O
the	O
associations	O
between	O
these	O
factors	O
.	O

Results	O
The	O
prevalence	O
of	O
the	O
use	O
of	O
supplements	O
during	O
pregnancy	O
was	O
48	O
%	O
for	O
folic	O
acid	O
,	O
45	O
.	O
3	O
%	O
for	O
iron	O
and	O
68	O
%	O
for	O
multivitamins	O
.	O

Above	O
-	O
average	O
nutritional	O
knowledge	O
was	O
independently	O
associated	O
with	O
the	O
use	O
of	O
folic	O
acid	O
(	O
aOR	O
,	O
4	O
.	O
7	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
6	O
-	O
13	O
.	O
8	O
),	O
iron	O
(	O
aOR	O
,	O
2	O
.	O
6	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
2	O
-	O
5	O
.	O
7	O
)	O
and	O
multivitamins	O
(	O
aOR	O
,	O
2	O
.	O
8	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
2	O
-	O
6	O
.	O
8	O
).	O

The	O
use	O
of	O
folic	O
acid	O
was	O
independently	O
associated	O
with	O
a	O
higher	O
level	O
of	O
formal	O
education	O
(	O
aOR	O
,	O
5	O
.	O
2	O
;	O
95	O
%	O
CI	O
,	O
2	O
.	O
1	O
-	O
12	O
.	O
8	O
)	O
and	O
an	O
early	O
start	O
in	O
prenatal	O
care	O
(	O
aOR	O
,	O
3	O
.	O
4	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
0	O
-	O
11	O
.	O
1	O
).	O

Women	O
with	O
a	O
higher	O
education	O
(	O
aOR	O
,	O
2	O
.	O
3	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
1	O
-	O
4	O
.	O
9	O
),	O
more	O
than	O
10	O
prenatal	O
visits	O
(	O
aOR	O
,	O
7	O
.	O
2	O
;	O
95	O
%	O
CI	O
,	O
3	O
.	O
4	O
-	O
15	O
.	O
0	O
)	O
and	O
those	O
who	O
received	O
advice	O
on	O
breastfeeding	O
(	O
aOR	O
,	O
2	O
.	O
0	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
1	O
-	O
3	O
.	O
5	O
)	O
were	O
more	O
likely	B
to	O
use	O
iron	O
during	O
pregnancy	O
.	O

Similar	O
results	O
were	O
found	O
when	O
analysing	O
the	O
contributing	O
factors	O
for	O
the	O
use	O
of	O
multivitamins	O
:	O
more	O
than	O
12	O
years	O
of	O
schooling	O
(	O
aOR	O
,	O
3	O
.	O
4	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
4	O
-	O
7	O
.	O
9	O
)	O
and	O
appropriate	O
prenatal	O
care	O
(	O
aOR	O
,	O
9	O
.	O
4	O
;	O
95	O
%	O
CI	O
,	O
4	O
.	O
5	O
-	O
19	O
.	O
5	O
).	O

Conclusions	O
Level	O
of	O
nutritional	O
knowledge	O
has	O
a	O
strong	O
independent	O
association	O
with	O
the	O
use	O
of	O
supplements	O
during	O
pregnancy	O
.	O

Background	O
Adequate	O
nutrition	O
during	O
pregnancy	O
is	O
associated	O
with	O
optimal	O
foetal	O
growth	O
[	O
1	O
,	O
2	O
],	O
normal	O
pregnancy	O
duration	O
[	O
3	O
]	O
and	O
a	O
decrease	O
in	O
the	O
risk	O
of	O
congenital	O
abnormalities	O
[	O
4	O
].	O

A	O
lack	O
of	O
vitamins	O
and	O
minerals	O
can	O
adversely	O
influence	O
the	O
newborn	O
’	O
s	O
weight	O
,	O
even	O
if	O
the	O
dietary	O
intake	O
of	O
proteins	O
and	O
energy	O
is	O
adequate	O
[	O
5	O
,	O
6	O
].	O

The	O
results	O
of	O
several	O
meta	O
-	O
analyses	O
reinforce	O
the	O
beneficial	O
role	O
of	O
iron	O
and	O
folic	O
acid	O
supplements	O
during	O
pregnancy	O
in	O
reducing	O
the	O
prevalence	O
of	O
neural	O
tube	O
defects	O
,	O
low	O
-	O
birth	O
weight	O
babies	O
,	O
small	O
for	O
gestational	O
age	O
newborns	O
and	O
maternal	O
anaemia	O
[	O
7	O
-	O
9	O
].	O

Some	O
cross	O
-	O
sectional	O
studies	O
show	O
the	O
same	O
positive	O
results	O
for	O
the	O
use	O
of	O
multivitamins	O
[	O
10	O
],	O
but	O
there	O
is	O
still	O
debate	O
as	O
to	O
whether	O
these	O
are	O
superior	O
to	O
iron	O
and	O
folic	O
acid	O
[	O
11	O
].	O

Anaemia	O
during	O
pregnancy	O
is	O
a	O
public	O
health	O
problem	O
that	O
affects	O
both	O
developed	O
and	O
developing	O
countries	O
and	O
has	O
an	O
impact	O
not	O
only	O
on	O
health	O
providers	O
,	O
but	O
also	O
on	O
the	O
socio	O
-	O
economic	O
environment	O
[	O
12	O
].	O

Prevention	O
strategies	O
for	O
iron	O
deficiency	O
and	O
maternal	O
anaemia	O
include	O
nutritional	O
education	O
,	O
promoting	O
the	O
intake	O
of	O
iron	O
and	O
folic	O
acid	O
supplements	O
,	O
and	O
food	O
fortification	O
[	O
13	O
].	O

Daily	O
use	O
of	O
iron	O
supplements	O
is	O
effective	O
when	O
administered	O
under	O
supervision	O
in	O
clinical	O
interventional	O
trials	O
,	O
but	O
is	O
less	O
so	O
in	O
public	O
health	O
programmes	O
because	O
of	O
difficulty	O
engaging	O
with	O
the	O
target	O
population	O
.	O

Lack	O
of	O
engagement	O
may	O
be	O
a	O
consequence	O
of	O
insufficient	O
involvement	O
of	O
policy	O
makers	O
,	O
issues	O
regarding	O
distribution	O
and	O
costs	O
and	O
difficulties	O
in	O
training	O
the	O
educators	O
,	O
or	O
the	O
beliefs	O
and	O
cultural	O
practices	O
of	O
the	O
target	O
population	O
and	O
the	O
characteristics	O
and	O
side	O
effects	O
of	O
supplements	O
[	O
11	O
,	O
14	O
].	O

In	O
Romania	O
,	O
a	O
study	O
conducted	O
by	O
the	O
Alfred	O
Rusescu	O
Institute	O
of	O
Mother	O
’	O
s	O
and	O
Child	O
’	O
s	O
Care	O
(	O
IOMC	O
),	O
found	O
that	O
the	O
use	O
of	O
iron	O
supplements	O
during	O
pregnancy	O
in	O
Romania	O
only	O
reduced	O
the	O
incidence	O
of	O
anaemia	O
at	O
birth	O
by	O
5	O
%	O
even	O
when	O
iron	O
supplements	O
were	O
provided	O
free	O
of	O
charge	O
under	O
reimbursement	O
arrangements	O
from	O
16	O
weeks	O
of	O
gestation	O
,	O
and	O
treatment	O
was	O
supervised	O
by	O
primary	O
care	O
physicians	O
[	O
14	O
].	O

Several	O
studies	O
emphasize	O
the	O
importance	O
of	O
the	O
relationship	O
between	O
iron	O
,	O
folic	O
acid	O
or	O
multivitamin	O
intake	O
and	O
socio	O
-	O
demographic	O
factors	O
such	O
as	O
age	O
,	O
level	O
of	O
education	O
,	O
area	O
of	O
residence	O
,	O
marital	O
status	O
,	O
parity	O
,	O
economical	O
status	O
and	O
characteristics	O
of	O
prenatal	O
care	O
(	O
including	O
gestational	O
age	O
at	O
the	O
beginning	O
of	O
prenatal	O
care	O
and	O
the	O
number	O
of	O
prenatal	O
consultations	O
)	O
[	O
15	O
-	O
19	O
].	O

More	O
frequent	O
use	O
of	O
supplements	O
during	O
pregnancy	O
was	O
found	O
to	O
be	O
associated	O
with	O
a	O
higher	O
socio	O
-	O
economic	O
status	O
,	O
higher	O
level	O
of	O
education	O
and	O
use	O
of	O
prenatal	O
medical	O
services	O
in	O
studies	O
conducted	O
in	O
Finland	O
[	O
15	O
],	O
the	O
United	O
Kingdom	O
[	O
16	O
],	O
the	O
United	O
States	O
of	O
America	O
[	O
17	O
],	O
Denmark	O
[	O
18	O
]	O
and	O
Tanzania	O
[	O
19	O
].	O

One	O
study	O
conducted	O
in	O
Poland	O
concluded	O
that	O
the	O
level	O
of	O
nutritional	O
knowledge	O
of	O
pregnant	O
women	O
regarding	O
mineral	O
and	O
vitamins	O
was	O
insufficient	O
,	O
without	O
focusing	O
on	O
the	O
relationship	O
with	O
their	O
intake	O
[	O
20	O
].	O

Another	O
study	O
showed	O
that	O
a	O
higher	O
level	O
of	O
nutritional	O
knowledge	O
was	O
associated	O
with	O
vitamin	O
/	O
mineral	O
supplementation	O
use	O
[	O
21	O
].	O

In	O
Romania	O
it	O
is	O
not	O
clear	O
whether	O
there	O
is	O
a	O
relationship	O
between	O
socio	O
-	O
demographic	O
factors	O
or	O
the	O
level	O
of	O
nutritional	O
knowledge	O
and	O
the	O
use	O
of	O
iron	O
,	O
folic	O
acid	O
and	O
multivitamins	O
in	O
pregnancy	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
assess	O
the	O
determinants	O
of	O
the	O
use	O
of	O
folic	O
acid	O
,	O
iron	O
and	O
multivitamins	O
supplements	O
by	O
expectant	O
mothers	O
in	O
Romania	O
,	O
in	O
terms	O
of	O
nutritional	O
knowledge	O
evaluated	O
by	O
a	O
structured	O
questionnaire	O
,	O
socio	O
-	O
demographic	O
factors	O
and	O
engagement	O
with	O
prenatal	O
care	O
.	O

Methods	O
Design	O
and	O
study	O
population	O
We	O
conducted	O
a	O
cross	O
-	O
sectional	O
study	O
during	O
August	O
and	O
September	O
2010	O
on	O
a	O
sample	O
of	O
400	O
consecutive	O
women	O
who	O
had	O
given	O
birth	O
in	O
a	O
regional	O
specialist	O
obstetric	O
centre	O
,	O
the	O
Cuza	O
-	O
Vodă	O
Clinical	O
Hospital	O
in	O
Iaşi	O
,	O
Romania	O
.	O

We	O
invited	O
women	O
aged	O
between	O
15	O
and	O
49	O
years	O
,	O
resident	O
in	O
Iaşi	O
county	O
,	O
with	O
singleton	O
pregnancies	O
to	O
participate	O
in	O
the	O
study	O
within	O
48	O
–	O
72	O
hours	O
of	O
giving	O
birth	O
.	O

We	O
excluded	O
stillbirths	O
,	O
those	O
who	O
declined	O
to	O
participate	O
,	O
those	O
with	O
obstetric	O
pathology	O
,	O
or	O
psychiatric	O
,	O
cognitive	O
or	O
other	O
disease	O
that	O
might	O
adversely	O
affect	O
understanding	O
of	O
the	O
study	O
objectives	O
or	O
the	O
ability	O
to	O
provide	O
accurate	O
information	O
.	O

Those	O
who	O
did	O
not	O
complete	O
the	O
interview	O
were	O
recorded	O
as	O
having	O
refused	O
to	O
participate	O
and	O
were	O
taken	O
into	O
account	O
when	O
calculating	O
the	O
refusal	O
rate	O
,	O
but	O
excluded	O
from	O
the	O
final	O
analysis	O
.	O

Sample	O
size	O
calculation	O
was	O
undertaken	O
using	O
the	O
single	O
proportion	O
formula	O
[	O
22	O
].	O

We	O
selected	O
a	O
95	O
%	O
confidence	O
level	O
and	O
an	O
assumed	B
prevalence	O
of	O
supplement	O
use	O
of	O
50	O
%,	O
informed	O
by	O
other	O
studies	O
[	O
15	O
-	O
19	O
,	O
22	O
],	O
due	O
to	O
the	O
lack	O
of	O
prior	O
data	O
in	O
our	O
region	O
.	O

It	O
is	O
the	O
single	O
proportion	O
formula	O
(	O
n	O
=	O
[	O
Z	O
α	O
/	O
2	O
]	O
2	O
P	O
(	O
1	O
-	O
p	O
]	O
/	O
d2	O
)	O
at	O
95	O
%	O
confidence	O
interval	O
,	O
where	O
Z	O
α	O
/	O
2	O
=	O
1	O
.	O
96	O
,	O
P	O
=	O
prevalence	O
of	O
50	O
%,	O
and	O
d	O
=	O
5	O
%	O
of	O
marginal	O
error	O
[	O
22	O
].	O

We	O
also	O
defined	O
a	O
reference	O
group	O
to	O
estimate	O
the	O
sample	O
size	O
.	O

Owing	O
to	O
the	O
lack	O
of	O
other	O
available	O
data	O
,	O
we	O
used	O
the	O
annual	O
number	O
of	O
live	O
births	O
in	O
Iaşi	O
county	O
reported	O
on	O
01	O
July	O
2009	O
(	O
n	O
=	O
9	O
,	O
499	O
)	O
to	O
define	O
the	O
size	O
of	O
the	O
reference	O
group	O
[	O
23	O
].	O

Based	O
on	O
these	O
calculations	O
,	O
the	O
minimum	O
sample	O
size	O
required	O
was	O
370	O
.	O

A	O
number	O
of	O
410	O
women	O
was	O
invited	O
to	O
participate	O
at	O
the	O
study	O
.	O

From	O
the	O
final	O
analysis	O
ten	O
questionnaires	O
were	O
excluded	O
representing	O
drop	O
-	O
outs	O
(	O
refusals	O
after	O
the	O
initial	O
moment	O
of	O
the	O
study	O
or	O
incomplete	O
questionnaires	O
).	O

Thus	O
,	O
the	O
rate	O
of	O
refusal	O
was	O
relatively	O
low	O
,	O
of	O
only	O
2	O
.	O
5	O
%	O
of	O
all	O
the	O
women	O
invited	O
to	O
participate	O
in	O
the	O
study	O
.	O

Data	O
collection	O
We	O
created	O
a	O
pro	O
forma	O
for	O
data	O
collection	O
that	O
was	O
completed	O
during	O
an	O
interview	O
conducted	O
48	O
to	O
72	O
hours	O
after	O
delivery	O
.	O

In	O
Romania	O
,	O
almost	O
all	O
women	O
are	O
hospitalised	O
for	O
at	O
least	O
3	O
days	O
post	O
-	O
partum	O
during	O
which	O
time	O
the	O
newborn	O
is	O
immunised	O
against	O
tuberculosis	O
and	O
hepatitis	O
B	O
;	O
it	O
is	O
very	O
uncommon	O
to	O
leave	O
the	O
hospital	O
earlier	O
.	O

We	O
collected	O
:	O
•	O
Demographic	O
data	O
:	O
age	O
,	O
area	O
of	O
residence	O
(	O
urban	O
or	O
rural	O
),	O
family	O
status	O
(	O
married	O
or	O
single	O
,	O
wanted	O
or	O
unwanted	O
pregnancy	O
,	O
parity	O
),	O
and	O
duration	O
of	O
formal	O
education	O
;	O
•	O
Engagement	O
with	O
prenatal	O
care	O
:	O
gestational	O
age	O
at	O
the	O
beginning	O
of	O
care	O
,	O
provider	O
of	O
care	O
(	O
general	O
practitioner	O
or	O
obstetrician	O
),	O
and	O
total	O
number	O
of	O
visits	O
.	O

The	O
latter	O
were	O
subdivided	O
into	O
three	O
categories	O
according	O
to	O
current	O
recommendations	O
:	O
≤	O
4	O
visits	O
(	O
inadequate	O
),	O
5	O
–	O
9	O
visits	O
(	O
intermediate	O
),	O
≥	O
10	O
visits	O
(	O
adequate	O
)	O
[	O
14	O
];	O
•	O
Components	O
of	O
prenatal	O
care	O
:	O
advice	O
given	O
on	O
breastfeeding	O
and	O
diet	O
(	O
yes	O
/	O
no	O
answers	O
);	O
•	O
Use	O
of	O
oral	O
supplements	O
:	O
including	O
folic	O
acid	O
,	O
iron	O
and	O
multivitamins	O
(	O
yes	O
/	O
no	O
answers	O
to	O
each	O
),	O
and	O
the	O
trade	O
names	O
of	O
supplements	O
used	O
.	O

Development	O
and	O
validation	O
of	O
the	O
nutritional	O
knowledge	O
questionnaire	O
To	O
evaluate	O
nutritional	O
knowledge	O
we	O
developed	O
a	O
questionnaire	O
based	O
on	O
the	O
recommendations	O
of	O
the	O
“	O
Pregnancy	O
Notebook	O
”	O
[	O
24	O
]	O
and	O
“	O
The	O
Principles	O
of	O
the	O
Child	O
’	O
s	O
and	O
Mother	O
’	O
s	O
Diet	O
:	O
Guidelines	O
for	O
Health	O
Providers	O
at	O
Community	O
Level	O
”	O
[	O
25	O
],	O
educational	O
tools	O
developed	O
by	O
the	O
Ministry	O
of	O
Health	O
in	O
Romania	O
.	O

A	O
draft	O
list	O
of	O
40	O
questions	O
was	O
revised	O
by	O
a	O
group	O
of	O
experts	O
.	O

These	O
were	O
divided	O
into	O
four	O
categories	O
and	O
concerned	O
knowledge	O
of	O
general	O
dietary	O
recommendations	O
during	O
pregnancy	O
,	O
the	O
sources	O
of	O
nutrients	O
,	O
the	O
roles	O
of	O
nutrients	O
during	O
pregnancy	O
,	O
and	O
the	O
importance	O
of	O
breastfeeding	O
.	O

Participants	O
could	O
respond	O
“	O
yes	O
”/“	O
no	O
”/“	O
don	O
’	O
t	O
know	O
”	O
to	O
each	O
question	O
.	O

After	O
expert	O
review	O
,	O
the	O
final	O
questionnaire	O
used	O
had	O
29	O
items	O
(	O
see	O
Additional	O
file1	O
).	O

To	O
validate	O
the	O
nutritional	O
knowledge	O
questionnaire	O
,	O
item	O
analysis	O
was	O
performed	O
to	O
determine	O
item	O
difficulty	O
and	O
item	O
discrimination	O
indices	O
to	O
increase	O
reliability	O
.	O

The	O
items	O
that	O
were	O
too	O
difficult	O
,	O
too	O
easy	O
,	O
or	O
that	O
were	O
found	O
to	O
have	O
near	O
-	O
zero	O
or	O
negative	O
discrimination	O
were	O
eliminated	O
.	O

As	O
a	O
result	O
,	O
26	O
items	O
were	O
included	O
in	O
the	O
final	O
analysis	O
.	O

The	O
Cronbach	O
’	O
s	O
α	O
coefficient	O
was	O
acceptable	O
for	O
all	O
sections	O
(	O
general	O
recommendations	O
,	O
0	O
.	O
66	O
;	O
sources	O
of	O
nutrients	O
,	O
0	O
.	O
77	O
;	O
the	O
role	O
of	O
nutrients	O
,	O
0	O
.	O
77	O
),	O
except	O
for	O
breastfeeding	O
(	O
0	O
.	O
60	O
),	O
which	O
was	O
therefore	O
eliminated	O
.	O

For	O
the	O
remaining	O
19	O
questions	O
,	O
the	O
internal	O
fidelity	O
was	O
satisfactory	O
(	O
the	O
correlation	O
coefficient	O
between	O
the	O
two	O
halves	O
-	O
0	O
.	O
83	O
;	O
the	O
-	O
split	O
half	O
reliability	O
-	O
0	O
.	O
91	O
;	O
Guttman	O
split	O
-	O
half	O
reliability	O
coefficient	O
-	O
0	O
.	O
91	O
and	O
Cronbach	O
’	O
s	O
α	O
coefficient	O
-	O
0	O
.	O
88	O
)	O
[	O
26	O
].	O

Construction	O
validity	O
was	O
also	O
found	O
to	O
be	O
satisfactory	O
(	O
ANOVA	O
F	O
statistic	O
=	O
39	O
.	O
9	O
,	O
p	O
<	O
.	O
001	O
),	O
and	O
post	O
hoc	O
testing	O
revealed	O
statistically	O
significant	O
differences	O
between	O
the	O
mean	O
score	O
of	O
the	O
questionnaire	O
according	O
to	O
each	O
category	O
of	O
formal	O
education	O
(	O
4	O
.	O
9	O
for	O
1	O
–	O
4	O
years	O
of	O
formal	O
education	O
;	O
8	O
.	O
35	O
for	O
5	O
–	O
8	O
years	O
of	O
education	O
;	O
10	O
.	O
8	O
for	O
9	O
–	O
12	O
years	O
of	O
education	O
;	O
and	O
13	O
.	O
7	O
for	O
more	O
than	O
12	O
years	O
;	O
p	O
<	O
.	O
001	O
).	O

Based	O
on	O
these	O
scores	O
,	O
we	O
created	O
the	O
following	O
categories	O
of	O
nutritional	O
knowledge	O
:	O
low	O
level	O
(<	O
mean	O
–	O
standard	O
deviation	O
),	O
medium	O
level	O
(	O
mean	O
±	O
standard	O
deviation	O
)	O
and	O
high	O
level	O
(>	O
mean	O
+	O
standard	O
deviation	O
).	O

The	O
mean	O
score	O
was	O
11	O
.	O
0	O
(	O
95	O
%	O
CI	O
,	O
10	O
.	O
5	O
-	O
11	O
.	O
5	O
)	O
and	O
standard	O
deviation	O
was	O
4	O
.	O
8	O
(	O
Table	O
1	O
).	O

Caption	O
(	O
TABLE	O
-	O
WRAP	O
):	O
TABLE	O
1	O
Background	O
characteristics	O
of	O
the	O
participantsBackground	O
characteristics	O
Age	O
,	O
years	O
(	O
mean	O
±	O
SD	O
)	O
27	O
.	O
5	O
±	O
5	O
.	O
59Urban	O
environment	O
,	O
N	O
(%)	O
218	O
(	O
54	O
.	O
3	O
)	O
Formal	O
education	O
,	O
number	O
of	O
years	O
≤	O
8	O
(%)	O
25	O
.	O
5	O
9	O
-	O
12	O
(%)	O
40	O
.	O
5	O
>	O
12	O
(%)	O
34Married	O
,	O
N	O
(%)	O
323	O
(	O
80	O
.	O
8	O
)	O
Number	O
of	O
births	O
,	O
N	O
(%)	O
Primiparous198	O
(	O
49	O
.	O
5	O
)	O
Secundiparous129	O
(	O
32	O
.	O
3	O
)	O
Multiparous73	O
(	O
18	O
.	O
2	O
)	O
Wanted	O
pregnancy	O
,	O
N	O
(%)	O
360	O
(	O
90	O
)	O
Gestational	O
age	O
at	O
first	O
prenatal	O
visit	O
,	O
mean	O
±	O
SD2	O
.	O
59	O
±	O
1	O
.	O
23First	O
prenatal	O
visit	O
at	O
≤	O
4	O
months	O
of	O
pregnancy	O
,	O
N	O
(%)	O
364	O
(	O
91	O
)	O
Number	O
of	O
prenatal	O
visits	O
at	O
general	O
practitioner	O
,	O
mean	O
±	O
SD4	O
.	O
82	O
±	O
2	O
.	O
54Number	O
of	O
prenatal	O
visits	O
at	O
obstetrician	O
,	O
mean	O
±	O
SD4	O
.	O
76	O
±	O
3	O
.	O
07Total	O
number	O
of	O
prenatal	O
visits	O
,	O
mean	O
±	O
SD9	O
.	O
58	O
±	O
4	O
.	O
88Nutritional	O
knowledge	O
score	O
,	O
mean	O
±	O
SD11	O
±	O
4	O
.	O
8Advice	O
on	O
diet	O
,	O
YES	O
(	O
N	O
,%)	O
168	O
(	O
42	O
)	O
Advice	O
on	O
breastfeeding	O
,	O
YES	O
(	O
N	O
,%)	O
334	O
(	O
83	O
.	O
5	O
)	O
Use	O
of	O
folic	O
acid	O
(	O
N	O
,%)	O
192	O
(	O
48	O
)	O
Use	O
of	O
iron	O
(	O
N	O
,%)	O
181	O
(	O
45	O
.	O
3	O
)	O
Use	O
of	O
multivitamins	O
(	O
N	O
,%)	O
272	O
(	O
68	O
)	O
Statistical	O
analysis	O
Associations	O
between	O
socio	O
-	O
demographic	O
factors	O
,	O
prenatal	O
care	O
,	O
the	O
level	O
of	O
nutritional	O
knowledge	O
and	O
the	O
intake	O
of	O
nutritional	O
supplements	O
were	O
evaluated	O
using	O
the	O
Chi	O
-	O
square	O
test	O
(	O
χ2	O
)	O
and	O
binomial	O
logistical	O
regression	O
[	O
24	O
].	O

Adjusted	O
odd	O
ratios	O
(	O
aORs	O
)	O
and	O
95	O
%	O
confidence	O
intervals	O
(	O
95	O
%	O
CI	O
)	O
were	O
first	O
determined	O
after	O
adjusting	O
for	O
the	O
number	O
of	O
prenatal	O
visits	O
,	O
then	O
after	O
adjusting	O
for	O
number	O
of	O
prenatal	O
visits	O
and	O
socio	O
-	O
demographic	O
factors	O
(	O
age	O
,	O
area	O
of	O
residence	O
,	O
level	O
of	O
education	O
).	O

The	O
Hosmer	O
-	O
Lemeshow	O
test	O
was	O
used	O
to	O
evaluate	O
the	O
strength	O
of	O
the	O
models	O
created	O
.	O

For	O
all	O
analyses	O
a	O
p	O
value	O
<	O
0	O
.	O
05	O
was	O
considered	O
significant	O
;	O
all	O
were	O
undertaken	O
using	O
the	O
Statistical	O
Package	O
for	O
Social	O
Science	O
(	O
SPSS	O
)	O
program	O
for	O
Windows	O
Version	O
13	O
.	O
0	O
(	O
SPSS	O
13	O
.	O
0	O
,	O
Chicago	O
,	O
IL	O
,	O
USA	O
).	O

Ethical	O
considerations	O
The	O
study	O
was	O
approved	O
by	O
the	O
ethics	O
committee	O
of	O
the	O
“	O
Grigore	O
T	O
.	O
Popa	O
”	O
University	O
of	O
Medicine	O
and	O
Pharmacy	O
in	O
Iaşi	O
and	O
permission	O
to	O
administer	O
the	O
questionnaires	O
was	O
received	O
from	O
the	O
Cuza	O
-	O
Vodă	O
Obstetrics	O
and	O
Gynaecology	O
Clinical	O
Hospital	O
.	O

Those	O
who	O
participated	O
gave	O
written	O
informed	O
consent	O
.	O

Those	O
younger	O
than	O
18	O
years	O
gave	O
their	O
consent	O
in	O
the	O
presence	O
of	O
and	O
with	O
the	O
approval	O
of	O
one	O
of	O
their	O
parents	O
or	O
legal	O
guardians	O
.	O

All	O
data	O
were	O
anonymised	O
to	O
maintain	O
participant	O
confidentiality	O
.	O

Results	O
We	O
found	O
that	O
48	O
.	O
0	O
%	O
of	O
participants	O
used	O
folic	O
acid	O
,	O
45	O
.	O
3	O
%	O
used	O
iron	O
supplements	O
and	O
68	O
.	O
0	O
%	O
used	O
multivitamins	O
during	O
pregnancy	O
(	O
Table	O
1	O
).	O

Socio	O
-	O
demographic	O
characteristics	O
of	O
the	O
study	O
group	O
and	O
description	O
of	O
prenatal	O
care	O
The	O
mean	O
age	O
of	O
participants	O
was	O
27	O
.	O
5	O
years	O
:	O
63	O
.	O
8	O
%	O
were	O
aged	O
between	O
19	O
and	O
30	O
years	O
,	O
5	O
.	O
3	O
%	O
were	O
≤	O
18	O
years	O
and	O
8	O
.	O
8	O
%	O
were	O
aged	O
over	O
35	O
years	O
.	O

The	O
majority	O
lived	O
in	O
an	O
urban	O
area	O
(	O
54	O
.	O
3	O
%).	O

Regarding	O
formal	O
education	O
,	O
25	O
.	O
5	O
%	O
had	O
completed	O
less	O
than	O
8	O
years	O
of	O
school	O
,	O
whereas	O
34	O
.	O
0	O
%	O
had	O
a	O
university	O
degree	O
.	O

The	O
majority	O
of	O
women	O
(	O
80	O
.	O
8	O
%)	O
were	O
married	O
.	O

Primiparous	O
and	O
secundiparous	O
women	O
were	O
predominant	O
(	O
49	O
.	O
5	O
%	O
and	O
32	O
.	O
3	O
%,	O
respectively	O
);	O
10	O
.	O
0	O
%	O
of	O
women	O
declared	O
that	O
the	O
pregnancy	O
was	O
unwanted	O
(	O
Table	O
1	O
).	O

Most	O
women	O
(	O
96	O
.	O
0	O
%)	O
registered	O
their	O
pregnancy	O
with	O
their	O
general	O
practitioner	O
and	O
had	O
the	O
first	O
prenatal	O
visit	O
in	O
the	O
second	O
(	O
61	O
.	O
0	O
%)	O
or	O
the	O
third	O
(	O
19	O
.	O
0	O
%)	O
month	O
;	O
only	O
9	O
.	O
0	O
%	O
of	O
women	O
had	O
the	O
first	O
visit	O
in	O
the	O
fifth	O
month	O
.	O

The	O
average	O
number	O
of	O
visits	O
to	O
the	O
general	O
practitioner	O
was	O
4	O
.	O
8	O
±	O
2	O
.	O
54	O
.	O

The	O
mean	O
number	O
of	O
check	O
-	O
ups	O
with	O
the	O
obstetrician	O
was	O
4	O
.	O
7	O
±	O
3	O
.	O
07	O
;	O
but	O
16	O
.	O
5	O
%	O
of	O
women	O
did	O
not	O
see	O
an	O
obstetrician	O
during	O
their	O
pregnancy	O
.	O

The	O
mean	O
total	O
number	O
of	O
combined	O
visits	O
was	O
9	O
.	O
58	O
±	O
4	O
.	O
88	O
:	O
18	O
%	O
of	O
participants	O
made	O
≤	O
4	O
visits	O
,	O
28	O
.	O
5	O
%	O
made	O
between	O
5	O
–	O
9	O
visits	O
and	O
53	O
.	O
3	O
%	O
had	O
≥	O
10	O
visits	O
.	O

Less	O
than	O
half	O
the	O
participants	O
(	O
42	O
.	O
0	O
%)	O
declared	O
they	O
received	O
advice	O
on	O
diet	O
during	O
pregnancy	O
and	O
83	O
.	O
5	O
%	O
stated	O
they	O
were	O
advised	O
to	O
breastfeed	O
(	O
Table	O
1	O
).	O

Factors	O
associated	O
with	O
vitamin	O
and	O
mineral	O
supplementation	O
during	O
pregnancy	O
Age	O
,	O
level	O
of	O
education	O
,	O
being	O
married	O
and	O
low	O
gestational	O
age	O
at	O
the	O
first	O
prenatal	O
check	O
-	O
up	O
and	O
total	O
number	O
of	O
prenatal	O
medical	O
visits	O
were	O
positively	O
associated	O
with	O
the	O
use	O
of	O
folic	O
acid	O
,	O
iron	O
and	O
multivitamin	O
supplements	O
.	O

The	O
intake	O
of	O
vitamin	O
and	O
mineral	O
supplements	O
was	O
significantly	O
less	O
common	O
in	O
women	O
who	O
declared	O
the	O
pregnancy	O
was	O
unwanted	O
.	O

Significant	O
differences	O
were	O
noted	O
in	O
the	O
use	O
of	O
folic	O
acid	O
and	O
multivitamin	O
supplements	O
,	O
but	O
not	O
in	O
the	O
use	O
of	O
iron	O
supplements	O
,	O
depending	O
on	O
area	O
of	O
residence	O
(	O
rural	O
versus	O
urban	O
)	O
and	O
parity	O
.	O

Women	O
with	O
a	O
higher	O
level	O
of	O
nutritional	O
knowledge	O
used	O
folic	O
acid	O
,	O
iron	O
and	O
multivitamin	O
supplements	O
more	O
frequently	O
(	O
Table	O
2	O
).	O

Caption	O
(	O
TABLE	O
-	O
WRAP	O
):	O
TABLE	O
2	O
Associations	O
between	O
use	O
of	O
supplements	O
and	O
socio	O
-	O
demographic	O
factors	O
,	O
pre	O
-	O
natal	O
care	O
and	O
nutritional	O
knowledge	O
Folic	O
acidIronVitamins	O
YES	O
YES	O
YES	O
N	O
%	O
pn	O
%	O
pn	O
%	O
p	O
Urban	O
environment13863	O
.	O
6	O
<	O
0	O
.	O
001	O
17178	O
.	O
80	O
.	O
1417178	O
.	O
8	O
<	O
0	O
.	O
001	O
Rural	O
environment5436	O
.	O
410155	O
.	O
210155	O
.	O
2Education	O
(	O
number	O
of	O
years	O
)	O
≤	O
8115	O
.	O
7	O
<	O
0	O
.	O
001	O
4524	O
.	O
9	O
<	O
0	O
.	O
001	O
4315	O
.	O
8	O
<	O
0	O
.	O
001	O
9	O
-	O
128242	O
.	O
77541	O
.	O
411040	O
.	O
4	O
>	O
129951	O
.	O
6	O
6133	O
.	O
7	O
11943	O
.	O
8	O
Age	O
(	O
years	O
old	O
)	O
<	O
1800	O
<	O
0	O
.	O
001	O
942	O
.	O
9	O
0	O
.	O
043	O
942	O
.	O
9	O
0	O
.	O
011	O
≥	O
1819250	O
.	O
726369	O
.	O
426369	O
.	O
4Number	O
of	O
births	O
≤	O
217352	O
.	O
624273	O
.	O
624273	O
.	O
6	O
>	O
21926	O
.	O
83042	O
.	O
33042	O
.	O
3Wanted	O
pregnancy17949	O
.	O
9	O
0	O
.	O
017	O
25470	O
.	O
8	O
0	O
.	O
009	O
25470	O
.	O
8	O
<	O
0	O
.	O
001	O
Unwanted	O
pregnancy1230	O
.	O
01742	O
.	O
51742	O
.	O
5	O
Married17654	O
.	O
5	O
<	O
0	O
.	O
001	O
23572	O
.	O
8	O
0	O
.	O
01	O
23572	O
.	O
8	O
<	O
0	O
.	O
001	O
Single1620	O
.	O
83748	O
.	O
13748	O
.	O
1Pregnancy	O
registration	O
General	O
practitioner	O
Yes18949	O
.	O
1	O
0	O
.	O
027	O
26769	O
.	O
40	O
.	O

006	O
26769	O
.	O
4	O
0	O
.	O
003	O
No320533	O
.	O
3533	O
.	O
3	O
Obstetrician	O
Yes18555	O
.	O
425576	O
.	O
325576	O
.	O
3	O
No710	O
.	O
61725	O
.	O
81725	O
.	O
8Total	O
number	O
or	O
prenatal	O
visits	O
≤	O
422	O
.	O
8	O
<	O
0	O
.	O
001	O
1825	O
.	O
0	O
<	O
0	O
.	O
001	O
1825	O
.	O
0	O
<	O
0	O
.	O
001	O
>	O
419057	O
.	O
925477	O
.	O
425477	O
.	O
4Gestational	O
age	O
at	O
registration	O
(	O
months	O
)	O
<	O
418053	O
.	O
7	O
<	O
0	O
.	O
001	O
19257	O
.	O
3	O
0	O
.	O
019	O
24472	O
.	O
8	O
<	O
0	O
.	O
001	O
≥	O
41218	O
.	O
52741	O
.	O
52843	O
.	O
1Nutritional	O
questionnaire	O
score	O
Low710	O
.	O
1	O
<	O
0	O
.	O
001	O
2333	O
.	O
3	O
<	O
0	O
.	O
001	O
2231	O
.	O
9	O
<	O
0	O
.	O
001	O
Medium13747	O
.	O
114756	O
.	O
819274	O
.	O
3	O
High4865	O
.	O
84967	O
.	O
65879	O
.	O
7	O
The	O
proportion	O
of	O
less	O
well	O
-	O
educated	O
women	O
(	O
less	O
than	O
8	O
years	O
of	O
school	O
completed	O
)	O
using	O
folic	O
acid	O
(	O
p	O
=	O
.	O
007	O
),	O
iron	O
(	O
p	O
<	O
.	O
001	O
)	O
and	O
multivitamins	O
(	O
p	O
<	O
.	O
001	O
)	O
increased	O
with	O
the	O
number	O
of	O
prenatal	O
visits	O
.	O

The	O
same	O
relationship	O
was	O
observed	O
for	O
women	O
with	O
9	O
–	O
12	O
years	O
of	O
formal	O
education	O
regarding	O
folic	O
acid	O
use	O
(	O
p	O
<	O
.	O
001	O
),	O
iron	O
(	O
p	O
=	O
.	O
001	O
)	O
and	O
multivitamins	O
(	O
p	O
<	O
.	O
001	O
).	O

There	O
was	O
no	O
significant	O
difference	O
of	O
using	O
folic	O
acid	O
,	O
iron	O
and	O
multivitamin	O
supplements	O
in	O
relation	O
to	O
the	O
number	O
of	O
prenatal	O
visits	O
,	O
for	O
women	O
with	O
higher	O
education	O
level	O
(	O
Table	O
3	O
).	O

When	O
analysing	O
separately	O
the	O
interaction	O
effect	O
between	O
education	O
and	O
prenatal	O
care	O
,	O
the	O
probability	B
of	O
using	O
folic	O
acid	O
,	O
iron	O
and	O
vitamins	O
supplements	O
was	O
increasing	O
with	O
the	O
level	O
of	O
formal	O
education	O
and	O
number	O
of	O
prenatal	O
visits	O
(	O
Table	O
4	O
).	O

Caption	O
(	O
TABLE	O
-	O
WRAP	O
):	O
TABLE	O
3	O
Associations	O
between	O
use	O
of	O
folic	O
acid	O
,	O
iron	O
and	O
multivitamin	O
supplements	O
and	O
number	O
of	O
prenatal	O
visits	O
,	O
among	O
categories	O
of	O
formal	O
educationFormal	O
education	O
(	O
years	O
)	O
Number	O
of	O
prenatal	O
visitsp	O
<	O
44	O
-	O
10	O
>	O
10	O
Folic	O
acid	O
use	O
(%)≤	O
8	O
2	O
.	O
114	O
.	O
630	O
.	O
8	O
.	O
007	O
9	O
-	O
12	O
4	O
.	O
344	O
.	O
372	O
.	O
5	O
<.	O
001	O
>	O
12	O
069	O
.	O
474	O
.	O
7	O
.	O
21	O
Iron	O
use	O
(%)≤	O
8	O
16	O
.	O
756	O
.	O
176	O
.	O
9	O
<.	O
001	O
9	O
-	O
12	O
21	O
.	O
751	O
.	O
466	O
.	O
7	O
<.	O
001	O
>	O
12	O
10077	O
.	O
862	O
.	O
6	O
.	O
19	O
Multivitamins	O
use	O
(%)≤	O
8	O
22	O
.	O
953	O
.	O
776	O
.	O
9	O
<.	O
001	O
9	O
-	O
12	O
26	O
.	O
17079	O
.	O
7	O
<.	O
001	O
>	O
12	O
10088	O
.	O
987	O
.	O
5	O
.	O
88	O
Caption	O
(	O
TABLE	O
-	O
WRAP	O
):	O
TABLE	O
4	O
Associations	O
between	O
use	O
of	O
folic	O
acid	O
,	O
iron	O
and	O
multivitamin	O
supplements	O
and	O
the	O
interaction	O
between	O
the	O
number	O
of	O
prenatal	O
visits	O
and	O
formal	O
education	O
level	O
Folic	O
acidIronVitamins	O
OR	O
(	O
95	O
%	O
CI	O
)	O
OR	O
#(	O
95	O
%	O
CI	O
)	O
OR	O
(	O
95	O
%	O
CI	O
)	O
OR	O
#(	O
95	O
%	O
CI	O
)	O
OR	O
(	O
95	O
%	O
CI	O
)	O
OR	O
#(	O
95	O
%	O
CI	O
)	O
Education	O
*	O
Prenatal	O
care	O
interaction	O
PC1	O
*	O
E1110	O
.	O
63	O
(	O
14	O
.	O
94	O
-	O
818	O
.	O
97	O
)	O
63	O
.	O
86	O
(	O
8	O
.	O
47	O
-	O
481	O
.	O
41	O
)	O
10	O
.	O
35	O
(	O
4	O
.	O
60	O
-	O
23	O
.	O
27	O
)	O
7	O
.	O
95	O
(	O
3	O
.	O
36	O
-	O
18	O
.	O
83	O
)	O
18	O
.	O
20	O
(	O
8	O
.	O
46	O
-	O
39	O
.	O
16	O
)	O
11	O
.	O
25	O
(	O
4	O
.	O
96	O
-	O
25	O
.	O
49	O
)	O
PC1	O
*	O
E251	O
.	O
78	O
(	O
6	O
.	O
83	O
-	O
392	O
.	O
29	O
)	O
32	O
.	O
281	O
(	O
4	O
.	O
97	O
-	O
294	O
.	O
63	O
)	O
7	O
.	O
45	O
(	O
2	O
.	O
66	O
-	O
20	O
.	O
88	O
)	O
6	O
.	O
20	O
(	O
2	O
.	O
17	O
-	O
17	O
.	O
73	O
)	O
15	O
.	O
33	O
(	O
5	O
.	O
64	O
-	O
41	O
.	O
68	O
)	O
11	O
.	O
71	O
(	O
4	O
.	O
17	O
-	O
32	O
.	O
87	O
)	O
PC2	O
*	O
E113	O
.	O
73	O
(	O
5	O
.	O
50	O
-	O
34	O
.	O
22	O
)	O
10	O
.	O
941	O
(	O
4	O
.	O
30	O
-	O
27	O
.	O
78	O
)	O
1	O
.	O
62	O
(	O
0	O
.	O
82	O
-	O
3	O
.	O
19	O
)	O
1	O
.	O
38	O
(	O
0	O
.	O
68	O
-	O
2	O
.	O
79	O
)	O
4	O
.	O
67	O
(	O
2	O
.	O
28	O
-	O
9	O
.	O
55	O
)	O
3	O
.	O
65	O
(	O
1	O
.	O
72	O
-	O
7	O
.	O
71	O
)	O
PC2	O
*	O
E22	O
.	O
96	O
(	O
1	O
.	O
70	O
-	O
5	O
.	O
15	O
)	O
2	O
.	O
51	O
(	O
1	O
.	O
41	O
-	O
4	O
.	O
49	O
)	O
1	O
.	O
95	O
(	O
1	O
.	O
13	O
-	O
3	O
.	O
38	O
)	O
1	O
.	O
73	O
(	O
1	O
.	O
10	O
-	O
3	O
.	O
03	O
)	O
2	O
.	O
31	O
(	O
1	O
.	O
23	O
-	O
4	O
.	O
34	O
)	O
2	O
.	O
03	O
(	O
1	O
.	O
05	O
-	O
3	O
.	O
91	O
)	O
Nutritional	O
knowledge	O
score	O
Low111111	O
Medium6	O
.	O
67	O
(	O
2	O
.	O
62	O
-	O
17	O
.	O
01	O
)	O
1	O
.	O
47	O
(	O
0	O
.	O
74	O
-	O
2	O
.	O
89	O
)	O
1	O
.	O
80	O
(	O
0	O
.	O
99	O
-	O
3	O
.	O
27	O
)	O
1	O
.	O
65	O
(	O
0	O
.	O
86	O
-	O
3	O
.	O
15	O
)	O
3	O
.	O
58	O
(	O
1	O
.	O
88	O
-	O
6	O
.	O
80	O
)	O
1	O
.	O
14	O
(	O
0	O
.	O
52	O
-	O
2	O
.	O
50	O
)	O
High8	O
.	O
30	O
(	O
2	O
.	O
99	O
-	O
23	O
.	O
4	O
)	O
7	O
.	O
13	O
(	O
2	O
.	O
33	O
-	O
21	O
.	O
80	O
)	O
2	O
.	O
41	O
(	O
1	O
.	O
14	O
-	O
5	O
.	O
14	O
)	O
2	O
.	O
37	O
(	O
1	O
.	O
50	O
-	O
5	O
.	O
65	O
)	O
3	O
.	O
48	O
(	O
1	O
.	O
50	O
-	O
8	O
.	O
10	O
)	O
3	O
.	O
62	O
(	O
1	O
.	O
38	O
-	O
9	O
.	O
51	O
)	O
PC1	O
–	O
prenatal	O
care	O
:≥	O
10	O
visits	O
;	O
PC2	O
-	O
prenatal	O
care	O
:	O
4	O
–	O
9	O
visits	O
;	O
reference	O
category	O
-	O
<	O
4	O
visits	O
.	O

E1	O
–	O
education	O
:	O
>	O
12	O
years	O
;	O
E2	O
–	O
9	O
–	O
12	O
years	O
;	O
reference	O
category	O
-	O
≤	O
8	O
years	O
.	O

OR	O
#-	O
adjusted	O
for	O
the	O
interaction	O
effect	O
(	O
PC	O
*	O
E	O
).	O

After	O
adjusting	O
for	O
the	O
total	O
number	O
of	O
prenatal	O
visits	O
,	O
we	O
noted	O
independent	O
effects	O
of	O
area	O
of	O
residence	O
and	O
level	O
of	O
education	O
on	O
the	O
use	O
of	O
supplements	O
:	O
women	O
from	O
urban	O
areas	O
and	O
those	O
with	O
more	O
than	O
9	O
years	O
of	O
formal	O
education	O
were	O
more	O
likely	B
to	O
have	O
used	O
folic	O
acid	O
(	O
urban	O
area	O
:	O
aOR	O
,	O
1	O
.	O
5	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
2	O
-	O
1	O
.	O
5	O
;	O
9	O
–	O
12	O
years	O
of	O
education	O
:	O
aOR	O
,	O
4	O
.	O
8	O
;	O
95	O
%	O
CI	O
,	O
2	O
.	O
3	O
-	O
10	O
.	O
0	O
;	O
>	O
12	O
years	O
of	O
school	O
:	O
aOR	O
,	O
8	O
.	O
1	O
;	O
95	O
%	O
CI	O
,	O
3	O
.	O
7	O
-	O
18	O
.	O
0	O
)	O
and	O
multivitamin	O
supplements	O
(	O
urban	O
area	O
:	O
aOR	O
,	O
1	O
.	O
7	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
0	O
-	O
2	O
.	O
7	O
;	O
>	O
12	O
years	O
of	O
school	O
:	O
aOR	O
,	O
3	O
.	O
5	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
7	O
-	O
7	O
.	O
4	O
)	O
(	O
Table	O
5	O
).	O

However	O
these	O
socio	O
-	O
demographic	O
factors	O
were	O
not	O
independent	O
determinants	O
of	O
the	O
use	O
of	O
iron	O
supplements	O
.	O

Caption	O
(	O
TABLE	O
-	O
WRAP	O
):	O
TABLE	O
5	O
Determinants	O
of	O
the	O
use	O
of	O
folic	O
acid	O
,	O
iron	O
and	O
vitamins	O
Folic	O
acidIronVitamins	O
OR	O
(	O
95	O
%	O
CI	O
)#	O
OR	O
(	O
95	O
%	O
CI	O
)##	O
OR	O
(	O
95	O
%	O
CI	O
)#	O
OR	O
(	O
95	O
%	O
CI	O
)##	O
OR	O
(	O
95	O
%	O
CI	O
)#	O
OR	O
(	O
95	O
%	O
CI	O
)##	O
Urban	O
environment	O
1	O
.	O
47	O
(	O
1	O
.	O
18	O
;	O
1	O
.	O
48	O
)	O
1	O
.	O
46	O
(	O
0	O
.	O
83	O
;	O
2	O
.	O
54	O
)	O
0	O
.	O
86	O
(	O
0	O
.	O
55	O
;	O
1	O
.	O
34	O
)	O
0	O
.	O
72	O
(	O
0	O
.	O
44	O
;	O
1	O
.	O
19	O
)	O
1	O
.	O
66	O
(	O
1	O
.	O
01	O
;	O
2	O
.	O
73	O
)	O
1	O
.	O
58	O
(	O
0	O
.	O
90	O
;	O
2	O
.	O
78	O
)	O
Age	O
(	O
yrs	O
)	O
≤	O
1911111119	O
-	O
342	O
.	O
061	O
.	O
271	O
.	O
050	O
.	O
931	O
.	O
551	O
.	O
18	O
(	O
0	O
.	O
66	O
;	O
6	O
.	O
47	O
)(	O
0	O
.	O
39	O
;	O
4	O
.	O
19	O
)(	O
0	O
.	O
47	O
;	O
2	O
.	O
37	O
)(	O
0	O
.	O
41	O
;	O
2	O
.	O
14	O
)	O
0	O
.	O
67	O
;	O
3	O
.	O
580	O
.	O
50	O
;	O
2	O
.	O
78	O
≥	O
353	O
.	O
111	O
.	O
590	O
.	O
760	O
.	O
640	O
.	O
790	O
.	O
50	O
(	O
0	O
.	O
84	O
;	O
11	O
.	O
46	O
)(	O
0	O
.	O
41	O
;	O
6	O
.	O
17	O
)(	O
0	O
.	O
28	O
;	O
2	O
.	O
08	O
)(	O
0	O
.	O
23	O
;	O
1	O
.	O
79	O
)	O
0	O
.	O
28	O
;	O
2	O
.	O
250	O
.	O
17	O
;	O
1	O
.	O
47Schooling	O
(	O
grades	O
)	O
≤	O
8	O
9	O
-	O
12	O
11	O
1111	O
4	O
.	O
764	O
.	O
01	O
1	O
.	O
141	O
.	O
341	O
.	O
631	O
.	O
640	O
>	O
12	O
(	O
2	O
.	O
28	O
;	O
9	O
.	O
97	O
)(	O
1	O
.	O
88	O
;	O
8	O
.	O
56	O
)	O
(	O
0	O
.	O
66	O
;	O
1	O
.	O
98	O
)(	O
0	O
.	O
75	O
;	O
2	O
.	O
37	O
)(	O
0	O
.	O
93	O
;	O
2	O
.	O
88	O
)(	O
0	O
.	O
908	O
;	O
2	O
.	O
964	O
)	O
8	O
.	O
125	O
.	O
21	O
1	O
.	O
54	O
2	O
.	O
303	O
.	O
543	O
.	O
372	O
(	O
3	O
.	O
67	O
;	O
17	O
.	O
96	O
)(	O
2	O
.	O
12	O
;	O
12	O
.	O
82	O
)	O
(	O
0	O
.	O
82	O
;	O
2	O
.	O
90	O
)	O
(	O
1	O
.	O
08	O
;	O
4	O
.	O
86	O
)(	O
1	O
.	O
68	O
;	O
7	O
.	O
43	O
)(	O
1	O
.	O
432	O
;	O
7	O
.	O
940	O
)	O
Married	O
2	O
.	O
68	O
1	O
.	O
931	O
.	O
300	O
.	O
741	O
.	O
491	O
.	O
330	O
(	O
1	O
.	O
34	O
;	O
5	O
.	O
36	O
)	O
(	O
0	O
.	O
93	O
;	O
4	O
.	O
01	O
)(	O
0	O
.	O
75	O
;	O
2	O
.	O
25	O
)(	O
0	O
.	O
45	O
;	O
1	O
.	O
22	O
)(	O
0	O
.	O
83	O
;	O
2	O
.	O
68	O
)(	O
0	O
.	O
712	O
;	O
2	O
.	O
487	O
)	O
Wanted	O
pregnancy0	O
.	O
960	O
.	O
821	O
.	O
611	O
.	O
480	O
.	O
961	O
.	O
49	O
(	O
0	O
.	O
40	O
;	O
2	O
.	O
30	O
)(	O
0	O
.	O
32	O
;	O
2	O
.	O
08	O
)(	O
0	O
.	O
78	O
;	O
3	O
.	O
33	O
)(	O
0	O
.	O
71	O
;	O
3	O
.	O
09	O
)(	O
0	O
.	O
40	O
;	O
2	O
.	O
30	O
)(	O
0	O
.	O
68	O
;	O
3	O
.	O
26First	O
birth1	O
.	O
3540	O
.	O
9470	O
.	O
9130	O
.	O
8982	O
.	O
0361	O
.	O
79	O
(	O
0	O
.	O
706	O
;	O
2	O
.	O
599	O
)(	O
0	O
.	O
474	O
;	O
1	O
.	O
891	O
)(	O
0	O
.	O
519	O
;	O
1	O
.	O
604	O
)(	O
0	O
.	O
506	O
;	O
1	O
.	O
593	O
)(	O
1	O
.	O
128	O
;	O
3	O
.	O
673	O
)(	O
0	O
.	O
98	O
;	O
3	O
.	O
26	O
)≤	O
4	O
pregnancy	O
registration	O
3	O
.	O
763	O
.	O
41	O
1	O
.	O
070	O
.	O
920	O
.	O
482	O
.	O
02	O
(	O
1	O
.	O
19	O
;	O
11	O
.	O
89	O
)(	O
1	O
.	O
05	O
;	O
11	O
.	O
14	O
)	O
(	O
0	O
.	O
52	O
;	O
2	O
.	O
24	O
)(	O
0	O
.	O
48	O
;	O
1	O
.	O
93	O
)(	O
0	O
.	O
22	O
;	O
1	O
.	O
05	O
)(	O
0	O
.	O
91	O
;	O
4	O
.	O
46	O
)	O
No	O
.	O

check	O
-	O
ups	O
<	O
4	O
4	O
-	O
9	O
111111	O
18	O
.	O
9212	O
.	O
065	O
.	O
705	O
.	O
555	O
.	O
344	O
.	O
12	O
≥	O
10	O
(	O
4	O
.	O
41	O
;	O
81	O
.	O
24	O
)*(	O
2	O
.	O
75	O
;	O
52	O
.	O
84	O
)**(	O
2	O
.	O
85	O
;	O
11	O
.	O
38	O
)*(	O
2	O
.	O
70	O
;	O
11	O
.	O
39	O
)**(	O
2	O
.	O
77	O
;	O
10	O
.	O
29	O
)*(	O
2	O
.	O
08	O
;	O
8	O
.	O
15	O
)**	O
83	O
.	O
0335	O
.	O
927	O
.	O
777	O
.	O
1616	O
.	O
449	O
.	O
38	O
(	O
19	O
.	O
5	O
;	O
344	O
.	O
7	O
)*(	O
8	O
.	O
24	O
;	O
156	O
.	O
5	O
)**(	O
4	O
.	O
02	O
;	O
14	O
.	O
67	O
)*(	O
3	O
.	O
42	O
;	O
15	O
.	O
00	O
)**(	O
8	O
.	O
59	O
;	O
31	O
.	O
51	O
)*(	O
4	O
.	O
50	O
;	O
19	O
.	O
48	O
)**	O
Low	O
score	O
111111	O
Medium	O
score	O
6	O
.	O
674	O
.	O
431	O
.	O
801	O
.	O
793	O
.	O
583	O
.	O
08	O
High	O
score	O
(	O
2	O
.	O
62	O
;	O
17	O
.	O
01	O
)(	O
1	O
.	O
70	O
;	O
11	O
.	O
55	O
)(	O
0	O
.	O
99	O
;	O
3	O
.	O
27	O
)(	O
0	O
.	O
95	O
;	O
3	O
.	O
35	O
)(	O
1	O
.	O
88	O
;	O
6	O
.	O
80	O
)(	O
1	O
.	O
58	O
;	O
6	O
.	O
01	O
)	O
8	O
.	O
304	O
.	O
722	O
.	O
412	O
.	O
583	O
.	O
482	O
.	O
81	O
(	O
2	O
.	O
99	O
;	O
23	O
.	O
40	O
)(	O
1	O
.	O
61	O
;	O
13	O
.	O
84	O
)(	O
1	O
.	O
14	O
;	O
5	O
.	O
14	O
)(	O
1	O
.	O
16	O
;	O
5	O
.	O
74	O
)(	O
1	O
.	O
50	O
;	O
8	O
.	O
10	O
)(	O
1	O
.	O
16	O
;	O
6	O
.	O
84	O
)	O
Breastfeeding	O
advice1	O
.	O
851	O
.	O
501	O
.	O
961	O
.	O
971	O
.	O
261	O
.	O
10	O
(	O
0	O
.	O
96	O
;	O
3	O
.	O
55	O
)(	O
0	O
.	O
76	O
;	O
2	O
.	O
95	O
)(	O
1	O
.	O
12	O
;	O
3	O
.	O
46	O
)(	O
1	O
.	O
11	O
;	O
3	O
.	O
50	O
)(	O
0	O
.	O
68	O
;	O
2	O
.	O
32	O
)(	O
0	O
.	O
59	O
;	O
2	O
.	O
06	O
)	O
Diet	O
advice1	O
.	O
531	O
.	O
39	O
1	O
.	O
56	O
1	O
.	O
53	O
1	O
.	O
71	O
1	O
.	O
59	O
(	O
0	O
.	O
96	O
;	O
2	O
.	O
44	O
)(	O
0	O
.	O
85	O
;	O
2	O
.	O
27	O
)	O
(	O
1	O
.	O
01	O
;	O
2	O
.	O
40	O
)	O
(	O
0	O
.	O
98	O
;	O
2	O
.	O
37	O
)	O
(	O
1	O
.	O
03	O
;	O
2	O
.	O
84	O
)	O
(	O
0	O
.	O
95	O
;	O
2	O
.	O
68	O
)	O
*:	O
crude	O
OR	O
;	O
**:	O
OR	O
adjusted	O
for	O
age	O
,	O
schooling	O
,	O
residence	O
area	O
.	O

#:	O
adjusted	O
OR	O
for	O
total	O
number	O
of	O
prenatal	O
medical	O
visits	O
.	O

##:	O
adjusted	O
OR	O
for	O
total	O
number	O
of	O
prenatal	O
checks	O
,	O
age	O
,	O
schooling	O
,	O
residence	O
area	O
.	O

With	O
bold	O
significant	O
OR	O
for	O
p	O
<	O
0	O
.	O
005	O
.	O

Women	O
who	O
stated	O
that	O
they	O
had	O
received	O
dietary	O
or	O
breastfeeding	O
advice	O
had	O
a	O
higher	O
probability	B
of	O
using	O
folic	O
acid	O
or	O
multivitamins	O
regardless	O
of	O
the	O
number	O
of	O
prenatal	O
visits	O
.	O

Early	O
pregnancy	O
registration	O
was	O
significantly	O
associated	O
with	O
the	O
intake	O
of	O
folic	O
acid	O
(	O
aOR	O
,	O
3	O
.	O
8	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
2	O
-	O
11	O
.	O
9	O
).	O

Primiparous	O
women	O
were	O
more	O
likely	B
to	O
use	O
multivitamins	O
regardless	O
of	O
the	O
number	O
of	O
prenatal	O
visits	O
(	O
aOR	O
,	O
2	O
.	O
0	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
1	O
-	O
3	O
.	O
7	O
).	O

Making	O
more	O
than	O
four	O
prenatal	O
visits	O
was	O
also	O
associated	O
with	O
folic	O
acid	O
,	O
iron	O
and	O
multivitamin	O
supplements	O
intake	O
,	O
a	O
positive	O
association	O
that	O
persisted	O
after	O
adjusting	O
for	O
socio	O
-	O
demographic	O
factors	O
(	O
Table	O
5	O
).	O

An	O
above	O
average	O
level	O
of	O
nutritional	O
knowledge	O
was	O
significantly	O
associated	O
with	O
the	O
use	O
of	O
supplements	O
,	O
regardless	O
of	O
the	O
number	O
of	O
prenatal	O
consultations	O
,	O
age	O
,	O
area	O
of	O
residence	O
or	O
formal	O
education	O
(	O
Table	O
5	O
),	O
but	O
also	O
when	O
the	O
interaction	O
effect	O
of	O
prenatal	O
care	O
and	O
formal	O
education	O
together	O
was	O
taken	O
into	O
consideration	O
(	O
Table	O
4	O
).	O

Discussion	O
In	O
our	O
study	O
,	O
less	O
than	O
half	O
the	O
participants	O
used	O
folic	O
acid	O
or	O
iron	O
during	O
their	O
pregnancy	O
,	O
while	O
approximately	O
two	O
thirds	O
took	O
multivitamin	O
supplements	O
.	O

Nutritional	O
knowledge	O
was	O
significantly	O
associated	O
with	O
the	O
intake	O
of	O
these	O
supplements	O
,	O
regardless	O
of	O
the	O
frequency	O
of	O
prenatal	O
visits	O
or	O
socio	O
-	O
demographic	O
characteristics	O
.	O

To	B
the	I
best	I
of	I
our	I
knowledge	I
,	O
this	O
is	O
the	O
first	O
study	O
to	O
have	O
examined	O
the	O
factors	O
that	O
influence	O
use	O
of	O
vitamin	O
and	O
mineral	O
supplements	O
during	O
pregnancy	O
in	O
Eastern	O
Europe	O
.	O

The	O
use	O
of	O
supplements	O
during	O
pregnancy	O
varies	O
widely	O
between	O
countries	O
.	O

These	O
differences	O
cannot	O
be	O
compared	O
directly	O
due	O
to	O
discrepancies	O
in	O
national	O
guidelines	O
and	O
the	O
financial	O
barriers	O
in	O
some	O
regions	O
[	O
27	O
].	O

The	O
most	O
popular	O
vitamin	O
and	O
mineral	O
supplements	O
contain	O
iron	O
,	O
folic	O
acid	O
and	O
vitamin	O
D	O
[	O
12	O
,	O
28	O
].	O

Routine	O
use	O
of	O
iron	O
supplements	O
is	O
common	O
,	O
as	B
it	O
is	O
difficult	O
to	O
ensure	O
adequate	O
intake	O
from	O
food	O
sources	O
,	O
even	O
from	O
those	O
with	O
relatively	O
high	O
iron	O
bioavailability	O
[	O
29	O
,	O
30	O
].	O

The	O
Institute	O
of	O
Medicine	O
recommends	O
a	O
daily	O
intake	O
of	O
400	O
μg	O
of	O
folic	O
acid	O
and	O
30	O
mg	O
of	O
iron	O
during	O
the	O
second	O
and	O
third	O
trimesters	O
[	O
31	O
].	O

Vitamin	O
and	O
mineral	O
supplements	O
are	O
recommended	O
for	O
women	O
with	O
multiple	O
pregnancy	O
,	O
those	O
who	O
misuse	O
alcohol	O
or	O
drugs	O
,	O
or	O
have	O
an	O
unbalanced	O
diet	O
[	O
32	O
].	O

The	O
World	O
Health	O
Organization	O
recommends	O
a	O
daily	O
intake	O
of	O
60	O
mg	O
iron	O
and	O
400	O
μg	O
folic	O
acid	O
for	O
six	O
months	O
to	O
prevent	O
anaemia	O
[	O
33	O
].	O

Romanian	O
recommendations	O
stipulate	O
that	O
women	O
with	O
a	O
haemoglobin	O
higher	O
than	O
11	O
g	O
/	O
dl	O
should	O
take	O
60	O
mg	O
of	O
iron	O
and	O
350	O
μg	O
of	O
folic	O
acid	O
from	O
the	O
16thweek	O
of	O
pregnancy	O
to	O
prevent	O
anaemia	O
,	O
but	O
only	O
iron	O
products	O
are	O
reimbursed	O
by	O
the	O
health	O
insurance	O
system	O
.	O

To	O
prevent	O
neural	O
tube	O
defects	O
,	O
400	O
μg	O
of	O
folic	O
acid	O
should	O
be	O
taken	O
daily	O
,	O
starting	O
one	O
month	O
before	O
conception	O
and	O
throughout	O
the	O
first	O
trimester	O
.	O

The	O
routine	O
use	O
of	O
multivitamins	O
is	O
not	O
recommended	O
[	O
34	O
].	O

We	O
evaluated	O
the	O
determinants	O
for	O
the	O
intake	O
of	O
multivitamins	O
as	O
previous	O
studies	O
,	O
as	O
well	O
as	O
the	O
common	O
practice	O
in	O
Romania	O
suggested	O
a	O
high	O
incidence	O
of	O
use	O
[	O
14	O
,	O
35	O
],	O
despite	O
the	O
lack	O
of	O
recommendation	O
.	O

We	O
found	O
that	O
48	O
.	O
0	O
%	O
of	O
women	O
took	O
folic	O
acid	O
at	O
some	O
stage	O
during	O
pregnancy	O
,	O
compared	O
with	O
27	O
.	O
0	O
%	O
in	O
the	O
IOMC	O
study	O
.	O

This	O
may	O
have	O
arisen	O
as	B
a	O
consequence	O
of	O
the	O
IOMC	O
study	O
only	O
examining	O
folic	O
acid	O
use	O
during	O
the	O
last	O
trimester	O
of	O
pregnancy	O
[	O
14	O
].	O

The	O
proportion	O
of	O
women	O
in	O
our	O
study	O
group	O
taking	O
folic	O
acid	O
is	O
still	O
low	O
,	O
despite	O
its	O
widely	O
recognised	O
benefits	O
,	O
but	O
could	O
be	O
explained	B
by	O
the	O
lack	O
of	O
reimbursement	O
for	O
the	O
cost	O
of	O
folic	O
acid	O
,	O
which	O
must	O
be	O
bought	O
over	O
the	O
counter	O
at	O
any	O
time	O
it	O
is	O
prescribed	O
,	O
during	O
pregnancy	O
or	O
before	O
conception	O
.	O

The	O
reported	O
adherence	O
rates	O
to	O
folic	O
acid	O
intake	O
in	O
other	O
countries	O
vary	O
depending	O
on	O
concomitant	O
recommendations	O
for	O
cereal	O
fortification	O
and	O
on	O
the	O
period	O
analysed	O
–	O
pre	O
-	O
or	O
peri	O
-	O
conception	O
.	O

In	O
a	O
meta	O
-	O
analysis	O
undertaken	O
by	O
Pena	O
-	O
Rosas	O
et	O
al	O
.	O

[	O
32	O
],	O
the	O
proportion	O
of	O
women	O
taking	O
folic	O
acid	O
varies	O
between	O
0	O
.	O
9	O
%	O
and	O
49	O
%	O
before	O
conception	O
and	O
between	O
0	O
.	O
5	O
%	O
and	O
52	O
%	O
in	O
the	O
peri	O
-	O
conception	O
period	O
.	O

Our	O
results	O
lie	O
within	O
these	O
ranges	O
,	O
but	O
it	O
is	O
difficult	O
to	O
make	O
a	O
comparison	O
,	O
as	B
the	O
variations	O
are	O
very	O
wide	O
and	O
we	O
recorded	O
the	O
use	O
of	O
folic	O
acid	O
throughout	O
pregnancy	O
without	O
focusing	O
on	O
the	O
first	O
trimester	O
.	O

It	O
could	O
be	O
argued	O
that	O
as	B
routine	O
prenatal	O
care	O
in	O
Romania	O
does	O
not	O
usually	O
begin	O
until	O
after	O
the	O
first	O
trimester	O
is	O
almost	O
ended	O
,	O
including	O
advice	O
about	O
folic	O
acid	O
as	O
part	O
of	O
prenatal	O
care	O
is	O
redundant	O
as	O
the	O
neural	O
tube	O
has	O
fully	O
developed	O
within	O
28	O
days	O
of	O
conception	O
[	O
9	O
].	O

Nonetheless	O
,	O
folic	O
acid	O
supplementation	O
might	O
address	O
other	O
forms	O
of	O
anaemia	O
,	O
and	O
the	O
advice	O
might	O
also	O
increase	O
the	O
likelihood	B
of	O
folic	O
acid	O
use	O
before	O
and	O
during	O
future	O
pregnancies	O
.	O

Among	O
the	O
factors	O
evaluated	O
in	O
our	O
study	O
,	O
area	O
of	O
residence	O
,	O
level	O
of	O
education	O
and	O
marital	O
status	O
were	O
associated	O
with	O
the	O
intake	O
of	O
folic	O
acid	O
during	O
pregnancy	O
,	O
independently	O
of	O
the	O
number	O
of	O
prenatal	O
visits	O
.	O

This	O
observation	O
could	O
be	O
a	O
consequence	O
of	O
social	O
inequity	O
or	O
particular	O
health	O
beliefs	O
.	O

The	O
number	O
of	O
prenatal	O
visits	O
,	O
registration	O
with	O
a	O
physician	O
early	O
in	O
pregnancy	O
and	O
the	O
level	O
of	O
nutritional	O
knowledge	O
were	O
independently	O
associated	O
with	O
the	O
use	O
of	O
folic	O
acid	O
,	O
after	O
adjusting	O
for	O
socio	O
-	O
demographic	O
factors	O
,	O
suggesting	O
that	O
educational	O
interventions	O
could	O
play	O
an	O
important	O
role	O
in	O
promoting	O
the	O
use	O
of	O
folic	O
acid	O
supplements	O
.	O

The	O
observation	O
that	O
early	O
registration	O
with	O
a	O
physician	O
in	O
pregnancy	O
was	O
associated	O
with	O
folic	O
acid	O
intake	O
could	O
indicate	O
the	O
recognised	B
importance	O
of	O
early	O
prenatal	O
care	O
.	O

Furthermore	O
,	O
it	O
is	O
perhaps	O
unsurprising	B
that	O
women	O
with	O
higher	O
educational	O
achievement	O
and	O
also	O
those	O
with	O
greater	O
engagement	O
with	O
prenatal	O
care	O
had	O
better	O
nutritional	O
knowledge	O
and	O
used	O
supplements	O
more	O
.	O

Importantly	O
,	O
we	O
also	O
found	O
that	O
less	O
well	O
-	O
educated	O
women	O
who	O
engaged	O
with	O
prenatal	O
care	O
were	O
more	O
likely	B
to	O
take	O
folic	O
acid	O
.	O

This	O
suggests	O
that	O
the	O
interventions	O
(	O
prenatal	O
visits	O
)	O
are	O
productive	O
,	O
and	O
that	O
the	O
Romanian	O
government	O
should	O
seek	O
ways	O
of	O
encouraging	O
less	O
well	O
-	O
educated	O
women	O
to	O
participate	O
.	O

Some	O
of	O
our	O
findings	O
are	O
comparable	O
with	O
those	O
of	O
studies	O
conducted	O
in	O
other	O
countries	O
.	O

Low	O
adherence	O
with	O
advice	O
about	O
supplements	O
was	O
associated	O
with	O
unwanted	O
pregnancy	O
,	O
low	O
maternal	O
age	O
and	O
low	O
economic	O
status	O
in	O
the	O
United	O
Kingdom	O
[	O
36	O
],	O
unplanned	O
pregnancy	O
and	O
lack	O
of	O
education	O
regarding	O
the	O
role	O
of	O
folic	O
acid	O
in	O
South	O
Korea	O
[	O
37	O
].	O

The	O
impact	O
of	O
nutritional	O
knowledge	O
on	O
the	O
use	O
of	O
folic	O
acid	O
was	O
emphasised	O
in	O
a	O
study	O
conducted	O
in	O
Turkey	O
,	O
where	O
factors	O
negatively	O
associated	O
with	O
pre	O
-	O
conception	O
supplementation	O
were	O
low	O
socio	O
-	O
economic	O
status	O
,	O
age	O
below	O
30	O
years	O
,	O
low	O
levels	O
of	O
education	O
and	O
unplanned	O
pregnancy	O
.	O

The	O
same	O
study	O
stressed	O
that	O
the	O
level	O
of	O
knowledge	O
about	O
food	O
sources	O
and	O
the	O
role	O
of	O
folic	O
acid	O
during	O
pregnancy	O
was	O
influenced	O
by	O
socio	O
-	O
demographic	O
factors	O
,	O
especially	O
the	O
level	O
of	O
education	O
[	O
38	O
].	O

In	O
our	O
study	O
,	O
the	O
level	O
of	O
nutritional	O
knowledge	O
was	O
an	O
independent	O
determinant	O
for	O
the	O
use	O
of	O
folic	O
acid	O
during	O
pregnancy	O
.	O

A	O
relatively	O
low	O
proportion	O
of	O
women	O
in	O
our	O
study	O
used	O
iron	O
supplements	O
(	O
45	O
.	O
3	O
%),	O
although	O
these	O
are	O
provided	O
free	O
of	O
charge	O
to	O
women	O
after	O
the	O
16thweek	O
of	O
pregnancy	O
.	O

A	O
previous	O
study	O
in	O
Romania	O
reported	O
that	O
supplemental	O
iron	O
was	O
taken	O
by	O
53	O
.	O
3	O
%	O
of	O
women	O
during	O
pregancy	O
[	O
14	O
].	O

A	O
Danish	O
study	O
reported	O
that	O
adherence	O
with	O
an	O
iron	O
supplementation	O
regime	O
was	O
associated	O
with	O
maternal	O
age	O
(	O
over	O
20	O
years	O
),	O
primiparity	O
and	O
educational	O
level	O
[	O
18	O
].	O

These	O
results	O
are	O
similar	O
to	O
ours	O
:	O
we	O
found	O
that	O
women	O
aged	O
over	O
18	O
years	O
,	O
with	O
parity	O
less	O
than	O
two	O
,	O
with	O
more	O
than	O
9	O
years	O
of	O
education	O
,	O
from	O
urban	O
areas	O
with	O
a	O
wanted	O
pregnancy	O
or	O
who	O
were	O
married	O
were	O
significantly	O
more	O
likely	B
to	O
use	O
iron	O
supplements	O
.	O

After	O
adjusting	O
for	O
socio	O
-	O
demographic	O
factors	O
,	O
more	O
than	O
four	O
prenatal	O
visits	O
and	O
level	O
of	O
nutritional	O
knowledge	O
remained	O
associated	O
with	O
iron	O
supplementation	O
.	O

This	O
highlights	O
the	O
importance	O
of	O
prenatal	O
care	O
,	O
both	O
in	O
terms	O
of	O
frequency	O
and	O
content	O
,	O
in	O
improving	O
adherence	O
to	O
programs	O
to	O
prevent	O
anaemia	O
.	O

Multivitamins	O
were	O
used	O
by	O
68	O
%	O
of	O
the	O
women	O
in	O
our	O
study	O
,	O
comparable	O
with	O
the	O
60	O
%	O
reported	O
by	O
the	O
IOMC	O
study	O
[	O
14	O
].	O

This	O
is	O
a	O
surprisingly	O
high	O
proportion	O
,	O
especially	O
when	O
there	O
is	O
no	O
strong	O
recommendation	O
for	O
the	O
use	O
of	O
multivitamins	O
in	O
Romania	O
or	O
internationally	O
.	O

Moreover	O
,	O
reimbursement	O
for	O
multivitamin	O
supplements	O
is	O
not	O
covered	O
by	O
insurance	O
in	O
Romania	O
,	O
suggesting	O
that	O
there	O
are	O
other	O
factors	O
contributing	O
to	O
their	O
use	O
.	O

Some	O
studies	O
describe	O
a	O
positive	O
association	O
between	O
the	O
use	O
of	O
multivitamins	O
during	O
pregnancy	O
and	O
certain	O
socio	O
-	O
demographic	O
characteristics	O
,	O
such	O
as	O
age	O
[	O
15	O
,	O
16	O
,	O
18	O
,	O
20	O
],	O
education	O
[	O
15	O
,	O
17	O
,	O
18	O
,	O
36	O
,	O
39	O
]	O
and	O
marital	O
status	O
[	O
17	O
];	O
but	O
others	O
have	O
reported	O
an	O
inverse	O
relation	O
between	O
education	O
and	O
the	O
use	O
of	O
multivitamins	O
[	O
27	O
].	O

There	O
is	O
also	O
evidence	O
of	O
a	O
relationship	O
between	O
engagement	O
with	O
prenatal	O
care	O
and	O
use	O
of	O
multivitamin	O
supplements	O
,	O
the	O
adequacy	O
of	O
prenatal	O
care	O
being	O
assessed	O
according	O
to	O
Adequacy	O
of	O
Prenatal	O
Care	O
Utilisation	O
Index	O
,	O
which	O
takes	O
into	O
account	O
the	O
month	O
of	O
initiation	O
of	O
care	O
and	O
the	O
proportion	O
of	O
recommended	O
visits	O
adjusted	O
for	O
the	O
gestational	O
age	O
at	O
initiation	O
of	O
care	O
and	O
gestational	O
age	O
at	O
delivery	O
[	O
27	O
].	O

This	O
index	O
is	O
not	O
recorded	O
in	O
Romania	O
;	O
instead	O
,	O
we	O
evaluated	O
engagement	O
in	O
prenatal	O
care	O
according	O
to	O
Ministry	O
of	O
Health	O
recommendations	O
,	O
which	O
refer	O
to	O
the	O
total	O
number	O
of	O
prenatal	O
consultations	O
and	O
time	O
of	O
initiation	O
of	O
care	O
.	O

The	O
content	O
of	O
prenatal	O
care	O
,	O
including	O
nutritional	O
education	O
,	O
is	O
an	O
important	O
factor	O
that	O
could	O
determine	O
the	O
use	O
of	O
supplements	O
during	O
pregnancy	O
,	O
but	O
women	O
may	O
also	O
receive	O
advice	O
from	O
friends	O
,	O
family	O
,	O
the	O
media	O
and	O
other	O
sources	O
.	O

In	O
our	O
study	O
,	O
women	O
who	O
scored	O
at	O
least	O
“	O
medium	O
”	O
in	O
the	O
nutritional	O
knowledge	O
questionnaire	O
were	O
more	O
likely	B
to	O
use	O
multivitamins	O
.	O

Thus	B
,	O
even	O
though	O
there	O
is	O
no	O
consensus	O
on	O
recommending	O
the	O
use	O
of	O
multivitamins	O
during	O
pregnancy	O
,	O
they	O
are	O
used	O
more	O
often	O
by	O
those	O
women	O
with	O
a	O
better	O
socio	O
-	O
economic	O
status	O
,	O
with	O
a	O
higher	O
level	O
of	O
education	O
and	O
who	O
attended	O
more	O
prenatal	O
consultations	O
.	O

Other	O
studies	O
show	O
that	O
factors	O
associated	O
with	O
multivitamin	O
supplementation	O
during	O
pregnancy	O
are	O
schooling	O
level	O
[	O
15	O
,	O
40	O
]	O
and	O
age	O
[	O
28	O
].	O

The	O
results	O
of	O
the	O
Behavioural	O
Risk	O
Factor	O
Surveillance	O
System	O
(	O
BRFSS	O
)	O
also	O
emphasize	O
the	O
role	O
of	O
income	O
and	O
marital	O
status	O
in	O
the	O
use	O
of	O
vitamin	O
and	O
mineral	O
supplements	O
[	O
40	O
].	O

In	O
our	O
study	O
,	O
after	O
adjusting	O
for	O
the	O
number	O
of	O
prenatal	O
consultations	O
,	O
the	O
only	O
socio	O
-	O
demographic	O
factors	O
that	O
persisted	O
on	O
being	O
associated	O
with	O
the	O
use	O
of	O
multivitamins	O
during	O
pregnancy	O
were	O
:	O
area	O
of	O
residence	O
;	O
level	O
of	O
education	O
;	O
parity	O
and	O
receipt	O
of	O
advice	O
about	O
diet	O
and	O
breastfeeding	O
.	O

This	O
might	O
suggest	O
the	O
existence	O
of	O
social	O
inequities	O
and	O
the	O
influence	O
of	O
economic	O
factors	O
in	O
making	O
health	O
-	O
related	O
decisions	O
,	O
as	O
in	O
our	O
country	O
,	O
women	O
in	O
the	O
urban	O
area	O
,	O
more	O
educated	O
and	O
with	O
less	O
children	O
are	O
usually	O
having	O
a	O
better	O
financial	O
status	O
.	O

After	O
adjusting	O
for	O
socio	O
-	O
demographic	O
factors	O
,	O
making	O
more	O
than	O
four	O
prenatal	O
consultations	O
remained	O
associated	O
with	O
the	O
use	O
of	O
multivitamin	O
supplements	O
.	O

These	O
supplements	O
are	O
not	O
necessary	O
in	O
most	O
pregnancies	O
,	O
which	O
raises	O
questions	O
about	O
women	O
’	O
s	O
motivation	O
to	O
use	O
them	O
in	O
the	O
absence	O
of	O
formal	O
recommendations	O
.	O

Level	O
of	O
nutritional	O
knowledge	O
was	O
associated	O
with	O
the	O
use	O
of	O
multivitamins	O
regardless	O
of	O
the	O
number	O
of	O
prenatal	O
visits	O
,	O
age	O
,	O
area	O
of	O
residence	O
and	O
level	O
of	O
education	O
,	O
which	O
could	O
suggest	O
that	O
the	O
decision	O
to	O
use	O
them	O
depends	O
on	O
other	O
factors	O
,	O
such	O
as	O
attitudes	O
towards	O
pregnancy	O
or	O
beliefs	O
about	O
the	O
importance	O
of	O
vitamins	O
during	O
pregnancy	O
,	O
areas	O
that	O
warrant	O
further	O
study	O
.	O

Limitations	O
This	O
study	O
is	O
based	O
on	O
retrospectively	O
self	O
-	O
reported	O
data	O
,	O
which	O
could	O
have	O
led	O
to	O
an	O
underestimation	O
of	O
the	O
use	O
of	O
supplements	O
,	O
especially	O
folic	O
acid	O
[	O
27	O
].	O

We	O
mitigated	O
against	O
this	O
possible	O
source	O
of	O
error	O
by	O
asking	O
additional	O
questions	O
about	O
the	O
type	O
of	O
supplement	O
and	O
its	O
commercial	O
name	O
.	O

This	O
was	O
the	O
first	O
use	O
of	O
a	O
newly	O
developed	O
questionnaire	O
,	O
which	O
we	O
administered	O
2	O
–	O
3	O
days	O
after	O
delivery	O
,	O
to	O
include	O
women	O
who	O
may	O
not	O
have	O
engaged	O
with	O
prenatal	O
care	O
.	O

Having	O
done	O
so	O
,	O
however	O
,	O
some	O
of	O
our	O
participants	O
may	O
not	O
have	O
accurately	O
remembered	O
their	O
use	O
of	O
supplements	O
early	O
in	O
pregnancy	O
or	O
before	O
conception	O
.	O

Even	O
though	O
our	O
results	O
highlight	O
the	O
importance	O
of	O
nutritional	O
knowledge	O
in	O
the	O
decision	O
to	O
use	O
iron	O
or	O
folic	O
acid	O
,	O
we	O
cannot	O
draw	O
conclusions	O
about	O
overall	O
compliance	O
with	O
supplement	O
regimes	O
,	O
because	O
we	O
did	O
not	O
record	O
the	O
dose	O
or	O
duration	O
of	O
iron	O
,	O
folic	O
acid	O
or	O
multivitamin	O
use	O
.	O

Furthermore	O
,	O
we	O
did	O
not	O
record	O
when	O
during	O
the	O
pregnancy	O
the	O
supplements	O
were	O
taken	O
,	O
which	O
is	O
of	O
particular	O
importance	O
for	O
folic	O
acid	O
.	O

The	O
sample	O
size	O
of	O
our	O
study	O
was	O
determined	O
based	O
on	O
an	O
unknown	O
prevalence	O
of	O
supplements	O
intake	O
(	O
which	O
was	O
set	O
by	O
default	O
to	O
be	O
50	O
%),	O
but	O
may	O
have	O
been	O
too	O
small	O
to	O
accommodate	O
some	O
subgroup	O
analyses	O
;	O
we	O
must	O
therefore	B
be	O
cautious	O
about	O
the	O
conclusions	B
that	O
can	O
be	O
drawn	O
from	O
subgroup	O
analysis	O
and	O
test	O
the	O
hypotheses	O
that	O
arise	O
from	O
these	O
findings	O
in	O
future	O
studies	O
.	O

As	B
this	O
is	O
an	O
observational	O
study	O
,	O
we	O
cannot	O
conclude	O
that	O
the	O
information	O
about	O
the	O
roles	O
or	O
sources	O
of	O
nutrients	O
or	O
general	O
recommendations	O
about	O
diet	O
during	O
pregnancy	O
directly	O
influence	O
the	O
frequency	O
with	O
which	O
supplements	O
are	O
used	O
,	O
despite	O
the	O
fact	O
that	O
nutritional	O
knowledge	O
appears	O
to	O
be	O
an	O
important	O
determinant	O
.	O

Additional	O
studies	O
are	O
required	O
better	O
to	O
understand	O
women	O
’	O
s	O
attitudes	O
towards	O
using	O
supplements	O
and	O
the	O
way	O
nutritional	O
knowledge	O
is	O
delivered	O
and	O
used	O
.	O

Conclusions	O
The	O
level	O
of	O
nutritional	O
knowledge	O
was	O
significantly	O
and	O
independently	O
associated	O
with	O
iron	O
,	O
folic	O
acid	O
and	O
multivitamin	O
supplements	O
use	O
during	O
pregnancy	O
.	O

Engagement	O
with	O
prenatal	O
care	O
appeared	O
to	O
increase	O
the	O
likelihood	B
that	O
less	O
well	O
-	O
educated	O
women	O
would	O
take	O
supplements	O
during	O
pregnancy	O
,	O
suggesting	O
that	O
the	O
prenatal	O
nutritional	O
advice	O
may	O
be	O
a	O
useful	O
intervention	O
.	O

From	O
a	O
public	O
health	O
perspective	O
,	O
this	O
is	O
crucially	O
important	O
,	O
and	O
should	O
motivate	O
more	O
effective	O
implementation	O
of	O
nutritional	O
educational	O
programmes	O
for	O
women	O
of	O
childbearing	O
age	O
.	O

Competing	O
interests	O
The	O
authors	O
declare	O
that	O
they	O
have	O
no	O
competing	O
interests	O
.	O

Authors	O
’	O
contributions	O
All	O
authors	O
listed	O
have	O
contributed	O
sufficiently	O
to	O
the	O
project	O
to	O
be	O
included	O
as	O
authors	O
,	O
and	O
all	O
those	O
who	O
are	O
qualified	O
to	O
be	O
authors	O
are	O
listed	O
in	O
the	O
author	O
byline	O
.	O

ADP	O
,	O
ON	O
,	O
LM	O
,	O
and	O
MG	O
contributed	O
to	O
the	O
study	O
conceptualization	O
and	O
design	O
,	O
acquisition	O
of	O
data	O
,	O
analysis	O
and	O
interpretation	O
of	O
data	O
and	O
writing	O
of	O
article	O
.	O

ADP	O
,	O
GEB	O
and	O
LIG	O
contributed	O
to	O
study	O
conceptualization	O
and	O
design	O
,	O
analysis	O
and	O
interpretation	O
of	O
data	O
and	O
writing	O
the	O
article	O
.	O

RMP	O
and	O
MG	O
commented	O
on	O
the	O
manuscript	O
.	O

All	O
authors	O
have	O
read	O
and	O
approved	O
the	O
submitted	O
manuscript	O
.	O

Pre	O
-	O
publication	O
history	O
The	O
pre	O
-	O
publication	O
history	O
for	O
this	O
paper	O
can	O
be	O
accessed	O
here	O
:	O
http	O
://	O
www	O
.	O
biomedcentral	O
.	O
com	O
/	O
1471	O
-	O
2458	O
/	O
13	O
/	O
1105	O
/	O
prepub	O
Supplementary	O
Material	O
Caption	O
(	O
SUPPLEMENTARY	O
-	O
MATERIAL	O
)	O
Additional	O
file	O
1	O
Nutritional	O
knowledge	O
questionnaire	O
.	O

Caption	O
(	O
MEDIA	O
)	O
Click	O
here	O
for	O
file	O
PubMed	O
Central	O
:	O

Vitamin	O
D	O
status	O
of	O
children	O
with	O
severe	O
early	O
childhood	O
caries	O
:	O
a	O
case	O
–	O
control	O
study	O
Abstract	O
Background	O
Severe	O
Early	O
Childhood	O
Caries	O
(	O
S	O
-	O
ECC	O
)	O
affects	O
the	O
health	O
and	O
well	O
-	O
being	O
of	O
young	O
children	O
.	O

There	O
is	O
limited	O
research	O
in	O
this	O
area	O
,	O
though	O
evidence	O
suggests	O
that	O
children	O
with	O
S	O
-	O
ECC	O
are	O
at	O
an	O
increased	O
risk	O
of	O
malnutrition	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
determine	O
the	O
association	O
between	O
vitamin	O
D	O
(	O
25	O
(	O
OH	O
)	O
D	O
)	O
levels	O
and	O
S	O
-	O
ECC	O
.	O

Methods	O
This	O
case	O
–	O
control	O
study	O
was	O
conducted	O
from	O
2009	O
to	O
2011	O
in	O
the	O
city	O
of	O
Winnipeg	O
,	O
Manitoba	O
,	O
Canada	O
.	O

144	O
preschool	O
children	O
with	O
S	O
-	O
ECC	O
were	O
recruited	O
from	O
a	O
local	O
health	O
centre	O
on	O
the	O
day	O
of	O
their	O
slated	O
dental	O
surgery	O
under	O
general	O
anesthetic	O
.	O

122	O
caries	O
-	O
free	O
controls	O
were	O
recruited	O
from	O
the	O
community	O
.	O

Children	O
underwent	O
a	O
blood	O
draw	O
for	O
vitamin	O
D	O
(	O
25	O
(	O
OH	O
)	O
D	O
),	O
calcium	O
,	O
parathyroid	O
hormone	O
,	O
and	O
albumin	O
levels	O
.	O

Parents	O
completed	O
an	O
interviewed	O
questionnaire	O
assessing	O
the	O
child	O
’	O
s	O
nutritional	O
habits	O
,	O
oral	O
health	O
,	O
and	O
family	O
demographics	O
.	O

Analyses	O
included	O
descriptive	O
and	O
bivariate	O
statistics	O
as	O
well	O
as	O
multiple	O
and	O
logistic	O
regression	O
.	O

A	O
p	O
value	O
≤	O
0	O
.	O
05	O
was	O
significant	O
.	O

Results	O
The	O
mean	O
age	O
of	O
participants	O
was	O
40	O
.	O
8	O
±	O
14	O
.	O
1	O
months	O
.	O

Children	O
with	O
S	O
-	O
ECC	O
had	O
significantly	O
lower	O
mean	O
25	O
(	O
OH	O
)	O
D	O
(	O
68	O
.	O
9	O
±	O
28	O
.	O
0	O
nmol	O
/	O
L	O
vs	O
.	O
82	O
.	O
9	O
±	O
31	O
.	O
1	O
,	O
p	O
<	O
0	O
.	O
001	O
),	O
calcium	O
(	O
p	O
<	O
0	O
.	O
001	O
),	O
and	O
albumin	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
levels	O
,	O
and	O
significantly	O
higher	O
parathyroid	O
hormone	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
levels	O
than	O
those	O
caries	O
-	O
free	O
.	O

Children	O
with	O
S	O
-	O
ECC	O
were	O
significantly	O
more	O
likely	B
to	O
have	O
vitamin	O
D	O
levels	O
below	O
recognized	B
thresholds	B
for	O
optimal	O
and	O
adequate	O
status	O
(	O
i	O
.	O
e	O
.	O

<	O
75	O
and	O
<	O
50	O
nmol	O
/	O
L	O
,	O
respectively	O
).	O

Multiple	O
regression	O
analysis	O
revealed	O
that	O
S	O
-	O
ECC	O
,	O
infrequent	O
milk	O
consumption	O
,	O
and	O
winter	O
season	O
were	O
significantly	O
associated	O
with	O
lower	O
25	O
(	O
OH	O
)	O
D	O
concentrations	O
.	O

Low	O
25	O
(	O
OH	O
)	O
D	O
levels	O
,	O
low	O
household	O
income	O
,	O
and	O
poorer	O
ratings	O
of	O
the	O
child	O
’	O
s	O
general	O
health	O
were	O
significantly	O
associated	O
with	O
S	O
-	O
ECC	O
on	O
logistic	O
regression	O
.	O

Conclusion	O
Children	O
with	O
S	O
-	O
ECC	O
appear	O
to	O
have	O
relatively	O
poor	O
nutritional	O
health	O
compared	O
to	O
caries	O
-	O
free	O
controls	O
,	O
and	O
were	O
significantly	O
more	O
likely	B
to	O
have	O
low	O
vitamin	O
D	O
,	O
calcium	O
,	O
and	O
albumin	O
concentrations	O
and	O
elevated	O
PTH	O
levels	O
.	O

Background	O
Early	O
Childhood	O
Caries	O
(	O
ECC	O
)	O
is	O
the	O
most	O
common	O
chronic	O
disease	O
of	O
childhood	O
and	O
is	O
defined	O
as	B
any	O
decay	O
in	O
the	O
primary	O
dentition	O
of	O
children	O
<	O
72	O
months	O
of	O
age	O
[	O
1	O
,	O
2	O
].	O

Some	O
children	O
develop	O
a	O
rampant	O
subtype	O
of	O
ECC	O
termed	O
Severe	O
Early	O
Childhood	O
Caries	O
(	O
S	O
-	O
ECC	O
),	O
a	O
condition	O
known	O
to	O
affect	O
health	O
and	O
well	O
-	O
being	O
[	O
3	O
].	O

The	O
extent	O
of	O
decay	O
that	O
they	O
experience	O
generally	B
warrants	O
rehabilitative	O
dental	O
surgery	O
under	O
general	O
anesthesia	O
(	O
GA	O
).	O

Unfortunately	O
,	O
dental	O
surgery	O
is	O
the	O
most	O
common	O
day	O
surgical	O
procedure	O
at	O
most	B
Canadian	O
pediatric	O
hospitals	O
[	O
4	O
].	O

While	O
dental	O
surgery	O
targets	O
the	O
visible	O
signs	O
of	O
the	O
disease	O
,	O
our	O
understanding	O
of	O
the	O
systemic	O
influence	O
of	O
S	O
-	O
ECC	O
on	O
overall	O
health	O
is	O
limited	O
.	O

Quality	O
of	O
life	O
is	O
reduced	O
among	O
those	O
suffering	O
from	O
S	O
-	O
ECC	O
[	O
3	O
,	O
5	O
,	O
6	O
].	O

This	O
can	O
include	O
pain	O
,	O
disturbed	O
sleep	O
and	O
behavioural	O
changes	O
[	O
6	O
-	O
8	O
].	O

Children	O
with	O
severe	O
decay	O
can	O
also	O
have	O
altered	O
eating	O
habits	O
and	O
preferences	O
[	O
5	O
,	O
9	O
].	O

Therefore	B
,	O
rampant	O
caries	O
can	O
influence	O
nutritional	O
health	O
.	O

A	O
few	O
reports	O
reveal	O
that	O
some	O
may	O
be	O
suffering	O
from	O
a	O
degree	O
of	O
malnutrition	O
,	O
specifically	O
anaemia	O
and	O
low	O
iron	O
concentrations	O
,	O
and	O
have	O
altered	O
growth	O
patterns	O
impacting	O
height	O
and	O
body	O
mass	O
index	O
[	O
10	O
-	O
13	O
].	O

It	O
is	O
plausible	O
that	O
those	O
with	O
S	O
-	O
ECC	O
are	O
also	O
deficient	O
in	O
important	O
vitamins	O
and	O
nutrients	O
,	O
including	O
vitamin	O
D	O
[	O
14	O
].	O

Vitamin	O
D	O
regulates	O
calcium	O
levels	O
and	O
plays	O
a	O
key	O
role	O
in	O
craniofacial	O
development	O
and	O
the	O
maintenance	O
of	O
good	O
oral	O
health	O
.	O

There	O
are	O
two	O
main	O
sources	O
of	O
obtaining	O
vitamin	O
D	O
:	O
endogenous	O
synthesis	O
and	O
exogenous	O
attainment	O
from	O
diet	O
and	O
supplementation	O
[	O
15	O
,	O
16	O
].	O

It	O
has	O
a	O
critical	O
role	O
in	O
enamel	O
,	O
dentin	O
,	O
and	O
oral	O
bone	O
formation	O
as	B
ameloblasts	O
and	O
odontoblasts	O
are	O
target	O
cells	O
for	O
1	O
,	O
25	O
-	O
dihydroxyvitamin	O
D	O
,	O
the	O
active	O
form	O
of	O
vitamin	O
D	O
[	O
17	O
].	O

Deficiency	O
in	O
vitamin	O
D	O
during	O
periods	O
of	O
tooth	O
development	O
may	O
also	O
result	O
in	O
developmental	O
defects	O
[	O
17	O
]	O
including	O
enamel	O
hypoplasia	O
,	O
a	O
significant	O
risk	O
factor	O
for	O
S	O
-	O
ECC	O
.	O

Vitamin	O
D	O
is	O
associated	O
with	O
the	O
two	O
main	O
oral	O
diseases	O
,	O
caries	O
and	O
periodontal	O
disease	O
[	O
14	O
,	O
18	O
-	O
23	O
].	O

In	B
general	I
,	O
higher	O
serum	O
levels	O
of	O
25	O
-	O
hydroxyvitamin	O
D	O
(	O
25	O
(	O
OH	O
)	O
D	O
)	O
are	O
associated	O
with	O
improved	O
oral	O
health	O
outcomes	O
[	O
14	O
,	O
20	O
-	O
22	O
].	O

Vitamin	O
D	O
also	O
has	O
an	O
immunological	O
role	O
as	B
it	O
can	O
induce	O
the	O
production	O
of	O
antimicrobial	O
peptides	O
such	O
as	O
cathelicidin	O
and	O
certain	O
defensins	O
,	O
which	O
protect	O
us	O
from	O
oral	O
pathogens	O
[	O
22	O
,	O
24	O
].	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
determine	O
the	O
association	O
between	O
serum	O
concentrations	O
of	O
25	O
(	O
OH	O
)	O
D	O
and	O
S	O
-	O
ECC	O
in	O
preschool	O
children	O
.	O

Methods	O
A	O
cross	O
-	O
sectional	O
case	O
–	O
control	O
study	O
was	O
undertaken	O
to	O
test	O
the	O
hypothesis	O
that	O
children	O
with	O
S	O
-	O
ECC	O
have	O
lower	O
serum	O
25	O
(	O
OH	O
)	O
D	O
,	O
calcium	O
,	O
albumin	O
,	O
and	O
higher	O
parathyroid	O
hormone	O
(	O
PTH	O
)	O
levels	O
than	O
caries	O
-	O
free	O
controls	O
.	O

Differences	O
in	O
ferritin	O
and	O
haemoglobin	O
between	O
these	O
groups	O
has	O
previously	O
been	O
reported	O
in	O
this	O
sample	O
[	O
12	O
].	O

This	O
study	O
was	O
approved	O
by	O
the	O
University	O
of	O
Manitoba	O
’	O
s	O
Health	O
Research	O
Ethics	O
Board	O
,	O
the	O
Misericordia	O
Health	O
Centre	O
(	O
MHC	O
),	O
and	O
the	O
Health	O
Sciences	O
Centre	O
(	O
HSC	O
),	O
Winnipeg	O
,	O
Canada	O
.	O

All	O
parents	O
provided	O
written	O
informed	O
consent	O
at	O
recruitment	O
,	O
and	O
a	O
small	O
honorarium	O
was	O
provided	O
.	O

From	O
October	O
2009	O
to	O
August	O
2011	O
,	O
otherwise	O
-	O
healthy	O
children	O
with	O
S	O
-	O
ECC	O
were	O
recruited	O
from	O
the	O
MHC	O
in	O
Winnipeg	O
,	O
Canada	O
(	O
49	O
°	O
53	O
′	O
North	O
)	O
on	O
the	O
day	O
of	O
their	O
dental	O
surgery	O
.	O

Since	O
the	O
case	O
definition	O
for	O
S	O
-	O
ECC	O
is	O
age	O
specific	O
,	O
participants	O
needed	O
to	O
be	O
≤	O
71	O
months	O
of	O
age	O
[	O
25	O
].	O

Age	O
-	O
matched	O
caries	O
-	O
free	O
controls	O
were	O
recruited	O
from	O
the	O
community	O
by	O
advertisement	O
and	O
underwent	O
a	O
dental	O
screening	O
by	O
a	O
study	O
team	O
member	O
(	O
RJS	O
).	O

Children	O
were	O
assessed	O
using	O
the	O
dmft	O
index	O
(	O
a	O
cumulative	O
score	O
of	O
decayed	O
,	O
missing	O
,	O
filled	O
primary	O
teeth	O
).	O

Those	O
having	O
a	O
dmft	O
score	O
of	O
0	O
were	O
considered	O
caries	O
-	O
free	O
.	O

Caregivers	O
completed	O
a	O
questionnaire	O
administered	O
by	O
staff	O
which	O
collected	O
information	O
about	O
the	O
child	O
and	O
caregiver	O
,	O
dietary	O
intakes	O
,	O
use	O
of	O
supplements	O
,	O
sun	O
exposure	O
and	O
skin	O
pigmentation	O
,	O
oral	O
hygiene	O
behaviours	O
,	O
and	O
socioeconomic	O
factors	O
including	O
household	O
income	O
,	O
parental	O
education	O
level	O
,	O
and	O
receipt	O
of	O
government	O
assistance	O
[	O
12	O
].	O

This	O
instrument	O
was	O
based	O
upon	O
a	O
previously	O
piloted	O
questionnaire	O
[	O
14	O
].	O

Venipunctures	O
for	O
children	O
with	O
S	O
-	O
ECC	O
were	O
drawn	O
by	O
the	O
attending	O
anesthetist	O
during	O
surgery	O
while	O
blood	O
samples	O
from	O
controls	O
were	O
obtained	O
by	O
a	O
research	O
nurse	O
at	O
the	O
Manitoba	O
Institute	O
of	O
Child	O
Health	O
following	O
the	O
application	O
of	O
a	O
topical	O
anaesthetic	O
(	O
EMLA	O
)	O
to	O
the	O
anticubital	O
fossa	O
.	O

Serum	O
analysis	O
for	O
calcium	O
,	O
PTH	O
,	O
and	O
albumin	O
was	O
performed	O
by	O
the	O
Department	O
of	O
Biochemistry	O
and	O
Genetics	O
Laboratory	O
at	O
HSC	O
.	O

In	O
cases	O
where	O
the	O
serum	O
albumin	O
levels	O
were	O
below	O
the	O
appropriate	O
thresholds	O
for	O
a	O
child	O
’	O
s	O
age	O
,	O
the	O
corrected	O
calcium	O
level	O
was	O
used	O
in	O
place	O
of	O
the	O
standard	O
calcium	O
values	O
.	O

Diagnostic	O
Services	O
of	O
Manitoba	O
laboratory	O
reference	O
ranges	O
were	O
adopted	O
for	O
calcium	O
(	O
2	O
.	O
1	O
-	O
2	O
.	O
6	O
mmol	O
/	O
L	O
),	O
albumin	O
(	O
35	O
–	O
47	O
g	O
/	O
L	O
for	O
those	O
<	O
48	O
months	O
and	O
33	O
–	O
39	O
g	O
/	O
L	O
for	O
those	O
≥	O
48	O
months	O
),	O
and	O
PTH	O
(	O
7	O
–	O
50	O
ng	O
/	O
L	O
).	O

Assays	O
for	O
25	O
(	O
OH	O
)	O
D	O
,	O
the	O
main	O
circulating	O
form	O
of	O
vitamin	O
D	O
,	O
were	O
conducted	O
by	O
the	O
Hospitals	O
in	O
Common	O
Laboratory	O
(	O
HICL	O
)	O
at	O
Mount	O
Sinai	O
Hospital	O
in	O
Toronto	O
,	O
Canada	O
using	O
Chemiluminescence	O
Immunoassay	O
.	O

The	O
key	O
thresholds	B
used	O
to	O
quantify	O
25	O
(	O
OH	O
)	O
D	O
levels	O
within	O
this	O
study	O
were	O
≥	O
75	O
nmol	O
/	O
L	O
(	O
optimal	O
based	B
on	I
HICL	O
and	O
HSC	O
),	O
≥	O
50	O
nmol	O
/	O
L	O
(	O
adequate	O
based	B
on	I
Institute	O
of	O
Medicine	O
(	O
IOM	O
)),	O
and	O
<	O
35	O
nmol	O
/	O
L	O
(	O
common	B
threshold	B
used	O
to	O
denote	O
deficiency	O
)	O
[	O
14	O
,	O
16	O
,	O
26	O
-	O
28	O
].	O

A	O
minimum	O
sample	O
of	O
120	O
children	O
in	O
each	O
group	O
was	O
expected	O
to	O
provide	O
80	O
%	O
power	O
to	O
detect	O
a	O
one	O
-	O
tailed	O
difference	O
in	O
25	O
(	O
OH	O
)	O
D	O
levels	O
between	O
the	O
groups	O
at	O
α	O
=	O
0	O
.	O
05	O
.	O

Lab	O
and	O
questionnaire	O
data	O
were	O
entered	O
into	O
an	O
Excel	O
(	O
Microsoft	O
Office	O
)	O
spreadsheet	O
and	O
analyzed	O
using	O
Number	O
Cruncher	O
Statistical	O
Software	O
(	O
NCSS	O
)	O
version	O
7	O
.	O
0	O
(	O
Kaysville	O
,	O
Utah	O
).	O

Analysis	O
included	O
descriptive	O
statistics	O
(	O
frequencies	O
,	O
means	O
±	O
Standard	O
Deviations	O
(	O
SD	O
)),	O
Chi	O
-	O
square	O
analysis	O
,	O
and	O
t	O
-	O
tests	O
.	O

Unadjusted	O
odds	O
ratios	O
(	O
OR	O
)	O
and	O
95	O
%	O
confidence	O
intervals	O
(	O
CI	O
)	O
were	O
also	O
calculated	O
.	O

Multiple	O
regression	O
analysis	O
was	O
performed	O
for	O
mean	O
25	O
(	O
OH	O
)	O
D	O
including	O
independent	O
variables	O
significantly	O
associated	O
with	O
vitamin	O
D	O
levels	O
on	O
bivariate	O
analysis	O
or	O
known	O
to	O
influence	O
vitamin	O
D	O
status	O
.	O

Logistic	O
regression	O
for	O
S	O
-	O
ECC	O
including	O
variables	O
associated	O
at	O
the	O
bivariate	O
level	O
was	O
also	O
performed	O
.	O

In	O
both	O
models	O
,	O
some	O
variables	O
were	O
excluded	O
when	O
there	O
was	O
evidence	O
of	O
multi	O
-	O
colinearity	O
.	O

A	O
p	O
value	O
≤	O
0	O
.	O
05	O
was	O
significant	O
.	O

Results	O
A	O
total	O
of	O
266	O
children	O
(	O
51	O
.	O
1	O
%	O
male	O
)	O
participated	O
;	O
144	O
children	O
with	O
S	O
-	O
ECC	O
and	O
122	O
caries	O
-	O
free	O
.	O

For	O
various	O
reasons	O
,	O
blood	O
samples	O
were	O
only	O
collected	O
for	O
97	O
.	O
9	O
%	O
(	O
n	O
=	O
141	O
)	O
of	O
children	O
with	O
S	O
-	O
ECC	O
and	O
99	O
.	O
2	O
%	O
(	O
n	O
=	O
121	O
)	O
of	O
controls	O
.	O

The	O
mean	O
age	O
was	O
40	O
.	O
8	O
±	O
14	O
.	O
1	O
months	O
.	O

The	O
groups	O
were	O
well	O
matched	O
for	O
age	O
and	O
sex	O
as	O
there	O
were	O
no	O
significant	O
differences	O
(	O
p	O
=	O
0	O
.	O
14	O
and	O
p	O
=	O
0	O
.	O
37	O
,	O
respectively	O
).	O

Characteristics	O
of	O
participants	O
and	O
their	O
parent	O
or	O
caregiver	O
appear	O
in	O
Table	O
1	O
.	O

As	B
S	O
-	O
ECC	O
is	O
influenced	O
by	O
the	O
social	O
determinants	O
of	O
health	O
,	O
there	O
were	O
differences	O
in	O
parental	O
education	O
levels	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
and	O
household	O
income	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
between	O
groups	O
,	O
with	O
lower	O
levels	O
of	O
both	O
education	O
and	O
household	O
income	O
in	O
the	O
S	O
-	O
ECC	O
group	O
.	O

Fewer	O
children	O
in	O
the	O
S	O
-	O
ECC	O
group	O
were	O
reported	O
as	O
having	O
good	O
or	O
very	O
good	O
oral	O
health	O
compared	O
to	O
controls	O
(	O
19	O
.	O
4	O
%	O
vs	O
.	O
95	O
.	O
9	O
%,	O
p	O
<	O
0	O
.	O
001	O
).	O

Significantly	O
more	O
children	O
with	O
S	O
-	O
ECC	O
had	O
a	O
first	O
visit	O
to	O
the	O
dentist	O
for	O
a	O
dental	O
problem	O
(	O
e	O
.	O
g	O
.	O

pain	O
or	O
caries	O
)	O
than	O
controls	O
(	O
40	O
.	O
7	O
%	O
vs	O
.	O
5	O
.	O
4	O
%,	O
p	O
<	O
0	O
.	O
001	O
).	O

Additionally	O
,	O
fewer	O
caregivers	O
of	O
children	O
with	O
S	O
-	O
ECC	O
indicated	O
that	O
their	O
child	O
’	O
s	O
overall	O
health	O
was	O
very	O
good	O
compared	O
to	O
those	O
whose	O
children	O
were	O
caries	O
-	O
free	O
(	O
58	O
.	O
3	O
%	O
vs	O
.	O
82	O
.	O
8	O
%,	O
p	O
<	O
0	O
.	O
001	O
).	O

Caption	O
(	O
TABLE	O
-	O
WRAP	O
):	O
TABLE	O
1	O
Association	O
between	O
caries	O
status	O
and	O
child	O
and	O
caregiver	O
characteristicsVariableOverall	O
valueCaries	O
statusP	O
valueS	O
-	O
ECCCaries	O
-	O
freeN	O
(%)	O
95	O
%	O
CIN	O
(%)	O
95	O
%	O
CIChild	O
Child	O
’	O
s	O
age	O
(	O
Months	O
)†	O
40	O
.	O
8	O
±	O
14	O
.	O
142	O
.	O
0	O
±	O
11	O
.	O
9	O
/	O
39	O
.	O
4	O
±	O
16	O
.	O
3	O
/	O
0	O
.	O
14Sex	O
*	O
Male13670	O
(	O
51	O
.	O
5	O
)	O
43	O
.	O
1	O
,	O
59	O
.	O
966	O
(	O
48	O
.	O
5	O
)	O
40	O
.	O
1	O
,	O
56	O
.	O
90	O
.	O
37Female13074	O
(	O
56	O
.	O
9	O
)	O
48	O
.	O
4	O
,	O
65	O
.	O
456	O
(	O
43	O
.	O
1	O
)	O
34	O
.	O
6	O
,	O
51	O
.	O
6	O
Height	O
(	O
cm	O
)†	O
98	O
.	O
4	O
±	O
9	O
.	O
799	O
.	O
3	O
±	O
8	O
.	O
1	O
/	O
97	O
.	O
3	O
±	O
11	O
.	O
1	O
/	O
0	O
.	O
10Weight	O
(	O
kg	O
)†	O
16	O
.	O
4	O
±	O
3	O
.	O
717	O
.	O
0	O
±	O
3	O
.	O
3	O
/	O
15	O
.	O
8	O
±	O
4	O
.	O
0	O
/	O
0	O
.	O
01Skin	O
colour	O
*	O
Dark	O
/	O
Mid	O
-	O
colour11676	O
(	O
65	O
.	O
6	O
)	O
56	O
.	O
9	O
,	O
74	O
.	O
240	O
(	O
34	O
.	O
5	O
)	O
25	O
.	O
8	O
,	O
43	O
.	O
10	O
.	O
001Light15068	O
(	O
45	O
.	O
3	O
)	O
37	O
.	O
4	O
,	O
53	O
.	O
382	O
(	O
54	O
.	O
7	O
)	O
46	O
.	O
7	O
,	O
62	O
.	O
6	O
Multivitamin	O
Use	O
*	O
Yes14376	O
(	O
53	O
.	O
1	O
)	O
45	O
.	O
0	O
,	O
61	O
.	O
367	O
(	O
46	O
.	O
9	O
)	O
38	O
.	O
7	O
,	O
55	O
.	O
00	O
.	O
73No12368	O
(	O
55	O
.	O
3	O
)	O
46	O
.	O
5	O
,	O
64	O
.	O
155	O
(	O
44	O
.	O
7	O
)	O
35	O
.	O
9	O
,	O
53	O
.	O
5	O
Age	O
started	O
cleaning	O
mouth	O
(	O
Months	O
)†	O
12	O
.	O
9	O
±	O
8	O
.	O
614	O
.	O
5	O
±	O
9	O
.	O
5	O
/	O
10	O
.	O
9	O
±	O
7	O
.	O
1	O
/<	O
0	O
.	O
001Mean	O
age	O
at	O
first	O
dental	O
visit	O
(	O
Months	O
)†	O
26	O
.	O
2	O
±	O
11	O
.	O
827	O
.	O
0	O
±	O
11	O
.	O
9	O
/	O
24	O
.	O
7	O
±	O
11	O
.	O
7	O
/	O
0	O
.	O
17Breast	O
-	O
fed	O
*	O
Yes20493	O
(	O
45	O
.	O
6	O
)	O
38	O
.	O
8	O
,	O
52	O
.	O
4111	O
(	O
54	O
.	O
4	O
)	O
48	O
.	O
0	O
,	O
61	O
.	O
0	O
<	O
0	O
.	O
001No6150	O
(	O
82	O
.	O
0	O
)	O
72	O
.	O
3	O
,	O
91	O
.	O
611	O
(	O
18	O
.	O
0	O
)	O
8	O
.	O
4	O
,	O
27	O
.	O
7	O
Bottle	O
-	O
fed	O
*	O
Yes194114	O
(	O
58	O
.	O
8	O
)	O
51	O
.	O
8	O
,	O
65	O
.	O
780	O
(	O
41	O
.	O
2	O
)	O
34	O
.	O
3	O
,	O
48	O
.	O
20	O
.	O
01No7129	O
(	O
40	O
.	O
8	O
)	O
29	O
.	O
4	O
,	O
52	O
.	O
342	O
(	O
59	O
.	O
2	O
)	O
47	O
.	O
7	O
,	O
70	O
.	O
6	O
Parent	O
/	O
Caregiver	O
Caregiver	O
status	O
Mother247132	O
(	O
53	O
.	O
4	O
)	O
47	O
.	O
2	O
,	O
59	O
.	O
7115	O
(	O
46	O
.	O
6	O
)	O
40	O
.	O
0	O
,	O
53	O
.	O
00	O
.	O
62Father159	O
(	O
60	O
.	O
0	O
)	O
35	O
.	O
2	O
,	O
84	O
.	O
86	O
(	O
40	O
.	O
0	O
)	O
15	O
.	O
2	O
,	O
64	O
.	O
8	O
Other43	O
(	O
75	O
.	O
0	O
)	O
32	O
.	O
6	O
,	O
117	O
.	O
41	O
(	O
25	O
.	O
0	O
)-	O
17	O
.	O
4	O
,	O
67	O
.	O
4	O
Graduated	O
high	O
school	O
*	O
<	O
0	O
.	O
001Grade	O
12	O
or	O
higher19786	O
(	O
43	O
.	O
7	O
)	O
36	O
.	O
7	O
,	O
50	O
.	O
6111	O
(	O
56	O
.	O
3	O
)	O
49	O
.	O
4	O
,	O
63	O
.	O
3	O
<	O
Grade	O
126655	O
(	O
83	O
.	O
3	O
)	O
74	O
.	O
0	O
,	O
92	O
.	O
011	O
(	O
16	O
.	O
7	O
)	O
7	O
.	O
7	O
,	O
25	O
.	O
7	O
Afford	O
dental	O
care	O
*	O
Yes222123	O
(	O
55	O
.	O
4	O
)	O
48	O
.	O
9	O
,	O
61	O
.	O
999	O
(	O
44	O
.	O
6	O
)	O
38	O
.	O
1	O
,	O
51	O
.	O
10	O
.	O
28No4119	O
(	O
46	O
.	O
3	O
)	O
331	O
.	O
1	O
,	O
61	O
.	O
622	O
(	O
53	O
.	O
7	O
)	O
38	O
.	O
0	O
,	O
69	O
.	O
0	O
Receives	O
social	O
assistance	O
*	O
<	O
0	O
.	O
001Yes10381	O
(	O
78	O
.	O
6	O
)	O
70	O
.	O
7	O
,	O
86	O
.	O
622	O
(	O
21	O
.	O
4	O
)	O
13	O
.	O
4	O
,	O
29	O
.	O
3	O
No15861	O
(	O
38	O
.	O
6	O
)	O
31	O
.	O
0	O
,	O
46	O
.	O
297	O
(	O
61	O
.	O
4	O
)	O
53	O
.	O
8	O
,	O
69	O
.	O
0	O
Yearly	O
household	O
income	O
*	O
<	O
0	O
.	O
001	O
<$	O
28	O
00011985	O
(	O
71	O
.	O
4	O
)	O
63	O
.	O
3	O
,	O
79	O
.	O
534	O
(	O
28	O
.	O
6	O
)	O
20	O
.	O
5	O
,	O
36	O
.	O
7	O
>$	O
28	O
00013447	O
(	O
35	O
.	O
1	O
)	O
27	O
.	O
0	O
,	O
43	O
.	O
087	O
(	O
64	O
.	O
9	O
)	O
56	O
.	O
8	O
,	O
73	O
.	O
0	O
S	O
-	O
ECC	O
=	O
Severe	O
Early	O
Childhood	O
Caries	O
.	O

†	O
t	O
-	O
test	O
,	O
*	O
chi	O
-	O
square	O
.	O

95	O
%	O
CI	O
=	O
95	O
%	O
Confidence	O
Intervals	O
.	O

One	O
child	O
had	O
a	O
mean	O
25	O
(	O
OH	O
)	O
D	O
level	O
above	O
four	O
SD	O
from	O
the	O
mean	O
and	O
was	O
excluded	O
from	O
subsequent	O
analyses	O
.	O

The	O
mean	O
25	O
(	O
OH	O
)	O
D	O
concentration	O
for	O
the	O
entire	O
sample	O
was	O
75	O
.	O
4	O
±	O
30	O
.	O
2	O
nmol	O
/	O
L	O
.	O

A	O
total	O
of	O
136	O
children	O
(	O
52	O
.	O
1	O
%)	O
had	O
levels	O
<	O
75	O
nmol	O
/	O
L	O
,	O
indicating	O
suboptimal	O
vitamin	O
D	O
while	O
43	O
children	O
(	O
16	O
.	O
5	O
%)	O
had	O
inadequate	O
vitamin	O
D	O
(<	O
50	O
nmol	O
/	O
L	O
).	O

Additionally	O
,	O
16	O
(	O
6	O
.	O
1	O
%)	O
had	O
deficient	O
vitamin	O
D	O
concentrations	O
(<	O
35	O
nmol	O
/	O
L	O
).	O

More	O
frequent	O
intake	O
of	O
foods	O
containing	O
or	O
fortified	O
with	O
vitamin	O
D	O
(	O
e	O
.	O
g	O
.	O

liver	O
,	O
eggs	O
,	O
fish	O
,	O
fortified	O
orange	O
juice	O
)	O
were	O
not	O
significantly	O
associated	O
with	O
higher	O
mean	O
25	O
(	O
OH	O
)	O
D	O
levels	O
(	O
data	O
not	O
shown	O
).	O

The	O
exception	O
were	O
regular	O
milk	O
drinkers	O
(≥	O
5	O
servings	O
weekly	O
),	O
who	O
had	O
significantly	O
higher	O
mean	O
vitamin	O
D	O
levels	O
than	O
non	O
-	O
regular	O
milk	O
drinkers	O
(	O
76	O
.	O
6	O
±	O
30	O
.	O
3	O
nmol	O
/	O
L	O
vs	O
.	O
63	O
.	O
2	O
±	O
27	O
.	O
0	O
,	O
p	O
=	O
0	O
.	O
042	O
).	O

Those	O
presently	O
taking	O
vitamin	O
D	O
drops	O
also	O
had	O
higher	O
25	O
(	O
OH	O
)	O
D	O
levels	O
(	O
92	O
.	O
2	O
±	O
34	O
.	O
6	O
nmol	O
/	O
L	O
vs	O
.	O
72	O
.	O
2	O
±	O
28	O
.	O
2	O
,	O
p	O
<	O
0	O
.	O
001	O
).	O

There	O
were	O
no	O
apparent	O
differences	O
in	O
the	O
intake	O
of	O
foods	O
containing	O
vitamin	O
D	O
between	O
the	O
S	O
-	O
ECC	O
and	O
caries	O
-	O
free	O
groups	O
,	O
including	O
the	O
frequency	O
of	O
milk	O
consumption	O
(	O
data	O
not	O
shown	O
).	O

However	O
,	O
significantly	O
more	O
children	O
receiving	O
vitamin	O
D	O
drops	O
belonged	O
to	O
the	O
caries	O
-	O
free	O
group	O
(	O
14	O
.	O
0	O
%	O
S	O
-	O
ECC	O
(	O
n	O
=	O
6	O
)	O
vs	O
.	O
86	O
.	O
0	O
%	O
caries	O
-	O
free	O
(	O
n	O
=	O
37	O
),	O
p	O
<	O
0	O
.	O
001	O
).	O

There	O
was	O
also	O
no	O
significant	O
difference	O
in	O
multivitamin	O
usage	O
between	O
the	O
groups	O
(	O
76	O
with	O
S	O
-	O
ECC	O
vs	O
.	O
67	O
caries	O
-	O
free	O
,	O
p	O
=	O
0	O
.	O
73	O
).	O

Significantly	O
more	O
children	O
in	O
the	O
S	O
-	O
ECC	O
group	O
were	O
bottle	O
-	O
fed	O
compared	O
to	O
controls	O
(	O
p	O
=	O
0	O
.	O
01	O
)	O
and	O
bottle	O
-	O
fed	O
to	O
a	O
later	O
age	O
(	O
19	O
.	O
7	O
±	O
8	O
.	O
7	O
months	O
vs	O
.	O
16	O
.	O
4	O
±	O
7	O
.	O
7	O
,	O
p	O
=	O
0	O
.	O
02	O
).	O

Meanwhile	O
,	O
fewer	O
children	O
with	O
S	O
-	O
ECC	O
were	O
breastfed	O
compared	O
to	O
the	O
caries	O
-	O
free	O
group	O
(	O
p	O
<	O
0	O
.	O
001	O
).	O

There	O
was	O
no	O
difference	O
in	O
the	O
frequency	O
of	O
daily	O
“	O
between	O
-	O
meal	O
”	O
snacking	O
between	O
the	O
groups	O
(	O
93	O
.	O
8	O
%	O
S	O
-	O
ECC	O
vs	O
.	O
96	O
.	O
7	O
%	O
caries	O
-	O
free	O
,	O
p	O
=	O
0	O
.	O
39	O
,	O
Fisher	O
’	O
s	O
Exact	O
Test	O
).	O

There	O
was	O
no	O
significant	O
difference	O
between	O
the	O
two	O
groups	O
with	O
respect	O
to	O
premature	O
birth	O
(	O
p	O
=	O
0	O
.	O
88	O
),	O
whether	O
mothers	O
took	O
vitamin	O
D	O
supplements	O
during	O
pregnancy	O
(	O
p	O
=	O
0	O
.	O
92	O
),	O
or	O
maternal	O
milk	O
intake	O
during	O
pregnancy	O
(	O
p	O
=	O
0	O
.	O
56	O
)	O
(	O
data	O
not	O
shown	O
).	O

Mean	O
25	O
(	O
OH	O
)	O
D	O
levels	O
were	O
significantly	O
lower	O
among	O
children	O
with	O
S	O
-	O
ECC	O
than	O
caries	O
-	O
free	O
controls	O
(	O
68	O
.	O
9	O
±	O
28	O
.	O
0	O
nmol	O
/	O
L	O
vs	O
.	O
82	O
.	O
9	O
±	O
31	O
.	O
1	O
,	O
p	O
<	O
0	O
.	O
001	O
)	O
(	O
Table	O
2	O
).	O

Even	O
after	O
stratifying	O
by	O
season	O
and	O
only	O
analyzing	O
data	O
collected	O
during	O
the	O
winter	O
(	O
October	O
-	O
April	O
)	O
to	O
control	O
for	O
endogenous	O
production	O
,	O
a	O
statistically	O
significant	O
difference	O
remained	O
(	O
63	O
.	O
5	O
±	O
27	O
.	O
7	O
nmol	O
/	O
L	O
vs	O
.	O
79	O
.	O
4	O
±	O
26	O
.	O
7	O
,	O
p	O
<	O
0	O
.	O
001	O
).	O

Caption	O
(	O
TABLE	O
-	O
WRAP	O
):	O
TABLE	O
2	O
25	O
(	O
OH	O
)	O
D	O
,	O
Calcium	O
,	O
Albumin	O
,	O
and	O
PTH	O
status	O
by	O
S	O
-	O
ECC	O
and	O
caries	O
-	O
free	O
groupVariableOverall	O
valueCaries	O
statusP	O
valueS	O
-	O
ECCCaries	O
-	O
FreeN	O
(%)	O
95	O
%	O
CIN	O
(%)	O
95	O
%	O
CI25	O
(	O
OH	O
)	O
D	O
status	O
Mean	O
(	O
nmol	O
/	O
L	O
)†	O
75	O
.	O
4	O
±	O
30	O
.	O
268	O
.	O
9	O
±	O
27	O
.	O
9	O
/	O
82	O
.	O
9	O
±	O
31	O
.	O
1	O
/	O
<	O
0	O
.	O
001Optimal	O
*	O
(≥	O
75	O
nmol	O
/	O
L	O
)	O
Yes12556	O
(	O
44	O
.	O
8	O
)	O
36	O
.	O
1	O
,	O
53	O
.	O
569	O
(	O
55	O
.	O
2	O
)	O
46	O
.	O
0	O
,	O
64	O
.	O
00	O
.	O
006No13684	O
(	O
61	O
.	O
8	O
)	O
53	O
.	O
6	O
,	O
69	O
.	O
952	O
(	O
38	O
.	O
2	O
)	O
30	O
.	O
1	O
,	O
46	O
.	O
4	O
Adequate	O
*	O
(≥	O
50	O
nmol	O
/	O
L	O
)	O
Yes218111	O
(	O
50	O
.	O
9	O
)	O
44	O
.	O
3	O
,	O
57	O
.	O
6107	O
(	O
49	O
.	O
1	O
)	O
42	O
.	O
4	O
,	O
55	O
.	O
70	O
.	O
05No4329	O
(	O
67	O
.	O
4	O
)	O
53	O
.	O
4	O
,	O
81	O
.	O
414	O
(	O
32	O
.	O
6	O
)	O
18	O
.	O
6	O
,	O
46	O
.	O
6	O
Deficient	O
*	O
(<	O
35	O
nmol	O
/	O
L	O
)	O
Yes1612	O
(	O
75	O
.	O
0	O
)	O
53	O
.	O
8	O
,	O
96	O
.	O
24	O
(	O
25	O
.	O
0	O
)	O
3	O
.	O
8	O
,	O
46	O
.	O
20	O
.	O
12aNo245128	O
(	O
52	O
.	O
2	O
)	O
46	O
.	O
0	O
,	O
58	O
.	O
5117	O
(	O
47	O
.	O
8	O
)	O
41	O
.	O
5	O
,	O
54	O
.	O
0	O
Calcium	O
status	O
Mean	O
(	O
mmol	O
/	O
L	O
)†	O
2	O
.	O
3	O
±	O
0	O
.	O
12	O
.	O
2	O
±	O
0	O
.	O
1	O
/	O
2	O
.	O
4	O
±	O
0	O
.	O
1	O
/<	O
0	O
.	O
001Low	O
calcium	O
*	O
Yes1010	O
(	O
100	O
.	O
0	O
)	O
100	O
,	O
1000	O
(	O
0	O
.	O
0	O
)	O
0	O
,	O
00	O
.	O
002aNo248130	O
(	O
52	O
.	O
4	O
)	O
46	O
.	O
2	O
,	O
58	O
.	O
6118	O
(	O
47	O
.	O
6	O
)	O
41	O
.	O
4	O
,	O
53	O
.	O
8	O
Low	O
calcium	O
(	O
Corrected	O
)*	O
Yes66	O
(	O
100	O
)	O
100	O
,	O
1000	O
(	O
0	O
.	O
0	O
)	O
0	O
,	O
0	O
No252134	O
(	O
53	O
.	O
2	O
)	O
47	O
.	O
0	O
,	O
59	O
.	O
3118	O
(	O
46	O
.	O
8	O
)	O
41	O
.	O
0	O
,	O
53	O
.	O
00	O
.	O
03aPTH	O
status	O
Mean	O
(	O
ng	O
/	O
L	O
)†	O
47	O
.	O
3	O
±	O
22	O
.	O
059	O
.	O
1	O
±	O
21	O
.	O
8	O
/	O
32	O
.	O
9	O
±	O
10	O
.	O
8	O
/<	O
0	O
.	O
001Elevated	O
PTH	O
*	O
Yes9285	O
(	O
92	O
.	O
4	O
)	O
87	O
.	O
0	O
,	O
97	O
.	O
87	O
(	O
7	O
.	O
6	O
)	O
2	O
.	O
2	O
,	O
13	O
.	O
0	O
<	O
0	O
.	O
001No16255	O
(	O
34	O
.	O
0	O
)	O
26	O
.	O
7	O
,	O
41	O
.	O
2107	O
(	O
66	O
.	O
0	O
)	O
58	O
.	O
7	O
,	O
73	O
.	O
3	O
Albumin	O
status	O
Mean	O
(	O
g	O
/	O
L	O
)†	O
38	O
.	O
4	O
±	O
3	O
.	O
736	O
.	O
8	O
±	O
3	O
.	O
1	O
/	O
40	O
.	O
3	O
±	O
3	O
.	O
5	O
/<	O
0	O
.	O
001Low	O
albumin	O
*	O
Yes3326	O
(	O
78	O
.	O
8	O
)	O
64	O
.	O
8	O
,	O
92	O
.	O
77	O
(	O
21	O
.	O
2	O
)	O
7	O
.	O
3	O
,	O
35	O
.	O
20	O
.	O
002No225114	O
(	O
50	O
.	O
7	O
)	O
44	O
.	O
1	O
,	O
57	O
.	O
2111	O
(	O
49	O
.	O
3	O
)	O
43	O
.	O
0	O
,	O
56	O
.	O
0	O
S	O
-	O
ECC	O
=	O
Severe	O
Early	O
Childhood	O
Caries	O
.	O

†	O
t	O
-	O
test	O
,	O
*	O
chi	O
-	O
square	O
,	O
aFisher	O
’	O
s	O
Exact	O
Test	O
.	O

95	O
%	O
CI	O
=	O
95	O
%	O
Confidence	O
Intervals	O
.	O

The	O
25	O
(	O
OH	O
)	O
D	O
distribution	O
based	O
on	O
caries	O
-	O
status	O
appears	O
in	O
Table	O
2	O
.	O

Those	O
in	O
the	O
S	O
-	O
ECC	O
group	O
were	O
found	O
to	O
have	O
relatively	O
poor	O
vitamin	O
D	O
status	O
compared	O
to	O
caries	O
-	O
free	O
children	O
.	O

Significantly	O
more	O
children	O
with	O
S	O
-	O
ECC	O
had	O
suboptimal	O
25	O
(	O
OH	O
)	O
D	O
concentrations	O
(<	O
75	O
nmol	O
/	O
L	O
)	O
compared	O
to	O
their	O
caries	O
-	O
free	O
peers	O
(	O
p	O
=	O
0	O
.	O
006	O
)	O
(	O
Table	O
2	O
).	O

In	O
fact	O
,	O
children	O
with	O
25	O
(	O
OH	O
)	O
D	O
levels	O
below	O
this	O
threshold	B
were	O
twice	O
as	O
likely	B
to	O
have	O
S	O
-	O
ECC	O
.	O

This	O
relationship	O
was	O
also	O
present	O
when	O
the	O
IOM	O
threshold	B
for	O
adequacy	O
(	O
50	O
nmol	O
/	O
L	O
)	O
was	O
applied	O
(	O
p	O
=	O
0	O
.	O
05	O
,	O
OR	O
=	O
0	O
.	O
5	O
).	O

When	O
the	O
“	O
deficient	O
”	O
threshold	B
(<	O
35	O
nmol	O
/	O
L	O
)	O
was	O
applied	O
,	O
this	O
relationship	O
failed	O
to	O
reach	O
significance	O
(	O
p	O
=	O
0	O
.	O
12	O
(	O
Fisher	O
’	O
s	O
Exact	O
Test	O
),	O
OR	O
=	O
2	O
.	O
7	O
).	O

There	O
was	O
no	O
association	O
between	O
the	O
education	O
level	O
of	O
the	O
primary	O
caregiver	O
and	O
the	O
child	O
’	O
s	O
vitamin	O
D	O
status	O
with	O
respect	O
to	O
both	O
the	O
mean	O
levels	O
and	O
the	O
proportion	O
with	O
levels	O
≥	O
75	O
nmol	O
/	O
L	O
(	O
p	O
=	O
0	O
.	O
74	O
and	O
p	O
=	O
0	O
.	O
35	O
,	O
respectively	O
).	O

However	O
,	O
higher	O
yearly	O
household	O
incomes	O
were	O
associated	O
with	O
higher	O
mean	O
25	O
(	O
OH	O
)	O
D	O
levels	O
and	O
having	O
concentrations	O
≥	O
75	O
nmol	O
/	O
L	O
(	O
p	O
=	O
0	O
.	O
002	O
and	O
p	O
=	O
0	O
.	O
002	O
,	O
respectively	O
).	O

Differences	O
in	O
mean	O
calcium	O
,	O
albumin	O
,	O
and	O
PTH	O
concentrations	O
between	O
the	O
groups	O
are	O
also	O
reported	O
in	O
Table	O
2	O
.	O

Children	O
with	O
S	O
-	O
ECC	O
had	O
significantly	O
lower	O
mean	O
calcium	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
and	O
mean	O
albumin	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
levels	O
as	O
well	O
as	O
higher	O
mean	O
PTH	O
concentrations	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
than	O
controls	O
.	O

Despite	O
small	O
cell	O
sizes	O
,	O
it	O
should	O
be	O
noted	O
that	O
all	O
of	O
the	O
children	O
with	O
low	O
calcium	O
concentrations	O
belonged	O
to	O
the	O
S	O
-	O
ECC	O
group	O
.	O

Children	O
with	O
S	O
-	O
ECC	O
were	O
23	O
.	O
6	O
times	O
more	O
likely	B
to	O
have	O
elevated	O
PTH	O
levels	O
compared	O
to	O
controls	O
and	O
3	O
.	O
6	O
times	O
more	O
likely	B
to	O
have	O
abnormally	O
low	O
albumin	O
concentrations	O
(	O
Table	O
2	O
).	O

Multiple	O
regression	O
for	O
25	O
(	O
OH	O
)	O
D	O
concentrations	O
revealed	O
that	O
levels	O
were	O
significantly	O
and	O
independently	O
associated	O
with	O
S	O
-	O
ECC	O
,	O
regular	O
milk	O
consumption	O
,	O
and	O
season	O
of	O
assessment	O
but	O
not	O
household	O
income	O
and	O
or	O
the	O
use	O
of	O
vitamin	O
D	O
drops	O
(	O
Table	O
3	O
).	O

S	O
-	O
ECC	O
,	O
infrequent	O
milk	O
intake	O
,	O
and	O
winter	O
season	O
were	O
associated	O
with	O
lower	O
25	O
(	O
OH	O
)	O
D	O
levels	O
,	O
but	O
not	O
household	O
income	O
or	O
vitamin	O
D	O
drop	O
use	O
.	O

Logistic	O
regression	O
for	O
caries	O
status	O
was	O
also	O
performed	O
,	O
revealing	O
that	O
lower	O
household	O
income	O
,	O
poorer	O
ratings	O
of	O
children	O
’	O
s	O
general	O
health	O
,	O
and	O
lower	O
vitamin	O
D	O
levels	O
were	O
significantly	O
associated	O
with	O
S	O
-	O
ECC	O
(	O
Table	O
4	O
).	O

Caption	O
(	O
TABLE	O
-	O
WRAP	O
):	O
TABLE	O
3	O
Multiple	O
regression	O
for	O
mean	O
vitamin	O
D	O
levelVariableUnstandardized	O
regression	O
coefficient	O
(	O
b	O
)±	O
95	O
%	O
confidence	O
intervalP	O
value	O
Intercept71	O
.	O
01	O
//	O
S	O
-	O
ECC	O
(	O
Reference	O
=	O
Yes	O
)	O
5	O
.	O
331	O
.	O
24	O
,	O
9	O
.	O
420	O
.	O
01Regular	O
milk	O
drinker	O
(	O
Reference	O
=	O
Yes	O
)-	O
6	O
.	O
60	O
-	O
13	O
.	O
16	O
,	O
-	O
0	O
.	O
030	O
.	O
05Season	O
(	O
Reference	O
=	O
Winter	O
)	O
5	O
.	O
221	O
.	O
37	O
,	O
9	O
.	O
060	O
.	O
008Vitamin	O
D	O
drop	O
user	O
(	O
Reference	O
=	O
Yes	O
)-	O
2	O
.	O
172	O
.	O
01	O
,	O
-	O
6	O
.	O
130	O
.	O
28Yearly	O
income	O
(	O
Reference	O
=	O
<	O
28	O
k	O
)	O
2	O
.	O
732	O
.	O
06	O
,	O
-	O
1	O
.	O
320	O
.	O
19	O
S	O
-	O
ECC	O
=	O
Severe	O
Early	O
Childhood	O
Caries	O
.	O

Adjusted	O
R2	O
=	O
8	O
.	O
37	O
%.	O

Caption	O
(	O
TABLE	O
-	O
WRAP	O
):	O
TABLE	O
4	O
Logistic	O
regression	O
for	O
S	O
-	O
ECCVariableAdjusted	O
odds	O
ratio	O
±	O
95	O
%	O
confidence	O
interval	O
for	O
odds	O
ratioP	O
value	O
Age	O
started	O
cleaning	O
teeth0	O
.	O
970	O
.	O
94	O
,	O
1	O
.	O
010	O
.	O
12Bottle	O
fed	O
(	O
Reference	O
=	O
Yes	O
)	O
0	O
.	O
730	O
.	O
37	O
,	O
1	O
.	O
460	O
.	O
37General	O
health	O
(	O
Reference	O
=	O
Very	O
Good	O
)	O
3	O
.	O
041	O
.	O
50	O
,	O
6	O
.	O
150	O
.	O
002Mean	O
vitamin	O
D1	O
.	O
011	O
.	O
00	O
,	O
1	O
.	O
020	O
.	O
04Vitamin	O
D	O
drop	O
usage	O
(	O
Reference	O
=	O
Yes	O
)	O
1	O
.	O
510	O
.	O
81	O
,	O
2	O
.	O
820	O
.	O
19Yearly	O
income	O
(	O
Reference	O
=	O
<	O
28	O
k	O
)	O
0	O
.	O
300	O
.	O
16	O
,	O
0	O
.	O
55	O
<	O
0	O
.	O
001	O
S	O
-	O
ECC	O
=	O
Severe	O
Early	O
Childhood	O
Caries	O
.	O

Discussion	O
The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
determine	O
whether	O
children	O
with	O
S	O
-	O
ECC	O
have	O
different	O
nutritional	O
profiles	O
than	O
their	O
caries	O
-	O
free	O
peers	O
,	O
specifically	O
vitamin	O
D	O
,	O
calcium	O
and	O
albumin	O
status	O
.	O

While	O
historical	O
evidence	O
suggests	O
that	O
vitamin	O
D	O
supplementation	O
can	O
prevent	O
caries	O
onset	O
and	O
progression	O
,	O
much	O
of	O
this	O
research	O
has	O
been	O
overlooked	O
[	O
18	O
,	O
29	O
,	O
30	O
].	O

In	O
a	O
pilot	O
study	O
published	O
in	O
2012	O
,	O
we	O
were	O
the	O
first	O
to	O
specifically	O
report	O
differences	O
in	O
actual	O
serum	O
25	O
(	O
OH	O
)	O
D	O
levels	O
between	O
children	O
with	O
and	O
without	O
severe	O
decay	O
[	O
14	O
].	O

The	O
present	O
study	O
involved	O
a	O
substantially	O
larger	O
sample	O
,	O
and	O
reinforces	O
the	O
observed	O
association	O
between	O
25	O
(	O
OH	O
)	O
D	O
levels	O
and	O
S	O
-	O
ECC	O
.	O

Much	O
of	O
the	O
early	O
research	O
in	O
this	O
field	O
was	O
conducted	O
by	O
May	O
Mellanby	O
,	O
who	O
identified	O
an	O
association	O
between	O
vitamin	O
D	O
supplementation	O
and	O
reduced	O
caries	O
-	O
risk	O
[	O
18	O
,	O
31	O
].	O

Recently	O
,	O
a	O
meta	O
-	O
analysis	O
reported	O
that	O
vitamin	O
D	O
supplementation	O
in	O
childhood	O
can	O
help	O
prevent	O
caries	O
[	O
30	O
],	O
and	O
it	O
has	O
also	O
been	O
suggested	O
that	O
concentrations	O
of	O
25	O
(	O
OH	O
)	O
D	O
between	O
75	O
–	O
100	O
nmol	O
/	O
L	O
may	O
reduce	O
the	O
risk	O
for	O
caries	O
[	O
22	O
].	O

Our	O
study	O
supports	O
these	O
findings	O
,	O
as	B
caries	O
-	O
free	O
children	O
were	O
twice	O
as	O
likely	B
to	O
have	O
optimal	O
25	O
(	O
OH	O
)	O
D	O
concentrations	O
(≥	O
75	O
nmol	O
/	O
L	O
)	O
and	O
those	O
with	O
S	O
-	O
ECC	O
were	O
at	O
nearly	O
three	O
times	O
the	O
odds	B
of	O
having	O
deficient	O
levels	O
(<	O
35	O
nmol	O
/	O
L	O
).	O

The	O
mean	O
25	O
(	O
OH	O
)	O
D	O
level	O
in	O
our	O
sample	O
was	O
adequate	O
,	O
mirroring	O
our	O
pilot	O
study	O
findings	O
[	O
14	O
]	O
and	O
those	O
of	O
the	O
Canadian	O
Health	O
Measures	O
Survey	O
[	O
32	O
].	O

This	O
may	O
be	O
attributed	O
to	O
regular	O
milk	O
intake	O
,	O
which	O
was	O
common	O
in	O
both	O
groups	O
.	O

Regular	O
milk	O
drinkers	O
had	O
better	O
vitamin	O
D	O
concentrations	O
,	O
a	O
finding	O
supported	O
by	O
a	O
large	O
-	O
scale	O
clinical	O
study	O
observing	O
an	O
association	O
between	O
frequent	O
milk	O
consumption	O
and	O
increased	O
25	O
(	O
OH	O
)	O
D	O
[	O
33	O
].	O

Regression	O
techniques	O
were	O
employed	O
to	O
determine	O
whether	O
the	O
association	O
between	O
caries	O
and	O
vitamin	O
D	O
status	O
remained	O
after	O
controlling	O
for	O
confounders	O
.	O

Even	O
after	O
controlling	O
for	O
seasonal	O
influence	O
on	O
endogenous	O
synthesis	O
,	O
low	O
household	O
income	O
,	O
and	O
infrequent	O
consumption	O
of	O
vitamin	O
D	O
drops	O
and	O
milk	O
,	O
the	O
significant	O
association	O
remained	O
.	O

Similarly	O
,	O
the	O
association	O
between	O
25	O
(	O
OH	O
)	O
D	O
concentrations	O
and	O
S	O
-	O
ECC	O
was	O
significant	O
after	O
logistic	O
regression	O
while	O
controlling	O
for	O
factors	O
such	O
as	O
general	O
health	O
status	O
,	O
the	O
age	O
when	O
teeth	O
cleaning	O
was	O
first	O
started	O
,	O
and	O
household	O
finances	O
.	O

As	B
there	O
was	O
a	O
strong	O
relationship	O
between	O
education	O
and	O
income	O
,	O
education	O
was	O
not	O
included	O
in	O
the	O
model	O
to	O
avoid	O
multi	O
-	O
colinearity	O
.	O

Our	O
study	O
also	O
reports	O
that	O
those	O
with	O
S	O
-	O
ECC	O
had	O
significantly	O
lower	O
calcium	O
and	O
elevated	O
PTH	O
levels	O
,	O
as	O
observed	O
in	O
our	O
pilot	O
study	O
[	O
14	O
].	O

These	O
metabolites	O
were	O
not	O
,	O
however	O
,	O
included	O
in	O
the	O
regression	O
models	O
as	B
they	O
were	O
strongly	B
correlated	O
with	O
25	O
(	O
OH	O
)	O
D	O
levels	O
.	O

This	O
multi	O
-	O
colinearity	O
is	O
expected	B
,	O
as	B
these	O
variables	O
are	O
physiologically	O
interrelated	O
.	O

Children	O
with	O
S	O
-	O
ECC	O
were	O
found	O
to	O
have	O
significantly	O
lower	O
albumin	O
levels	O
than	O
caries	O
-	O
free	O
controls	O
.	O

Our	O
finding	O
that	O
18	O
.	O
6	O
%	O
in	O
the	O
S	O
-	O
ECC	O
group	O
had	O
low	O
albumin	O
is	O
comparable	O
to	O
the	O
15	O
%	O
reported	O
in	O
another	O
Canadian	O
sample	O
.	O

Albumin	O
is	O
a	O
serum	O
protein	O
that	O
can	O
be	O
used	O
as	B
an	O
additional	O
indicator	O
of	O
overall	O
nutritional	O
status	O
and	O
malnutrition	O
[	O
34	O
].	O

A	O
deficiency	O
in	O
this	O
protein	O
in	O
conjunction	O
with	O
undesirable	O
vitamin	O
D	O
,	O
PTH	O
,	O
and	O
calcium	O
levels	O
may	O
suggest	O
that	O
children	O
with	O
S	O
-	O
ECC	O
have	O
nutritional	O
deficiencies	O
.	O

We	O
have	O
recently	O
reported	O
that	O
children	O
with	O
S	O
-	O
ECC	O
from	O
this	O
same	O
study	O
group	O
were	O
more	O
likely	B
to	O
have	O
low	O
ferritin	O
and	O
hemoglobin	O
levels	O
along	O
with	O
iron	O
deficiency	O
anaemia	O
[	O
12	O
].	O

Others	O
have	O
also	O
reported	O
that	O
rampant	O
caries	O
can	O
negatively	O
impact	O
nutritional	O
health	O
status	O
and	O
well	O
-	O
being	O
[	O
3	O
,	O
10	O
,	O
13	O
,	O
35	O
].	O

Therefore	B
,	O
health	O
professionals	O
should	O
be	O
aware	O
of	O
the	O
potential	O
nutritional	O
deficiencies	O
in	O
children	O
suffering	O
from	O
extensive	O
dental	O
caries	O
.	O

It	O
is	O
important	O
to	O
consider	O
how	O
S	O
-	O
ECC	O
and	O
poor	O
nutritional	O
status	O
are	O
connected	O
.	O

Vitamin	O
D	O
and	O
calcium	O
disturbances	O
during	O
tooth	O
development	O
may	O
result	O
in	O
dentin	O
and	O
enamel	O
defects	O
,	O
which	O
can	O
increase	O
the	O
risk	O
for	O
caries	O
.	O

However	O
,	O
children	O
with	O
S	O
-	O
ECC	O
may	O
experience	O
ongoing	O
pain	O
which	O
may	O
alter	O
their	O
eating	O
habits	O
.	O

This	O
can	O
improve	O
after	O
dental	O
surgery	O
under	O
GA	O
[	O
3	O
,	O
9	O
].	O

Avoidance	O
of	O
food	O
because	O
of	O
severe	O
dental	O
problems	O
may	O
,	O
in	O
turn	O
,	O
contribute	O
to	O
the	O
nutritional	O
deficiencies	O
identified	O
in	O
this	O
sample	O
[	O
12	O
].	O

This	O
case	O
–	O
control	O
study	O
has	O
some	O
limitations	O
.	O

While	O
we	O
did	O
not	O
assess	O
caries	O
rates	O
,	O
all	O
children	O
with	O
S	O
-	O
ECC	O
had	O
multiple	O
cavitated	O
caries	O
lesions	O
necessitating	O
surgery	O
.	O

The	O
cross	O
-	O
sectional	O
design	O
did	O
not	O
allow	O
us	O
to	O
distinguish	O
between	O
cause	O
and	O
effect	O
.	O

Additionally	O
,	O
children	O
in	O
our	O
study	O
were	O
matched	O
by	O
age	O
and	O
sex	O
,	O
but	O
we	O
were	O
unable	O
to	O
match	O
by	O
household	O
economics	O
and	O
caregiver	O
education	O
levels	O
.	O

The	O
majority	B
of	O
S	O
-	O
ECC	O
children	O
came	O
from	O
lower	O
-	O
income	O
households	O
.	O

Identifying	O
caries	O
-	O
free	O
controls	O
living	O
in	O
these	O
same	O
communities	O
proved	B
challenging	O
.	O

Naturally	O
,	O
some	O
factors	O
are	O
difficult	O
to	O
control	O
for	O
as	B
they	O
are	O
critical	O
to	O
explaining	B
why	O
children	O
are	O
at	O
risk	O
for	O
caries	O
(	O
e	O
.	O
g	O
.	O

household	O
income	O
,	O
parental	O
education	O
,	O
etc	O
.).	O

Fortunately	O
,	O
we	O
controlled	O
for	O
household	O
income	O
in	O
the	O
regression	O
models	O
.	O

Additionally	O
,	O
the	O
caregiver	O
questionnaire	O
involved	O
retrospective	O
questions	O
on	O
prenatal	O
diet	O
and	O
the	O
child	O
’	O
s	O
first	O
12	O
months	O
of	O
life	O
which	O
may	O
have	O
introduced	O
recall	O
bias	O
.	O

In	O
retrospect	O
,	O
a	O
comprehensive	B
food	O
frequency	O
assessment	O
would	O
have	O
been	O
a	O
useful	O
addition	O
to	O
the	O
study	O
.	O

Despite	O
these	O
limitations	O
,	O
the	O
large	O
sample	O
size	O
provided	B
sufficient	O
statistical	O
power	O
,	O
allowing	O
greater	O
confidence	O
in	O
our	O
findings	O
.	O

Conclusion	O
Based	B
on	I
the	O
findings	O
of	O
this	O
study	O
,	O
we	O
conclude	B
that	O
:	O
•	O
Children	O
with	O
S	O
-	O
ECC	O
appear	O
to	O
be	O
at	O
significantly	O
greater	O
odds	O
of	O
having	O
low	O
vitamin	O
D	O
status	O
compared	O
to	O
their	O
caries	O
-	O
free	O
controls	O
.	O

•	O
Children	O
with	O
S	O
-	O
ECC	O
are	O
likely	B
malnourished	O
,	O
as	B
they	O
displayed	O
significantly	O
lower	O
levels	O
of	O
calcium	O
and	O
serum	O
albumin	O
as	O
well	O
as	O
higher	O
levels	O
of	O
PTH	O
compared	O
to	O
the	O
control	O
group	O
.	O

This	O
study	O
suggests	O
a	O
clear	B
relationship	O
between	O
vitamin	O
D	O
levels	O
and	O
the	O
caries	O
status	O
of	O
preschool	O
children	O
.	O

As	B
a	O
result	O
of	O
these	O
findings	O
,	O
it	O
may	O
be	O
advantageous	O
for	O
primary	O
care	O
providers	O
(	O
including	O
dentists	O
and	O
physicians	O
)	O
to	O
consider	O
serum	O
25	O
(	O
OH	O
)	O
D	O
status	O
when	O
assessing	O
the	O
child	O
’	O
s	O
overall	O
health	O
.	O

Specifically	O
,	O
recommending	O
vitamin	O
D	O
supplementation	O
for	O
children	O
at	O
risk	O
of	O
dental	O
caries	O
may	O
result	O
in	O
a	O
decrease	O
in	O
the	O
overall	O
prevalence	O
of	O
S	O
-	O
ECC	O
and	O
,	O
ultimately	O
,	O
reduce	O
the	O
burden	O
on	O
pediatric	O
day	O
surgery	O
centres	O
.	O

Abbreviations	O
CI	O
:	O
Confidence	O
intervals	O
;	O
dmft	O
:	O
decayed	O
,	O
missing	O
,	O
filled	O
teeth	O
;	O
ECC	O
:	O
Early	O
childhood	O
caries	O
;	O
GA	O
:	O
General	O
anesthesia	O
;	O
HSC	O
:	O
Health	O
sciences	O
centre	O
;	O
IOM	O
:	O
Institute	O
of	O
medicine	O
;	O
MHC	O
:	O
Misericordia	O
health	O
centre	O
;	O
OR	O
:	O
Odds	O
ratio	O
;	O
PTH	O
:	O
Parathyroid	O
hormone	O
;	O
SD	O
:	O
Standard	O
deviation	O
;	O
S	O
-	O
ECC	O
:	O
Severe	O
early	O
childhood	O
caries	O
.	O

Competing	O
interests	O
The	O
authors	O
declare	O
that	O
no	O
competing	O
interests	O
(	O
financial	O
or	O
personal	O
)	O
exist	O
with	O
regards	O
to	O
this	O
manuscript	O
.	O

Authors	O
’	O
contributions	O
RS	O
:	O
Conception	O
and	O
design	O
,	O
acquisition	O
of	O
data	O
,	O
analysis	O
and	O
interpretation	O
of	O
data	O
,	O
drafting	O
of	O
article	O
,	O
revising	O
article	O
critically	O
for	O
important	O
intellectual	O
content	O
,	O
and	O
final	O
approval	O
of	O
version	O
to	O
be	O
published	O
.	O

JL	O
:	O
Acquisition	O
of	O
data	O
,	O
analysis	O
and	O
interpretation	O
of	O
data	O
,	O
drafting	O
of	O
article	O
,	O
revising	O
article	O
critically	O
for	O
important	O
intellectual	O
content	O
,	O
and	O
final	O
approval	O
of	O
version	O
to	O
be	O
published	O
.	O

ES	O
:	O
Analysis	O
and	O
interpretation	O
of	O
data	O
,	O
revising	O
article	O
critically	O
for	O
important	O
intellectual	O
content	O
,	O
and	O
final	O
approval	O
of	O
version	O
to	O
be	O
published	O
.	O

JF	O
:	O
Analysis	O
and	O
interpretation	O
of	O
data	O
,	O
revising	O
article	O
critically	O
for	O
important	O
intellectual	O
content	O
,	O
and	O
final	O
approval	O
of	O
version	O
to	O
be	O
published	O
.	O

EK	O
:	O
Acquisition	O
of	O
data	O
,	O
revising	O
article	O
critically	O
for	O
important	O
intellectual	O
content	O
,	O
and	O
final	O
approval	O
of	O
version	O
to	O
be	O
published	O
.	O

MM	O
:	O
Conception	O
and	O
design	O
,	O
analysis	O
and	O
interpretation	O
of	O
data	O
,	O
revising	O
article	O
critically	O
for	O
important	O
intellectual	O
content	O
,	O
and	O
final	O
approval	O
of	O
version	O
to	O
be	O
published	O
.	O

All	O
authors	O
read	O
and	O
approved	O
the	O
final	O
manuscript	O
.	O

Pre	O
-	O
publication	O
history	O
The	O
pre	O
-	O
publication	O
history	O
for	O
this	O
paper	O
can	O
be	O
accessed	O
here	O
:	O
http	O
://	O
www	O
.	O
biomedcentral	O
.	O
com	O
/	O
1471	O
-	O
2431	O
/	O
13	O
/	O
174	O
/	O
prepub	O
PubMed	O
Central	O
:	O

Brown	O
adipose	O
tissue	O
activity	O
as	O
a	O
target	O
for	O
the	O
treatment	O
of	O
obesity	O
/	O
insulin	O
resistance	O
Abstract	O
Presence	O
of	O
brown	O
adipose	O
tissue	O
(	O
BAT	O
),	O
characterized	O
by	O
the	O
expression	O
of	O
the	O
thermogenic	O
uncoupling	O
protein	O
1	O
(	O
UCP1	O
),	O
has	O
recently	O
been	O
described	O
in	O
adult	O
humans	O
.	O

UCP1	O
is	O
expressed	O
in	O
classical	O
brown	O
adipocytes	O
,	O
as	O
well	O
as	O
in	O
“	O
beige	O
cells	O
”	O
in	O
white	O
adipose	O
tissue	O
(	O
WAT	O
).	O

The	O
thermogenic	O
activity	O
of	O
BAT	O
is	O
mainly	O
controlled	O
by	O
the	O
sympathetic	O
nervous	O
system	O
.	O

Endocrine	O
factors	O
,	O
such	O
as	O
fibroblast	O
growth	O
factor	O
21	O
(	O
FGF21	O
)	O
and	O
bone	O
morphogenic	O
protein	O
factor	O
-	O
9	O
(	O
BMP	O
-	O
9	O
),	O
predominantly	O
produced	O
in	O
the	O
liver	O
,	O
were	O
shown	O
to	O
lead	O
to	O
activation	O
of	O
BAT	O
thermogenesis	O
,	O
as	O
well	O
as	O
to	O
“	O
browning	O
”	O
of	O
WAT	O
.	O

This	O
was	O
also	O
observed	O
in	O
response	O
to	O
irisin	O
,	O
a	O
hormone	O
secreted	O
by	O
skeletal	O
muscles	O
.	O

Different	O
approaches	O
were	O
used	O
to	O
delineate	O
the	O
impact	O
of	O
UCP1	O
on	O
insulin	O
sensitivity	O
.	O

When	O
studied	O
under	O
thermoneutral	O
conditions	O
,	O
UCP1	O
knockout	O
mice	O
exhibited	O
markedly	O
increased	O
metabolic	O
efficiency	O
due	O
to	O
impaired	O
thermogenesis	O
.	O

The	O
impact	O
of	O
UCP1	O
deletion	O
on	O
insulin	O
sensitivity	O
in	O
these	O
mice	O
was	O
not	O
reported	O
.	O

Conversely	O
,	O
several	O
studies	O
in	O
both	O
rodents	O
and	O
humans	O
have	O
shown	O
that	O
BAT	O
activation	O
(	O
by	O
cold	O
exposure	O
,	O
β3	O
-	O
agonist	O
treatment	O
,	O
transplantation	O
and	O
others	O
)	O
improves	O
glucose	O
tolerance	O
and	O
insulin	O
sensitivity	O
.	O

Interestingly	O
,	O
similar	O
results	O
were	O
obtained	O
by	O
adipose	O
tissue	O
-	O
specific	O
overexpression	O
of	O
PR	O
-	O
domain	O
-	O
containing	O
16	O
(	O
PRDM16	O
)	O
or	O
BMP4	O
in	O
mice	O
.	O

The	O
mediators	O
of	O
such	O
beneficial	O
effects	O
seem	O
to	O
include	O
FGF21	O
,	O
interleukin	O
-	O
6	O
,	O
BMP8B	O
and	O
prostaglandin	O
D2	O
synthase	O
.	O

Interestingly	O
,	O
some	O
of	O
these	O
molecules	O
can	O
be	O
secreted	O
by	O
BAT	O
itself	O
,	O
indicating	O
the	O
occurrence	O
of	O
autocrine	O
effects	O
.	O

Stimulation	O
of	O
BAT	O
activity	O
and	O
/	O
or	O
recruitment	O
of	O
UCP1	O
-	O
positive	O
cells	O
are	O
therefore	B
relevant	O
targets	O
for	O
the	O
treatment	O
of	O
obesity	O
/	O
type	O
2	O
diabetes	O
in	O
humans	O
.	O

Introduction	O
Obesity	O
,	O
well	O
known	O
to	O
be	O
associated	O
with	O
a	O
number	O
of	O
comorbidities	O
,	O
including	O
insulin	O
resistance	O
and	O
type	O
2	O
diabetes	O
,	O
has	O
become	O
a	O
major	O
public	O
health	O
problem	O
in	O
recent	O
decades	O
,	O
and	O
has	O
reached	O
epidemic	O
proportions	O
,	O
not	O
only	O
in	O
high	O
-	O
income	O
countries	O
,	O
but	O
also	O
in	O
most	O
middle	O
-	O
income	O
societies	O
.	O

It	O
is	O
defined	O
as	O
an	O
accumulation	O
of	O
adipose	O
tissue	O
that	O
is	O
of	O
sufficient	O
magnitude	O
to	O
impair	O
health	O
(	O
WHO	O
,	O
2014	O
).	O

Excess	O
weight	O
is	O
usually	O
defined	O
by	O
the	O
body	O
mass	O
index	O
or	O
BMI	O
.	O

The	O
normal	O
BMI	O
range	O
is	O
18	O
.	O
5	O
–	O
25	O
kg	O
/	O
m2	O
,	O
although	O
the	O
range	O
may	O
vary	O
for	O
different	O
countries	O
.	O

Individuals	O
with	O
a	O
BMI	O
above	O
30	O
kg	O
/	O
m2are	O
classified	O
as	O
obese	O
;	O
those	O
with	O
a	O
BMI	O
between	O
25	O
and	O
30	O
kg	O
/	O
m2are	O
considered	O
to	O
be	O
overweight	O
.	O

In	O
general	O
,	O
the	O
term	O
obesity	O
applies	O
to	O
both	O
the	O
obese	O
and	O
the	O
overweight	O
subjects	O
.	O

More	O
than	O
the	O
total	O
body	O
weight	O
,	O
the	O
distribution	O
of	O
the	O
stored	O
fat	O
is	O
of	O
importance	O
for	O
the	O
development	O
of	O
obesity	O
and	O
its	O
comorbidities	O
.	O

Thus	O
,	O
central	O
or	O
visceral	O
obesity	O
,	O
in	O
which	O
fat	O
accumulates	O
in	O
the	O
trunk	O
and	O
in	O
the	O
abdominal	O
cavity	O
(	O
in	O
the	O
mesentery	O
and	O
around	O
the	O
viscera	O
),	O
is	O
associated	O
with	O
a	O
much	O
higher	O
risk	O
for	O
several	O
diseases	O
than	O
excess	O
subcutaneous	O
fat	O
accumulation	O
.	O

Obesity	O
has	O
profound	O
effects	O
on	O
tissue	O
insulin	O
sensitivity	O
,	O
and	O
therefore	O
on	O
systemic	O
glucose	O
homeostasis	O
.	O

Insulin	O
resistance	O
is	O
present	O
even	O
in	O
simple	O
obesity	O
,	O
without	O
hyperglycemia	O
,	O
indicating	O
a	O
fundamental	O
abnormality	O
of	O
insulin	O
signaling	O
in	O
states	O
of	O
excess	O
adipose	O
tissue	O
mass	O
.	O

The	O
epidemiologic	O
association	O
of	O
obesity	O
,	O
particularly	O
of	O
the	O
visceral	O
type	O
,	O
with	O
type	O
2	O
diabetes	O
has	O
been	O
recognized	O
for	O
decades	O
.	O

According	O
to	O
the	O
World	O
Health	O
Organization	O
,	O
347	O
millions	O
of	O
people	O
are	O
diabetic	O
in	O
the	O
world	O
,	O
and	O
it	O
is	O
predicted	O
that	O
in	O
2030	O
,	O
diabetes	O
will	O
be	O
the	O
7th	O
cause	O
of	O
death	O
considering	O
the	O
worldwide	O
population	O
(	O
WHO	O
,	O
2014	O
).	O

Although	O
the	O
pathogenesis	O
of	O
obesity	O
is	O
extremely	O
complex	O
and	O
is	O
far	O
from	O
being	O
unraveled	O
,	O
the	O
key	O
component	O
of	O
the	O
obesity	O
epidemic	O
is	O
long	O
-	O
term	O
dysregulation	O
of	O
energy	O
balance	O
,	O
comprising	O
increased	O
energy	O
intake	O
and	O
/	O
or	O
reduced	O
energy	O
expenditure	O
.	O

Despite	O
active	O
research	O
and	O
impressive	O
improvements	O
in	O
the	O
understanding	O
of	O
the	O
regulation	O
of	O
energy	O
balance	O
,	O
there	O
are	O
only	O
a	O
very	O
limited	O
number	O
of	O
drugs	O
that	O
can	O
be	O
used	O
for	O
the	O
efficient	O
treatment	O
of	O
obesity	O
and	O
its	O
comorbidities	O
.	O

Targeting	O
specific	O
components	O
of	O
the	O
neuroendocrine	O
regulation	O
of	O
energy	O
intake	O
,	O
such	O
as	O
leptin	O
or	O
hypothalamic	O
neuropeptides	O
,	O
has	O
disappointingly	O
revealed	O
unsuccessful	O
as	O
yet	O
.	O

New	O
alternatives	O
focusing	O
on	O
adipose	O
tissue	O
function	O
could	O
potentially	O
be	O
of	O
therapeutic	O
relevance	O
in	O
the	O
future	O
.	O

Two	O
different	O
types	O
of	O
adipose	O
tissue	O
have	O
been	O
described	O
:	O
brown	O
adipose	O
tissue	O
(	O
BAT	O
),	O
composed	O
mainly	O
of	O
brown	O
adipocytes	O
,	O
and	O
white	O
adipose	O
tissue	O
(	O
WAT	O
),	O
defined	O
by	O
a	O
majority	O
of	O
white	O
adipocytes	O
,	O
both	O
tissues	O
being	O
able	O
to	O
accumulate	O
lipids	O
in	O
intracellular	O
droplets	O
.	O

WAT	O
is	O
an	O
energy	O
-	O
storing	O
tissue	O
that	O
has	O
evolutionary	O
enabled	O
humans	O
to	O
survive	O
for	O
longer	O
periods	O
between	O
meals	O
,	O
storing	O
energy	O
mainly	O
as	O
triglycerides	O
and	O
releasing	O
fatty	O
acids	O
during	O
fasting	O
periods	O
.	O

In	O
recent	O
times	O
,	O
when	O
food	O
has	O
become	O
cheaper	O
and	O
more	O
widely	O
available	O
,	O
excessive	O
WAT	O
storage	O
contributed	O
to	O
the	O
worldwide	O
alarming	O
development	O
of	O
obesity	O
mentioned	O
above	O
(	O
World	O
Health	O
Organization	O
,	O
2009	O
).	O

White	O
adipocytes	O
are	O
composed	O
of	O
a	O
large	O
single	O
,	O
spherical	O
lipid	O
vacuole	O
and	O
a	O
peripherally	O
located	O
nucleus	O
,	O
together	O
with	O
few	O
mitochondria	O
.	O

WAT	O
has	O
endocrine	O
activity	O
,	O
secreting	O
several	O
factors	O
and	O
hormones	O
,	O
such	O
as	O
leptin	O
and	O
adiponectin	O
.	O

Under	O
certain	O
conditions	O
,	O
another	O
type	O
of	O
adipocytes	O
,	O
named	O
brite	O
or	O
beige	O
cells	O
,	O
can	O
be	O
found	O
dispersed	O
within	O
some	O
of	O
the	O
WAT	O
depots	O
.	O

These	O
cells	O
,	O
which	O
will	O
be	O
discussed	O
below	O
,	O
present	O
a	O
phenotype	O
with	O
metabolic	O
properties	O
that	O
are	O
closest	O
to	O
brown	O
than	O
to	O
white	O
adipocytes	O
.	O

BAT	O
consists	O
in	O
brown	O
adipocytes	O
,	O
characterized	O
by	O
multiple	O
,	O
small	O
,	O
multilocular	O
lipid	O
droplets	O
with	O
a	O
central	O
nucleus	O
and	O
a	O
high	O
number	O
of	O
mitochondria	O
.	O

BAT	O
is	O
a	O
highly	O
vascularized	O
tissue	O
innervated	O
by	O
the	O
sympathetic	O
nervous	O
system	O
.	O

The	O
mitochondria	O
of	O
BAT	O
are	O
characterized	O
by	O
the	O
presence	O
of	O
uncoupling	O
protein	O
-	O
1	O
(	O
UCP1	O
)	O
in	O
the	O
inner	O
mitochondrial	O
membrane	O
.	O

When	O
activated	O
,	O
this	O
protein	O
uncouples	O
mitochondrial	O
respiration	O
from	O
ATP	O
synthesis	O
,	O
resulting	O
in	O
heat	O
production	O
,	O
a	O
process	O
that	O
consumes	O
substantial	O
amounts	O
of	O
fuels	O
.	O

BAT	O
,	O
the	O
principal	O
effector	O
organ	O
of	O
non	O
-	O
shivering	O
thermogenesis	O
(	O
i	O
.	O
e	O
.,	O
heat	O
production	O
that	O
does	O
not	O
involve	O
skeletal	O
muscle	O
contraction	O
),	O
is	O
present	O
in	O
most	O
mammals	O
and	O
its	O
maturation	O
in	O
the	O
perinatal	O
period	O
varies	O
between	O
species	O
,	O
according	O
to	O
their	O
developmental	O
status	O
at	O
birth	O
(	O
Tews	O
and	O
Wabitsch	O
,	O
2011	O
).	O

In	O
humans	O
,	O
BAT	O
develops	O
in	O
the	O
fetus	O
during	O
gestation	O
.	O

Thus	O
,	O
the	O
amount	O
of	O
UCP1	O
increases	O
during	O
fetal	O
development	O
,	O
peaks	O
at	O
birth	O
,	O
before	O
declining	O
over	O
the	O
first	O
9	O
months	O
(	O
Lean	O
et	O
al	O
.,	O
1986	O
;	O
Tews	O
and	O
Wabitsch	O
,	O
2011	O
).	O

The	O
notion	O
that	O
human	O
BAT	O
is	O
solely	O
apparent	O
during	O
the	O
neonatal	O
stage	O
prevailed	O
for	O
decades	O
(	O
Heaton	O
,	O
1972	O
;	O
Nedergaard	O
et	O
al	O
.,	O
2007	O
).	O

In	O
2009	O
,	O
functional	O
human	O
BAT	O
was	O
identified	O
in	O
adults	O
by	O
a	O
combination	O
of	O
CT	O
scans	O
and	O
fluorodeoxyglucose	O
positron	O
emission	O
tomography	O
(	O
FDG	O
-	O
PET	O
)	O
(	O
Cypess	O
et	O
al	O
.,	O
2009	O
;	O
van	O
Marken	O
Lichtenbelt	O
et	O
al	O
.,	O
2009	O
;	O
Virtanen	O
et	O
al	O
.,	O
2009	O
).	O

The	O
areas	O
in	O
which	O
BAT	O
is	O
observed	O
in	O
adult	O
humans	O
include	O
supraclavicular	O
,	O
neck	O
,	O
paravertebral	O
,	O
and	O
suprarenal	O
sites	O
(	O
Nedergaard	O
et	O
al	O
.,	O
2007	O
).	O

Estimates	O
of	O
BAT	O
mass	O
and	O
activity	O
from	O
FDG	O
-	O
PET	O
studies	O
suggest	O
that	O
humans	O
have	O
,	O
on	O
average	O
,	O
50	O
–	O
80	O
g	O
of	O
BAT	O
(	O
Peirce	O
et	O
al	O
.,	O
2014	O
).	O

Quantitatively	O
,	O
it	O
was	O
estimated	O
that	O
50	O
g	O
of	O
BAT	O
can	O
burn	O
as	O
much	O
as	O
20	O
%	O
of	O
daily	O
energy	O
intake	O
(	O
Rothwell	O
and	O
Stock	O
,	O
1983	O
).	O

As	O
an	O
example	O
,	O
in	O
a	O
subject	O
with	O
63	O
g	O
of	O
supraclavicular	O
BAT	O
,	O
it	O
was	O
calculated	O
that	O
if	O
the	O
depot	O
was	O
fully	O
activated	O
,	O
it	O
would	O
burn	O
an	O
amount	O
of	O
energy	O
equivalent	O
to	O
4	O
.	O
1	O
kg	O
of	O
WAT	O
(	O
Virtanen	O
et	O
al	O
.,	O
2009	O
).	O

It	O
can	O
therefore	B
be	O
concluded	O
that	O
,	O
even	O
though	O
the	O
BAT	O
depots	O
are	O
present	O
in	O
small	O
amounts	O
,	O
the	O
activated	O
tissue	O
has	O
the	O
potential	O
to	O
substantially	O
contribute	O
to	O
energy	O
expenditure	O
(	O
Nedergaard	O
et	O
al	O
.,	O
2007	O
).	O

BAT	O
activity	O
is	O
well	O
known	O
to	O
mostly	O
rely	O
on	O
lipid	O
metabolism	O
,	O
UCP1	O
being	O
directly	O
activated	O
by	O
fatty	O
acids	O
(	O
Cannon	O
and	O
Nedergaard	O
,	O
2004	O
).	O

Along	O
this	O
line	O
,	O
it	O
was	O
recently	O
demonstrated	O
that	O
chronic	O
activation	O
of	O
the	O
β3	O
adrenoreceptor	O
induces	O
coupled	O
increases	O
in	O
lipolysis	O
,	O
de	O
novo	O
lipogenesis	O
and	O
fatty	O
acid	O
beta	O
-	O
oxidation	O
not	O
only	O
in	O
white	O
,	O
but	O
also	O
in	O
BAT	O
(	O
Mottillo	O
et	O
al	O
.,	O
2014	O
).	O

Thus	B
,	O
the	O
continuous	O
cycling	O
of	O
triglyceride	O
hydrolysis	O
coupled	O
to	O
resynthesis	O
,	O
which	O
requires	O
large	O
amounts	O
of	O
ATP	O
,	O
could	O
be	O
another	O
important	O
mechanism	O
to	O
increase	O
thermogenesis	O
in	O
BAT	O
,	O
in	O
addition	O
to	O
the	O
role	O
of	O
UCP1	O
activation	O
in	O
this	O
process	O
(	O
Mottillo	O
et	O
al	O
.,	O
2014	O
).	O

Similarly	O
to	O
what	O
was	O
proposed	O
for	O
skeletal	O
muscle	O
(	O
Dulloo	O
et	O
al	O
.,	O
2004	O
),	O
this	O
may	O
contribute	O
to	O
dissipate	O
excess	O
lipids	O
as	O
occurs	O
during	O
prolonged	O
stimulation	O
of	O
lipolysis	O
(	O
e	O
.	O
g	O
.,	O
chronic	O
β3	O
adrenoreceptor	O
treatment	O
).	O

In	O
addition	O
to	O
using	O
lipids	O
,	O
BAT	O
also	O
displays	O
a	O
very	O
high	O
rate	O
of	O
glucose	O
uptake	O
,	O
particularly	O
under	O
sympathetic	O
activation	O
(	O
Cannon	O
and	O
Nedergaard	O
,	O
2004	O
).	O

Interestingly	O
,	O
BAT	O
glucose	O
uptake	O
is	O
close	O
to	O
the	O
values	O
observed	O
for	O
metastasis	O
in	O
cancer	O
in	O
humans	O
(	O
Aukema	O
et	O
al	O
.,	O
2010	O
).	O

This	O
tissue	O
also	O
responds	O
to	O
insulin	O
with	O
a	O
5	O
-	O
fold	O
increase	O
in	O
glucose	O
uptake	O
,	O
without	O
any	O
change	O
in	O
blood	O
flow	O
(	O
Orava	O
et	O
al	O
.,	O
2011	O
),	O
while	O
under	O
cold	O
exposure	O
,	O
glucose	O
uptake	O
increases	O
by	O
12	O
-	O
folds	O
,	O
dissipating	O
energy	O
as	O
a	O
function	O
of	O
increased	O
blood	O
flow	O
(	O
Orava	O
et	O
al	O
.,	O
2011	O
).	O

Regarding	O
the	O
fate	O
of	O
glucose	O
in	O
brown	O
adipocytes	O
under	O
anabolic	O
conditions	O
characterized	O
by	O
high	O
insulin	O
levels	O
,	O
it	O
is	O
essentially	O
metabolized	O
to	O
provide	O
glycerol	O
-	O
3	O
-	O
phosphate	O
for	O
triglyceride	O
synthesis	O
or	O
acetyl	O
-	O
CoA	O
for	O
de	O
novo	O
fatty	O
acid	O
synthesis	O
(	O
Cannon	O
and	O
Nedergaard	O
,	O
2004	O
).	O

To	O
investigate	O
the	O
role	O
of	O
BAT	O
,	O
of	O
UCP1	O
in	O
particular	O
,	O
studies	O
were	O
carried	O
out	O
in	O
UCP1	O
knockout	O
mice	O
.	O

Surprisingly	O
,	O
no	O
particular	O
phenotype	O
was	O
noted	O
in	O
these	O
mice	O
when	O
they	O
were	O
kept	O
at	O
23	O
°	O
C	O
,	O
except	O
for	O
their	O
increased	O
cold	O
sensitivity	O
(	O
Enerback	O
et	O
al	O
.,	O
1997	O
;	O
Kontani	O
et	O
al	O
.,	O
2005	O
).	O

In	O
contrast	O
,	O
when	O
bred	O
under	O
thermoneutral	O
conditions	O
(	O
29	O
°	O
C	O
),	O
UCP1	O
knockout	O
mice	O
exhibited	O
markedly	O
enhanced	O
metabolic	O
efficiency	O
due	O
to	O
impaired	O
thermogenesis	O
(	O
Feldmann	O
et	O
al	O
.,	O
2009	O
).	O

Altogether	O
,	O
the	O
existing	O
literature	O
suggests	O
that	O
BAT	O
activation	O
is	O
not	O
only	O
involved	O
in	O
non	O
-	O
shivering	O
thermogenesis	O
,	O
but	O
also	O
in	O
the	O
regulation	O
of	O
insulin	O
-	O
mediated	O
glucose	O
disposal	O
.	O

Whether	O
brown	O
and	O
brite	O
adipocytes	O
display	O
some	O
degree	O
of	O
specialization	O
with	O
regard	O
to	O
these	O
different	O
functions	O
has	O
to	O
be	O
established	O
.	O

The	O
aims	O
of	O
this	O
review	O
are	O
to	O
describe	O
some	O
of	O
the	O
main	O
factors	O
regulating	O
UCP1	O
activity	O
in	O
brown	O
and	O
brite	O
adipocytes	O
,	O
as	O
well	O
as	O
to	O
discuss	O
the	O
potential	O
role	O
of	O
UCP1	O
activation	O
for	O
the	O
treatment	O
of	O
insulin	O
resistance	O
and	O
type	O
2	O
diabetes	O
associated	O
with	O
obesity	O
.	O

Factors	O
affecting	O
BAT	O
function	O
and	O
energy	O
metabolism	O
improve	O
overall	O
metabolism	O
In	O
rodents	O
,	O
brown	O
adipocytes	O
are	O
found	O
in	O
discrete	O
areas	O
,	O
such	O
as	O
interscapular	O
,	O
cervical	O
,	O
peri	O
-	O
aortic	O
,	O
peri	O
-	O
renal	O
,	O
intercostal	O
and	O
mediastinal	O
depots	O
(	O
Cinti	O
,	O
2001	O
),	O
which	O
are	O
referred	O
to	O
as	O
“	O
classical	O
”	O
BAT	O
depots	O
.	O

In	O
addition	O
,	O
brown	O
adipocytes	O
can	O
be	O
found	O
scattered	O
in	O
WAT	O
,	O
especially	O
upon	O
cold	O
exposure	O
(	O
Young	O
et	O
al	O
.,	O
1984	O
;	O
Guerra	O
et	O
al	O
.,	O
1998	O
),	O
treatment	O
with	O
β	O
-	O
adrenergic	O
(	O
Himms	O
-	O
Hagen	O
et	O
al	O
.,	O
2000	O
),	O
or	O
with	O
peroxisome	O
-	O
proliferator	O
-	O
activated	O
receptor	O
-	O
γ	O
(	O
PPAR	O
-	O
γ	O
)	O
agonists	O
(	O
Petrovic	O
et	O
al	O
.,	O
2010	O
).	O

These	O
brown	O
-	O
like	O
adipocytes	O
have	O
interchangeably	O
been	O
called	O
“	O
recruitable	O
”	O
(	O
Tseng	O
et	O
al	O
.,	O
2008	O
;	O
Schulz	O
et	O
al	O
.,	O
2013	O
),	O
“	O
beige	O
”	O
(	O
Ishibashi	O
and	O
Seale	O
,	O
2010	O
;	O
Auffret	O
et	O
al	O
.,	O
2012	O
;	O
Wu	O
et	O
al	O
.,	O
2012	O
),	O
or	O
“	O
brite	O
”	O
(	O
for	O
brown	O
to	O
white	O
)	O
(	O
Petrovic	O
et	O
al	O
.,	O
2010	O
;	O
Gburcik	O
et	O
al	O
.,	O
2012	O
)	O
cells	O
.	O

Lineage	O
-	O
tracing	O
studies	O
showed	O
that	O
brown	O
adipocytes	O
in	O
classic	O
BAT	O
areas	O
derive	O
from	O
myogenic	O
factor	O
5	O
(	O
Myf	O
5	O
+)-	O
positive	O
progenitor	O
cells	O
,	O
similarly	O
to	O
skeletal	O
myocytes	O
(	O
Timmons	O
et	O
al	O
.,	O
2007	O
).	O

In	O
contrast	O
,	O
“	O
brite	O
”	O
adipocytes	O
have	O
been	O
shown	O
to	O
originate	O
from	O
Myf	O
-	O
negative	O
(	O
Myf	O
5	O
−)	O
progenitor	O
cells	O
,	O
much	O
like	O
white	O
adipocytes	O
(	O
Petrovic	O
et	O
al	O
.,	O
2010	O
;	O
Long	O
et	O
al	O
.,	O
2014	O
).	O

Whether	O
“	O
brite	O
”	O
adipocytes	O
descend	O
from	O
unique	O
precursors	O
,	O
or	O
share	O
progenitors	O
with	O
either	O
white	O
or	O
classic	O
brown	O
adipocytes	O
still	O
remains	O
to	O
be	O
established	O
(	O
for	O
rev	O
.,	O
see	O
Chechi	O
et	O
al	O
.,	O
2013	O
).	O

Interestingly	O
,	O
the	O
“	O
browning	O
”	O
of	O
WAT	O
(	O
i	O
.	O
e	O
.,	O
increased	O
proportion	O
of	O
brown	O
adipocytes	O
)	O
may	O
also	O
involve	O
transdifferentiation	O
of	O
white	O
-	O
to	O
-	O
brown	O
adipose	O
cells	O
(	O
Smorlesi	O
et	O
al	O
.,	O
2012	O
;	O
Frontini	O
et	O
al	O
.,	O
2013	O
),	O
although	O
this	O
issue	O
is	O
still	O
a	O
matter	O
of	O
debate	O
(	O
Wu	O
et	O
al	O
.,	O
2012	O
).	O

Whatever	O
their	O
developmental	O
origin	O
,	O
white	O
,	O
“	O
brite	O
”	O
and	O
brown	O
adipocytes	O
seem	O
to	O
greatly	O
differ	O
in	O
their	O
function	O
.	O

As	O
mentioned	O
above	O
,	O
BAT	O
is	O
the	O
effector	O
organ	O
of	O
non	O
-	O
shivering	O
thermogenesis	O
(	O
both	O
cold	O
and	O
diet	O
-	O
induced	O
)	O
that	O
,	O
by	O
utilizing	O
large	O
quantities	O
of	O
glucose	O
and	O
lipids	O
from	O
the	O
circulation	O
,	O
can	O
promote	O
negative	O
energy	O
balance	O
.	O

Moreover	O
,	O
the	O
role	O
of	O
BAT	O
activation	O
appears	O
to	O
be	O
broader	O
than	O
solely	O
the	O
promotion	O
of	O
negative	O
energy	O
balance	O
(	O
for	O
rev	O
.,	O
see	O
Peirce	O
and	O
Vidal	O
-	O
Puig	O
,	O
2013	O
).	O

Indeed	O
,	O
BAT	O
is	O
now	O
known	O
to	O
exert	O
anti	O
-	O
type	O
2	O
diabetic	O
effects	O
associated	O
with	O
improvments	O
of	O
dyslipidemia	O
and	O
insulin	O
secretion	O
as	O
well	O
as	O
decrease	O
insulin	O
resistance	O
in	O
type	O
2	O
diabetes	O
(	O
de	O
Souza	O
et	O
al	O
.,	O
1997	O
;	O
Liu	O
et	O
al	O
.,	O
1998	O
;	O
Frontini	O
et	O
al	O
.,	O
2013	O
;	O
Peirce	O
and	O
Vidal	O
-	O
Puig	O
,	O
2013	O
).	O

These	O
effects	O
are	O
partly	O
interrelated	O
,	O
but	O
can	O
also	O
be	O
dissociated	O
and	O
exerted	O
by	O
different	O
UCP1	O
-	O
expressing	O
types	O
of	O
adipocytes	O
(	O
i	O
.	O
e	O
.,	O
brown	O
and	O
“	O
brite	O
”	O
adipocytes	O
).	O

However	O
,	O
as	O
these	O
different	O
cells	O
are	O
often	O
mixed	O
,	O
such	O
as	O
occurs	O
for	O
classical	O
and	O
“	O
brite	O
”	O
adipocytes	O
in	O
some	O
human	O
depots	O
(	O
Wu	O
et	O
al	O
.,	O
2012	O
;	O
Cypess	O
et	O
al	O
.,	O
2013	O
;	O
Jespersen	O
et	O
al	O
.,	O
2013	O
),	O
only	O
the	O
use	O
of	O
specific	O
cell	O
surface	O
markers	O
(	O
i	O
.	O
e	O
.,	O
ASC	O
-	O
1	O
,	O
PAT2	O
,	O
and	O
P2RX5	O
for	O
white	O
,	O
“	O
brite	O
”	O
and	O
brown	O
adipocytes	O
,	O
respectively	O
)	O
will	O
allow	O
for	O
their	O
identification	O
,	O
as	O
well	O
as	O
for	O
the	O
precise	O
understanding	O
of	O
their	O
respective	O
therapeutic	O
properties	O
(	O
Ussar	O
et	O
al	O
.,	O
2014	O
).	O

BAT	O
activation	O
by	O
cold	O
exposure	O
,	O
β3	O
-	O
agonist	O
or	O
thyroid	O
hormone	O
treatment	O
was	O
shown	O
to	O
improve	O
glucose	O
tolerance	O
and	O
insulin	O
sensitivity	O
(	O
Cawthorne	O
et	O
al	O
.,	O
1984	O
;	O
Forest	O
et	O
al	O
.,	O
1987	O
;	O
Peirce	O
and	O
Vidal	O
-	O
Puig	O
,	O
2013	O
).	O

Similar	O
observations	O
were	O
obtained	O
by	O
adipose	O
tissue	O
-	O
specific	O
overexpression	O
of	O
PR	O
-	O
domain	O
-	O
containing	O
16	O
(	O
PRDM16	O
)	O
in	O
mice	O
.	O

This	O
Zinc	O
-	O
finger	O
transcription	O
factor	O
induces	O
differentiation	O
of	O
brown	O
adipocytes	O
(	O
Seale	O
et	O
al	O
.,	O
2011	O
).	O

The	O
main	O
mediators	O
of	O
such	O
beneficial	O
effects	O
seem	O
to	O
include	O
fibroblast	O
growth	O
factor	O
21	O
(	O
FGF21	O
),	O
interleukin	O
-	O
6	O
(	O
IL	O
-	O
6	O
),	O
bone	O
morphogenic	O
proteins	O
(	O
BMPs	O
)	O
and	O
prostaglandin	O
D2	O
synthase	O
.	O

Interestingly	O
,	O
some	O
of	O
these	O
molecules	O
,	O
called	O
batokines	O
,	O
can	O
be	O
secreted	O
by	O
BAT	O
itself	O
,	O
indicating	O
the	O
occurrence	O
of	O
autocrine	O
effects	O
.	O

Fibroblast	O
growth	O
factor	O
21	O
is	O
a	O
member	O
of	O
the	O
fibroblast	O
growth	O
factor	O
(	O
FGF	O
)	O
family	O
that	O
acts	O
as	O
a	O
hormone	O
and	O
that	O
,	O
in	O
contrast	O
to	O
other	O
endocrine	O
FGFs	O
,	O
is	O
devoid	O
of	O
proliferative	O
activity	O
(	O
Itoh	O
,	O
2014	O
).	O

It	O
is	O
expressed	O
in	O
BAT	O
and	O
WAT	O
,	O
although	O
its	O
main	O
production	O
site	O
is	O
the	O
liver	O
(	O
Nishimura	O
et	O
al	O
.,	O
2000	O
;	O
Muise	O
et	O
al	O
.,	O
2008	O
;	O
Schulz	O
et	O
al	O
.,	O
2013	O
;	O
Zafrir	O
,	O
2013	O
).	O

Tissue	O
-	O
specific	O
FGF21	O
regulation	O
was	O
shown	O
to	O
occur	O
in	O
response	O
to	O
chronic	O
cold	O
exposure	O
in	O
mice	O
(	O
Fisher	O
et	O
al	O
.,	O
2012	O
).	O

Under	O
this	O
condition	O
,	O
FGF21	O
expression	O
was	O
indeed	O
decreased	O
in	O
the	O
liver	O
,	O
but	O
enhanced	O
in	O
BAT	O
,	O
as	O
well	O
as	O
in	O
WAT	O
,	O
where	O
it	O
acted	O
to	O
markedly	O
increase	O
UCP1	O
expression	O
and	O
the	O
“	O
browning	O
”	O
of	O
subcutaneous	O
tissue	O
(	O
Fisher	O
et	O
al	O
.,	O
2012	O
).	O

Interestingly	O
,	O
in	O
humans	O
,	O
a	O
mild	O
cold	O
exposure	O
(	O
12	O
h	O
to	O
19	O
°	O
C	O
)	O
was	O
recently	O
shown	O
to	O
increase	O
the	O
diurnal	O
plasma	O
FGF21	O
levels	O
,	O
with	O
a	O
positive	O
correlation	O
with	O
the	O
changes	O
in	O
adipose	O
tissue	O
microdialysate	O
glycerol	O
and	O
total	O
energy	O
expenditure	O
(	O
Lee	O
et	O
al	O
.,	O
2013	O
).	O

This	O
suggested	O
that	O
FGF21	O
could	O
play	O
a	O
similar	O
role	O
in	O
humans	O
as	O
in	O
rodents	O
in	O
promoting	O
cold	O
-	O
induced	O
metabolic	O
changes	O
(	O
i	O
.	O
e	O
.,	O
lipolysis	O
and	O
cold	O
-	O
induced	O
thermogenesis	O
).	O

In	O
adipose	O
tissue	O
,	O
it	O
appears	O
that	O
PPARγ	O
transcriptionally	O
controls	O
FGF21	O
,	O
which	O
then	O
acts	O
as	O
an	O
autocrine	O
or	O
paracrine	O
way	O
to	O
increase	O
PPARγ	O
transcriptional	O
activity	O
in	O
a	O
feed	O
-	O
forward	O
loop	O
system	O
(	O
Wang	O
et	O
al	O
.,	O
2008	O
;	O
Dutchak	O
et	O
al	O
.,	O
2012	O
).	O

FGF21	O
deficiency	O
in	O
mice	O
was	O
shown	O
to	O
result	O
in	O
impaired	O
ability	O
to	O
adapt	O
to	O
long	O
-	O
term	O
cold	O
exposure	O
with	O
diminished	O
“	O
browning	O
”	O
of	O
WAT	O
(	O
Fisher	O
et	O
al	O
.,	O
2012	O
).	O

At	O
the	O
opposite	O
,	O
systemic	O
administration	O
of	O
FGF21	O
in	O
obese	O
mice	O
resulted	O
in	O
reduced	O
adiposity	O
,	O
improved	O
glycemic	O
control	O
,	O
as	O
well	O
as	O
increased	O
energy	O
expenditure	O
,	O
as	O
mentioned	O
by	O
the	O
authors	O
(	O
Coskun	O
et	O
al	O
.,	O
2008	O
).	O

Altogether	O
,	O
these	O
observations	O
suggest	O
that	O
FGF21	O
may	O
be	O
a	O
key	O
factor	O
linking	O
UCP1	O
expression	O
to	O
improved	O
glucose	O
metabolism	O
.	O

It	O
may	O
also	O
exert	O
determinant	O
developmental	O
effects	O
,	O
given	O
the	O
observation	O
that	O
the	O
postnatal	O
maturation	O
of	O
BAT	O
appears	O
to	O
relate	O
to	O
the	O
onset	O
of	O
feeding	O
and	O
initiation	O
of	O
hepatic	O
function	O
,	O
as	O
mediated	O
by	O
the	O
release	O
of	O
FGF21	O
(	O
Hondares	O
et	O
al	O
.,	O
2010	O
).	O

In	O
addition	O
,	O
it	O
was	O
recently	O
proposed	O
that	O
FGF21	O
could	O
act	O
within	O
the	O
central	O
nervous	O
system	O
,	O
both	O
at	O
the	O
level	O
of	O
the	O
hypothalamus	O
and	O
the	O
hindbrain	O
to	O
promote	O
a	O
set	O
of	O
responses	O
that	O
occur	O
during	O
starvation	O
(	O
i	O
.	O
e	O
.	O

increase	O
in	O
corticosterone	O
levels	O
,	O
suppression	O
of	O
physical	O
activity	O
,	O
alteration	O
in	O
circadian	O
behavior	O
)	O
(	O
Bookout	O
et	O
al	O
.,	O
2013	O
).	O

This	O
raises	O
the	O
possibility	O
that	O
,	O
in	O
contrast	O
to	O
its	O
beneficial	O
effects	O
on	O
peripheral	O
metabolism	O
,	O
FGF21	O
may	O
exert	O
deleterious	O
effects	O
by	O
acting	O
centrally	O
.	O

Interleukin	O
-	O
6	O
(	O
IL	O
-	O
6	O
),	O
predominantly	O
known	O
as	O
a	O
pro	O
-	O
inflammatory	O
cytokine	O
,	O
is	O
secreted	O
by	O
skeletal	O
muscle	O
(	O
Pal	O
et	O
al	O
.,	O
2014	O
),	O
helper	O
T	O
cells	O
,	O
as	O
well	O
as	O
by	O
WAT	O
and	O
BAT	O
(	O
Mohamed	O
-	O
Ali	O
et	O
al	O
.,	O
1997	O
;	O
Cannon	O
et	O
al	O
.,	O
1998	O
).	O

Several	O
studies	O
implicated	O
IL	O
-	O
6	O
as	O
a	O
co	O
-	O
inducer	O
of	O
the	O
development	O
of	O
obesity	O
-	O
associated	O
insulin	O
resistance	O
preceding	O
the	O
onset	O
of	O
type	O
2	O
diabetes	O
(	O
Pal	O
et	O
al	O
.,	O
2014	O
).	O

This	O
is	O
in	O
keeping	O
with	O
the	O
observation	O
of	O
increased	O
plasma	O
IL	O
-	O
6	O
levels	O
in	O
obese	O
patients	O
(	O
Cottam	O
et	O
al	O
.,	O
2004	O
).	O

In	O
such	O
patients	O
,	O
IL	O
-	O
6	O
is	O
preferentially	O
secreted	O
from	O
visceral	O
rather	O
than	O
from	O
subcutaneous	O
adipocytes	O
and	O
may	O
participate	O
in	O
the	O
prevailing	O
increase	O
in	O
sympathetic	O
outflow	O
by	O
exerting	O
central	O
effects	O
(	O
Wallenius	O
et	O
al	O
.,	O
2002	O
;	O
Fain	O
et	O
al	O
.,	O
2004	O
).	O

Paradoxically	O
,	O
central	O
IL	O
-	O
6	O
delivery	O
was	O
shown	O
to	O
suppress	O
weight	O
gain	O
and	O
visceral	O
obesity	O
,	O
without	O
affecting	O
food	O
intake	O
(	O
Li	O
et	O
al	O
.,	O
2002	O
).	O

The	O
treatment	O
also	O
enhanced	O
UCP1	O
protein	O
levels	O
in	O
BAT	O
,	O
via	O
stimulation	O
of	O
the	O
sympathetic	O
nervous	O
system	O
(	O
Li	O
et	O
al	O
.,	O
2002	O
).	O

This	O
was	O
mediated	O
by	O
phosphorylation	O
of	O
the	O
signal	O
transducer	O
and	O
activator	O
of	O
transcription	O
3	O
(	O
pSTAT3	O
).	O

Interestingly	O
,	O
chronic	O
central	O
IL	O
-	O
6	O
stimulation	O
desensitized	O
IL	O
-	O
6	O
signal	O
transduction	O
characterized	O
by	O
reversal	O
of	O
elevated	O
pSTAT3	O
levels	O
(	O
Li	O
et	O
al	O
.,	O
2002	O
).	O

Such	O
desensitization	O
is	O
likely	B
occurring	O
in	O
situations	O
of	O
chronic	O
elevation	O
in	O
IL	O
-	O
6	O
levels	O
,	O
such	O
as	O
occurs	O
in	O
human	O
obesity	O
.	O

It	O
should	O
be	O
added	O
that	O
the	O
understanding	O
of	O
the	O
role	O
of	O
IL	O
-	O
6	O
is	O
more	O
complex	O
,	O
as	B
this	O
cytokine	O
is	O
known	O
to	O
be	O
secreted	O
by	O
skeletal	O
muscle	O
in	O
response	O
to	O
exercise	O
,	O
exerting	O
insulin	O
sensitizing	O
effects	O
(	O
Kelly	O
et	O
al	O
.,	O
2004	O
;	O
Petersen	O
and	O
Pedersen	O
,	O
2005	O
).	O

Along	O
this	O
line	O
,	O
it	O
was	O
recently	O
shown	O
that	O
BAT	O
transplantation	O
into	O
the	O
abdominal	O
cavity	O
of	O
high	O
fat	O
diet	O
-	O
induced	O
obese	O
mice	O
was	O
able	O
to	O
improve	O
their	O
glucose	O
tolerance	O
,	O
increase	O
their	O
insulin	O
sensitivity	O
,	O
lower	O
their	O
body	O
weight	O
,	O
decrease	O
their	O
fat	O
mass	O
and	O
completely	O
reverse	O
their	O
insulin	O
resistance	O
(	O
Stanford	O
et	O
al	O
.,	O
2013	O
).	O

BAT	O
transplantation	O
also	O
increased	O
insulin	O
-	O
stimulated	O
glucose	O
uptake	O
in	O
BAT	O
,	O
WAT	O
,	O
and	O
heart	O
,	O
but	O
not	O
in	O
skeletal	O
muscle	O
(	O
Stanford	O
et	O
al	O
.,	O
2013	O
).	O

Importantly	O
,	O
the	O
improved	O
metabolic	O
profile	O
was	O
lost	O
when	O
BAT	O
used	O
for	O
transplantation	O
came	O
from	O
IL	O
-	O
6	O
knockout	O
mice	O
,	O
clearly	B
demonstrating	I
that	O
BAT	O
-	O
derived	O
IL	O
-	O
6	O
is	O
required	O
for	O
the	O
profound	O
effects	O
of	O
BAT	O
transplantation	O
on	O
glucose	O
homeostasis	O
and	O
insulin	O
sensitivity	O
(	O
Stanford	O
et	O
al	O
.,	O
2013	O
).	O

Apart	O
from	O
IL	O
-	O
6	O
,	O
another	O
circulating	O
factor	O
,	O
named	O
irisin	O
,	O
was	O
shown	O
to	O
be	O
produced	O
by	O
skeletal	O
muscles	O
during	O
physical	O
exercise	O
in	O
rodents	O
(	O
De	O
Matteis	O
et	O
al	O
.,	O
2013	O
).	O

Irisin	O
,	O
obtained	O
by	O
cleavage	O
from	O
the	O
precursor	O
protein	O
,	O
fibronectin	O
type	O
III	O
domain	O
containing	O
5	O
(	O
FNDC5	O
),	O
was	O
described	O
as	O
promoting	O
the	O
appearance	O
/	O
recruitment	O
of	O
“	O
brite	O
”	O
cells	O
in	O
white	O
adipose	O
depots	O
(	O
Bostrom	O
et	O
al	O
.,	O
2012	O
;	O
Lee	O
et	O
al	O
.,	O
2014a	O
).	O

However	O
,	O
the	O
existence	O
of	O
this	O
protein	O
and	O
its	O
role	O
in	O
humans	O
is	O
still	O
a	O
matter	O
of	O
debate	O
(	O
Elsen	O
et	O
al	O
.,	O
2014a	O
).	O

Thyroid	O
hormones	O
(	O
THs	O
)	O
are	O
well	O
known	O
mediators	O
of	O
overall	O
energy	O
expenditure	O
(	O
Klieverik	O
et	O
al	O
.,	O
2009	O
).	O

Treatment	O
with	O
THs	O
induces	O
UCP1	O
expression	O
in	O
brown	O
adipocytes	O
in	O
rats	O
,	O
following	O
their	O
binding	O
to	O
TH	O
-	O
responsive	O
elements	O
in	O
the	O
UCP1	O
promoter	O
(	O
Guerra	O
et	O
al	O
.,	O
1996	O
).	O

Type	O
2	O
iodothyronine	O
deiodinase	O
(	O
D2	O
),	O
responsible	O
for	O
the	O
transformation	O
of	O
thyroxine	O
(	O
T4	O
)	O
to	O
triiodothyronine	O
(	O
T3	O
),	O
is	O
also	O
inducing	O
UCP1	O
expression	O
locally	O
,	O
in	O
BAT	O
(	O
de	O
Jesus	O
et	O
al	O
.,	O
2001	O
).	O

Furthermore	O
,	O
treatment	O
of	O
brown	O
adipocytes	O
and	O
human	O
skeletal	O
myocytes	O
with	O
bile	O
acids	O
(	O
BA	O
)	O
were	O
shown	O
to	O
increase	O
D2	O
activity	O
and	O
oxygen	O
consumption	O
via	O
the	O
activation	O
of	O
UCP1	O
(	O
Watanabe	O
et	O
al	O
.,	O
2006	O
).	O

In	O
both	O
rodents	O
and	O
humans	O
,	O
this	O
BA	O
-	O
D2	O
-	O
UCP1	O
pathway	O
appears	O
to	O
be	O
crucial	O
for	O
the	O
fine	O
-	O
tuning	O
of	O
energy	O
homeostasis	O
,	O
improving	O
the	O
metabolic	O
control	O
(	O
Watanabe	O
et	O
al	O
.,	O
2006	O
).	O

Thyroid	O
receptors	O
(	O
TRs	O
)	O
are	O
composed	O
of	O
several	O
isoforms	O
that	O
specifically	O
regulate	O
UCP1	O
expression	O
and	O
thermogenesis	O
.	O

The	O
α	O
isoform	O
was	O
shown	O
to	O
regulate	O
adaptive	O
thermogenesis	O
,	O
whereas	O
the	O
β	O
isoform	O
appears	O
to	O
modulate	O
UCP1	O
expression	O
,	O
without	O
increasing	O
thermogenesis	O
(	O
Ribeiro	O
et	O
al	O
.,	O
2001	O
).	O

In	O
humans	O
,	O
a	O
unique	O
patient	O
suffering	O
from	O
extreme	O
diabetes	O
due	O
to	O
a	O
mutation	O
in	O
the	O
insulin	O
receptor	O
gene	O
had	O
to	O
undergo	O
total	O
thyroidectomy	O
because	O
of	O
the	O
presence	O
of	O
a	O
papillary	O
carcinoma	O
.	O

Thirty	O
months	O
after	O
the	O
initial	O
treatment	O
of	O
the	O
thyroid	O
cancer	O
(	O
radioiodine	O
and	O
levothyroxine	O
),	O
remarkable	O
improvements	O
in	O
glycemia	O
were	O
noted	O
and	O
the	O
anti	O
-	O
diabetic	O
treatment	O
could	O
even	O
be	O
discontinued	O
.	O

A	O
PET	O
/	O
CT	O
study	O
revealed	O
the	O
presence	O
of	O
BAT	O
depots	O
in	O
the	O
lower	O
neck	O
,	O
suprascapular	O
,	O
mediastinal	O
,	O
and	O
thoracic	O
paravertebral	O
regions	O
.	O

Interestingly	O
,	O
increased	O
FDG	O
uptake	O
was	O
also	O
noted	O
in	O
the	O
subcutaneous	O
fat	O
,	O
in	O
particular	O
in	O
the	O
pelvic	O
area	O
and	O
over	O
the	O
lower	O
extremities	O
.	O

Overall	O
,	O
the	O
sequence	O
of	O
events	O
in	O
this	O
patient	O
suggests	O
that	O
the	O
metabolic	O
and	O
trophic	O
effects	O
of	O
THs	O
on	O
BAT	O
may	O
play	O
a	O
critical	O
role	O
in	O
non	O
-	O
insulin	O
-	O
mediated	O
glucose	O
utilization	O
,	O
ultimately	O
leading	O
to	O
near	O
-	O
normal	O
glucose	O
levels	O
(	O
Skarulis	O
et	O
al	O
.,	O
2010	O
).	O

Bone	O
morphogenic	O
proteins	O
(	O
BMPs	O
)	O
are	O
members	O
of	O
the	O
transforming	O
growth	O
factor	O
β	O
superfamily	O
(	O
TGF	O
-	O
β	O
).	O

They	O
were	O
originally	O
thought	O
to	O
be	O
factors	O
inducing	O
bone	O
formation	O
,	O
but	O
were	O
then	O
described	O
to	O
be	O
involved	O
in	O
the	O
development	O
and	O
function	O
of	O
many	O
tissues	O
,	O
such	O
as	O
the	O
intestine	O
,	O
brain	O
and	O
WAT	O
(	O
Hogan	O
,	O
1996	O
).	O

Some	O
members	O
of	O
the	O
BMP	O
family	O
were	O
shown	O
to	O
play	O
a	O
role	O
in	O
energy	O
homeostasis	O
and	O
the	O
early	O
steps	O
of	O
adipogenesis	O
,	O
in	O
particular	O
.	O

Among	O
the	O
20	O
BMP	O
family	O
members	O
,	O
BMP	O
-	O
7	O
has	O
been	O
implicated	O
in	O
the	O
development	O
of	O
BAT	O
,	O
being	O
able	O
to	O
drive	O
the	O
complete	O
brown	O
fat	O
differentiation	O
program	O
,	O
including	O
PRDM16	O
expression	O
(	O
Modica	O
and	O
Wolfrum	O
,	O
2013	O
).	O

BMP	O
-	O
7	O
can	O
also	O
affect	O
energy	O
homeostasis	O
by	O
acting	O
on	O
mature	O
brown	O
adipocytes	O
,	O
resulting	O
in	O
the	O
induction	O
of	O
UCP1	O
,	O
thereby	O
enhancing	O
thermogenesis	O
.	O

As	O
it	O
is	O
not	O
expressed	O
in	O
mature	O
brown	O
adipocytes	O
,	O
BMP7	O
appears	O
to	O
exert	O
its	O
action	O
on	O
BAT	O
as	O
an	O
endocrine	O
factor	O
.	O

In	O
addition	O
to	O
its	O
effect	O
on	O
BAT	O
,	O
BMP	O
-	O
7	O
was	O
also	O
reported	O
to	O
induce	O
the	O
“	O
browning	O
”	O
of	O
WAT	O
and	O
to	O
improve	O
insulin	O
sensitivity	O
(	O
Schulz	O
et	O
al	O
.,	O
2011	O
).	O

Finally	O
,	O
several	O
hypothalamic	O
nuclei	O
were	O
shown	O
to	O
express	O
BMP	O
-	O
7	O
,	O
suggesting	O
that	O
it	O
may	O
regulate	O
BAT	O
function	O
via	O
a	O
central	O
mechanism	O
,	O
also	O
responsible	O
for	O
decreased	O
food	O
intake	O
(	O
Modica	O
and	O
Wolfrum	O
,	O
2013	O
).	O

BMP8B	O
,	O
another	O
member	O
of	O
the	O
BMP	O
family	O
,	O
was	O
found	O
to	O
be	O
expressed	O
in	O
BAT	O
,	O
as	O
well	O
as	O
in	O
the	O
hypothalamus	O
(	O
Contreras	O
et	O
al	O
.,	O
2014	O
).	O

Central	O
administration	O
of	O
BMP8B	O
induced	O
thermogenesis	O
and	O
increased	O
core	O
temperature	O
,	O
leading	O
to	O
weight	O
loss	O
(	O
Contreras	O
et	O
al	O
.,	O
2014	O
).	O

This	O
effect	O
,	O
exerted	O
within	O
the	O
ventromedial	O
hypothalamus	O
(	O
VMH	O
),	O
was	O
described	O
as	O
being	O
AMPK	O
-	O
dependent	O
,	O
resulting	O
in	O
the	O
activation	O
of	O
the	O
sympathetic	O
outlflow	O
to	O
BAT	O
,	O
without	O
any	O
change	O
in	O
the	O
feeding	O
behavior	O
(	O
Whittle	O
et	O
al	O
.,	O
2012	O
;	O
Contreras	O
et	O
al	O
.,	O
2014	O
).	O

In	O
contrast	O
to	O
BMP7	O
and	O
BMP8B	O
,	O
BMP4	O
was	O
shown	O
to	O
promote	O
the	O
differentiation	O
of	O
mesenchymal	O
stem	O
cells	O
into	O
white	O
adipocytes	O
,	O
inducing	O
fat	O
storage	O
and	O
decreasing	O
energy	O
expenditure	O
in	O
rodents	O
(	O
Modica	O
and	O
Wolfrum	O
,	O
2013	O
;	O
Contreras	O
et	O
al	O
.,	O
2014	O
).	O

However	O
,	O
in	O
primary	O
human	O
adipose	O
stem	O
cells	O
,	O
both	O
BMP4	O
and	O
BMP7	O
induced	O
a	O
white	O
-	O
to	O
-	O
brown	O
adipocyte	O
transdifferentiation	O
(	O
Elsen	O
et	O
al	O
.,	O
2014b	O
),	O
pointing	O
to	O
the	O
occurrence	O
of	O
different	O
effects	O
,	O
depending	O
on	O
the	O
model	O
used	O
for	O
investigation	O
.	O

Further	O
studies	O
are	O
needed	O
to	O
clarify	O
and	O
strengthen	O
the	O
role	O
of	O
BMP	O
proteins	O
in	O
the	O
regulation	O
of	O
BAT	O
or	O
“	O
brite	O
”	O
cells	O
and	O
their	O
consequences	O
on	O
metabolic	O
homeostasis	O
.	O

Phosphatase	O
and	O
tensin	O
homolog	O
deleted	O
on	O
chromosome	O
ten	O
(	O
PTEN	O
),	O
a	O
well	O
-	O
known	O
tumor	O
suppressor	O
is	O
a	O
phosphatase	O
that	O
specifically	O
catalyzes	O
the	O
dephosphorylation	O
of	O
phosphatidylinositol	O
-	O
3	O
,	O
4	O
,	O
5	O
-	O
triphosphate	O
(	O
PIP3	O
),	O
in	O
phosphatidylinositol	O
-	O
4	O
,	O
5	O
-	O
diphosphate	O
PIP2	O
(	O
Cantley	O
and	O
Neel	O
,	O
1999	O
).	O

This	O
enzyme	O
counteracts	O
the	O
action	O
of	O
phosphatidylinositol	O
-	O
4	O
,	O
5	O
-	O
bisphosphate	O
3	O
-	O
kinase	O
(	O
PI3K	O
),	O
resulting	O
in	O
inhibition	O
of	O
the	O
AKT	O
signaling	O
pathway	O
involved	O
in	O
multiple	O
biological	O
processes	O
,	O
including	O
insulin	O
action	O
.	O

Activation	O
of	O
AKT	O
is	O
known	O
to	O
trigger	O
a	O
complex	O
cascade	O
of	O
events	O
that	O
include	O
the	O
inhibition	O
of	O
FOXO	O
transcription	O
factors	O
(	O
Ortega	O
-	O
Molina	O
et	O
al	O
.,	O
2012	O
).	O

Interestingly	O
,	O
mice	O
carrying	O
additional	O
copies	O
of	O
Pten	O
(	O
Ptentgmice	O
)	O
are	O
not	O
only	O
protected	O
from	O
cancer	O
and	O
exhibit	O
extended	O
longevity	O
,	O
but	O
,	O
according	O
to	O
the	O
authors	O
,	O
they	O
also	O
present	O
enhanced	O
energy	O
expenditure	O
that	O
participates	O
in	O
counteracting	O
the	O
development	O
of	O
obesity	O
.	O

This	O
is	O
related	O
to	O
lower	O
BAT	O
levels	O
of	O
phosphorylated	O
AKT	O
and	O
FOXO1	O
,	O
higher	O
BAT	O
and	O
WAT	O
expression	O
of	O
UCP1	O
,	O
as	O
well	O
as	O
of	O
its	O
transcriptional	O
regulator	O
,	O
PGC1	O
-	O
α	O
(	O
Ortega	O
-	O
Molina	O
et	O
al	O
.,	O
2012	O
).	O

In	O
addition	O
,	O
specific	O
deletion	O
of	O
Pten	O
in	O
the	O
liver	O
in	O
LPTENKO	O
mice	O
induces	O
a	O
strong	O
hepatic	O
steatosis	O
(	O
Stiles	O
et	O
al	O
.,	O
2004	O
;	O
Peyrou	O
et	O
al	O
.,	O
2015	O
),	O
but	O
improves	O
the	O
overall	O
insulin	O
sensitivity	O
,	O
and	O
decreases	O
the	O
fat	O
mass	O
.	O

“	O
Browning	O
”	O
of	O
WAT	O
could	O
be	O
one	O
of	O
the	O
mechanisms	O
underlying	O
the	O
increased	O
insulin	O
sensitivity	O
of	O
LPTENKO	O
mice	O
,	O
in	O
keeping	O
with	O
the	O
observation	O
of	O
increased	O
WAT	O
glucose	O
uptake	O
(	O
Peyrou	O
et	O
al	O
.,	O
2015	O
).	O

In	O
humans	O
,	O
PTEN	O
haploinsufficiency	O
was	O
shown	O
to	O
have	O
divergent	O
effects	O
,	O
as	O
they	O
increase	O
the	O
risk	O
of	O
obesity	O
,	O
while	O
decreasing	O
that	O
of	O
type	O
2	O
diabetes	O
by	O
markedly	O
improving	O
insulin	O
sensitivity	O
(	O
Pal	O
et	O
al	O
.,	O
2012	O
).	O

In	O
a	O
very	O
recent	O
study	O
,	O
the	O
grizzly	O
bear	O
was	O
used	O
as	O
a	O
hibernation	O
model	O
,	O
in	O
which	O
obesity	O
is	O
a	O
natural	O
adaptation	O
to	O
survive	O
months	O
of	O
fasting	O
(	O
Nelson	O
et	O
al	O
.,	O
2014	O
).	O

It	O
was	O
remarkably	O
observed	O
that	O
preparation	O
for	O
hibernation	O
was	O
characterized	O
by	O
striking	O
increases	O
in	O
body	O
weight	O
and	O
in	O
fat	O
mass	O
.	O

Animals	O
were	O
shown	O
to	O
exhibit	O
enhanced	O
insulin	O
sensitivity	O
,	O
while	O
they	O
become	O
obese	O
and	O
to	O
develop	O
insulin	O
resistance	O
a	O
few	O
weeks	O
later	O
,	O
during	O
hibernation	O
,	O
to	O
finally	O
recover	O
their	O
insulin	O
sensitivity	O
upon	O
awakening	O
.	O

The	O
modification	O
of	O
insulin	O
sensitivity	O
occurs	O
via	O
the	O
effect	O
of	O
the	O
PTEN	O
/	O
AKT	O
-	O
mediated	O
regulation	O
of	O
adipose	O
tissue	O
lipolysis	O
.	O

These	O
results	O
support	O
the	O
notion	O
that	O
adipose	O
tissue	O
is	O
very	O
insulin	O
sensitive	O
in	O
the	O
fed	O
state	O
,	O
while	O
being	O
able	O
to	O
drive	O
insulin	O
resistance	O
in	O
the	O
fasting	O
state	O
,	O
independently	O
from	O
insulin	O
levels	O
(	O
Nelson	O
et	O
al	O
.,	O
2014	O
).	O

In	O
humans	O
,	O
the	O
only	O
physiological	O
recovery	O
of	O
insulin	O
sensitivity	O
after	O
a	O
period	O
of	O
insulin	O
resistance	O
,	O
partially	O
due	O
to	O
an	O
increase	O
in	O
food	O
intake	O
and	O
lipogenesis	O
,	O
is	O
observed	O
in	O
women	O
after	O
pregnancy	O
(	O
Barbour	O
et	O
al	O
.,	O
2007	O
).	O

The	O
present	O
knowledge	O
on	O
the	O
impact	O
of	O
the	O
main	O
batokines	O
,	O
as	O
well	O
as	O
of	O
the	O
principal	O
other	O
UCP1	O
modulators	O
on	O
peripheral	O
metabolism	O
is	O
schematized	O
by	O
Figure1	O
.	O

Caption	O
(	O
FIG	O
):	O
FIGURE	O
1	O
Schematic	O
representation	O
of	O
the	O
main	O
factors	O
described	O
in	O
the	O
review	O
,	O
which	O
modulate	O
UCP1	O
activity	O
.	O

TL	O
,	O
T	O
lymphocytes	O
;	O
SNS	O
,	O
sympathetic	O
nervous	O
system	O
.	O

For	O
other	O
abbreviations	O
,	O
see	O
text	O
.	O

Full	O
lines	O
indicate	O
stimulatory	O
effects	O
,	O
whereas	O
dotted	O
lines	O
represent	O
inhibitory	O
ones	O
.	O

?	O

indicates	O
the	O
existence	O
of	O
conflicting	O
data	O
in	O
the	O
literature	O
with	O
regard	O
to	O
the	O
impact	O
of	O
the	O
factor	O
on	O
UCP1	O
activity	O
.	O

Impact	O
of	O
perinatal	O
nutritional	O
changes	O
Epidemiological	O
evidence	O
in	O
humans	O
strongly	O
suggests	O
that	O
the	O
intrauterine	O
and	O
early	O
postnatal	O
environments	O
have	O
a	O
significant	O
long	O
-	O
term	O
influence	O
on	O
body	O
weight	O
and	O
energy	O
homeostasis	O
in	O
offspring	O
(	O
for	O
rev	O
.,	O
see	O
Breton	O
,	O
2013	O
).	O

Thus	B
,	O
both	O
maternal	O
underfeeding	O
or	O
overfeeding	O
were	O
reported	O
to	O
exert	O
a	O
predisposing	O
effect	O
for	O
the	O
development	O
of	O
later	O
obesity	O
(	O
Breton	O
,	O
2013	O
).	O

Rodents	O
are	O
commonly	O
used	O
to	O
investigate	O
the	O
mechanisms	O
underlying	O
long	O
-	O
term	O
programming	O
of	O
energy	O
balance	O
in	O
the	O
offspring	O
.	O

High	O
fat	O
feeding	O
of	O
pregnant	O
or	O
lactating	O
mothers	O
was	O
shown	O
to	O
induce	O
glucose	O
intolerance	O
and	O
the	O
development	O
of	O
obesity	O
in	O
the	O
progeny	O
during	O
adult	O
life	O
(	O
Bayol	O
et	O
al	O
.,	O
2008	O
;	O
Samuelsson	O
et	O
al	O
.,	O
2008	O
).	O

The	O
signals	O
that	O
mediate	O
the	O
effects	O
of	O
maternal	O
metabolic	O
disorders	O
in	O
overfed	O
offspring	O
have	O
not	O
been	O
fully	O
identified	O
.	O

They	O
include	O
hormones	O
,	O
such	O
as	O
insulin	O
,	O
leptin	O
and	O
glucocorticoids	O
,	O
proinflammatory	O
cytokines	O
,	O
as	O
well	O
as	O
complex	O
epigenetic	O
modifications	O
(	O
Tamashiro	O
and	O
Moran	O
,	O
2010	O
;	O
Lukaszewski	O
et	O
al	O
.,	O
2013	O
).	O

In	O
this	O
context	O
,	O
the	O
sheep	O
appears	O
to	O
be	O
a	O
very	O
good	O
model	O
,	O
because	O
as	O
for	O
humans	O
,	O
the	O
major	O
source	O
of	O
BAT	O
in	O
the	O
fetus	O
is	O
around	O
central	O
organs	O
and	O
is	O
replaced	O
by	O
WAT	O
after	O
birth	O
,	O
whereas	O
in	O
rodents	O
,	O
the	O
primary	O
BAT	O
depot	O
is	O
interscapular	O
and	O
it	O
remains	O
throughout	O
life	O
(	O
Symonds	O
et	O
al	O
.,	O
2012	O
).	O

In	O
sheep	O
,	O
the	O
mother	O
'	O
s	O
diet	O
during	O
pregnancy	O
determines	O
the	O
size	O
of	O
the	O
placenta	O
and	O
can	O
affect	O
both	O
the	O
BAT	O
and	O
WAT	O
mass	O
,	O
depending	O
on	O
the	O
timing	O
and	O
the	O
nature	O
of	O
the	O
diet	O
perturbation	O
.	O

In	O
other	O
words	O
,	O
the	O
respective	O
growth	O
of	O
the	O
BAT	O
and	O
WAT	O
depots	O
depends	O
on	O
the	O
maternal	O
diet	O
during	O
gestation	O
and	O
it	O
may	O
be	O
responsible	O
for	O
the	O
development	O
of	O
obesity	O
,	O
insulin	O
resistance	O
and	O
type	O
2	O
diabetes	O
in	O
the	O
offspring	O
,	O
later	O
in	O
life	O
(	O
Symonds	O
et	O
al	O
.,	O
2012	O
).	O

Gestational	O
diabetes	O
in	O
humans	O
is	O
a	O
situation	O
of	O
increased	O
nutrient	O
supply	O
that	O
,	O
together	O
with	O
the	O
high	O
maternal	O
body	O
mass	O
index	O
,	O
can	O
be	O
accompanied	O
by	O
enhanced	O
birth	O
-	O
weight	O
and	O
adverse	O
long	O
-	O
term	O
metabolic	O
consequences	O
,	O
as	O
described	O
by	O
the	O
World	O
Health	O
Organization	O
(	O
2003	O
),	O
as	O
well	O
as	O
in	O
several	O
publications	O
(	O
Larsson	O
et	O
al	O
.,	O
1986	O
;	O
Dabelea	O
et	O
al	O
.,	O
2000	O
;	O
Singh	O
et	O
al	O
.,	O
2006	O
).	O

However	O
,	O
in	O
a	O
recent	O
study	O
,	O
the	O
role	O
of	O
diabetes	O
during	O
gestation	O
on	O
such	O
adverse	O
long	O
-	O
term	O
metabolic	O
consequences	O
has	O
been	O
seriously	O
questioned	O
,	O
as	O
they	O
seem	O
to	O
relate	O
more	O
on	O
known	O
confounders	O
,	O
such	O
as	O
the	O
BMI	O
of	O
either	O
one	O
of	O
the	O
parents	O
(	O
Donovan	O
and	O
Cundy	O
,	O
2014	O
).	O

Among	O
the	O
regulators	O
that	O
may	O
link	O
the	O
maternal	O
diet	O
during	O
gestation	O
with	O
the	O
metabolic	O
outcome	O
of	O
the	O
offspring	O
,	O
leptin	O
is	O
one	O
of	O
the	O
main	O
candidates	O
.	O

It	O
is	O
a	O
well	O
-	O
known	O
hormone	O
increasing	O
BAT	O
activity	O
and	O
inducing	O
“	O
browning	O
”	O
of	O
WAT	O
via	O
activation	O
of	O
the	O
sympathetic	O
nervous	O
system	O
and	O
resulting	O
increased	O
β3	O
adrenoceptor	O
signaling	O
(	O
Haynes	O
et	O
al	O
.,	O
1997	O
;	O
Commins	O
et	O
al	O
.,	O
2000	O
).	O

Rodent	O
models	O
of	O
leptin	O
deficiency	O
exhibit	O
marked	O
decreases	O
in	O
BAT	O
thermogenic	O
capacity	O
,	O
as	O
well	O
as	O
activity	O
(	O
Ueno	O
et	O
al	O
.,	O
1998	O
).	O

Moreover	O
,	O
it	O
was	O
shown	O
that	O
leptin	O
injection	O
in	O
the	O
early	O
stage	O
of	O
life	O
in	O
lambs	O
decreases	O
UCP1	O
expression	O
in	O
BAT	O
,	O
but	O
improves	O
thermoregulation	O
,	O
suggesting	O
a	O
particular	O
role	O
of	O
leptin	O
at	O
such	O
a	O
stage	O
in	O
life	O
in	O
large	O
mammals	O
(	O
Mostyn	O
et	O
al	O
.,	O
2002	O
).	O

Another	O
study	O
revealed	O
that	O
the	O
ability	O
of	O
leptin	O
to	O
increase	O
the	O
metabolic	O
rate	O
early	O
in	O
life	O
is	O
independent	O
from	O
its	O
anorectic	O
action	O
(	O
Mistry	O
et	O
al	O
.,	O
1999	O
).	O

No	O
data	O
are	O
available	O
as	O
yet	O
with	O
regard	O
to	O
the	O
impact	O
of	O
early	O
leptin	O
administration	O
on	O
the	O
subsequent	O
“	O
browning	O
”	O
of	O
WAT	O
and	O
the	O
related	O
regulation	O
of	O
glucose	O
metabolism	O
,	O
as	O
well	O
as	O
the	O
response	O
to	O
hypercaloric	O
diets	O
later	O
in	O
life	O
in	O
the	O
offspring	O
.	O

Attempts	O
at	O
stimulating	O
BAT	O
function	O
in	O
humans	O
With	O
regard	O
to	O
the	O
relationship	O
between	O
BAT	O
and	O
body	O
weight	O
in	O
humans	O
,	O
an	O
inverse	O
correlation	O
between	O
BMI	O
and	O
the	O
amount	O
of	O
BAT	O
was	O
described	O
,	O
already	O
5	O
years	O
ago	O
(	O
Cypess	O
et	O
al	O
.,	O
2009	O
;	O
van	O
Marken	O
Lichtenbelt	O
et	O
al	O
.,	O
2009	O
).	O

In	O
addition	O
,	O
more	O
recent	O
studies	O
indicated	O
that	O
,	O
compared	O
to	O
individuals	O
without	O
BAT	O
,	O
the	O
BAT	O
-	O
positive	O
subjects	O
were	O
younger	O
,	O
had	O
lower	O
body	O
mass	O
index	O
,	O
fasting	O
insulin	O
,	O
insulin	O
resistance	O
,	O
but	O
a	O
greater	O
level	O
of	O
high	O
-	O
density	O
lipoprotein	O
cholesterol	O
(	O
Zhang	O
et	O
al	O
.,	O
2013	O
).	O

During	O
acute	O
cold	O
exposure	O
,	O
BAT	O
was	O
shown	O
as	O
a	O
significant	O
independent	O
determinant	O
of	O
plasma	O
glucose	O
and	O
HbA1c	O
levels	O
(	O
Matsushita	O
et	O
al	O
.,	O
2014	O
).	O

A	O
parallel	O
increase	O
in	O
BAT	O
activity	O
and	O
cold	O
-	O
induced	O
energy	O
expenditure	O
was	O
also	O
observed	O
in	O
response	O
to	O
acute	O
cold	O
exposure	O
in	O
subjects	O
with	O
low	O
BAT	O
activity	O
,	O
demonstrating	O
the	O
possible	O
occurrence	O
of	O
BAT	O
recruitment	O
in	O
humans	O
(	O
Yoneshiro	O
et	O
al	O
.,	O
2013	O
).	O

Very	O
recently	O
,	O
chronic	O
cold	O
acclimation	O
in	O
human	O
subjects	O
was	O
reported	O
to	O
increase	O
the	O
volume	O
of	O
metabolically	O
active	O
BAT	O
,	O
increasing	O
its	O
oxidative	O
capacity	O
,	O
therefore	O
its	O
contribution	O
to	O
cold	O
-	O
induced	O
thermogenesis	O
(	O
Blondin	O
et	O
al	O
.,	O
2014	O
).	O

In	O
another	O
study	O
,	O
the	O
cold	O
-	O
induced	O
increase	O
in	O
thermogenesis	O
was	O
accompanied	O
by	O
a	O
decrease	O
in	O
body	O
weight	O
,	O
mainly	B
affecting	O
the	O
fat	O
mass	O
compartment	O
(	O
Yoneshiro	O
et	O
al	O
.,	O
2013	O
).	O

Cold	O
-	O
acclimation	O
was	O
also	O
shown	O
to	O
increase	O
diet	O
-	O
induced	O
thermogenesis	O
and	O
postprandial	O
insulin	O
sensitivity	O
,	O
without	O
impacting	O
cold	O
-	O
induced	O
thermogenesis	O
(	O
Lee	O
et	O
al	O
.,	O
2014b	O
).	O

These	O
results	O
are	O
in	O
keeping	O
with	O
data	O
showing	O
a	O
physiological	O
role	O
of	O
BAT	O
in	O
whole	O
-	O
body	O
energy	O
expenditure	O
,	O
glucose	O
homeostasis	O
,	O
and	O
insulin	O
sensitivity	O
in	O
humans	O
during	O
prolonged	O
cold	O
exposure	O
(	O
Chondronikola	O
et	O
al	O
.,	O
2014	O
).	O

Much	O
more	O
work	O
is	O
needed	O
to	O
identify	O
other	O
ways	O
than	O
cold	O
exposure	O
to	O
increase	O
BAT	O
activity	O
in	O
obese	O
subjects	O
.	O

To	O
this	O
end	O
,	O
one	O
of	O
the	O
very	O
useful	O
tools	O
is	O
the	O
use	O
of	O
rodent	O
strains	O
with	O
different	O
sensitivities	O
to	O
diet	O
-	O
induced	O
obesity	O
and	O
insulin	O
resistance	O
.	O

Indeed	O
,	O
resistance	O
to	O
the	O
development	O
of	O
obesity	O
has	O
at	B
least	I
partly	O
been	O
attributed	O
to	O
elevated	O
recruitment	O
of	O
brown	O
adipocytes	O
in	O
skeletal	O
muscle	O
or	O
WAT	O
(	O
Guerra	O
et	O
al	O
.,	O
1998	O
;	O
Almind	O
et	O
al	O
.,	O
2007	O
;	O
Veyrat	O
-	O
Durebex	O
et	O
al	O
.,	O
2009	O
;	O
Harms	O
and	O
Seale	O
,	O
2013	O
).	O

These	O
studies	O
are	O
highly	O
therapeutically	O
relevant	O
,	O
as	B
BAT	O
activation	O
in	O
overweight	O
or	O
obese	O
subjects	O
will	O
activate	O
thermogenesis	O
and	O
dissipate	O
heat	O
,	O
while	O
at	O
the	O
same	O
time	O
improving	O
glucose	O
metabolism	O
and	O
insulin	O
resistance	O
.	O

It	O
should	O
be	O
added	O
at	O
that	O
point	O
that	O
,	O
although	O
β3	O
adrenoceptors	O
are	O
expressed	O
in	O
humans	O
(	O
for	O
rev	O
.,	O
see	O
Mund	O
and	O
Frishman	O
,	O
2013	O
)	O
and	O
β3	O
agonists	O
are	O
potent	O
UCP1	O
activators	O
in	O
rodents	O
,	O
the	O
molecules	O
which	O
are	O
active	O
in	O
rodents	O
cannot	O
be	O
used	O
in	O
humans	O
due	O
to	O
inter	O
-	O
species	O
differences	O
.	O

This	O
should	O
be	O
solved	O
in	O
the	O
future	O
by	O
the	O
identification	O
of	O
selective	O
human	O
β3	O
agonists	O
(	O
Mund	O
and	O
Frishman	O
,	O
2013	O
;	O
Bordicchia	O
et	O
al	O
.,	O
2014	O
).	O

Conclusion	O
To	O
conclude	O
,	O
UCP1	O
is	O
an	O
excellent	O
target	O
to	O
struggle	O
diabetes	O
and	O
decrease	O
body	O
fat	O
mass	O
,	O
improving	O
whole	O
metabolism	O
.	O

Indeed	O
,	O
it	O
negatively	O
regulates	O
the	O
energy	O
balance	O
by	O
increasing	O
energy	O
expenditure	O
.	O

It	O
also	O
secretes	O
several	O
batokines	O
,	O
allowing	O
for	O
inter	O
-	O
organ	O
communication	O
.	O

Finally	O
,	O
it	O
is	O
easily	O
inducible	O
,	O
such	O
as	O
during	O
mild	O
cold	O
exposure	O
with	O
resulting	O
beneficial	O
effects	O
.	O

Finding	O
a	O
molecule	O
with	O
as	O
much	O
efficiency	O
as	O
the	O
β3	O
agonist	O
in	O
rodents	O
,	O
would	O
be	O
of	O
considerable	O
therapeutic	O
relevance	O
for	O
the	O
treatment	O
of	O
obesity	O
,	O
insulin	O
resistance	O
and	O
type	O
2	O
diabetes	O
in	O
humans	O
.	O

Conflict	O
of	O
interest	O
statement	O
The	O
authors	O
declare	O
that	O
the	O
research	O
was	O
conducted	O
in	O
the	O
absence	O
of	O
any	O
commercial	O
or	O
financial	O
relationships	O
that	O
could	O
be	O
construed	O
as	O
a	O
potential	O
conflict	O
of	O
interest	O
.	O

PubMed	O
Central	O
:	O

Risk	O
factors	O
for	O
gestational	O
diabetes	O
mellitus	O
in	O
a	O
sample	O
of	O
pregnant	O
women	O
diagnosed	O
with	O
the	O
disease	O
Background	O
The	O
known	O
risk	O
factors	O
for	O
Gestational	O
Diabetes	O
Mellitus	O
(	O
GDM	O
)	O
are	O
advanced	O
age	O
(≥	O
35	O
yrs	O
.	O

),	O
overweight	O
or	O
obesity	O
,	O
excessive	O
gestational	O
weight	O
gain	O
,	O
excessive	O
central	O
body	O
fat	O
deposition	O
,	O
family	O
history	O
of	O
diabetes	O
,	O
short	O
stature	O
(<	O
1	O
.	O
50	O
m	O
),	O
excessive	O
fetal	O
growth	O
,	O
polyhydramnios	O
,	O
hypertension	O
or	O
preeclampsia	O
in	O
the	O
current	O
pregnancy	O
,	O
history	O
of	O
recurrent	O
miscarriage	O
,	O
offspring	O
malformation	O
,	O
fetal	O
or	O
neonatal	O
death	O
,	O
macrosomia	O
,	O
GDM	O
during	O
prior	O
pregnancies	O
and	O
polycystic	O
ovary	O
syndrome	O
.	O

In	O
addition	O
to	O
the	O
most	O
common	O
factors	O
the	O
sedentary	O
lifestyle	O
may	O
also	O
be	O
a	O
risk	O
factor	O
for	O
GDM	O
.	O

Objective	O
To	O
identify	O
the	O
presence	O
of	O
GDM	O
risk	O
factors	O
during	O
pregnancy	O
at	O
the	O
time	O
of	O
diagnosis	O
of	O
this	O
pathology	O
.	O

Materials	O
and	O
methods	O
Cross	O
-	O
sectional	O
study	O
of	O
76	O
pregnant	O
women	O
who	O
were	O
referred	O
to	O
a	O
multidisciplinary	O
clinic	O
for	O
high	O
risk	O
pregnancies	O
,	O
in	O
a	O
tertiary	O
hospital	O
in	O
southern	O
Brazil	O
,	O
at	O
the	O
time	O
of	O
GDM	O
diagnosis	O
.	O

A	O
trained	O
interviewer	O
administered	O
a	O
questionnaire	O
to	O
gather	O
sociodemographic	O
,	O
clinical	O
,	O
anthropometric	O
and	O
lifestyle	O
habits	O
data	O
.	O

Pre	O
-	O
pregnancy	O
nutritional	O
status	O
and	O
weight	O
gain	O
were	O
classified	O
according	O
to	O
the	O
Institute	O
of	O
Medicine	O
guidelines	O
.	O

Current	O
Body	O
Mass	O
Index	O
(	O
BMI	O
)	O
was	O
classified	O
by	O
gestational	O
week	O
,	O
according	O
to	O
Atalah	O
.	O

Because	O
the	O
risk	O
of	O
developing	O
GDM	O
gradually	O
increases	O
in	O
overweight	O
and	O
obese	O
women	O
,	O
the	O
total	O
sample	O
was	O
divided	O
into	O
three	O
pre	O
-	O
pregnancy	O
BMI	O
groups	O
for	O
comparison	O
:	O
BMI	O
<	O
25	O
kg	O
/	O
m2	O
,	O
BMI	O
≥	O
25	O
kg	O
/	O
m2and	O
<	O
30	O
kg	O
/	O
m2and	O
BMI	O
≥	O
30	O
kg	O
/	O
m2	O
.	O

Pearson	O
Chi	O
-	O
square	O
test	O
,	O
analysis	O
of	O
variance	O
and	O
Kruskal	O
-	O
Wallis	O
were	O
employed	O
.	O

Results	O
Seventy	O
-	O
six	O
women	O
were	O
evaluated	O
,	O
53	O
(	O
69	O
.	O
7	O
%)	O
had	O
10	O
yrs	O
.	O

of	O
education	O
or	O
less	O
and	O
23	O
(	O
30	O
.	O
3	O
%)	O
had	O
11	O
yrs	O
.	O

or	O
more	O
.	O

In	O
this	O
sample	O
there	O
was	O
a	O
high	O
prevalence	O
of	O
:	O
unfavorable	O
pre	O
-	O
pregnancy	O
nutritional	O
status	O
(	O
overweight	O
or	O
obesity	O
),	O
gestational	O
weight	O
gain	O
above	O
recommendations	O
(	O
PPBMI	O
<	O
25	O
kg	O
/	O
m2is	O
associated	O
with	O
greater	O
weight	O
gain	O
compared	O
to	O
obese	O
),	O
family	O
history	O
of	O
diabetes	O
,	O
advanced	O
age	O
(	O
38	O
.	O
2	O
%)	O
and	O
low	O
levels	O
of	O
physical	O
activity	O
(	O
data	O
shown	O
in	O
Figure1	O
).	O

Caption	O
(	O
FIG	O
):	O
FIGURE	O
1	O
Risk	O
factors	O
related	O
to	O
the	O
development	O
of	O
Gestational	O
Diabetes	O
Mellitus	O
stratified	O
by	O
pre	O
-	O
pregnancy	O
Body	O
Mass	O
Index	O
(	O
PPBMI	O
)	O
classification	O
in	O
a	O
sample	O
of	O
pregnant	O
women	O
at	O
diagnosis	O
of	O
the	O
disease	O
,	O
Rio	O
Grande	O
do	O
Sul	O
/	O
Brazil	O
,	O
2014	O
.	O

Conclusion	O
We	O
observed	O
a	O
high	O
prevalence	O
of	O
risk	O
factors	O
for	O
GDM	O
in	O
this	O
sample	O
.	O

An	O
adequate	O
pre	O
-	O
pregnancy	O
nutritional	O
status	O
was	O
associated	O
with	O
gestational	O
weight	O
gain	O
above	O
recommendations	O
.	O

These	O
Results	O
emphasize	O
the	O
need	O
for	O
pregnant	O
women	O
to	O
be	O
professionally	O
monitored	O
so	O
that	O
modifiable	O
risk	O
factors	O
can	O
be	O
managed	O
.	O

PubMed	O
Central	O
:	O

Are	O
Attributes	O
of	O
Pregnancy	O
and	O
the	O
Delivery	O
Room	O
Experience	O
Related	O
to	O
Development	O
of	O
Autism	O
?	O

A	O
Review	O
of	O
the	O
Perinatal	O
and	O
Labor	O
Risk	O
Factors	O
and	O
Autism	O
Abstract	O
Autism	O
is	O
a	O
neurodevelopmental	O
disorder	O
marked	O
by	O
severe	O
deficits	O
in	O
social	O
communication	O
and	O
interactions	O
.	O

It	O
is	O
a	O
complex	O
condition	O
that	O
lacks	O
an	O
established	O
preventive	O
method	O
,	O
warranting	O
a	O
need	O
for	O
research	O
to	O
identify	O
possible	O
environmental	O
triggers	O
.	O

The	O
identification	O
of	O
external	O
factors	O
particularly	O
perinatal	O
risk	O
factors	O
forms	O
the	O
initial	O
critical	O
step	O
in	O
preventing	O
and	O
alleviating	O
risks	O
.	O

We	O
conducted	O
a	O
literature	O
review	O
to	O
assess	O
evidence	O
suggested	O
in	O
the	O
worldwide	O
literature	O
.	O

Perinatal	O
risk	O
factors	O
that	O
have	O
a	O
suggested	O
association	O
include	O
β	O
2	O
adrenergic	O
receptor	O
agonists	O
,	O
labor	O
induction	O
and	O
augmentation	O
,	O
maternal	O
infection	O
and	O
disease	O
(	O
i	O
.	O
e	O
.,	O
antiphospholipid	O
syndrome	O
),	O
antiepileptic	O
drugs	O
,	O
cocaine	O
use	O
,	O
and	O
oral	O
supplements	O
.	O

Smoking	O
has	O
not	O
been	O
found	O
to	O
have	O
a	O
direct	O
association	O
.	O

Pollutants	O
,	O
selective	O
serotonin	O
reuptake	O
inhibitors	O
,	O
artificial	O
insemination	O
,	O
and	O
fertility	O
medications	O
may	O
have	O
a	O
link	O
,	O
but	O
results	O
are	O
often	O
conflicted	O
.	O

Factors	O
related	O
to	O
the	O
delivery	O
room	O
experience	O
may	O
be	O
associated	O
with	O
meconium	O
aspiration	O
syndrome	O
,	O
birth	O
weight	O
,	O
and	O
labor	O
time	O
.	O

Several	O
risk	O
factors	O
during	O
the	O
pregnancy	O
and	O
labor	O
periods	O
have	O
been	O
associated	O
with	O
autism	O
;	O
yet	O
further	O
studies	O
with	O
large	O
populations	O
are	O
needed	O
to	O
establish	O
definitive	O
associations	O
.	O

The	O
fact	O
that	O
several	O
risk	O
factors	O
during	O
the	O
prenatal	O
and	O
labor	O
periods	O
are	O
implicated	O
in	O
autism	O
should	O
prompt	O
the	O
medical	O
community	O
to	O
focus	O
on	O
the	O
pregnancy	O
and	O
labor	O
periods	O
as	O
preventive	O
measures	O
to	O
curb	O
the	O
incidence	O
of	O
autism	O
.	O

1	O
.	O

Introduction	O
Autism	O
is	O
a	O
complex	O
condition	O
that	O
lacks	O
an	O
established	O
method	O
of	O
prevention	O
;	O
thus	B
there	O
is	O
a	O
need	O
for	O
research	O
to	O
identify	O
its	O
possible	O
causative	O
factors	O
.	O

Identification	O
of	O
environmental	O
factors	O
is	O
the	O
first	O
step	O
in	O
preventing	O
and	O
mitigating	O
risks	O
by	O
primary	O
prevention	O
[	O
1	O
].	O

Statistical	O
estimates	O
show	O
that	O
one	O
out	O
of	O
every	O
88	O
individuals	O
in	O
the	O
United	O
States	O
is	O
diagnosed	O
with	O
autism	O
.	O

The	O
condition	O
may	O
be	O
defined	O
as	O
a	O
chronic	O
neurodevelopmental	O
disorder	O
that	O
first	O
becomes	O
prevalent	O
in	O
an	O
individual	O
during	O
his	O
/	O
her	O
early	O
childhood	O
.	O

Consequently	B
,	O
autism	O
results	O
in	O
a	O
patient	O
experiencing	O
a	O
life	O
that	O
is	O
marked	O
by	O
the	O
ongoing	O
challenge	O
of	O
its	O
negative	O
effects	O
on	O
communication	O
and	O
interaction	O
with	O
others	O
.	O

The	O
disorder	O
is	O
debilitating	O
for	O
the	O
patient	O
and	O
immensely	O
challenging	O
for	O
his	O
/	O
her	O
family	O
.	O

An	O
initial	O
diagnosis	O
of	O
autism	O
occurs	O
as	O
an	O
individual	O
is	O
noticeably	O
unable	O
to	O
achieve	O
certain	O
early	O
childhood	O
milestones	O
in	O
terms	O
of	O
communication	O
and	O
socialization	O
.	O

Furthermore	O
,	O
while	O
the	O
incidence	O
and	O
the	O
prevalence	O
of	O
autism	O
also	O
tend	O
to	O
raise	O
on	O
an	O
ever	O
-	O
increasing	O
basis	O
,	O
public	O
health	O
concerns	O
over	O
the	O
disorder	O
have	O
also	O
been	O
coupled	O
with	O
concerns	O
over	O
its	O
etiology	O
,	O
which	O
is	O
still	O
in	O
the	O
investigative	O
stage	O
of	O
clinical	O
research	O
[	O
2	O
].	O

Initial	O
research	O
efforts	O
,	O
which	O
were	O
embarked	O
upon	O
during	O
the	O
1950s	O
,	O
assert	B
that	O
complications	O
in	O
a	O
given	O
pregnancy	O
,	O
the	O
birthing	O
process	O
,	O
and	O
the	O
incidence	O
of	O
autism	O
are	O
linked	O
.	O

Over	O
the	O
past	O
several	O
decades	O
,	O
continuing	O
research	O
has	O
been	O
conducted	O
,	O
and	O
much	O
literature	O
has	O
been	O
published	O
that	O
has	O
supported	O
the	O
existence	O
of	O
the	O
links	O
between	O
autism	O
and	O
factors	O
that	O
relate	O
to	O
pre	O
-,	O
peri	O
-,	O
and	O
neonatal	O
care	O
.	O

Such	O
commonly	O
identified	O
,	O
prenatal	O
risk	O
factors	O
may	O
include	O
advanced	O
-	O
aged	O
parents	O
,	O
a	O
short	O
gestation	O
period	O
,	O
low	O
birth	O
weight	O
,	O
hyperbilirubinemia	O
,	O
and	O
breech	O
presentation	O
[	O
3	O
].	O

Another	O
key	O
factor	O
may	O
be	O
the	O
use	O
of	O
any	O
prenatal	O
,	O
prescription	O
medication	O
[	O
4	O
–	O
6	O
].	O

Autism	O
,	O
to	O
reiterate	O
,	O
impairs	O
an	O
individual	O
'	O
s	O
ability	O
to	O
use	O
language	O
to	O
effectively	O
communicate	O
and	O
navigate	O
social	O
situations	O
.	O

The	O
assertion	O
that	O
autism	O
patients	O
engage	O
in	O
repetitive	O
,	O
behavioral	O
patterns	O
has	O
arguably	O
become	O
stereotyped	O
.	O

The	O
symptoms	O
of	O
autism	O
become	O
notable	O
in	O
patient	O
in	O
the	O
first	O
three	O
years	O
of	O
life	O
and	O
may	O
necessitate	O
lifelong	O
care	O
that	O
must	O
be	O
provided	O
by	O
family	O
members	O
,	O
guardians	O
,	O
or	O
healthcare	O
professionals	O
.	O

Autism	O
and	O
autism	O
spectrum	O
disorders	O
(	O
ASDs	O
),	O
including	O
Asperger	O
'	O
s	O
syndrome	O
and	O
pervasive	O
developmental	O
disorder	O
,	O
have	O
become	O
increasingly	O
diagnosed	O
over	O
the	O
past	O
decade	O
.	O

Accordingly	O
,	O
population	O
studies	O
,	O
which	O
have	O
been	O
conducted	O
by	O
the	O
United	O
States	O
Centers	O
for	O
Disease	O
Control	O
and	O
Prevention	O
,	O
have	O
reported	O
a	O
prevalence	O
of	O
ASDs	O
of	O
1	O
of	O
68	O
children	O
at	O
risk	O
.	O

It	O
should	O
be	O
noted	O
,	O
however	O
,	O
that	O
,	O
from	O
a	O
stand	O
-	O
alone	O
perspective	O
,	O
each	O
of	O
the	O
factors	O
(	O
as	O
listed	O
above	O
)	O
that	O
link	O
autism	O
with	O
pre	O
-,	O
peri	O
-,	O
and	O
neonatal	O
care	O
does	O
not	O
correlate	O
consistently	O
as	B
the	O
incidence	O
of	O
autism	O
is	O
reviewed	O
in	O
terms	O
of	O
its	O
cross	O
-	O
reference	O
amongst	O
various	O
research	O
studies	O
.	O

It	O
should	O
also	O
be	O
noted	O
that	O
,	O
despite	O
ongoing	O
research	O
efforts	O
,	O
relatively	O
little	O
has	O
yet	O
been	O
divulged	O
regarding	O
delivery	O
-	O
room	O
attributes	O
that	O
may	O
be	O
directly	O
or	O
indirectly	O
associated	O
with	O
the	O
incidence	O
of	O
autism	O
.	O

Furthermore	O
,	O
the	O
nature	O
of	O
the	O
precise	O
catalyst	O
of	O
autism	O
has	O
not	O
been	O
revealed	O
as	O
of	O
yet	O
.	O

Early	O
diagnosis	O
of	O
autism	O
and	O
any	O
subsequent	O
related	O
intervention	O
(	O
s	O
)	O
may	O
serve	O
to	O
alleviate	O
the	O
challenges	O
that	O
are	O
faced	O
by	O
those	O
individuals	O
,	O
who	O
must	O
manage	O
the	O
effects	O
of	O
autism	O
on	O
an	O
ongoing	O
basis	O
,	O
including	O
patients	O
,	O
their	O
guardians	O
and	O
/	O
or	O
families	O
,	O
and	O
related	O
healthcare	O
professionals	O
.	O

The	O
following	O
narrative	O
review	O
aims	O
to	O
better	O
understand	O
the	O
existing	O
evidence	O
for	O
perinatal	O
and	O
labor	O
-	O
related	O
associations	O
with	O
autism	O
.	O

2	O
.	O

Discussion	O
The	O
etiology	O
of	O
autism	O
is	O
unknown	O
,	O
although	O
perinatal	O
and	O
neonatal	O
exposures	O
have	O
been	O
the	O
focus	O
of	O
recent	O
epidemiologic	O
research	O
[	O
57	O
].	O

Exposure	O
to	O
certain	O
medications	O
such	O
as	O
perinatal	O
medications	O
,	O
antiepileptic	O
drugs	O
,	O
supplements	O
,	O
and	O
SSRIs	O
has	O
been	O
studied	O
as	O
well	O
as	O
drug	O
exposure	O
to	O
cocaine	O
and	O
smoking	O
.	O

Artificial	O
insemination	O
and	O
fertility	O
medications	O
,	O
meconium	O
aspiration	O
syndrome	O
,	O
and	O
birth	O
weight	O
have	O
also	O
all	O
been	O
subjects	O
of	O
focus	O
and	O
the	O
respective	O
association	O
with	O
pregnancy	O
and	O
neurodevelopmental	O
complications	O
such	O
as	O
autism	O
.	O

Several	O
studies	O
have	O
suggested	O
the	O
association	O
between	O
perinatal	O
factors	O
and	O
the	O
onset	O
of	O
autism	O
.	O

A	O
recent	O
case	O
control	O
study	O
done	O
in	O
New	O
South	O
Wales	O
,	O
Australia	O
,	O
focused	O
on	O
determining	O
risk	O
factors	O
for	O
autism	O
.	O

Four	O
factors	O
were	O
shown	O
to	O
be	O
significantly	O
associated	O
with	O
autism	O
:	O
being	O
male	O
,	O
premature	O
birth	O
,	O
maternal	O
age	O
greater	O
than	O
or	O
equal	O
to	O
35	O
years	O
,	O
and	O
mothers	O
born	O
outside	O
of	O
Australia	O
,	O
with	O
highest	O
risk	O
found	O
in	O
mothers	O
from	O
North	O
-	O
East	O
or	O
South	O
-	O
East	O
Asia	O
[	O
7	O
].	O

A	O
separate	O
study	O
from	O
Western	O
Australia	O
concluded	O
that	O
autistic	O
children	O
generally	B
had	O
parents	O
who	O
were	O
older	O
and	O
had	O
greater	O
frequencies	O
of	O
threatened	O
abortions	O
,	O
epidural	O
anesthesia	O
,	O
labor	O
induction	O
,	O
and	O
labor	O
duration	O
of	O
less	O
than	O
1	O
hour	O
.	O

These	O
children	O
were	O
more	O
often	O
born	O
first	O
,	O
had	O
a	O
low	O
Apgar	O
score	O
,	O
and	O
tended	O
to	O
have	O
more	O
complications	O
[	O
8	O
].	O

Similar	O
studies	O
using	O
a	O
Swedish	O
medical	O
birth	O
registry	O
observed	O
different	O
factors	O
that	O
affected	O
autism	O
spectrum	O
disorders	O
.	O

The	O
researchers	O
found	O
that	O
prematurity	O
,	O
low	O
Apgar	O
scores	O
,	O
growth	O
restriction	O
,	O
or	O
macrosomia	O
,	O
and	O
if	O
the	O
mother	O
was	O
from	O
sub	O
-	O
Saharan	O
Africa	O
or	O
East	O
Asia	O
had	O
a	O
positive	O
correlation	O
with	O
autism	O
spectrum	O
disorders	O
[	O
9	O
].	O

Information	O
obtained	O
from	O
the	O
Finnish	O
prenatal	O
study	O
of	O
autism	O
and	O
autism	O
spectrum	O
disorders	O
correlated	O
advanced	O
paternal	O
age	O
with	O
an	O
increased	O
risk	O
of	O
ASD	O
[	O
10	O
].	O

A	O
group	O
in	O
Norway	O
assessed	O
the	O
association	O
between	O
interpregnancy	O
lengths	O
and	O
ASD	O
and	O
found	O
that	O
interpregnancy	O
intervals	O
for	O
less	O
than	O
9	O
months	O
and	O
interpregnancy	O
between	O
9	O
and	O
11	O
months	O
carried	O
an	O
increased	O
risk	O
for	O
ASD	O
[	O
11	O
].	O

Further	O
evidence	O
is	O
suggested	O
by	O
other	O
studies	O
.	O

Subjects	O
used	O
in	O
an	O
Australian	O
study	O
were	O
diagnosed	O
with	O
autism	O
spectrum	O
disorder	O
and	O
compared	O
to	O
control	O
subjects	O
.	O

The	O
mothers	O
of	O
autistic	O
children	O
were	O
studied	O
,	O
and	O
it	O
was	O
demonstrated	O
that	O
the	O
cases	O
with	O
autism	O
had	O
more	O
pregnancy	O
complications	O
.	O

The	O
mothers	O
had	O
greater	O
frequencies	O
of	O
threatened	O
abortions	O
,	O
epidural	O
caudal	O
anesthesia	O
use	O
,	O
labor	O
induction	O
,	O
and	O
labor	O
duration	O
of	O
less	O
than	O
one	O
hour	O
.	O

They	O
were	O
more	O
likely	B
to	O
have	O
experienced	O
fetal	O
distress	O
,	O
been	O
delivered	O
by	O
an	O
elective	O
or	O
emergency	O
cesarean	O
section	O
,	O
and	O
had	O
an	O
Apgar	O
score	O
of	O
less	O
than	O
6	O
at	O
one	O
minute	O
.	O

It	O
was	O
concluded	O
that	O
although	O
autism	O
is	O
unlikely	B
to	O
be	O
caused	O
by	O
a	O
single	O
obstetric	O
factor	O
,	O
there	O
was	O
an	O
increased	O
prevalence	O
of	O
obstetric	O
complications	O
among	O
autism	O
cases	O
that	O
is	O
most	B
likely	I
due	O
to	O
underlying	O
genetic	O
factors	O
and	O
an	O
interaction	O
of	O
these	O
factors	O
with	O
the	O
environment	O
[	O
8	O
].	O

Another	O
Australian	O
study	O
evaluated	O
maternal	O
conditions	O
and	O
perinatal	O
characteristics	O
associated	O
with	O
ASD	O
and	O
intellectual	O
disability	O
.	O

Although	O
a	O
weak	O
correlation	O
was	O
found	O
between	O
poor	O
intrauterine	O
environments	O
and	O
ASD	O
with	O
intellectual	O
disabilities	O
,	O
there	O
was	O
no	O
relationship	O
found	O
between	O
ASD	O
without	O
intellectual	O
disabilities	O
and	O
perinatal	O
factors	O
[	O
12	O
].	O

ASD	O
may	O
involve	O
additional	O
pathologies	O
at	O
the	O
neuroanatomical	O
level	O
.	O

A	O
recent	O
study	O
illustrates	O
that	O
the	O
neuropathology	O
of	O
some	O
individuals	O
who	O
are	O
diagnosed	O
as	O
having	O
ASD	O
may	O
actually	O
also	O
have	O
focal	O
cortical	O
dysplasias	O
,	O
which	O
could	O
explain	B
the	O
high	O
incidence	O
of	O
sensory	O
irregularities	O
and	O
seizures	O
in	O
ASD	O
diagnosed	O
patients	O
[	O
59	O
].	O

Thus	B
,	O
focal	O
cortical	O
dysplasias	O
may	O
be	O
a	O
risk	O
factor	O
for	O
ASD	O
patients	O
.	O

No	O
specific	O
article	O
examined	O
specific	O
aspects	O
such	O
as	O
room	O
temperature	O
,	O
lack	O
of	O
equipment	O
,	O
time	O
spent	O
with	O
the	O
mother	O
,	O
or	O
proximity	O
to	O
other	O
neonates	O
.	O

However	O
,	O
some	O
sources	O
did	O
cite	O
other	O
factors	O
that	O
could	O
potentially	O
be	O
associated	O
with	O
the	O
delivery	O
room	O
itself	O
.	O

These	O
include	O
the	O
type	O
of	O
birth	O
,	O
such	O
as	O
whether	O
it	O
was	O
breech	O
,	O
a	O
prolonged	O
birth	O
,	O
or	O
an	O
induced	O
birth	O
,	O
along	O
with	O
various	O
forms	O
of	O
fetal	O
measures	O
such	O
as	O
birth	O
cry	O
,	O
fetal	O
distress	O
,	O
low	O
heart	O
rate	O
,	O
or	O
high	O
fetal	O
blood	O
pressure	O
[	O
2	O
,	O
3	O
,	O
13	O
–	O
15	O
,	O
60	O
].	O

Further	O
,	O
a	O
possible	O
association	O
exists	O
with	O
ventilation	O
of	O
neonates	O
[	O
16	O
].	O

Feeding	O
practices	O
have	O
also	O
been	O
looked	O
at	O
,	O
as	O
well	O
as	O
maternal	O
states	O
such	O
as	O
high	O
temperature	O
or	O
an	O
unhappy	O
maternal	O
emotional	O
state	O
[	O
17	O
–	O
19	O
,	O
58	O
].	O

Lastly	O
,	O
the	O
environmental	O
impact	O
of	O
perinatal	O
air	O
pollutants	O
has	O
also	O
been	O
observed	O
[	O
20	O
,	O
21	O
].	O

Because	O
these	O
studies	O
have	O
pointed	O
to	O
all	O
of	O
these	O
various	O
factors	O
which	O
in	O
and	O
of	O
themselves	O
can	O
all	O
occur	O
within	O
a	O
delivery	O
room	O
atmosphere	O
,	O
they	O
warrant	O
a	O
further	O
look	O
into	O
even	O
more	O
specific	O
delivery	O
room	O
attributes	O
to	O
see	O
if	O
there	O
is	O
a	O
more	O
direct	O
association	O
between	O
them	O
and	O
autism	O
.	O

2	O
.	O
1	O
.	O
β	O
2	O
Adrenergic	O
Receptor	O
Agonists	O
Beyond	O
the	O
cases	O
conducted	O
to	O
study	O
the	O
relationship	O
between	O
pregnancy	O
complications	O
and	O
augmented	O
childbirth	O
to	O
autism	O
,	O
several	O
studies	O
have	O
been	O
done	O
to	O
investigate	O
the	O
association	O
between	O
prenatal	O
exposures	O
to	O
β	O
2	O
adrenergic	O
receptor	O
agonists	O
to	O
autism	O
spectrum	O
disorders	O
.	O

These	O
agents	O
include	O
terbutaline	O
,	O
which	O
is	O
commonly	O
used	O
as	O
a	O
tocolytic	O
and	O
a	O
bronchodilator	O
in	O
obstetrics	O
.	O

Terbutaline	O
can	O
cross	O
the	O
placenta	O
and	O
potentially	O
affect	O
the	O
developing	O
neonatal	O
brain	O
[	O
22	O
].	O

In	O
a	O
study	O
of	O
neonatal	O
rats	O
,	O
Zerrate	O
et	O
al	O
.	O

found	O
neuroinflammatory	O
and	O
behavioral	O
changes	O
,	O
similar	O
to	O
that	O
in	O
autism	O
,	O
after	O
administering	O
terbutaline	O
to	O
subjects	O
.	O

The	O
results	O
demonstrated	O
that	O
terbutaline	O
increased	O
microglial	O
activation	O
in	O
the	O
subjects	O
'	O
cerebral	O
cortex	O
,	O
cerebellar	O
,	O
and	O
cerebrocortical	O
white	O
matter	O
[	O
23	O
].	O

Nucleotide	O
polymorphism	O
of	O
the	O
β	O
2	O
adrenergic	O
receptor	O
gene	O
has	O
also	O
been	O
implicated	O
as	O
risk	O
factors	O
for	O
autism	O
,	O
namely	O
,	O
Gly	O
16	O
and	O
Glu	O
27	O
[	O
24	O
,	O
25	O
].	O

The	O
researchers	O
of	O
independent	O
subjects	O
and	O
dizygotic	O
twins	O
found	O
that	O
activation	O
of	O
receptors	O
with	O
either	O
polymorphism	O
has	O
been	O
link	O
with	O
increased	O
signaling	O
,	O
secondary	O
to	O
decreased	O
downregulation	O
of	O
the	O
β	O
2	O
adrenergic	O
receptor	O
gene	O
.	O

Critics	O
of	O
these	O
genetic	O
predisposition	O
argued	O
that	O
since	O
many	O
genes	O
are	O
involved	O
in	O
the	O
etiology	O
of	O
autism	O
,	O
the	O
role	O
of	O
any	O
single	O
gene	O
polymorphism	O
in	O
causing	O
autism	O
is	O
small	O
.	O

The	O
effect	O
of	O
each	O
gene	O
is	O
further	O
diluted	O
by	O
variable	O
penetrance	O
[	O
61	O
].	O

In	O
clinical	O
studies	O
,	O
researchers	O
from	O
Kaiser	O
Permanente	O
Northern	O
California	O
Hospitals	O
examined	O
291	O
children	O
born	O
from	O
1995	O
to	O
1999	O
,	O
compared	O
to	O
284	O
controls	O
.	O

They	O
showed	O
that	O
there	O
was	O
no	O
evidence	O
linking	O
β	O
2	O
adrenergic	O
receptor	O
agonist	O
exposure	O
in	O
pregnancy	O
with	O
an	O
increase	O
in	O
autism	O
risk	O
,	O
except	O
exposure	O
to	O
terbutaline	O
during	O
the	O
third	O
trimester	O
for	O
more	O
than	O
two	O
days	O
[	O
26	O
,	O
62	O
].	O

The	O
authors	O
suggested	O
that	O
future	O
studies	O
with	O
larger	O
sample	O
sizes	O
would	O
be	O
helpful	O
to	O
endorse	O
or	O
challenge	O
their	O
findings	O
.	O

Based	O
on	O
aggregated	O
evidence	O
from	O
animal	O
and	O
human	O
studies	O
,	O
Witter	O
et	O
al	O
.	O

proposed	O
that	O
permanent	O
changes	O
in	O
autonomic	O
tone	O
could	O
result	O
in	O
neurological	O
changes	O
in	O
the	O
fetus	O
,	O
especially	O
after	O
two	O
or	O
more	O
weeks	O
of	O
high	O
dose	O
β	O
2	O
adrenergic	O
receptor	O
agonist	O
exposure	O
.	O

These	O
functional	O
and	O
behavioral	O
changes	O
may	O
contribute	O
to	O
the	O
signs	O
and	O
symptoms	O
of	O
autism	O
[	O
27	O
].	O

2	O
.	O
2	O
.	O

Maternal	O
Disease	O
In	O
addition	O
to	O
environmental	O
factors	O
,	O
infection	O
and	O
disease	O
may	O
play	O
a	O
role	O
in	O
the	O
development	O
of	O
autism	O
.	O

Children	O
born	O
to	O
mothers	O
with	O
antiphospholipid	O
syndrome	O
were	O
observed	O
to	O
have	O
a	O
higher	O
frequency	O
of	O
autism	O
spectrum	O
disorders	O
in	O
comparison	O
to	O
mothers	O
without	O
antiphospholipid	O
syndrome	O
,	O
which	O
further	O
supports	O
findings	O
that	O
perinatal	O
complications	O
increase	O
the	O
risk	O
of	O
autism	O
in	O
children	O
[	O
28	O
].	O

Another	O
study	O
was	O
organized	O
to	O
determine	O
ASD	O
in	O
children	O
born	O
preterm	O
and	O
the	O
role	O
of	O
exposure	O
to	O
perinatal	O
inflammation	O
.	O

It	O
was	O
a	O
review	O
that	O
covered	O
the	O
evidence	O
supporting	O
the	O
idea	O
that	O
prenatal	O
infection	O
on	O
the	O
central	O
nervous	O
system	O
may	O
increase	O
the	O
incidence	O
of	O
autism	O
spectrum	O
disorders	O
[	O
63	O
].	O

An	O
increase	O
in	O
C	O
-	O
reactive	O
protein	O
indicates	O
inflammation	O
,	O
which	O
is	O
common	O
in	O
infection	O
.	O

This	O
increase	O
in	O
C	O
-	O
reactive	O
protein	O
has	O
been	O
found	O
to	O
have	O
a	O
correlation	O
with	O
a	O
risk	O
for	O
autism	O
spectrum	O
disorders	O
[	O
29	O
].	O

2	O
.	O
3	O
.	O

Antiepileptic	O
Drugs	O
Although	O
it	O
has	O
been	O
shown	O
that	O
autism	O
is	O
unlikely	B
to	O
be	O
caused	O
by	O
a	O
single	O
factor	O
,	O
there	O
have	O
been	O
many	O
studies	O
conducted	O
studying	O
the	O
relationship	O
between	O
the	O
use	O
of	O
certain	O
medications	O
during	O
pregnancy	O
and	O
the	O
associated	O
risk	O
of	O
autism	O
.	O

For	O
example	O
,	O
the	O
increased	O
prevalence	O
of	O
the	O
use	O
of	O
anticonvulsant	O
medications	O
during	O
pregnancy	O
is	O
correlated	O
with	O
an	O
increased	O
risk	O
of	O
autism	O
.	O

Valproate	O
is	O
used	O
for	O
the	O
treatment	O
of	O
epilepsy	O
and	O
other	O
neuropsychological	O
disorders	O
and	O
is	O
considered	O
one	O
of	O
the	O
only	O
available	O
treatment	O
options	O
for	O
women	O
of	O
childbearing	O
potential	O
[	O
6	O
].	O

Recent	O
studies	O
,	O
however	O
,	O
have	O
shown	O
that	O
exposure	O
to	O
valproate	O
during	O
pregnancy	O
indicates	O
a	O
significantly	O
increased	O
risk	O
of	O
autism	O
spectrum	O
disorder	O
,	O
even	O
after	O
adjusting	O
for	O
maternal	O
epilepsy	O
.	O

In	O
fact	O
,	O
valproate	O
use	O
during	O
pregnancy	O
showed	O
an	O
11	O
.	O
3	O
%	O
increased	O
risk	O
in	O
developmental	O
malformations	O
,	O
and	O
it	O
relied	O
heavily	O
on	O
the	O
dosage	O
prescribed	O
[	O
64	O
].	O

Women	O
who	O
were	O
prescribed	O
increased	O
doses	O
of	O
valproic	O
acid	O
showed	O
a	O
twofold	O
increase	O
in	O
risk	O
of	O
developmental	O
malformations	O
and	O
significantly	O
reduced	O
intelligence	O
[	O
30	O
].	O

Studies	O
exposing	O
pregnant	O
rats	O
and	O
mice	O
to	O
valproate	O
demonstrated	O
increased	O
autistic	O
-	O
like	O
behaviors	O
in	O
the	O
offspring	O
.	O

This	O
behavior	O
included	O
social	O
behavior	O
deficits	O
,	O
increased	O
repetitive	O
behaviors	O
,	O
and	O
deficits	O
in	O
communication	O
.	O

The	O
animal	O
studies	O
performed	O
by	O
Roullet	O
have	O
been	O
used	O
as	O
a	O
model	O
to	O
ameliorate	O
and	O
improve	O
upon	O
studies	O
that	O
focus	O
on	O
the	O
association	O
between	O
the	O
risk	O
of	O
autism	O
and	O
the	O
maternal	O
need	O
for	O
anticonvulsants	O
[	O
5	O
].	O

The	O
current	O
recommendation	O
of	O
health	O
care	O
professionals	O
is	O
to	O
avoid	O
anticonvulsant	O
drug	O
use	O
such	O
as	O
valproate	O
during	O
pregnancy	O
.	O

It	O
is	O
important	O
,	O
however	O
,	O
to	O
assess	O
the	O
intrinsic	O
iatrogenic	O
risk	O
of	O
birth	O
defects	O
or	O
perinatal	O
complications	O
and	O
the	O
general	O
safety	O
for	O
the	O
expectant	O
mother	O
before	O
discontinuing	O
anticonvulsants	O
[	O
31	O
].	O

2	O
.	O
4	O
.	O

Oral	O
Supplements	O
Prenatal	O
supplements	O
are	O
an	O
important	O
component	O
of	O
a	O
healthy	O
pregnancy	O
.	O

Prenatal	O
folic	O
acid	O
supplements	O
have	O
been	O
shown	O
to	O
reduce	O
the	O
risk	O
of	O
neural	O
tube	O
defects	O
in	O
children	O
and	O
are	O
associated	O
with	O
a	O
lower	O
risk	O
of	O
autistic	O
disorder	O
[	O
32	O
].	O

In	O
this	O
study	O
following	O
270	O
children	O
,	O
of	O
the	O
children	O
whose	O
mothers	O
took	O
folic	O
acid	O
,	O
0	O
.	O
1	O
%	O
developed	O
autistic	O
disorder	O
[	O
32	O
].	O

Those	O
children	O
whose	O
mothers	O
were	O
not	O
exposed	O
to	O
folic	O
acid	O
comprised	O
0	O
.	O
21	O
%	O
of	O
the	O
group	O
.	O

This	O
study	O
also	O
analyzed	O
the	O
use	O
of	O
fish	O
oil	O
supplements	O
,	O
which	O
showed	O
no	O
association	O
with	O
autistic	O
disorder	O
[	O
32	O
].	O

Although	O
no	O
causality	O
was	O
found	O
,	O
it	O
was	O
determined	O
that	O
prenatal	O
folic	O
acid	O
supplements	O
taken	O
during	O
pregnancy	O
were	O
associated	O
with	O
a	O
decreased	O
risk	O
of	O
autistic	O
disorder	O
.	O

Vitamin	O
D	O
,	O
which	O
has	O
a	O
unique	O
role	O
in	O
brain	O
homeostasis	O
,	O
embryogenesis	O
and	O
neurodevelopment	O
,	O
neural	O
differentiation	O
,	O
and	O
gene	O
regulation	O
,	O
has	O
recently	O
been	O
proposed	O
as	O
a	O
possible	O
environmental	O
risk	O
factor	O
for	O
autism	O
during	O
early	O
childhood	O
.	O

Children	O
with	O
autism	O
had	O
significantly	O
lower	O
serum	O
levels	O
of	O
25	O
-	O
hydroxy	O
vitamin	O
D	O
than	O
healthy	O
children	O
.	O

On	O
the	O
other	O
hand	O
,	O
the	O
involvement	O
of	O
maternal	O
vitamin	O
D	O
during	O
pregnancy	O
in	O
autism	O
requires	O
proper	O
investigation	O
.	O

Recent	O
studies	O
have	O
shown	O
that	O
a	O
wide	O
range	O
of	O
disorders	O
,	O
including	O
neuropsychiatric	O
disorders	O
and	O
autism	O
,	O
are	O
associated	O
with	O
increased	O
homocysteine	O
levels	O
in	O
biological	O
fluids	O
.	O

Homocysteine	O
is	O
an	O
amino	O
acid	O
,	O
which	O
plays	O
several	O
important	O
roles	O
in	O
human	O
physiology	O
.	O

Various	O
B	O
vitamins	O
such	O
as	O
B6	O
(	O
pyridoxine	O
),	O
B12	O
(	O
cobalamin	O
),	O
and	O
B9	O
(	O
folic	O
acid	O
)	O
are	O
required	O
as	O
cofactors	O
by	O
the	O
enzymes	O
involved	O
in	O
homocysteine	O
metabolism	O
.	O

Therefore	B
,	O
it	O
is	O
crucial	O
to	O
monitor	O
the	O
homocysteine	O
levels	O
in	O
body	O
fluids	O
of	O
autistic	O
children	O
.	O

It	O
can	O
provide	O
information	O
on	O
genetic	O
and	O
physiological	O
diseases	O
,	O
improper	O
lifestyle	O
(	O
including	O
dietary	O
habits	O
),	O
and	O
a	O
variety	O
of	O
pathological	O
conditions	O
.	O

2	O
.	O
5	O
.	O

Illicit	O
Drug	O
Exposure	O
,	O
Smoking	O
,	O
and	O
Pollutants	O
Drug	O
exposure	O
may	O
have	O
very	O
serious	O
complications	O
during	O
pregnancy	O
.	O

A	O
study	O
was	O
conducted	O
to	O
evaluate	O
the	O
association	O
between	O
autism	O
and	O
developmental	O
abnormalities	O
in	O
children	O
with	O
perinatal	O
cocaine	O
exposure	O
.	O

It	O
was	O
concluded	O
that	O
most	O
of	O
the	O
cases	O
had	O
language	O
delays	O
and	O
difficulties	O
with	O
expressive	O
skills	O
and	O
communication	O
disorders	O
.	O

Significant	O
neurodevelopmental	O
abnormalities	O
were	O
observed	O
and	O
a	O
high	O
frequency	O
of	O
autism	O
was	O
found	O
in	O
children	O
exposed	O
to	O
cocaine	O
,	O
especially	O
in	O
comparison	O
to	O
those	O
exposed	O
to	O
alcohol	O
or	O
opiates	O
alone	O
[	O
33	O
].	O

Smoking	O
has	O
been	O
found	O
to	O
be	O
an	O
environmental	O
hazard	O
.	O

Studies	O
have	O
been	O
done	O
determining	O
the	O
effects	O
of	O
smoking	O
in	O
a	O
pregnant	O
patient	O
and	O
the	O
risk	O
of	O
autism	O
in	O
the	O
mother	O
'	O
s	O
offspring	O
.	O

Epidemiological	O
data	O
were	O
obtained	O
from	O
children	O
with	O
autism	O
,	O
including	O
residential	O
history	O
of	O
the	O
mother	O
,	O
which	O
was	O
compared	O
to	O
the	O
traffic	O
-	O
related	O
air	O
pollution	O
assigned	O
to	O
each	O
location	O
using	O
measures	O
from	O
the	O
Environmental	O
Protection	O
Agency	O
'	O
s	O
Air	O
Quality	O
System	O
data	O
.	O

It	O
was	O
assessed	O
that	O
maternal	O
smoking	O
was	O
related	O
to	O
a	O
modest	O
increase	O
in	O
the	O
risk	O
of	O
Pervasive	O
Developmental	O
Disorders	O
,	O
however	O
,	O
there	O
was	O
no	O
known	O
association	O
between	O
maternal	O
smoking	O
and	O
childhood	O
autism	O
[	O
34	O
].	O

Interestingly	O
,	O
the	O
amount	O
of	O
air	O
pollution	O
that	O
a	O
mother	O
and	O
child	O
were	O
exposed	O
to	O
including	O
traffic	O
related	O
air	O
pollution	O
and	O
nitrogen	O
dioxide	O
,	O
both	O
during	O
pregnancy	O
and	O
during	O
the	O
first	O
year	O
of	O
life	O
,	O
was	O
associated	O
with	O
autism	O
[	O
35	O
].	O

2	O
.	O
6	O
.	O

SSRIs	O
Selective	O
serotonin	O
reuptake	O
inhibitors	O
(	O
SSRIs	O
)	O
are	O
a	O
class	O
of	O
drugs	O
currently	O
and	O
increasingly	O
prescribed	O
for	O
anxiety	O
disorders	O
and	O
depression	O
.	O

These	O
drugs	O
,	O
such	O
as	O
Fluoxetine	O
,	O
Sertraline	O
,	O
and	O
Citalopram	O
,	O
work	O
by	O
inhibiting	O
the	O
reuptake	O
of	O
the	O
neurotransmitter	O
serotonin	O
,	O
resulting	O
in	O
a	O
greater	O
amount	O
of	O
serotonin	O
at	O
the	O
synapse	O
.	O

Much	O
like	O
anticonvulsants	O
and	O
other	O
drug	O
exposures	O
,	O
the	O
use	O
of	O
SSRIs	O
in	O
pregnant	O
women	O
and	O
its	O
association	O
to	O
autism	O
have	O
been	O
explored	O
.	O

Previous	O
studies	O
have	O
shown	O
an	O
increased	O
blood	O
level	O
of	O
serotonin	O
in	O
individuals	O
affected	O
with	O
autism	O
spectrum	O
disorder	O
,	O
warranting	O
the	O
exploration	O
of	O
a	O
possible	O
association	O
[	O
65	O
].	O

The	O
risk	O
of	O
autism	O
spectrum	O
disorders	O
was	O
shown	O
to	O
be	O
doubled	O
with	O
maternal	O
use	O
of	O
SSRIs	O
in	O
a	O
recent	O
case	O
controlled	O
study	O
of	O
298	O
children	O
,	O
with	O
prenatal	O
exposure	O
reported	O
for	O
20	O
of	O
those	O
children	O
[	O
36	O
].	O

This	O
was	O
seen	O
by	O
evaluating	O
medical	O
records	O
,	O
considering	O
both	O
the	O
SSRI	O
exposure	O
and	O
the	O
mental	O
health	O
history	O
of	O
the	O
mother	O
,	O
and	O
pointing	O
to	O
a	O
high	O
association	O
with	O
SSRI	O
treatment	O
and	O
autism	O
during	O
the	O
first	O
trimester	O
.	O

However	O
,	O
the	O
sample	O
size	O
for	O
this	O
study	O
is	O
small	O
.	O

A	O
recent	O
study	O
conducted	O
in	O
Sweden	O
by	O
Rai	O
et	O
al	O
.	O

[	O
37	O
]	O
expanded	O
on	O
this	O
and	O
illustrated	O
a	O
case	O
control	O
study	O
of	O
4429	O
children	O
with	O
autism	O
.	O

It	O
demonstrated	O
an	O
association	O
between	O
in	O
utero	O
exposure	O
to	O
both	O
SSRIs	O
and	O
nonselective	O
monoamine	O
reuptake	O
inhibitors	O
with	O
an	O
increased	O
risk	O
of	O
autism	O
spectrum	O
disorders	O
,	O
particularly	O
without	O
intellectual	O
disability	O
.	O

However	O
,	O
there	O
is	O
again	O
a	O
limitation	O
with	O
interpreting	O
medical	O
records	O
,	O
such	O
as	O
prescribed	O
versus	O
actual	O
use	O
of	O
SSRIs	O
.	O

Further	O
,	O
other	O
studies	O
using	O
animal	O
models	O
show	O
that	O
preclinical	O
findings	O
in	O
rodents	O
exposed	O
to	O
SSRIs	O
during	O
development	O
point	O
to	O
an	O
increase	O
in	O
depression	O
and	O
anxiety	O
,	O
exhibiting	O
alteration	O
in	O
social	O
behaviors	O
in	O
the	O
offspring	O
.	O

The	O
data	O
show	O
adverse	O
effects	O
of	O
maternal	O
mental	O
illness	O
on	O
pregnancy	O
outcomes	O
and	O
infant	O
neurodevelopment	O
but	O
are	O
not	O
robust	O
enough	O
to	O
discourage	O
the	O
use	O
of	O
SSRIs	O
during	O
human	O
pregnancy	O
[	O
66	O
].	O

In	O
a	O
study	O
by	O
Gur	O
et	O
al	O
.	O

[	O
66	O
],	O
it	O
was	O
shown	O
that	O
the	O
manipulation	O
of	O
serotonin	O
during	O
early	O
development	O
in	O
both	O
in	O
vitro	O
and	O
in	O
vivo	O
models	O
disturbs	O
characteristic	O
chemoarchitectural	O
and	O
electrophysiological	O
brain	O
features	O
.	O

This	O
includes	O
changes	O
in	O
raphe	O
and	O
callosal	O
connections	O
,	O
sensory	O
processing	O
,	O
myelin	O
sheath	O
formation	O
,	O
neophobia	O
,	O
and	O
disrupted	O
juvenile	O
play	O
behavior	O
.	O

These	O
findings	O
indicate	O
that	O
serotonin	O
homeostasis	O
is	O
necessary	O
for	O
proper	O
brain	O
maturation	O
and	O
fetal	O
development	O
.	O

Although	O
SSRIs	O
are	O
not	O
contraindicated	O
for	O
use	O
during	O
pregnancy	O
,	O
the	O
effects	O
should	O
be	O
examined	O
more	O
carefully	O
[	O
66	O
].	O

In	O
a	O
similar	O
study	O
done	O
by	O
Simpson	O
et	O
al	O
.	O

[	O
38	O
],	O
animal	O
models	O
were	O
used	O
to	O
study	O
the	O
importance	O
of	O
serotonin	O
homeostasis	O
for	O
the	O
development	O
of	O
rat	O
pups	O
'	O
brains	O
.	O

It	O
was	O
demonstrated	O
that	O
when	O
the	O
serotonin	O
levels	O
were	O
altered	O
by	O
SSRIs	O
during	O
early	O
development	O
of	O
brain	O
structure	O
,	O
the	O
functions	O
were	O
altered	O
.	O

This	O
alteration	O
was	O
also	O
more	O
evident	O
in	O
males	O
than	O
in	O
females	O
.	O

This	O
suggests	O
that	O
SSRIs	O
may	O
have	O
similar	O
effects	O
in	O
human	O
neonates	O
[	O
38	O
].	O

Conversely	O
,	O
other	O
recent	O
studies	O
have	O
suggested	O
that	O
there	O
may	O
actually	O
not	O
be	O
a	O
strong	O
association	O
between	O
SSRI	O
intake	O
and	O
the	O
subsequent	O
development	O
of	O
autism	O
.	O

A	O
recent	O
cohort	O
study	O
of	O
live	O
births	O
in	O
Denmark	O
from	O
1996	O
to	O
2005	O
involving	O
3	O
,	O
892	O
cases	O
of	O
ASD	O
found	O
no	O
significant	O
association	O
,	O
as	B
only	O
52	O
cases	O
of	O
SSRI	O
use	O
were	O
found	O
[	O
39	O
].	O

Larger	O
observational	O
studies	O
are	O
required	O
to	O
establish	O
a	O
true	B
link	O
between	O
the	O
use	O
of	O
SSRIs	O
and	O
autism	O
.	O

Furthermore	O
,	O
it	O
must	O
be	O
noted	O
that	O
the	O
effect	O
of	O
depression	O
itself	O
as	O
a	O
factor	O
in	O
autism	O
separate	O
from	O
the	O
administration	O
of	O
SSRIs	O
is	O
a	O
possibility	O
.	O

Thus	B
,	O
it	O
may	O
be	O
that	O
,	O
in	O
some	O
cases	O
,	O
depression	O
itself	O
or	O
other	O
concomitant	O
factors	O
have	O
a	O
combined	O
effect	O
that	O
is	O
not	O
necessarily	O
due	O
to	O
the	O
use	O
of	O
SSRIs	O
.	O

2	O
.	O
7	O
.	O

Artificial	O
Insemination	O
and	O
Fertility	O
Medications	O
There	O
is	O
an	O
increase	O
in	O
prevalence	O
in	O
the	O
number	O
of	O
women	O
utilizing	O
fertility	O
measures	O
,	O
thus	B
calling	O
for	O
studies	O
to	O
determine	O
the	O
association	O
between	O
assisted	O
reproductive	O
therapy	O
and	O
neurodevelopmental	O
complications	O
,	O
and	O
more	O
specifically	O
autism	O
.	O

A	O
nested	O
case	O
control	O
study	O
done	O
by	O
Lyall	O
et	O
al	O
.	O

[	O
40	O
]	O
shows	O
that	O
assisted	O
reproductive	O
therapy	O
and	O
a	O
history	O
of	O
infertility	O
do	O
not	O
increase	O
the	O
risk	O
for	O
autism	O
spectrum	O
disorders	O
.	O

However	O
,	O
the	O
age	O
of	O
the	O
mother	O
needs	O
to	O
be	O
taken	O
into	O
consideration	O
,	O
as	B
artificial	O
insemination	O
among	O
older	O
mothers	O
has	O
been	O
studied	O
to	O
lead	O
to	O
more	O
complications	O
.	O

Women	O
under	O
the	O
age	O
of	O
35	O
using	O
fertility	O
therapies	O
such	O
as	O
ovulation	O
inducing	O
drugs	O
and	O
artificial	O
insemination	O
did	O
not	O
increase	O
the	O
risk	O
for	O
having	O
a	O
child	O
with	O
autism	O
,	O
while	O
researchers	O
suggest	O
that	O
the	O
rise	O
in	O
fertility	O
treatments	O
in	O
older	O
women	O
above	O
35	O
may	O
increase	O
the	O
risk	O
of	O
having	O
a	O
child	O
with	O
autism	O
for	O
those	O
using	O
artificial	O
insemination	O
and	O
/	O
or	O
ovulation	O
inducing	O
drugs	O
.	O

While	O
the	O
study	O
is	O
strong	O
in	O
that	O
it	O
uses	O
a	O
large	O
national	O
sample	O
,	O
it	O
is	O
important	O
to	O
note	O
that	O
both	O
diagnoses	O
and	O
fertility	O
treatments	O
were	O
self	O
-	O
reported	O
[	O
40	O
].	O

Conversely	O
,	O
a	O
recent	O
cohort	O
study	O
conducted	O
by	O
Bay	O
et	O
al	O
.	O

showed	O
a	O
statistically	O
significant	O
increase	O
in	O
autism	O
and	O
other	O
mental	O
health	O
disorders	O
following	O
ovulation	O
induction	O
[	O
41	O
].	O

This	O
was	O
done	O
through	O
a	O
cohort	O
study	O
using	O
555	O
,	O
828	O
children	O
in	O
Denmark	O
using	O
information	O
from	O
a	O
birth	O
register	O
and	O
evaluated	O
with	O
statistical	O
analyses	O
.	O

There	O
were	O
no	O
significant	O
associations	O
found	O
with	O
in	O
vitro	O
fertilization	O
/	O
intracytoplasmic	O
sperm	O
injection	O
(	O
ICSI	O
)	O
or	O
with	O
cryopreserved	O
embryos	O
or	O
gametes	O
,	O
types	O
of	O
hormones	O
,	O
or	O
cause	O
of	O
infertility	O
.	O

The	O
strength	O
in	O
this	O
study	O
includes	O
long	O
followup	O
and	O
low	O
risk	O
of	O
selection	O
bias	O
,	O
but	O
numerous	O
subgroup	O
analyses	O
may	O
lead	O
to	O
risk	O
of	O
chance	O
influencing	O
significant	O
associations	O
.	O

In	O
an	O
epidemiological	O
study	O
conducted	O
in	O
India	O
by	O
Mamidala	O
et	O
al	O
.,	O
maternal	O
hormonal	O
intervention	O
was	O
a	O
significant	O
risk	O
factor	O
for	O
ASD	O
,	O
possibly	O
due	O
to	O
maternal	O
hormone	O
disturbances	O
causing	O
obstetric	O
complications	O
,	O
which	O
in	O
turn	O
are	O
a	O
risk	O
for	O
ASD	O
[	O
42	O
].	O

While	O
there	O
was	O
a	O
large	O
sample	O
size	O
,	O
there	O
was	O
an	O
absence	O
of	O
detailed	O
information	O
on	O
dosage	O
and	O
frequency	O
of	O
hormonal	O
intervention	O
.	O

Thus	B
,	O
with	O
differing	O
results	O
it	O
is	O
evident	B
that	O
more	O
specific	O
studies	O
need	O
to	O
be	O
conducted	O
on	O
infertility	O
treatments	O
keeping	O
in	O
mind	O
specific	O
subtypes	O
and	O
their	O
effect	O
on	O
autism	O
in	O
children	O
.	O

Controls	O
for	O
age	O
can	O
also	O
be	O
accounted	O
for	O
,	O
and	O
adverse	O
effects	O
can	O
be	O
more	O
accurately	O
studied	O
in	O
the	O
future	O
.	O

2	O
.	O
8	O
.	O

Meconium	O
Aspiration	O
Syndrome	O
Meconium	O
aspiration	O
syndrome	O
,	O
which	O
occurs	O
when	O
a	O
fetus	O
who	O
is	O
under	O
stress	O
and	O
not	O
getting	O
enough	O
oxygen	O
inhales	O
waste	O
products	O
inside	O
the	O
womb	O
,	O
was	O
linked	O
to	O
a	O
sevenfold	O
increase	O
in	O
the	O
likelihood	B
that	O
a	O
child	O
would	O
later	O
develop	O
autism	O
.	O

A	O
study	O
examined	O
the	O
incidence	O
of	O
autism	O
in	O
the	O
neonatal	O
intensive	O
care	O
unit	O
and	O
risk	O
factors	O
connected	O
with	O
autistic	O
development	O
.	O

Findings	O
in	O
this	O
study	O
indicate	O
that	O
children	O
with	O
autism	O
had	O
a	O
significantly	O
higher	O
history	O
of	O
meconium	O
aspiration	O
syndrome	O
than	O
the	O
controls	O
[	O
43	O
].	O

However	O
,	O
there	O
is	O
insufficient	O
evidence	O
to	O
implicate	O
any	O
one	O
perinatal	O
or	O
neonatal	O
factor	O
in	O
autism	O
etiology	O
,	O
although	O
there	O
is	O
some	O
evidence	O
to	O
suggest	O
that	O
exposure	O
to	O
a	O
broad	O
class	O
of	O
conditions	O
reflecting	O
general	O
compromises	O
to	O
perinatal	O
and	O
neonatal	O
health	O
may	O
increase	O
the	O
risk	O
.	O

Therefore	B
meconium	O
aspiration	O
syndrome	O
cannot	O
be	O
the	O
cause	O
of	O
autistic	O
disorder	O
in	O
children	O
,	O
but	O
it	O
can	O
be	O
a	O
contributing	O
factor	O
[	O
57	O
].	O

2	O
.	O
9	O
.	O

Birth	O
Weight	O
Many	O
studies	O
have	O
evaluated	O
the	O
association	O
between	O
birth	O
weight	O
and	O
the	O
development	O
of	O
autism	O
.	O

A	O
significant	O
fourfold	O
increased	O
risk	O
was	O
observed	O
in	O
low	O
birth	O
weight	O
females	O
for	O
autism	O
accompanied	O
by	O
mental	O
retardation	O
.	O

In	O
low	O
birth	O
weight	O
males	O
there	O
was	O
no	O
significant	O
increased	O
risk	O
observed	O
for	O
autism	O
alone	O
.	O

Though	O
this	O
implies	O
a	O
certain	O
etiological	O
premise	O
of	O
difference	O
in	O
gender	O
,	O
it	O
is	O
also	O
important	O
to	O
note	O
that	O
while	O
the	O
population	O
cohort	O
design	O
is	O
strong	O
,	O
there	O
was	O
not	O
a	O
large	O
number	O
overall	O
of	O
the	O
lower	O
birth	O
weight	O
categories	O
in	O
females	O
[	O
44	O
].	O

An	O
earlier	O
study	O
by	O
Wilkerson	O
supports	O
this	O
finding	O
as	B
it	O
determined	O
that	O
birth	O
weight	O
was	O
a	O
factor	O
for	O
the	O
risk	O
of	O
autism	O
spectrum	O
disorders	O
,	O
with	O
significant	O
associations	O
between	O
autism	O
and	O
gestational	O
age	O
,	O
maternal	O
morphology	O
and	O
intrauterine	O
stress	O
.	O

Specifically	O
,	O
it	O
is	O
the	O
prescriptions	O
taken	O
during	O
pregnancy	O
,	O
the	O
length	O
of	O
labor	O
,	O
viral	O
infection	O
,	O
abnormal	O
presentation	O
at	O
delivery	O
,	O
and	O
finally	O
low	O
birth	O
weight	O
that	O
were	O
associated	O
with	O
autism	O
.	O

In	O
this	O
study	O
only	O
183	O
autistic	O
children	O
were	O
considered	O
and	O
medical	O
conditions	O
of	O
the	O
mother	O
based	O
on	O
a	O
maternal	O
self	O
-	O
report	O
[	O
18	O
].	O

Further	O
,	O
several	O
studies	O
examined	O
head	O
circumference	O
and	O
height	O
abnormalities	O
in	O
autism	O
patients	O
.	O

Their	O
studies	O
suggest	O
that	O
the	O
abnormal	O
growth	O
in	O
children	O
with	O
autism	O
spectrum	O
disorders	O
may	O
be	O
related	O
to	O
the	O
causal	O
factors	O
that	O
also	O
increase	O
the	O
risk	O
for	O
ASD	O
,	O
as	O
it	O
was	O
found	O
that	O
children	O
with	O
ASD	O
had	O
proportionally	O
smaller	O
head	O
circumference	O
compared	O
to	O
height	O
during	O
their	O
first	O
year	O
of	O
life	O
,	O
which	O
was	O
absent	O
in	O
premature	O
/	O
low	O
birth	O
weight	O
children	O
with	O
ASD	O
.	O

Even	O
more	O
importantly	O
,	O
the	O
body	O
grew	O
faster	O
than	O
the	O
head	O
for	O
those	O
with	O
ASD	O
by	O
the	O
end	O
of	O
the	O
first	O
year	O
of	O
life	O
,	O
suggesting	O
a	O
closer	O
following	O
of	O
length	O
to	O
circumference	O
during	O
development	O
.	O

However	O
,	O
there	O
may	O
have	O
been	O
some	O
recall	O
bias	O
and	O
head	O
circumference	O
could	O
only	O
be	O
measured	O
on	O
the	O
first	O
year	O
of	O
life	O
all	O
within	O
a	O
modest	O
sample	O
size	O
,	O
indicating	O
a	O
need	O
for	O
replicating	O
the	O
study	O
in	O
a	O
larger	O
cohort	O
[	O
45	O
].	O

Similar	O
studies	O
were	O
conducted	O
illustrating	O
that	O
relative	O
microcephaly	O
was	O
more	O
frequent	O
in	O
children	O
with	O
ASD	O
.	O

However	O
microcephaly	O
can	O
also	O
be	O
caused	O
by	O
other	O
factors	O
such	O
as	O
low	O
intelligence	O
and	O
heredity	O
,	O
which	O
could	O
not	O
be	O
controlled	O
for	O
,	O
and	O
also	O
only	O
focused	O
on	O
measurements	O
obtained	O
at	O
birth	O
[	O
46	O
].	O

Expanding	O
on	O
this	O
,	O
a	O
matched	O
case	O
control	O
studies	O
of	O
children	O
in	O
Stockholm	O
county	O
showed	O
a	O
correlation	O
between	O
low	O
growth	O
for	O
gestation	O
age	O
and	O
preterm	O
birth	O
with	O
ASD	O
combined	O
with	O
intellectual	O
disabilities	O
.	O

The	O
strength	O
of	O
this	O
study	O
lies	O
in	O
its	O
comprehensive	O
sample	O
and	O
size	O
but	O
did	O
not	O
measure	O
some	O
other	O
maternal	O
factors	O
such	O
as	O
substance	O
abuse	O
and	O
nutritional	O
influence	O
[	O
47	O
].	O

Several	O
other	O
studies	O
have	O
focused	O
on	O
maternal	O
changes	O
during	O
pregnancy	O
and	O
their	O
association	O
with	O
autism	O
.	O

A	O
population	O
-	O
based	O
study	O
in	O
Utah	O
(	O
US	O
)	O
looked	O
at	O
prenatal	O
variables	O
of	O
autistic	O
children	O
and	O
focused	O
on	O
gestational	O
weight	O
.	O

It	O
was	O
found	O
that	O
maternal	O
prenatal	O
weight	O
gain	O
,	O
but	O
not	O
prepregnancy	O
body	O
mass	O
index	O
,	O
is	O
directly	O
related	O
to	O
an	O
increased	O
risk	O
of	O
ASD	O
.	O

Because	O
of	O
use	O
of	O
cohort	O
and	O
control	O
groups	O
,	O
it	O
not	O
only	O
allowed	O
a	O
representative	O
sample	O
of	O
Utah	O
children	O
,	O
but	O
also	O
as	O
a	O
surveillance	O
study	O
could	O
not	O
directly	O
assess	O
cases	O
and	O
controls	O
[	O
48	O
].	O

However	O
,	O
a	O
recent	O
longitudinal	O
study	O
using	O
birth	O
data	O
from	O
4800	O
children	O
from	O
the	O
United	O
States	O
showed	O
that	O
children	O
born	O
to	O
over	O
-/	O
underweight	O
mothers	O
during	O
prepregnancy	O
had	O
increased	O
incidences	O
of	O
being	O
born	O
with	O
a	O
low	O
birth	O
weight	O
.	O

The	O
group	O
noted	O
that	O
low	O
birth	O
weight	O
increased	O
chances	O
of	O
developing	O
ASD	O
,	O
as	O
well	O
as	O
rapid	O
head	O
growth	O
.	O

This	O
study	O
concluded	O
that	O
abnormal	O
maternal	O
gestational	O
weight	O
indirectly	O
caused	O
an	O
increased	O
chance	O
of	O
developing	O
ASD	O
[	O
49	O
].	O

In	O
addition	O
to	O
a	O
lower	O
birth	O
weight	O
population	O
,	O
a	O
secondary	O
analysis	O
longitudinal	O
design	O
study	O
using	O
cranial	O
ultrasound	O
evidence	O
of	O
14	O
study	O
participants	O
diagnosed	O
with	O
ASD	O
identified	O
that	O
children	O
with	O
ventricular	O
enlargement	O
were	O
strong	O
indicators	O
of	O
the	O
potential	O
risk	O
for	O
autism	O
spectrum	O
disorders	O
[	O
50	O
].	O

Overall	O
,	O
these	O
birth	O
weight	O
studies	O
illustrate	O
that	O
more	O
research	O
with	O
larger	O
populations	O
needs	O
to	O
be	O
conducted	O
to	O
determine	O
whether	O
autism	O
etiology	O
is	O
genetic	O
in	O
relation	O
to	O
birth	O
weight	O
,	O
whether	O
birth	O
weight	O
is	O
a	O
risk	O
factor	O
or	O
a	O
cause	O
of	O
autism	O
,	O
how	O
much	O
mother	O
'	O
s	O
gestational	O
age	O
plays	O
a	O
role	O
,	O
and	O
whether	O
pre	O
-	O
or	O
postpregnancy	O
weight	O
of	O
the	O
mother	O
has	O
a	O
larger	O
effect	O
on	O
prevalence	O
of	O
autism	O
and	O
ASD	O
as	B
research	O
currently	O
supports	O
a	O
variety	O
of	O
findings	O
.	O

2	O
.	O
10	O
.	O

Labor	O
Induction	O
and	O
Augmentation	O
Since	O
the	O
early	O
1990s	O
,	O
a	O
number	O
of	O
studies	O
have	O
suggested	O
the	O
link	O
between	O
ASD	O
and	O
labor	O
induction	O
,	O
such	O
as	O
the	O
use	O
of	O
oxytocin	O
[	O
67	O
].	O

The	O
research	O
that	O
ensued	O
found	O
significantly	O
different	O
results	O
between	O
population	O
-	O
based	O
studies	O
and	O
clinic	O
based	O
studies	O
.	O

Gardener	O
et	O
al	O
.	O

'	O
s	O
analysis	O
showed	O
induction	O
increase	O
in	O
the	O
risk	O
of	O
autism	O
by	O
72	O
%	O
in	O
three	O
clinic	O
based	O
studies	O
,	O
while	O
the	O
selected	O
population	O
-	O
based	O
studies	O
reported	O
no	O
association	O
[	O
57	O
].	O

Recently	O
,	O
however	O
,	O
labor	O
induction	O
was	O
positively	O
correlated	O
with	O
autism	O
in	O
a	O
large	O
population	O
study	O
comparing	O
birth	O
records	O
in	O
North	O
Carolina	O
(	O
1990	O
–	O
1998	O
)	O
and	O
corresponding	O
school	O
records	O
of	O
autistic	O
children	O
(	O
1997	O
–	O
2007	O
).	O

The	O
study	O
controlled	O
for	O
environmental	O
factors	O
such	O
as	O
socioeconomic	O
status	O
,	O
maternal	O
health	O
,	O
pregnancy	O
-	O
related	O
events	O
and	O
conditions	O
,	O
and	O
birth	O
year	O
.	O

The	O
authors	O
reported	O
that	O
the	O
link	O
was	O
particularly	O
significant	O
in	O
males	O
.	O

The	O
lack	O
of	O
differentiation	O
of	O
underlying	O
complications	O
in	O
pregnancy	O
,	O
which	O
lead	O
to	O
eventual	O
use	O
of	O
induction	O
,	O
could	O
be	O
the	O
cause	O
of	O
these	O
conflicting	O
findings	O
[	O
51	O
].	O

Juul	O
-	O
Dam	O
et	O
al	O
.	O

summarized	O
causes	O
of	O
prolonged	O
labor	O
,	O
including	O
“	O
fetal	O
malposition	O
,	O
fetopelvic	O
disproportion	O
,	O
excess	O
sedation	O
,	O
inadequate	O
contraction	O
,	O
and	O
rupture	O
of	O
fetal	O
membranes	O
before	O
the	O
onset	O
of	O
active	O
labor	O
.”	O
However	O
,	O
these	O
complications	O
differ	O
in	O
severity	O
and	O
may	O
require	O
varied	O
quantity	O
of	O
induction	O
agent	O
used	O
at	O
distinctive	O
stages	O
of	O
labor	O
.	O

Further	O
research	O
is	O
necessary	O
to	O
differentiate	O
between	O
the	O
underlying	O
obstetric	O
complications	O
that	O
lead	O
to	O
the	O
eventual	O
use	O
of	O
induction	O
and	O
their	O
respective	O
potential	O
association	O
with	O
autism	O
[	O
52	O
].	O

2	O
.	O
11	O
.	O

Labor	O
Time	O
A	O
review	O
of	O
literature	O
found	O
limited	O
number	O
of	O
researches	O
on	O
the	O
topic	O
of	O
labor	O
time	O
and	O
autism	O
.	O

The	O
few	O
identified	O
studies	O
abound	O
with	O
conflicting	O
evidence	O
.	O

The	O
research	O
done	O
by	O
Glasson	O
et	O
al	O
.	O

purports	O
that	O
labor	O
duration	O
of	O
less	O
than	O
1	O
hour	O
carries	O
an	O
increased	O
risk	O
of	O
developing	O
ASD	O
[	O
8	O
].	O

On	O
the	O
other	O
hand	O
,	O
Wilkerson	O
et	O
al	O
.	O

found	O
that	O
a	O
prolonged	O
labor	O
(	O
greater	O
than	O
18	O
–	O
24	O
hours	O
)	O
resulted	O
in	O
an	O
increased	O
risk	O
for	O
autism	O
[	O
18	O
].	O

One	O
of	O
the	O
latest	O
cohort	O
studies	O
on	O
the	O
topic	O
that	O
involved	O
268	O
subjects	O
also	O
suggests	O
positive	O
association	O
between	O
prolonged	O
labor	O
and	O
autism	O
[	O
53	O
].	O

However	O
,	O
among	O
Gardener	O
et	O
al	O
.	O

'	O
s	O
meta	O
-	O
analysis	O
of	O
nine	O
studies	O
on	O
this	O
subject	O
,	O
five	O
have	O
neutral	O
results	O
,	O
only	O
three	O
have	O
positive	O
association	O
,	O
and	O
one	O
has	O
negative	O
association	O
[	O
57	O
].	O

Current	O
understanding	O
suggests	O
that	O
hypoxia	O
is	O
one	O
of	O
the	O
complications	O
of	O
prolonged	O
labor	O
,	O
along	O
with	O
infection	O
,	O
or	O
head	O
trauma	O
from	O
extended	O
pressure	O
.	O

All	O
of	O
these	O
complications	O
could	O
lead	O
to	O
permanent	O
damages	O
in	O
the	O
neonates	O
'	O
developing	O
brain	O
[	O
52	O
].	O

Neonatal	O
oxygen	O
deprivation	O
can	O
be	O
quantified	O
by	O
several	O
measurements	O
,	O
including	O
low	O
Apgar	O
score	O
,	O
fetal	O
distress	O
,	O
caesarian	O
delivery	O
,	O
threatened	O
abortion	O
,	O
and	O
hemorrhage	O
during	O
pregnancy	O
[	O
68	O
].	O

Four	O
large	O
cohort	O
studies	O
conducted	O
across	O
Sweden	O
,	O
Australia	O
,	O
and	O
Denmark	O
found	O
that	O
an	O
Apgar	O
score	O
of	O
7	O
has	O
a	O
strong	O
predictive	O
value	O
of	O
autism	O
[	O
18	O
,	O
54	O
–	O
56	O
];	O
similar	O
findings	O
were	O
reported	O
by	O
Garderner	O
et	O
al	O
.	O

[	O
57	O
].	O

Finally	O
,	O
Guinchat	O
et	O
al	O
.	O

[	O
2	O
]	O
hypothesize	O
that	O
the	O
increased	O
prevalence	O
of	O
autism	O
may	O
be	O
in	O
part	O
due	O
to	O
higher	O
success	O
in	O
obstetric	O
and	O
neonatal	O
care	O
,	O
which	O
resulted	O
in	O
an	O
increased	O
survival	O
rates	O
of	O
hypoxic	O
neonates	O
with	O
brain	O
damage	O
.	O

In	O
summary	O
,	O
some	O
investigations	O
have	O
shown	O
an	O
association	O
between	O
length	O
of	O
labor	O
and	O
autism	O
,	O
but	O
findings	O
have	O
been	O
inconsistent	O
owing	O
to	O
differences	O
in	O
sampling	O
and	O
methods	O
.	O

While	O
there	O
is	O
still	O
room	O
for	O
much	O
further	O
research	O
,	O
current	O
understanding	O
suggests	O
that	O
length	O
of	O
labor	O
is	O
possibly	O
associated	O
with	O
autism	O
.	O

Prolonged	O
delivery	O
due	O
to	O
oversedation	O
,	O
inappropriate	O
position	O
of	O
the	O
fetus	O
,	O
and	O
unbalanced	O
fetopelvic	O
size	O
and	O
oversedation	O
,	O
which	O
results	O
in	O
induction	O
,	O
can	O
play	O
a	O
role	O
.	O

It	O
is	O
also	O
possible	O
that	O
children	O
who	O
become	O
autistic	O
may	O
also	O
be	O
slow	O
to	O
deliver	O
that	O
the	O
prolonged	O
delivery	O
is	O
a	O
symptom	O
of	O
,	O
rather	O
than	O
a	O
cause	O
of	O
,	O
autism	O
.	O

3	O
.	O

Conclusion	O
In	O
summary	O
,	O
several	O
attributes	O
of	O
the	O
perinatal	O
and	O
labor	O
experiences	O
may	O
be	O
associated	O
with	O
the	O
development	O
of	O
autism	O
.	O

Yet	O
,	O
importantly	O
,	O
these	O
factors	O
may	O
work	O
separately	O
or	O
may	O
work	O
together	O
with	O
other	O
stimuli	O
.	O
Table	O
1provides	O
a	O
summary	O
of	O
the	O
findings	O
in	O
the	O
studies	O
explored	O
in	O
this	O
article	O
.	O

While	O
association	O
between	O
β	O
2	O
adrenergic	O
receptor	O
agonists	O
and	O
autism	O
spectrum	O
disorders	O
is	O
not	O
strong	O
,	O
exposure	O
to	O
terbutaline	O
during	O
the	O
third	O
trimester	O
has	O
shown	O
to	O
increase	O
incidence	O
.	O

Furthermore	O
terbutaline	O
has	O
been	O
shown	O
to	O
increase	O
microglial	O
activation	O
associated	O
with	O
behavioral	O
abnormalities	O
akin	O
to	O
autism	O
.	O

Labor	O
induction	O
and	O
augmentation	O
appear	O
to	O
be	O
an	O
area	O
of	O
association	O
.	O

While	O
one	O
study	O
showed	O
that	O
children	O
whose	O
mothers	O
received	O
augmented	O
and	O
/	O
or	O
induced	O
childbirth	O
showed	O
a	O
greater	O
risk	O
for	O
autism	O
compared	O
with	O
controls	O
,	O
further	O
research	O
is	O
needed	O
to	O
prove	O
an	O
association	O
.	O

The	O
role	O
of	O
maternal	O
disease	O
cannot	O
be	O
ignored	O
as	B
antiphospholipid	O
syndrome	O
and	O
perinatal	O
inflammation	O
may	O
have	O
important	O
roles	O
in	O
the	O
eventual	O
development	O
of	O
autism	O
.	O

Antiepileptic	O
drugs	O
and	O
oral	O
supplements	O
may	O
play	O
a	O
role	O
in	O
later	O
onset	O
.	O

Cocaine	O
has	O
been	O
associated	O
with	O
an	O
increase	O
in	O
the	O
onset	O
of	O
neurodevelopmental	O
abnormalities	O
,	O
but	O
the	O
direct	O
influence	O
on	O
autism	O
development	O
is	O
still	O
lacking	O
.	O

While	O
a	O
link	O
between	O
smoking	O
and	O
autism	O
could	O
not	O
be	O
established	O
,	O
air	O
pollution	O
may	O
have	O
a	O
role	O
.	O

Several	O
studies	O
have	O
implicated	O
SSRIs	O
in	O
autism	O
,	O
but	O
a	O
larger	O
recent	O
cohort	O
study	O
showed	O
no	O
association	O
.	O

Artificial	O
insemination	O
and	O
fertility	O
medications	O
were	O
largely	O
found	O
to	O
have	O
to	O
link	O
,	O
yet	O
reports	O
are	O
conflicted	O
.	O

Prolonged	O
labor	O
may	O
also	O
lead	O
to	O
neurological	O
deficits	O
and	O
thus	B
autism	O
.	O

Attributes	O
of	O
the	O
delivery	O
room	O
and	O
birthing	O
experience	O
also	O
may	O
have	O
a	O
role	O
in	O
autism	O
.	O

While	O
some	O
evidence	O
suggests	O
that	O
meconium	O
aspiration	O
syndrome	O
may	O
have	O
a	O
link	O
as	O
a	O
contributing	O
factor	O
,	O
more	O
studies	O
are	O
needed	O
.	O

Birth	O
weight	O
,	O
gestational	O
age	O
,	O
and	O
preterm	O
birth	O
may	O
correlate	O
with	O
autism	O
and	O
intellectual	O
disabilities	O
.	O

The	O
identification	O
of	O
prenatal	O
factors	O
that	O
are	O
linked	O
to	O
autism	O
may	O
serve	O
as	O
a	O
paradigm	O
shift	O
in	O
our	O
current	O
view	O
and	O
management	O
of	O
autism	O
.	O

The	O
fact	O
that	O
several	O
risk	O
factors	O
during	O
the	O
prenatal	O
and	O
labor	O
periods	O
are	O
implicated	O
in	O
autism	O
should	O
prompt	O
the	O
medical	O
community	O
to	O
focus	O
on	O
the	O
pregnancy	O
and	O
labor	O
periods	O
as	O
preventive	O
measures	O
to	O
curb	O
the	O
incidence	O
of	O
autism	O
.	O

PubMed	O
Central	O
:	O

Mother	O
’	O
s	O
Milk	O
and	O
the	O
Environment	O
:	O
Might	O
Chemical	O
Exposures	O
Impair	O
Lactation	O
?	O

Most	O
studies	O
on	O
breastfeeding	O
over	O
the	O
past	O
few	O
decades	O
have	O
focused	O
on	O
the	O
advantages	O
of	O
breastfeeding	O
and	O
how	O
to	O
get	O
more	O
women	O
to	O
breastfeed	O
their	O
babies	O
.	O

Relatively	O
few	O
women	O
worldwide	O
meet	O
the	O
World	O
Health	O
Organization	O
’	O
s	O
recommendation	O
that	O
infants	O
breastfeed	O
exclusively	O
for	O
the	O
first	O
6	O
months	O
of	O
life	O
,	O
with	O
continued	O
breastfeeding	O
combined	O
with	O
appropriate	O
foods	O
thereafter	O
for	O
2	O
years	O
or	O
more1	O
—	O
even	O
those	O
who	O
intend	O
to	O
do	O
so	O
at	O
the	O
outset	O
.	O

Many	O
factors	O
influence	O
how	O
long	O
a	O
mother	O
nurses	O
,	O
but	O
new	O
mothers	O
often	B
state	O
a	O
common	B
problem	O
when	O
asked	O
why	O
they	O
quit	O
breastfeeding	O
earlier	O
than	O
they	O
wanted	O
:	O
They	O
can	O
’	O
t	O
produce	O
enough	O
milk	O
.	O
2	O
Caption	O
(	O
FIG	O
)	O
New	O
mothers	O
who	O
quit	O
breastfeeding	O
earlier	O
than	O
they	O
had	O
wanted	O
often	B
chalk	O
it	O
up	O
to	O
not	O
being	O
able	O
to	O
produce	O
enough	O
milk	O
.	O

But	O
a	O
handful	O
of	O
researchers	O
are	O
exploring	O
whether	O
certain	O
environmental	O
exposures	O
may	O
affect	O
some	O
women	O
’	O
s	O
ability	O
to	O
lactate	O
.	O

©	O
Tony	O
Anderson	O
/	O
Getty	O
Images	O
There	O
is	O
much	O
about	O
lactation	O
that	O
remains	O
unknown	O
.	O

We	O
know	O
a	O
lot	O
about	O
the	O
benefits	O
of	O
breastfeeding	O
for	O
mothers	O
and	O
babies	O
,	O
says	O
Alison	O
Stuebe	O
,	O
an	O
obstetrician	O
/	O
gynecologist	O
at	O
the	O
University	O
of	O
North	O
Carolina	O
School	O
of	O
Medicine	O
,	O
but	O
“	O
we	O
know	O
far	O
less	O
than	O
we	O
should	O
about	O
how	O
the	O
breast	O
functions	O
in	O
lactation	O
and	O
what	O
specific	O
factors	O
might	O
be	O
making	O
it	O
harder	O
than	O
evolution	O
had	O
intended	O
.”	O
“	O
Very	O
few	O
studies	O
have	O
looked	O
at	O
the	O
factors	O
that	O
may	O
interfere	O
with	O
lactation	O
,”	O
agrees	O
Philippe	O
Grandjean	O
,	O
an	O
epidemiologist	O
at	O
the	O
Harvard	O
School	O
of	O
Public	O
Health	O
and	O
the	O
University	O
of	O
Southern	O
Denmark	O
.	O

Grandjean	O
and	O
others	O
have	O
begun	O
to	O
investigate	O
the	O
potential	O
impacts	O
of	O
chemical	O
exposures	O
on	O
the	O
process	O
of	O
lactation	O
itself	O
.	O

A	O
burgeoning	O
body	O
of	O
research	O
—	O
from	O
rodent	O
toxicology	O
to	O
human	O
epidemiology	O
studies	O
—	O
suggests	O
that	O
certain	O
environmental	O
exposures	O
may	O
impair	O
a	O
mother	O
’	O
s	O
ability	O
to	O
nurse	O
her	O
child	O
.	O

Current	O
Thinking	O
on	O
Low	O
Milk	O
Production	O
Standard	O
lactation	O
support	O
guidelines3are	B
based	B
on	I
the	O
assumption	O
that	O
virtually	B
any	O
woman	O
can	O
breastfeed	O
normally	B
.	O

“	O
The	O
conventional	B
wisdom	I
has	O
been	O
that	O
mothers	O
’	O
worries	O
about	O
milk	O
supply	O
are	O
due	B
either	I
to	I
their	O
misperception	O
of	O
normal	O
lactation	O
and	O
infant	O
breastfeeding	O
behaviors	O
or	O
to	O
mismanagement	O
of	O
breastfeeding	O
technique	O
,	O
and	O
only	O
on	O
very	O
rare	O
occasions	O
due	B
to	I
an	O
intrinsic	O
inability	O
to	O
make	O
enough	O
milk	O
,”	O
says	O
Laurie	O
Nommsen	O
-	O
Rivers	O
,	O
a	O
perinatal	O
nutrition	O
specialist	O
at	O
the	O
University	O
of	O
Cincinnati	O
College	O
of	O
Allied	O
Health	O
Sciences	O
.	O

This	O
belief	B
among	O
public	O
health	O
and	O
medical	O
professional	O
is	O
justifiable	B
,	O
says	O
Nommsen	O
-	O
Rivers	O
,	O
because	B
formula	O
companies	O
have	O
a	O
long	O
history	O
of	O
dubious	O
marketing	O
practices	O
that	O
can	O
undermine	O
a	O
woman	O
’	O
s	O
confidence	O
in	O
her	O
ability	O
to	O
nourish	O
her	O
baby	O
without	O
the	O
use	O
of	O
their	O
products	O
.	O
4	O
,	O
5Breastfeeding	O
rates	O
began	O
to	O
dwindle	O
worldwide	O
with	O
the	O
advent	O
of	O
infant	O
formula	O
in	O
the	O
1860s	O
.	O
4They	O
reached	O
an	O
all	O
-	O
time	O
low	O
in	O
the	O
United	O
States	O
in	O
1971	O
,	O
when	O
fewer	O
than	O
25	O
%	O
of	O
new	O
mothers	O
initiated	O
breastfeeding	O
at	O
all	O
,	O
and	O
only	O
5	O
%	O
of	O
mothers	O
were	O
still	O
breastfeeding	O
at	O
6	O
months	O
.	O
6Today	O
,	O
largely	O
due	B
to	I
parent	O
education	O
efforts	O
and	O
improved	O
support	O
for	O
lactating	O
mothers	O
,	O
more	O
than	O
75	O
%	O
of	O
U	O
.	O
S	O
.	O
mothers	O
initiate	O
breastfeeding	O
,	O
and	O
about	O
20	O
%	O
of	O
U	O
.	O
S	O
.	O
babies	O
are	O
breastfed	O
exclusively	O
through	O
6	O
months	O
.	O
7	O
Robust	O
milk	O
production	O
depends	O
on	O
frequent	O
and	O
thorough	O
draining	O
of	O
the	O
breast	O
through	O
suckling	O
or	O
pumping	O
.	O

So	B
a	O
perceived	B
problem	O
with	O
supply	O
can	O
quickly	O
become	O
a	O
real	O
problem	O
once	O
a	O
mother	O
introduces	O
formula	O
and	O
the	O
frequency	O
of	O
breastfeeding	O
declines	O
,	O
especially	O
if	O
formula	O
is	O
offered	O
while	O
a	O
mother	O
is	O
still	O
trying	O
to	O
establish	O
her	O
milk	O
supply	O
.	O
8	O
To	O
complicate	O
matters	O
,	O
a	O
number	O
of	O
key	O
socioeconomic	O
,	O
cultural	O
,	O
and	O
clinical	O
factors	O
also	O
can	O
prevent	O
some	O
women	O
from	O
breastfeeding	O
as	O
long	O
as	O
they	O
would	O
like	O
.	O

Such	O
barriers	O
may	O
include	O
lack	O
of	O
prenatal	O
education	O
about	O
breastfeeding	O
,	O
inadequate	O
lactation	O
support	O
from	O
healthcare	O
providers	O
after	O
delivery	O
,	O
disapproval	O
from	O
spouses	O
or	O
family	O
members	O
,	O
short	O
maternity	O
leave	O
,	O
and	O
few	O
opportunities	O
to	O
pump	O
at	O
work	O
.	O

Lactation	O
support	O
includes	O
breastfeeding	O
-	O
related	O
counseling	O
and	O
education	O
from	O
trained	O
specialists	O
both	O
in	O
the	O
hospital	O
shortly	O
after	O
birth	O
and	O
at	O
home	O
for	O
the	O
first	O
months	O
of	O
the	O
baby	O
’	O
s	O
life	O
.	O
9	O
While	O
an	O
absolute	O
inability	O
to	O
lactate	O
is	O
rare	O
,	O
estimated	O
to	O
occur	O
in	O
less	O
than	O
2	O
%	O
of	O
mothers	O
,	O
10	O
“	O
we	O
have	O
no	O
idea	O
about	O
the	O
prevalence	O
of	O
women	O
who	O
are	O
lactating	O
less	O
than	O
optimally	O
,	O
who	O
may	O
be	O
unable	O
to	O
exclusively	O
breastfeed	O
a	O
baby	O
no	O
matter	O
how	O
frequently	O
and	O
thoroughly	O
they	O
breastfeed	O
,”	O
says	O
Nommsen	O
-	O
Rivers	O
.	O

Stuebe	O
’	O
s	O
research	O
suggests	O
that	O
as	B
many	I
1	O
in	O
8	O
women	O
wean	O
earlier	O
than	O
they	O
want	O
to	O
,	O
despite	O
receiving	O
lactation	O
care	O
.	O
11Yet	O
there	O
are	O
no	O
real	O
tests	O
to	O
measure	O
optimal	O
breast	O
function	O
,	O
she	O
says	O
.	O

When	O
a	O
woman	O
struggles	O
,	O
Stuebe	O
says	O
,	O
“	O
she	O
is	O
often	B
told	O
to	O
try	O
harder	O
.”	O
Early	O
Environmental	O
Clues	O
In	O
1949	O
Morton	O
Biskind	O
,	O
a	O
Connecticut	O
physician	O
,	O
treated	O
a	O
pregnant	O
patient	O
with	O
acute	O
DDT	O
poisoning	O
.	O

After	O
the	O
woman	O
gave	O
birth	O
and	O
began	O
to	O
breastfeed	O
,	O
Biskind	O
noted	O
that	O
her	O
symptoms	O
,	O
which	O
included	O
vomiting	O
,	O
abdominal	O
pain	O
,	O
hyper	O
-	O
irritability	O
,	O
and	O
muscle	O
weakness	O
,	O
began	O
to	O
dissipate	O
.	O

When	O
he	O
analyzed	O
her	O
milk	O
,	O
he	O
found	O
it	O
contained	O
exorbitant	O
levels	O
of	O
DDT	O
.	O
12	O
Two	O
years	O
later	O
,	O
researchers	O
examined	O
milk	O
samples	O
from	O
32	O
black	O
women	O
at	O
a	O
Washington	O
,	O
DC	O
,	O
hospital	O
.	O
13None	O
of	O
the	O
women	O
worked	O
with	O
pesticides	O
or	O
reported	O
an	O
acute	O
exposure	O
to	O
DDT	O
,	O
yet	O
their	O
milk	O
contained	O
trace	O
amounts	O
of	O
the	O
chemical	O
.	O

The	O
study	O
provided	O
the	O
first	O
scientific	O
evidence	O
that	O
even	O
low	O
-	O
level	O
exposures	O
to	O
environmental	O
chemicals	O
could	O
contaminate	O
human	O
milk	O
.	O

By	O
1978	O
environmental	O
chemicals	O
were	O
known	O
to	O
be	O
widespread	O
contaminants	O
in	O
human	O
milk	O
.	O

Researchers	O
at	O
the	O
National	O
Institute	O
of	O
Environmental	O
Health	O
Sciences	O
initiated	O
the	O
North	O
Carolina	O
Breast	O
Milk	O
and	O
Formula	O
Project	O
.	O

Led	O
by	O
institute	O
scientists	O
Walter	O
Rogan	O
and	O
Beth	O
Gladen	O
,	O
both	O
now	O
retired	O
,	O
the	O
study	O
aimed	O
to	O
gather	O
data	O
on	O
health	O
effects	O
in	O
infants	O
who	O
were	O
exposed	O
via	O
breast	O
milk	O
to	O
polychlorinated	O
biphenyls	O
(	O
PCBs	O
)	O
and	O
to	O
DDT14	O
—	O
which	O
by	O
then	O
had	O
been	O
banned	O
.	O

The	O
researchers	O
studied	O
858	O
mother	O
–	O
infant	O
pairs	O
between	O
1978	O
and	O
1982	O
.	O

They	O
collected	O
milk	O
samples	O
at	O
multiple	O
points	O
throughout	O
lactation	O
and	O
estimated	O
concentrations	O
of	O
PCBs	O
and	O
DDE	O
(	O
a	O
breakdown	O
product	O
of	O
DDT	O
)	O
in	O
milk	O
at	O
birth	O
.	O

Then	O
they	O
compared	O
concentrations	O
of	O
these	O
compounds	O
in	O
mother	O
’	O
s	O
milk	O
to	O
outcomes	O
of	O
child	O
health	O
,	O
growth	O
,	O
and	O
development	O
.	O

While	O
neither	O
PCBs	O
nor	O
DDE	O
were	O
associated	O
with	O
a	O
discernible	O
difference	O
in	O
how	O
much	O
weight	O
the	O
infant	O
gained	O
or	O
the	O
number	O
of	O
doctor	O
visits	O
for	O
illnesses	O
in	O
the	O
first	O
year	O
of	O
life	O
,	O
the	O
researchers	O
did	O
note	O
one	O
surprising	O
result	O
:	O
The	O
median	O
duration	O
of	O
breastfeeding	O
was	O
shorter	O
in	O
mothers	O
with	O
higher	O
estimated	O
levels	O
of	O
DDE	O
in	O
their	O
milk	O
compared	O
with	O
mothers	O
who	O
had	O
lower	O
levels	O
,	O
an	O
association	O
that	O
was	O
not	O
seen	O
with	O
PCBs	O
.	O

They	O
speculated	O
that	O
“	O
DDE	O
may	O
be	O
interfering	O
with	O
the	O
mother	O
’	O
s	O
ability	O
to	O
lactate	O
,	O
possibly	O
because	B
of	O
its	O
estrogenic	O
properties	O
.”	O
14	O
Over	O
the	O
next	O
three	O
decades	O
,	O
these	O
and	O
other	O
researchers	O
tried	O
to	O
replicate	O
the	O
findings	O
of	O
the	O
North	O
Carolina	O
study	O
.	O

Their	O
work	O
turned	O
up	O
mixed	O
results	O
,	O
which	O
are	O
hard	O
to	O
compare	O
due	O
to	O
differences	O
in	O
study	O
design	O
,	O
such	O
as	O
the	O
timing	O
of	O
sample	O
collection	O
.	O

For	O
example	O
,	O
in	O
a	O
study	O
of	O
women	O
and	O
infants	O
living	O
in	O
a	O
cotton	O
-	O
growing	O
region	O
of	O
northern	O
Mexico	O
where	O
DDT	O
was	O
heavily	O
used	O
,	O
Gladen	O
and	O
Rogan	O
found	O
that	O
women	O
with	O
the	O
lowest	O
DDE	O
levels	O
in	O
their	O
milk	O
shortly	O
after	O
birth	O
nursed	O
for	O
a	O
median	O
of	O
7	O
.	O
5	O
months	O
,	O
while	O
mothers	O
with	O
the	O
highest	O
DDE	O
levels	O
nursed	O
for	O
a	O
median	O
of	O
only	O
3	O
months	O
.	O
15A	O
study	O
in	O
Michigan	O
estimated	O
serum	O
levels	O
of	O
DDE	O
at	O
the	O
time	O
of	O
pregnancy	O
based	O
on	I
sampling	O
conducted	O
after	O
birth	O
.	O

Among	O
primiparous	O
(	O
first	O
-	O
time	O
)	O
mothers	O
,	O
women	O
with	O
the	O
highest	O
estimated	O
serum	O
levels	O
of	O
DDE	O
at	O
delivery	O
breastfed	O
for	O
a	O
median	O
of	O
13	O
.	O
0	O
weeks	O
,	O
compared	O
with	O
a	O
median	O
of	O
30	O
.	O
3	O
weeks	O
for	O
women	O
with	O
the	O
lowest	O
levels	O
;	O
among	O
multiparous	O
mothers	O
—	O
women	O
who	O
had	O
given	O
birth	O
previously	O
—	O
these	O
numbers	O
were	O
13	O
.	O
0	O
and	O
21	O
.	O
7	O
weeks	O
,	O
respectively	O
.	O

These	O
associations	O
were	O
strongest	O
in	O
nonsmokers	O
.	O
16	O
Caption	O
(	O
FIG	O
)	O
Lactation	O
support	O
includes	O
teaching	O
women	O
techniques	O
to	O
breastfeed	O
and	O
build	O
their	O
milk	O
supply	O
,	O
as	O
well	O
as	O
reassuring	O
them	O
of	O
their	O
ability	O
to	O
nourish	O
their	O
infants	O
.	O

©	O
Phanie	O
/	O
Alamy	O
Stock	O
Photo	O
Caption	O
(	O
FIG	O
)	O
Education	O
and	O
counseling	O
have	O
been	O
important	O
tools	O
in	O
boosting	O
breastfeeding	O
rates	O
,	O
after	O
decades	O
of	O
marketing	O
messages	O
that	O
insinuated	O
breast	O
milk	O
was	O
insufficient	O
to	O
nourish	O
young	O
babies	O
.	O

Mellin	O
’	O
s	O
Food	O
Company	O
On	O
the	O
other	O
hand	O
,	O
two	O
other	O
studies	O
found	O
no	O
association	O
between	O
DDE	O
/	O
DDT	O
and	O
shortened	O
lactation	O
time	O
.	O

One	O
of	O
the	O
studies	O
looked	O
at	O
serum	O
levels	O
in	O
samples	O
collected	O
from	O
Mexican	O
mothers	O
within	O
a	O
day	O
of	O
birth	O
,	O
17while	O
the	O
other	O
used	O
maternal	O
serum	O
samples	O
collected	O
during	O
the	O
second	O
trimester	O
from	O
Mexican	O
-	O
American	O
women	O
who	O
lived	O
in	O
California	O
’	O
s	O
Salinas	O
Valley	O
,	O
a	O
major	O
agricultural	O
region	O
.	O
18	O
Reverse	O
causality	O
is	O
a	O
major	O
concern	O
in	O
environmental	O
health	O
research	O
,	O
and	O
Amalie	O
Timmermann	O
,	O
a	O
research	O
assistant	O
in	O
the	O
Department	O
of	O
Environmental	O
Medicine	O
at	O
the	O
University	O
of	O
Southern	O
Denmark	O
,	O
points	O
it	O
out	O
as	B
a	O
potential	O
explanation	O
for	O
findings	O
in	O
studies	O
such	O
as	O
these	O
.	O

When	O
a	O
woman	O
lactates	O
,	O
she	O
reduces	O
her	O
own	O
body	O
burden	O
of	O
certain	O
chemicals	O
by	O
transferring	O
them	O
to	O
her	O
nursing	O
child	O
via	O
milk	O
.	O

Therefore	B
,	O
women	O
who	O
have	O
already	O
breastfed	O
or	O
those	O
who	O
breastfeed	O
longer	O
could	O
have	O
lower	O
levels	O
of	O
chemicals	O
in	O
their	O
bodies	O
simply	O
because	B
they	O
have	O
already	O
excreted	O
some	O
of	O
their	O
body	O
burden	O
,	O
not	O
because	B
lower	O
exposures	O
allowed	O
them	O
to	O
lactate	O
normally	O
.	O

Caption	O
(	O
FIG	O
)	O
Introduced	O
in	O
the	O
1940s	O
,	O
DDT	O
was	O
widely	O
used	O
until	O
it	O
was	O
banned	O
for	O
most	O
uses	O
in	O
the	O
1970s	O
.	O

The	O
1949	O
discovery	O
of	O
DDT	O
in	O
breast	O
milk	O
was	O
an	O
early	O
glimpse	O
into	O
the	O
understanding	O
that	O
a	O
mother	O
’	O
s	O
environmental	O
exposures	O
may	O
also	O
affect	O
her	O
baby	O
.	O

Courtesy	O
U	O
.	O
S	O
.	O
National	O
Archives	O
There	O
are	O
other	O
reasons	B
why	O
reported	O
associations	O
may	O
not	O
actually	O
reveal	O
much	O
about	O
environmental	O
impacts	O
on	O
lactation	O
.	O

For	O
example	O
,	O
Michael	O
Kramer	O
,	O
a	O
perinatal	O
epidemiologist	O
at	O
McGill	O
University	O
in	O
Montreal	O
,	O
points	O
out	O
that	O
investigators	O
are	O
more	O
likely	B
to	O
submit	O
,	O
and	O
journal	O
editors	O
to	O
accept	O
,	O
papers	O
reporting	O
significant	O
associations	O
than	O
those	O
showing	O
no	O
such	O
association	O
—	O
a	O
phenomenon	O
known	B
as	O
publication	O
bias	O
,	O
which	O
can	O
affect	O
observational	O
studies	O
in	O
any	O
field	O
.	O

He	O
also	O
suggests	O
that	O
if	O
a	O
lactating	O
mother	O
were	O
informed	O
of	O
the	O
contaminant	O
levels	O
in	O
her	O
milk	O
,	O
she	O
may	O
be	O
scared	O
to	O
continue	O
breastfeeding	O
or	O
even	O
discouraged	O
from	O
doing	O
so	O
by	O
her	O
healthcare	O
provider	O
.	O

New	O
Evidence	O
Emerges	O
For	O
nearly	O
30	O
years	O
Philippe	O
Grandjean	O
has	O
led	O
studies	O
on	O
the	O
effects	O
of	O
marine	O
contaminants	O
on	O
the	O
health	O
of	O
adults	O
and	O
children	O
in	O
the	O
Faroe	O
Islands	O
,	O
19an	O
archipelago	O
in	O
the	O
North	O
Atlantic	O
about	O
halfway	O
between	O
Scotland	O
and	O
Iceland	O
.	O

Among	O
other	O
findings	O
,	O
Grandjean	O
’	O
s	O
team	O
linked	O
postnatal	O
exposure	O
to	O
a	O
group	O
of	O
chemicals	O
called	O
perfluoroalkyl	O
substances	O
(	O
PFASs	O
)	O
with	O
lower	O
immune	O
response	O
to	O
tetanus	O
and	O
diphtheria	O
vaccinations	O
in	O
Faroese	O
children	O
.	O
20PFASs	O
are	O
widely	O
used	O
chemicals	O
that	O
build	O
up	O
in	O
the	O
bodies	O
of	O
humans	O
and	O
other	O
animals	O
.	O

They	O
are	O
present	O
in	O
most	O
humans	O
and	O
are	O
found	O
in	O
breast	O
milk	O
.	O
21	O
Grandjean	O
wanted	O
to	O
know	O
how	O
breastfeeding	O
correlated	O
with	O
some	O
of	O
the	O
child	O
health	O
outcomes	O
his	O
group	O
had	O
observed	O
.	O

“	O
We	O
started	O
to	O
look	O
at	O
breastfeeding	O
as	B
a	O
confounding	O
factor	O
in	O
our	O
studies	O
primarily	B
because	B
it	O
is	O
known	O
to	O
be	O
beneficial	O
to	O
child	O
health	O
,”	O
he	O
says	O
.	O

Not	B
surprisingly	I
,	O
they	O
found	O
that	O
children	O
who	O
breastfed	O
longer	O
had	O
higher	O
levels	O
of	O
PFASs	O
in	O
their	O
blood	O
.	O

When	O
Grandjean	O
and	O
his	O
team	O
dug	O
a	O
little	O
deeper	O
,	O
they	O
saw	O
that	O
women	O
with	O
the	O
highest	O
PFAS	O
levels	O
in	O
their	O
blood	O
tended	O
to	O
spend	O
less	O
time	O
breastfeeding	O
their	O
babies	O
.	O
22	O
In	O
the	O
study	O
,	O
led	O
by	O
Timmermann	O
—	O
who	O
at	O
the	O
time	O
was	O
pursuing	O
her	O
PhD	O
under	O
Grandjean	O
’	O
s	O
supervision	O
—	O
the	O
researchers	O
estimated	O
the	O
average	O
duration	O
of	O
total	O
breastfeeding	O
(	O
i	O
.	O
e	O
.,	O
with	O
or	O
without	O
any	O
other	O
sources	O
of	O
nutrition	O
)	O
in	O
association	O
with	O
serum	O
levels	O
of	O
two	O
PFASs	O
,	O
perfluorooctane	O
sulfonic	O
acid	O
(	O
PFOS	O
)	O
and	O
perfluorooctanoic	O
acid	O
(	O
PFOA	O
).	O

The	O
study	O
combined	O
two	O
cohorts	O
,	O
and	O
serum	O
samples	O
were	O
collected	O
late	O
in	O
pregnancy	O
or	O
approximately	O
2	O
weeks	O
after	O
birth	O
.	O

Timmermann	O
and	O
colleagues	O
estimated	O
that	O
breastfeeding	O
was	O
1	O
.	O
4	O
months	O
shorter	O
when	O
women	O
’	O
s	O
serum	O
levels	O
of	O
PFOS	O
were	O
doubled	O
and	O
1	O
.	O
3	O
months	O
shorter	O
when	O
their	O
levels	O
of	O
PFOA	O
were	O
doubled	O
.	O

The	O
PFAS	O
levels	O
of	O
the	O
Faroese	O
women	O
were	O
comparable	O
to	O
levels	O
reported	O
for	O
pregnant	O
women	O
in	O
Denmark	O
and	O
lower	O
than	O
those	O
reported	O
for	O
a	O
group	O
of	O
U	O
.	O
S	O
.	O
pregnant	O
women	O
.	O
22	O
The	O
findings	O
echoed	O
a	O
2010	O
Danish	O
national	O
study	O
,	O
which	O
found	O
associations	O
between	O
higher	O
levels	O
of	O
PFASs	O
in	O
maternal	O
serum	O
samples	O
and	O
shorter	O
duration	O
of	O
breastfeeding	O
.	O
23Yet	O
the	O
Danish	O
study	O
found	O
that	O
this	O
association	O
held	O
true	B
only	O
for	O
multiparous	O
women	O
,	O
and	O
not	O
primiparous	O
mothers	O
.	O

In	O
contrast	O
,	O
in	O
the	O
Faroe	O
Islands	O
study	O
researchers	O
found	O
that	O
exposure	O
to	O
PFASs	O
was	O
associated	O
with	O
shorter	O
breastfeeding	O
duration	O
among	O
both	O
primiparous	O
and	O
multiparous	O
mothers	O
.	O

“	O
This	O
gives	B
us	O
more	O
confidence	I
that	O
the	O
association	O
is	O
not	B
due	O
to	I
reverse	O
causation	O
and	O
is	O
real	O
,”	O
says	O
Timmermann	O
.	O

Meanwhile	O
,	O
in	O
the	O
United	O
States	O
,	O
another	O
team	O
of	O
researchers	O
pursued	O
a	O
similar	O
line	O
of	O
investigation	O
.	O

Megan	O
Romano	O
,	O
then	O
a	O
postdoctoral	O
research	O
associate	O
at	O
Brown	O
University	O
,	O
looked	O
at	O
336	O
women	O
who	O
gave	O
birth	O
at	O
Cincinnati	O
hospitals	O
.	O

Sampling	O
during	O
pregnancy	O
and	O
delivery	O
showed	O
that	O
the	O
women	O
had	O
unusually	O
high	O
serum	O
levels	O
of	O
PFOA	O
—	O
twice	O
the	O
U	O
.	O
S	O
.	O
average	O
—	O
possibly	O
due	B
to	I
the	O
presence	O
of	O
a	O
chemical	O
plant	O
nearby	O
.	O

Caption	O
(	O
FIG	O
)	O
Many	O
studies	O
on	O
DDT	O
exposures	O
and	O
lactation	O
have	O
been	O
conducted	O
with	O
populations	O
of	O
Hispanic	O
women	O
who	O
work	O
on	O
farms	O
or	O
live	O
in	O
agricultural	O
areas	O
.	O

The	O
results	O
from	O
these	O
and	O
other	O
lactation	O
studies	O
have	O
been	O
mixed	O
.	O

©	O
David	O
Litman	O
/	O
Shutterstock	O
.	O
com	O
Romano	O
and	O
colleagues	O
reported	O
that	O
women	O
with	O
the	O
highest	O
PFOA	O
levels	O
were	O
77	O
%	O
more	O
likely	B
to	O
stop	O
exclusive	O
breastfeeding	O
by	O
3	O
months	O
and	O
41	O
%	O
more	O
likely	B
to	O
stop	O
by	O
6	O
months	O
than	O
women	O
with	O
the	O
lowest	O
levels	O
.	O

More	O
than	O
three	O
-	O
quarters	O
of	O
the	O
Cincinnati	O
women	O
breastfed	O
exclusively	O
for	O
less	O
than	O
1	O
month	O
.	O

Roughly	O
two	O
-	O
thirds	O
of	O
the	O
participants	O
were	O
white	O
,	O
and	O
half	O
had	O
attained	O
a	O
college	O
degree	O
or	O
higher	O
.	O

PFAS	O
levels	O
were	O
similar	O
across	O
women	O
’	O
s	O
reported	O
reasons	O
for	O
ending	O
breastfeeding	O
,	O
and	O
the	O
researchers	O
saw	O
no	O
clear	O
differences	O
between	O
primiparous	O
and	O
multiparous	O
mothers	O
.	O
24	O
“	O
You	O
have	O
three	O
studies	O
telling	O
a	O
similar	O
story	O
from	O
different	O
parts	O
of	O
the	O
world	O
.	O

I	O
think	O
it	O
is	O
cause	O
for	O
concern	O
,”	O
says	O
Romano	O
,	O
now	O
an	O
assistant	O
professor	O
at	O
the	O
Geisel	O
School	O
of	O
Medicine	O
at	O
Dartmouth	O
.	O

“	O
Unfortunately	O
,	O
we	O
don	O
’	O
t	O
have	O
a	O
good	O
understanding	O
of	O
what	O
could	O
be	O
going	O
on	O
‘	O
under	O
the	O
hood	O
’—	O
what	O
biological	O
mechanisms	O
could	O
be	O
driving	O
these	O
associations	O
,”	O
she	O
says	O
.	O

However	O
,	O
some	O
researchers	O
think	O
mammary	O
gland	O
development	O
and	O
maternal	O
metabolism	O
may	O
provide	B
some	O
clues	O
.	O

What	O
Might	O
Delay	O
Lactogenesis	O
?	O

Unlike	O
most	O
organs	O
,	O
which	O
develop	O
mostly	O
in	O
utero	O
,	O
the	O
mammary	O
gland	O
develops	O
in	O
stages	O
:	O
before	O
birth	O
,	O
at	O
puberty	O
,	O
and	O
in	O
pregnancy	O
.	O

In	O
that	O
final	O
stage	O
,	O
the	O
milk	O
duct	O
system	O
forms	O
in	O
preparation	O
for	O
lactation	O
and	O
breastfeeding	O
.	O

Changes	O
in	O
hormonal	O
levels	O
dictate	O
breast	O
development	O
at	O
each	O
step	O
.	O
25	O
“	O
We	O
know	O
from	O
animal	O
studies	O
that	O
there	O
are	O
chemicals	O
that	O
can	O
adversely	O
affect	O
breast	O
development	O
and	O
lactation	O
,”	O
says	O
Sue	O
Fenton	O
,	O
leader	O
of	O
the	O
Reproductive	O
Endocrinology	O
Group	O
at	O
the	O
National	O
Toxicology	O
Program	O
,	O
based	O
at	O
the	O
NIEHS	O
.	O

Fenton	O
and	O
colleagues	O
have	O
shown	O
that	O
gestational	O
exposure	O
to	O
PFOA	O
altered	O
the	O
normal	O
formation	O
of	O
the	O
milk	O
duct	O
system	O
in	O
mice	O
.	O
26In	O
a	O
multigenerational	O
mouse	O
follow	O
-	O
up	O
study	O
,	O
they	O
showed	O
that	O
PFOA	O
exposure	O
not	O
only	O
impaired	O
the	O
mouse	O
mothers	O
’	O
ability	O
to	O
lactate	O
,	O
but	O
also	O
adversely	O
affected	O
prenatal	O
development	O
of	O
the	O
mammary	O
gland	O
in	O
their	O
female	O
offspring	O
.	O

However	O
,	O
neither	O
study	O
was	O
designed	O
to	O
replicate	O
typical	O
human	O
exposures	O
to	O
PFOA	O
,	O
and	O
the	O
doses	O
were	O
much	O
higher	O
than	O
the	O
levels	O
people	O
are	O
typically	B
exposed	O
to	O
in	O
the	O
real	O
world	O
.	O
27	O
It	O
is	O
not	O
clear	O
whether	O
altered	O
development	O
of	O
the	O
mammary	O
gland	O
itself	O
or	O
disruptions	O
in	O
hormonal	O
status	O
are	O
responsible	B
for	O
the	O
negative	O
impacts	O
on	O
lactation	O
that	O
Fenton	O
observed	O
.	O

There	O
is	O
also	O
evidence	O
that	O
PFOA	O
can	O
alter	O
the	O
expression	O
of	O
milk	O
protein	O
genes	O
,	O
which	O
are	O
important	O
for	O
the	O
production	O
of	O
milk	O
.	O
26Fenton	O
further	O
notes	O
that	O
PFASs	O
are	O
only	O
one	O
class	O
of	O
environmental	O
chemicals	O
that	O
may	O
cause	O
concern	O
for	O
lactation	O
.	O
28	O
Poor	O
maternal	O
metabolic	O
health	O
may	O
be	O
another	O
factor	O
that	O
hampers	O
lactation	O
.	O

Multiple	O
national	O
cohort	O
studies	O
have	O
found	O
associations	O
between	O
maternal	O
obesity	O
and	O
shorter	O
duration	O
of	O
breastfeeding	O
,	O
29although	O
the	O
reasons	B
for	O
this	O
relationship	O
are	O
not	O
clear	O
.	O

Nommsen	O
-	O
Rivers	O
,	O
the	O
perinatal	O
nutrition	O
expert	O
from	O
the	O
University	O
of	O
Cincinnati	O
,	O
initiated	O
breastfeeding	O
studies	O
in	O
both	O
California	O
and	O
Ohio	O
,	O
which	O
were	O
part	O
of	O
the	O
World	O
Health	O
Organization	O
Multicentre	O
Growth	O
Reference	O
Study	O
.	O
30	O
“	O
Our	O
goal	O
was	O
to	O
enable	O
as	O
many	O
women	O
as	O
possible	O
to	O
follow	O
breastfeeding	O
guidelines	O
by	O
providing	O
lactation	O
support	O
,”	O
she	O
says	O
.	O

Yet	O
she	O
was	O
surprised	O
by	O
the	O
high	O
prevalence	O
of	O
delayed	O
lactogenesis	O
—	O
meaning	O
no	O
signs	O
of	O
copious	O
milk	O
production	O
within	O
the	O
first	O
72	O
hours	O
of	O
giving	O
birth	O
—	O
in	O
mothers	O
who	O
were	O
striving	O
to	O
breastfeed	O
exclusively	O
.	O
31	O
“	O
I	O
kept	O
thinking	O
,	O
how	O
did	O
our	O
species	O
survive	O
?”	O
she	O
says	O
.	O

“	O
It	O
’	O
s	O
not	O
supposed	B
to	O
be	O
this	O
hard	O
.”	O
Nommsen	O
-	O
Rivers	O
also	O
observed	O
a	O
cluster	O
of	O
variables	O
,	O
all	O
linked	O
with	O
glucose	O
intolerance	O
,	O
that	O
were	O
significantly	O
associated	O
with	O
delayed	O
lactogenesis	O
.	O

This	O
prompted	O
her	O
to	O
begin	O
investigating	O
the	O
role	O
of	O
insulin	O
in	O
stimulating	O
milk	O
production	O
.	O

Although	O
insulin	O
resistance	O
is	O
a	O
physiologic	O
hallmark	O
of	O
obesity	O
,	O
she	O
says	O
insulin	O
previously	O
was	O
thought	O
to	O
have	O
little	O
,	O
if	O
any	O
,	O
role	O
in	O
lactation	O
.	O

Caption	O
(	O
FIG	O
)	O
Maternal	O
obesity	O
has	O
been	O
associated	O
with	O
shorter	O
duration	O
of	O
breastfeeding	O
.	O

Although	O
the	O
explanation	B
for	O
this	O
association	O
is	O
still	O
unknown	O
,	O
studies	O
in	O
the	O
past	O
several	O
years	O
have	O
hinted	O
that	O
insulin	O
resistance	O
may	O
be	O
involved	O
in	O
reduced	O
lactation	O
.	O

©	O
BSIP	O
/	O
UIG	O
/	O
Getty	O
Images	O
She	O
found	O
that	O
measures	O
of	O
glucose	O
intolerance	O
predicted	O
delayed	O
lactogenesis	O
in	O
a	O
group	O
of	O
primiparous	O
Sacramento	O
-	O
area	O
mothers	O
.	O
10In	O
a	O
small	O
group	O
of	O
Cincinnati	O
mothers	O
,	O
she	O
showed	O
that	O
women	O
with	O
weaker	O
insulin	O
response	O
tended	O
to	O
start	O
lactating	O
later	O
than	O
those	O
with	O
good	O
insulin	O
response	O
,	O
with	O
the	O
onset	O
of	O
lactogenesis	O
ranging	O
from	O
10	O
to	O
121	O
hours	O
postpartum	O
.	O
32When	O
Nommsen	O
-	O
Rivers	O
looked	O
at	O
insulin	O
-	O
sensitive	O
genes	O
in	O
the	O
human	O
mammary	O
gland	O
,	O
she	O
found	O
a	O
potential	O
biomarker	O
linking	O
insulin	O
resistance	O
and	O
difficulty	O
lactating	O
.	O
33	O
She	O
then	O
compared	O
milk	O
production	O
over	O
a	O
24	O
-	O
hour	O
period	O
in	O
mothers	O
with	O
evidence	O
of	O
insulin	O
resistance	O
versus	O
mothers	O
without	O
.	O

This	O
work	O
showed	O
that	O
women	O
with	O
signs	O
of	O
insulin	O
resistance	O
produced	O
about	O
half	O
as	O
much	O
milk	O
as	O
those	O
without	O
.	O
34It	O
is	O
important	O
to	O
note	O
,	O
she	O
says	O
,	O
that	O
all	O
the	O
women	O
in	O
this	O
study	O
had	O
concerns	O
about	O
their	O
milk	O
production	O
and	O
were	O
already	O
supplementing	O
with	O
formula	O
.	O

Many	O
Research	O
Gaps	O
to	O
Fill	O
Many	O
experts	B
point	O
out	O
that	O
the	O
health	O
benefits	O
of	O
breastfeeding	O
almost	B
always	I
outweigh	O
the	O
costs	O
of	O
exposure	O
to	O
environmental	O
chemicals	O
through	O
breast	O
milk	O
.	O
35Worldwide	O
,	O
breastfeeding	O
has	O
been	O
shown	O
to	O
lower	O
the	O
rate	O
of	O
infant	O
infection	O
,	O
and	O
in	O
developing	O
countries	O
it	O
is	O
strongly	B
protective	O
against	O
death	O
from	O
infection	O
in	O
the	O
first	O
few	O
years	O
of	O
life	O
.	O
36Breastfed	O
babies	O
also	O
are	O
less	O
likely	B
to	O
die	O
of	O
sudden	O
infant	O
death	O
syndrome	O
.	O
37Mothers	O
who	O
breastfeed	O
have	O
a	O
lower	O
risk	O
of	O
breast	O
cancer	O
later	O
in	O
life	O
.	O
38	O
In	O
the	O
developed	O
world	O
,	O
the	O
most	B
important	O
health	O
gains	O
associated	O
with	O
breastfeeding	O
may	O
be	O
cognitive	O
,	O
says	O
Kramer	O
.	O

Some	O
epidemiological	O
evidence	O
suggests	O
that	O
children	O
who	O
are	O
breastfed	O
exclusively	O
during	O
the	O
first	O
several	O
months	O
tend	O
to	O
have	O
higher	O
IQs	O
than	O
those	O
fed	O
formula	O
or	O
a	O
combination	O
of	O
formula	O
and	O
breast	O
milk	O
.	O
39However	O
,	O
there	O
is	O
some	O
debate	O
as	O
to	O
whether	O
breastfeeding	O
actually	O
makes	O
children	O
more	O
intelligent	O
or	O
whether	O
associations	O
between	O
breastfeeding	O
and	O
IQ	O
could	O
be	O
due	O
largely	O
to	O
parents	O
’	O
intelligence	O
.	O
40Some	O
studies	O
also	O
suggest	O
that	O
breastfed	O
babies	O
have	O
a	O
lower	O
risk	O
of	O
obesity	O
,	O
asthma	O
,	O
and	O
other	O
allergies	O
.	O
41	O
But	O
despite	O
the	O
body	O
of	O
evidence	O
in	O
humans	O
and	O
animals	O
suggesting	O
that	O
ubiquitous	O
environmental	O
exposures	O
may	O
interfere	O
with	O
this	O
highly	O
beneficial	O
process	O
,	O
opportunities	O
to	O
further	O
probe	O
these	O
associations	O
remain	O
spotty	O
at	O
best	O
,	O
say	O
many	O
of	O
the	O
researchers	O
interviewed	O
for	O
this	O
article	O
.	O

Part	O
of	O
the	O
problem	O
is	O
that	O
it	O
is	O
difficult	O
to	O
design	O
breastfeeding	O
studies	O
.	O

“	O
There	O
are	O
inherent	O
difficulties	O
with	O
studying	O
breastfeeding	O
prospectively	O
in	O
a	O
rigorous	O
manner	O
,”	O
explains	O
Tonse	O
Raju	O
,	O
chief	O
of	O
the	O
Pregnancy	O
and	O
Perinatology	O
Branch	O
at	O
the	O
Eunice	O
Kennedy	O
Shriver	O
National	O
Institute	O
of	O
Child	O
Health	O
and	O
Human	O
Development	O
.	O

For	O
example	O
,	O
researchers	O
could	O
not	O
ethically	O
randomize	O
people	O
such	O
that	O
some	O
were	O
not	O
allowed	O
to	O
breastfeed	O
.	O

As	B
a	O
result	O
,	O
breastfeeding	O
studies	O
may	O
not	O
pass	O
muster	O
with	O
funding	O
committees	O
,	O
says	O
Raju	O
.	O

In	O
2011	O
the	O
U	O
.	O
S	O
.	O

Surgeon	O
General	O
issued	O
“	O
A	O
Call	O
to	O
Action	O
to	O
Support	O
Breastfeeding	O
.”	O
42This	O
document	O
urged	O
more	O
research	O
support	O
for	O
topics	O
related	O
to	O
lactation	O
.	O

In	O
response	O
,	O
Raju	O
helped	O
to	O
initiate	O
the	O
Breastfeeding	O
and	O
Human	O
Lactation	O
Research	O
Scientific	O
Interest	O
Group	O
,	O
a	O
group	O
of	O
scientists	O
organized	O
under	O
the	O
auspices	O
of	O
the	O
National	O
Institutes	O
of	O
Health	O
to	O
identify	O
and	O
discuss	O
research	O
gaps	O
.	O
43	O
“	O
The	O
intention	O
is	O
to	O
increase	O
dialogue	O
across	O
institutions	O
and	O
various	O
funding	O
agencies	O
to	O
stimulate	O
interest	O
in	O
breastfeeding	O
research	O
,”	O
says	O
Raju	O
.	O

He	O
believes	O
there	O
is	O
far	O
more	O
research	O
that	O
needs	O
to	O
be	O
done	O
to	O
understand	O
the	O
barriers	O
to	O
breastfeeding	O
and	O
why	O
some	O
women	O
have	O
difficulties	O
with	O
lactation	O
.	O

PubMed	O
Central	O
:	O

Birth	O
Weight	O
and	O
Its	O
Relationship	O
with	O
the	O
Cardiac	O
Autonomic	O
Balance	O
in	O
Healthy	O
Children	O
Abstract	O
Several	O
studies	O
indicate	O
that	O
the	O
fetal	O
environment	O
plays	O
a	O
significant	O
role	O
in	O
the	O
development	O
of	O
cardiometabolic	O
disease	O
later	O
in	O
life	O
.	O

However	O
,	O
a	O
few	O
studies	O
present	O
conflicting	O
data	O
about	O
the	O
correlation	O
between	O
birth	O
weight	O
and	O
the	O
impairment	O
of	O
cardiac	O
autonomic	O
modulation	O
.	O

The	O
purpose	O
of	O
the	O
present	O
study	O
was	O
to	O
provide	O
further	O
knowledge	O
to	O
elucidate	O
this	O
contradictory	O
relationship	O
.	O

One	O
hundred	O
children	O
aged	O
5	O
and	O
14	O
years	O
had	O
anthropometric	O
parameters	O
,	O
body	O
composition	O
and	O
blood	O
pressure	O
levels	O
determined	O
.	O

Heart	O
rate	O
variability	O
(	O
HRV	O
)	O
was	O
evaluated	O
by	O
heart	O
rate	O
monitoring	O
,	O
including	O
measurements	O
of	O
both	O
the	O
time	O
and	O
frequency	O
domains	O
.	O

The	O
results	O
showed	O
inverse	O
correlation	O
between	O
the	O
HRV	O
parameters	O
with	O
BMI	O
(	O
RMSSD	O
:	O
P	O
=	O
0	O
.	O
047	O
;	O
PNN50	O
:	O
P	O
=	O
0	O
.	O
021	O
;	O
HF	O
:	O
P	O
=	O
0	O
.	O
041	O
),	O
systolic	O
(	O
RMSSD	O
:	O
P	O
=	O
0	O
.	O
023	O
;	O
PNN50	O
:	O
P	O
=	O
0	O
.	O
032	O
)	O
and	O
diastolic	O
(	O
PNN50	O
:	O
P	O
=	O
0	O
.	O
030	O
)	O
blood	O
pressure	O
levels	O
.	O

On	O
the	O
other	O
hand	O
,	O
there	O
were	O
consistent	O
positive	O
correlations	O
between	O
the	O
HRV	O
parameters	O
and	O
birth	O
weight	O
(	O
RMSSD	O
:	O
P	O
=	O
0	O
.	O
001	O
;	O
PNN50	O
:	O
P	O
=	O
0	O
.	O
001	O
;	O
HF	O
:	O
P	O
=	O
0	O
.	O
002	O
).	O

To	O
determine	O
the	O
effect	O
of	O
birth	O
weight	O
on	O
HRV	O
parameters	O
,	O
we	O
perform	O
multivariate	O
linear	O
regression	O
analysis	O
adjusted	O
for	O
potentially	O
confounding	O
factors	O
(	O
prematurity	O
,	O
gender	O
,	O
age	O
,	O
BMI	O
,	O
physical	O
activity	O
index	O
and	O
SBP	O
levels	O
).	O

These	O
findings	O
were	O
preserved	O
even	O
after	O
adjusting	O
for	O
these	O
confounders	O
.	O

Our	O
results	O
suggested	O
that	O
impaired	O
cardiac	O
autonomic	O
modulation	O
characterized	O
by	O
a	O
reduction	O
in	O
the	O
parasympathetic	O
activity	O
occurs	O
in	O
children	O
with	O
low	O
birth	O
weight	O
.	O

One	O
possible	O
interpretation	B
for	O
these	O
data	O
is	O
that	O
a	O
vagal	O
withdrawal	O
,	O
rather	O
than	O
a	O
sympathetic	O
overactivity	O
,	O
could	O
precede	O
the	O
development	O
of	O
hypertension	O
and	O
other	O
cardiometabolic	O
diseases	O
in	O
children	O
with	O
low	O
birth	O
weight	O
.	O

However	O
,	O
long	O
-	O
term	O
studies	O
should	O
be	O
performed	O
to	O
investigate	O
this	O
possibility	O
.	O

Introduction	O
Birth	O
weight	O
has	O
been	O
considered	O
an	O
important	O
measure	O
for	O
assessing	O
fetal	O
growth	O
and	O
is	O
an	O
indicator	O
of	O
neonatal	O
morbidity	O
,	O
survival	O
,	O
and	O
development	O
in	O
children	O
[	O
1	O
–	O
3	O
].	O

It	B
is	I
clear	I
that	O
the	O
processes	O
arising	O
during	O
fetal	O
development	O
can	O
influence	O
health	O
later	O
in	O
life	O
.	O

In	O
fact	O
,	O
adaptations	O
of	O
the	O
fetus	O
to	O
the	O
inadequate	O
intrauterine	O
environment	O
promote	O
alterations	O
in	O
tissue	O
development	O
and	O
function	O
and	O
can	O
result	O
in	O
increased	O
susceptibility	O
to	O
chronic	O
diseases	O
in	O
adulthood	O
[	O
4	O
,	O
5	O
].	O

It	O
is	O
known	O
that	O
the	O
two	O
ends	O
of	O
the	O
birth	O
weight	O
spectrum	O
,	O
low	O
and	O
high	O
birth	O
weight	O
,	O
are	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
cardiovascular	O
events	O
in	O
childhood	O
[	O
6	O
–	O
8	O
]	O
and	O
adult	O
life	O
[	O
9	O
,	O
10	O
].	O

Previous	O
studies	O
have	O
demonstrated	O
that	O
those	O
born	O
with	O
low	O
or	O
high	O
birth	O
weight	O
have	O
impairment	O
of	O
the	O
arterial	O
vascular	O
system	O
with	O
modifications	O
in	O
both	O
functional	O
(	O
e	O
.	O
g	O
.,	O
endothelium	O
dysfunction	O
,	O
reduction	O
in	O
nitric	O
oxide	O
production	O
)	O
and	O
structural	O
/	O
mechanical	O
(	O
e	O
.	O
g	O
.,	O
higher	O
arterial	O
intima	O
-	O
media	O
thickness	O
,	O
elastin	O
synthesis	O
deficiency	O
,	O
increased	O
arterial	O
stiffness	O
)	O
properties	O
[	O
8	O
,	O
9	O
,	O
11	O
–	O
14	O
].	O

However	O
,	O
it	O
should	O
also	O
be	O
considered	O
that	O
the	O
high	O
incidence	O
of	O
cardiovascular	O
disorders	O
could	O
be	O
due	O
to	I
alterations	O
in	O
autonomic	O
control	O
.	O

Exposure	O
to	O
an	O
adverse	O
intrauterine	O
environment	O
during	O
sensitive	O
periods	O
of	O
fetal	O
development	O
produces	O
long	O
-	O
term	O
alterations	O
in	O
the	O
autonomic	O
nervous	O
system	O
(	O
ANS	O
)	O
[	O
15	O
,	O
16	O
,	O
17	O
].	O

An	O
increasing	O
body	O
of	O
evidence	O
suggests	O
that	O
low	O
birth	O
weight	O
is	O
correlated	O
with	O
alterations	O
in	O
autonomic	O
responses	O
[	O
15	O
–	O
20	O
].	O

Weitz	O
et	O
al	O
.	O

[	O
19	O
]	O
found	O
that	O
individuals	O
born	O
with	O
very	O
low	O
birth	O
weight	O
have	O
lower	O
sympathetic	O
nerve	O
activity	O
under	O
resting	O
conditions	O
.	O

Meanwhile	O
,	O
Jones	O
et	O
al	O
.	O

[	O
20	O
]	O
report	O
autonomic	O
dysfunction	O
in	O
adults	O
with	O
low	O
birth	O
weight	O
,	O
characterized	O
by	O
increased	O
sympathetic	O
activity	O
and	O
reduced	O
parasympathetic	O
activity	O
and	O
baroreflex	O
sensitivity	O
.	O

Although	O
some	O
studies	O
have	O
found	O
evidence	O
of	O
a	O
correlation	O
between	O
low	O
birth	O
weight	O
and	O
autonomic	O
dysfunction	O
,	O
the	O
results	O
remain	O
inconclusive	O
.	O

Thus	B
,	O
the	O
purpose	O
of	O
this	O
study	O
was	O
to	O
conduct	O
a	O
cross	O
-	O
sectional	O
study	O
of	O
children	O
stratified	O
by	O
birth	O
weight	O
quartiles	O
to	O
identify	O
alterations	O
in	O
autonomic	O
function	O
through	O
the	O
analysis	O
of	O
heart	O
rate	O
variability	O
(	O
HRV	O
).	O

Materials	O
and	O
Methods	O
This	O
study	O
was	O
a	O
cross	O
-	O
sectional	O
survey	O
conducted	O
in	O
a	O
representative	O
group	O
of	O
children	O
identified	O
in	O
the	O
Youth	O
Healthcare	O
Centre	O
located	O
near	O
the	O
Federal	O
University	O
of	O
São	O
Paulo	O
(	O
UNIFESP	O
,	O
São	O
Paulo	O
,	O
SP	O
,	O
Brazil	O
).	O

A	O
total	O
of	O
100	O
children	O
were	O
identified	O
during	O
the	O
study	O
period	O
.	O

No	O
child	O
had	O
any	O
clinical	O
signs	O
of	O
endocrine	O
,	O
renal	O
or	O
cardiovascular	O
disease	O
.	O

Personal	O
and	O
family	O
medical	O
histories	O
were	O
obtained	O
using	O
a	O
questionnaire	O
completed	O
during	O
an	O
interview	O
with	O
the	O
parents	O
.	O

The	O
prenatal	O
data	O
from	O
the	O
mother	O
’	O
s	O
recall	O
was	O
confirmed	O
with	O
medical	O
records	O
.	O

The	O
Ethics	O
Committee	O
of	O
the	O
Federal	O
University	O
of	O
São	O
Paulo	O
approved	O
the	O
study	O
protocol	O
(	O
Number	O
:	O
214	O
.	O
956	O
).	O

All	O
parents	O
and	O
children	O
signed	O
written	O
informed	O
consent	O
/	O
assent	O
forms	O
.	O

All	O
children	O
were	O
evaluated	O
twice	O
on	O
different	O
days	O
.	O

On	O
the	O
first	O
day	O
,	O
the	O
Baecke	O
questionnaire	O
was	O
administered	O
and	O
body	O
composition	O
was	O
assessed	O
.	O

On	O
the	O
second	O
day	O
,	O
anthropometric	O
measures	O
,	O
blood	O
pressure	O
,	O
and	O
HRV	O
were	O
evaluated	O
.	O

All	O
procedures	O
were	O
conducted	O
in	O
a	O
quiet	O
room	O
with	O
minimum	O
disturbance	O
between	O
9	O
:	O
00	O
and	O
11	O
:	O
00	O
am	O
.	O

All	O
participants	O
sat	O
still	O
for	O
at	O
least	O
5	O
minutes	O
to	O
assess	O
blood	O
pressure	O
and	O
heart	O
rate	O
at	O
rest	O
.	O

All	O
measurements	O
were	O
made	O
by	O
the	O
same	O
trained	O
researcher	O
who	O
was	O
blinded	O
to	O
the	O
clinical	O
data	O
.	O

Physical	O
Activity	O
Level	O
The	O
physical	O
activity	O
level	O
was	O
evaluated	O
by	O
the	O
total	O
score	O
obtained	O
with	O
the	O
Habitual	O
Physical	O
Activity	O
Questionnaire	O
proposed	O
by	O
Baecke	O
et	O
al	O
.	O

[	O
21	O
]	O
and	O
validated	O
in	O
a	O
young	O
adolescent	O
population	O
[	O
22	O
].	O

Anthropometry	O
Body	O
weight	O
and	O
height	O
were	O
measured	O
in	O
light	O
clothing	O
without	O
shoes	O
using	O
a	O
standard	O
balance	O
beam	O
scale	O
.	O

Waist	O
and	O
hip	O
circumferences	O
were	O
measured	O
using	O
inextensible	O
tape	O
.	O

Waist	O
circumference	O
(	O
WC	O
)	O
was	O
recorded	O
at	O
a	O
level	O
midway	O
between	O
the	O
lower	O
rib	O
margin	O
and	O
the	O
iliac	O
crest	O
at	O
the	O
end	O
of	O
normal	O
expiration	O
.	O

Hip	O
circumference	O
(	O
HP	O
)	O
was	O
measured	O
at	O
the	O
maximum	O
circumference	O
of	O
the	O
buttocks	O
.	O

For	O
both	O
measurements	O
,	O
the	O
tape	O
was	O
positioned	O
at	O
a	O
level	O
parallel	O
to	O
the	O
floor	O
,	O
and	O
the	O
waist	O
-	O
to	O
-	O
hip	O
ratio	O
was	O
calculated	O
.	O

Body	O
mass	O
index	O
(	O
BMI	O
)	O
was	O
computed	O
using	O
the	O
formula	O
weight	O
(	O
kg	O
)/	O
height	O
(	O
m2	O
).	O

Children	O
were	O
classified	O
as	O
overweight	O
(+	O
1	O
SDS	O
)	O
or	O
obese	O
(+	O
2	O
SDS	O
)	O
according	O
to	O
BMI	O
-	O
for	O
-	O
age	O
following	O
the	O
cut	O
-	O
off	O
parameters	O
of	O
the	O
WHO	O
growth	O
standards	O
[	O
23	O
].	O

Body	O
Composition	O
Body	O
composition	O
was	O
evaluated	O
using	O
bioelectrical	O
impedance	O
(	O
BIA	O
)	O
with	O
a	O
single	O
-	O
frequency	O
hand	O
-	O
to	O
-	O
foot	O
(	O
ImpediMed	O
DF50	O
monitor	O
,	O
Impedimed	O
,	O
Australia	O
)	O
[	O
24	O
].	O

Children	O
were	O
asked	O
to	O
avoid	O
physical	O
activity	O
and	O
to	O
consume	O
liquids	O
2	O
hours	O
before	O
evaluation	O
to	O
prevent	O
errors	O
in	O
measurement	O
due	O
to	O
fluid	O
imbalances	O
.	O

This	O
evaluation	O
was	O
performed	O
after	O
5	O
minutes	O
of	O
rest	O
in	O
the	O
supine	O
position	O
,	O
and	O
the	O
electrodes	O
were	O
applied	O
to	O
the	O
hand	O
,	O
wrist	O
,	O
ankle	O
and	O
foot	O
of	O
the	O
right	O
-	O
hand	O
side	O
of	O
the	O
body	O
.	O

Body	O
fat	O
(%	O
BF	O
)	O
was	O
calculated	O
from	O
BIA	O
data	O
with	O
prediction	O
equations	O
[	O
25	O
].	O

Hemodynamic	O
Variables	O
and	O
Heart	O
Rate	O
Variability	O
(	O
HRV	O
)	O
Blood	O
pressure	O
(	O
BP	O
)	O
levels	O
were	O
measured	O
twice	O
in	O
the	O
right	O
arm	O
with	O
the	O
child	O
in	O
a	O
seated	O
position	O
using	O
an	O
automated	O
oscillometric	O
device	O
(	O
Omron	O
HEM907XL	O
;	O
Omron	O
Healthcare	O
;	O
USA	O
)	O
with	O
an	O
appropriate	O
cuff	O
size	O
.	O

The	O
blood	O
pressure	O
value	O
was	O
the	O
average	O
of	O
three	O
measurements	O
made	O
at	O
2	O
-	O
min	O
intervals	O
[	O
26	O
].	O

After	O
this	O
procedure	O
,	O
children	O
were	O
asked	O
to	O
lay	O
silently	O
in	O
a	O
supine	O
position	O
on	O
a	O
bed	O
with	O
minimal	O
body	O
movement	O
and	O
to	O
maintain	O
spontaneous	O
breathing	O
for	O
10	O
minutes	O
to	O
record	O
both	O
resting	O
heart	O
rate	O
and	O
short	O
-	O
term	O
HRV	O
using	O
a	O
Polar	O
S810i	O
monitor	O
(	O
Polar	O
Electro	O
OY	O
,	O
Finland	O
;	O
sampling	O
rate	O
=	O
100Hz	O
)	O
[	O
27	O
,	O
28	O
].	O

The	O
same	O
researcher	O
blinded	O
to	O
the	O
clinical	O
data	O
conducted	O
the	O
assessment	O
of	O
all	O
children	O
.	O

To	O
minimize	O
the	O
effect	O
of	O
stress	O
during	O
HRV	O
assessment	O
,	O
we	O
conducted	O
a	O
pilot	O
project	O
two	O
months	O
prior	O
to	O
begin	O
the	O
current	O
study	O
.	O

Processing	O
of	O
the	O
HRV	O
Data	O
The	O
HRV	O
indices	O
were	O
calculated	O
as	O
previously	O
described	O
[	O
27	O
,	O
28	O
].	O

Briefly	O
,	O
normal	O
beat	O
to	O
beat	O
intervals	O
(	O
RR	O
)	O
were	O
transferred	O
from	O
Polar	O
S810i	O
to	O
Precision	O
Performance	O
Software	O
by	O
an	O
infrared	O
interface	O
device	O
.	O

These	O
data	O
were	O
processed	O
in	O
a	O
specific	O
previous	O
routine	O
designed	O
in	O
MatLab	O
(	O
Math	O
Works	O
,	O
6	O
.	O
0	O
version	O
,	O
USA	O
)	O
for	O
the	O
automatic	O
selection	O
of	O
5	O
minutes	O
RR	O
with	O
the	O
smallest	O
variance	O
[	O
29	O
].	O

Afterwards	O
,	O
these	O
time	O
series	O
lasting	O
5	O
minutes	O
were	O
analyzed	O
in	O
Kubios	O
software	O
(	O
Biosignal	O
Analysis	O
and	O
Medical	O
Image	O
Group	O
,	O
University	O
of	O
Kuopio	O
,	O
Finland	O
).	O

In	O
this	O
software	O
,	O
the	O
artifacts	O
were	O
corrected	O
with	O
a	O
moderated	O
filter	O
,	O
and	O
the	O
time	O
-	O
domain	O
components	O
were	O
calculated	O
.	O

The	O
following	O
time	O
-	O
domain	O
indices	O
were	O
analyzed	O
:	O
heart	O
rate	O
(	O
HR	O
),	O
MNN	O
(	O
average	O
of	O
all	O
normal	O
RR	O
interval	O
),	O
SDNN	O
(	O
standard	O
deviation	O
of	O
RR	O
intervals	O
),	O
RMSSD	O
(	O
root	O
mean	O
square	O
of	O
successive	O
differences	O
RR	O
intervals	O
),	O
and	O
pNN50	O
(	O
percent	O
RR	O
intervals	O
with	O
a	O
difference	O
in	O
duration	O
higher	O
than	O
50	O
ms	O
).	O

The	O
frequency	O
-	O
domain	O
components	O
were	O
also	O
evaluated	O
by	O
a	O
2	O
power	O
spectrum	O
.	O

The	O
classical	O
frequency	O
low	O
frequency	O
(	O
LF	O
=	O
0	O
.	O
041	O
–	O
0	O
.	O
15	O
Hz	O
)	O
and	O
high	O
frequency	O
(	O
HF	O
=	O
0	O
.	O
15	O
–	O
0	O
.	O
40	O
Hz	O
)	O
bands	O
were	O
expressed	O
in	O
normalized	O
units	O
(	O
n	O
.	O
u	O
.).	O

Moreover	O
,	O
the	O
ratio	O
of	O
LF	O
/	O
HF	O
was	O
also	O
calculated	O
.	O

Spectral	O
analysis	O
was	O
estimated	O
as	O
recommended	O
using	O
the	O
non	O
-	O
parametric	O
method	O
of	O
fast	O
Fourier	O
Transform	O
Algorithms	O
[	O
28	O
,	O
29	O
].	O

Statistical	O
Analysis	O
Statistical	O
analyses	O
were	O
conducted	O
using	O
SPSS	O
version	O
21	O
.	O
0	O
for	O
Windows	O
(	O
IBM	O
Corporation	O
,	O
USA	O
).	O

All	O
continuous	O
variables	O
were	O
examined	O
for	O
normality	O
with	O
the	O
Shapiro	O
-	O
Wilk	O
test	O
and	O
expressed	O
as	O
the	O
mean	O
±	O
Standard	O
Deviation	O
(	O
SD	O
).	O

Categorical	O
variables	O
were	O
expressed	O
as	O
percentage	O
.	O

Pearson	O
’	O
s	O
correlation	O
and	O
multiple	O
linear	O
regression	O
analyses	O
were	O
performed	O
to	O
verify	O
the	O
relationship	O
between	O
HRV	O
parameters	O
and	O
independent	O
factors	O
.	O

Multicollinearity	O
was	O
evaluated	O
using	O
variance	O
inflation	O
factor	O
(	O
VIF	O
)	O
and	O
significance	O
level	O
was	O
set	O
at	O
P	O
<	O
0	O
.	O
05	O
.	O

Results	O
The	O
present	O
study	O
was	O
conducted	O
on	O
100	O
children	O
(	O
63	O
boys	O
and	O
37	O
girls	O
)	O
with	O
a	O
mean	O
age	O
of	O
8	O
.	O
85	O
years	O
(	O
Range	O
:	O
6	O
–	O
14	O
;	O
SD	O
=	O
1	O
.	O
82	O
years	O
).	O

The	O
mean	O
BW	O
was	O
3008	O
g	O
(	O
Range	O
:	O
1400	O
to	O
4590	O
;	O
SD	O
=	O
605	O
g	O
)	O
with	O
birth	O
length	O
47	O
.	O
1	O
cm	O
(	O
Range	O
:	O
39	O
.	O
0	O
–	O
53	O
.	O
0	O
;	O
SD	O
=	O
3	O
.	O
28	O
cm	O
).	O

For	O
entire	O
cohort	O
,	O
we	O
found	O
a	O
positive	O
correlation	O
between	O
BW	O
and	O
birth	O
length	O
(	O
r	O
=	O
0	O
.	O
603	O
,	O
P	O
<	O
0	O
.	O
001	O
).	O

Preterm	O
delivery	O
occurred	O
in	O
ten	O
pregnancies	O
.	O

We	O
also	O
found	O
that	O
33	O
%	O
of	O
children	O
have	O
excess	O
weight	O
and	O
16	O
%	O
of	O
them	O
were	O
already	O
obese	O
.	O

General	O
characteristics	O
of	O
the	O
children	O
are	O
listed	O
inTable	O
1	O
.	O
10	O
.	O
1371	O
/	O
journal	O
.	O
pone	O
.	O
0167328	O
.	O
t001	O
Caption	O
(	O
TABLE	O
-	O
WRAP	O
):	O
TABLE	O
1	O
General	O
Characteristics	O
and	O
Linear	O
Index	O
Values	O
of	O
Heart	O
Rate	O
Variability	O
(	O
Time	O
and	O
Frequency	O
Domain	O
)	O
in	O
the	O
Study	O
Population	O
(	O
n	O
=	O
100	O
).	O
General	O
CharacteristicsBirth	O
Weight	O
(	O
g	O
)	O
3008	O
±	O
605Birth	O
Length	O
(	O
cm	O
)	O
47	O
.	O
3	O
±	O
3	O
.	O
29Prematurity	O
(%)	O
Yes10No90Age	O
(	O
Years	O
)	O
8	O
.	O
85	O
±	O
1	O
.	O
82Gender	O
(%)	O
Female37Male63Weight	O
(	O
kg	O
)	O
34	O
.	O
83	O
±	O
13	O
.	O
52Height	O
(	O
cm	O
)	O
135	O
.	O
83	O
±	O
11	O
.	O
93BMI	O
(	O
kg	O
/	O
m2	O
)	O
18	O
.	O
59	O
±	O
4	O
.	O
60WC	O
(	O
cm	O
)	O
60	O
.	O
55	O
±	O
9	O
.	O
55HC	O
(	O
cm	O
)	O
71	O
.	O
99	O
±	O
12	O
.	O
43BF	O
(%)	O
25	O
.	O
78	O
±	O
6	O
.	O
77Nutritional	O
Status	O
(%)	O
Normal67Overweight17Obesity16Physical	O
Activity	O
Index8	O
.	O
18	O
±	O
1	O
.	O
14SBP	O
(	O
mmHg	O
)	O
100	O
±	O
7	O
.	O
50DBP	O
(	O
mmHg	O
)	O
66	O
±	O
4	O
.	O
20	O
Time	O
Domain	O
HR	O
(	O
bpm	O
)	O
83	O
.	O
89	O
±	O
8	O
.	O
12MNN	O
(	O
ms	O
)	O
708	O
.	O
65	O
±	O
85	O
.	O
60SDNN	O
(	O
ms	O
)	O
48	O
.	O
98	O
±	O
20	O
.	O
00RMSSD	O
(	O
ms	O
)	O
51	O
.	O
45	O
±	O
20	O
.	O
64PNN50	O
(%)	O
39	O
.	O
88	O
±	O
12	O
.	O
95	O
Frequency	O
Domain	O
LF	O
(	O
n	O
.	O
u	O
.	O

)	O
52	O
.	O
50	O
±	O
14	O
.	O
25HF	O
(	O
n	O
.	O
u	O
.	O

)	O
45	O
.	O
02	O
±	O
13	O
.	O
32LF	O
/	O
HF	O
Ratio1	O
.	O
37	O
±	O
0	O
.	O
87	O
Values	O
expressed	O
as	O
percentage	O
or	O
mean	O
±	O
SD	O
.	O

BMI	O
—	O
Body	O
Mass	O
Index	O
;	O
WC	O
—	O
Waist	O
Circumference	O
;	O
HP	O
—	O
Hip	O
Circumference	O
;	O
BF	O
—	O
Body	O
Fat	O
;	O
SBP	O
—	O
Systolic	O
Blood	O
Pressure	O
;	O
DBP	O
—	O
Diastolic	O
Blood	O
;	O
HR	O
—	O
Heart	O
Rate	O
;	O
SDNN	O
—	O
Standard	O
Deviation	O
Normal	O
-	O
to	O
-	O
Normal	O
Intervals	O
;	O
RMSSD	O
—	O
Root	O
Mean	O
Square	O
of	O
Successive	O
Differences	O
;	O
pNN50	O
—	O
Percentage	O
of	O
Differences	O
Between	O
Adjacent	O
Normal	O
-	O
to	O
-	O
Normal	O
Intervals	O
that	O
is	O
Greater	O
than	O
50	O
Milliseconds	O
;	O
LF	O
(	O
n	O
.	O
u	O
.	O

)—	O
Low	O
Frequency	O
in	O
Normalized	O
Units	O
;	O
HF	O
(	O
n	O
.	O
u	O
.	O

)—	O
High	O
Frequency	O
in	O
Normalized	O
Units	O
.	O

Considering	O
the	O
HRV	O
analysis	O
,	O
there	O
was	O
no	O
significant	O
gender	O
effects	O
with	O
respect	O
to	O
the	O
time	O
-	O
domain	O
(	O
HR	O
:	O
P	O
=	O
0	O
.	O
098	O
;	O
MNN	O
:	O
P	O
=	O
0	O
.	O
271	O
;	O
SDNN	O
:	O
P	O
=	O
0	O
.	O
208	O
;	O
RMSSD	O
:	O
P	O
=	O
0	O
.	O
624	O
;	O
PNN50	O
:	O
P	O
=	O
0	O
.	O
882	O
)	O
or	O
frequency	O
-	O
domain	O
(	O
LF	O
:	O
P	O
=	O
0	O
.	O
294	O
;	O
HF	O
:	O
P	O
=	O
0	O
.	O
844	O
;	O
ratio	O
LF	O
/	O
HF	O
:	O
P	O
=	O
0	O
.	O
546	O
)	O
indices	O
;	O
therefore	B
,	O
analyses	O
were	O
performed	O
considering	O
boys	O
and	O
girls	O
together	O
.	O

For	O
the	O
entire	O
cohort	O
,	O
inverse	O
correlations	O
were	O
observed	O
between	O
the	O
HRV	O
parameters	O
with	O
BMI	O
(	O
RMSSD	O
:	O
r	O
=	O
-	O
0	O
.	O
199	O
,	O
P	O
=	O
0	O
.	O
047	O
;	O
PNN50	O
:	O
r	O
=	O
-	O
0	O
.	O
231	O
,	O
P	O
=	O
0	O
.	O
021	O
;	O
HF	O
:	O
r	O
=	O
-	O
0	O
.	O
205	O
,	O
P	O
=	O
0	O
.	O
041	O
),	O
systolic	O
(	O
RMSSD	O
:	O
r	O
=	O
-	O
0	O
.	O
227	O
,	O
P	O
=	O
0	O
.	O
023	O
;	O
PNN50	O
:	O
r	O
=	O
-	O
0	O
.	O
214	O
,	O
P	O
=	O
0	O
.	O
032	O
)	O
and	O
diastolic	O
(	O
PNN50	O
:	O
r	O
=	O
-	O
0	O
.	O
217	O
,	O
P	O
=	O
0	O
.	O
030	O
)	O
BP	O
levels	O
.	O

On	O
the	O
other	O
hand	O
,	O
resting	O
HR	O
values	O
were	O
positive	O
correlated	O
with	O
BMI	O
(	O
r	O
=	O
0	O
.	O
300	O
,	O
P	O
=	O
0	O
.	O
002	O
)	O
and	O
blood	O
pressure	O
levels	O
(	O
SBP	O
:	O
r	O
=	O
0	O
.	O
382	O
,	O
P	O
<	O
0	O
.	O
001	O
;	O
DBP	O
:	O
r	O
=	O
0	O
.	O
317	O
,	O
P	O
=	O
0	O
.	O
001	O
).	O

Additionally	O
,	O
we	O
observed	O
an	O
inverse	O
correlation	O
between	O
BW	O
and	O
systolic	O
BP	O
levels	O
(	O
r	O
=	O
-	O
0	O
.	O
261	O
,	O
P	O
=	O
0	O
.	O
009	O
)	O
(	O
Fig	O
1A	O
).	O

Meanwhile	O
,	O
diastolic	O
BP	O
(	O
r	O
=	O
-	O
0	O
.	O
182	O
;	O
P	O
=	O
0	O
.	O
070	O
)	O
was	O
not	O
influenced	O
by	O
BW	O
in	O
these	O
children	O
(	O
Fig	O
1B	O
).	O

Interestingly	O
,	O
there	O
were	O
consistent	O
positive	O
correlations	O
between	O
BW	O
with	O
parameters	O
of	O
the	O
time	O
domain	O
(	O
RMSSD	O
:	O
r	O
=	O
0	O
.	O
328	O
,	O
P	O
=	O
0	O
.	O
001	O
;	O
PNN50	O
:	O
r	O
=	O
0	O
.	O
386	O
,	O
P	O
=	O
0	O
.	O
001	O
)	O
(	O
Fig	O
2	O
)	O
and	O
frequency	O
domain	O
(	O
HF	O
:	O
r	O
=	O
0	O
.	O
332	O
,	O
P	O
=	O
0	O
.	O
002	O
)	O
(	O
Fig	O
3	O
),	O
suggesting	O
that	O
impaired	O
vagal	O
modulation	O
to	O
the	O
heart	O
in	O
children	O
is	O
influenced	O
by	O
low	O
birth	O
weight	O
.	O

To	O
determine	O
the	O
effect	O
of	O
birth	O
weight	O
on	O
HRV	O
parameters	O
,	O
we	O
perform	O
multivariate	O
linear	O
regression	O
analysis	O
adjusted	O
for	O
potentially	O
confounding	O
factors	O
(	O
prematurity	O
,	O
gender	O
,	O
age	O
,	O
BMI	O
,	O
physical	O
activity	O
index	O
and	O
SBP	O
levels	O
).	O

When	O
RMSSD	O
was	O
tested	O
as	O
the	O
dependent	O
variable	O
,	O
we	O
found	O
that	O
only	O
birth	O
weight	O
emerged	O
as	O
independent	O
determinant	O
for	O
this	O
HRV	O
parameter	O
(	O
Table	O
2	O
).	O

In	O
the	O
current	O
study	O
the	O
birth	O
weight	O
explained	O
15	O
%	O
of	O
the	O
variance	O
in	O
RMSSD	O
index	O
(	O
R2	O
=	O
0	O
.	O
15	O
)	O
(	O
Table	O
2	O
).	O

On	O
the	O
other	O
hand	O
,	O
multiple	O
regression	O
analysis	O
revealed	O
a	O
significant	O
interaction	O
of	O
the	O
three	O
independent	O
variables	O
birth	O
weight	O
,	O
age	O
and	O
BMI	O
in	O
predicting	O
PNN50	O
(	O
Table	O
2	O
).	O

These	O
independent	O
variables	O
explained	O
23	O
%	O
of	O
the	O
variability	O
in	O
PNN50	O
index	O
(	O
R2	O
=	O
0	O
.	O
23	O
)	O
(	O
Table	O
2	O
).	O

Finally	O
,	O
regression	O
analysis	O
revealed	O
that	O
birth	O
weight	O
was	O
the	O
only	O
significant	O
predictor	O
of	O
HF	O
,	O
and	O
explained	O
16	O
%	O
of	O
the	O
variance	O
in	O
HF	O
(	O
R2	O
=	O
0	O
.	O
16	O
)	O
(	O
Table	O
2	O
).	O
10	O
.	O
1371	O
/	O
journal	O
.	O
pone	O
.	O
0167328	O
.	O
g001	O
Caption	O
(	O
FIG	O
):	O
FIG	O
1	O
Scatter	O
plots	O
showing	O
the	O
correlation	O
between	O
birth	O
weight	O
with	O
systolic	O
(	O
A	O
)	O
and	O
diastolic	O
(	O
B	O
)	O
blood	O
pressure	O
levels	O
.	O

The	O
lines	O
represent	O
the	O
weighted	O
regression	O
with	O
its	O
95	O
%	O
confidence	O
interval	O
.	O
10	O
.	O
1371	O
/	O
journal	O
.	O
pone	O
.	O
0167328	O
.	O
g002	O
Caption	O
(	O
FIG	O
):	O
FIG	O
2	O
Scatter	O
plots	O
showing	O
the	O
correlation	O
between	O
birth	O
weight	O
with	O
parameters	O
of	O
the	O
time	O
domain	O
:	O
(	O
A	O
)	O
RMSSD	O
and	O
(	O
B	O
)	O
PNN50	O
.	O

The	O
lines	O
represent	O
the	O
weighted	O
regression	O
with	O
its	O
95	O
%	O
confidence	O
interval	O
.	O
10	O
.	O
1371	O
/	O
journal	O
.	O
pone	O
.	O
0167328	O
.	O
g003	O
Caption	O
(	O
FIG	O
):	O
FIG	O
3	O
Scatter	O
plots	O
showing	O
the	O
correlation	O
between	O
birth	O
weight	O
with	O
HF	O
,	O
parameter	O
of	O
the	O
frequency	O
domain	O
.	O

The	O
lines	O
represent	O
the	O
weighted	O
regression	O
with	O
its	O
95	O
%	O
confidence	O
interval	O
.	O
10	O
.	O
1371	O
/	O
journal	O
.	O
pone	O
.	O
0167328	O
.	O
t002	O
Caption	O
(	O
TABLE	O
-	O
WRAP	O
):	O
TABLE	O
2	O
Multiple	O
Linear	O
Regression	O
Analyses	O
for	O
the	O
Dependent	O
Variables	O
RMSSD	O
,	O
PNN50	O
and	O
HF	O
index	O
.	O
βSECI	O
(	O
95	O
%)	O
P	O
Value	O
RMSSD	O
(	O
ms	O
)	O
Birth	O
Weight0	O
.	O
0110	O
.	O
004	O
(	O
0	O
.	O
002	O
to	O
0	O
.	O
019	O
)	O
0	O
.	O
018	O
PNN50	O
(%)	O
Birth	O
Weight0	O
.	O
0080	O
.	O
003	O
(	O
0	O
.	O
002	O
to	O
0	O
.	O
012	O
)	O
0	O
.	O
007Age1	O
.	O
3650	O
.	O
677	O
(	O
0	O
.	O
019	O
to	O
2	O
.	O
710	O
)	O
0	O
.	O
047BMI	O
-	O
0	O
.	O
7530	O
.	O
308	O
(-	O
1	O
.	O
364	O
to	O
-	O
0	O
.	O
142	O
)	O
0	O
.	O
016	O
HF	O
(	O
n	O
.	O
u	O
.)	O

Birth	O
Weight0	O
.	O
0070	O
.	O
003	O
(	O
0	O
.	O
002	O
to	O
0	O
.	O
013	O
)	O
0	O
.	O
013	O
Confounding	O
factors	O
(	O
prematurity	O
,	O
birth	O
weight	O
,	O
gender	O
,	O
age	O
,	O
BMI	O
,	O
physical	O
activity	O
index	O
and	O
SBP	O
levels	O
)	O
were	O
included	O
in	O
the	O
same	O
regression	O
model	O
.	O

β	O
:	O
Parameter	O
estimate	O
indicating	O
the	O
alteration	O
in	O
HRV	O
components	O
caused	O
by	O
one	O
unit	O
of	O
change	O
in	O
the	O
independent	O
variable	O
;	O
SE	O
:	O
Standard	O
error	O
;	O
CI	O
:	O
Confidence	O
interval	O
;	O
BMI	O
—	O
Body	O
Mass	O
Index	O
;	O
RMSSD	O
—	O
Root	O
Mean	O
Square	O
of	O
Successive	O
Differences	O
;	O
pNN50	O
—	O
Percentage	O
of	O
Differences	O
Between	O
Adjacent	O
Normal	O
-	O
to	O
-	O
Normal	O
Intervals	O
that	O
is	O
Greater	O
than	O
50	O
Milliseconds	O
;	O
HF	O
(	O
n	O
.	O
u	O
.	O

)—	O
High	O
Frequency	O
in	O
Normalized	O
Units	O
.	O

Discussion	O
It	O
is	O
known	O
that	O
the	O
ANS	O
development	O
begins	O
in	O
fetal	O
life	O
and	O
persists	O
after	O
birth	O
[	O
30	O
,	O
31	O
].	O

There	O
is	O
evidence	O
suggesting	O
that	O
negative	O
insults	O
during	O
intrauterine	O
development	O
promote	O
functional	O
disorders	O
in	O
the	O
ANS	O
,	O
which	O
may	O
persist	O
later	O
in	O
life	O
[	O
32	O
].	O

Moreover	O
,	O
it	O
should	O
be	O
noted	O
that	O
alterations	O
in	O
autonomic	O
nervous	O
function	O
are	O
associated	O
with	O
low	O
birth	O
weight	O
and	O
cardiometabolic	O
abnormalities	O
[	O
17	O
,	O
19	O
,	O
20	O
,	O
33	O
].	O

Findings	O
from	O
the	O
present	O
study	O
demonstrated	O
that	O
children	O
with	O
low	O
birth	O
weight	O
have	O
abnormal	O
autonomic	O
modulation	O
,	O
suggesting	O
that	O
variation	O
in	O
birth	O
weight	O
seems	O
associated	O
with	O
the	O
differences	O
in	O
autonomic	O
function	O
observed	O
in	O
later	O
childhood	O
.	O

We	O
found	O
that	O
the	O
RMSSD	O
,	O
pNN50	O
index	O
and	O
HF	O
band	O
(	O
n	O
.	O
u	O
.)	O

an	O
indicative	B
of	O
the	O
cardiac	O
vagal	O
modulation	O
were	O
positively	O
correlated	O
with	O
birth	O
weight	O
.	O

These	O
findings	O
preserved	O
even	O
after	O
adjusting	O
for	O
prematurity	O
,	O
gender	O
,	O
age	O
,	O
BMI	O
,	O
physical	O
activity	O
index	O
and	O
SBP	O
levels	O
.	O

One	O
possible	O
interpretation	B
for	O
our	O
present	O
data	O
is	O
that	O
a	O
vagal	O
withdrawal	O
,	O
rather	O
than	O
a	O
sympathetic	O
overactivity	O
,	O
could	O
precede	O
the	O
development	O
of	O
hypertension	O
and	O
other	O
cardiometabolic	O
diseases	O
in	O
children	O
with	O
low	O
birth	O
weight	O
.	O

It	O
has	O
been	O
reported	O
that	O
low	O
birth	O
weight	O
is	O
related	O
to	O
modulation	O
of	O
both	O
the	O
sympathetic	O
and	O
parasympathetic	O
function	O
from	O
the	O
prenatal	O
period	O
through	O
childhood	O
and	O
adult	O
life	O
[	O
17	O
,	O
19	O
,	O
20	O
,	O
34	O
–	O
38	O
].	O

Decreases	O
in	O
the	O
HRV	O
parameters	O
were	O
noted	O
in	O
newborns	O
at	O
term	O
with	O
low	O
weight	O
[	O
34	O
],	O
while	O
other	O
studies	O
observed	O
a	O
normal	O
cardiac	O
autonomic	O
balance	O
in	O
these	O
neonates	O
[	O
17	O
,	O
35	O
].	O

A	O
recent	O
study	O
on	O
children	O
with	O
low	O
birth	O
weight	O
found	O
a	O
reduction	O
in	O
the	O
overall	O
activity	O
of	O
the	O
ANS	O
[	O
15	O
].	O

A	O
study	O
examining	O
young	O
adults	O
with	O
low	O
birth	O
weight	O
found	O
that	O
these	O
subjects	O
possessed	O
significantly	O
increased	O
parasympathetic	O
parameters	O
of	O
the	O
time	O
domain	O
[	O
19	O
].	O

Another	O
study	O
found	O
increased	O
sympathetic	O
activation	O
and	O
reduced	O
parasympathetic	O
activity	O
,	O
demonstrating	O
autonomic	O
imbalance	O
only	O
in	O
women	O
with	O
low	O
birth	O
weight	O
who	O
submitted	O
to	O
a	O
stress	O
test	O
[	O
20	O
].	O

Ward	O
et	O
al	O
.	O

[	O
36	O
]	O
also	O
observed	O
a	O
negative	O
correlation	O
between	O
birth	O
weight	O
and	O
heart	O
rate	O
in	O
response	O
to	O
psychological	O
stress	O
in	O
women	O
.	O

Other	O
studies	O
found	O
a	O
significant	O
correlation	O
between	O
low	O
birth	O
weight	O
and	O
increased	O
sympathetic	O
activity	O
in	O
adolescent	O
twin	O
pairs	O
and	O
young	O
adults	O
;	O
however	O
,	O
this	O
result	O
did	O
not	O
observed	O
gender	O
differences	O
[	O
37	O
,	O
38	O
].	O

Our	O
present	O
findings	O
indicate	O
a	O
reduction	O
in	O
activity	O
of	O
the	O
parasympathetic	O
ANS	O
associated	O
with	O
low	O
birth	O
weight	O
.	O

This	O
correlation	O
remained	O
significant	O
even	O
after	O
controlling	O
for	O
multiple	O
confounders	O
.	O

Therefore	B
,	O
our	O
data	O
are	O
consistent	O
and	O
complements	O
the	O
results	O
of	O
previous	O
studies	O
reporting	O
the	O
presence	O
of	O
impairment	O
in	O
the	O
vagal	O
cardiac	O
autonomic	O
modulation	O
in	O
children	O
born	O
with	O
low	O
weight	O
[	O
15	O
,	O
34	O
,	O
39	O
].	O

One	O
important	O
factor	O
that	O
could	O
contribute	O
to	O
these	O
discrepant	O
findings	O
is	O
the	O
use	O
of	O
birth	O
weight	O
as	B
a	O
unique	O
marker	O
of	O
fetal	O
development	O
.	O

The	O
deleterious	O
effects	O
on	O
development	O
often	B
vary	O
in	O
accordance	O
to	O
nature	O
of	O
the	O
cause	O
and	O
period	O
of	O
exposure	O
to	O
adverse	O
factors	O
which	O
have	O
led	O
to	O
low	O
birth	O
weight	O
.	O

It	O
is	O
well	O
known	O
that	O
lower	O
HRV	O
parameters	O
are	O
associated	O
with	O
increased	O
mortality	O
due	O
to	O
heart	O
failure	O
,	O
coronary	O
heart	O
disease	O
and	O
ischemic	O
cardiomyopathy	O
during	O
adulthood	O
[	O
40	O
].	O

There	O
is	O
also	O
evidence	O
that	O
decreased	O
parasympathetic	O
activity	O
is	O
correlated	O
with	O
high	O
blood	O
pressure	O
and	O
obesity	O
in	O
childhood	O
[	O
41	O
].	O

Thus	B
,	O
significant	O
correlation	O
between	O
lower	O
HRV	O
parameters	O
and	O
low	O
birth	O
weight	O
found	O
in	O
healthy	O
children	O
may	O
have	O
adverse	O
prognostic	O
effects	O
and	O
serve	O
as	B
an	O
early	O
sign	O
of	O
cardiometabolic	O
diseases	O
.	O

The	O
reason	B
why	O
low	O
birth	O
weight	O
promotes	O
alterations	O
in	O
cardiac	O
ANS	O
activity	O
among	O
health	O
individuals	O
is	O
unknown	O
.	O

Considering	B
that	O
ANS	O
is	O
stable	O
from	O
intrauterine	O
life	O
through	O
the	O
postnatal	O
period	O
[	O
42	O
–	O
44	O
],	O
an	O
inadequate	O
fetal	O
environment	O
can	O
lead	O
to	O
negative	O
changes	O
in	O
ANS	O
development	O
and	O
functionality	O
,	O
thus	B
promoting	O
long	O
-	O
lasting	O
consequences	O
later	O
in	O
life	O
.	O

It	O
has	O
been	O
demonstrated	O
that	O
children	O
born	O
to	O
parents	O
with	O
socioeconomic	O
problems	O
have	O
a	O
higher	O
probability	B
of	O
low	O
birth	O
weight	O
and	O
ANS	O
dysfunction	O
[	O
45	O
].	O

Interestingly	O
,	O
maternal	O
prenatal	O
stress	O
could	O
have	O
negative	O
effects	O
on	O
fetal	O
ANS	O
[	O
46	O
].	O

There	O
is	O
also	O
evidence	O
that	O
prenatal	O
supplementation	O
with	O
zinc	O
has	O
a	O
positive	O
effect	O
on	O
birth	O
weight	O
[	O
47	O
]	O
and	O
fetal	O
HRV	O
measures	O
[	O
48	O
,	O
49	O
].	O

Caulfield	O
et	O
al	O
.	O

[	O
50	O
]	O
found	O
that	O
the	O
beneficial	O
effects	O
of	O
prenatal	O
zinc	O
supplementation	O
on	O
the	O
ANS	O
balance	O
persisted	O
until	O
early	O
infancy	O
,	O
suggesting	O
that	O
the	O
nutritional	O
status	O
of	O
the	O
mother	O
is	O
important	O
to	O
fetal	O
ANS	O
development	O
.	O

These	O
findings	O
are	O
consistent	O
with	O
the	O
premise	O
that	O
modification	O
in	O
the	O
fetal	O
environment	O
could	O
alter	O
ANS	O
development	O
.	O

More	O
detailed	O
data	O
about	O
issues	O
during	O
pregnancy	O
should	O
be	O
obtained	O
in	O
an	O
attempt	O
to	O
identify	O
specific	O
periods	O
during	O
gestation	O
that	O
are	O
important	O
for	O
the	O
programming	O
of	O
the	O
fetal	O
autonomic	O
system	O
.	O

Other	O
potential	O
mechanism	O
that	O
would	O
explain	B
the	O
impairment	O
of	O
the	O
vagal	O
modulation	O
observed	O
in	O
children	O
with	O
low	O
birth	O
weight	O
could	O
be	O
mediated	O
by	O
renin	O
-	O
angiotensin	O
system	O
(	O
RAS	O
).	O

There	O
is	O
evidence	O
that	O
angiotensin	O
II	O
inhibits	O
parasympathetic	O
modulation	O
[	O
51	O
].	O

In	O
accordance	O
to	O
this	O
,	O
an	O
inverse	O
correlation	O
has	O
been	O
described	O
between	O
birth	O
weight	O
with	O
both	O
angiotensin	O
II	O
and	O
ACE	O
activity	O
[	O
52	O
–	O
54	O
].	O

This	O
is	O
important	O
since	B
children	O
with	O
low	O
birth	O
weight	O
with	O
higher	O
plasma	O
ACE	O
activity	O
would	O
presumably	B
have	O
high	O
angiotensin	O
II	O
levels	O
and	O
lower	O
associated	O
levels	O
of	O
cardiac	O
vagal	O
activity	O
.	O

Therefore	B
,	O
it	O
is	O
possible	O
that	O
the	O
RAS	O
hyperactivity	O
could	O
,	O
at	B
least	I
in	I
part	I
,	O
mediate	O
the	O
impairment	O
of	O
cardiac	O
vagal	O
tone	O
observed	O
in	O
low	O
birth	O
weight	O
children	O
.	O

It	O
is	O
noteworthy	O
,	O
however	O
,	O
that	O
complementary	O
researches	O
are	O
necessary	O
to	O
determine	O
the	O
mechanisms	O
involved	O
as	O
well	O
as	O
the	O
potential	O
influence	O
of	O
birth	O
weight	O
on	O
the	O
cardiac	O
autonomic	O
modulation	O
.	O

The	O
limitations	O
of	O
this	O
study	O
include	O
the	O
small	O
sample	O
size	O
based	O
on	O
a	O
cross	O
-	O
sectional	O
analysis	O
,	O
which	O
prevent	O
us	O
from	O
establishing	O
causal	O
relationships	O
.	O

Despite	O
these	O
,	O
our	O
study	O
was	O
able	O
to	O
replicate	O
findings	O
reported	O
in	O
individuals	O
from	O
developed	O
countries	O
.	O

In	O
conclusion	O
,	O
our	O
study	O
revealed	O
that	O
children	O
born	O
with	O
low	O
weight	O
presents	O
detriment	O
of	O
the	O
cardiac	O
vagal	O
autonomic	O
modulation	O
.	O

Therefore	B
,	O
the	O
high	O
risk	O
of	O
cardiometabolic	O
diseases	O
among	O
these	O
children	O
could	O
be	O
attributed	O
,	O
at	B
least	I
in	I
part	I
,	O
to	O
a	O
reduction	O
in	O
the	O
protective	O
actions	O
of	O
the	O
cardiac	O
vagal	O
tone	O
.	O

The	O
interaction	O
between	O
low	O
birth	O
weight	O
and	O
reduction	O
in	O
parasympathetic	O
regulation	O
observed	O
in	O
the	O
present	O
study	O
occurs	O
independently	O
of	O
prematurity	O
,	O
gender	O
,	O
age	O
,	O
BMI	O
,	O
physical	O
activity	O
index	O
and	O
SBP	O
levels	O
.	O

PubMed	O
Central	O
:	O

Impact	O
of	O
an	O
Intensive	O
Perinatal	O
Handwashing	O
Promotion	O
Intervention	O
on	O
Maternal	O
Handwashing	O
Behavior	O
in	O
the	O
Neonatal	O
Period	O
:	O
Findings	O
from	O
a	O
Randomized	O
Controlled	O
Trial	O
in	O
Rural	O
Bangladesh	O
Abstract	O
One	O
-	O
quarter	O
of	O
neonatal	O
deaths	O
are	O
attributed	O
to	O
infections	O
.	O

Maternal	O
handwashing	O
with	O
soap	O
may	O
prevent	O
neonatal	O
sepsis	O
.	O

We	O
examined	O
impact	O
of	O
intensive	O
handwashing	O
promotion	O
on	O
handwashing	O
behavior	O
of	O
mothers	O
of	O
neonates	O
.	O

In	O
Matlab	O
,	O
Bangladesh	O
,	O
we	O
randomly	O
allocated	O
pregnant	O
women	O
at	O
28	O
–	O
32	O
weeks	O
'	O
gestation	O
to	O
intensive	O
handwashing	O
promotion	O
or	O
control	O
.	O

Behavior	O
change	O
communicators	O
used	O
a	O
participatory	O
approach	O
to	O
motivate	O
maternal	O
handwashing	O
with	O
soap	O
and	O
provided	O
soap	O
and	O
handwashing	O
stations	O
.	O

In	O
the	O
neonatal	O
period	O
,	O
we	O
observed	O
soap	O
and	O
water	O
at	O
handwashing	O
places	O
and	O
,	O
at	O
the	O
end	O
of	O
the	O
neonatal	O
period	O
,	O
we	O
estimated	O
impact	O
on	O
maternal	O
handwashing	O
by	O
structured	O
observation	O
.	O

Among	O
253	O
women	O
enrolled	O
,	O
intervention	O
households	O
were	O
between	O
5	O
.	O
7	O
and	O
15	O
.	O
2	O
times	O
as	O
likely	B
as	O
control	O
households	O
to	O
have	O
soap	O
and	O
water	O
present	O
at	O
the	O
handwashing	O
station	O
in	O
the	O
baby	O
'	O
s	O
sleeping	O
area	O
.	O

Intervention	O
mothers	O
washed	O
hands	O
with	O
soap	O
4	O
.	O
1	O
times	O
as	O
frequently	O
as	O
controls	O
(	O
95	O
%	O
CI	O
2	O
.	O
55	O
–	O
6	O
.	O
59	O
);	O
handwashing	O
with	O
soap	O
at	O
recommended	O
times	O
was	O
infrequent	O
in	O
both	O
intervention	O
(	O
9	O
%)	O
and	O
control	O
(	O
2	O
%)	O
groups	O
.	O

Intensively	O
promoting	O
handwashing	O
with	O
soap	O
resulted	O
in	O
increased	O
availability	O
of	O
soap	O
and	O
water	O
at	O
handwashing	O
places	O
,	O
but	O
only	O
a	O
modest	O
increase	O
in	O
maternal	O
handwashing	O
with	O
soap	O
.	O

Novel	O
approaches	O
to	O
motivating	O
handwashing	O
behavior	O
to	O
protect	O
newborns	O
should	O
be	O
developed	O
and	O
evaluated	O
.	O

1	O
.	O

Introduction	O
In	O
2013	O
,	O
an	O
estimated	O
2	O
.	O
8	O
million	O
deaths	O
occurred	O
in	O
the	O
neonatal	O
period	O
globally	O
[	O
1	O
].	O

Among	O
these	O
,	O
one	O
-	O
quarter	O
are	O
attributed	O
to	O
infectious	O
causes	O
.	O

Infections	O
in	O
the	O
newborn	O
period	O
typically	O
include	O
pneumonia	O
,	O
sepsis	O
,	O
and	O
those	O
of	O
the	O
umbilical	O
cord	O
[	O
1	O
].	O

Deaths	O
in	O
the	O
neonatal	O
period	O
have	O
reduced	O
more	O
slowly	O
than	O
those	O
in	O
the	O
postneonatal	O
period	O
since	O
2000	O
.	O

With	O
the	O
current	O
complement	O
and	O
pace	O
of	O
public	O
health	O
efforts	O
,	O
neonatal	O
sepsis	O
is	O
projected	O
to	O
continue	O
to	O
cause	O
roughly	B
123	O
,	O
000	O
preventable	O
deaths	O
per	O
1000	O
live	O
births	O
in	O
2030	O
[	O
1	O
].	O

In	O
an	O
observational	O
study	O
of	O
23	O
,	O
662	O
infants	O
in	O
Nepal	O
,	O
Rhee	O
and	O
colleagues	O
found	O
that	O
neonates	O
of	O
mothers	O
who	O
reported	O
washing	O
their	O
hands	O
were	O
at	O
44	O
%	O
lower	O
risk	O
of	O
mortality	O
than	O
neonates	O
of	O
mothers	O
who	O
did	O
not	O
report	O
handwashing	O
[	O
2	O
].	O

In	O
the	O
same	O
region	O
,	O
Mullany	O
and	O
colleagues	O
found	O
that	O
reported	O
caregiver	O
handwashing	O
was	O
associated	O
with	O
a	O
24	O
%	O
lower	O
risk	O
of	O
umbilical	O
cord	O
infection	O
[	O
3	O
].	O

Although	O
these	O
results	O
are	O
provocative	O
,	O
reported	O
handwashing	O
behavior	O
consistently	B
exaggerates	O
observed	O
handwashing	O
behavior	O
and	O
so	O
reported	O
handwashing	O
behavior	O
is	O
not	O
a	O
valid	O
measure	O
of	O
handwashing	O
[	O
4	O
–	O
6	O
].	O

Indeed	O
,	O
reported	O
handwashing	O
behavior	O
is	O
susceptible	O
to	O
social	O
desirability	O
bias	O
,	O
with	O
wealthier	O
or	O
more	O
educated	O
respondents	O
;	O
that	O
is	O
,	O
those	O
whose	O
children	O
are	O
already	O
at	O
lower	O
risk	O
of	O
neonatal	O
mortality	O
,	O
potentially	O
more	O
likely	B
to	O
overreport	O
handwashing	O
behavior	O
than	O
less	O
wealthy	O
or	O
less	O
educated	O
counterparts	O
[	O
7	O
,	O
8	O
].	O

In	O
a	O
four	O
-	O
arm	O
cluster	O
-	O
randomized	O
controlled	O
trial	O
in	O
Pakistan	O
investigating	O
the	O
neonatal	O
mortality	O
effects	O
of	O
umbilical	O
cord	O
cleansing	O
with	O
chlorhexidine	O
and	O
handwashing	O
with	O
soap	O
promotion	O
separately	O
and	O
together	O
,	O
Soofi	O
and	O
colleagues	O
found	O
no	O
benefit	O
from	O
promoting	O
handwashing	O
with	O
soap	O
[	O
9	O
].	O

The	O
handwashing	O
intervention	O
tested	O
in	O
Pakistan	O
consisted	O
of	O
provision	O
of	O
a	O
bar	O
of	O
soap	O
and	O
“	O
encouragement	O
”	O
by	O
birth	O
attendants	O
for	O
mothers	O
and	O
other	O
family	O
members	O
to	O
wash	O
hands	O
“	O
before	O
handling	O
the	O
newborn	O
infant	O
.”	O
There	O
was	O
no	O
assessment	O
of	O
handwashing	O
behavior	O
measures	O
and	O
thus	B
,	O
it	O
is	O
not	O
clear	O
whether	O
the	O
intervention	O
did	O
not	O
affect	O
handwashing	O
behavior	O
or	O
whether	O
improved	O
handwashing	O
behavior	O
did	O
not	O
reduce	O
neonatal	O
mortality	O
.	O

Thus	B
,	O
there	O
is	O
a	O
lack	O
of	O
published	O
information	O
regarding	O
the	O
efficacy	O
of	O
perinatal	O
handwashing	O
promotion	O
interventions	O
on	O
maternal	O
handwashing	O
behavior	O
in	O
the	O
neonatal	O
period	O
and	O
on	O
neonatal	O
mortality	O
.	O

Greenland	O
and	O
colleagues	O
found	O
maternal	O
handwashing	O
in	O
the	O
neonatal	O
period	O
in	O
Indonesia	O
to	O
be	O
infrequent	O
,	O
with	O
handwashing	O
occurring	O
typically	O
because	O
of	O
discomfort	O
(	O
e	O
.	O
g	O
.,	O
due	O
to	O
sticky	O
substances	O
)	O
or	O
disgust	O
-	O
related	O
motivators	O
(	O
such	O
as	O
apparent	O
smell	O
)	O
[	O
10	O
].	O

In	O
Bangladesh	O
,	O
Parveen	O
and	O
colleagues	O
found	O
that	O
mothers	O
perceived	O
handwashing	O
is	O
an	O
important	O
approach	O
to	O
nurturing	O
their	O
newborns	O
and	O
young	O
children	O
and	O
that	O
they	O
were	O
more	O
likely	O
to	O
practice	O
the	O
behavior	O
when	O
supported	O
to	O
do	O
so	O
by	O
their	O
families	O
.	O

Not	O
having	O
necessary	O
materials	O
for	O
washing	O
hands	O
in	O
close	O
proximity	O
was	O
an	O
important	O
barrier	O
to	O
maternal	O
handwashing	O
in	O
the	O
neonatal	O
period	O
,	O
particularly	O
given	B
prevalent	O
social	O
expectations	O
regarding	O
mothers	O
and	O
newborns	O
staying	O
almost	O
exclusively	O
in	O
just	O
1	O
-	O
2	O
rooms	O
or	O
immediately	O
outside	O
the	O
home	O
[	O
11	O
,	O
12	O
].	O

A	O
barrier	O
to	O
maternal	O
handwashing	O
in	O
rural	O
Bangladesh	O
was	O
the	O
lack	O
of	O
self	O
-	O
efficacy	O
on	O
the	O
part	O
of	O
the	O
mother	O
to	O
prioritize	O
and	O
carry	O
out	O
the	O
behavior	O
because	O
of	O
conflicting	O
opinions	O
from	O
her	O
in	O
-	O
laws	O
,	O
who	O
may	O
drive	O
decision	O
-	O
making	O
regarding	O
childcare	O
and	O
household	O
expenditures	O
.	O

Also	O
,	O
mothers	O
felt	O
that	O
the	O
neonatal	O
period	O
is	O
a	O
particularly	O
busy	O
time	O
,	O
with	O
increased	O
childcare	O
responsibilities	O
and	O
sometimes	O
increased	O
housework	O
,	O
which	O
interfere	O
with	O
her	O
ability	O
to	O
wash	O
hands	O
even	O
when	O
she	O
feels	O
she	O
should	O
[	O
13	O
].	O

We	O
developed	O
an	O
intensive	O
intervention	O
to	O
improve	O
maternal	O
handwashing	O
behavior	O
during	O
the	O
neonatal	O
period	O
,	O
addressing	O
several	O
of	O
the	O
key	O
barriers	O
and	O
motivators	O
identified	O
by	O
Parveen	O
and	O
colleagues	O
,	O
described	O
above	O
.	O

Our	O
objective	O
,	O
in	O
a	O
randomized	O
controlled	O
trial	O
in	O
rural	O
Bangladesh	O
,	O
was	O
to	O
investigate	O
the	O
impact	O
of	O
this	O
intervention	O
on	O
the	O
handwashing	O
behavior	O
of	O
mothers	O
in	O
the	O
neonatal	O
period	O
.	O

2	O
.	O

Materials	O
and	O
Methods	O
This	O
study	O
was	O
conducted	O
in	O
Matlab	O
,	O
a	O
rural	O
area	O
55	O
km	O
southeast	O
of	O
Dhaka	O
,	O
Bangladesh	O
.	O

In	O
2007	O
,	O
44	O
%	O
of	O
mothers	O
in	O
the	O
study	O
area	O
reported	O
not	O
receiving	O
any	O
antenatal	O
care	O
in	O
the	O
third	O
trimester	O
and	O
72	O
%	O
of	O
births	O
were	O
attended	O
by	O
traditional	O
birth	O
attendants	O
[	O
14	O
].	O

The	O
neonatal	O
mortality	O
rate	O
in	O
this	O
area	O
was	O
estimated	O
at	O
29	O
.	O
9	O
deaths	O
per	O
1000	O
live	O
births	O
[	O
14	O
].	O

The	O
Health	O
and	O
Demographic	O
Surveillance	O
System	O
(	O
HDSS	O
)	O
in	O
Matlab	O
identifies	O
pregnant	O
women	O
within	O
two	O
months	O
of	O
conception	O
through	O
bimonthly	O
home	O
visits	O
.	O

A	O
Community	O
Health	O
Research	O
Worker	O
confirms	O
a	O
pregnancy	O
in	O
all	O
women	O
of	O
child	O
bearing	O
age	O
who	O
have	O
missed	O
a	O
menstrual	O
cycle	O
with	O
a	O
urine	O
test	O
during	O
the	O
bimonthly	O
visit	O
.	O

Estimated	O
delivery	O
dates	O
and	O
contact	O
information	O
for	O
each	O
pregnant	O
woman	O
identified	O
in	O
the	O
surveillance	O
area	O
are	O
maintained	O
by	O
icddr	O
,	O
b	O
Matlab	O
field	O
site	O
staff	O
.	O

We	O
recruited	O
from	O
49	O
villages	O
in	O
the	O
study	O
area	O
,	O
which	O
were	O
not	O
receiving	O
any	O
active	O
maternal	O
and	O
child	O
health	O
or	O
nutrition	O
interventions	O
.	O

Between	O
October	O
2010	O
and	O
October	O
2011	O
,	O
data	O
collectors	O
approached	O
primiparous	O
women	O
identified	O
in	O
the	O
study	O
area	O
through	O
the	O
HDSS	O
pregnancy	O
database	O
with	O
a	O
due	O
date	O
between	O
December	O
1	O
,	O
2010	O
,	O
and	O
December	O
1	O
,	O
2011	O
.	O

We	O
included	O
primiparous	O
mothers	O
for	O
the	O
handwashing	O
study	O
because	O
we	O
anticipated	O
that	O
they	O
would	O
be	O
at	O
a	O
uniquely	O
teachable	O
moment	O
[	O
15	O
,	O
16	O
].	O

Primiparous	O
women	O
were	O
eligible	O
if	O
the	O
following	O
criteria	O
were	O
met	O
:	O
Woman	O
planned	O
to	O
remain	O
in	O
the	O
study	O
area	O
for	O
at	O
least	O
one	O
month	O
before	O
and	O
one	O
month	O
after	O
delivery	O
.	O

No	O
other	O
women	O
living	O
in	O
the	O
same	O
household	O
compound	O
had	O
previously	O
taken	O
part	O
in	O
either	O
arm	O
of	O
the	O
study	O
.	O

Women	O
were	O
not	O
from	O
household	O
compounds	O
that	O
had	O
participated	O
in	O
the	O
qualitative	O
research	O
on	O
motivators	O
and	O
barriers	O
to	O
handwashing	O
in	O
the	O
neonatal	O
period	O
.	O

Women	O
were	O
not	O
enrolled	O
in	O
any	O
other	O
study	O
;	O
in	O
some	O
of	O
the	O
villages	O
,	O
a	O
study	O
on	O
antenatal	O
nutrition	O
that	O
enrolled	O
women	O
early	O
in	O
pregnancy	O
was	O
being	O
implemented	O
concurrently	O
.	O
Eligible	O
women	O
were	O
requested	O
to	O
provide	O
signed	O
informed	O
consent	O
.	O

Prior	O
to	O
randomization	O
,	O
we	O
recorded	O
baseline	O
knowledge	O
of	O
hygiene	O
and	O
beliefs	O
pertaining	O
to	O
childcare	O
and	O
neonatal	O
illness	O
,	O
perceptions	O
of	O
risk	O
and	O
severity	O
of	O
neonatal	O
illness	O
,	O
antenatal	O
care	O
,	O
and	O
demographic	O
information	O
,	O
using	O
questionnaires	O
and	O
observations	O
.	O

Staff	O
regularly	O
contacted	O
women	O
during	O
the	O
two	O
weeks	O
preceding	O
their	O
estimated	O
due	O
date	O
to	O
identify	O
births	O
as	O
soon	O
as	O
possible	O
after	O
delivery	O
;	O
women	O
and	O
their	O
families	O
were	O
also	O
encouraged	O
to	O
contact	O
study	O
staff	O
for	O
birth	O
notification	O
.	O

We	O
used	O
block	O
randomization	O
,	O
using	O
blocks	O
of	O
4	O
,	O
to	O
randomize	O
participants	O
to	O
either	O
the	O
intervention	O
or	O
control	O
arm	O
.	O

A	O
study	O
team	O
member	O
not	O
involved	O
in	O
day	O
-	O
to	O
-	O
day	O
field	O
operations	O
constructed	O
the	O
assignment	O
table	O
.	O

The	O
field	O
team	O
leader	O
consulted	O
the	O
assignment	O
table	O
in	O
order	O
to	O
determine	O
the	O
arm	O
to	O
which	O
the	O
participant	O
was	O
allocated	O
.	O

Data	O
collectors	O
were	O
not	O
blinded	O
to	O
the	O
assignment	O
status	O
of	O
participants	O
,	O
since	O
the	O
intervention	O
included	O
various	O
hardware	O
(	O
handwashing	O
stations	O
and	O
visual	O
materials	O
hung	O
in	O
the	O
home	O
),	O
which	O
were	O
expected	O
to	O
be	O
visible	O
during	O
the	O
data	O
collector	O
'	O
s	O
visit	O
to	O
the	O
household	O
.	O

2	O
.	O
1	O
.	O

Intervention	O
We	O
trained	O
female	O
behavior	O
change	O
communicators	O
,	O
who	O
typically	O
have	O
Master	O
'	O
s	O
degrees	O
and	O
experience	O
in	O
data	O
collection	O
,	O
to	O
implement	O
the	O
intervention	O
.	O

The	O
training	O
consisted	O
of	O
didactic	O
sessions	O
,	O
role	O
plays	O
,	O
and	O
field	O
pilots	O
and	O
was	O
delivered	O
over	O
16	O
days	O
.	O

Both	O
intervention	O
and	O
control	O
participants	O
received	O
maternal	O
and	O
neonatal	O
health	O
counseling	O
,	O
patterned	B
on	I
information	O
delivered	O
in	O
Projahnmo	O
[	O
17	O
]	O
(	O
see	O
visit	O
schedule	O
inFigure	O
1	O
).	O

The	O
behavior	O
change	O
communication	O
strategy	O
was	O
based	B
on	I
a	O
theoretical	O
model	O
constructed	O
a	O
priori	O
that	O
included	O
concepts	O
of	O
the	O
Health	O
Belief	O
Model	O
and	O
the	O
heuristic	B
model	O
for	O
teachable	O
moments	O
,	O
described	O
by	O
McBride	O
and	O
colleagues	O
[	O
13	O
,	O
15	O
,	O
18	O
].	O

As	O
shown	O
in	O
a	O
companion	O
qualitative	O
investigation	O
,	O
this	O
model	O
was	O
used	O
to	O
understand	O
drivers	O
of	O
maternal	O
handwashing	O
in	O
the	O
neonatal	O
period	O
[	O
11	O
].	O

Consistent	O
with	O
the	O
findings	O
from	O
the	O
qualitative	O
work	O
,	O
behavior	O
change	O
communicators	O
used	O
an	O
interactive	O
approach	O
to	O
validate	O
the	O
prevalent	O
perceived	O
susceptibility	O
of	O
the	O
neonatal	O
period	O
.	O

They	O
sought	O
to	O
have	O
the	O
mother	O
and	O
family	O
members	O
identify	O
perceived	O
barriers	O
to	O
their	O
own	O
handwashing	O
,	O
to	O
address	O
those	O
barriers	O
through	O
behavioral	O
solutions	O
,	O
and	O
to	O
enhance	O
maternal	O
self	O
-	O
efficacy	O
for	O
handwashing	O
in	O
the	O
neonatal	O
period	O
.	O

Study	O
staff	O
also	O
improved	O
access	O
to	O
handwashing	O
materials	O
in	O
the	O
physical	O
environment	O
to	O
facilitate	O
handwashing	O
[	O
18	O
,	O
19	O
].	O

Key	O
constructs	O
addressed	O
in	O
the	O
handwashing	O
intervention	O
included	O
the	O
following	O
:	O
nurture	O
as	O
motivator	O
for	O
handwashing	O
(	O
to	O
have	O
healthy	O
baby	O
who	O
grows	O
well	O
,	O
mother	O
'	O
s	O
desire	O
to	O
take	O
good	O
care	O
of	O
baby	O
)	O
improved	O
convenience	O
(	O
three	O
handwashing	O
stations	O
were	O
provided	O
for	O
continuous	O
stocking	O
with	O
soap	O
and	O
water	O
,	O
including	O
in	O
the	O
room	O
where	O
the	O
baby	O
would	O
likely	O
spend	O
time	O
;	O
soap	O
was	O
replenished	O
by	O
study	O
staff	O
as	O
needed	O
throughout	O
the	O
perinatal	O
period	O
)	O
cues	O
to	O
action	O
(	O
encouraged	O
verbal	O
reminders	O
,	O
provided	O
cue	O
cards	O
with	O
times	O
for	O
handwashing	O
)	O
There	O
is	O
prior	O
observational	O
evidence	O
supporting	O
the	O
beneficial	O
effect	O
of	O
maternal	O
handwashing	O
before	O
contact	O
with	O
the	O
umbilical	O
cord	O
for	O
prevention	O
of	O
neonatal	O
infections	O
[	O
3	O
].	O

Otherwise	O
,	O
we	O
found	O
no	O
clear	O
published	O
evidence	O
for	O
times	O
at	O
which	O
maternal	O
or	O
other	O
caregiver	O
handwashing	O
may	O
prevent	O
pathogen	O
transfer	O
to	O
/	O
from	O
hands	O
in	O
low	O
-	O
income	O
settings	O
.	O

Therefore	B
,	O
we	O
recommended	O
the	O
following	O
times	O
of	O
possible	O
pathogen	O
transmission	O
to	O
the	O
neonate	O
for	O
handwashing	O
with	O
soap	O
:	O
after	O
respiratory	O
secretion	O
contact	O
,	O
before	O
umbilical	O
cord	O
care	O
,	O
before	O
breastfeeding	O
,	O
and	O
after	O
fecal	O
contact	O
.	O

To	O
stay	O
consistent	O
with	O
typical	O
handwashing	O
promotion	O
messages	O
,	O
we	O
also	O
recommended	O
handwashing	O
with	O
soap	O
before	O
food	O
preparation	O
.	O

2	O
.	O
2	O
.	O

Outcome	O
Measures	O
We	O
used	O
two	O
principal	O
methods	O
to	O
measure	O
handwashing	O
behavior	O
:	O
rapid	O
assessments	O
of	O
the	O
presence	O
of	O
handwashing	O
materials	O
and	O
direct	O
(	O
structured	O
)	O
observations	O
.	O

At	O
baseline	O
and	O
during	O
postnatal	O
days	O
4	O
-	O
5	O
,	O
10	O
–	O
12	O
,	O
13	O
–	O
15	O
,	O
and	O
20	O
–	O
22	O
,	O
the	O
data	O
collector	O
identified	O
the	O
presence	O
and	O
location	O
of	O
a	O
designated	O
handwashing	O
station	O
(	O
s	O
),	O
and	O
the	O
presence	O
of	O
water	O
and	O
soap	O
at	O
the	O
handwashing	O
station	O
(	O
s	O
)	O
(	O
Figure	O
1	O
).	O

She	O
assessed	O
the	O
presence	O
of	O
fully	O
stocked	O
handwashing	O
stations	O
anywhere	O
in	O
the	O
home	O
and	O
specifically	O
in	O
the	O
room	O
where	O
the	O
newborn	O
spent	O
most	O
of	O
his	O
/	O
her	O
time	O
.	O

Rapid	O
assessments	O
were	O
unannounced	O
.	O

The	O
structured	O
observation	O
was	O
conducted	O
on	O
days	O
30	O
–	O
32	O
postpartum	O
and	O
lasted	O
3	O
hours	O
.	O

During	O
the	O
observation	O
period	O
,	O
a	O
data	O
collector	O
positioned	O
herself	O
in	O
the	O
home	O
/	O
compound	O
in	O
order	O
to	O
assess	O
handwashing	O
behaviors	O
at	O
times	O
of	O
possible	O
pathogen	O
transmission	O
to	O
the	O
neonate	O
.	O

Typically	O
,	O
the	O
subject	O
of	O
observation	O
was	O
the	O
mother	O
;	O
other	O
family	O
members	O
interacting	O
with	O
the	O
neonate	O
(	O
including	O
touching	O
,	O
cooing	O
,	O
feeding	O
,	O
and	O
bathing	O
)	O
were	O
observed	O
as	O
well	O
.	O

The	O
primary	O
outcome	O
of	O
interest	O
was	O
maternal	O
handwashing	O
with	O
soap	O
at	O
times	O
of	O
possible	O
pathogen	O
transmission	O
to	O
the	O
neonate	O
.	O

Secondary	O
outcomes	O
included	O
the	O
total	O
number	O
of	O
times	O
mothers	O
were	O
observed	O
washing	O
hands	O
with	O
soap	O
during	O
3	O
-	O
hour	O
observations	O
;	O
the	O
maintenance	O
of	O
soap	O
and	O
water	O
for	O
handwashing	O
anywhere	O
in	O
the	O
home	O
and	O
specifically	O
where	O
newborns	O
rest	O
for	O
most	O
of	O
the	O
day	O
;	O
handwashing	O
with	O
soap	O
by	O
other	O
household	O
members	O
at	O
times	O
of	O
possible	O
pathogen	O
transmission	O
;	O
and	O
the	O
number	O
of	O
events	O
observed	O
among	O
household	O
members	O
other	O
than	O
the	O
mother	O
washing	O
hands	O
with	O
soap	O
during	O
the	O
3	O
-	O
hour	O
observations	O
.	O

2	O
.	O
3	O
.	O

Sample	O
Size	O
Estimation	O
When	O
this	O
study	O
was	O
being	O
planned	O
,	O
we	O
were	O
not	O
aware	O
of	O
data	O
describing	O
the	O
observed	O
frequency	O
of	O
hand	O
cleansing	O
before	O
cord	O
cleansing	O
.	O

Substantially	O
more	O
information	O
is	O
available	O
regarding	O
the	O
frequency	O
of	O
hand	O
cleansing	O
after	O
defecation	O
.	O

Thus	O
,	O
to	O
estimate	O
the	O
required	O
sample	O
size	O
for	O
measuring	O
the	O
impact	O
of	O
handwashing	O
promotion	O
on	O
maternal	O
handwashing	O
behavior	O
,	O
we	O
assumed	B
that	O
the	O
probability	O
of	O
observed	O
handwashing	O
with	O
soap	O
after	O
a	O
fecal	O
contact	O
event	O
would	O
be	O
0	O
.	O
20	O
in	O
the	O
control	O
arm	O
[	O
20	O
]	O
and	O
that	O
the	O
probability	O
would	O
increase	O
to	O
0	O
.	O
40	O
in	O
the	O
intervention	O
arm	O
.	O

We	O
also	O
assumed	B
one	O
fecal	O
contact	O
event	O
to	O
be	O
detected	O
per	O
3	O
-	O
hour	O
structured	O
observation	O
.	O

Based	O
on	O
these	O
assumptions	O
,	O
80	O
%	O
power	O
,	O
and	O
a	O
.	O
05	O
significance	O
level	O
,	O
we	O
estimated	O
that	O
we	O
would	O
need	O
to	O
conduct	O
3	O
-	O
hour	O
structured	O
observations	O
among	O
80	O
respondents	O
in	O
each	O
study	O
arm	O
.	O

To	O
account	O
for	O
clustering	O
of	O
behavior	O
at	O
the	O
individual	O
level	O
(	O
i	O
.	O
e	O
.,	O
an	O
individual	O
is	O
more	O
likely	O
to	O
behave	O
like	O
herself	O
than	O
she	O
is	O
to	O
behave	O
like	O
others	O
),	O
we	O
introduced	O
a	O
design	O
effect	O
of	O
2	O
,	O
increasing	O
the	O
sample	O
size	O
up	O
to	O
160	O
in	O
each	O
arm	O
.	O

We	O
further	O
increased	O
the	O
desired	O
sample	O
to	O
200	O
per	O
arm	O
to	O
account	O
for	O
potential	O
loss	O
to	O
follow	O
-	O
up	O
,	O
and	O
adverse	O
perinatal	O
outcomes	O
such	O
as	O
maternal	O
or	O
neonatal	O
death	O
,	O
since	O
structured	O
observations	O
would	O
not	O
be	O
feasible	O
or	O
appropriate	O
in	O
such	O
cases	O
.	O

2	O
.	O
4	O
.	O

Data	O
Analysis	O
The	O
primary	O
outcome	O
of	O
interest	O
was	O
based	O
on	O
structured	O
observation	O
data	O
and	O
reflects	O
the	O
proportion	O
of	O
intervention	O
-	O
recommended	O
times	O
at	O
which	O
one	O
or	O
both	O
hands	O
were	O
washed	O
with	O
soap	O
.	O

In	O
order	O
to	O
compare	O
the	O
frequency	O
of	O
handwashing	O
during	O
the	O
observation	O
period	O
between	O
treatment	O
arms	O
,	O
we	O
used	O
mixed	O
linear	O
regression	O
to	O
calculate	O
the	O
difference	O
in	O
the	O
mean	O
number	O
of	O
observed	O
handwashing	O
events	O
between	O
arms	O
,	O
separately	O
among	O
and	O
other	O
household	O
members	O
,	O
in	O
an	O
intent	O
-	O
to	O
-	O
treat	O
analysis	O
.	O

Although	O
not	O
prespecified	O
,	O
we	O
also	O
generated	O
rate	O
ratios	O
to	O
compare	O
the	O
proportion	O
of	O
intervention	O
-	O
recommended	O
times	O
at	O
which	O
hands	O
were	O
washed	O
in	O
the	O
two	O
study	O
arms	O
;	O
we	O
used	O
log	O
binomial	O
regression	O
,	O
accounting	O
for	O
repeated	O
measures	O
at	O
the	O
caregiver	O
level	O
to	O
adjust	O
standard	O
errors	O
.	O

We	O
assessed	O
differences	O
between	O
the	O
study	O
arms	O
,	O
with	O
respect	O
to	O
observed	O
handwashing	O
with	O
soap	O
among	O
other	O
family	O
members	O
interacting	O
with	O
the	O
neonate	O
.	O

In	O
supplemental	O
multivariate	O
analyses	O
,	O
we	O
adjusted	O
for	O
baseline	O
differences	O
between	O
study	O
arms	O
.	O

We	O
also	O
report	O
the	O
proportion	O
of	O
mothers	O
who	O
maintained	O
soap	O
and	O
water	O
at	O
at	O
least	O
one	O
handwashing	O
station	O
in	O
the	O
home	O
and	O
at	O
a	O
handwashing	O
station	O
in	O
the	O
room	O
where	O
the	O
neonate	O
was	O
cared	O
for	O
and	O
compare	O
the	O
intervention	O
and	O
control	O
groups	O
at	O
each	O
time	O
point	O
that	O
this	O
outcome	O
was	O
observed	O
.	O

This	O
trial	O
was	O
registered	O
athttp	O
://	O
www	O
.	O
clinicaltrials	O
.	O
gov	O
(	O
Identifier	O
:	O
NCT01309321	O
).	O

This	O
study	O
was	O
reviewed	O
and	O
approved	O
by	O
the	O
Research	O
and	O
Ethical	O
Review	O
Committees	O
at	O
icddr	O
,	O
b	O
:	O
International	O
Centre	O
for	O
Diarrhoeal	O
Diseases	O
Research	O
,	O
Bangladesh	O
(	O
PR	O
-	O
10036	O
).	O

3	O
.	O

Results	O
Between	O
October	O
2010	O
and	O
October	O
2011	O
,	O
we	O
identified	O
695	O
pregnant	O
women	O
reported	O
to	O
be	O
between	O
28	O
and	O
32	O
weeks	O
of	O
gestation	O
in	O
the	O
study	O
villages	O
(	O
Figure	O
2	O
).	O

Common	O
reasons	O
for	O
ineligibility	O
included	O
identification	O
too	O
late	O
in	O
the	O
pregnancy	O
or	O
a	O
due	O
date	O
too	O
late	O
for	O
complete	O
data	O
collection	O
(	O
24	O
%),	O
previous	O
enrollment	O
of	O
another	O
pregnant	O
woman	O
in	O
the	O
same	O
compound	O
(	O
11	O
%),	O
and	O
enrollment	O
in	O
another	O
study	O
(	O
6	O
%).	O

Of	O
the	O
256	O
(	O
37	O
%)	O
women	O
who	O
met	O
eligibility	O
criteria	O
,	O
253	O
(	O
99	O
%)	O
consented	O
to	O
take	O
part	O
.	O

We	O
randomized	O
126	O
(	O
49	O
.	O
8	O
%)	O
participants	O
to	O
the	O
intervention	O
arm	O
and	O
127	O
(	O
50	O
.	O
2	O
%)	O
to	O
the	O
control	O
arm	O
.	O

One	O
participant	O
assigned	O
to	O
the	O
intervention	O
arm	O
and	O
two	O
in	O
the	O
control	O
arm	O
were	O
later	O
found	O
to	O
be	O
ineligible	O
because	O
another	O
woman	O
residing	O
in	O
the	O
same	O
household	O
compound	O
had	O
previously	O
been	O
enrolled	O
in	O
the	O
study	O
;	O
data	O
collection	O
was	O
discontinued	O
upon	O
identification	O
of	O
the	O
ineligibility	O
criteria	O
.	O

Therefore	O
,	O
we	O
analyzed	O
data	O
from	O
125	O
women	O
in	O
each	O
arm	O
.	O

Participants	O
in	O
the	O
two	O
treatment	O
arms	O
had	O
similar	O
baseline	O
measures	O
,	O
including	O
demographics	O
,	O
soap	O
and	O
water	O
at	O
a	O
handwashing	O
station	O
,	O
wealth	O
measures	O
,	O
and	O
number	O
of	O
years	O
of	O
education	O
for	O
the	O
mother	O
(	O
Table	O
1	O
).	O

The	O
arms	O
were	O
similar	O
with	O
respect	O
to	O
roof	O
and	O
wall	O
materials	O
.	O

Whereas	O
the	O
number	O
of	O
years	O
of	O
education	O
for	O
the	O
participant	O
herself	O
was	O
similar	O
in	O
the	O
two	O
arms	O
,	O
participants	O
in	O
the	O
control	O
arm	O
reported	O
a	O
mean	O
of	O
7	O
.	O
2	O
years	O
(	O
SD	O
3	O
.	O
3	O
)	O
of	O
education	O
for	O
the	O
husband	O
,	O
compared	O
to	O
those	O
in	O
the	O
intervention	O
arm	O
who	O
reported	O
a	O
mean	O
of	O
8	O
.	O
8	O
years	O
(	O
SD	O
12	O
.	O
0	O
).	O

Access	O
to	O
a	O
deep	O
tubewell	O
was	O
also	O
somewhat	O
different	O
between	O
the	O
two	O
groups	O
(	O
59	O
%	O
controls	O
,	O
68	O
%	O
intervention	O
).	O

At	O
baseline	O
,	O
the	O
majority	O
in	O
each	O
arm	O
,	O
67	O
%	O
of	O
controls	O
and	O
60	O
%	O
of	O
intervention	O
participants	O
,	O
indicated	O
that	O
their	O
main	O
handwashing	O
station	O
was	O
near	O
the	O
tubewell	O
.	O

None	O
of	O
the	O
participants	O
in	O
the	O
control	O
arm	O
and	O
only	O
2	O
(	O
2	O
%)	O
in	O
the	O
intervention	O
arm	O
were	O
observed	O
to	O
have	O
their	O
main	O
handwashing	O
station	O
inside	O
the	O
house	O
.	O

Almost	O
all	O
participants	O
were	O
found	O
to	O
have	O
water	O
,	O
but	O
just	O
15	O
(	O
12	O
%)	O
in	O
each	O
arm	O
were	O
observed	O
to	O
have	O
bar	O
soap	O
at	O
the	O
main	O
handwashing	O
station	O
;	O
other	O
types	O
of	O
soap	O
were	O
rarely	O
observed	O
.	O

We	O
documented	O
2	O
(	O
2	O
%)	O
stillbirths	O
and	O
4	O
(	O
3	O
%)	O
neonatal	O
deaths	O
in	O
the	O
intervention	O
arm	O
and	O
6	O
(	O
5	O
%)	O
stillbirths	O
and	O
2	O
(	O
6	O
%)	O
neonatal	O
deaths	O
in	O
the	O
control	O
arm	O
.	O

There	O
were	O
no	O
maternal	O
deaths	O
.	O

All	O
births	O
were	O
notified	O
either	O
by	O
the	O
respondent	O
/	O
family	O
or	O
upon	O
telephone	O
call	O
by	O
study	O
staff	O
following	O
the	O
estimated	O
date	O
of	O
delivery	O
.	O

During	O
rapid	O
assessments	O
conducted	O
on	O
postnatal	O
days	O
4	O
-	O
5	O
,	O
the	O
proportion	O
of	O
households	O
observed	O
to	O
have	O
soap	O
and	O
water	O
at	O
a	O
handwashing	O
place	O
was	O
77	O
%	O
in	O
the	O
intervention	O
arm	O
and	O
27	O
%	O
in	O
the	O
control	O
arm	O
(	O
RR	O
3	O
.	O
0	O
,	O
95	O
%	O
CI	O
2	O
.	O
11	O
–	O
4	O
.	O
15	O
,	O
p	O
<	O
.	O
0001	O
)	O
(	O
Figure	O
3	O
).	O

At	O
all	O
five	O
assessments	O
made	O
during	O
the	O
neonatal	O
period	O
,	O
households	O
in	O
the	O
intervention	O
arm	O
were	O
3	O
or	O
more	O
times	O
as	O
likely	B
as	O
households	O
in	O
the	O
control	O
arm	O
to	O
have	O
at	O
least	O
one	O
handwashing	O
station	O
observed	O
to	O
have	O
soap	O
and	O
water	O
present	O
.	O

All	O
five	O
assessments	O
were	O
successfully	O
completed	O
in	O
104	O
intervention	O
households	O
and	O
97	O
control	O
households	O
.	O

Among	O
these	O
,	O
39	O
%	O
of	O
intervention	O
households	O
and	O
3	O
%	O
of	O
control	O
households	O
were	O
observed	O
to	O
have	O
soap	O
and	O
water	O
at	O
a	O
handwashing	O
station	O
at	O
all	O
of	O
the	O
visits	O
.	O

The	O
majority	O
(	O
84	O
%)	O
of	O
respondents	O
in	O
the	O
intervention	O
arm	O
and	O
44	O
%	O
of	O
respondents	O
in	O
the	O
control	O
arm	O
reported	O
that	O
the	O
primary	O
handwashing	O
station	O
used	O
by	O
the	O
respondent	O
was	O
located	O
in	O
the	O
baby	O
'	O
s	O
sleeping	O
area	O
,	O
at	O
postnatal	O
days	O
4	O
-	O
5	O
(	O
RR	O
=	O
2	O
.	O
2	O
,	O
95	O
%	O
CI	O
1	O
.	O
72	O
–	O
2	O
.	O
92	O
,	O
p	O
<	O
.	O
0001	O
),	O
decaying	O
to	O
51	O
%	O
of	O
respondents	O
in	O
the	O
intervention	O
arm	O
and	O
9	O
%	O
of	O
respondents	O
in	O
the	O
control	O
arm	O
during	O
the	O
last	O
week	O
of	O
the	O
neonatal	O
period	O
(	O
RR	O
=	O
4	O
.	O
7	O
,	O
95	O
%	O
CI	O
2	O
.	O
53	O
–	O
8	O
.	O
76	O
,	O
p	O
<	O
.	O
0001	O
).	O

Soap	O
and	O
water	O
were	O
observed	O
at	O
the	O
handwashing	O
station	O
in	O
the	O
baby	O
'	O
s	O
sleeping	O
area	O
at	O
65	O
%	O
of	O
intervention	O
households	O
and	O
10	O
%	O
of	O
control	O
households	O
at	O
the	O
observation	O
conducted	O
at	O
postnatal	O
days	O
4	O
-	O
5	O
(	O
RR	O
=	O
5	O
.	O
6	O
,	O
95	O
%	O
CI	O
3	O
.	O
12	O
–	O
10	O
.	O
14	O
,	O
p	O
<	O
.	O
0001	O
)	O
(	O
Figure	O
4	O
).	O

Across	O
the	O
five	O
visits	O
made	O
in	O
the	O
neonatal	O
period	O
,	O
intervention	O
households	O
were	O
between	O
5	O
.	O
7	O
and	O
15	O
.	O
2	O
times	O
as	O
likely	B
as	O
control	O
households	O
to	O
have	O
soap	O
and	O
water	O
present	O
at	O
the	O
handwashing	O
station	O
in	O
the	O
baby	O
'	O
s	O
sleeping	O
area	O
.	O

During	O
days	O
30	O
–	O
32	O
,	O
we	O
completed	O
3	O
-	O
hour	O
structured	O
observations	O
of	O
106	O
(	O
85	O
%)	O
control	O
and	O
112	O
(	O
90	O
%)	O
intervention	O
participants	O
(	O
Table	O
2	O
).	O

Loss	O
to	O
follow	O
-	O
up	O
is	O
described	O
inFigure	O
2	O
.	O

Whereas	O
the	O
frequency	O
of	O
handwashing	O
with	O
water	O
alone	O
was	O
similar	O
in	O
the	O
two	O
groups	O
(	O
mean	O
1	O
.	O
6	O
events	O
in	O
intervention	O
arm	O
,	O
1	O
.	O
5	O
events	O
in	O
control	O
arm	O
),	O
mothers	O
in	O
the	O
intervention	O
arm	O
washed	O
their	O
hands	O
with	O
soap	O
with	O
a	O
mean	O
of	O
0	O
.	O
82	O
times	O
(	O
SD	O
1	O
.	O
2	O
)	O
during	O
the	O
3	O
-	O
hour	O
observation	O
period	O
,	O
compared	O
to	O
0	O
.	O
20	O
times	O
by	O
mothers	O
in	O
the	O
control	O
arm	O
(	O
RD	O
0	O
.	O
61	O
,	O
95	O
%	O
CI	O
=	O
0	O
.	O
37	O
–	O
0	O
.	O
86	O
)	O
(	O
Table	O
2	O
).	O

During	O
the	O
3	O
-	O
hour	O
structured	O
observations	O
,	O
45	O
%	O
in	O
the	O
intervention	O
group	O
,	O
compared	O
to	O
17	O
%	O
in	O
the	O
control	O
group	O
,	O
were	O
observed	O
to	O
wash	O
hands	O
with	O
soap	O
and	O
water	O
at	O
least	O
once	O
.	O

Mothers	O
in	O
the	O
intervention	O
arm	O
were	O
3	O
.	O
9	O
times	O
as	O
likely	B
as	O
those	O
in	O
the	O
control	O
arm	O
to	O
be	O
observed	O
washing	O
their	O
hands	O
at	O
the	O
times	O
recommended	O
as	O
part	O
of	O
the	O
handwashing	O
intervention	O
(	O
95	O
%	O
CI	O
1	O
.	O
23	O
–	O
2	O
.	O
02	O
).	O

The	O
risk	O
differences	O
and	O
risk	O
ratios	O
were	O
not	O
substantively	O
altered	O
in	O
multivariate	O
analyses	O
accounting	O
for	O
baseline	O
differences	O
between	O
the	O
groups	O
with	O
respect	O
to	O
mother	O
'	O
s	O
education	O
and	O
water	O
source	O
.	O

Handwashing	O
with	O
soap	O
was	O
more	O
frequently	O
observed	O
among	O
intervention	O
mothers	O
than	O
controls	O
before	O
breastfeeding	O
(	O
RD	O
0	O
.	O
65	O
,	O
95	O
%	O
CI	O
0	O
.	O
03	O
–	O
0	O
.	O
99	O
)	O
and	O
after	O
fecal	O
contact	O
(	O
RD	O
0	O
.	O
10	O
,	O
95	O
%	O
CI	O
0	O
.	O
04	O
–	O
0	O
.	O
17	O
)	O
(	O
Table	O
3	O
).	O

Overall	O
,	O
the	O
prevalence	O
of	O
handwashing	O
with	O
soap	O
at	O
both	O
these	O
times	O
was	O
low	O
,	O
even	O
in	O
the	O
intervention	O
group	O
(	O
8	O
%	O
before	O
breastfeeding	O
and	O
14	O
%	O
after	O
fecal	O
contact	O
).	O

There	O
were	O
no	O
significant	O
differences	O
between	O
the	O
two	O
groups	O
in	O
handwashing	O
with	O
water	O
alone	O
at	O
either	O
of	O
these	O
times	O
.	O

No	O
umbilical	O
cord	O
care	O
events	O
were	O
observed	O
,	O
given	O
that	O
observations	O
were	O
conducted	O
after	O
the	O
typical	O
time	O
of	O
cord	O
separation	O
.	O

None	O
of	O
the	O
respiratory	O
secretion	O
contact	O
events	O
in	O
either	O
group	O
were	O
followed	O
by	O
handwashing	O
with	O
soap	O
.	O

Handwashing	O
with	O
soap	O
was	O
significantly	O
more	O
frequently	O
observed	O
in	O
intervention	O
arm	O
household	O
members	O
overall	O
and	O
at	O
the	O
recommended	O
times	O
;	O
however	O
,	O
handwashing	O
with	O
soap	O
was	O
infrequent	O
in	O
household	O
members	O
in	O
both	O
arms	O
(	O
handwashing	O
at	O
6	O
%	O
of	O
recommended	O
times	O
in	O
intervention	O
arm	O
and	O
1	O
%	O
of	O
recommended	O
times	O
in	O
the	O
control	O
arm	O
).	O

At	O
baseline	O
,	O
23	O
%	O
of	O
control	O
(	O
29	O
/	O
124	O
)	O
and	O
20	O
%	O
of	O
intervention	O
(	O
25	O
/	O
125	O
)	O
participants	O
said	O
that	O
another	O
person	O
reminded	O
them	O
to	O
wash	O
hands	O
on	O
a	O
typical	O
day	O
.	O

At	O
follow	O
-	O
up	O
,	O
28	O
%	O
of	O
control	O
arm	O
(	O
30	O
/	O
106	O
)	O
and	O
36	O
%	O
(	O
40	O
/	O
110	O
)	O
of	O
intervention	O
said	O
that	O
someone	O
reminded	O
them	O
.	O

At	O
baseline	O
,	O
40	O
%	O
of	O
control	O
(	O
50	O
/	O
124	O
)	O
and	O
46	O
%	O
of	O
intervention	O
(	O
57	O
/	O
125	O
)	O
participants	O
said	O
they	O
reminded	O
someone	O
else	O
to	O
wash	O
hands	O
on	O
a	O
typical	O
day	O
.	O

At	O
follow	O
-	O
up	O
,	O
44	O
%	O
(	O
47	O
/	O
106	O
)	O
in	O
the	O
control	O
arm	O
and	O
70	O
%	O
in	O
the	O
intervention	O
arm	O
(	O
77	O
/	O
110	O
)	O
reported	O
doing	O
so	O
.	O

4	O
.	O

Discussion	O
Intensive	O
handwashing	O
promotion	O
employing	O
emotional	O
drivers	O
,	O
improving	O
convenience	O
,	O
and	O
providing	O
visual	O
cues	O
led	O
to	O
only	O
a	O
modest	O
increase	O
in	O
the	O
frequency	O
of	O
handwashing	O
with	O
soap	O
among	O
new	O
mothers	O
in	O
rural	O
Bangladesh	O
during	O
the	O
first	O
30	O
days	O
after	O
the	O
birth	O
of	O
their	O
child	O
.	O

The	O
intervention	O
resulted	O
in	O
greater	O
maintenance	O
of	O
handwashing	O
materials	O
in	O
locations	O
where	O
mothers	O
are	O
cocooned	O
with	O
neonate	O
.	O

However	O
,	O
the	O
overall	O
proportion	O
of	O
events	O
accompanied	O
by	O
handwashing	O
was	O
low	O
in	O
the	O
intervention	O
arm	O
compared	O
with	O
the	O
times	O
that	O
we	O
recommended	O
for	O
handwashing	O
.	O

Handwashing	O
with	O
soap	O
was	O
significantly	O
higher	O
before	O
breastfeeding	O
and	O
after	O
fecal	O
contact	O
among	O
intervention	O
mothers	O
than	O
among	O
controls	O
;	O
however	O
,	O
washing	O
with	O
soap	O
after	O
fecal	O
contact	O
was	O
less	O
common	O
than	O
the	O
prevalence	O
of	O
this	O
behavior	O
observed	O
among	O
mothers	O
of	O
young	O
children	O
in	O
Bangladesh	O
and	O
elsewhere	O
,	O
underscoring	O
the	O
substantial	O
barriers	O
to	O
handwashing	O
faced	O
by	O
mothers	O
of	O
neonates	O
[	O
21	O
].	O

McBride	O
et	O
al	O
.	O

has	O
described	O
that	O
pregnancy	O
is	O
a	O
transformative	O
moment	O
in	O
a	O
woman	O
'	O
s	O
life	O
,	O
at	O
which	O
time	O
she	O
is	O
reenvisioning	O
her	O
role	O
of	O
herself	O
as	O
well	O
as	O
creating	O
and	O
reacting	O
to	O
the	O
expectancies	O
of	O
her	O
pregnancy	O
outcome	O
(	O
i	O
.	O
e	O
.,	O
the	O
new	O
baby	O
she	O
will	O
care	O
for	O
)	O
[	O
15	O
].	O

Curtis	O
and	O
colleagues	O
have	O
found	O
that	O
mothers	O
and	O
other	O
caregivers	O
commonly	B
report	O
that	O
they	O
wash	O
hands	O
out	O
of	O
a	O
wish	O
to	O
nurture	O
their	O
young	O
children	O
[	O
22	O
].	O

Despite	O
employing	O
nurture	O
as	O
a	O
primary	O
driver	O
of	O
handwashing	O
behavior	O
and	O
including	O
in	O
the	O
intervention	O
all	O
secondary	O
caregivers	O
,	O
not	O
only	O
the	O
mother	O
,	O
there	O
was	O
limited	O
behavioral	O
impact	O
of	O
the	O
intervention	O
.	O

We	O
sought	O
to	O
increase	O
the	O
convenience	O
of	O
handwashing	O
by	O
providing	O
soap	O
and	O
handwashing	O
stations	O
and	O
encouraged	O
maintenance	O
of	O
soap	O
and	O
water	O
at	O
handwashing	O
locations	O
throughout	O
the	O
newborn	O
period	O
.	O

Handwashing	O
station	O
placement	O
was	O
guided	O
by	O
the	O
mother	O
and	O
other	O
relatives	O
such	O
that	O
the	O
mother	O
would	O
have	O
access	O
to	O
soap	O
and	O
water	O
in	O
the	O
key	O
locations	O
where	O
she	O
expected	O
to	O
spend	O
time	O
with	O
the	O
neonate	O
.	O

Still	O
,	O
the	O
finding	O
that	O
only	O
39	O
%	O
of	O
households	O
in	O
the	O
intervention	O
were	O
found	O
to	O
have	O
soap	O
and	O
water	O
at	O
a	O
handwashing	O
place	O
at	O
all	O
five	O
of	O
the	O
rapid	O
observations	O
suggests	O
that	O
maintaining	O
handwashing	O
materials	O
at	O
fixed	O
locations	O
at	O
all	O
times	O
was	O
difficult	O
in	O
the	O
newborn	O
period	O
,	O
that	O
such	O
maintenance	O
had	O
not	O
become	O
habitual	O
,	O
or	O
that	O
this	O
approach	O
to	O
handwashing	O
was	O
not	O
acceptable	O
to	O
our	O
study	O
population	O
.	O

Hand	O
cleansing	O
technology	O
that	O
does	O
not	O
necessitate	O
as	O
frequent	O
replenishment	O
may	O
be	O
needed	O
to	O
further	O
improve	O
hand	O
hygiene	O
in	O
the	O
newborn	O
period	O
.	O

While	O
the	O
intervention	O
increased	O
the	O
frequency	O
of	O
handwashing	O
,	O
mothers	O
and	O
others	O
washed	O
hands	O
with	O
soap	O
at	O
less	O
than	O
10	O
%	O
of	O
the	O
times	O
we	O
recommended	O
for	O
handwashing	O
.	O

Since	O
we	O
completed	O
structured	O
observations	O
at	O
the	O
end	O
of	O
the	O
neonatal	O
period	O
during	O
postnatal	O
days	O
30	O
–	O
32	O
,	O
we	O
cannot	O
know	O
whether	O
handwashing	O
was	O
more	O
common	O
or	O
less	O
common	O
during	O
the	O
early	O
days	O
of	O
the	O
newborn	O
period	O
,	O
when	O
babies	O
may	O
have	O
been	O
perceived	O
to	O
be	O
particularly	O
vulnerable	O
but	O
mothers	O
may	O
have	O
been	O
particularly	O
fatigued	O
or	O
getting	O
adjusted	O
to	O
the	O
new	O
household	O
routine	O
following	O
the	O
birth	O
.	O

Mothers	O
in	O
several	O
low	O
-	O
income	O
countries	O
have	O
indicated	O
that	O
their	O
responsibilities	O
increase	O
in	O
the	O
postnatal	O
period	O
,	O
often	O
without	O
increased	O
support	O
for	O
household	O
or	O
child	O
care	O
activities	O
from	O
others	O
[	O
12	O
].	O

We	O
recommended	O
handwashing	O
after	O
respiratory	O
secretion	O
contact	O
,	O
before	O
umbilical	O
cord	O
care	O
,	O
before	O
breastfeeding	O
,	O
after	O
fecal	O
contact	O
,	O
and	O
before	O
food	O
preparation	O
.	O

Observational	O
findings	O
of	O
the	O
benefit	O
of	O
washing	O
hands	O
before	O
contact	O
with	O
the	O
umbilical	O
stump	O
[	O
3	O
]	O
and	O
the	O
available	O
evidence	O
that	O
a	O
number	O
of	O
Gram	O
positive	O
organisms	O
that	O
colonize	O
the	O
nasopharynx	O
and	O
Gram	O
negative	O
organisms	O
found	O
in	O
stool	O
are	O
commonly	O
associated	O
with	O
sepsis	O
in	O
neonates	O
and	O
young	O
infants	O
[	O
23	O
,	O
24	O
]	O
drove	B
the	O
decision	O
-	O
making	O
regarding	O
recommendation	O
of	O
handwashing	O
after	O
respiratory	O
secretion	O
contact	O
,	O
before	O
umbilical	O
cord	O
care	O
,	O
before	O
breastfeeding	O
,	O
and	O
after	O
fecal	O
contact	O
.	O

Handwashing	O
with	O
food	O
preparation	O
was	O
added	O
in	O
order	O
to	O
stay	O
consistent	O
with	O
typical	O
handwashing	O
promotion	O
efforts	O
in	O
Bangladesh	O
and	O
to	O
facilitate	O
the	O
development	O
of	O
maternal	O
handwashing	O
behavior	O
relevant	O
to	O
postneonatal	O
morbidity	O
.	O

For	O
busy	O
new	O
mothers	O
to	O
comply	O
with	O
handwashing	O
at	O
all	O
the	O
recommended	O
times	O
may	O
have	O
been	O
extremely	O
difficult	O
.	O

Increasing	O
evidence	O
regarding	O
the	O
role	O
of	O
healthy	O
intestinal	O
,	O
skin	O
,	O
and	O
mucosal	O
microbiota	O
affirms	B
that	O
most	B
organisms	O
transmitted	O
from	O
mothers	O
to	O
neonates	O
are	O
not	O
pathogenic	O
.	O

Indeed	O
,	O
transfer	O
of	O
many	O
commensal	O
organisms	O
from	O
mother	O
to	O
neonate	O
represents	B
an	O
important	O
element	O
of	O
developing	O
healthy	O
microbiota	O
and	O
immune	O
systems	O
[	O
25	O
–	O
28	O
].	O

Therefore	B
,	O
recommendations	O
regarding	O
the	O
optimal	O
times	O
to	O
interrupt	O
pathogen	O
transmission	O
,	O
while	O
preserving	O
the	O
transfer	O
of	O
healthy	O
microbiota	O
to	O
neonates	O
,	O
should	O
be	O
articulated	O
based	B
on	I
an	O
increased	O
understanding	O
of	O
the	O
mechanisms	O
of	O
transmission	O
of	O
pathogenic	O
and	O
commensal	O
organisms	O
from	O
mothers	O
to	O
neonates	O
.	O

Hands	O
get	O
recontaminated	O
after	O
handwashing	O
quickly	O
in	O
heavily	O
contaminated	O
household	O
environments	O
such	O
as	O
rural	O
Bangladesh	O
[	O
29	O
]	O
and	O
,	O
thus	B
,	O
infrequent	O
handwashing	O
may	O
contribute	O
to	O
pathogen	O
transmission	O
to	O
neonates	O
.	O

We	O
do	O
not	O
yet	O
understand	O
how	O
much	O
handwashing	O
of	O
mothers	O
and	O
others	O
needs	O
to	O
be	O
increased	O
,	O
and	O
at	O
which	O
times	O
of	O
potential	O
pathogen	O
transmission	O
,	O
in	O
order	O
to	O
reduce	O
the	O
risk	O
of	O
infection	O
in	O
newborns	O
.	O

There	O
may	O
also	O
be	O
a	O
role	O
for	O
hand	O
cleansing	O
options	O
that	O
are	O
waterless	O
or	O
that	O
can	O
confer	O
residual	O
bacteriostatic	O
benefit	O
to	O
improve	O
the	O
convenience	O
and	O
thereby	O
the	O
frequency	O
of	O
hand	O
cleansing	O
,	O
or	O
the	O
effects	O
of	O
even	O
infrequent	O
hand	O
cleansing	O
.	O

We	O
restricted	O
our	O
study	O
to	O
primiparous	O
mothers	O
,	O
since	O
they	O
might	O
have	O
been	O
more	O
susceptible	O
to	O
behavior	O
change	O
given	B
their	O
relatively	O
larger	O
change	O
in	O
self	O
-	O
definition	O
,	O
compared	O
to	O
multiparous	O
mothers	O
.	O

However	O
,	O
this	O
sample	O
may	O
have	O
decreased	O
the	O
representativeness	O
of	O
our	O
study	O
;	O
mothers	O
with	O
a	O
newborn	O
who	O
also	O
have	O
infants	O
or	O
older	O
children	O
to	O
care	O
for	O
may	O
be	O
less	O
likely	B
to	O
change	O
handwashing	O
behavior	O
because	O
of	O
time	O
constraints	O
,	O
or	O
because	O
their	O
current	O
pregnancy	O
does	O
not	O
lead	O
to	O
a	O
dramatic	O
alteration	O
of	O
their	O
self	O
-	O
definition	O
or	O
role	O
in	O
the	O
family	O
and	O
society	O
since	O
they	O
already	O
have	O
children	O
.	O

We	O
used	O
observed	O
handwashing	O
as	O
our	O
primary	O
outcome	O
of	O
interest	O
.	O

Persons	O
being	O
observed	O
by	O
a	O
stranger	O
,	O
such	O
as	O
a	O
study	O
data	O
collector	O
,	O
may	O
alter	O
their	O
behavior	O
compared	O
to	O
usual	O
practice	O
,	O
potentially	O
increasing	O
their	O
handwashing	O
in	O
the	O
presence	O
of	O
the	O
observer	O
[	O
29	O
,	O
30	O
].	O

Such	O
reactivity	O
may	O
be	O
exacerbated	O
by	O
the	O
provision	O
of	O
handwashing	O
materials	O
and	O
promotion	O
of	O
handwashing	O
behavior	O
in	O
the	O
intervention	O
arm	O
.	O

Our	O
observations	O
took	O
place	O
at	O
the	O
end	O
of	O
the	O
neonatal	O
period	O
.	O

Handwashing	O
behavior	O
may	O
have	O
been	O
different	O
earlier	O
in	O
the	O
newborn	O
period	O
,	O
when	O
threat	O
perceptions	O
may	O
have	O
been	O
higher	O
but	O
household	O
routines	O
may	O
have	O
been	O
disrupted	O
by	O
the	O
arrival	O
of	O
the	O
new	O
baby	O
.	O

Lastly	O
,	O
we	O
did	O
not	O
perform	O
a	O
formal	O
process	O
evaluation	O
,	O
a	O
process	O
that	O
can	O
elucidate	O
whether	O
the	O
intervention	O
was	O
not	O
implemented	O
as	O
designed	O
or	O
whether	O
the	O
implementation	O
proceeded	O
as	O
planned	O
but	O
the	O
intervention	O
was	O
not	O
efficacious	O
in	O
changing	O
behavior	O
as	O
intended	O
.	O

4	O
.	O
1	O
.	O

Conclusion	O
We	O
found	O
that	O
a	O
handwashing	O
promotion	O
strategy	O
that	O
consisted	O
of	O
both	O
providing	O
the	O
necessary	O
materials	O
for	O
handwashing	O
and	O
intensive	O
behavior	O
change	O
communication	O
resulted	O
in	O
anemic	O
improvements	O
in	O
handwashing	O
behavior	O
among	O
mothers	O
of	O
newborns	O
.	O

While	O
mothers	O
in	O
the	O
intervention	O
arm	O
were	O
significantly	O
more	O
likely	B
to	O
maintain	O
needed	O
handwashing	O
materials	O
in	O
the	O
places	O
where	O
they	O
spent	O
time	O
with	O
their	O
newborns	O
,	O
and	O
more	O
frequently	O
washed	O
their	O
hands	O
,	O
handwashing	O
with	O
soap	O
was	O
observed	O
at	O
a	O
minority	O
of	O
the	O
times	O
we	O
recommended	O
.	O

Promotion	O
of	O
handwashing	O
with	O
soap	O
before	O
umbilical	O
cord	O
care	O
should	O
be	O
emphasized	O
in	O
antenatal	O
and	O
neonatal	O
care	O
messaging	O
,	O
given	B
existing	O
evidence	O
supporting	O
prevention	O
of	O
umbilical	O
cord	O
infections	O
by	O
caregiver	O
handwashing	O
.	O

Understanding	O
the	O
extent	O
to	O
which	O
hand	O
hygiene	O
behavior	O
of	O
mothers	O
and	O
other	O
caregivers	O
needs	O
to	O
improve	O
at	O
other	O
times	O
of	O
potential	O
pathogen	O
transmission	O
would	O
support	O
the	O
development	O
of	O
feasible	B
guidance	O
on	O
handwashing	O
to	O
reduce	O
neonatal	O
infections	O
.	O

Novel	O
and	O
feasible	B
approaches	O
to	O
motivating	O
handwashing	O
behavior	O
change	O
among	O
mothers	O
and	O
other	O
caregivers	O
to	O
protect	O
newborns	O
should	O
be	O
developed	O
and	O
evaluated	O
and	O
,	O
if	O
effective	O
,	O
their	O
impacts	O
on	O
neonatal	O
health	O
should	O
be	O
investigated	O
.	O

PubMed	O
Central	O
:	O

Maternal	O
25	O
(	O
OH	O
)	O
D	O
concentrations	O
≥	O
40	O
ng	O
/	O
mL	O
associated	O
with	O
60	O
%	O
lower	O
preterm	O
birth	O
risk	O
among	O
general	O
obstetrical	O
patients	O
at	O
an	O
urban	O
medical	O
center	O
Abstract	O
Background	O
Given	O
the	O
high	O
rate	O
of	O
preterm	O
birth	O
(	O
PTB	O
)	O
nationwide	O
and	O
data	O
from	O
RCTs	O
demonstrating	O
risk	O
reduction	O
with	O
vitamin	O
D	O
supplementation	O
,	O
the	O
Medical	O
University	O
of	O
South	O
Carolina	O
(	O
MUSC	O
)	O
implemented	O
a	O
new	O
standard	O
of	O
care	O
for	O
pregnant	O
women	O
to	O
receive	O
vitamin	O
D	O
testing	O
and	O
supplementation	O
.	O

Objectives	O
To	O
determine	O
if	O
the	O
reported	O
inverse	O
relationship	O
between	O
maternal	O
25	O
(	O
OH	O
)	O
D	O
and	O
PTB	O
risk	O
could	O
be	O
replicated	O
at	O
MUSC	O
,	O
an	O
urban	O
medical	O
center	O
treating	O
a	O
large	O
,	O
diverse	O
population	O
.	O

Methods	O
Medical	O
record	O
data	O
were	O
obtained	O
for	O
pregnant	O
patients	O
aged	O
18	O
–	O
45	O
years	O
between	O
September	O
2015	O
and	O
December	O
2016	O
.	O

During	O
this	O
time	O
,	O
a	O
protocol	O
that	O
included	O
25	O
(	O
OH	O
)	O
D	O
testing	O
at	O
first	O
prenatal	O
visit	O
with	O
recommended	O
follow	O
-	O
up	O
testing	O
was	O
initiated	O
.	O

Free	O
vitamin	O
D	O
supplements	O
were	O
offered	O
and	O
the	O
treatment	O
goal	O
was	O
≥	O
40	O
ng	O
/	O
mL	O
.	O

PTB	O
rates	O
(<	O
37	O
weeks	O
)	O
were	O
calculated	O
,	O
and	O
logistic	O
regression	O
and	O
locally	O
weighted	O
regression	O
(	O
LOESS	O
)	O
were	O
used	O
to	O
explore	O
the	O
association	O
between	O
25	O
(	O
OH	O
)	O
D	O
and	O
PTB	O
.	O

Subgroup	O
analyses	O
were	O
also	O
conducted	O
.	O

Results	O
Among	O
women	O
with	O
a	O
live	O
,	O
singleton	O
birth	O
and	O
at	O
least	O
one	O
25	O
(	O
OH	O
)	O
D	O
test	O
during	O
pregnancy	O
(	O
N	O
=	O
1	O
,	O
064	O
),	O
the	O
overall	O
PTB	O
rate	O
was	O
13	O
%.	O

The	O
LOESS	O
curve	O
showed	O
gestational	O
age	O
rising	O
with	O
increasing	O
25	O
(	O
OH	O
)	O
D	O
.	O
Women	O
with	O
25	O
(	O
OH	O
)	O
D	O
≥	O
40	O
ng	O
/	O
mL	O
had	O
a	O
62	O
%	O
lower	O
risk	O
of	O
PTB	O
compared	O
to	O
those	O
<	O
20	O
ng	O
/	O
mL	O
(	O
p	O
<	O
0	O
.	O
0001	O
).	O

After	O
adjusting	O
for	O
socioeconomic	O
variables	O
,	O
this	O
lower	O
risk	O
remained	O
(	O
OR	O
=	O
0	O
.	O
41	O
,	O
p	O
=	O
0	O
.	O
002	O
).	O

Similar	O
decreases	O
in	O
PTB	O
risk	O
were	O
observed	O
for	O
PTB	O
subtypes	O
(	O
spontaneous	O
:	O
58	O
%,	O
p	O
=	O
0	O
.	O
02	O
;	O
indicated	O
:	O
61	O
%,	O
p	O
=	O
0	O
.	O
006	O
),	O
by	O
race	O
/	O
ethnicity	O
(	O
white	O
:	O
65	O
%,	O
p	O
=	O
0	O
.	O
03	O
;	O
non	O
-	O
white	O
:	O
68	O
%,	O
p	O
=	O
0	O
.	O
008	O
),	O
and	O
among	O
women	O
with	O
a	O
prior	O
PTB	O
(	O
80	O
%,	O
p	O
=	O
0	O
.	O
02	O
).	O

Among	O
women	O
with	O
initial	O
25	O
(	O
OH	O
)	O
D	O
<	O
40	O
ng	O
/	O
mL	O
,	O
PTB	O
rates	O
were	O
60	O
%	O
lower	O
for	O
those	O
with	O
≥	O
40	O
vs	O
.	O
<	O
40	O
ng	O
/	O
mL	O
on	O
a	O
follow	O
-	O
up	O
test	O
(	O
p	O
=	O
0	O
.	O
006	O
);	O
38	O
%	O
for	O
whites	O
(	O
p	O
=	O
0	O
.	O
33	O
)	O
and	O
78	O
%	O
for	O
non	O
-	O
whites	O
(	O
p	O
=	O
0	O
.	O
01	O
).	O

Conclusions	O
Maternal	O
25	O
(	O
OH	O
)	O
D	O
concentrations	O
≥	O
40	O
ng	O
/	O
mL	O
were	O
associated	O
with	O
substantial	O
reduction	O
in	O
PTB	O
risk	O
in	O
a	O
large	O
,	O
diverse	O
population	O
of	O
women	O
.	O

Introduction	O
There	O
were	O
15	O
million	O
preterm	O
births	O
(	O
PTB	O
)	O
(<	O
37	O
weeks	O
)	O
worldwide	O
and	O
more	O
than	O
1	O
million	O
infant	O
deaths	O
from	O
PTB	O
complications	O
in	O
2010	O
[	O
1	O
].	O

PTB	O
rates	O
ranged	O
from	O
5	O
%	O
to	O
18	O
%	O
around	O
the	O
world	O
and	O
the	O
rate	O
in	O
the	O
United	O
States	O
was	O
disproportionately	O
high	O
(	O
12	O
%)	O
compared	O
to	O
other	O
developed	O
counties	O
[	O
1	O
].	O

Substantial	O
racial	O
disparities	O
in	O
PTB	O
rates	O
have	O
also	O
been	O
found	O
in	O
the	O
United	O
States	O
:	O
18	O
%	O
among	O
African	O
Americans	O
,	O
12	O
%	O
among	O
Hispanics	O
,	O
and	O
11	O
%	O
among	O
whites	O
in	O
2009	O
[	O
2	O
].	O

Since	B
PTB	O
is	O
the	O
leading	O
cause	O
of	O
neonatal	O
death	O
and	O
multiple	O
short	O
and	O
long	O
term	O
health	O
problems	O
[	O
3	O
],	O
it	O
is	O
critical	O
to	O
identify	O
modifiable	O
maternal	O
risk	O
factors	O
that	O
could	O
significantly	O
reduce	O
PTB	O
risk	O
at	O
the	O
population	O
level	O
.	O

Multiple	O
epidemiologic	O
studies	O
have	O
found	O
an	O
association	O
between	O
higher	O
maternal	O
serum	O
25	O
-	O
hydroxyvitamin	O
D	O
[	O
25	O
(	O
OH	O
)	O
D	O
]	O
concentration	O
,	O
the	O
physiological	O
measure	O
of	O
vitamin	O
D	O
status	O
,	O
and	O
lower	O
PTB	O
risk	O
[	O
4	O
–	O
10	O
].	O

Serum	O
25	O
(	O
OH	O
)	O
D	O
concentration	O
captures	O
the	O
effect	O
of	O
multiple	O
vitamin	O
D	O
input	O
sources	O
(	O
supplement	O
,	O
sun	O
,	O
and	O
food	O
)	O
and	O
makes	O
provision	O
for	O
inter	O
-	O
individual	O
variability	O
in	O
dose	O
response	O
[	O
11	O
].	O

Additionally	O
,	O
a	O
post	O
-	O
hoc	O
analysis	O
of	O
two	O
pregnancy	O
supplementation	O
trials	O
by	O
Hollis	O
and	O
Wagner	O
et	O
al	O
.	O

found	O
that	O
women	O
with	O
serum	O
25	O
(	O
OH	O
)	O
D	O
concentrations	O
≥	O
40	O
ng	O
/	O
mL	O
had	O
a	O
59	O
%	O
lower	O
risk	O
of	O
PTB	O
compared	O
to	O
women	O
with	O
concentrations	O
≤	O
20	O
ng	O
/	O
mL	O
(	O
p	O
=	O
0	O
.	O
02	O
)	O
[	O
12	O
].	O

In	O
those	O
clinical	O
trials	O
,	O
4000	O
IU	O
/	O
day	O
of	O
vitamin	O
D	O
was	O
found	O
to	O
safely	O
achieve	O
a	O
concentration	O
of	O
at	O
least	O
32	O
ng	O
/	O
mL	O
by	O
early	O
in	O
the	O
second	O
trimester	O
in	O
a	O
diverse	O
group	O
of	O
pregnant	O
women	O
[	O
13	O
–	O
15	O
].	O

Further	O
,	O
the	O
conversion	O
of	O
25	O
(	O
OH	O
)	O
D	O
to	O
the	O
active	O
form	O
of	O
the	O
hormone	O
,	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D	O
,	O
was	O
optimized	O
at	O
40	O
ng	O
/	O
mL	O
among	O
pregnant	O
women	O
[	O
13	O
].	O

Based	B
on	I
the	O
demonstrated	O
reductions	O
in	O
PTB	O
in	O
the	O
Hollis	O
and	O
Wagner	O
et	O
al	O
.	O

trials	O
,	O
the	O
Medical	O
University	O
of	O
South	O
Carolina	O
(	O
MUSC	O
)	O
initiated	O
a	O
new	O
standard	O
of	O
care	O
for	O
pregnant	O
women	O
that	O
included	O
routine	O
vitamin	O
D	O
testing	O
and	O
supplementation	O
in	O
September	O
2015	O
.	O

MUSC	O
is	O
a	O
comprehensive	O
,	O
urban	O
medical	O
center	O
treating	O
a	O
large	O
,	O
diverse	O
population	O
of	O
women	O
(~	O
3000	O
deliveries	O
/	O
year	O
).	O

The	O
objective	O
of	O
this	O
analysis	O
was	O
to	O
determine	O
if	O
the	O
inverse	O
relationship	O
between	O
maternal	O
25	O
(	O
OH	O
)	O
D	O
concentration	O
and	O
the	O
rate	O
of	O
PTB	O
found	O
in	O
the	O
earlier	O
randomized	O
controlled	O
trials	O
by	O
Hollis	O
and	O
Wagner	O
et	O
al	O
.	O

could	O
be	O
replicated	O
in	O
the	O
general	O
obstetrical	O
population	O
at	O
MUSC	O
.	O

Materials	O
and	O
methods	O
For	O
this	O
study	O
,	O
following	O
IRB	O
approval	O
(	O
HR	O
#	O
Pro00020570	O
),	O
de	O
-	O
identified	O
medical	O
record	O
data	O
were	O
obtained	O
for	O
all	O
pregnant	O
women	O
aged	O
18	O
–	O
45	O
years	O
who	O
received	O
a	O
25	O
(	O
OH	O
)	O
D	O
test	O
and	O
delivered	O
at	O
MUSC	O
between	O
September	O
2015	O
and	O
December	O
2016	O
.	O

During	O
this	O
time	O
,	O
a	O
protocol	O
was	O
instituted	O
which	O
included	O
routine	O
25	O
(	O
OH	O
)	O
D	O
testing	O
at	O
each	O
patient	O
’	O
s	O
first	O
prenatal	O
visit	O
.	O

Follow	O
-	O
up	O
testing	O
was	O
recommended	O
between	O
24	O
–	O
28	O
weeks	O
and	O
prior	O
to	O
delivery	O
by	O
provider	O
request	O
.	O

Testing	O
increased	O
in	O
May	O
2016	O
when	O
the	O
initial	O
25	O
(	O
OH	O
)	O
D	O
test	O
was	O
automated	O
as	O
part	O
of	O
initial	O
prenatal	O
screening	O
.	O

Total	O
circulating	O
25	O
(	O
OH	O
)	O
D	O
(	O
ng	O
/	O
mL	O
)	O
was	O
measured	O
using	O
standardized	O
methodology	O
for	O
LC	O
/	O
MS	O
analysis	O
in	O
a	O
MUSC	O
Clinical	O
Laboratory	O
Improvement	O
Amendments	O
(	O
CLIA	O
)-	O
certified	O
clinical	O
laboratory	O
.	O

Additionally	O
,	O
obstetrical	O
health	O
care	O
providers	O
received	O
education	O
regarding	O
the	O
potential	O
health	O
impact	O
of	O
low	O
vitamin	O
D	O
status	O
via	O
continuing	O
medical	O
education	O
(	O
CME	O
)	O
and	O
nurses	O
provided	O
vitamin	O
D	O
education	O
and	O
standard	O
recommendations	O
for	O
improving	O
vitamin	O
D	O
status	O
using	O
supplements	O
to	O
obstetrical	O
(	O
OB	O
)	O
patients	O
at	O
the	O
initial	O
visit	O
.	O

Vitamin	O
D	O
posters	O
and	O
brochures	O
were	O
available	O
for	O
all	O
patients	O
at	O
MUSC	O
clinics	O
and	O
educational	O
materials	O
were	O
included	O
in	O
the	O
prenatal	O
packet	O
received	O
by	O
all	O
first	O
time	O
OB	O
patients	O
.	O

New	O
OB	O
patients	O
were	O
offered	O
a	O
free	O
bottle	O
of	O
Bio	O
-	O
Tech	O
Pharmacal	O
,	O
Inc	O
.	O
(	O
Fayetteville	O
,	O
AR	O
)	O
vitamin	O
D	O
supplements	O
(	O
5000	O
IU	O
per	O
capsule	O
)	O
at	O
their	O
first	O
visit	O
and	O
personalized	O
dosing	O
recommendations	O
were	O
provided	O
based	O
on	O
the	O
result	O
of	O
their	O
initial	O
25	O
(	O
OH	O
)	O
D	O
test	O
using	O
an	O
algorithm	O
of	O
existing	O
dose	O
-	O
response	O
data	O
[	O
11	O
].	O

The	O
a	B
priori	I
goal	O
was	O
the	O
achievement	O
of	O
a	O
maternal	O
25	O
(	O
OH	O
)	O
D	O
concentration	O
of	O
≥	O
40	O
ng	O
/	O
mL	O
to	O
achieve	O
maximal	O
production	O
of	O
the	O
active	O
hormone	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D	O
[	O
13	O
].	O

Any	O
needed	O
dosing	O
adjustments	O
were	O
made	O
based	O
on	O
follow	O
-	O
up	O
testing	O
.	O

PTB	O
was	O
defined	O
as	O
delivery	O
of	O
a	O
liveborn	O
infant	O
at	O
<	O
37	O
weeks	O
gestation	O
.	O

For	O
this	O
analysis	O
,	O
women	O
pregnant	O
with	O
multiples	O
and	O
those	O
participating	O
in	O
vitamin	O
D	O
clinical	O
trials	O
at	O
MUSC	O
were	O
excluded	O
.	O

Chart	O
reviews	O
were	O
conducted	O
to	O
determine	O
whether	O
the	O
PTBs	O
were	O
spontaneous	O
(	O
occurring	O
after	O
preterm	O
labor	O
with	O
intact	O
membranes	O
or	O
preterm	O
pre	O
-	O
labor	O
rupture	O
of	O
the	O
fetal	O
membranes	O
)	O
or	O
indicated	O
.	O

If	O
the	O
PTB	O
was	O
indicated	O
,	O
the	O
reason	O
was	O
also	O
collected	O
.	O

Maternal	O
serum	O
25	O
(	O
OH	O
)	O
D	O
concentrations	O
closest	O
to	O
delivery	O
were	O
plotted	O
against	O
gestational	O
age	O
at	O
birth	O
and	O
locally	O
weighted	O
regression	O
(	O
LOESS	O
)	O
was	O
used	O
to	O
explore	O
the	O
relationship	O
in	O
more	O
detail	O
and	O
compare	O
to	O
the	O
Hollis	O
and	O
Wagner	O
et	O
al	O
.	O

trial	O
cohort	O
[	O
12	O
].	O

PTB	O
rates	O
were	O
calculated	O
for	O
the	O
overall	O
population	O
as	O
well	O
as	O
among	O
women	O
with	O
25	O
(	O
OH	O
)	O
D	O
concentrations	O
of	O
<	O
20	O
ng	O
/	O
mL	O
,	O
20	O
to	O
<	O
30	O
ng	O
/	O
mL	O
,	O
30	O
to	O
<	O
40	O
ng	O
/	O
mL	O
and	O
≥	O
40	O
ng	O
/	O
mL	O
closest	O
to	O
delivery	O
.	O

These	O
clinically	O
relevant	O
cut	O
points	O
(	O
20	O
ng	O
/	O
mL	O
from	O
the	O
Institute	O
of	O
Medicine	O
guidelines	B
[	O
16	O
],	O
30	O
ng	O
/	O
mL	O
from	O
the	O
Endocrine	O
Society	O
Clinical	O
Practice	O
Guideline	O
[	O
17	O
],	O
and	O
40	O
ng	O
/	O
mL	O
from	O
the	O
25	O
(	O
OH	O
)	O
D	O
concentration	O
found	O
to	O
achieve	O
maximal	O
production	O
of	O
the	O
active	O
hormone	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D	O
[	O
13	O
])	O
are	O
similar	O
to	O
quartiles	O
based	O
on	O
the	O
distribution	O
of	O
25	O
(	O
OH	O
)	O
D	O
concentrations	O
(	O
21	O
,	O
31	O
and	O
41	O
ng	O
/	O
mL	O
).	O

The	O
incidence	O
of	O
PTB	O
across	O
25	O
(	O
OH	O
)	O
D	O
groups	O
was	O
tested	O
for	O
trend	O
.	O

Logistic	O
regression	O
was	O
used	O
to	O
estimate	O
odds	O
ratios	O
(	O
OR	O
)	O
and	O
95	O
%	O
confidence	O
intervals	O
for	O
the	O
association	O
between	O
serum	O
25	O
(	O
OH	O
)	O
D	O
and	O
the	O
risk	O
of	O
PTB	O
.	O

Since	O
socioeconomic	O
status	O
plays	O
a	O
significant	O
role	O
in	O
PTB	O
risk	O
,	O
multivariate	O
logistic	O
regression	O
was	O
used	O
to	O
adjust	O
for	O
socioeconomic	O
status	O
(	O
SES	O
)	O
proxy	O
variables	O
(	O
insurance	O
status	O
and	O
education	O
).	O

Absolute	O
risk	O
reduction	O
(	O
ARR	O
)	O
and	O
number	O
needed	O
to	O
treat	O
(	O
NNT	O
)	O
were	O
also	O
calculated	O
.	O

To	O
identify	O
differences	O
by	O
race	O
/	O
ethnic	O
group	O
,	O
PTB	O
rates	O
were	O
calculated	O
and	O
logistic	O
regression	O
was	O
conducted	O
for	O
white	O
and	O
non	O
-	O
white	O
women	O
.	O

Additionally	O
,	O
since	B
women	O
with	O
a	O
history	O
of	O
PTB	O
have	O
a	O
known	O
2	O
to	O
3	O
-	O
fold	O
increased	O
risk	O
of	O
a	O
recurrent	O
premature	O
delivery	O
compared	O
to	O
women	O
without	O
a	O
history	O
of	O
PTB	O
[	O
18	O
],	O
logistic	O
regression	O
was	O
conducted	O
for	O
this	O
subgroup	O
as	O
well	O
.	O

While	O
maternal	O
age	O
is	O
also	O
a	O
known	O
risk	O
factor	O
,	O
it	O
was	O
not	O
associated	O
with	O
PTB	O
in	O
univariate	O
analysis	O
within	O
this	O
cohort	O
(	O
p	O
=	O
0	O
.	O
87	O
).	O

To	O
assess	O
whether	O
serum	O
25	O
(	O
OH	O
)	O
D	O
concentrations	O
increased	O
among	O
pregnant	O
patients	O
at	O
MUSC	O
during	O
this	O
time	O
period	O
,	O
first	O
test	O
results	O
and	O
test	O
results	O
closest	O
to	O
delivery	O
were	O
compared	O
using	O
a	O
paired	O
t	O
-	O
test	O
for	O
those	O
with	O
≥	O
2	O
tests	O
.	O

The	O
impact	O
of	O
raising	O
25	O
(	O
OH	O
)	O
D	O
concentrations	O
to	O
≥	O
40	O
ng	O
/	O
mL	O
was	O
assessed	O
by	O
comparing	O
PTB	O
rates	O
for	O
women	O
who	O
achieved	O
≥	O
40	O
ng	O
/	O
mL	O
on	O
a	O
follow	O
-	O
up	O
test	O
vs	O
.	O
those	O
who	O
did	O
not	O
among	O
women	O
with	O
low	O
25	O
(	O
OH	O
)	O
D	O
concentrations	O
(<	O
40	O
ng	O
/	O
mL	O
)	O
on	O
their	O
first	O
test	O
.	O

Serum	O
calcium	O
concentrations	O
were	O
monitored	O
as	O
clinically	O
indicated	O
.	O

Any	O
cases	O
with	O
identified	O
hypercalcemia	O
(≥	O
11	O
mg	O
/	O
dL	O
)	O
were	O
reviewed	O
by	O
a	O
member	O
of	O
the	O
Maternal	O
-	O
Fetal	O
Medicine	O
Division	O
at	O
MUSC	O
.	O

Statistical	O
analyses	O
were	O
performed	O
using	O
the	O
R	O
software	O
(	O
www	O
.	O
r	O
-	O
project	O
.	O
org	O
).	O

Results	O
Between	O
September	O
2015	O
and	O
December	O
2016	O
,	O
delivery	O
information	O
was	O
available	O
for	O
1	O
,	O
064	O
women	O
with	O
at	O
least	O
one	O
25	O
(	O
OH	O
)	O
D	O
test	O
result	O
during	O
pregnancy	O
.	O

The	O
characteristics	O
of	O
this	O
cohort	O
are	O
found	O
inTable	O
1	O
.	O
10	O
.	O
1371	O
/	O
journal	O
.	O
pone	O
.	O
0180483	O
.	O
t001	O
Caption	O
(	O
TABLE	O
-	O
WRAP	O
):	O
TABLE	O
1	O
Maternal	O
sociodemographic	O
and	O
clinical	O
characteristics	O
of	O
cohort	O
.	O
CharacteristicMUSC	O
Cohort	O
(	O
N	O
=	O
1	O
,	O
064	O
)	O
Race	O
/	O
ethnicity	O
(	O
N	O
,	O
%)	O
*	O
White488	O
(	O
46	O
%)	O
African	O
American395	O
(	O
37	O
%)	O
Hispanic117	O
(	O
11	O
%)	O
Asian	O
/	O
PI19	O
(	O
2	O
%)	O
Multiple	O
/	O
Other39	O
(	O
4	O
%)	O
Maternal	O
age	O
,	O
years	O
(	O
median	O
and	O
range	O
)	O
29	O
(	O
18	O
–	O
45	O
)	O
Parity	O
(	O
median	O
and	O
range	O
)	O
1	O
(	O
0	O
–	O
9	O
)	O
Gravidity	O
(	O
median	O
and	O
range	O
)	O
2	O
(	O
1	O
–	O
11	O
)	O
Pre	O
-	O
pregnancy	O
BMI	O
(	O
median	O
and	O
range	O
)	O
*	O
25	O
(	O
12	O
–	O
66	O
)	O
Marital	O
status	O
(	O
N	O
,%)	O
Married530	O
(	O
50	O
%)	O
Insurance	O
status	O
(	O
N	O
,%)	O
None	O
/	O
Medicaid519	O
(	O
49	O
%)	O
Education	O
,	O
years	O
(	O
median	O
and	O
range	O
)	O
*	O
13	O
(	O
4	O
–	O
20	O
)	O
History	O
of	O
Preterm	O
Birth	O
(	O
N	O
,%)	O
Yes140	O
(	O
13	O
%)	O
Birth	O
Outcome	O
(	O
N	O
,%)	O
Preterm	O
(<	O
37	O
weeks	O
)	O
139	O
(	O
13	O
%)	O
*	O
6	O
women	O
missing	O
race	O
/	O
ethnicity	O
data	O
,	O
31	O
missing	O
BMI	O
data	O
,	O
and	O
91	O
missing	O
education	O
data	O
.	O

There	O
were	O
139	O
(	O
13	O
%)	O
PTBs	O
(<	O
37	O
weeks	O
),	O
of	O
which	O
20	O
were	O
very	O
preterm	O
(<	O
32	O
weeks	O
),	O
21	O
were	O
moderately	O
preterm	O
(	O
32	O
to	O
<	O
34	O
weeks	O
),	O
and	O
98	O
were	O
late	O
preterm	O
(	O
34	O
to	O
<	O
37	O
weeks	O
).	O

A	O
plot	O
of	O
gestational	O
age	O
at	O
birth	O
as	O
a	O
function	O
of	O
maternal	O
25	O
(	O
OH	O
)	O
D	O
concentration	O
with	O
the	O
fitted	O
LOESS	O
curves	O
for	O
both	O
the	O
MUSC	O
cohort	O
and	O
the	O
Hollis	O
and	O
Wagner	O
et	O
al	O
.	O

RCT	O
cohort	O
[	O
12	O
]	O
for	O
comparison	O
is	O
shown	O
inFig	O
1	O
.	O

The	O
LOESS	O
curve	O
for	O
the	O
MUSC	O
cohort	O
closely	O
tracks	O
the	O
LOESS	O
curve	O
for	O
the	O
Hollis	O
and	O
Wagner	O
et	O
al	O
.	O

trial	O
cohort	O
.	O

A	O
zoom	O
of	O
the	O
fitted	O
LOESS	O
curve	O
for	O
the	O
MUSC	O
cohort	O
with	O
confidence	O
bounds	O
superimposed	O
shows	O
gestational	O
age	O
at	O
birth	O
initially	O
rising	O
steadily	O
with	O
increasing	O
maternal	O
25	O
(	O
OH	O
)	O
D	O
concentration	O
and	O
then	O
reaching	O
a	O
plateau	O
at	O
approximately	O
30	O
–	O
50	O
ng	O
/	O
mL	O
(	O
Fig	O
2	O
).	O
10	O
.	O
1371	O
/	O
journal	O
.	O
pone	O
.	O
0180483	O
.	O
g001	O
Caption	O
(	O
FIG	O
):	O
FIG	O
1	O
Maternal	O
25	O
(	O
OH	O
)	O
D	O
concentration	O
by	O
gestational	O
age	O
(	O
weeks	O
)	O
at	O
birth	O
.	O

Term	O
birth	O
is	O
≥	O
37	O
weeks	O
of	O
gestation	O
,	O
late	O
preterm	O
birth	O
is	O
34	O
to	O
<	O
37	O
weeks	O
,	O
moderately	O
preterm	O
is	O
32	O
to	O
<	O
34	O
weeks	O
,	O
and	O
very	O
preterm	O
is	O
<	O
32	O
weeks	O
.	O

Solid	O
gray	O
circles	O
and	O
solid	O
black	O
line	O
represent	O
MUSC	O
cohort	O
(	O
N	O
=	O
1064	O
)	O
and	O
open	O
circles	O
and	O
dashed	O
line	O
represent	O
Hollis	O
and	O
Wagner	O
et	O
al	O
.	O

trial	O
cohort	O
(	O
N	O
=	O
509	O
).	O
10	O
.	O
1371	O
/	O
journal	O
.	O
pone	O
.	O
0180483	O
.	O
g002	O
Caption	O
(	O
FIG	O
):	O
FIG	O
2	O
Zoom	O
of	O
the	O
fitted	O
LOESS	O
curve	O
of	O
maternal	O
25	O
(	O
OH	O
)	O
D	O
concentration	O
and	O
gestational	O
age	O
(	O
weeks	O
)	O
at	O
birth	O
with	O
1	O
and	O
2	O
SD	O
windows	O
superimposed	O
.	O

Black	O
line	O
represents	O
fitted	O
LOESS	O
curve	O
,	O
dark	O
gray	O
area	O
represents	O
1	O
standard	O
deviation	O
,	O
and	O
light	O
gray	O
area	O
represents	O
2	O
standard	O
deviations	O
.	O

PTB	O
rates	O
were	O
20	O
%	O
in	O
women	O
with	O
25	O
(	O
OH	O
)	O
D	O
<	O
20	O
ng	O
/	O
mL	O
(	O
N	O
=	O
248	O
),	O
12	O
%	O
in	O
women	O
with	O
25	O
(	O
OH	O
)	O
D	O
20	O
to	O
<	O
30	O
ng	O
/	O
mL	O
(	O
N	O
=	O
267	O
),	O
13	O
%	O
in	O
women	O
with	O
25	O
(	O
OH	O
)	O
D	O
30	O
to	O
<	O
40	O
ng	O
/	O
mL	O
(	O
N	O
=	O
255	O
)	O
and	O
9	O
%	O
in	O
women	O
with	O
25	O
(	O
OH	O
)	O
D	O
≥	O
40	O
ng	O
/	O
mL	O
(	O
N	O
=	O
294	O
)	O
(	O
Table	O
2	O
).	O

Those	O
with	O
serum	O
25	O
(	O
OH	O
)	O
D	O
concentrations	O
≥	O
40	O
ng	O
/	O
mL	O
had	O
a	O
62	O
%	O
lower	O
risk	O
of	O
PTB	O
compared	O
to	O
those	O
with	O
concentrations	O
<	O
20	O
ng	O
/	O
mL	O
(	O
OR	O
=	O
0	O
.	O
38	O
,	O
95	O
%	O
CI	O
=	O
0	O
.	O
23	O
–	O
0	O
.	O
63	O
,	O
p	O
<	O
0	O
.	O
0001	O
;	O
AAR	O
=	O
11	O
.	O
3	O
%;	O
NNT	O
=	O
9	O
)	O
(	O
Table	O
2	O
).	O

There	O
was	O
a	O
similar	O
lower	O
risk	O
(	O
59	O
%)	O
after	O
adjusting	O
for	O
SES	O
variables	O
(	O
insurance	O
status	O
and	O
education	O
)	O
(	O
OR	O
=	O
0	O
.	O
41	O
,	O
95	O
%	O
CI	O
=	O
0	O
.	O
24	O
–	O
0	O
.	O
72	O
,	O
p	O
=	O
0	O
.	O
002	O
).	O
10	O
.	O
1371	O
/	O
journal	O
.	O
pone	O
.	O
0180483	O
.	O
t002	O
Caption	O
(	O
TABLE	O
-	O
WRAP	O
):	O
TABLE	O
2	O
Association	O
between	O
maternal	O
25	O
(	O
OH	O
)	O
D	O
concentration	O
and	O
the	O
risk	O
of	O
preterm	O
birth	O
(	O
N	O
=	O
1064	O
).	O
Preterm	O
Birth	O
(<	O
37	O
Weeks	O
)	O
Term	O
Birth	O
(≥	O
37	O
Weeks	O
)	O
p	O
-	O
value	O
(	O
test	O
for	O
trend	O
)	O
ORSES	O
Adjusted	O
†	O
OR	O
(	O
95	O
%	O
CI	O
)(	O
95	O
%	O
CI	O
)<	O
20	O
ng	O
/	O
mL49	O
(	O
20	O
%)	O
199	O
(	O
80	O
%)	O
0	O
.	O
0003	O
1	O
.	O
01	O
.	O
0N	O
(%)	O
20	O
to	O
<	O
30	O
ng	O
/	O
mL33	O
(	O
12	O
%)	O
234	O
(	O
88	O
%)	O
0	O
.	O
57	O
0	O
.	O
63	O
(	O
0	O
.	O
37	O
,	O
1	O
.	O
04	O
)	O
N	O
(%)	O
(	O
0	O
.	O
35	O
,	O
0	O
.	O
93	O
)	O
30	O
to	O
<	O
40	O
ng	O
/	O
mL32	O
(	O
13	O
%)	O
223	O
(	O
87	O
%)	O
0	O
.	O
580	O
.	O
53	O
(	O
0	O
.	O
31	O
,	O
0	O
.	O
91	O
)	O
N	O
(%)	O
(	O
0	O
.	O
36	O
,	O
0	O
.	O
95	O
)	O
≥	O
40	O
ng	O
/	O
mL25	O
(	O
9	O
%)	O
269	O
(	O
91	O
%)	O
0	O
.	O
380	O
.	O
41	O
(	O
0	O
.	O
24	O
,	O
0	O
.	O
72	O
)	O
N	O
(%)	O
(	O
0	O
.	O
23	O
,	O
0	O
.	O
63	O
)	O
Bold	O
values	O
signify	O
significance	O
at	O
p	O
<	O
0	O
.	O
05	O
.	O

†	O
Adjusted	O
for	O
insurance	O
status	O
and	O
years	O
of	O
education	O
(	O
social	O
economic	O
status	O
proxy	O
variables	O
).	O

Of	O
the	O
139	O
PTBs	O
,	O
approximately	O
half	O
were	O
spontaneous	O
(	O
47	O
%)	O
and	O
half	O
were	O
indicated	O
(	O
53	O
%),	O
of	O
the	O
latter	O
,	O
66	O
%	O
were	O
indicated	O
for	O
maternal	O
hypertensive	O
disorders	O
.	O

PTB	O
rates	O
by	O
serum	O
25	O
(	O
OH	O
)	O
D	O
group	O
and	O
PTB	O
subtype	O
are	O
shown	O
inTable	O
3	O
.	O

For	O
those	O
with	O
25	O
(	O
OH	O
)	O
D	O
concentrations	O
≥	O
40	O
ng	O
/	O
mL	O
compared	O
to	O
those	O
with	O
25	O
(	O
OH	O
)	O
D	O
concentrations	O
<	O
20	O
ng	O
/	O
mL	O
,	O
there	O
was	O
a	O
58	O
%	O
lower	O
risk	O
of	O
spontaneous	O
PTB	O
(	O
OR	O
=	O
0	O
.	O
42	O
,	O
95	O
%	O
CI	O
=	O
0	O
.	O
20	O
–	O
0	O
.	O
89	O
,	O
p	O
=	O
0	O
.	O
02	O
;	O
AAR	O
=	O
4	O
.	O
8	O
%;	O
NNT	O
=	O
21	O
)	O
and	O
a	O
61	O
%	O
lower	O
risk	O
of	O
indicated	O
PTB	O
(	O
OR	O
=	O
0	O
.	O
39	O
,	O
95	O
%	O
CI	O
=	O
0	O
.	O
20	O
–	O
0	O
.	O
76	O
,	O
p	O
=	O
0	O
.	O
006	O
;	O
AAR	O
=	O
6	O
.	O
5	O
%;	O
NNT	O
=	O
15	O
)	O
(	O
Table	O
3	O
).	O
10	O
.	O
1371	O
/	O
journal	O
.	O
pone	O
.	O
0180483	O
.	O
t003	O
Caption	O
(	O
TABLE	O
-	O
WRAP	O
):	O
TABLE	O
3	O
Association	O
between	O
maternal	O
25	O
(	O
OH	O
)	O
D	O
concentration	O
and	O
the	O
risk	O
of	O
preterm	O
birth	O
by	O
preterm	O
birth	O
subtype	O
.	O
Spontaneous	O
Preterm	O
Birth	O
RatesSpontaneous	O
Preterm	O
Birth	O
:	O
ORIndicated	O
Preterm	O
Birth	O
RatesIndicated	O
Preterm	O
Birth	O
:	O
OR	O
(<	O
37	O
Weeks	O
)(	O
95	O
%	O
CI	O
)(<	O
37	O
Weeks	O
)(	O
95	O
%	O
CI	O
)<	O
20	O
ng	O
/	O
mL	O
(	O
N	O
=	O
248	O
)	O
21	O
(	O
8	O
%)	O
1	O
.	O
028	O
(	O
11	O
%)	O
1	O
.	O
0N	O
preterm	O
(%)	O
20	O
to	O
<	O
30	O
ng	O
/	O
mL	O
(	O
N	O
=	O
267	O
)	O
17	O
(	O
6	O
%)	O
0	O
.	O
7416	O
(	O
6	O
%)	O
0	O
.	O
50	O
N	O
preterm	O
(%)(	O
0	O
.	O
38	O
,	O
1	O
.	O
43	O
)	O
(	O
0	O
.	O
26	O
,	O
0	O
.	O
95	O
)	O
30	O
to	O
<	O
40	O
ng	O
/	O
mL	O
(	O
N	O
=	O
255	O
)	O
16	O
(	O
6	O
%)	O
0	O
.	O
7216	O
(	O
6	O
%)	O
0	O
.	O
53	O
N	O
preterm	O
(%)(	O
0	O
.	O
37	O
,	O
1	O
.	O
42	O
)	O
(	O
0	O
.	O
28	O
,	O
0	O
.	O
99	O
)	O
≥	O
40	O
ng	O
/	O
mL	O
(	O
N	O
=	O
294	O
)	O
11	O
(	O
4	O
%)	O
0	O
.	O
42	O
14	O
(	O
5	O
%)	O
0	O
.	O
39	O
N	O
preterm	O
(%)	O
(	O
0	O
.	O
20	O
,	O
0	O
.	O
89	O
)(	O
0	O
.	O
20	O
,	O
0	O
.	O
76	O
)	O
Bold	O
values	O
signify	O
significance	O
at	O
p	O
<	O
0	O
.	O
05	O
.	O

The	O
frequency	O
of	O
PTB	O
was	O
10	O
%	O
among	O
white	O
women	O
and	O
15	O
%	O
among	O
non	O
-	O
white	O
women	O
.	O

African	O
American	O
women	O
accounted	O
for	O
a	O
majority	O
(	O
69	O
%)	O
of	O
the	O
non	O
-	O
white	O
births	O
and	O
had	O
a	O
19	O
%	O
PTB	O
rate	O
.	O

There	O
was	O
a	O
65	O
%	O
lower	O
risk	O
of	O
PTB	O
among	O
white	O
women	O
with	O
25	O
(	O
OH	O
)	O
D	O
≥	O
40	O
ng	O
/	O
mL	O
compared	O
to	O
those	O
<	O
20	O
ng	O
/	O
mL	O
(	O
OR	O
=	O
0	O
.	O
35	O
,	O
95	O
%	O
CI	O
=	O
0	O
.	O
13	O
–	O
0	O
.	O
92	O
,	O
p	O
=	O
0	O
.	O
03	O
;	O
AAR	O
=	O
13	O
.	O
8	O
%;	O
NNT	O
=	O
7	O
)	O
and	O
a	O
68	O
%	O
lower	O
risk	O
among	O
non	O
-	O
white	O
women	O
(	O
OR	O
=	O
0	O
.	O
32	O
,	O
95	O
%	O
CI	O
=	O
0	O
.	O
14	O
–	O
0	O
.	O
74	O
,	O
p	O
=	O
0	O
.	O
008	O
;	O
AAR	O
=	O
11	O
.	O
7	O
%;	O
NNT	O
=	O
9	O
).	O

Since	O
having	O
had	O
a	O
previous	O
PTB	O
is	O
a	O
significant	O
risk	O
factor	O
for	O
a	O
recurrent	O
PTB	O
,	O
we	O
also	O
assessed	O
the	O
relationship	O
between	O
PTB	O
and	O
25	O
(	O
OH	O
)	O
D	O
for	O
these	O
women	O
separately	O
.	O

Among	O
the	O
140	O
women	O
(	O
13	O
%	O
of	O
cohort	O
)	O
with	O
a	O
prior	O
PTB	O
,	O
29	O
%	O
experienced	O
a	O
recurrent	O
PTB	O
.	O

A	O
plot	O
of	O
gestational	O
age	O
at	O
birth	O
as	O
a	O
function	O
of	O
maternal	O
25	O
(	O
OH	O
)	O
D	O
concentration	O
with	O
the	O
fitted	O
LOESS	O
curve	O
for	O
women	O
with	O
a	O
history	O
of	O
PTB	O
is	O
shown	O
inFig	O
3	O
.	O

Recurrent	O
PTB	O
rates	O
for	O
this	O
subgroup	O
were	O
42	O
%	O
in	O
women	O
with	O
25	O
(	O
OH	O
)	O
D	O
<	O
20	O
ng	O
/	O
mL	O
(	O
N	O
=	O
57	O
),	O
24	O
%	O
in	O
women	O
with	O
25	O
(	O
OH	O
)	O
D	O
20	O
to	O
<	O
30	O
ng	O
/	O
mL	O
(	O
N	O
=	O
34	O
),	O
24	O
%	O
in	O
women	O
with	O
25	O
(	O
OH	O
)	O
D	O
30	O
to	O
<	O
40	O
ng	O
/	O
mL	O
(	O
N	O
=	O
25	O
)	O
and	O
13	O
%	O
in	O
women	O
with	O
25	O
(	O
OH	O
)	O
D	O
≥	O
40	O
ng	O
/	O
mL	O
(	O
N	O
=	O
24	O
).	O

There	O
was	O
an	O
80	O
%	O
lower	O
risk	O
of	O
recurrent	O
PTB	O
with	O
25	O
(	O
OH	O
)	O
D	O
≥	O
40	O
ng	O
/	O
mL	O
compared	O
to	O
those	O
<	O
20	O
ng	O
/	O
mL	O
among	O
women	O
with	O
a	O
prior	O
PTB	O
(	O
OR	O
=	O
0	O
.	O
20	O
,	O
95	O
%	O
CI	O
=	O
0	O
.	O
05	O
–	O
0	O
.	O
74	O
,	O
p	O
=	O
0	O
.	O
02	O
;	O
AAR	O
=	O
29	O
.	O
6	O
%;	O
NNT	O
=	O
3	O
).	O
10	O
.	O
1371	O
/	O
journal	O
.	O
pone	O
.	O
0180483	O
.	O
g003	O
Caption	O
(	O
FIG	O
):	O
FIG	O
3	O
Maternal	O
25	O
(	O
OH	O
)	O
D	O
concentration	O
by	O
gestational	O
age	O
(	O
weeks	O
)	O
at	O
birth	O
for	O
women	O
with	O
a	O
prior	O
preterm	O
birth	O
.	O

Term	O
birth	O
is	O
≥	O
37	O
weeks	O
of	O
gestation	O
,	O
late	O
preterm	O
birth	O
is	O
34	O
to	O
<	O
37	O
weeks	O
,	O
moderately	O
preterm	O
is	O
32	O
to	O
<	O
34	O
weeks	O
,	O
and	O
very	O
preterm	O
is	O
<	O
32	O
weeks	O
.	O

Black	O
line	O
represents	O
fitted	O
LOESS	O
curve	O
.	O

Among	O
women	O
with	O
≥	O
2	O
tests	O
(	O
N	O
=	O
390	O
),	O
there	O
was	O
an	O
increase	O
in	O
mean	O
25	O
(	O
OH	O
)	O
D	O
concentration	O
from	O
24	O
ng	O
/	O
mL	O
to	O
39	O
ng	O
/	O
mL	O
(	O
p	O
<	O
0	O
.	O
0001	O
).	O

For	O
those	O
with	O
≥	O
2	O
measurements	O
and	O
initial	O
25	O
(	O
OH	O
)	O
D	O
concentrations	O
<	O
40	O
ng	O
/	O
mL	O
at	O
20	O
weeks	O
or	O
earlier	O
(	O
N	O
=	O
344	O
),	O
the	O
PTB	O
rate	O
was	O
60	O
%	O
(	O
95	O
%	O
CI	O
=	O
20	O
–	O
80	O
%,	O
p	O
=	O
0	O
.	O
006	O
)	O
lower	O
for	O
those	O
who	O
achieved	O
≥	O
40	O
ng	O
/	O
mL	O
on	O
a	O
follow	O
-	O
up	O
test	O
compared	O
to	O
those	O
who	O
did	O
not	O
raise	O
their	O
25	O
(	O
OH	O
)	O
D	O
concentrations	O
to	O
the	O
target	O
concentration	O
of	O
≥	O
40	O
ng	O
/	O
mL	O
on	O
a	O
follow	O
-	O
up	O
test	O
(	O
6	O
%	O
and	O
16	O
%	O
respectively	O
,	O
AAR	O
=	O
9	O
.	O
6	O
%;	O
NNT	O
=	O
10	O
)	O
(	O
Fig	O
4	O
).	O

By	O
race	O
/	O
ethnicity	O
,	O
the	O
PTB	O
rate	O
was	O
38	O
%	O
(	O
95	O
%	O
CI	O
=	O
-	O
58	O
-	O
75	O
%,	O
p	O
=	O
0	O
.	O
33	O
)	O
lower	O
among	O
white	O
women	O
(	O
8	O
%	O
and	O
13	O
%	O
respectively	O
,	O
AAR	O
=	O
4	O
.	O
8	O
%,	O
NNT	O
=	O
21	O
)	O
and	O
78	O
%	O
(	O
95	O
%	O
CI	O
=	O
12	O
–	O
95	O
%,	O
p	O
=	O
0	O
.	O
01	O
)	O
lower	O
among	O
non	O
-	O
white	O
women	O
(	O
4	O
%	O
and	O
18	O
%	O
respectively	O
,	O
AAR	O
=	O
13	O
.	O
8	O
%,	O
NNT	O
=	O
7	O
).	O

There	O
were	O
no	O
cases	O
of	O
vitamin	O
D	O
toxicity	O
based	O
on	O
elevated	O
serum	O
calcium	O
levels	O
(≥	O
11	O
mg	O
/	O
dL	O
).	O
10	O
.	O
1371	O
/	O
journal	O
.	O
pone	O
.	O
0180483	O
.	O
g004	O
Caption	O
(	O
FIG	O
):	O
FIG	O
4	O
Preterm	O
birth	O
rates	O
among	O
women	O
with	O
low	O
initial	O
25	O
(	O
OH	O
)	O
D	O
concentrations	O
(<	O
40	O
ng	O
/	O
mL	O
at	O
≤	O
20	O
weeks	O
),	O
comparing	O
those	O
with	O
concentrations	O
≥	O
40	O
ng	O
/	O
mL	O
vs	O
.	O
those	O
with	O
concentrations	O
<	O
40	O
ng	O
/	O
mL	O
on	O
a	O
follow	O
-	O
up	O
test	O
.	O

Discussion	O
We	O
found	O
a	O
clear	O
association	O
between	O
maternal	O
25	O
(	O
OH	O
)	O
D	O
concentration	O
and	O
PTB	O
risk	O
in	O
the	O
general	O
obstetrical	O
population	O
at	O
an	O
urban	O
medical	O
center	O
treating	O
a	O
large	O
,	O
diverse	O
population	O
of	O
women	O
.	O

Women	O
with	O
a	O
25	O
(	O
OH	O
)	O
D	O
concentration	O
of	O
≥	O
40	O
ng	O
/	O
mL	O
had	O
a	O
62	O
%	O
lower	O
risk	O
of	O
PTB	O
compared	O
to	O
those	O
with	O
concentrations	O
<	O
20	O
ng	O
/	O
mL	O
.	O

Similar	O
or	O
greater	O
magnitudes	O
of	O
decreased	O
risk	O
were	O
observed	O
for	O
PTB	O
subtypes	O
,	O
race	O
/	O
ethnic	O
groups	O
,	O
and	O
among	O
women	O
with	O
a	O
prior	O
PTB	O
.	O

Additionally	O
,	O
among	O
women	O
with	O
low	O
initial	O
25	O
(	O
OH	O
)	O
D	O
concentrations	O
(<	O
40	O
ng	O
/	O
mL	O
),	O
PTB	O
rates	O
were	O
significantly	O
lower	O
(	O
60	O
%)	O
for	O
those	O
who	O
achieved	O
≥	O
40	O
ng	O
/	O
mL	O
on	O
a	O
follow	O
-	O
up	O
test	O
vs	O
.	O
those	O
who	O
did	O
not	O
,	O
especially	O
for	O
non	O
-	O
white	O
women	O
(	O
78	O
%).	O

These	O
findings	O
support	O
the	O
inverse	O
association	O
between	O
maternal	O
25	O
(	O
OH	O
)	O
D	O
and	O
PTB	O
risk	O
found	O
in	O
the	O
Hollis	O
and	O
Wagner	O
et	O
al	O
.	O

randomized	O
clinical	O
trials	O
[	O
12	O
,	O
14	O
,	O
15	O
]	O
as	O
well	O
as	O
epidemiological	O
studies	O
[	O
4	O
–	O
10	O
].	O

Wagner	O
et	O
al	O
.	O

found	O
a	O
59	O
%	O
lower	O
risk	O
of	O
PTB	O
for	O
women	O
with	O
serum	O
25	O
(	O
OH	O
)	O
D	O
concentrations	O
≥	O
40	O
ng	O
/	O
mL	O
compared	O
to	O
those	O
with	O
concentrations	O
≤	O
20	O
ng	O
/	O
mL	O
(	O
p	O
=	O
0	O
.	O
02	O
)	O
[	O
12	O
].	O

Bodnar	O
et	O
al	O
.	O

found	O
a	O
56	O
%	O
lower	O
risk	O
of	O
PTB	O
among	O
those	O
with	O
25	O
(	O
OH	O
)	O
D	O
≥	O
30	O
ng	O
/	O
mL	O
compared	O
to	O
<	O
20	O
ng	O
/	O
mL	O
(	O
95	O
%	O
CI	O
=	O
23	O
–	O
62	O
%)	O
[	O
4	O
].	O

A	O
70	O
%	O
lower	O
risk	O
of	O
PTB	O
was	O
found	O
for	O
women	O
≥	O
20	O
ng	O
/	O
mL	O
vs	O
.	O
<	O
20	O
ng	O
/	O
mL	O
in	O
a	O
study	O
by	O
Perez	O
-	O
Ferre	O
et	O
al	O
.	O

(	O
p	O
=	O
0	O
.	O
002	O
)	O
[	O
5	O
].	O

Two	O
recent	O
meta	O
-	O
analyses	O
also	O
found	O
that	O
higher	O
25	O
(	O
OH	O
)	O
D	O
concentrations	O
significantly	O
decreased	O
the	O
risk	O
of	O
PTB	O
[	O
9	O
,	O
10	O
].	O

Post	O
-	O
hoc	O
analysis	O
of	O
the	O
Hollis	O
and	O
Wagner	O
et	O
al	O
.	O

trials	O
[	O
12	O
]	O
and	O
the	O
Bodnar	O
et	O
al	O
.	O

study	O
[	O
4	O
]	O
assessed	O
the	O
non	O
-	O
linear	O
relationship	O
between	O
25	O
(	O
OH	O
)	O
D	O
and	O
PTB	O
,	O
both	O
identifying	O
a	O
decreasing	O
risk	O
of	O
PTB	O
as	B
25	O
(	O
OH	O
)	O
D	O
increased	O
to	O
approximately	O
40	O
ng	O
/	O
mL	O
.	O
Fig	O
1shows	O
that	O
the	O
increase	O
in	O
gestational	O
age	O
at	O
birth	O
with	O
rising	O
25	O
(	O
OH	O
)	O
D	O
concentrations	O
is	O
similar	O
between	O
the	O
general	O
obstetrical	O
population	O
at	O
MUSC	O
and	O
the	O
Hollis	O
and	O
Wagner	O
et	O
al	O
.	O

RCT	O
cohorts	O
[	O
12	O
].	O

Similar	O
magnitudes	O
of	O
decreased	O
risk	O
for	O
women	O
with	O
25	O
(	O
OH	O
)	O
D	O
concentrations	O
≥	O
40	O
ng	O
/	O
mL	O
vs	O
.	O
<	O
20	O
ng	O
/	O
mL	O
were	O
observed	O
among	O
PTB	O
subtypes	O
:	O
spontaneous	O
PTB	O
(	O
58	O
%)	O
and	O
indicated	O
PTB	O
(	O
61	O
%).	O

Bodnar	O
et	O
al	O
.	O

also	O
found	O
similar	O
reductions	O
in	O
PTB	O
risk	O
for	O
spontaneous	O
and	O
medically	O
indicated	O
PTBs	O
[	O
4	O
].	O

These	O
findings	O
show	O
that	O
higher	O
vitamin	O
D	O
status	O
is	O
significantly	O
associated	O
with	O
lower	O
PTB	O
risk	O
for	O
both	O
PTB	O
subtypes	O
and	O
that	O
vitamin	O
D	O
plays	O
an	O
important	O
role	O
in	O
the	O
underlying	O
causes	O
of	O
indicated	O
PTB	O
including	O
maternal	O
hypertension	O
,	O
pre	O
-	O
existing	O
diabetes	O
,	O
and	O
non	O
-	O
reassuring	O
fetal	O
status	O
.	O

Improving	O
the	O
vitamin	O
D	O
status	O
of	O
women	O
with	O
underlying	O
conditions	O
may	O
avert	O
the	O
need	O
for	O
a	O
medically	O
indicated	O
preterm	O
delivery	O
.	O

Subgroup	O
analyses	O
revealed	O
some	O
potentially	O
key	O
findings	O
.	O

The	O
association	O
between	O
25	O
(	O
OH	O
)	O
D	O
and	O
reduced	O
risk	O
of	O
PTB	O
was	O
consistent	O
across	O
race	O
/	O
ethnic	O
groups	O
.	O

There	O
were	O
significant	O
decreases	O
in	O
PTB	O
risk	O
for	O
≥	O
40	O
ng	O
/	O
mL	O
vs	O
.	O
<	O
20	O
ng	O
/	O
mL	O
for	O
both	O
white	O
(	O
65	O
%)	O
and	O
non	O
-	O
white	O
women	O
(	O
68	O
%).	O

These	O
findings	O
suggest	O
that	O
improvements	O
in	O
vitamin	O
D	O
status	O
may	O
decrease	O
the	O
disparity	O
in	O
PTB	O
rates	O
between	O
race	O
/	O
ethnic	O
groups	O
.	O

Additionally	O
,	O
for	O
women	O
with	O
a	O
prior	O
PTB	O
,	O
the	O
substantial	O
decrease	O
in	O
recurrent	O
PTB	O
risk	O
(	O
80	O
%)	O
for	O
≥	O
40	O
ng	O
/	O
mL	O
vs	O
.	O
<	O
20	O
ng	O
/	O
mL	O
indicates	O
that	O
improving	O
vitamin	O
D	O
status	O
in	O
this	O
high	O
risk	O
subgroup	O
could	O
sizably	O
reduce	O
PTB	O
rates	O
.	O

Among	O
women	O
with	O
initial	O
25	O
(	O
OH	O
)	O
D	O
concentrations	O
<	O
40	O
ng	O
/	O
mL	O
,	O
the	O
significantly	O
lower	O
PTB	O
rate	O
(	O
60	O
%)	O
for	O
those	O
who	O
achieved	O
≥	O
40	O
ng	O
/	O
mL	O
compared	O
to	O
those	O
who	O
did	O
not	O
reach	O
the	O
target	O
concentration	O
on	O
a	O
follow	O
-	O
up	O
test	O
suggests	O
that	O
maternal	O
vitamin	O
D	O
status	O
is	O
a	O
modifiable	O
risk	O
factor	O
that	O
can	O
be	O
addressed	O
during	O
the	O
prenatal	O
period	O
.	O

Especially	O
notable	O
is	O
the	O
considerably	O
lower	O
PTB	O
rate	O
for	O
those	O
who	O
reached	O
≥	O
40	O
ng	O
/	O
mL	O
vs	O
.	O
those	O
who	O
did	O
not	O
(	O
78	O
%)	O
among	O
non	O
-	O
white	O
women	O
.	O

This	O
indicates	O
that	O
improving	O
the	O
vitamin	O
D	O
status	O
of	O
non	O
-	O
white	O
women	O
,	O
who	O
are	O
known	O
to	O
have	O
particularly	O
low	O
vitamin	O
D	O
concentrations	O
,	O
could	O
dramatically	B
decrease	O
racial	O
disparities	O
in	O
PTB	O
rates	O
.	O

These	O
findings	O
are	O
supported	O
by	O
the	O
Hollis	O
and	O
Wagner	O
et	O
al	O
.	O

randomized	O
controlled	O
trials	O
which	O
found	O
that	O
among	O
women	O
with	O
low	O
baseline	O
25	O
(	O
OH	O
)	O
D	O
concentrations	O
(≤	O
20	O
ng	O
/	O
mL	O
),	O
there	O
was	O
a	O
lower	O
risk	O
of	O
PTB	O
(	O
78	O
%)	O
for	O
those	O
who	O
achieved	O
≥	O
40	O
ng	O
/	O
mL	O
compared	O
to	O
those	O
who	O
did	O
not	O
(	O
RR	O
=	O
0	O
.	O
22	O
,	O
95	O
%	O
CI	O
=	O
0	O
.	O
05	O
–	O
0	O
.	O
92	O
)	O
[	O
12	O
].	O

Strengths	O
of	O
this	O
analysis	O
include	O
assessing	O
the	O
relationship	O
between	O
maternal	O
25	O
(	O
OH	O
)	O
D	O
and	O
PTB	O
risk	O
in	O
the	O
general	O
obstetrical	O
population	O
using	O
medical	O
record	O
data	O
at	O
an	O
urban	O
medical	O
center	O
treating	O
a	O
large	O
,	O
diverse	O
population	O
of	O
women	O
.	O

This	O
overcomes	B
the	O
bias	O
of	O
subject	O
selection	O
and	O
allowed	O
a	O
large	O
sample	O
that	O
was	O
more	O
representative	O
of	O
the	O
larger	O
obstetrical	O
population	O
since	B
it	O
included	O
a	O
diversity	O
of	O
socioeconomic	O
backgrounds	O
,	O
race	O
/	O
ethnic	O
groups	O
,	O
pregnancy	O
-	O
related	O
conditions	O
,	O
and	O
medical	O
histories	O
.	O

A	O
larger	O
sample	O
size	O
also	O
enabled	O
subgroup	O
analysis	O
by	O
PTB	O
subtype	O
,	O
race	O
/	O
ethnicity	O
,	O
and	O
among	O
women	O
with	O
a	O
previous	O
PTB	O
.	O

Additionally	O
,	O
using	O
serum	O
25	O
(	O
OH	O
)	O
D	O
concentration	O
is	O
a	O
better	B
indicator	O
of	O
vitamin	O
D	O
status	O
and	O
statistically	O
more	O
powerful	O
than	O
using	O
reported	O
intake	O
because	O
it	O
accounts	O
for	O
all	O
vitamin	O
D	O
input	O
sources	O
(	O
sun	O
exposure	O
,	O
food	O
,	O
and	O
supplements	O
)	O
and	O
makes	O
provision	O
for	O
inter	O
-	O
individual	O
variability	O
in	O
vitamin	O
D	O
dose	O
response	O
.	O

A	O
limitation	O
of	O
this	O
study	O
was	O
that	O
nearly	O
two	O
-	O
thirds	O
of	O
the	O
women	O
(	O
63	O
%)	O
had	O
only	O
one	O
25	O
(	O
OH	O
)	O
D	O
test	O
during	O
pregnancy	O
,	O
which	O
prohibited	O
assessment	O
by	O
trimester	O
and	O
a	O
more	O
thorough	O
analysis	O
of	O
vitamin	O
D	O
benefit	O
among	O
those	O
with	O
low	O
initial	O
levels	O
.	O

This	O
is	O
due	B
to	I
follow	O
-	O
up	O
testing	O
being	O
on	O
the	O
recommended	O
test	O
order	O
set	O
but	O
still	O
needing	O
provider	O
selection	O
compared	O
to	O
the	O
initial	O
test	O
which	O
is	O
automated	O
as	O
part	O
of	O
the	O
initial	O
prenatal	O
screening	O
.	O

Additionally	O
,	O
the	O
initial	O
test	O
was	O
not	O
automated	O
until	O
May	O
2016	O
so	B
many	O
women	O
who	O
delivered	O
during	O
the	O
early	O
study	O
time	O
period	O
did	O
not	O
have	O
a	O
25	O
(	O
OH	O
)	O
D	O
measurement	O
and	O
therefore	B
could	O
not	O
be	O
included	O
in	O
this	O
analysis	O
.	O

Since	B
this	O
new	O
standard	O
of	O
care	O
was	O
implemented	O
in	O
September	O
2015	O
,	O
there	O
have	O
been	O
ongoing	O
improvements	O
in	O
automation	O
,	O
provider	O
practice	O
,	O
and	O
integration	O
within	O
the	O
existing	O
MUSC	O
health	O
care	O
system	O
.	O

Further	O
evaluation	O
of	O
the	O
vitamin	O
D	O
testing	O
and	O
supplementation	O
protocol	O
is	O
planned	O
.	O

Vitamin	O
D	O
status	O
is	O
a	O
key	O
modifiable	O
maternal	O
risk	O
factor	O
for	O
the	O
prevention	O
of	O
PTB	O
.	O

The	O
findings	O
from	O
this	O
analysis	O
support	O
the	O
previously	O
identified	O
association	O
between	O
higher	O
maternal	O
25	O
(	O
OH	O
)	O
D	O
concentrations	O
and	O
reduced	O
risk	O
of	O
PTB	O
and	O
shows	O
that	O
the	O
benefits	O
identified	O
in	O
the	O
RCTs	O
by	O
Hollis	O
and	O
Wagner	O
et	O
al	O
.	O

are	O
achievable	O
in	O
a	O
general	O
obstetrical	O
population	O
.	O

These	O
findings	O
also	O
highlight	O
the	O
importance	O
of	O
achieving	O
a	O
25	O
(	O
OH	O
)	O
D	O
concentration	O
substantially	O
above	O
20	O
ng	O
/	O
mL	O
,	O
the	O
concentration	O
recommended	O
by	O
the	O
IOM	O
for	O
pregnant	O
women	O
[	O
16	O
],	O
for	O
PTB	O
prevention	O
.	O

Having	O
a	O
25	O
(	O
OH	O
)	O
D	O
concentration	O
of	O
at	O
least	O
40	O
ng	O
/	O
mL	O
during	O
pregnancy	O
could	O
reduce	O
PTB	O
risk	O
by	O
>	O
60	O
%	O
and	O
would	O
achieve	O
the	O
optimal	O
conversion	O
of	O
25	O
(	O
OH	O
)	O
D	O
to	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D	O
[	O
13	O
].	O

Vitamin	O
D	O
testing	O
and	O
supplementation	O
of	O
pregnant	O
women	O
is	O
a	O
safe	O
,	O
affordable	O
prevention	O
tool	O
that	O
could	O
substantially	B
reduce	O
the	O
occurrence	O
of	O
PTB	O
and	O
the	O
heavy	O
burden	O
of	O
associated	O
morbidity	O
,	O
mortality	O
and	O
economic	O
costs	O
.	O

PubMed	O
Central	O
:	O

Season	O
and	O
vitamin	O
D	O
status	O
are	O
independently	O
associated	O
with	O
glucose	O
homeostasis	O
in	O
pregnancy	O
Abstract	O
Background	O
Vitamin	O
D	O
status	O
and	O
season	O
are	O
intrinsically	O
linked	O
,	O
and	O
both	O
have	O
been	O
proposed	O
to	O
be	O
associated	O
with	O
glucose	O
homeostasis	O
in	O
pregnancy	O
,	O
with	O
conflicting	O
results	O
.	O

We	O
aimed	O
to	O
determine	O
if	O
exposure	O
to	O
winter	O
and	O
low	O
maternal	O
25	O
hydroxyvitamin	O
D	O
(	O
25OHD	O
)	O
in	O
early	O
pregnancy	O
were	O
associated	O
with	O
maternal	O
glucose	O
metabolism	O
.	O

Methods	O
This	O
is	O
a	O
secondary	O
data	O
analysis	O
of	O
334	O
pregnant	O
women	O
enrolled	O
in	O
the	O
ROLO	O
study	O
,	O
Dublin	O
.	O

Serum	O
25OHD	O
,	O
fasting	O
glucose	O
,	O
insulin	O
and	O
insulin	O
resistance	O
(	O
HOMA	O
-	O
IR	O
)	O
were	O
measured	O
in	O
early	O
(	O
12	O
weeks	O
’	O
gestation	O
)	O
and	O
late	O
pregnancy	O
(	O
28	O
weeks	O
’	O
gestation	O
).	O

Season	O
of	O
first	O
antenatal	O
visit	O
was	O
categorised	O
as	O
extended	O
winter	O
(	O
November	O
–	O
April	O
)	O
or	O
extended	O
summer	O
(	O
May	O
–	O
October	O
).	O

Multiple	O
linear	O
regression	O
models	O
,	O
adjusted	O
for	O
confounders	O
,	O
were	O
used	O
for	O
analysis	O
.	O

Results	O
Those	O
who	O
attended	O
their	O
first	O
antenatal	O
visit	O
in	O
extended	O
winter	O
had	O
lower	O
25OHD	O
compared	O
to	O
extended	O
summer	O
(	O
32	O
.	O
9	O
nmol	O
/	O
L	O
vs	O
.	O
44	O
.	O
1	O
nmol	O
/	O
L	O
,	O
P	O
<	O
0	O
.	O
001	O
).	O

Compared	O
to	O
those	O
who	O
attended	O
their	O
first	O
antenatal	O
visit	O
during	O
extended	O
summer	O
,	O
extended	O
winter	O
was	O
associated	O
with	O
increased	O
HOMA	O
-	O
IR	O
in	O
early	O
-	O
pregnancy	O
(	O
46	O
.	O
7	O
%)	O
and	O
late	O
pregnancy	O
(	O
53	O
.	O
7	O
%),	O
independent	O
of	O
25OHD	O
<	O
30	O
nmol	O
/	O
L	O
and	O
confounders	O
.	O

Early	O
pregnancy	O
25OHD	O
<	O
30	O
nmol	O
/	O
L	O
and	O
extended	O
winter	O
were	O
independently	O
associated	O
with	O
significantly	O
higher	O
fasting	O
glucose	O
in	O
late	O
pregnancy	O
(	O
B	O
=	O
0	O
.	O
15	O
and	O
0	O
.	O
13	O
,	O
respectively	O
).	O

Conclusions	O
Women	O
who	O
attended	O
their	O
first	O
antenatal	O
visit	O
during	O
the	O
months	O
of	O
extended	O
winter	O
were	O
more	O
likely	B
to	O
have	O
raised	O
insulin	O
resistance	O
in	O
early	O
pregnancy	O
,	O
which	O
had	O
a	O
lasting	O
association	O
to	O
28	O
weeks	O
,	O
and	O
was	O
independent	O
of	O
25OHD	O
.	O

Our	O
novel	O
findings	O
imply	B
that	O
seasonal	O
variation	O
in	O
insulin	O
resistance	O
may	O
not	O
be	O
fully	O
explained	B
by	O
differences	O
in	O
vitamin	O
D	O
status	O
.	O

This	O
could	O
reflect	O
circannual	O
rhythm	O
or	O
seasonal	O
lifestyle	O
behaviours	O
,	O
and	O
requires	O
further	O
exploration	O
.	O

Trial	O
registration	O
ISRCTN	O
registry	O
,	O
ISRCTN54392969	O
,	O
date	O
of	O
registration	O
:	O
22	O
/	O
04	O
/	O
2009	O
,	O
retrospectively	O
registered	O
.	O

Electronic	O
supplementary	O
material	O
The	O
online	O
version	O
of	O
this	O
article	O
(	O
doi	O
:	O
10	O
.	O
1186	O
/	O
s12986	O
-	O
017	O
-	O
0203	O
-	O
5	O
)	O
contains	O
supplementary	O
material	O
,	O
which	O
is	O
available	O
to	O
authorized	O
users	O
.	O

Background	O
Vitamin	O
D	O
status	O
and	O
season	O
are	O
intrinsically	O
linked	O
;	O
upon	O
exposure	O
to	O
natural	O
ultraviolet	O
solar	O
radiation	O
,	O
endogenous	O
skin	O
production	O
of	O
vitamin	O
D	O
occurs	O
.	O

However	O
,	O
in	O
countries	O
at	O
northern	O
latitudes	O
,	O
such	O
as	O
Ireland	O
(	O
51	O
–	O
55	O
°	O
N	O
),	O
production	O
reduces	O
substantially	O
from	O
October	O
to	O
March	O
[	O
1	O
,	O
2	O
]	O
with	O
striking	O
seasonal	O
variation	O
observed	O
in	O
25	O
-	O
hydroxyvitamin	O
D	O
(	O
25OHD	O
)	O
in	O
pregnant	O
and	O
non	O
-	O
pregnant	O
populations	O
[	O
3	O
–	O
5	O
].	O

The	O
presence	O
of	O
vitamin	O
D	O
receptors	O
and	O
expression	O
of	O
1	O
-	O
α	O
-	O
hydroxylase	O
enzyme	O
in	O
pancreatic	O
beta	O
cells	O
suggest	O
that	O
vitamin	O
D	O
may	O
be	O
a	O
modulator	O
of	O
insulin	O
secretion	O
and	O
thus	B
,	O
influence	O
glucose	O
homeostasis	O
[	O
6	O
].	O

In	O
pregnancy	O
,	O
the	O
association	O
between	O
low	O
vitamin	O
D	O
levels	O
and	O
abnormalities	O
in	O
glucose	O
tolerance	O
is	O
the	O
subject	O
of	O
scientific	O
debate	O
,	O
with	O
some	O
studies	O
reporting	O
that	O
maternal	O
insulin	O
sensitivity	O
,	O
fasting	O
glucose	O
and	O
gestational	O
diabetes	O
are	O
not	O
associated	O
with	O
25OHD	O
[	O
7	O
],	O
while	O
others	O
have	O
found	O
inverse	O
associations	O
between	O
25OHD	O
,	O
fasting	O
glucose	O
[	O
8	O
]	O
and	O
risk	O
of	O
gestational	O
diabetes	O
[	O
9	O
].	O

However	O
,	O
the	O
majority	B
of	O
vitamin	O
D	O
supplementation	O
intervention	O
trials	O
in	O
pregnancy	O
have	O
not	O
had	O
a	O
significant	O
impact	O
on	O
maternal	O
and	O
offspring	O
health	O
[	O
10	O
].	O

The	O
physiological	O
response	O
to	O
sunlight	O
exposure	O
,	O
beyond	O
that	O
of	O
vitamin	O
D	O
production	O
,	O
includes	O
regulation	O
of	O
biological	O
circadian	O
and	O
circannual	O
rhythms	O
,	O
control	O
of	O
circulating	O
melatonin	O
,	O
as	O
well	O
as	O
production	O
of	O
nitric	O
oxide	O
,	O
a	O
vasodilator	O
,	O
and	O
beta	O
-	O
endorphins	O
which	O
promote	O
a	O
feeling	O
of	O
well	O
-	O
being	O
[	O
11	O
–	O
13	O
].	O

Circadian	O
rhythms	O
follow	O
the	O
daily	O
,	O
24	O
-	O
h	O
light	O
-	O
dark	O
cycle	O
[	O
14	O
],	O
while	O
seasonal	O
fluctuations	O
influence	O
circannual	O
rhythms	O
[	O
15	O
].	O

Disruption	O
of	O
our	O
circadian	O
clock	O
,	O
for	O
example	O
though	O
shift	O
work	O
that	O
interferes	O
with	O
light	O
-	O
dark	O
environmental	O
phases	O
,	O
can	O
negatively	O
affect	O
cardiometabolic	O
function	O
and	O
increase	O
insulin	O
resistance	O
[	O
16	O
].	O

The	O
duration	O
of	O
natural	O
sunlight	O
in	O
our	O
environment	O
varies	O
depending	O
on	O
season	O
,	O
and	O
although	O
it	O
is	O
known	O
that	O
many	O
animals	O
adapt	O
physiologically	O
and	O
behaviourally	O
in	O
order	O
to	O
survive	O
the	O
changing	O
seasons	O
,	O
there	O
is	O
also	O
evidence	O
of	O
circannual	O
biological	O
clocks	O
among	O
humans	O
[	O
15	O
,	O
17	O
].	O

Epidemiological	O
data	O
suggest	O
that	O
seasonality	O
in	O
sunlight	O
and	O
vitamin	O
D	O
are	O
related	O
to	O
mortality	O
and	O
infection	O
rates	O
[	O
18	O
].	O

Seasonal	O
variation	O
has	O
been	O
reported	O
in	O
HbA1cand	O
glucose	O
concentrations	O
among	O
individuals	O
with	O
type	O
2	O
diabetes	O
,	O
with	O
highest	O
levels	O
observed	O
in	O
winter	O
and	O
lowest	O
in	O
summer	O
[	O
19	O
–	O
23	O
].	O

Two	O
separate	O
cohort	O
studies	O
recently	O
reported	O
the	O
prevalence	O
of	O
gestational	O
diabetes	O
diagnosis	O
to	O
be	O
significantly	O
higher	O
in	O
summer	O
compared	O
to	O
winter	O
[	O
24	O
,	O
25	O
].	O

These	O
findings	O
are	O
in	O
keeping	O
with	O
another	O
study	O
that	O
found	O
the	O
highest	O
incidence	O
of	O
gestational	O
diabetes	O
in	O
pregnancies	O
with	O
winter	O
conception	O
[	O
26	O
].	O

However	O
,	O
conflicting	O
evidence	O
exists	O
[	O
27	O
,	O
28	O
].	O

The	O
seasonal	O
differences	O
outlined	O
in	O
the	O
studies	O
above	O
could	O
be	O
attributed	O
to	O
seasonal	O
25OHD	O
,	O
or	O
evolutionary	O
circannual	O
rhythms	O
to	O
protect	O
mother	O
and	O
fetus	O
.	O

There	O
are	O
also	O
other	O
factors	O
that	O
are	O
influenced	O
by	O
season	O
:	O
diet	O
[	O
29	O
],	O
physical	O
activity	O
levels	O
[	O
30	O
],	O
and	O
even	O
body	O
mass	O
index	O
[	O
31	O
].	O

Due	O
to	O
the	O
seasonal	O
nature	O
of	O
25OHD	O
concentrations	O
in	O
many	O
parts	O
of	O
the	O
world	O
[	O
32	O
],	O
and	O
the	O
observed	O
associations	O
between	O
vitamin	O
D	O
and	O
insulin	O
resistance	O
,	O
it	O
would	O
seem	O
prudent	O
to	O
hypothesise	O
that	O
seasonal	O
variation	O
of	O
glucose	O
homeostasis	O
may	O
be	O
mediated	O
through	O
25OHD	O
.	O

In	O
2016	O
the	O
Scientific	O
Advisory	O
Committee	O
on	O
Nutrition	O
stated	O
that	O
the	O
metabolic	O
implications	O
of	O
seasonal	O
variation	O
in	O
serum	O
25OHD	O
remain	O
unknown	O
,	O
highlighting	O
the	O
necessity	O
for	O
research	O
on	O
this	O
topic	O
[	O
33	O
].	O

We	O
hypothesised	O
that	O
gestating	O
through	O
winter	O
in	O
early	O
pregnancy	O
is	O
associated	O
with	O
both	O
reduced	O
serum	O
25OHD	O
and	O
increased	O
markers	O
of	O
glucose	O
metabolism	O
(	O
fasting	O
glucose	O
and	O
insulin	O
resistance	O
);	O
that	O
reduced	O
serum	O
25OHD	O
is	O
associated	O
with	O
increased	O
markers	O
of	O
glucose	O
metabolism	O
;	O
and	O
that	O
seasonal	O
differences	O
in	O
these	O
markers	O
are	O
associated	O
with	O
seasonal	O
variation	O
in	O
serum	O
25OHD	O
.	O

Given	B
the	O
exploratory	O
nature	O
of	O
this	O
work	O
,	O
we	O
also	O
planned	O
to	O
conduct	O
post	O
-	O
hoc	O
exploratory	O
analyses	O
where	O
appropriate	O
.	O

Methods	O
Study	O
design	O
and	O
setting	O
This	O
is	O
a	O
secondary	O
data	O
analysis	O
of	O
334	O
pregnant	O
women	O
enrolled	O
in	O
the	O
ROLO	O
(	O
Randomised	O
cOntrol	O
trial	O
of	O
a	O
LOw	O
glycaemic	O
index	O
diet	O
in	O
pregnancy	O
to	O
prevent	O
macrosomia	O
)	O
study	O
between	O
2007	O
and	O
2011	O
at	O
The	O
National	O
Maternity	O
Hospital	O
,	O
Dublin	O
,	O
Ireland	O
.	O

Detailed	O
methods	O
and	O
results	O
of	O
this	O
study	O
have	O
been	O
previously	O
published	O
[	O
34	O
,	O
35	O
].	O

In	O
brief	O
,	O
800	O
secundigravida	O
women	O
,	O
who	O
had	O
previously	O
delivered	O
a	O
macrosomic	O
infant	O
(>	O
4000	O
g	O
),	O
were	O
randomised	O
to	O
receive	O
either	O
low	O
glycaemic	O
index	O
dietary	O
advice	O
or	O
usual	O
care	O
(	O
no	O
dietary	O
advice	O
)	O
[	O
34	O
].	O

Although	O
the	O
primary	O
outcome	O
of	O
birth	O
weight	O
did	O
not	O
significantly	O
differ	O
between	O
the	O
intervention	O
and	O
control	O
group	O
,	O
the	O
secondary	O
outcomes	O
of	O
dietary	O
glycaemic	O
index	O
,	O
gestational	O
weight	O
gain	O
and	O
glucose	O
intolerance	O
were	O
significantly	O
reduced	O
in	O
the	O
intervention	O
arm	O
.	O

Insulin	O
,	O
but	O
not	O
HOMA	O
,	O
was	O
significantly	O
reduced	O
in	O
the	O
intervention	O
arm	O
.	O

No	O
difference	O
in	O
serum	O
25OHD	O
was	O
noted	O
between	O
groups	O
.	O

The	O
study	O
was	O
conducted	O
per	O
the	O
guidelines	O
laid	O
down	O
in	O
the	O
Declaration	O
of	O
Helsinki	O
with	O
institutional	O
ethical	O
approval	O
and	O
written	O
maternal	O
consent	O
.	O

Patient	O
eligibility	O
Participants	O
were	O
recruited	O
at	O
the	O
first	O
antenatal	O
hospital	O
visit	O
.	O

Eligible	O
participants	O
were	O
10	O
–	O
18	O
weeks	O
’	O
gestation	O
,	O
with	O
a	O
singleton	O
pregnancy	O
,	O
over	O
18	O
years	O
of	O
age	O
,	O
not	O
taking	O
any	O
medication	O
,	O
and	O
without	O
previous	O
or	O
current	O
gestational	O
diabetes	O
.	O

Only	O
those	O
who	O
had	O
completed	O
the	O
2	O
-	O
year	O
follow	O
-	O
up	O
appointment	O
had	O
serum	O
25OHD	O
measured	O
in	O
the	O
pregnancy	O
sample	O
,	O
thus	O
334	O
participants	O
were	O
included	O
.	O

Data	O
collection	O
At	O
the	O
first	O
antenatal	O
consultation	O
,	O
participants	O
were	O
weighed	O
in	O
light	O
clothing	O
using	O
a	O
SECA	O
weighing	O
scales	O
(	O
SECA	O
GmbH	O
&	O
Co	O
.	O
Kg	O
.	O

Germany	O
)	O
to	O
the	O
nearest	O
0	O
.	O
1	O
kg	O
and	O
height	O
was	O
measured	O
without	O
shoes	O
to	O
the	O
nearest	O
0	O
.	O
1	O
cm	O
using	O
a	O
wall	O
-	O
mounted	O
stadiometer	O
.	O

Body	O
mass	O
index	O
(	O
BMI	O
)	O
(	O
kg	O
/	O
m2	O
)	O
was	O
calculated	O
.	O

Food	O
and	O
beverages	O
consumed	O
over	O
three	O
consecutive	O
days	O
were	O
recorded	O
by	O
participants	O
during	O
each	O
trimester	O
using	O
3	O
-	O
day	O
food	O
diaries	O
.	O

For	O
this	O
study	O
,	O
we	O
analysed	O
the	O
early	O
-	O
pregnancy	O
food	O
diaries	O
only	O
.	O

Dietary	O
data	O
from	O
food	O
diaries	O
were	O
analysed	O
using	O
NetWISP	O
version	O
3	O
.	O
0	O
(	O
Tinuviel	O
Software	O
,	O
Llanfechell	O
,	O
Anglesey	O
,	O
UK	O
).	O

Participants	O
also	O
completed	O
a	O
questionnaire	O
about	O
use	O
of	O
dietary	O
supplements	O
.	O

Information	O
about	O
the	O
quantity	O
of	O
vitamin	O
D	O
within	O
supplements	O
was	O
not	O
collected	O
.	O

Emotional	O
well	O
-	O
being	O
was	O
examined	O
using	O
the	O
5	O
-	O
item	O
World	O
Health	O
Organization	O
Well	O
-	O
Being	O
Index	O
(	O
WHO	O
-	O
5	O
)	O
[	O
36	O
].	O

Physical	O
activity	O
,	O
smoking	O
and	O
educational	O
attainment	O
were	O
also	O
self	O
-	O
reported	O
.	O

Fasting	O
serum	O
blood	O
samples	O
were	O
collected	O
at	O
the	O
first	O
antenatal	O
visit	O
(	O
early	O
pregnancy	O
)	O
and	O
at	O
the	O
28	O
-	O
week	O
gestation	O
visit	O
(	O
late	O
pregnancy	O
)	O
for	O
the	O
measurement	O
of	O
insulin	O
and	O
25OHD	O
.	O

Fasting	O
blood	O
glucose	O
was	O
measured	O
at	O
both	O
time	O
points	O
,	O
and	O
a	O
glucose	O
challenge	O
test	O
(	O
1	O
-	O
h	O
post	O
a	O
50	O
-	O
g	O
glucose	O
load	O
)	O
was	O
performed	O
at	O
28	O
weeks	O
’	O
gestation	O
.	O

Laboratory	O
analysis	O
Serum	O
25OHD	O
concentrations	O
were	O
determined	O
using	O
the	O
Elecsys	O
Vitamin	O
D	O
Total	O
(	O
Roche	O
Diagnostics	O
GmbH	O
,	O
Mannheim	O
,	O
Germany	O
)	O
automated	O
competitive	O
binding	O
protein	O
assay	O
[	O
3	O
].	O

The	O
coefficients	O
of	O
variation	O
(	O
CV	O
)	O
for	O
the	O
25OHD	O
assay	O
determined	O
at	O
assay	O
verification	O
were	O
as	O
follows	O
:	O
inter	O
-	O
assay	O
CV	O
,	O
8	O
.	O
9	O
%	O
at	O
a	O
concentration	O
of	O
49	O
.	O
5	O
nmol	O
/	O
L	O
and	O
3	O
.	O
7	O
%	O
at	O
103	O
nmol	O
/	O
L	O
(	O
intra	O
-	O
assay	O
CV	O
,	O
2	O
.	O
9	O
%	O
and	O
1	O
.	O
4	O
%	O
respectively	O
).	O

To	O
ensure	O
a	O
high	O
standard	O
of	O
analysis	O
for	O
serum	O
25OHD	O
concentrations	O
,	O
the	O
laboratory	O
participates	O
in	O
an	O
external	O
quality	O
assurance	O
scheme	O
;	O
Vitamin	O
D	O
External	O
Quality	O
Assessment	O
Scheme	O
(	O
DEQAS	O
).	O

Multianalyte	O
profiling	O
was	O
performed	O
on	O
the	O
Luminex	O
Magpix	O
system	O
(	O
Luminex	O
Corporation	O
Austin	O
,	O
USA	O
).	O

Plasma	O
concentrations	O
of	O
insulin	O
were	O
determined	O
by	O
the	O
Human	O
Endocrine	O
Panel	O
.	O

Maternal	O
insulin	O
resistance	O
was	O
calculated	O
using	O
the	O
Homeostasis	O
Model	O
Assessment	O
(	O
HOMA	O
-	O
IR	O
)	O
equation	O
:	O
[	O
fasting	O
serum	O
insulin	O
(	O
μU	O
/	O
ml	O
)	O
×	O
fasting	O
plasma	O
glucose	O
(	O
mmol	O
/	O
l	O
)/	O
22	O
.	O
5	O
].	O

Statistical	O
analysis	O
Serum	O
25OHD	O
concentrations	O
in	O
early	O
pregnancy	O
were	O
categorised	O
according	O
to	O
the	O
Institute	O
of	O
Medicine	O
;	O
<	O
30	O
nmol	O
/	O
L	O
and	O
<	O
50	O
nmol	O
/	O
L	O
[	O
37	O
].	O

The	O
change	O
in	O
25OHD	O
from	O
early	O
pregnancy	O
to	O
late	O
pregnancy	O
was	O
calculated	O
.	O

Participants	O
were	O
dichotomised	O
into	O
the	O
season	O
during	O
which	O
the	O
first	O
antenatal	O
visit	O
took	O
place	O
;	O
extended	O
summer	O
(	O
May	O
–	O
October	O
)	O
or	O
extended	O
winter	O
(	O
November	O
–	O
April	O
).	O

Data	O
were	O
assessed	O
for	O
normality	O
using	O
the	O
Kolmogorov	O
-	O
Smirnov	O
test	O
and	O
visual	O
inspection	O
of	O
histograms	O
.	O

Non	O
-	O
normally	O
distributed	O
variables	O
were	O
log	O
transformed	O
prior	O
to	O
regression	O
analysis	O
.	O

Maternal	O
characteristics	O
were	O
explored	O
using	O
independent	O
t	O
tests	O
,	O
Mann	O
-	O
Whitney	O
U	O
tests	O
and	O
Chi	O
-	O
square	O
tests	O
.	O

Simple	O
linear	O
regression	O
was	O
used	O
to	O
determine	O
the	O
univariate	O
associations	O
between	O
metabolic	O
markers	O
,	O
25OHD	O
,	O
and	O
early	O
-	O
pregnancy	O
season	O
.	O

Multiple	O
linear	O
regression	O
models	O
were	O
created	O
using	O
a	O
forced	O
-	O
enter	O
approach	O
and	O
were	O
adjusted	O
for	O
confounders	O
.	O

To	O
estimate	O
the	O
association	O
between	O
exposure	O
to	O
extended	O
winter	O
and	O
the	O
transformed	O
metabolic	O
markers	O
,	O
the	O
reverse	O
transformation	O
of	O
the	O
B	O
values	O
from	O
regression	O
models	O
were	O
computed	O
.	O

Percentage	O
differences	O
in	O
metabolic	O
markers	O
were	O
calculated	O
using	O
the	O
equation	O
:	O
([	O
eB	O
-	O
1	O
]*	O
100	O
).	O

We	O
carried	O
out	O
sensitivity	O
analysis	O
using	O
different	O
thresholds	O
for	O
25OHD	O
in	O
the	O
multiple	O
regression	O
models	O
.	O

Statistical	O
analyses	O
were	O
performed	O
using	O
IBM	O
SPSS	O
Statistics	O
for	O
Windows	O
,	O
Version	O
20	O
.	O
0	O
(	O
IBM	O
,	O
Armonk	O
,	O
NY	O
).	O

Results	O
were	O
considered	O
statistically	O
significant	O
if	O
P	O
<	O
0	O
.	O
05	O
.	O

Results	O
Participant	O
characteristics	O
-	O
demographics	O
Half	O
of	O
the	O
participants	O
attended	O
their	O
first	O
antenatal	O
visit	O
during	O
extended	O
winter	O
(	O
November	O
–	O
April	O
)	O
(	O
n	O
=	O
166	O
[	O
49	O
.	O
7	O
%]).	O

Maternal	O
characteristics	O
,	O
as	O
described	O
in	O
Table1	O
,	O
did	O
not	O
differ	O
between	O
those	O
who	O
attended	O
their	O
first	O
antenatal	O
visit	O
during	O
extended	O
winter	O
or	O
summer	O
.	O

A	O
comparison	O
of	O
the	O
maternal	O
characteristics	O
between	O
those	O
included	O
(	O
n	O
=	O
334	O
)	O
and	O
excluded	O
from	O
the	O
original	O
ROLO	O
study	O
is	O
included	O
in	O
Additional	O
file1	O
:	O
Table	O
S1	O
.	O

Caption	O
(	O
TABLE	O
-	O
WRAP	O
):	O
TABLE	O
1	O
Participant	O
CharacteristicsSeason	O
at	O
first	O
antenatal	O
visitCharacteristicTotal	O
Group	O
(	O
n	O
=	O
334	O
)	O
Winter	O
(	O
n	O
=	O
166	O
)	O
Summer	O
(	O
n	O
=	O
168	O
)	O
PaAge	O
(	O
years	O
)	O
33	O
.	O
0	O
(	O
3	O
.	O
9	O
)	O
32	O
.	O
8	O
(	O
3	O
.	O
7	O
)	O
33	O
.	O
2	O
(	O
4	O
.	O
0	O
)	O
0	O
.	O
409Gestation	O
at	O
first	O
antenatal	O
visit	O
(	O
weeks	O
)	O
12	O
.	O
8	O
(	O
2	O
.	O
3	O
)	O
12	O
.	O
7	O
(	O
2	O
.	O
3	O
)	O
12	O
.	O
9	O
(	O
2	O
.	O
2	O
)	O
0	O
.	O
556BMI	O
at	O
first	O
antenatal	O
visit	O
Mean	O
(	O
SD	O
),	O
(	O
kg	O
/	O
m2	O
)	O
26	O
.	O
3	O
(	O
4	O
.	O
5	O
)	O
26	O
.	O
3	O
(	O
4	O
.	O
4	O
)	O
26	O
.	O
2	O
(	O
4	O
.	O
7	O
)	O
0	O
.	O
948	O
Underweight	O
(	O
BMI	O
<	O
18	O
.	O
5	O
kg	O
/	O
m2	O
)	O
[	O
n	O
(%)]	O
2	O
(	O
0	O
.	O
6	O
)	O
1	O
(	O
0	O
.	O
6	O
)	O
1	O
(	O
0	O
.	O
6	O
)	O
0	O
.	O
953	O
Normal	O
(	O
BMI	O
18	O
.	O
5	O
–	O
24	O
.	O
9	O
kg	O
/	O
m2	O
)	O
[	O
n	O
(%)]	O
153	O
(	O
45	O
.	O
8	O
)	O
78	O
(	O
46	O
.	O
4	O
)	O
75	O
(	O
45	O
.	O
2	O
)	O
Overweight	O
(	O
BMI	O
25	O
.	O
0	O
–	O
29	O
.	O
9	O
kg	O
/	O
m2	O
)	O
[	O
n	O
(%)]	O
125	O
(	O
37	O
.	O
4	O
)	O
60	O
(	O
35	O
.	O
7	O
)	O
65	O
(	O
39	O
.	O
2	O
)	O
Obese	O
(	O
BMI	O
>	O
30	O
.	O
0	O
kg	O
/	O
m2	O
)	O
[	O
n	O
(%)]	O
52	O
(	O
15	O
.	O
6	O
)	O
27	O
(	O
16	O
.	O
1	O
)	O
25	O
(	O
15	O
.	O
1	O
)	O
Smoking	O
at	O
baseline	O
[	O
n	O
(%)]	O
7	O
(	O
2	O
.	O
1	O
)	O
4	O
(	O
2	O
.	O
4	O
)	O
3	O
(	O
1	O
.	O
8	O
)	O
0	O
.	O
697Intervention	O
group	O
[	O
n	O
(%)]	O
171	O
(	O
51	O
.	O
2	O
)	O
84	O
(	O
50	O
.	O
6	O
)	O
87	O
(	O
50	O
.	O
9	O
)	O
0	O
.	O
829Ethnicity	O
:	O
Caucasian	O
[	O
n	O
(%)]	O
331	O
(	O
99	O
.	O
1	O
)	O
166	O
(	O
100	O
.	O
0	O
)	O
165	O
(	O
98	O
.	O
2	O
)	O
0	O
.	O
250Achieved	O
3rd	O
level	O
education	O
[	O
n	O
(%)]	O
177	O
(	O
53	O
.	O
0	O
)	O
87	O
(	O
52	O
.	O
6	O
)	O
90	O
(	O
53	O
.	O
6	O
)	O
0	O
.	O
940Birth	O
weight	O
(	O
g	O
)	O
4065	O
.	O
9	O
(	O
470	O
.	O
0	O
)	O
4043	O
.	O
1	O
(	O
434	O
.	O
4	O
)	O
4088	O
.	O
4	O
(	O
503	O
.	O
0	O
)	O
0	O
.	O
382	O
Data	O
are	O
presented	O
as	O
mean	O
(	O
SD	O
)	O
unless	O
otherwise	O
stated	O
aComparison	O
between	O
winter	O
and	O
summer	O
Participant	O
characteristics	O
-	O
25OHD	O
,	O
season	O
and	O
markers	O
of	O
glucose	O
metabolism	O
Median	O
(	O
IQR	O
)	O
25OHD	O
concentrations	O
were	O
39	O
.	O
2	O
nmol	O
/	O
L	O
(	O
27	O
.	O
2	O
nmol	O
/	O
L	O
)	O
and	O
35	O
.	O
8	O
nmol	O
/	O
L	O
(	O
27	O
.	O
3	O
nmol	O
/	O
L	O
)	O
in	O
early	O
and	O
late	O
pregnancy	O
,	O
respectively	O
.	O

In	O
early	O
pregnancy	O
,	O
attending	O
the	O
first	O
antenatal	O
visit	O
during	O
extended	O
winter	O
was	O
associated	O
with	O
significantly	O
lower	O
25OHD	O
concentrations	O
than	O
extended	O
summer	O
(	O
32	O
.	O
9	O
nmol	O
/	O
L	O
[	O
22	O
.	O
6	O
nmol	O
/	O
L	O
]	O
vs	O
.	O
44	O
.	O
1	O
nmol	O
/	O
L	O
[	O
27	O
.	O
6	O
nmol	O
/	O
L	O
],	O
P	O
<	O
0	O
.	O
001	O
).	O

In	O
early	O
pregnancy	O
,	O
those	O
who	O
attended	O
their	O
first	O
antenatal	O
visit	O
in	O
extended	O
winter	O
were	O
significantly	O
more	O
likely	B
to	O
be	O
at	O
risk	O
of	O
25OHD	O
deficiency	O
(<	O
30	O
nmol	O
/	O
L	O
)	O
and	O
25OHD	O
inadequacy	O
(<	O
50	O
nmol	O
/	O
L	O
),	O
than	O
those	O
who	O
attended	O
their	O
first	O
antenatal	O
visit	O
in	O
extended	O
summer	O
(	O
Table2	O
).	O

The	O
median	O
(	O
IQR	O
)	O
change	O
in	O
25OHD	O
from	O
early	O
pregnancy	O
to	O
late	O
pregnancy	O
among	O
women	O
attending	O
the	O
first	O
antenatal	O
visit	O
during	O
extended	O
winter	O
was	O
0	O
.	O
60	O
nmol	O
/	O
L	O
(	O
22	O
.	O
42	O
)	O
and	O
during	O
extended	O
summer	O
was	O
−	O
11	O
.	O
14	O
nmol	O
/	O
L	O
(	O
22	O
.	O
75	O
).	O

Mean	O
early	O
pregnancy	O
25OHD	O
versus	O
month	O
of	O
first	O
antenatal	O
visit	O
is	O
displayed	O
in	O
Additional	O
file1	O
:	O
Fig	O
.	O

S1	O
.	O

In	O
early	O
pregnancy	O
,	O
insulin	O
and	O
HOMA	O
-	O
IR	O
,	O
but	O
not	O
glucose	O
,	O
were	O
significantly	O
higher	O
among	O
those	O
who	O
attended	O
their	O
first	O
antenatal	O
visit	O
in	O
extended	O
winter	O
(	O
Table2	O
).	O

Caption	O
(	O
TABLE	O
-	O
WRAP	O
):	O
TABLE	O
2	O
Maternal	O
25OHD	O
and	O
markers	O
of	O
glucose	O
metabolism	O
in	O
early	O
and	O
late	O
pregnancy	O
among	O
the	O
total	O
group	O
and	O
categorised	O
by	O
season	O
of	O
first	O
antenatal	O
visitSeason	O
at	O
first	O
antenatal	O
visitTotal	O
Group	O
(	O
n	O
=	O
334	O
)	O
Winter	O
(	O
n	O
=	O
166	O
)	O
Summer	O
(	O
n	O
=	O
168	O
)	O
Pd25OHD	O
early	O
<	O
30	O
nmol	O
/	O
La90	O
(	O
26	O
.	O
9	O
)	O
64	O
(	O
38	O
.	O
6	O
)	O
26	O
(	O
15	O
.	O
5	O
)<	O
0	O
.	O
00125OHD	O
early	O
<	O
50	O
nmol	O
/	O
La205	O
(	O
61	O
.	O
4	O
)	O
121	O
(	O
72	O
.	O
9	O
)	O
84	O
(	O
50	O
.	O
0	O
)	O
0	O
.	O
00225OHD	O
28	O
weeks	O
<	O
30	O
nmol	O
/	O
La111	O
(	O
33	O
.	O
2	O
)	O
56	O
(	O
33	O
.	O
7	O
)	O
55	O
(	O
32	O
.	O
7	O
)	O
0	O
.	O
66225OHD	O
28	O
weeks	O
<	O
50	O
nmol	O
/	O
La211	O
(	O
63	O
.	O
2	O
)	O
103	O
(	O
62	O
.	O
0	O
)	O
107	O
(	O
63	O
.	O
7	O
)	O
0	O
.	O
999HOMA	O
-	O
IR	O
earlyb2	O
.	O
1	O
(	O
2	O
.	O
6	O
)	O
2	O
.	O
4	O
(	O
2	O
.	O
8	O
)	O
1	O
.	O
7	O
(	O
2	O
.	O
0	O
)	O
0	O
.	O
004HOMA	O
-	O
IR	O
28	O
weeksb2	O
.	O
8	O
(	O
3	O
.	O
15	O
)	O
2	O
.	O
9	O
(	O
3	O
.	O
4	O
)	O
2	O
.	O
6	O
(	O
2	O
.	O
6	O
)	O
0	O
.	O
064Insulin	O
early	O
(	O
μU	O
/	O
mL	O
)	O
b11	O
.	O
3	O
(	O
12	O
.	O
3	O
)	O
12	O
.	O
8	O
(	O
13	O
.	O
1	O
)	O
9	O
.	O
3	O
(	O
11	O
.	O
1	O
)	O
0	O
.	O
002Insulin	O
28	O
weeks	O
(	O
μU	O
/	O
mL	O
)	O
b14	O
.	O
4	O
(	O
15	O
.	O
6	O
)	O
14	O
.	O
6	O
(	O
16	O
.	O
8	O
)	O
14	O
.	O
1	O
(	O
11	O
.	O
8	O
)	O
0	O
.	O
108Fasting	O
glucose	O
early	O
(	O
mmol	O
/	O
L	O
)	O
c4	O
.	O
48	O
(	O
0	O
.	O
35	O
)	O
4	O
.	O
47	O
(	O
0	O
.	O
33	O
)	O
4	O
.	O
49	O
(	O
0	O
.	O
37	O
)	O
0	O
.	O
566Fasting	O
glucose	O
28	O
weeks	O
(	O
mmol	O
/	O
L	O
)	O
c4	O
.	O
46	O
(	O
0	O
.	O
46	O
)	O
4	O
.	O
49	O
(	O
0	O
.	O
45	O
)	O
4	O
.	O
42	O
(	O
0	O
.	O
46	O
)	O
0	O
.	O
1571	O
-	O
h	O
GCT	O
28	O
weeks	O
(	O
mmol	O
/	O
L	O
)	O
c6	O
.	O
48	O
(	O
1	O
.	O
44	O
)	O
6	O
.	O
47	O
(	O
1	O
.	O
39	O
)	O
6	O
.	O
50	O
(	O
1	O
.	O
48	O
)	O
0	O
.	O
864	O
Data	O
presented	O
asan	O
(%),	O
bmedian	O
(	O
interquartile	O
range	O
),	O
cmean	O
(	O
SD	O
)	O
dComparison	O
between	O
winter	O
and	O
summer	O
Unadjusted	O
analysis	O
–	O
25OHD	O
,	O
season	O
and	O
markers	O
of	O
glucose	O
metabolism	O
On	O
unadjusted	O
,	O
simple	O
linear	O
regression	O
,	O
early	O
-	O
pregnancy	O
25OHD	O
<	O
30	O
nmol	O
/	O
L	O
was	O
not	O
associated	O
with	O
any	O
marker	O
of	O
glucose	O
metabolism	O
in	O
early	O
or	O
late	O
pregnancy	O
(	O
Table3	O
[	O
a	O
]).	O

Attendance	O
at	O
the	O
first	O
antenatal	O
visit	O
during	O
extended	O
winter	O
,	O
compared	O
to	O
summer	O
,	O
was	O
associated	O
with	O
significantly	O
higher	O
early	O
-	O
pregnancy	O
HOMA	O
-	O
IR	O
(	O
31	O
.	O
1	O
%)	O
and	O
insulin	O
(	O
30	O
.	O
6	O
%),	O
but	O
not	O
glucose	O
(	O
Table3	O
[	O
b	O
]).	O

Caption	O
(	O
TABLE	O
-	O
WRAP	O
):	O
TABLE	O
3	O
Unadjusted	O
regression	O
analysis	O
:	O
Percentage	O
difference	O
in	O
markers	O
of	O
glucose	O
metabolism	O
associated	O
with	O
,	O
(	O
a	O
)	O
Early	O
-	O
pregnancy	O
25OHD	O
<	O
30	O
nmol	O
/	O
L	O
,	O
and	O
(	O
b	O
)	O
first	O
antenatal	O
visit	O
in	O
extended	O
winter	O
(	O
a	O
)	O
Early	O
-	O
pregnancy	O
25OHD	O
<	O
30	O
nmol	O
/	O
L	O
(	O
b	O
)	O
First	O
antenatal	O
visit	O
in	O
extended	O
winterDependent	O
Variable	O
%	O
∆	O
aB95	O
%	O
CI	O
P	O
%	O
∆	O
aB95	O
%	O
CI	O
P	O
HOMA	O
-	O
IR	O
early18	O
.	O
5	O
%	O
0	O
.	O
17	O
(−	O
0	O
.	O
04	O
,	O
0	O
.	O
39	O
)	O
0	O
.	O
11031	O
.	O
1	O
%	O
0	O
.	O
27	O
(	O
0	O
.	O
08	O
,	O
0	O
.	O
46	O
)	O
0	O
.	O
006HOMA	O
-	O
IR	O
28	O
weeks11	O
.	O
6	O
%	O
0	O
.	O
11	O
(−	O
0	O
.	O
13	O
,	O
0	O
.	O
39	O
)	O
0	O
.	O
37121	O
.	O
9	O
%	O
0	O
.	O
20	O
(	O
0	O
.	O
00	O
,	O
0	O
.	O
40	O
)	O
0	O
.	O
051Insulin	O
early	O
(	O
μU	O
/	O
mL	O
)	O
16	O
.	O
2	O
%	O
0	O
.	O
15	O
(−	O
0	O
.	O
06	O
,	O
0	O
.	O
35	O
)	O
0	O
.	O
17330	O
.	O
6	O
%	O
0	O
.	O
27	O
(	O
0	O
.	O
08	O
,	O
0	O
.	O
45	O
)	O
0	O
.	O
005Insulin	O
28	O
weeks	O
(	O
μU	O
/	O
mL	O
)	O
7	O
.	O
3	O
%	O
0	O
.	O
07	O
(−	O
0	O
.	O
16	O
,	O
0	O
.	O
30	O
)	O
0	O
.	O
52819	O
.	O
2	O
%	O
0	O
.	O
18	O
(−	O
0	O
.	O
02	O
,	O
0	O
.	O
37	O
)	O
0	O
.	O
074Fasting	O
glucose	O
early	O
(	O
mmol	O
/	O
L	O
)	O
0	O
.	O
03	O
(−	O
0	O
.	O
06	O
,	O
0	O
.	O
12	O
)	O
0	O
.	O
541	O
−	O
0	O
.	O
02	O
(−	O
0	O
.	O
09	O
,	O
0	O
.	O
05	O
)	O
0	O
.	O
566Fasting	O
glucose	O
28	O
weeks	O
(	O
mmol	O
/	O
L	O
)	O
0	O
.	O
09	O
(−	O
0	O
.	O
02	O
,	O
0	O
.	O
21	O
)	O
0	O
.	O
1120	O
.	O
07	O
(−	O
0	O
.	O
03	O
,	O
0	O
.	O
17	O
)	O
0	O
.	O
1571	O
-	O
h	O
GCT	O
28	O
weeks	O
(	O
mmol	O
/	O
L	O
)	O
0	O
.	O
04	O
(−	O
0	O
.	O
32	O
,	O
0	O
.	O
41	O
)	O
0	O
.	O
824	O
−	O
0	O
.	O
03	O
(−	O
0	O
.	O
34	O
,	O
0	O
.	O
29	O
)	O
0	O
.	O
864	O
a	O
%	O
difference	O
in	O
metabolic	O
marker	O
Adjusted	O
analysis	O
(	O
model	O
1	O
)	O
–	O
25OHD	O
,	O
season	O
and	O
markers	O
of	O
glucose	O
metabolism	O
Multiple	O
linear	O
regression	O
models	O
(	O
Table4	O
)	O
included	O
both	O
25OHD	O
<	O
30	O
nmol	O
/	O
L	O
and	O
extended	O
winter	O
as	O
predictors	O
of	O
the	O
metabolic	O
markers	O
(	O
Model	O
1	O
),	O
and	O
were	O
also	O
adjusted	O
for	O
confounders	O
(	O
Model	O
2	O
).	O

Prior	O
to	O
analysis	O
,	O
collinearity	O
between	O
the	O
two	O
predictor	O
variables	O
was	O
measured	O
using	O
Spearman	O
’	O
s	O
rho	O
to	O
ensure	O
they	O
were	O
independent	O
;	O
relatively	O
low	O
correlation	O
was	O
observed	O
between	O
the	O
variables	O
(	O
r	O
=	O
0	O
.	O
24	O
,	O
P	O
<	O
0	O
.	O
001	O
).	O

Attendance	O
at	O
the	O
first	O
antenatal	O
visit	O
in	O
extended	O
winter	O
,	O
compared	O
to	O
summer	O
,	O
was	O
associated	O
with	O
significantly	O
higher	O
HOMA	O
-	O
IR	O
(	O
32	O
.	O
8	O
%)	O
and	O
insulin	O
(	O
32	O
.	O
4	O
%)	O
in	O
early	O
pregnancy	O
,	O
independent	O
of	O
25OHD	O
<	O
30	O
nmol	O
/	O
L	O
.	O

Neither	O
extended	O
winter	O
nor	O
25OHD	O
<	O
30	O
nmol	O
/	O
L	O
were	O
associated	O
with	O
glucose	O
in	O
early	O
or	O
late	O
pregnancy	O
,	O
or	O
the	O
GCT	O
in	O
late	O
pregnancy	O
(	O
Model	O
1	O
,	O
Table4	O
).	O

An	O
interaction	O
term	O
(	O
early	O
-	O
pregnancy	O
25OHD	O
<	O
30	O
nmol	O
/	O
L	O
*	O
winter	O
)	O
was	O
subsequently	O
added	O
to	O
the	O
model	O
,	O
but	O
was	O
not	O
significant	O
in	O
any	O
model	O
(	O
data	O
not	O
shown	O
).	O

Caption	O
(	O
TABLE	O
-	O
WRAP	O
):	O
TABLE	O
4	O
Multiple	O
Linear	O
Regression	O
analysis	O
and	O
associated	O
percentage	O
difference	O
in	O
markers	O
of	O
glucose	O
metabolism	O
(	O
Model	O
1	O
unadjusted	O
,	O
and	O
Model	O
2	O
adjusted	O
)	O
Model	O
1	O
–	O
Unadjusted	O
modelModel	O
2	O
–	O
Final	O
Adjusted	O
modelDependent	O
VariableIndependent	O
variable	O
(	O
early	O
pregnancy	O
)%	O
∆	O
aB95	O
%	O
CI	O
P	O
Model	O
P	O
%	O
∆	O
aB95	O
%	O
CI	O
P	O
Model	O
P	O
HOMA	O
-	O
IR	O
earlyWinter32	O
.	O
8	O
%	O
0	O
.	O
28	O
(	O
0	O
.	O
08	O
,	O
0	O
.	O
49	O
)	O
0	O
.	O
0080	O
.	O
00846	O
.	O
72	O
%	O
0	O
.	O
38	O
(	O
0	O
.	O
15	O
,	O
0	O
.	O
62	O
)	O
0	O
.	O
001	O
<	O
0	O
.	O
00125OHD	O
<	O
30	O
nmol	O
/	O
L11	O
.	O
6	O
%	O
0	O
.	O
11	O
(−	O
0	O
.	O
11	O
,	O
0	O
.	O
32	O
)	O
0	O
.	O
32511	O
.	O
64	O
%	O
0	O
.	O
11	O
(−	O
0	O
.	O
14	O
,	O
0	O
.	O
36	O
)	O
0	O
.	O
382HOMA	O
-	O
IR	O
28	O
weeks	O
’	O
Winter29	O
.	O
7	O
%	O
0	O
.	O
26	O
(	O
0	O
.	O
04	O
,	O
0	O
.	O
49	O
)	O
0	O
.	O
0240	O
.	O
05153	O
.	O
70	O
%	O
0	O
.	O
43	O
(	O
0	O
.	O
17	O
,	O
0	O
.	O
69	O
)	O
0	O
.	O
0020	O
.	O
00125OHD	O
<	O
30	O
nmol	O
/	O
L4	O
.	O
1	O
%	O
0	O
.	O
04	O
(−	O
0	O
.	O
20	O
,	O
0	O
.	O
28	O
)	O
0	O
.	O
7533	O
.	O
00	O
%	O
0	O
.	O
03	O
(−	O
0	O
.	O
25	O
,	O
0	O
.	O
31	O
)	O
0	O
.	O
837Insulin	O
early	O
(	O
μU	O
/	O
mL	O
)	O
Winter32	O
.	O
4	O
%	O
0	O
.	O
28	O
(	O
0	O
.	O
08	O
,	O
0	O
.	O
48	O
)	O
0	O
.	O
0070	O
.	O
01047	O
.	O
57	O
%	O
0	O
.	O
39	O
(	O
0	O
.	O
16	O
,	O
0	O
.	O
62	O
)	O
0	O
.	O
001	O
<	O
0	O
.	O
00125OHD	O
<	O
30	O
nmol	O
/	O
L8	O
.	O
3	O
%	O
0	O
.	O
08	O
(−	O
0	O
.	O
14	O
,	O
0	O
.	O
29	O
)	O
0	O
.	O
4748	O
.	O
16	O
%	O
0	O
.	O
08	O
(−	O
0	O
.	O
17	O
,	O
0	O
.	O
32	O
)	O
0	O
.	O
530Insulin	O
28	O
weeks	O
(	O
μU	O
/	O
mL	O
)	O
Winter25	O
.	O
9	O
%	O
0	O
.	O
23	O
(	O
0	O
.	O
01	O
,	O
0	O
.	O
46	O
)	O
0	O
.	O
0410	O
.	O
10249	O
.	O
53	O
%	O
0	O
.	O
40	O
(	O
0	O
.	O
14	O
,	O
0	O
.	O
66	O
)	O
0	O
.	O
0030	O
.	O
00225OHD	O
<	O
30	O
nmol	O
/	O
L1	O
.	O
0	O
%	O
0	O
.	O
01	O
(−	O
0	O
.	O
22	O
,	O
0	O
.	O
24	O
)	O
0	O
.	O
927	O
−	O
0	O
.	O
17	O
%	O
0	O
.	O
00	O
(−	O
0	O
.	O
28	O
,	O
0	O
.	O
28	O
)	O
0	O
.	O
991Fasting	O
glucose	O
early	O
(	O
mmol	O
/	O
L	O
)	O
Winter	O
−	O
0	O
.	O
02	O
(−	O
0	O
.	O
11	O
,	O
0	O
.	O
06	O
)	O
0	O
.	O
5830	O
.	O
713	O
−	O
0	O
.	O
04	O
(−	O
0	O
.	O
13	O
,	O
0	O
.	O
06	O
)	O
0	O
.	O
4350	O
.	O
02125OHD	O
<	O
30	O
nmol	O
/	O
L0	O
.	O
03	O
(−	O
0	O
.	O
06	O
,	O
0	O
.	O
13	O
)	O
0	O
.	O
4690	O
.	O
06	O
(−	O
0	O
.	O
04	O
,	O
0	O
.	O
16	O
)	O
0	O
.	O
257Fasting	O
glucose	O
28	O
weeks	O
(	O
mmol	O
/	O
L	O
)	O
Winter0	O
.	O
07	O
(−	O
0	O
.	O
04	O
,	O
0	O
.	O
18	O
)	O
0	O
.	O
1850	O
.	O
1180	O
.	O
13	O
(	O
0	O
.	O
00	O
,	O
0	O
.	O
26	O
)	O
0	O
.	O
0450	O
.	O
01525OHD	O
<	O
30	O
nmol	O
/	O
L0	O
.	O
08	O
(−	O
0	O
.	O
04	O
,	O
0	O
.	O
19	O
)	O
0	O
.	O
2080	O
.	O
15	O
(	O
0	O
.	O
01	O
,	O
0	O
.	O
29	O
)	O
0	O
.	O
0411	O
-	O
h	O
GCT	O
28	O
weeks	O
(	O
mmol	O
/	O
L	O
)	O
Winter0	O
.	O
04	O
(−	O
0	O
.	O
31	O
,	O
0	O
.	O
39	O
)	O
0	O
.	O
8060	O
.	O
9460	O
.	O
02	O
(−	O
0	O
.	O
41	O
,	O
0	O
.	O
45	O
)	O
0	O
.	O
9300	O
.	O
68825OHD	O
<	O
30	O
nmol	O
/	O
L0	O
.	O
03	O
(−	O
0	O
.	O
35	O
,	O
0	O
.	O
41	O
)	O
0	O
.	O
8730	O
.	O
02	O
(−	O
0	O
.	O
45	O
,	O
0	O
.	O
50	O
)	O
0	O
.	O
923	O
a	O
%	O
difference	O
in	O
metabolic	O
marker	O
Model	O
1	O
:	O
model	O
not	O
controlled	O
for	O
confounders	O
.	O

Model	O
2	O
:	O
model	O
controlled	O
for	O
BMI	O
(	O
kg	O
/	O
m2	O
),	O
education	O
>	O
secondary	O
school	O
,	O
being	O
part	O
of	O
the	O
ROLO	O
study	O
intervention	O
group	O
,	O
early	O
-	O
pregnancy	O
energy	O
(	O
kcal	O
),	O
early	O
-	O
pregnancy	O
protein	O
(	O
g	O
),	O
early	O
-	O
pregnancy	O
fat	O
(	O
g	O
),	O
moderate	O
-	O
vigorous	O
activity	O
,	O
well	O
-	O
being	O
score	O
and	O
dietary	O
supplements	O
Post	O
-	O
hoc	O
analysis	O
-	O
exploring	O
potential	O
confounders	O
Dietary	O
intakes	O
,	O
lifestyle	O
behaviours	O
,	O
and	O
emotional	O
well	O
-	O
being	O
were	O
analysed	O
by	O
season	O
of	O
first	O
antenatal	O
visit	O
(	O
Additional	O
file1	O
:	O
Table	O
S2	O
).	O

Attendance	O
at	O
the	O
first	O
antenatal	O
visit	O
during	O
extended	O
winter	O
was	O
associated	O
with	O
reduced	O
intake	O
of	O
energy	O
(	O
kcal	O
)	O
(	O
winter	O
vs	O
.	O
summer	O
;	O
1795	O
.	O
2	O
±	O
412	O
.	O
0	O
vs	O
.	O
1904	O
.	O
7	O
±	O
418	O
.	O
2	O
,	O
P	O
=	O
0	O
.	O
031	O
),	O
protein	O
(	O
g	O
)	O
(	O
winter	O
vs	O
.	O
summer	O
;	O
74	O
.	O
4	O
±	O
17	O
.	O
4	O
vs	O
79	O
.	O
7	O
±	O
20	O
.	O
7	O
,	O
P	O
=	O
0	O
.	O
023	O
)	O
and	O
fat	O
(	O
g	O
)	O
(	O
winter	O
vs	O
.	O
summer	O
;	O
69	O
.	O
9	O
±	O
19	O
.	O
7	O
vs	O
77	O
.	O
2	O
±	O
22	O
.	O
8	O
,	O
P	O
=	O
0	O
.	O
005	O
).	O

Physical	O
activity	O
and	O
emotional	O
well	O
-	O
being	O
scores	O
were	O
similar	O
between	O
extended	O
winter	O
and	O
extended	O
summer	O
groups	O
.	O

Adjusted	O
analysis	O
(	O
model	O
2	O
)	O
–	O
25OHD	O
,	O
season	O
and	O
markers	O
of	O
glucose	O
metabolism	O
The	O
final	O
adjusted	O
,	O
multiple	O
linear	O
regression	O
model	O
included	O
extended	O
winter	O
at	O
first	O
antenatal	O
visit	O
,	O
25OHD	O
<	O
30	O
nmol	O
/	O
L	O
,	O
and	O
the	O
following	O
confounders	O
:	O
BMI	O
(	O
kg	O
/	O
m2	O
),	O
education	O
,	O
being	O
part	O
of	O
the	O
ROLO	O
study	O
intervention	O
group	O
,	O
early	O
-	O
pregnancy	O
energy	O
(	O
kcal	O
),	O
protein	O
(	O
g	O
)	O
and	O
fat	O
(	O
g	O
),	O
physical	O
activity	O
and	O
well	O
-	O
being	O
score	O
(	O
Model	O
2	O
,	O
Table4	O
).	O

Compared	O
to	O
those	O
who	O
attended	O
their	O
first	O
antenatal	O
visit	O
during	O
extended	O
summer	O
,	O
extended	O
winter	O
was	O
associated	O
with	O
increased	O
early	O
-	O
pregnancy	O
HOMA	O
-	O
IR	O
(	O
46	O
.	O
7	O
%)	O
and	O
insulin	O
(	O
47	O
.	O
6	O
%),	O
independent	O
of	O
25OHD	O
<	O
30	O
nmol	O
/	O
L	O
and	O
confounders	O
.	O

The	O
early	O
-	O
pregnancy	O
exposure	O
to	O
extended	O
winter	O
,	O
compared	O
to	O
extended	O
summer	O
,	O
was	O
also	O
associated	O
with	O
increased	O
HOMA	O
-	O
IR	O
(	O
53	O
.	O
7	O
%)	O
and	O
insulin	O
(	O
49	O
.	O
5	O
%)	O
in	O
late	O
pregnancy	O
.	O

Early	O
-	O
pregnancy	O
25OHD	O
<	O
30	O
nmol	O
/	O
L	O
and	O
exposure	O
to	O
extended	O
winter	O
were	O
independently	O
associated	O
with	O
significantly	O
higher	O
glucose	O
in	O
late	O
pregnancy	O
(	O
B	O
=	O
0	O
.	O
15	O
,	O
and	O
0	O
.	O
13	O
,	O
respectively	O
),	O
controlling	O
for	O
confounders	O
.	O

Sensitivity	O
analysis	O
There	O
were	O
no	O
significant	O
changes	O
in	O
the	O
multiple	O
regression	O
models	O
using	O
different	O
25OHD	O
variables	O
as	O
independent	O
variables	O
associated	O
with	O
markers	O
of	O
glucose	O
metabolism	O
;	O
early	O
pregnancy	O
25OHD	O
(	O
continuous	O
);	O
greater	O
or	O
less	O
than	O
50	O
nmol	O
/	O
L	O
(	O
insufficiency	O
),	O
greater	O
or	O
less	O
than	O
39	O
.	O
2	O
nmol	O
/	O
L	O
(	O
median	O
)	O
(	O
data	O
not	O
shown	O
).	O

Model	O
2	O
of	O
the	O
multiple	O
linear	O
regression	O
analysis	O
was	O
additionally	O
controlled	O
for	O
change	O
in	O
25OHD	O
from	O
early	O
to	O
late	O
pregnancy	O
(	O
Additional	O
file1	O
:	O
Table	O
S3	O
).	O

An	O
increase	O
in	O
25OHD	O
from	O
early	O
to	O
late	O
pregnancy	O
was	O
not	O
associated	O
with	O
markers	O
of	O
glucose	O
metabolism	O
.	O

Discussion	O
Exposure	O
to	O
extended	O
winter	O
in	O
early	O
pregnancy	O
is	O
associated	O
with	O
increased	O
insulin	O
resistance	O
in	O
early	O
and	O
late	O
pregnancy	O
,	O
and	O
increased	O
fasting	O
glucose	O
in	O
late	O
pregnancy	O
,	O
independent	O
of	O
25OHD	O
status	O
.	O

Additionally	O
,	O
those	O
at	O
risk	O
of	O
vitamin	O
D	O
deficiency	O
in	O
early	O
pregnancy	O
are	O
more	O
likely	B
to	O
have	O
increased	O
fasting	O
glucose	O
in	O
late	O
pregnancy	O
,	O
independent	O
of	O
season	O
.	O

Given	B
that	O
the	O
association	O
between	O
early	O
gestation	O
through	O
extended	O
winter	O
and	O
insulin	O
resistance	O
is	O
independent	O
of	O
serum	O
25OHD	O
<	O
30	O
nmol	O
/	O
L	O
,	O
our	O
novel	O
findings	O
imply	B
that	O
seasonal	O
variation	O
in	O
insulin	O
resistance	O
may	O
not	O
be	O
fully	O
explained	B
by	O
differences	O
in	O
vitamin	O
D	O
status	O
.	O

Furthermore	O
,	O
no	O
interaction	O
effect	O
was	O
observed	O
between	O
season	O
and	O
vitamin	O
D	O
with	O
regards	O
to	O
glucose	O
homeostasis	O
.	O

Additionally	O
,	O
lifestyle	O
behaviours	O
that	O
may	O
be	O
influenced	O
by	O
seasonal	O
changes	O
(	O
dietary	O
intakes	O
,	O
physical	O
activity	O
,	O
and	O
well	O
-	O
being	O
)	O
did	O
not	O
explain	O
the	O
associations	O
between	O
exposure	O
to	O
winter	O
at	O
the	O
first	O
antenatal	O
visit	O
and	O
markers	O
of	O
glucose	O
metabolism	O
.	O

Although	O
the	O
seasonal	O
variation	O
observed	O
in	O
insulin	O
resistance	O
may	O
be	O
caused	O
by	O
unknown	O
seasonal	O
behaviours	O
or	O
residual	O
confounding	O
factors	O
that	O
we	O
have	O
not	O
included	O
in	O
this	O
analysis	O
,	O
it	O
is	O
possible	O
that	O
there	O
is	O
an	O
unequivocal	O
seasonal	O
cause	O
or	O
circannual	O
rhythm	O
associated	O
with	O
increased	O
insulin	O
resistance	O
in	O
early	O
pregnancy	O
during	O
winter	O
months	O
.	O

Regardless	O
of	O
the	O
underlying	O
cause	O
for	O
increased	O
markers	O
of	O
glucose	O
metabolism	O
,	O
our	O
findings	O
suggest	O
that	O
during	O
early	O
pregnancy	O
,	O
exposure	O
to	O
a	O
typical	O
winter	O
in	O
the	O
northern	O
hemisphere	O
,	O
which	O
often	B
includes	O
low	O
serum	O
25OHD	O
,	O
is	O
unfavourable	O
for	O
maternal	O
glucose	O
homeostasis	O
.	O

Circannual	O
rhythms	O
and	O
glucose	O
homeostasis	O
Circannual	O
rhythms	O
have	O
been	O
researched	O
in	O
animals	O
with	O
regards	O
to	O
reproduction	O
,	O
migration	O
and	O
hibernation	O
,	O
and	O
are	O
biological	O
survival	O
mechanisms	O
to	O
allow	O
certain	O
events	O
to	O
occur	O
at	O
the	O
most	O
favourable	O
time	O
in	O
the	O
year	O
[	O
38	O
].	O

Humans	O
also	O
evolved	O
to	O
adapt	O
to	O
environmental	O
daily	O
and	O
seasonal	O
changes	O
,	O
with	O
a	O
central	O
biological	O
clock	O
located	O
in	O
the	O
suprachiasmatic	O
nucleus	O
of	O
the	O
hypothalamus	O
,	O
responsible	O
for	O
timing	O
of	O
metabolism	O
,	O
physiology	O
and	O
behaviours	O
[	O
17	O
].	O

During	O
hunter	O
-	O
gatherer	O
times	O
,	O
summer	O
was	O
a	O
season	O
of	O
increased	O
daylight	O
and	O
nutritional	O
abundance	O
that	O
prepared	O
our	O
ancestors	O
for	O
harsher	O
winter	O
conditions	O
by	O
depositing	O
fat	O
reserves	O
during	O
autumn	O
[	O
17	O
].	O

Through	O
technological	O
advances	O
,	O
humans	O
have	O
access	O
to	O
light	O
continuously	O
and	O
are	O
no	O
longer	O
dependant	O
on	O
the	O
rising	O
and	O
setting	O
of	O
the	O
sun	O
to	O
regulate	O
circannual	O
rhythms	O
.	O

However	O
,	O
circadian	O
clock	O
genes	O
that	O
respond	O
to	O
light	O
are	O
still	O
part	O
of	O
our	O
genome	O
[	O
39	O
].	O

Melatonin	O
,	O
a	O
pineal	O
hormone	O
regulated	O
by	O
light	O
exposure	O
,	O
peaks	O
during	O
night	O
after	O
the	O
onset	O
of	O
sleep	O
,	O
with	O
little	O
production	O
during	O
daylight	O
hours	O
[	O
13	O
].	O

Melatonin	O
inhibits	O
the	O
release	O
of	O
insulin	O
from	O
pancreatic	O
beta	O
cells	O
[	O
40	O
,	O
41	O
],	O
although	O
conflicting	O
research	O
exists	O
with	O
the	O
Nurses	O
’	O
Health	O
Study	O
finding	O
low	O
melatonin	O
associated	O
with	O
increased	O
risk	O
of	O
type	O
2	O
diabetes	O
,	O
potentially	O
medicated	O
through	O
increased	O
insulin	O
resistance	O
[	O
42	O
].	O

It	O
may	O
be	O
hypothesised	O
that	O
during	O
winter	O
months	O
,	O
which	O
are	O
characterised	O
by	O
increased	O
darkness	O
,	O
women	O
may	O
be	O
exposed	O
to	O
melatonin	O
close	O
to	O
morning	O
and	O
evening	O
meals	O
,	O
reducing	O
their	O
ability	O
to	O
deal	O
with	O
carbohydrate	O
based	O
foods	O
.	O

It	O
is	O
also	O
possible	O
that	O
the	O
milieu	O
of	O
higher	O
melatonin	O
and	O
insulin	O
resistance	O
during	O
winter	O
in	O
early	O
pregnancy	O
may	O
set	O
the	O
scene	O
for	O
glucose	O
homeostasis	O
throughout	O
the	O
remaining	O
months	O
of	O
pregnancy	O
.	O

This	O
could	O
explain	B
why	O
our	O
findings	O
of	O
exposure	O
to	O
extended	O
winter	O
in	O
early	O
pregnancy	O
is	O
associated	O
with	O
increased	O
HOMA	O
and	O
fasting	O
glucose	O
at	O
28	O
weeks	O
’	O
gestation	O
,	O
although	O
research	O
is	O
needed	O
to	O
explain	B
this	O
potential	O
hypothesis	O
.	O

The	O
phenomenon	O
of	O
circannual	O
rhythms	O
has	O
also	O
been	O
explored	O
in	O
relation	O
to	O
gestational	O
diabetes	O
[	O
24	O
–	O
26	O
,	O
28	O
].	O

Recently	O
,	O
Moses	O
et	O
al	O
.	O

prospectively	O
evaluated	O
7369	O
oral	O
glucose	O
tolerance	O
tests	O
(	O
OGTT	O
)	O
over	O
a	O
3	O
-	O
year	O
period	O
in	O
Australia	O
[	O
24	O
].	O

The	O
prevalence	O
of	O
gestational	O
diabetes	O
diagnosed	O
on	O
1	O
-	O
h	O
OGTT	O
result	O
was	O
45	O
%	O
higher	O
in	O
November	O
(	O
summer	O
)	O
and	O
46	O
%	O
lower	O
in	O
July	O
(	O
winter	O
)	O
than	O
the	O
overall	O
prevalence	O
,	O
however	O
,	O
diagnoses	O
based	O
on	O
fasting	O
glucose	O
concentrations	O
were	O
similar	O
across	O
the	O
year	O
.	O

The	O
OGTTs	O
were	O
carried	O
out	O
at	O
24	O
–	O
28	O
weeks	O
’	O
gestation	O
;	O
thus	O
,	O
summer	O
at	O
the	O
time	O
of	O
OGTT	O
would	O
correspond	O
approximately	O
with	O
winter	O
in	O
early	O
pregnancy	O
in	O
our	O
population	O
.	O

Similarly	O
,	O
in	O
Sweden	O
,	O
Katsarou	O
et	O
al	O
.	O

analysed	O
11	O
,	O
538	O
pregnancies	O
,	O
and	O
found	O
a	O
51	O
%	O
increase	O
in	O
gestational	O
diabetes	O
diagnosed	O
by	O
OGTT	O
in	O
the	O
months	O
of	O
June	O
to	O
July	O
(	O
summer	O
),	O
compared	O
to	O
other	O
months	O
[	O
25	O
].	O

Verburg	O
et	O
al	O
.	O

reported	O
that	O
conception	O
during	O
winter	O
was	O
associated	O
with	O
a	O
significantly	O
higher	O
incidence	O
of	O
gestational	O
diabetes	O
than	O
during	O
summer	O
[	O
26	O
].	O

We	O
carried	O
out	O
glucose	O
challenge	O
tests	O
(	O
1	O
-	O
h	O
post	O
50	O
g	O
glucose	O
load	O
)	O
for	O
all	O
women	O
in	O
our	O
population	O
,	O
not	O
OGTT	O
as	O
in	O
the	O
above	O
studies	O
.	O

Exposure	O
to	O
winter	O
in	O
early	O
pregnancy	O
was	O
not	O
associated	O
with	O
glucose	O
challenge	O
test	O
results	O
,	O
however	O
it	O
was	O
associated	O
with	O
increased	O
fasting	O
glucose	O
and	O
insulin	O
resistance	O
at	O
28	O
weeks	O
.	O

Conversely	O
,	O
Janghorbani	O
et	O
al	O
.	O

did	O
not	O
find	O
an	O
association	O
between	O
season	O
and	O
gestational	O
diabetes	O
incidence	O
among	O
4942	O
British	O
women	O
between	O
1996	O
and	O
1997	O
[	O
28	O
].	O

In	O
non	O
-	O
pregnant	O
adult	O
populations	O
,	O
conflicting	O
results	O
have	O
been	O
reported	O
regarding	O
seasonal	O
variation	O
HbA1c	O
(	O
a	O
measure	O
that	O
reflects	O
average	O
circulating	O
blood	O
glucose	O
concentrations	O
for	O
the	O
previous	O
90	O
days	O
)	O
and	O
glucose	O
concentrations	O
among	O
individuals	O
with	O
type	O
2	O
diabetes	O
[	O
19	O
,	O
43	O
].	O

Carney	O
et	O
al	O
.	O

observed	O
significantly	O
higher	O
HbA1cin	O
the	O
UK	O
among	O
female	O
patients	O
with	O
type	O
2	O
diabetes	O
in	O
the	O
months	O
February	O
,	O
March	O
and	O
June	O
,	O
and	O
suggested	O
that	O
poorer	O
diet	O
and	O
reduced	O
physical	O
activity	O
associated	O
with	O
Christmas	O
and	O
Easter	O
celebrations	O
may	O
be	O
involved	O
[	O
20	O
].	O

Fasting	O
glucose	O
and	O
HbA1cwere	O
lowest	O
among	O
Greek	O
patients	O
with	O
type	O
2	O
diabetes	O
during	O
August	O
and	O
September	O
[	O
23	O
].	O

The	O
authors	O
suggested	O
that	O
a	O
combination	O
of	O
seasonal	O
changes	O
to	O
an	O
individuals	O
’	O
physical	O
activity	O
,	O
diet	O
,	O
sunlight	O
exposure	O
,	O
weather	O
pattern	O
,	O
psychological	O
variables	O
,	O
and	O
weight	O
changes	O
may	O
be	O
contributing	O
factors	O
[	O
23	O
].	O

In	O
our	O
cohort	O
,	O
dietary	O
energy	O
,	O
protein	O
and	O
fat	O
were	O
significantly	O
higher	O
during	O
extended	O
summer	O
,	O
while	O
carbohydrates	O
,	O
glycaemic	O
index	O
,	O
glycaemic	O
load	O
,	O
physical	O
activity	O
and	O
well	O
-	O
being	O
were	O
no	O
different	O
across	O
seasons	O
.	O

During	O
summer	O
,	O
early	O
pregnancy	O
energy	O
(	O
kcal	O
)	O
was	O
associated	O
with	O
a	O
negligible	O
reduction	O
in	O
late	O
pregnancy	O
insulin	O
resistance	O
(−	O
0	O
.	O
1	O
%),	O
while	O
fat	O
(	O
g	O
)	O
was	O
associated	O
with	O
a	O
small	O
increase	O
in	O
late	O
pregnancy	O
insulin	O
resistance	O
(	O
1	O
.	O
4	O
%).	O

The	O
other	O
seasonal	O
behaviours	O
were	O
not	O
significantly	O
associated	O
with	O
metabolic	O
markers	O
.	O

Traditionally	O
,	O
and	O
in	O
may	O
regions	O
of	O
the	O
world	O
today	O
,	O
seasonal	O
availability	O
of	O
food	O
determines	O
dietary	O
intakes	O
.	O

However	O
,	O
in	O
developed	O
countries	O
,	O
seasonal	O
availablity	O
of	O
food	O
has	O
a	O
limited	O
impact	O
on	O
diet	O
,	O
although	O
seasonal	O
differences	O
in	O
dietary	O
intakes	O
among	O
pregnant	O
women	O
have	O
been	O
observed	O
[	O
29	O
].	O

It	O
is	O
possible	O
that	O
the	O
increased	O
energy	O
,	O
protein	O
and	O
fat	O
observed	O
in	O
our	O
study	O
during	O
extended	O
summer	O
could	O
be	O
due	O
to	O
changes	O
in	O
dietary	O
habits	O
during	O
the	O
summer	O
holidays	O
.	O

Debate	O
also	O
exists	O
in	O
relation	O
to	O
seasonality	O
of	O
physical	O
activity	O
levels	O
[	O
30	O
,	O
44	O
].	O

Our	O
study	O
did	O
not	O
find	O
a	O
difference	O
in	O
self	O
-	O
reported	O
physical	O
activity	O
across	O
the	O
seasons	O
.	O

Whether	O
environmentally	O
or	O
biologically	O
driven	O
,	O
we	O
found	O
novel	O
evidence	O
of	O
seasonal	O
rhythms	O
in	O
insulin	O
resistance	O
.	O

It	O
could	O
be	O
hypothesised	O
that	O
increased	O
insulin	O
resistance	O
during	O
winter	O
pregnancies	O
is	O
an	O
evolutionary	O
protective	O
mechanism	O
for	O
the	O
mother	O
and	O
fetus	O
,	O
of	O
laying	O
down	O
additional	O
fat	O
stores	O
to	O
ensure	O
survival	O
through	O
winter	O
.	O

Further	O
research	O
is	O
required	O
to	O
determine	O
the	O
physiological	O
pathways	O
and	O
clinical	O
significance	O
of	O
our	O
observations	O
.	O

25OHD	O
and	O
glucose	O
homeostasis	O
Within	O
our	O
cohort	O
,	O
early	O
-	O
pregnancy	O
25OHD	O
<	O
30	O
nmol	O
/	O
L	O
was	O
associated	O
with	O
significantly	O
higher	O
fasting	O
glucose	O
at	O
28	O
weeks	O
’	O
gestation	O
,	O
independent	O
of	O
season	O
and	O
potential	O
confounders	O
.	O

Low	O
25OHD	O
at	O
the	O
first	O
antenatal	O
visit	O
was	O
not	O
associated	O
with	O
insulin	O
resistance	O
in	O
early	O
or	O
late	O
pregnancy	O
when	O
controlling	O
for	O
season	O
and	O
confounders	O
.	O

Our	O
results	O
are	O
similar	O
to	O
those	O
of	O
the	O
HAPO	O
trial	O
,	O
which	O
found	O
that	O
maternal	O
insulin	O
sensitivity	O
and	O
gestational	O
diabetes	O
were	O
not	O
associated	O
with	O
25OHD	O
[	O
7	O
].	O

However	O
,	O
unlike	O
the	O
HAPO	O
trial	O
,	O
we	O
found	O
increased	O
fasting	O
plasma	O
glucose	O
in	O
late	O
pregnancy	O
among	O
those	O
at	O
risk	O
of	O
vitamin	O
D	O
deficiency	O
.	O

A	O
recent	O
meta	O
-	O
analysis	O
of	O
observational	O
studies	O
reported	O
that	O
vitamin	O
D	O
<	O
50	O
nmol	O
/	O
L	O
was	O
associated	O
with	O
an	O
increased	O
risk	O
(	O
OR	O
=	O
1	O
.	O
53	O
)	O
of	O
developing	O
gestational	O
diabetes	O
[	O
9	O
].	O

Many	O
women	O
who	O
gestate	O
through	O
a	O
typical	O
winter	O
in	O
the	O
northern	O
hemisphere	O
are	O
at	O
risk	O
of	O
vitamin	O
D	O
deficiency	O
[	O
4	O
,	O
5	O
].	O

Poor	O
vitamin	O
D	O
intakes	O
have	O
been	O
reported	O
among	O
pregnant	O
women	O
living	O
in	O
Ireland	O
[	O
5	O
].	O

In	O
the	O
clinical	O
setting	O
,	O
pregnant	O
women	O
should	O
receive	O
advice	O
about	O
vitamin	O
D	O
,	O
especially	O
during	O
winter	O
.	O

Winter	O
-	O
time	O
supplementation	O
of	O
1000	O
IU	O
/	O
day	O
vitamin	O
D	O
is	O
an	O
effective	B
strategy	B
to	O
improve	O
25OHD	O
in	O
pregnancy	O
[	O
45	O
].	O

At	O
present	O
,	O
there	O
remains	O
a	O
lack	O
of	O
consensus	O
regarding	O
recommendations	O
for	O
UVB	O
exposure	O
for	O
the	O
production	O
of	O
vitamin	O
D	O
for	O
pregnant	O
women	O
[	O
46	O
].	O

Our	O
findings	O
suggest	O
that	O
women	O
at	O
risk	O
of	O
vitamin	O
D	O
deficiency	O
in	O
early	O
pregnancy	O
have	O
altered	O
glucose	O
metabolism	O
in	O
later	O
gestation	O
,	O
but	O
the	O
evidence	O
is	O
not	O
consistent	O
for	O
insulin	O
resistance	O
.	O

Thus	B
,	O
recommendations	O
for	O
vitamin	O
D	O
supplementation	O
to	O
improve	O
glucose	O
homeostasis	O
in	O
pregnancy	O
cannot	O
be	O
made	O
based	B
on	I
our	O
results	O
.	O

Strengths	O
and	O
limitations	O
A	O
potential	O
limitation	O
of	O
our	O
work	O
is	O
the	O
dichotomised	O
seasonal	O
divisions	O
.	O

However	O
,	O
we	O
chose	O
these	O
for	O
multiple	O
reasons	B
;	O
the	O
HAPO	O
study	O
used	O
similar	O
divisions	O
in	O
countries	O
with	O
a	O
latitude	O
of	O
41	O
.	O
9	O
–	O
43	O
.	O
7	O
°	O
North	O
[	O
7	O
],	O
mean	O
daily	O
temperatures	O
in	O
Ireland	O
are	O
highest	O
during	O
the	O
months	O
May	O
to	O
October	O
[	O
47	O
],	O
and	O
we	O
based	O
these	O
seasons	O
on	O
25OHD	O
concentrations	O
for	O
the	O
month	O
of	O
the	O
first	O
antenatal	O
visit	O
(	O
Additional	O
file1	O
:	O
Fig	O
.	O

S1	O
).	O

Some	O
studies	O
have	O
attributed	O
seasonal	O
differences	O
in	O
gestational	O
diabetes	O
to	O
temperature	O
changes	O
.	O

Although	O
we	O
did	O
not	O
collect	O
data	O
on	O
daily	O
temperature	O
,	O
the	O
temperatures	O
in	O
Ireland	O
are	O
relatively	O
stable	O
across	O
the	O
year	O
,	O
with	O
mean	O
temperature	O
of	O
5	O
.	O
3	O
°	O
C	O
in	O
January	O
and	O
15	O
.	O
6	O
°	O
C	O
in	O
July	O
[	O
47	O
],	O
reducing	B
the	I
likelihood	I
that	O
temperature	O
is	O
responsible	B
.	O

Detailed	O
data	O
on	O
micronutrient	O
supplement	O
use	O
were	O
not	O
available	O
,	O
however	O
,	O
use	O
of	O
dietary	O
supplements	O
(	O
yes	O
/	O
no	O
)	O
was	O
included	O
as	O
a	O
confounder	O
in	O
multiple	O
regression	O
models	O
.	O

Data	O
relating	O
to	O
pre	O
-	O
pregnancy	O
lifestyle	O
behaviours	O
were	O
not	O
collected	O
.	O

The	O
generalisability	O
of	O
our	O
findings	O
may	O
be	O
limited	O
,	O
as	B
participants	O
had	O
previously	O
given	O
birth	O
to	O
a	O
macrosomic	O
infant	O
(>	O
4000	O
g	O
),	O
and	O
half	O
the	O
women	O
received	O
advice	O
to	O
follow	O
a	O
low	O
glycaemic	O
diet	O
.	O

We	O
controlled	O
for	O
intervention	O
grouping	O
in	O
the	O
multiple	O
linear	O
regression	O
models	O
.	O

Furthermore	O
,	O
only	O
women	O
who	O
attended	O
the	O
2	O
-	O
year	O
follow	O
-	O
up	O
appointment	O
had	O
pregnancy	O
serum	O
25OHD	O
measured	O
,	O
and	O
some	O
differences	O
were	O
observed	O
in	O
the	O
baseline	O
characteristics	O
of	O
those	O
included	O
and	O
excluded	O
from	O
this	O
analysis	O
[	O
48	O
].	O

Our	O
research	O
would	O
be	O
strengthened	O
with	O
the	O
addition	O
of	O
HbA1cdata	O
in	O
pregnancy	O
and	O
additional	O
maternal	O
lifestyle	O
variables	O
to	O
allow	O
the	O
associations	O
to	O
be	O
teased	O
out	O
.	O

The	O
use	O
of	O
GTT	O
(	O
75	O
g	O
glucose	O
load	O
),	O
rather	O
than	O
glucose	O
challenge	O
test	O
,	O
would	O
have	O
allowed	O
for	O
better	O
comparison	O
with	O
the	O
seasonal	O
gestational	O
diabetes	O
papers	O
discussed	O
,	O
however	O
universal	O
screening	O
for	O
gestational	O
diabetes	O
using	O
GTT	O
is	O
not	O
currently	O
standard	O
practice	O
in	O
Ireland	O
.	O

Additionally	O
,	O
our	O
findings	O
are	O
observational	O
in	O
nature	O
thus	O
we	O
cannot	O
determine	O
causality	O
.	O

Conclusions	O
Women	O
who	O
attend	O
their	O
first	O
antenatal	O
visit	O
during	O
the	O
months	O
of	O
extended	O
winter	O
were	O
more	O
likely	B
to	O
have	O
raised	O
insulin	O
resistance	O
in	O
early	O
and	O
late	O
pregnancy	O
,	O
and	O
increased	O
fasting	O
glucose	O
in	O
late	O
pregnancy	O
,	O
independent	O
of	O
25OHD	O
status	O
.	O

Participants	O
at	O
risk	O
of	O
vitamin	O
D	O
deficiency	O
at	O
their	O
first	O
antenatal	O
visit	O
were	O
likely	B
to	O
have	O
increased	O
fasting	O
glucose	O
at	O
28	O
weeks	O
’	O
gestation	O
,	O
regardless	O
of	O
season	O
.	O

While	O
no	O
interaction	O
effect	O
was	O
observed	O
between	O
season	O
and	O
vitamin	O
D	O
with	O
regards	O
to	O
glucose	O
homeostasis	O
,	O
it	O
is	O
well	O
recognised	B
that	O
25OHD	O
declines	O
in	O
winter	O
,	O
and	O
is	O
a	O
modifiable	O
factor	O
.	O

Our	O
novel	O
finding	O
of	O
the	O
association	O
between	O
season	O
and	O
insulin	O
resistance	O
,	O
independent	O
of	O
25OHD	O
,	O
could	O
reflect	O
circannual	O
rhythm	O
or	O
seasonal	O
lifestyle	O
behaviours	O
and	O
requires	O
further	O
exploration	O
.	O

PubMed	O
Central	O
:	O

Response	O
to	O
Antenatal	O
Cholecalciferol	O
Supplementation	O
Is	O
Associated	O
With	O
Common	O
Vitamin	O
D	O
–	O
Related	O
Genetic	O
Variants	O
Abstract	O
Context	O
:	O
Single	O
-	O
nucleotide	O
polymorphisms	O
(	O
SNPs	O
)	O
in	O
genes	O
related	O
to	O
vitamin	O
D	O
metabolism	O
have	O
been	O
associated	O
with	O
serum	O
25	O
-	O
hydroxyvitamin	O
D	O
[	O
25	O
(	O
OH	O
)	O
D	O
]	O
concentration	O
,	O
but	O
these	O
relationships	O
have	O
not	O
been	O
examined	O
following	O
antenatal	O
cholecalciferol	O
supplementation	O
.	O

Objective	O
:	O
To	O
determine	O
whether	O
SNPs	O
in	O
DHCR7	O
,	O
CYP2R1	O
,	O
CYP24A1	O
,	O
and	O
GC	O
are	O
associated	O
with	O
the	O
response	O
to	O
gestational	O
cholecalciferol	O
supplementation	O
.	O

Design	O
:	O
Within	O
-	O
randomization	O
group	O
analysis	O
of	O
the	O
Maternal	O
Vitamin	O
D	O
Osteoporosis	O
Study	O
trial	O
of	O
antenatal	O
cholecalciferol	O
supplementation	O
.	O

Setting	O
:	O
Hospital	O
antenatal	O
clinics	O
.	O

Participants	O
:	O
In	O
total	O
,	O
682	O
women	O
of	O
white	O
ethnicity	O
(	O
351	O
placebo	O
,	O
331	O
cholecalciferol	O
)	O
were	O
included	O
.	O

SNPs	O
at	O
rs12785878	O
(	O
DHCR7	O
),	O
rs10741657	O
(	O
CYP2R1	O
),	O
rs6013897	O
(	O
CYP24A1	O
),	O
and	O
rs2282679	O
(	O
GC	O
)	O
were	O
genotyped	O
.	O

Interventions	O
:	O
1000	O
IU	O
/	O
d	O
cholecalciferol	O
from	O
14	O
weeks	O
of	O
gestation	O
until	O
delivery	O
.	O

Main	O
Outcome	O
Measure	O
:	O
25	O
(	O
OH	O
)	O
D	O
at	O
randomization	O
and	O
34	O
weeks	O
of	O
gestation	O
were	O
measured	O
in	O
a	O
single	O
batch	O
(	O
Liaison	O
;	O
Diasorin	O
,	O
Dartford	O
,	O
UK	O
).	O

Associations	O
between	O
25	O
(	O
OH	O
)	O
D	O
and	O
the	O
SNPs	O
were	O
assessed	O
by	O
linear	O
regression	O
using	O
an	O
additive	O
model	O
[	O
β	O
represents	O
the	O
change	O
in	O
25	O
(	O
OH	O
)	O
D	O
per	O
additional	O
common	O
allele	O
].	O

Results	O
:	O
Only	O
rs12785878	O
(	O
DHCR7	O
)	O
was	O
associated	O
with	O
baseline	O
25	O
(	O
OH	O
)	O
D	O
[	O
β	O
=	O
3	O
.	O
1	O
nmol	O
/	O
L	O
;	O
95	O
%	O
confidence	O
interval	O
(	O
CI	O
),	O
1	O
.	O
0	O
to	O
5	O
.	O
2	O
nmol	O
/	O
L	O
;	O
P	O
<	O
0	O
.	O
004	O
].	O

In	O
contrast	O
,	O
rs10741657	O
(	O
CYP2R1	O
)	O
(	O
β	O
=	O
−	O
5	O
.	O
2	O
nmol	O
/	O
L	O
;	O
95	O
%	O
CI	O
,	O
−	O
8	O
.	O
2	O
to	O
−	O
2	O
.	O
2	O
nmol	O
/	O
L	O
;	O
P	O
=	O
0	O
.	O
001	O
)	O
and	O
rs2282679	O
(	O
GC	O
)	O
(	O
β	O
=	O
4	O
.	O
2	O
nmol	O
/	O
L	O
;	O
95	O
%	O
CI	O
,	O
0	O
.	O
9	O
to	O
7	O
.	O
5	O
nmol	O
/	O
L	O
;	O
P	O
=	O
0	O
.	O
01	O
)	O
were	O
associated	O
with	O
achieved	O
25	O
(	O
OH	O
)	O
D	O
status	O
following	O
supplementation	O
,	O
whereas	O
rs12785878	O
and	O
rs6013897	O
(	O
CYP24A1	O
)	O
were	O
not	O
.	O

Conclusions	O
:	O
Genetic	O
variation	O
in	O
DHCR7	O
,	O
which	O
encodes	O
7	O
-	O
dehyrocholesterol	O
reductase	O
in	O
the	O
epidermal	O
vitamin	O
D	O
biosynthesis	O
pathway	O
,	O
appears	O
to	O
modify	O
baseline	O
25	O
(	O
OH	O
)	O
D	O
.	O
In	O
contrast	O
,	O
the	O
response	O
to	O
antenatal	O
cholecalciferol	O
supplementation	O
was	O
associated	O
with	O
SNPs	O
in	O
CYP2R1	O
,	O
which	O
may	O
alter	O
25	O
-	O
hydroxylase	O
activity	O
,	O
and	O
GC	O
,	O
which	O
may	O
affect	O
vitamin	O
D	O
binding	O
protein	O
synthesis	O
or	O
metabolite	O
affinity	O
.	O

Abstract	O
:	O
TEASER	O
Associations	O
between	O
SNPs	O
in	O
the	O
vitamin	O
D	O
metabolism	O
pathway	O
and	O
25	O
(	O
OH	O
)	O
D	O
were	O
assessed	O
before	O
and	O
after	O
antenatal	O
vitamin	O
D	O
supplementation	O
.	O

The	O
associations	O
differed	O
at	O
the	O
two	O
time	O
points	O
.	O

Antenatal	O
vitamin	O
D	O
supplementation	O
is	O
now	O
recommended	O
for	O
all	O
pregnant	O
women	O
in	O
many	O
national	O
guidelines	B
(	O
1	O
–	O
3	O
)	O
as	B
severe	O
maternal	O
vitamin	O
D	O
deficiency	O
can	O
result	O
in	O
symptomatic	O
neonatal	O
hypocalcemia	O
(	O
4	O
).	O

Furthermore	O
,	O
associations	O
between	O
maternal	O
vitamin	O
D	O
status	O
and	O
obstetric	O
complications	O
(	O
4	O
)	O
and	O
offspring	O
musculoskeletal	O
development	O
(	O
5	O
–	O
7	O
)	O
have	O
been	O
reported	O
.	O

Risk	O
factors	O
for	O
vitamin	O
D	O
deficiency	O
,	O
in	O
addition	O
to	O
geographic	O
and	O
seasonal	O
variation	O
,	O
are	O
well	B
established	I
.	O

These	O
include	O
ethnicity	O
,	O
extent	O
of	O
skin	O
covering	O
,	O
liberal	O
use	O
of	O
sun	O
protection	O
,	O
adiposity	O
,	O
and	O
age	O
.	O

It	O
is	O
also	O
increasingly	O
recognized	B
that	O
genetic	O
variation	O
influences	O
25	O
-	O
hydroxyvitamin	O
D	O
[	O
25	O
(	O
OH	O
)	O
D	O
]	O
status	O
.	O

In	O
a	O
previous	O
genome	O
-	O
wide	O
association	O
study	O
(	O
GWAS	O
),	O
we	O
demonstrated	O
that	O
a	O
number	O
of	O
single	O
-	O
nucleotide	O
polymorphisms	O
(	O
SNPs	O
)	O
in	O
or	O
near	O
to	O
genes	O
encoding	O
key	O
components	O
of	O
the	O
vitamin	O
D	O
metabolism	O
pathway	O
are	O
associated	O
with	O
serum	O
25	O
(	O
OH	O
)	O
D	O
level	O
(	O
8	O
).	O

These	O
include	O
DHCR7	O
encoding	O
7	O
-	O
dehydrocholesterol	O
(	O
7	O
-	O
DHC	O
)	O
reductase	O
;	O
CYP2R1	O
and	O
CYP24A1	O
encoding	O
25	O
-	O
hydroxylase	O
and	O
24	O
-	O
hydroxylase	O
,	O
respectively	O
;	O
and	O
GC	O
encoding	O
vitamin	O
D	O
binding	O
protein	O
(	O
VDP	O
).	O

Several	O
of	O
these	O
SNPs	O
have	O
been	O
associated	O
with	O
the	O
serum	O
25	O
(	O
OH	O
)	O
D	O
increase	O
in	O
response	O
to	O
vitamin	O
D	O
supplementation	O
in	O
small	O
studies	O
(	O
9	O
–	O
11	O
).	O

Pregnancy	O
is	O
a	O
physiologically	O
unique	O
period	O
,	O
involving	O
hemodilution	O
and	O
hormonal	O
and	O
metabolic	O
changes	O
.	O

For	O
example	O
,	O
VDP	O
rises	O
early	O
in	O
pregnancy	O
,	O
and	O
1	O
,	O
25	O
-	O
dihydroxyvitamin	O
D	O
increases	O
during	O
the	O
second	O
and	O
third	O
trimesters	O
(	O
12	O
).	O

Supplementation	O
with	O
cholecalciferol	O
increases	O
maternal	O
serum	O
25	O
(	O
OH	O
)	O
D	O
concentration	O
(	O
7	O
),	O
and	O
we	O
have	O
previously	O
demonstrated	O
that	O
the	O
25	O
(	O
OH	O
)	O
D	O
achieved	O
in	O
response	O
to	O
supplementation	O
in	O
pregnancy	O
is	O
associated	O
with	O
pregnancy	O
weight	O
gain	O
,	O
compliance	O
,	O
and	O
baseline	O
25	O
(	O
OH	O
)	O
D	O
(	O
13	O
).	O

In	O
the	O
previous	O
study	O
,	O
in	O
contrast	O
to	O
data	O
from	O
nonpregnant	O
adults	O
,	O
baseline	O
body	O
mass	O
index	O
(	O
BMI	O
),	O
measures	O
of	O
adiposity	O
,	O
and	O
maternal	O
age	O
were	O
not	O
associated	O
with	O
response	O
to	O
cholecalciferol	O
supplementation	O
in	O
pregnancy	O
(	O
13	O
).	O

Considering	B
this	O
and	O
the	O
physiological	O
changes	O
to	O
the	O
vitamin	O
D	O
pathway	O
in	O
pregnancy	O
,	O
it	O
is	O
therefore	B
possible	O
that	O
the	O
genetic	O
variants	O
associated	O
with	O
baseline	O
serum	O
25	O
(	O
OH	O
)	O
D	O
status	O
and	O
the	O
response	O
to	O
supplementation	O
also	O
differ	O
between	O
the	O
pregnant	O
and	O
nonpregnant	O
state	O
.	O

We	O
therefore	B
undertook	O
this	O
study	O
to	O
determine	O
whether	O
SNPs	O
within	O
the	O
vitamin	O
D	O
metabolism	O
pathway	O
known	O
to	O
modify	O
vitamin	O
D	O
status	O
are	O
also	O
associated	O
with	O
the	O
response	O
to	O
antenatal	O
vitamin	O
D	O
supplementation	O
.	O

Materials	O
and	O
Methods	O
The	O
Maternal	O
Vitamin	O
D	O
Osteoporosis	O
Study	O
The	O
Maternal	O
Vitamin	O
D	O
Osteoporosis	O
Study	O
is	O
a	O
multicenter	O
,	O
double	O
-	O
blind	O
,	O
randomized	O
,	O
placebo	O
-	O
controlled	O
trial	O
of	O
vitamin	O
D	O
supplementation	O
in	O
pregnancy	O
.	O

The	O
primary	O
outcome	O
was	O
neonatal	O
bone	O
mass	O
.	O

A	O
detailed	O
description	O
of	O
the	O
study	O
methods	O
(	O
14	O
)	O
and	O
primary	O
findings	O
have	O
been	O
published	O
previously	O
(	O
7	O
).	O

The	O
study	O
was	O
approved	O
by	O
the	O
Southampton	O
and	O
South	O
West	O
Hampshire	O
Research	O
Ethics	O
Committee	O
.	O

The	O
Maternal	O
Vitamin	O
D	O
Osteoporosis	O
Study	O
was	O
registered	O
prospectively	O
(	O
ISRCTN	O
:	O
82927713	O
;	O
EUDRACT	O
:	O
2007	O
-	O
001716	O
-	O
23	O
);	O
full	O
approval	O
from	O
UK	O
Medicines	O
and	O
Healthcare	O
Products	O
Regulatory	O
Agency	O
was	O
granted	O
,	O
and	O
written	O
,	O
informed	O
consent	O
was	O
obtained	O
from	O
all	O
participants	O
.	O

Briefly	O
,	O
women	O
attending	O
one	O
of	O
three	O
UK	O
hospitals	O
[	O
University	O
Hospital	O
Southampton	O
National	O
Health	O
Service	O
(	O
NHS	O
)	O
Foundation	O
Trust	O
,	O
Southampton	O
,	O
UK	O
(	O
latitude	O
50	O
.	O
9	O
°	O
North	O
);	O
Oxford	O
University	O
Hospitals	O
NHS	O
Foundation	O
Trust	O
,	O
Oxford	O
,	O
UK	O
(	O
latitude	O
51	O
.	O
8	O
°	O
North	O
);	O
Sheffield	O
Hospitals	O
NHS	O
Trust	O
(	O
University	O
of	O
Sheffield	O
),	O
Sheffield	O
,	O
UK	O
(	O
latitude	O
53	O
.	O
4	O
°	O
North	O
)]	O
for	O
early	O
pregnancy	O
ultrasound	O
screening	O
(	O
11	O
to	O
14	O
weeks	O
of	O
gestation	O
)	O
between	O
6	O
October	O
2008	O
and	O
11	O
February	O
2014	O
were	O
invited	O
to	O
participate	O
in	O
the	O
study	O
.	O

Inclusion	O
criteria	O
were	O
as	O
follows	O
:	O
age	O
older	O
than	O
18	O
years	O
,	O
singleton	O
pregnancy	O
,	O
and	O
gestation	O
less	O
than	O
17	O
weeks	O
based	O
on	O
last	O
menstrual	O
period	O
and	O
ultrasound	O
measurements	O
.	O

Women	O
with	O
known	O
metabolic	O
bone	O
disease	O
,	O
renal	O
stones	O
,	O
hyperparathyroidism	O
or	O
hypercalciuria	O
,	O
those	O
taking	O
medication	O
known	O
to	O
interfere	O
with	O
fetal	O
growth	O
,	O
fetal	O
anomalies	O
on	O
ultrasonography	O
,	O
and	O
women	O
already	O
using	O
>	O
400	O
IU	O
/	O
d	O
vitamin	O
D	O
supplementation	O
were	O
excluded	O
.	O

A	O
screening	O
blood	O
sample	O
was	O
obtained	O
and	O
analyzed	O
on	O
the	O
local	O
NHS	O
platform	O
[	O
all	O
three	O
laboratories	O
(	O
Southampton	O
,	O
Oxford	O
,	O
and	O
Sheffield	O
)	O
participate	O
in	O
the	O
Vitamin	O
D	O
External	O
Quality	O
Assessment	O
Scheme	O
(	O
http	O
://	O
www	O
.	O
deqas	O
.	O
org	O
/)].	O

Women	O
with	O
25	O
(	O
OH	O
)	O
D	O
between	O
25	O
and	O
100	O
nmol	O
/	O
L	O
and	O
serum	O
calcium	O
<	O
2	O
.	O
75	O
mmol	O
/	O
L	O
were	O
eligible	O
to	O
enroll	O
fully	O
in	O
the	O
study	O
.	O

Participants	O
were	O
randomized	O
to	O
either	O
cholecalciferol	O
1000	O
IU	O
/	O
d	O
or	O
matched	O
placebo	O
[	O
Merck	O
KGaA	O
,	O
Darmstadt	O
,	O
Germany	O
/	O
Sharp	O
Clinical	O
Services	O
,	O
Crickhowell	O
,	O
United	O
Kingdom	O
(	O
previously	O
DHP	O
-	O
Bilcare	O
)],	O
which	O
was	O
commenced	O
before	O
17	O
weeks	O
of	O
gestation	O
.	O

Packs	O
of	O
study	O
treatment	O
were	O
randomly	O
assigned	O
in	O
a	O
1	O
:	O
1	O
ratio	O
by	O
Sharp	O
Clinical	O
Services	O
by	O
a	O
computer	O
-	O
generated	O
sequence	O
in	O
randomly	O
permuted	O
blocks	O
of	O
10	O
,	O
starting	O
randomly	O
midway	O
through	O
the	O
block	O
,	O
and	O
sequentially	O
numbered	O
,	O
before	O
delivery	O
to	O
the	O
study	O
sites	O
,	O
and	O
then	O
dispensed	O
in	O
order	O
by	O
each	O
study	O
pharmacist	O
.	O

The	O
study	O
medication	O
was	O
provided	O
in	O
a	O
blister	O
pack	O
in	O
a	O
single	O
box	O
containing	O
all	O
medication	O
for	O
the	O
whole	O
pregnancy	O
.	O

The	O
participants	O
,	O
individuals	O
providing	O
antenatal	O
and	O
intrapartum	O
care	O
,	O
and	O
all	O
field	O
researchers	O
involved	O
in	O
data	O
collection	O
and	O
sample	O
analysis	O
were	O
blinded	O
to	O
the	O
assignment	O
to	O
the	O
intervention	O
.	O

All	O
participants	O
received	O
standard	O
antenatal	O
care	O
and	O
could	O
continue	O
self	O
-	O
administration	O
of	O
dietary	O
supplements	O
containing	O
up	O
to	O
400	O
IU	O
/	O
d	O
vitamin	O
D	O
.	O
Maternal	O
assessments	O
during	O
pregnancy	O
Prior	O
to	O
commencing	O
the	O
study	O
medication	O
and	O
again	O
at	O
34	O
weeks	O
of	O
gestation	O
,	O
the	O
women	O
attended	O
the	O
research	O
center	O
for	O
a	O
detailed	O
assessment	O
of	O
diet	O
(	O
including	O
supplement	O
use	O
),	O
lifestyle	O
(	O
smoking	O
,	O
physical	O
activity	O
participation	O
,	O
employment	O
),	O
and	O
health	O
(	O
medical	O
history	O
,	O
current	O
medication	O
use	O
)	O
using	O
interviewer	O
-	O
led	O
questionnaires	O
.	O

Ethnicity	O
was	O
reported	O
by	O
the	O
participant	O
and	O
subsequently	O
categorized	O
as	O
white	O
or	O
nonwhite	O
.	O

Anthropometric	O
measurements	O
included	O
height	O
,	O
measured	O
to	O
the	O
nearest	O
0	O
.	O
1	O
cm	O
using	O
a	O
stadiometer	O
,	O
and	O
weight	O
,	O
assessed	O
to	O
the	O
nearest	O
0	O
.	O
1	O
kg	O
using	O
calibrated	O
electronic	O
scales	O
.	O

Pregnancy	O
weight	O
gain	O
was	O
calculated	O
as	O
the	O
difference	O
between	O
the	O
weights	O
at	O
commencing	O
the	O
study	O
medication	O
and	O
at	O
34	O
weeks	O
of	O
gestation	O
.	O

Compliance	O
with	O
study	O
medication	O
was	O
assessed	O
by	O
asking	O
participants	O
to	O
bring	O
any	O
remaining	O
study	O
medication	O
to	O
each	O
assessment	O
.	O

The	O
pills	O
were	O
counted	O
and	O
compliance	O
calculated	O
as	O
the	O
number	O
consumed	O
divided	O
by	O
the	O
expected	O
consumption	O
based	O
on	O
the	O
number	O
of	O
days	O
since	O
the	O
medication	O
was	O
dispensed	O
and	O
expressed	O
as	O
a	O
percentage	O
.	O

Assessment	O
of	O
25	O
(	O
OH	O
)	O
D	O
On	O
the	O
day	O
that	O
the	O
study	O
medication	O
was	O
dispensed	O
and	O
at	O
34	O
weeks	O
of	O
gestation	O
,	O
a	O
nonfasted	O
venous	O
blood	O
sample	O
was	O
obtained	O
and	O
serum	O
stored	O
at	O
−	O
80	O
°	O
C	O
.	O

25	O
(	O
OH	O
)	O
D	O
concentration	O
was	O
assessed	O
by	O
chemiluminescence	O
immunoassay	O
(	O
Liaison	O
automated	O
platform	O
;	O
Diasorin	O
,	O
Dartford	O
,	O
UK	O
).	O

All	O
samples	O
were	O
analyzed	O
in	O
a	O
single	O
batch	O
at	O
the	O
end	O
of	O
the	O
study	O
at	O
Medical	O
Research	O
Council	O
Human	O
Nutrition	O
Research	O
(	O
Cambridge	O
,	O
United	O
Kingdom	O
).	O

Details	O
of	O
assay	O
performance	O
and	O
quality	O
control	O
through	O
participation	O
in	O
Vitamin	O
D	O
External	O
Quality	O
Assessment	O
Scheme	O
,	O
National	O
Institute	O
of	O
Standards	O
and	O
Technology	O
,	O
and	O
UK	O
National	O
External	O
Quality	O
Assessment	O
Service	O
are	O
given	O
elsewhere	O
(	O
15	O
,	O
16	O
).	O

Analysis	O
of	O
SNPs	O
Genotyping	O
was	O
undertaken	O
by	O
LGC	O
Genomics	O
(	O
Hoddeston	O
,	O
UK	O
)	O
using	O
KASP	O
competitive	O
allele	O
-	O
specific	O
polymerase	O
chain	O
reaction	O
.	O

SNPs	O
selected	O
for	O
analysis	O
were	O
based	O
on	O
the	O
findings	O
of	O
a	O
previous	O
GWAS	O
(	O
8	O
).	O

These	O
were	O
rs12785878	O
(	O
DHCR7	O
),	O
rs10741657	O
(	O
CYP2R1	O
),	O
rs6013897	O
(	O
CYP24A1	O
),	O
and	O
rs2282679	O
(	O
GC	O
).	O

Statistical	O
analysis	O
Women	O
who	O
had	O
a	O
measurement	O
of	O
25	O
(	O
OH	O
)	O
D	O
at	O
both	O
14	O
and	O
34	O
weeks	O
of	O
gestation	O
,	O
had	O
genetic	O
analysis	O
,	O
and	O
delivered	O
a	O
live	O
-	O
born	O
infant	O
were	O
included	O
in	O
the	O
analysis	O
.	O

The	O
SNPs	O
included	O
in	O
this	O
analysis	O
were	O
chosen	O
based	O
on	O
findings	O
in	O
the	O
previous	O
GWAS	O
,	O
which	O
included	O
only	O
individuals	O
of	O
European	O
ancestry	O
(	O
8	O
).	O

We	O
therefore	B
limited	O
our	O
study	O
population	O
to	O
only	O
women	O
of	O
white	O
ethnicity	O
(	O
95	O
.	O
8	O
%	O
of	O
eligible	O
women	O
).	O

All	O
outcomes	O
were	O
assessed	O
for	O
normality	O
using	O
visual	O
inspection	O
.	O

Serum	O
25	O
(	O
OH	O
)	O
D	O
concentrations	O
at	O
14	O
and	O
34	O
weeks	O
of	O
gestation	O
were	O
normally	O
distributed	O
.	O

Characteristics	O
of	O
the	O
women	O
in	O
the	O
two	O
treatment	O
arms	O
were	O
compared	O
using	O
the	O
t	O
test	O
,	O
Mann	O
-	O
Whitney	O
U	O
test	O
,	O
and	O
χ2test	O
for	O
normally	O
distributed	O
,	O
nonnormally	O
distributed	O
,	O
and	O
categorical	O
variables	O
,	O
respectively	O
.	O

All	O
participants	O
were	O
analyzed	O
in	O
the	O
group	O
to	O
which	O
they	O
were	O
originally	O
randomized	O
.	O

Linear	O
regression	O
was	O
used	O
to	O
examine	O
the	O
association	O
between	O
the	O
four	O
SNPs	O
and	O
the	O
outcomes	O
using	O
an	O
additive	O
model	O
with	O
the	O
homozygous	O
low	O
-	O
frequency	O
allele	O
(	O
for	O
this	O
cohort	O
)	O
as	O
the	O
reference	O
group	O
.	O

The	O
additive	O
model	O
thus	O
expresses	O
the	O
change	O
in	O
outcome	O
per	O
additional	O
common	O
allele	O
.	O

The	O
outcomes	O
assessed	O
were	O
25	O
(	O
OH	O
)	O
D	O
at	O
14	O
weeks	O
of	O
gestation	O
in	O
all	O
study	O
participants	O
and	O
the	O
achieved	O
25	O
(	O
OH	O
)	O
D	O
at	O
34	O
weeks	O
of	O
gestation	O
in	O
the	O
participants	O
randomized	O
to	O
cholecalciferol	O
.	O

In	O
addition	O
,	O
in	O
women	O
randomized	O
to	O
cholecalciferol	O
,	O
we	O
assessed	O
the	O
relationship	O
between	O
the	O
SNPs	O
and	O
the	O
change	O
in	O
vitamin	O
D	O
using	O
the	O
residuals	O
of	O
25	O
(	O
OH	O
)	O
D	O
at	O
34	O
weeks	O
of	O
gestation	O
regressed	O
on	O
25	O
(	O
OH	O
)	O
D	O
at	O
14	O
weeks	O
of	O
gestation	O
as	O
the	O
outcome	O
.	O

Multivariate	O
linear	O
regression	O
was	O
then	O
used	O
to	O
adjust	O
for	O
relevant	O
confounders	O
.	O

Maternal	O
age	O
,	O
BMI	O
,	O
physical	O
activity	O
and	O
smoking	O
status	O
at	O
14	O
weeks	O
of	O
gestation	O
,	O
educational	O
attainment	O
,	O
and	O
season	O
of	O
blood	O
measurement	O
were	O
included	O
in	O
the	O
model	O
for	O
baseline	O
25	O
(	O
OH	O
)	O
D	O
as	B
these	O
have	O
been	O
shown	O
to	O
be	O
associated	O
with	O
serum	O
25	O
(	O
OH	O
)	O
D	O
status	O
in	O
pregnancy	O
(	O
17	O
–	O
21	O
).	O

For	O
the	O
models	O
for	O
the	O
25	O
(	O
OH	O
)	O
D	O
achieved	O
at	O
34	O
weeks	O
of	O
gestation	O
,	O
compliance	O
with	O
study	O
medication	O
,	O
baseline	O
25	O
(	O
OH	O
)	O
D	O
,	O
and	O
pregnancy	O
weight	O
gain	O
(	O
instead	O
of	O
BMI	O
)	O
were	O
also	O
included	O
as	B
we	O
have	O
previously	O
demonstrated	O
in	O
this	O
cohort	O
of	O
women	O
that	O
these	O
factors	O
are	O
associated	O
with	O
the	O
response	O
to	O
cholecalciferol	O
supplementation	O
(	O
13	O
).	O

Seasons	O
were	O
defined	O
according	O
to	O
the	O
UK	O
Meteorological	O
Office	O
recommendations	O
(	O
www	O
.	O
metoffice	O
.	O
gov	O
.	O
uk	O
)	O
with	O
winter	O
(	O
December	O
to	O
February	O
),	O
spring	O
(	O
March	O
to	O
May	O
),	O
summer	O
(	O
June	O
to	O
August	O
),	O
and	O
autumn	O
(	O
September	O
to	O
November	O
).	O

As	O
four	O
SNPs	O
were	O
assessed	O
,	O
a	O
Bonferroni	O
correction	O
was	O
used	O
to	O
account	O
for	O
multiple	O
testing	O
.	O

We	O
also	O
undertook	O
sensitivity	O
analysis	O
in	O
which	O
women	O
who	O
reported	O
having	O
taken	O
any	O
additional	O
vitamin	O
D	O
–	O
containing	O
supplements	O
within	O
90	O
days	O
of	O
the	O
late	O
-	O
pregnancy	O
blood	O
sampling	O
were	O
excluded	O
.	O

Finally	O
,	O
to	O
determine	O
the	O
combined	O
effects	O
of	O
SNPs	O
,	O
a	O
genotype	O
risk	O
score	O
(	O
GRS	O
)	O
was	O
calculated	O
as	O
the	O
sum	O
of	O
the	O
number	O
of	O
risk	O
alleles	O
at	O
rs10741657	O
(	O
G	O
)	O
and	O
rs2282679	O
(	O
C	O
),	O
as	O
identified	O
in	O
the	O
previous	O
analysis	O
.	O

The	O
GRS	O
score	O
ranged	O
from	O
0	O
to	O
4	O
,	O
with	O
a	O
score	O
of	O
0	O
representing	O
no	O
risk	O
alleles	O
.	O

Multivariate	O
linear	O
regression	O
was	O
used	O
to	O
determine	O
the	O
association	O
of	O
GRS	O
with	O
25	O
(	O
OH	O
)	O
D	O
,	O
using	O
the	O
same	O
confounding	O
factors	O
as	O
before	O
.	O

All	O
analyses	O
were	O
performed	O
in	O
Stata	O
v14	O
.	O
2	O
(	O
StataCorp	O
,	O
College	O
Station	O
,	O
TX	O
).	O

A	O
P	O
value	O
of	O
<	O
0	O
.	O
05	O
was	O
considered	O
statistically	O
significant	O
.	O

Results	O
In	O
total	O
,	O
682	O
women	O
were	O
included	O
in	O
the	O
analysis	O
(	O
Fig	O
.	O

1	O
).	O

Women	O
who	O
delivered	O
a	O
live	O
-	O
born	O
infant	O
but	O
who	O
were	O
not	O
included	O
in	O
this	O
analysis	O
due	O
to	O
missing	O
25	O
(	O
OH	O
)	O
D	O
or	O
genetic	O
analysis	O
were	O
of	O
similar	O
age	O
,	O
smoking	O
status	O
,	O
and	O
BMI	O
to	O
those	O
included	O
in	O
the	O
analysis	O
(	O
P	O
>	O
0	O
.	O
05	O
for	O
all	O
).	O

Baseline	O
characteristics	O
of	O
the	O
women	O
randomized	O
to	O
placebo	O
and	O
cholecalciferol	O
were	O
similar	O
(	O
Table	O
1	O
).	O

The	O
distributions	O
of	O
alleles	O
within	O
the	O
SNPs	O
of	O
interest	O
were	O
also	O
similar	O
between	O
the	O
two	O
groups	O
(	O
Table	O
1	O
).	O

Caption	O
(	O
FIG	O
):	O
FIGURE	O
1	O
.	O

Consolidated	O
Standards	O
of	O
Reporting	O
Trials	O
diagram	O
.	O

Caption	O
(	O
TABLE	O
-	O
WRAP	O
):	O
TABLE	O
1	O
.	O

Characteristics	O
of	O
Women	O
Included	O
in	O
the	O
AnalysisCharacteristic	O
Placebo	O
(	O
n	O
=	O
351	O
)	O
Cholecalciferol	O
1000	O
IU	O
/	O
d	O
(	O
n	O
=	O
331	O
)	O
Age	O
(	O
years	O
),	O
mean	O
(	O
SD	O
)	O
30	O
.	O
8	O
(	O
5	O
.	O
4	O
)	O
30	O
.	O
8	O
(	O
5	O
.	O
0	O
)	O
Current	O
smoking	O
,	O
n	O
(%)	O
29	O
(	O
8	O
.	O
3	O
)	O
24	O
(	O
7	O
.	O
3	O
)	O
Educational	O
attainment	O
≥	O
A	O
level	O
(	O
high	O
school	O
),	O
n	O
(%)	O
258	O
(	O
74	O
.	O
4	O
)	O
264	O
(	O
80	O
.	O
0	O
)	O
BMI	O
(	O
kg	O
/	O
m2	O
),	O
median	O
(	O
IQR	O
)	O
25	O
.	O
5	O
(	O
23	O
.	O
0	O
to	O
29	O
.	O
7	O
)	O
24	O
.	O
7	O
(	O
22	O
.	O
3	O
to	O
29	O
.	O
3	O
)	O
Pregnancy	O
weight	O
gain	O
(	O
kg	O
),	O
mean	O
(	O
SD	O
)	O
9	O
.	O
5	O
(	O
3	O
.	O
6	O
)	O
9	O
.	O
5	O
(	O
3	O
.	O
4	O
)	O
Strenuous	O
exercise	O
≥	O
once	O
per	O
week	O
,	O
n	O
(%)	O
45	O
(	O
13	O
.	O
8	O
)	O
50	O
(	O
16	O
.	O
2	O
)	O
25	O
(	O
OH	O
)	O
D	O
at	O
14	O
weeks	O
(	O
nmol	O
/	O
L	O
),	O
mean	O
(	O
SD	O
)	O
45	O
.	O
4	O
(	O
16	O
.	O
5	O
)	O
46	O
.	O
1	O
(	O
17	O
.	O
0	O
)	O
rs12785878	O
(	O
DHCR7	O
),	O
n	O
(%)	O
G	O
:	O
G17	O
(	O
4	O
.	O
8	O
)	O
14	O
(	O
4	O
.	O
3	O
)	O
T	O
:	O
G114	O
(	O
32	O
.	O
5	O
)	O
120	O
(	O
36	O
.	O
6	O
)	O
T	O
:	O
T220	O
(	O
62	O
.	O
7	O
)	O
194	O
(	O
59	O
.	O
1	O
)	O
rs10741657	O
(	O
CYP2R1	O
),	O
n	O
(%)	O
A	O
:	O
A57	O
(	O
16	O
.	O
6	O
)	O
51	O
(	O
15	O
.	O
5	O
)	O
G	O
:	O
A156	O
(	O
45	O
.	O
3	O
)	O
148	O
(	O
45	O
.	O
1	O
)	O
G	O
:	O
G131	O
(	O
38	O
.	O
1	O
)	O
129	O
(	O
39	O
.	O
3	O
)	O
rs6013897	O
(	O
CYP24A1	O
),	O
n	O
(%)	O
A	O
:	O
A10	O
(	O
2	O
.	O
9	O
)	O
15	O
(	O
4	O
.	O
6	O
)	O
T	O
:	O
A126	O
(	O
36	O
.	O
5	O
)	O
102	O
(	O
31	O
.	O
4	O
)	O
T	O
:	O
T209	O
(	O
60	O
.	O
6	O
)	O
208	O
(	O
64	O
.	O
0	O
)	O
rs2282679	O
(	O
GC	O
),	O
n	O
(%)	O
C	O
:	O
C37	O
(	O
10	O
.	O
6	O
)	O
34	O
(	O
10	O
.	O
3	O
)	O
C	O
:	O
A149	O
(	O
42	O
.	O
6	O
)	O
136	O
(	O
41	O
.	O
3	O
)	O
A	O
:	O
A164	O
(	O
46	O
.	O
9	O
)	O
159	O
(	O
48	O
.	O
3	O
)	O
Abbreviation	O
:	O
IQR	O
,	O
interquartile	O
range	O
.	O

25	O
(	O
OH	O
)	O
D	O
was	O
similar	O
at	O
baseline	O
between	O
the	O
two	O
groups	O
but	O
significantly	O
higher	O
in	O
the	O
women	O
randomized	O
to	O
cholecalciferol	O
at	O
34	O
weeks	O
of	O
gestation	O
[	O
mean	O
(	O
standard	O
deviation	O
),	O
67	O
.	O
3	O
(	O
20	O
.	O
8	O
)	O
nmol	O
/	O
L	O
]	O
compared	O
with	O
placebo	O
[	O
mean	O
(	O
standard	O
deviation	O
),	O
43	O
.	O
0	O
(	O
22	O
.	O
2	O
)	O
nmol	O
/	O
L	O
,	O
P	O
<	O
0	O
.	O
001	O
].	O

Associations	O
with	O
baseline	O
25	O
(	O
OH	O
)	O
D	O
Among	O
all	O
682	O
women	O
,	O
the	O
common	O
allele	O
(	O
T	O
)	O
of	O
rs12785878	O
(	O
DHCR7	O
)	O
was	O
associated	O
with	O
greater	O
baseline	O
serum	O
25	O
(	O
OH	O
)	O
D	O
concentration	O
(	O
Table	O
2	O
).	O

This	O
association	O
persisted	O
in	O
multivariate	O
analysis	O
adjusting	O
for	O
maternal	O
age	O
,	O
BMI	O
,	O
smoking	O
status	O
,	O
physical	O
activity	O
,	O
educational	O
achievement	O
and	O
season	O
of	O
blood	O
sampling	O
[	O
β	O
=	O
3	O
.	O
1	O
nmol	O
/	O
L	O
per	O
T	O
allele	O
;	O
95	O
%	O
confidence	O
interval	O
(	O
CI	O
),	O
1	O
.	O
0	O
to	O
5	O
.	O
2	O
nmol	O
/	O
L	O
;	O
P	O
=	O
0	O
.	O
016	O
].	O

There	O
were	O
no	O
statistically	O
significant	O
associations	O
between	O
the	O
SNPs	O
at	O
rs10741657	O
(	O
CYP2R1	O
),	O
rs6013897	O
(	O
CYP24A1	O
),	O
and	O
rs2282679	O
(	O
GC	O
)	O
and	O
baseline	O
25	O
(	O
OH	O
)	O
D	O
in	O
the	O
fully	O
adjusted	O
model	O
(	O
Table	O
2	O
).	O

Caption	O
(	O
TABLE	O
-	O
WRAP	O
):	O
TABLE	O
2	O
.	O

Association	O
of	O
SNPs	O
With	O
Baseline	O
25	O
(	O
OH	O
)	O
D	O
in	O
Early	O
PregnancySNPReference	O
AlleleCommon	O
AlleleUnivariateAdjustedaCorrected	O
P	O
Valuebnβ	O
(	O
95	O
%	O
CI	O
)	O
P	O
Valuenβ	O
(	O
95	O
%	O
CI	O
)	O
P	O
Value	O
rs12785878	O
(	O
DHCR7	O
)	O
GT6793	O
.	O
7	O
(	O
1	O
.	O
5	O
to	O
5	O
.	O
8	O
)	O
0	O
.	O
0016223	O
.	O
1	O
(	O
1	O
.	O
0	O
to	O
5	O
.	O
2	O
)	O
0	O
.	O
0040	O
.	O
012rs10741657	O
(	O
CYP2R1	O
)	O
AG672	O
−	O
1	O
.	O
1	O
(−	O
2	O
.	O
9	O
to	O
0	O
.	O
7	O
)	O
0	O
.	O
24616	O
−	O
1	O
.	O
4	O
(−	O
3	O
.	O
2	O
to	O
0	O
.	O
4	O
)	O
0	O
.	O
120	O
.	O
47rs6013897	O
(	O
CYP24A1	O
)	O
AT6701	O
.	O
2	O
(−	O
1	O
.	O
1	O
to	O
3	O
.	O
4	O
)	O
0	O
.	O
316130	O
.	O
8	O
(−	O
1	O
.	O
4	O
to	O
3	O
.	O
0	O
)	O
0	O
.	O
461	O
.	O
0rs2282679	O
(	O
GC	O
)	O
CA6792	O
.	O
2	O
(	O
0	O
.	O
3	O
to	O
4	O
.	O
1	O
)	O
0	O
.	O
026221	O
.	O
7	O
(−	O
0	O
.	O
2	O
to	O
3	O
.	O
5	O
)	O
0	O
.	O
080	O
.	O
31	O
The	O
homozygous	O
low	O
-	O
frequency	O
gene	O
variant	O
was	O
used	O
as	O
the	O
reference	O
group	O
,	O
and	O
β	O
represents	O
the	O
change	O
in	O
25	O
(	O
OH	O
)	O
D	O
(	O
nmol	O
/	O
L	O
)	O
per	O
common	O
allele	O
.	O

Adjusted	O
for	O
age	O
,	O
BMI	O
,	O
smoking	O
status	O
(	O
yes	O
/	O
no	O
),	O
physical	O
activity	O
(	O
strenuous	O
activity	O
more	O
than	O
once	O
per	O
week	O
,	O
yes	O
/	O
no	O
),	O
educational	O
achievement	O
(	O
A	O
levels	O
or	O
higher	O
,	O
yes	O
/	O
no	O
),	O
and	O
season	O
of	O
blood	O
sampling	O
(	O
winter	O
,	O
spring	O
,	O
summer	O
,	O
autumn	O
).	O

Bonferroni	O
-	O
corrected	O
P	O
values	O
.	O

Associations	O
with	O
25	O
(	O
OH	O
)	O
D	O
following	O
supplementation	O
In	O
women	O
who	O
were	O
randomized	O
to	O
cholecalciferol	O
supplements	O
,	O
the	O
common	O
G	O
allele	O
of	O
rs10741657	O
(	O
CYP2R1	O
)	O
was	O
associated	O
with	O
lower	O
serum	O
25	O
(	O
OH	O
)	O
D	O
concentration	O
at	O
34	O
weeks	O
of	O
gestation	O
,	O
whereas	O
the	O
common	O
A	O
allele	O
of	O
rs2282679	O
(	O
GC	O
)	O
was	O
associated	O
with	O
greater	O
34	O
-	O
week	O
serum	O
25	O
(	O
OH	O
)	O
D	O
(	O
Table	O
3	O
).	O

These	O
associations	O
persisted	O
after	O
adjustment	O
for	O
potential	O
confounding	O
factors	O
(	O
maternal	O
age	O
,	O
physical	O
activity	O
,	O
and	O
smoking	O
status	O
at	O
14	O
weeks	O
of	O
gestation	O
;	O
educational	O
attainment	O
;	O
season	O
of	O
blood	O
measurement	O
;	O
compliance	O
with	O
study	O
medication	O
;	O
baseline	O
25	O
(	O
OH	O
)	O
D	O
;	O
and	O
pregnancy	O
weight	O
gain	O
).	O

There	O
were	O
no	O
significant	O
associations	O
between	O
the	O
SNPs	O
at	O
rs12785878	O
(	O
DHCR7	O
)	O
and	O
rs6013897	O
(	O
CYP24A1	O
)	O
and	O
25	O
(	O
OH	O
)	O
D	O
at	O
34	O
weeks	O
of	O
gestation	O
(	O
Table	O
3	O
).	O

When	O
both	O
rs10741657	O
(	O
CYP2R1	O
)	O
(	O
β	O
=	O
−	O
5	O
.	O
0	O
nmol	O
/	O
L	O
per	O
G	O
allele	O
;	O
95	O
%	O
CI	O
,	O
−	O
8	O
.	O
0	O
to	O
−	O
1	O
.	O
9	O
nmol	O
/	O
L	O
per	O
G	O
allele	O
;	O
P	O
=	O
0	O
.	O
001	O
)	O
and	O
rs2282679	O
(	O
GC	O
)	O
(	O
β	O
=	O
3	O
.	O
8	O
nmol	O
/	O
L	O
per	O
A	O
allele	O
;	O
95	O
%	O
CI	O
,	O
0	O
.	O
6	O
to	O
7	O
.	O
1	O
nmol	O
/	O
L	O
per	O
A	O
allele	O
;	O
P	O
=	O
0	O
.	O
021	O
)	O
were	O
included	O
simultaneously	O
in	O
a	O
regression	O
model	O
with	O
confounders	O
,	O
the	O
effect	O
sizes	O
were	O
maintained	O
.	O

Furthermore	O
,	O
a	O
GRS	O
including	O
rs10741657	O
and	O
rs2282679	O
showed	O
that	O
for	O
each	O
additional	O
risk	O
allele	O
,	O
late	O
pregnancy	O
serum	O
25	O
(	O
OH	O
)	O
D	O
concentration	O
after	O
supplementation	O
with	O
cholecalciferol	O
was	O
lower	O
by	O
4	O
.	O
4	O
nmol	O
/	O
L	O
(	O
95	O
%	O
CI	O
,	O
2	O
.	O
3	O
to	O
6	O
.	O
6	O
nmol	O
/	O
L	O
,	O
P	O
<	O
0	O
.	O
001	O
).	O

This	O
association	O
between	O
the	O
GRS	O
and	O
25	O
(	O
OH	O
)	O
D	O
was	O
not	O
present	O
presupplementation	O
in	O
early	O
pregnancy	O
(	O
Fig	O
.	O

2	O
).	O

Caption	O
(	O
TABLE	O
-	O
WRAP	O
):	O
TABLE	O
3	O
.	O

Association	O
of	O
SNPs	O
With	O
Achieved	O
25	O
(	O
OH	O
)	O
D	O
at	O
34	O
Weeks	O
of	O
Gestation	O
Following	O
Supplementation	O
With	O
1000	O
IU	O
/	O
d	O
Cholecalciferol	O
in	O
PregnancySNPReference	O
AlleleCommon	O
AlleleUnivariateAdjustedaCorrected	O
P	O
Valuebnβ	O
(	O
95	O
%	O
CI	O
)	O
P	O
Valuenβ	O
(	O
95	O
%	O
CI	O
)	O
P	O
Value	O
rs12785878	O
(	O
DHCR7	O
)	O
GT3282	O
.	O
6	O
(−	O
1	O
.	O
4	O
to	O
6	O
.	O
5	O
)	O
0	O
.	O
203040	O
.	O
3	O
(−	O
3	O
.	O
5	O
to	O
4	O
.	O
0	O
)	O
0	O
.	O
891	O
.	O
0rs10741657	O
(	O
CYP2R1	O
)	O
AG328	O
−	O
4	O
.	O
8	O
(−	O
8	O
.	O
0	O
to	O
−	O
1	O
.	O
6	O
)	O
0	O
.	O
004304	O
−	O
5	O
.	O
2	O
(−	O
8	O
.	O
2	O
to	O
−	O
2	O
.	O
2	O
)	O
0	O
.	O
0010	O
.	O
004rs6013897	O
(	O
CYP24A1	O
)	O
AT325	O
−	O
3	O
.	O
2	O
(−	O
7	O
.	O
1	O
to	O
0	O
.	O
8	O
)	O
0	O
.	O
11301	O
−	O
1	O
.	O
0	O
(−	O
4	O
.	O
8	O
to	O
2	O
.	O
8	O
)	O
0	O
.	O
601	O
.	O
0rs2282679	O
(	O
GC	O
)	O
CA3294	O
.	O
3	O
(	O
0	O
.	O
9	O
to	O
7	O
.	O
7	O
)	O
0	O
.	O
013054	O
.	O
2	O
(	O
0	O
.	O
9	O
to	O
7	O
.	O
5	O
)	O
0	O
.	O
010	O
.	O
04	O
The	O
homozygous	O
low	O
frequency	O
gene	O
variant	O
was	O
used	O
as	O
the	O
reference	O
group	O
.	O

β	O
represents	O
the	O
effect	O
on	O
achieved	O
25	O
(	O
OH	O
)	O
D	O
(	O
nmol	O
/	O
L	O
)	O
per	O
common	O
allele	O
.	O

Adjusted	O
for	O
age	O
,	O
pregnancy	O
weight	O
gain	O
,	O
smoking	O
status	O
(	O
yes	O
/	O
no	O
),	O
physical	O
activity	O
(	O
strenuous	O
activity	O
more	O
than	O
once	O
per	O
week	O
,	O
yes	O
/	O
no	O
),	O
educational	O
achievement	O
(	O
A	O
levels	O
or	O
higher	O
,	O
yes	O
/	O
no	O
),	O
season	O
of	O
blood	O
sampling	O
(	O
winter	O
,	O
spring	O
,	O
summer	O
,	O
autumn	O
),	O
compliance	O
with	O
study	O
protocol	O
,	O
and	O
baseline	O
25	O
(	O
OH	O
)	O
D	O
.	O
Bonferroni	O
-	O
corrected	O
P	O
values	O
.	O

Caption	O
(	O
FIG	O
):	O
FIGURE	O
2	O
.	O

25	O
(	O
OH	O
)	O
D	O
before	O
and	O
after	O
supplementation	O
with	O
cholecalciferol	O
in	O
pregnancy	O
according	O
to	O
GRS	O
for	O
the	O
SNPs	O
rs10741657	O
(	O
CYP2R1	O
)	O
and	O
rs2282679	O
(	O
GC	O
).	O

Shown	O
as	O
mean	O
and	O
95	O
%	O
CI	O
for	O
each	O
group	O
.	O

P	O
is	O
for	O
trend	O
by	O
linear	O
regression	O
with	O
adjustment	O
for	O
confounders	O
.	O

Similarly	O
,	O
rs10741657	O
(	O
CYP2R1	O
)	O
and	O
rs2282679	O
(	O
GC	O
)	O
were	O
associated	O
with	O
the	O
change	O
in	O
25	O
(	O
OH	O
)	O
D	O
from	O
14	O
to	O
34	O
weeks	O
of	O
gestation	O
in	O
women	O
who	O
received	O
the	O
cholecalciferol	O
supplement	O
,	O
whereas	O
rs12785878	O
(	O
DHCR7	O
)	O
and	O
rs6013897	O
(	O
CYP24A1	O
)	O
were	O
not	O
(	O
Fig	O
.	O

3	O
).	O

The	O
GRS	O
was	O
also	O
negatively	O
associated	O
with	O
the	O
change	O
in	O
serum	O
25	O
(	O
OH	O
)	O
D	O
concentration	O
(	O
β	O
=	O
−	O
4	O
.	O
4	O
nmol	O
/	O
L	O
per	O
risk	O
allele	O
;	O
95	O
%	O
CI	O
,	O
−	O
6	O
.	O
6	O
to	O
−	O
2	O
.	O
3	O
nmol	O
/	O
L	O
per	O
risk	O
allele	O
;	O
P	O
<	O
0	O
.	O
001	O
),	O
such	O
that	O
women	O
who	O
had	O
more	O
risk	O
alleles	O
had	O
a	O
smaller	O
increment	O
in	O
25	O
(	O
OH	O
)	O
D	O
.	O
Caption	O
(	O
FIG	O
):	O
FIGURE	O
3	O
.	O

Associations	O
between	O
SNPs	O
and	O
change	O
in	O
25	O
(	O
OH	O
)	O
D	O
from	O
14	O
to	O
34	O
weeks	O
of	O
gestation	O
following	O
supplementation	O
with	O
1000	O
IU	O
/	O
d	O
cholecalciferol	O
.	O

Shown	O
as	O
β	O
and	O
95	O
%	O
CI	O
.	O

The	O
homozygous	O
low	O
-	O
frequency	O
allele	O
was	O
used	O
as	O
the	O
reference	O
group	O
,	O
with	O
the	O
β	O
representing	O
the	O
change	O
in	O
25	O
(	O
OH	O
)	O
D	O
(	O
nmol	O
/	O
L	O
)	O
per	O
common	O
allele	O
(	O
additive	O
model	O
).	O

Models	O
were	O
adjusted	O
for	O
age	O
,	O
physical	O
activity	O
,	O
smoking	O
status	O
,	O
educational	O
attainment	O
,	O
season	O
of	O
blood	O
sampling	O
,	O
compliance	O
,	O
and	O
pregnancy	O
weight	O
gain	O
.	O

Sensitivity	O
analysis	O
As	O
the	O
women	O
were	O
allowed	O
to	O
continue	O
taking	O
vitamin	O
D	O
supplements	O
containing	O
up	O
to	O
400	O
IU	O
/	O
d	O
,	O
in	O
sensitivity	O
analyses	O
,	O
we	O
included	O
only	O
women	O
who	O
were	O
not	O
taking	O
additional	O
vitamin	O
D	O
–	O
containing	O
supplements	O
at	O
34	O
weeks	O
of	O
gestation	O
(	O
n	O
=	O
224	O
,	O
67	O
.	O
7	O
%).	O

The	O
relationships	O
were	O
similar	O
to	O
those	O
in	O
the	O
whole	O
cohort	O
.	O

Discussion	O
This	O
study	O
assessed	O
the	O
relationships	O
between	O
common	O
genetic	O
variants	O
and	O
the	O
response	O
to	O
vitamin	O
D	O
supplementation	O
in	O
pregnancy	O
;	O
rs12785878	O
in	O
DHCR7	O
was	O
associated	O
with	O
25	O
(	O
OH	O
)	O
D	O
status	O
in	O
early	O
pregnancy	O
prior	O
to	O
vitamin	O
D	O
supplementation	O
,	O
whereas	O
rs10741657	O
in	O
CYP2R1	O
and	O
rs2282679	O
in	O
GC	O
were	O
associated	O
with	O
both	O
the	O
achieved	O
and	O
change	O
in	O
25	O
(	O
OH	O
)	O
D	O
concentration	O
following	O
supplementation	O
with	O
1000	O
IU	O
/	O
d	O
cholecalciferol	O
.	O

GWAS	O
has	O
been	O
used	O
to	O
identify	O
SNPs	O
associated	O
with	O
serum	O
25	O
(	O
OH	O
)	O
D	O
status	O
(	O
8	O
,	O
22	O
).	O

However	O
,	O
there	O
are	O
few	O
studies	O
investigating	O
whether	O
common	O
genetic	O
variants	O
modify	O
the	O
response	O
to	O
supplementation	O
and	O
,	O
to	B
our	I
knowledge	I
,	O
no	O
previous	O
studies	O
in	O
pregnant	O
women	O
.	O

Two	O
previous	O
studies	O
in	O
nonpregnant	O
adults	O
similarly	O
found	O
that	O
rs2282679	O
(	O
GC	O
)	O
and	O
rs10741567	O
(	O
CYP2R1	O
)	O
are	O
associated	O
with	O
serum	O
25	O
(	O
OH	O
)	O
D	O
increment	O
in	O
response	O
to	O
supplementation	O
(	O
10	O
,	O
11	O
),	O
whereas	O
Barry	O
et	O
al	O
.	O

(	O
9	O
)	O
did	O
not	O
identify	O
these	O
associations	O
.	O

The	O
observed	O
difference	O
in	O
achieved	O
25	O
(	O
OH	O
)	O
D	O
between	O
the	O
homozygous	O
gene	O
variants	O
was	O
higher	O
in	O
the	O
studies	O
by	O
Sollid	O
et	O
al	O
.	O

(	O
10	O
)	O
and	O
Didriksen	O
et	O
al	O
.	O

(	O
11	O
)	O
(	O
15	O
to	O
18	O
nmol	O
/	O
L	O
)	O
than	O
our	O
cohort	O
(	O
9	O
to	O
10	O
nmol	O
/	O
L	O
),	O
but	O
this	O
could	O
reflect	O
the	O
higher	O
cholecalciferol	O
doses	O
used	O
in	O
those	O
studies	O
and	O
/	O
or	O
alterations	O
in	O
vitamin	O
D	O
metabolism	O
and	O
volume	O
of	O
distribution	O
in	O
pregnancy	O
.	O

In	O
our	O
population	O
,	O
the	O
SNPs	O
associated	O
with	O
baseline	O
25	O
(	O
OH	O
)	O
D	O
differed	O
from	O
those	O
associated	O
with	O
the	O
response	O
to	O
cholecalciferol	O
supplementation	O
.	O

The	O
published	O
GWAS	O
(	O
8	O
,	O
22	O
)	O
did	O
not	O
stratify	O
individuals	O
by	O
vitamin	O
D	O
supplement	O
usage	O
,	O
which	O
could	O
account	B
for	I
differing	O
associations	O
before	O
and	O
after	O
supplementation	O
in	O
our	O
cohort	O
,	O
or	O
the	O
differing	O
findings	O
might	O
reflect	O
the	O
lower	O
power	O
in	O
our	O
study	O
.	O

Nonetheless	O
,	O
although	O
the	O
functional	O
consequences	O
of	O
these	O
genetic	O
markers	O
remain	O
the	O
subject	O
of	O
research	O
,	O
these	O
differences	O
are	O
biologically	O
plausible	O
.	O

The	O
DHCR7	O
gene	O
encodes	O
7	O
-	O
DHC	O
reductase	O
,	O
which	O
converts	O
7	O
-	O
DHC	O
back	O
to	O
cholesterol	O
,	O
thereby	O
reducing	O
the	O
availability	O
of	O
7	O
-	O
DHC	O
for	O
conversion	O
to	O
previtamin	O
D	O
.	O
The	O
association	O
of	O
this	O
SNP	O
with	O
only	O
baseline	O
25	O
(	O
OH	O
)	O
D	O
is	O
biologically	O
consistent	O
with	O
the	O
notion	O
that	O
the	O
relative	O
proportion	O
of	O
25	O
(	O
OH	O
)	O
D	O
obtained	O
from	O
vitamin	O
D	O
biosynthesis	O
in	O
the	O
skin	O
as	O
opposed	O
to	O
dietary	O
intake	O
is	O
lower	O
following	O
supplementation	O
.	O

CYP2R1	O
encodes	O
a	O
25	O
-	O
hydroxylase	O
,	O
a	O
key	O
enzyme	O
involved	O
in	O
the	O
conversion	O
of	O
vitamin	O
D	O
to	O
25	O
(	O
OH	O
)	O
D	O
(	O
23	O
).	O

Hepatic	O
hydroxylation	O
of	O
previtamin	O
D	O
to	O
25	O
(	O
OH	O
)	O
D	O
is	O
thought	O
not	O
to	O
be	O
regulated	O
and	O
is	O
therefore	B
primarily	B
dependent	O
on	O
availability	O
of	O
the	O
substrate	O
.	O

We	O
found	O
that	O
the	O
rs10741657	O
SNP	O
was	O
not	O
associated	O
with	O
baseline	O
25	O
(	O
OH	O
)	O
D	O
but	O
was	O
associated	O
with	O
the	O
response	O
to	O
gestational	O
vitamin	O
D	O
supplementation	O
,	O
therefore	B
suggesting	O
that	O
this	O
SNP	O
only	O
modifies	O
25	O
(	O
OH	O
)	O
D	O
status	O
when	O
the	O
substrate	O
is	O
more	O
readily	O
available	O
and	O
that	O
at	O
the	O
baseline	O
measurement	O
,	O
saturation	O
of	O
the	O
enzyme	O
had	O
not	O
been	O
reached	O
.	O

rs10741657	O
is	O
located	O
within	O
the	O
promoter	O
region	O
of	O
the	O
CYP2R1	O
gene	O
,	O
and	O
our	O
findings	O
would	O
suggest	O
that	O
presence	O
of	O
the	O
A	O
allele	O
increases	O
enzyme	O
production	O
.	O

Because	O
the	O
G	O
allele	O
at	O
rs10741657	O
,	O
which	O
was	O
more	O
frequent	O
in	O
our	O
population	O
,	O
was	O
associated	O
with	O
lower	O
25	O
(	O
OH	O
)	O
D	O
following	O
supplementation	O
,	O
it	O
could	O
be	O
postulated	O
that	O
this	O
allele	O
previously	O
conferred	O
an	O
evolutionary	O
advantage	O
to	O
prevent	O
vitamin	O
D	O
toxicity	O
.	O

In	O
addition	O
to	O
associations	O
with	O
25	O
(	O
OH	O
)	O
D	O
,	O
rs2282679	O
in	O
GC	O
has	O
also	O
been	O
associated	O
with	O
serum	O
VDP	O
concentrations	O
,	O
with	O
carriers	O
of	O
the	O
low	O
-	O
frequency	O
C	O
allele	O
having	O
reduced	O
concentrations	O
of	O
VDP	O
and	O
25	O
(	O
OH	O
)	O
D	O
(	O
8	O
).	O

SNPs	O
in	O
GC	O
have	O
also	O
been	O
associated	O
with	O
the	O
binding	O
affinities	O
of	O
25	O
(	O
OH	O
)	O
D	O
to	O
VDP	O
(	O
24	O
),	O
although	O
the	O
effect	O
of	O
rs2282679	O
on	O
binding	O
affinity	O
has	O
not	O
been	O
established	O
.	O

We	O
similarly	O
found	O
that	O
the	O
C	O
allele	O
was	O
associated	O
with	O
lower	O
achieved	O
25	O
(	O
OH	O
)	O
D	O
following	O
antenatal	O
vitamin	O
D	O
supplementation	O
.	O

Unfortunately	O
,	O
analysis	O
of	O
VDP	O
was	O
not	O
available	O
in	O
this	O
cohort	O
of	O
women	O
.	O

It	O
is	O
well	O
recognized	B
that	O
individuals	O
with	O
darker	O
skin	O
pigmentation	O
living	O
at	O
higher	O
latitudes	O
tend	O
to	O
have	O
lower	O
25	O
(	O
OH	O
)	O
D	O
.	O
This	O
may	O
in	O
part	O
reflect	O
clustering	O
of	O
genotypes	O
within	O
ethnic	O
groups	O
.	O

For	O
example	O
,	O
the	O
G	O
allele	O
at	O
rs12785878	O
(	O
DHCR7	O
)	O
is	O
typically	O
more	O
prevalent	O
in	O
nonwhite	O
populations	O
(	O
25	O
–	O
29	O
).	O

Although	O
our	O
study	O
included	O
only	O
women	O
of	O
white	O
ethnicity	O
,	O
the	O
G	O
allele	O
was	O
associated	O
with	O
lower	O
baseline	O
25	O
(	O
OH	O
)	O
D	O
.	O
The	O
greater	O
prevalence	O
of	O
the	O
G	O
allele	O
at	O
rs12785878	O
with	O
a	O
resulting	O
increase	O
in	O
7	O
-	O
DHC	O
reductase	O
activity	O
(	O
either	O
due	O
to	O
a	O
functional	O
modification	O
or	O
increased	O
synthesis	O
)	O
leading	O
to	O
reduced	O
availability	O
of	O
7	O
-	O
DHC	O
for	O
conversion	O
to	O
previtamin	O
D	O
might	O
contribute	O
to	O
lower	O
25	O
(	O
OH	O
)	O
D	O
in	O
individuals	O
with	O
darker	O
skin	O
pigmentation	O
.	O

Furthermore	O
,	O
it	O
has	O
previously	O
been	O
shown	O
that	O
rs2282679	O
(	O
GC	O
)	O
was	O
only	O
significantly	O
associated	O
with	O
25	O
(	O
OH	O
)	O
D	O
in	O
European	O
Americans	O
and	O
not	O
African	O
Americans	O
(	O
30	O
),	O
suggesting	O
further	O
ethnicity	O
-	O
specific	O
associations	O
,	O
which	O
might	O
form	O
the	O
basis	O
of	O
future	O
study	O
,	O
and	O
consideration	O
in	O
clinical	O
approaches	O
to	O
supplementation	O
.	O

There	O
are	O
a	O
number	O
of	O
limitations	O
to	O
our	O
findings	O
.	O

First	O
,	O
due	O
to	O
stipulations	O
made	O
during	O
the	O
ethics	O
approval	O
process	O
,	O
we	O
were	O
unable	O
to	O
include	O
participants	O
with	O
a	O
baseline	O
25	O
(	O
OH	O
)	O
D	O
less	O
than	O
25	O
nmol	O
/	O
L	O
or	O
greater	O
than	O
100	O
nmol	O
/	O
L	O
.	O

As	B
such	I
,	O
confirmation	O
of	O
these	O
findings	O
in	O
severely	O
vitamin	O
D	O
–	O
deficient	O
women	O
is	O
needed	O
as	B
it	O
is	O
possible	O
that	O
women	O
with	O
specific	O
genotypes	O
were	O
selectively	O
excluded	O
by	O
this	O
inclusion	O
criterion	O
.	O

Second	O
,	O
we	O
did	O
not	O
identify	O
associations	O
between	O
several	O
SNPs	O
and	O
either	O
baseline	O
and	O
/	O
or	O
achieved	O
25	O
(	O
OH	O
)	O
D	O
that	O
had	O
previously	O
been	O
associated	O
with	O
25	O
(	O
OH	O
)	O
D	O
in	O
GWAS	O
(	O
8	O
,	O
22	O
).	O

This	O
may	O
reflect	O
the	O
lower	O
power	O
of	O
this	O
study	O
,	O
although	O
our	O
findings	O
are	O
similar	O
to	O
other	O
small	O
studies	O
(	O
10	O
,	O
11	O
).	O

Furthermore	O
,	O
in	O
this	O
study	O
,	O
we	O
performed	O
analysis	O
only	O
of	O
candidate	O
SNPs	O
previously	O
identified	O
to	O
be	O
associated	O
with	O
differences	O
in	O
25	O
(	O
OH	O
)	O
D	O
status	O
.	O

However	O
,	O
it	O
is	O
possible	O
that	O
alternate	O
SNPs	O
/	O
genes	O
that	O
are	O
not	O
clinically	O
important	O
to	O
25	O
(	O
OH	O
)	O
D	O
level	O
in	O
nonpregnant	O
adults	O
would	O
be	O
significant	O
in	O
pregnant	O
women	O
and	O
could	O
be	O
identified	O
by	O
GWAS	O
.	O

In	O
conclusion	O
,	O
common	O
genetic	O
variation	O
is	O
associated	O
with	O
baseline	O
25	O
(	O
OH	O
)	O
D	O
in	O
pregnancy	O
and	O
the	O
response	O
to	O
antenatal	O
supplementation	O
with	O
1000	O
IU	O
/	O
d	O
cholecalciferol	O
,	O
but	O
with	O
differing	O
SNPs	O
appearing	O
to	O
be	O
important	O
before	O
and	O
after	O
supplementation	O
.	O

Our	O
findings	O
suggest	O
that	O
analysis	O
of	O
SNPs	O
may	O
have	O
an	O
important	O
role	O
in	O
identifying	O
high	O
-	O
risk	O
categories	O
of	O
individuals	O
who	O
are	O
likely	B
to	O
require	O
higher	O
doses	O
of	O
vitamin	O
D	O
to	O
achieve	O
repletion	O
,	O
and	O
studies	O
are	O
needed	O
to	O
establish	O
clinical	O
approaches	O
to	O
vitamin	O
D	O
supplementation	O
that	O
are	O
centered	O
on	O
individual	O
characteristics	O
.	O

PubMed	O
Central	O
:	O

Trajectory	O
of	O
vitamin	O
D	O
status	O
during	O
pregnancy	O
in	O
relation	O
to	O
neonatal	O
birth	O
size	O
and	O
fetal	O
survival	O
:	O
a	O
prospective	O
cohort	O
study	O
Abstract	O
Background	O
We	O
investigated	O
the	O
associations	O
between	O
vitamin	O
D	O
status	O
in	O
early	O
and	O
late	O
pregnancy	O
with	O
neonatal	O
small	O
for	O
gestational	O
age	O
(	O
SGA	O
),	O
low	O
birth	O
weight	O
(	O
LBW	O
)	O
and	O
preterm	O
delivery	O
.	O

Furthermore	O
,	O
associations	O
between	O
vitamin	O
D	O
status	O
and	O
pregnancy	O
loss	O
were	O
studied	O
.	O

Methods	O
Serum	O
25	O
-	O
hydroxyvitamin	O
D	O
(	O
25OHD	O
)	O
was	O
sampled	O
in	O
gestational	O
week	O
≤	O
16	O
(	O
trimester	O
1	O
(	O
T1	O
),	O
N	O
=	O
2046	O
)	O
and	O
>	O
31	O
(	O
trimester	O
3	O
(	O
T3	O
),	O
N	O
=	O
1816	O
)	O
and	O
analysed	O
using	O
liquid	O
chromatography	O
tandem	O
mass	O
spectrometry	O
.	O

Pregnant	O
women	O
were	O
recruited	O
at	O
antenatal	O
clinics	O
in	O
south	O
-	O
west	O
Sweden	O
at	O
latitude	O
57	O
–	O
58	O
°	O
N	O
.	O

Gestational	O
and	O
neonatal	O
data	O
were	O
retrieved	O
from	O
medical	O
records	O
.	O

Multiple	O
gestations	O
and	O
terminated	O
pregnancies	O
were	O
excluded	O
from	O
the	O
analyses	O
.	O

SGA	O
was	O
defined	O
as	O
weight	O
and	O
/	O
or	O
length	O
at	O
birth	O
<	O
2	O
SD	O
of	O
the	O
population	O
mean	O
and	O
LBW	O
as	O
<	O
2500	O
g	O
.	O
Preterm	O
delivery	O
was	O
defined	O
as	O
delivery	O
<	O
37	O
+	O
0	O
gestational	O
weeks	O
and	O
pregnancy	O
loss	O
as	O
spontaneous	O
abortion	O
or	O
intrauterine	O
fetal	O
death	O
.	O

Associations	O
between	O
neonatal	O
outcomes	O
and	O
25OHD	O
at	O
T1	O
,	O
T3	O
and	O
change	O
in	O
25OHD	O
(	O
T3	O
-	O
T1	O
)	O
were	O
studied	O
using	O
logistic	O
regression	O
.	O

Results	O
T1	O
25OHD	O
was	O
negatively	O
associated	O
with	O
pregnancy	O
loss	O
and	O
1	O
nmol	O
/	O
L	O
increase	O
in	O
25OHD	O
was	O
associated	O
with	O
1	O
%	O
lower	O
odds	O
of	O
pregnancy	O
loss	O
(	O
OR	O
0	O
.	O
99	O
,	O
p	O
=	O
0	O
.	O
046	O
).	O

T3	O
25OHD	O
≥	O
100	O
nmol	O
/	O
L	O
(	O
equal	O
to	O
40	O
ng	O
/	O
ml	O
)	O
was	O
associated	O
with	O
lower	O
odds	O
of	O
SGA	O
(	O
OR	O
0	O
.	O
3	O
,	O
p	O
=	O
0	O
.	O
031	O
)	O
and	O
LBW	O
(	O
OR	O
0	O
.	O
2	O
,	O
p	O
=	O
0	O
.	O
046	O
),	O
compared	O
to	O
vitamin	O
D	O
deficiency	O
(	O
25OHD	O
<	O
30	O
nmol	O
/	O
L	O
,	O
or	O
12	O
ng	O
/	O
ml	O
).	O

Women	O
with	O
a	O
≥	O
30	O
nmol	O
/	O
L	O
increment	O
in	O
25OHD	O
from	O
T1	O
to	O
T3	O
had	O
the	O
lowest	O
odds	O
of	O
SGA	O
,	O
LBW	O
and	O
preterm	O
delivery	O
.	O

Conclusions	O
Vitamin	O
D	O
deficiency	O
in	O
late	O
pregnancy	O
was	O
associated	O
with	O
higher	O
odds	O
of	O
SGA	O
and	O
LBW	O
.	O

Lower	O
25OHD	O
in	O
early	O
pregnancy	O
was	O
only	O
associated	O
with	O
pregnancy	O
loss	O
.	O

Vitamin	O
D	O
status	O
trajectory	O
from	O
early	O
to	O
late	O
pregnancy	O
was	O
inversely	O
associated	O
with	O
SGA	O
,	O
LBW	O
and	O
preterm	O
delivery	O
with	O
the	O
lowest	O
odds	O
among	O
women	O
with	O
the	O
highest	O
increment	O
in	O
25OHD	O
.	O

Thus	B
,	O
both	O
higher	O
vitamin	O
D	O
status	O
in	O
late	O
pregnancy	O
and	O
gestational	O
vitamin	O
D	O
status	O
trajectory	O
can	O
be	O
suspected	B
to	O
play	O
a	O
role	O
in	O
healthy	O
pregnancy	O
.	O

Background	O
Placental	O
pathology	O
is	O
often	B
found	O
in	O
pregnancies	O
complicated	O
by	O
intrauterine	O
growth	O
restriction	O
,	O
preeclampsia	O
or	O
intrauterine	O
fetal	O
death	O
.	O

It	O
is	O
associated	O
with	O
inadequate	O
invasion	O
of	O
extravillous	O
trophoblasts	O
and	O
inadequate	O
angiogenesis	O
,	O
with	O
insufficient	O
conversion	O
of	O
arterial	O
spiral	O
arteries	O
in	O
the	O
decidua	O
[	O
1	O
].	O

These	O
processes	O
are	O
complex	O
and	O
normal	O
development	O
is	O
dependent	O
on	O
several	O
factors	O
.	O

Vitamin	O
D	O
status	O
(	O
measured	O
as	O
25	O
-	O
hydroxyvitamin	O
D	O
(	O
25OHD	O
))	O
of	O
pregnant	O
women	O
has	O
been	O
inversely	O
associated	O
with	O
adverse	O
gestational	O
outcomes	O
and	O
associated	O
with	O
uteroplacental	O
dysfunction	O
[	O
2	O
].	O

We	O
have	O
previously	O
shown	O
that	O
higher	O
vitamin	O
D	O
status	O
in	O
late	O
pregnancy	O
and	O
larger	O
increase	O
in	O
vitamin	O
D	O
status	O
during	O
pregnancy	O
is	O
associated	O
with	O
lower	O
risk	O
of	O
preeclampsia	O
[	O
3	O
].	O

Associations	O
have	O
also	O
been	O
shown	O
between	O
vitamin	O
D	O
insufficiency	O
(<	O
50	O
nmol	O
/	O
L	O
)	O
and	O
increased	O
risk	O
of	O
infant	O
small	O
for	O
gestational	O
age	O
(	O
SGA	O
)	O
and	O
low	O
birth	O
weight	O
(	O
LBW	O
)	O
[	O
4	O
].	O

Circulating	O
concentrations	O
of	O
25OHD	O
below	O
25	O
or	O
30	O
nmol	O
/	O
L	O
have	O
been	O
associated	O
with	O
50	O
–	O
300	O
%	O
increased	O
odds	O
of	O
SGA	O
,	O
compared	O
to	O
higher	O
concentrations	O
[	O
5	O
–	O
7	O
].	O

Also	O
,	O
maternal	O
25OHD	O
<	O
28	O
nmol	O
/	O
L	O
in	O
late	O
,	O
but	O
not	O
early	O
,	O
pregnancy	O
have	O
been	O
associated	O
with	O
lower	O
infant	O
birth	O
size	O
and	O
shorter	O
gestational	O
length	O
in	O
a	O
smaller	O
longitudinal	O
study	O
[	O
8	O
].	O

However	O
,	O
there	O
is	O
also	O
limited	O
evidence	O
for	O
a	O
U	O
-	O
shaped	O
association	O
where	O
high	O
25OHD	O
concentrations	O
(>	O
80	O
nmol	O
/	O
L	O
)	O
may	O
be	O
related	O
to	O
higher	O
risk	O
of	O
SGA	O
[	O
9	O
].	O

Thus	B
,	O
the	O
association	O
between	O
vitamin	O
D	O
status	O
and	O
neonatal	O
birth	O
size	O
is	O
not	O
clear	O
and	O
warrants	O
further	O
investigation	O
.	O

A	O
recent	O
meta	O
-	O
analysis	O
of	O
10	O
studies	O
concluded	O
that	O
25OHD	O
concentrations	O
<	O
50	O
nmol	O
/	O
L	O
were	O
associated	O
with	O
an	O
approximately	O
30	O
%	O
increased	O
risk	O
of	O
preterm	O
delivery	O
[	O
10	O
].	O

Bodnar	O
et	O
al	O
.	O

found	O
that	O
early	O
pregnancy	O
25OHD	O
concentrations	O
<	O
75	O
nmol	O
/	O
L	O
were	O
associated	O
with	O
higher	O
risk	O
of	O
both	O
medically	O
indicated	O
and	O
spontaneous	O
preterm	O
delivery	O
[	O
11	O
].	O

Lower	O
vitamin	O
D	O
status	O
has	O
also	O
been	O
associated	O
with	O
a	O
medical	O
history	O
of	O
recurrent	O
miscarriage	O
[	O
12	O
]	O
but	O
only	O
two	O
prospective	O
studies	O
have	O
investigated	O
this	O
,	O
without	O
finding	O
that	O
lower	O
25OHD	O
concentrations	O
increases	O
the	O
risk	O
of	O
pregnancy	O
loss	O
[	O
5	O
,	O
13	O
].	O

Both	O
these	O
prospective	O
studies	O
had	O
relatively	O
few	O
cases	O
of	O
pregnancy	O
loss	O
and	O
may	O
therefore	B
have	O
been	O
insufficiently	O
powered	O
to	O
study	O
this	O
association	O
.	O

Thus	B
,	O
the	O
association	O
between	O
vitamin	O
D	O
status	O
and	O
risk	O
of	O
miscarriage	O
needs	O
further	O
investigation	O
.	O

To	B
our	I
knowledge	I
,	O
no	O
previous	O
study	O
has	O
related	O
25OHD	O
concentration	O
in	O
both	O
early	O
and	O
late	O
pregnancy	O
to	O
neonatal	O
outcomes	O
related	O
to	O
placental	O
dysfunction	O
.	O

Therefore	B
,	O
it	O
has	O
not	O
been	O
possible	O
to	O
ascertain	O
whether	O
the	O
associations	O
at	O
implantation	O
in	O
early	O
pregnancy	O
differ	O
from	O
those	O
during	O
the	O
fetal	O
growth	O
spurt	O
in	O
late	O
pregnancy	O
.	O

Our	O
objectives	O
were	O
to	O
study	O
the	O
associations	O
between	O
vitamin	O
D	O
status	O
in	O
both	O
early	O
and	O
late	O
pregnancy	O
,	O
as	O
well	O
as	O
change	O
in	O
vitamin	O
D	O
status	O
during	O
pregnancy	O
with	O
neonatal	O
SGA	O
,	O
LBW	O
and	O
preterm	O
delivery	O
.	O

Associations	O
between	O
vitamin	O
D	O
status	O
in	O
early	O
pregnancy	O
and	O
pregnancy	O
loss	O
were	O
also	O
studied	O
.	O

Methods	O
The	O
GraviD	O
study	O
is	O
a	O
prospective	O
cohort	O
study	O
,	O
conducted	O
in	O
parts	O
of	O
the	O
Västra	O
Götaland	O
region	O
in	O
the	O
southwest	O
of	O
Sweden	O
,	O
at	O
latitude	O
57	O
–	O
58	O
°	O
N	O
[	O
3	O
].	O

Pregnant	O
women	O
were	O
recruited	O
from	O
gestational	O
week	O
4	O
during	O
fall	O
2013	O
and	O
spring	O
2014	O
,	O
when	O
registering	O
at	O
one	O
of	O
the	O
participating	O
antenatal	O
care	O
units	O
.	O

The	O
only	O
exclusion	O
criterion	O
was	O
pregnancy	O
exceeding	O
16	O
gestational	O
weeks	O
at	O
inclusion	O
.	O

Gestational	O
age	O
at	O
delivery	O
and	O
data	O
collection	O
was	O
determined	O
by	O
routine	O
ultrasound	O
in	O
the	O
second	O
trimester	O
,	O
but	O
gestational	O
age	O
at	O
inclusion	O
was	O
based	O
on	O
the	O
date	O
of	O
the	O
last	O
menstrual	O
period	O
.	O

Women	O
who	O
terminated	O
the	O
pregnancy	O
(	O
N	O
=	O
31	O
),	O
were	O
lost	O
to	O
follow	O
-	O
up	O
(	O
N	O
=	O
13	O
)	O
or	O
carried	O
more	O
than	O
one	O
foetus	O
(	O
N	O
=	O
26	O
)	O
were	O
excluded	O
from	O
the	O
present	O
analyses	O
.	O

Pregnancy	O
termination	O
was	O
mostly	O
due	O
to	O
fetal	O
malformations	O
.	O

Women	O
who	O
were	O
lost	O
to	O
follow	O
-	O
up	O
had	O
moved	O
and	O
their	O
medical	O
records	O
could	O
not	O
be	O
retrieved	O
.	O

This	O
study	O
was	O
conducted	O
according	O
to	O
the	O
Declaration	O
of	O
Helsinki	O
and	O
all	O
procedures	O
were	O
approved	O
by	O
the	O
Regional	O
Ethics	O
Committee	O
in	O
Gothenburg	O
,	O
Sweden	O
.	O

Written	O
informed	O
consent	O
was	O
obtained	O
from	O
all	O
participants	O
.	O

Outcomes	O
SGA	O
was	O
defined	O
as	O
either	O
weight	O
or	O
length	O
at	O
birth	O
below	O
2	O
SD	O
of	O
the	O
gender	O
-	O
specific	O
population	O
mean	O
[	O
14	O
].	O

LBW	O
was	O
defined	O
as	O
weight	O
at	O
birth	O
<	O
2500	O
g	O
.	O
Preterm	O
delivery	O
was	O
defined	O
as	O
delivery	O
before	O
gestational	O
week	O
+	O
days	O
37	O
+	O
0	O
,	O
including	O
both	O
induced	O
and	O
spontaneous	O
preterm	O
delivery	O
.	O

Pregnancy	O
loss	O
was	O
defined	O
as	O
both	O
spontaneous	O
abortions	O
from	O
gestational	O
week	O
4	O
and	O
intrauterine	O
fetal	O
death	O
(	O
IUFD	O
).	O

Late	O
pregnancy	O
loss	O
was	O
defined	O
as	O
spontaneous	O
abortion	O
at	O
gestational	O
week	O
≥	O
14	O
+	O
0	O
,	O
including	O
IUFD	O
.	O

IUFD	O
was	O
defined	O
as	O
pregnancy	O
loss	O
at	O
gestational	O
week	O
≥	O
22	O
+	O
0	O
.	O

Pregnancy	O
loss	O
before	O
gestational	O
week	O
22	O
was	O
based	O
on	O
self	O
-	O
report	O
data	O
and	O
medical	O
records	O
to	O
verify	O
miscarriage	O
were	O
not	O
available	O
.	O

Information	O
on	O
IUFD	O
was	O
collected	O
from	O
medical	O
records	O
from	O
the	O
obstetrics	O
care	O
.	O

Exposure	O
Maternal	O
blood	O
samples	O
were	O
collected	O
from	O
each	O
participant	O
at	O
two	O
time	O
points	O
;	O
before	O
gestational	O
week	O
16	O
(	O
predominantly	O
week	O
8	O
–	O
12	O
,	O
first	O
trimester	O
,	O
T1	O
)	O
and	O
after	O
gestational	O
week	O
31	O
(	O
predominantly	O
week	O
32	O
–	O
35	O
,	O
third	O
trimester	O
,	O
T3	O
).	O

Non	O
-	O
fasting	O
venous	O
blood	O
samples	O
were	O
drawn	O
in	O
gel	O
serum	O
separating	O
tubes	O
and	O
centrifuged	O
for	O
10	O
min	O
within	O
2	O
h	O
of	O
sampling	O
.	O

Serum	O
was	O
stored	O
at	O
−	O
70	O
°	O
C	O
until	O
analysis	O
of	O
25OHD	O
.	O

Analyses	O
were	O
performed	O
by	O
liquid	O
chromatography	O
tandem	O
mass	O
spectrometry	O
(	O
LC	O
-	O
MS	O
/	O
MS	O
,	O
Mass	O
spectrometer	O
API	O
4000	O
)	O
by	O
the	O
clinical	O
chemistry	O
laboratory	O
in	O
Region	O
Skåne	O
,	O
Sweden	O
,	O
certified	O
by	O
the	O
Vitamin	O
D	O
External	O
Quality	O
Assessment	O
Scheme	O
[	O
15	O
].	O

The	O
LC	O
-	O
MS	O
/	O
MS	O
method	O
has	O
a	O
measuring	O
range	O
of	O
6	O
–	O
450	O
nmol	O
/	O
L	O
for	O
25OHD3and	O
of	O
6	O
–	O
225	O
nmol	O
/	O
L	O
for	O
25OHD2	O
.	O

The	O
inter	O
-	O
assay	O
coefficient	O
of	O
variation	O
is	O
6	O
%	O
at	O
40	O
nmol	O
/	O
L	O
for	O
both	O
25OHD3and	O
25OHD2	O
.	O

Sampling	O
and	O
laboratory	O
analyses	O
have	O
been	O
described	O
previously	O
[	O
3	O
].	O

Maternal	O
serum	O
T1	O
and	O
T3	O
samples	O
were	O
analysed	O
in	O
sequence	O
.	O

At	O
T1	O
and	O
T3	O
,	O
participants	O
answered	O
questionnaires	O
regarding	O
lifestyle	O
factors	O
and	O
background	O
data	O
.	O

Neonatal	O
and	O
gestational	O
data	O
were	O
obtained	O
from	O
antenatal	O
and	O
obstetrics	O
medical	O
records	O
.	O

Information	O
on	O
BMI	O
at	O
T1	O
and	O
season	O
of	O
conception	O
(	O
December	O
–	O
May	O
or	O
June	O
–	O
November	O
)	O
was	O
obtained	O
from	O
the	O
medical	O
records	O
.	O

Season	O
was	O
coded	O
as	O
a	O
binary	O
variable	O
,	O
since	O
this	O
explained	B
30	O
%	O
of	O
vitamin	O
D	O
status	O
in	O
a	O
previous	O
study	O
in	O
pregnant	O
women	O
at	O
the	O
same	O
latitude	O
[	O
16	O
].	O

Data	O
on	O
education	O
level	O
(≤	O
primary	O
level	O
,	O
secondary	O
level	O
or	O
university	O
level	O
)	O
and	O
origin	O
(	O
continent	O
of	O
birth	O
:	O
Northern	O
Europe	O
,	O
Continental	O
Europe	O
,	O
America	O
,	O
Asia	O
,	O
Africa	O
)	O
were	O
collected	O
from	O
study	O
questionnaires	O
.	O

Statistical	O
analysis	O
Concentrations	O
of	O
25OHD	O
at	O
T1	O
and	O
T3	O
were	O
used	O
as	O
categorical	O
variables	O
,	O
grouped	O
into	O
25OHD	O
<	O
30	O
(	O
used	O
as	O
reference	O
category	O
),	O
30	O
–	O
49	O
.	O
9	O
,	O
50	O
–	O
74	O
.	O
9	O
,	O
75	O
–	O
99	O
.	O
9	O
and	O
≥	O
100	O
nmol	O
/	O
L	O
.	O

These	O
groups	O
were	O
chosen	O
to	O
study	O
whether	O
vitamin	O
D	O
insufficiency	O
(	O
30	O
–	O
50	O
nmol	O
/	O
L	O
),	O
sufficiency	O
(≥	O
50	O
nmol	O
/	O
L	O
)	O
or	O
high	O
status	O
(≥	O
75	O
or	O
≥	O
100	O
nmol	O
/	O
L	O
)	O
was	O
associated	O
with	O
the	O
outcomes	O
studied	O
,	O
compared	O
to	O
vitamin	O
D	O
deficiency	O
(<	O
30	O
nmol	O
/	O
L	O
).	O

Quartiles	O
were	O
not	O
used	O
because	O
the	O
distribution	O
of	O
25OHD	O
was	O
different	O
at	O
T1	O
and	O
T3	O
.	O

T1	O
25OHD	O
was	O
also	O
investigated	O
as	O
a	O
continuous	O
variable	O
as	O
there	O
were	O
few	O
cases	O
in	O
some	O
categories	O
.	O

Change	O
in	O
25OHD	O
was	O
calculated	O
as	O
the	O
difference	O
between	O
T3	O
and	O
T1	O
(	O
T3	O
-	O
T1	O
)	O
and	O
was	O
coded	O
into	O
3	O
groups	O
:	O
decrease	O
in	O
25OHD	O
(≤	O
0	O
nmol	O
/	O
L	O
),	O
small	O
increase	O
(	O
0	O
.	O
1	O
–	O
29	O
.	O
99	O
nmol	O
/	O
L	O
)	O
or	O
large	O
increase	O
(≥	O
30	O
nmol	O
/	O
L	O
).	O

Multivariable	O
logistic	O
regression	O
analyses	O
of	O
the	O
outcome	O
variables	O
SGA	O
,	O
LBW	O
and	O
preterm	O
delivery	O
were	O
performed	O
with	O
25OHD	O
at	O
T1	O
,	O
T3	O
and	O
change	O
in	O
25OHD	O
during	O
pregnancy	O
as	O
the	O
independent	O
variables	O
.	O

For	O
SGA	O
,	O
appropriate	O
for	O
gestational	O
age	O
and	O
large	O
for	O
gestational	O
age	O
were	O
combined	O
as	O
reference	O
.	O

Potential	O
confounders	O
for	O
the	O
associations	O
studied	O
were	O
identified	O
using	O
directed	O
acyclic	O
graphs	O
(	O
www	O
.	O
dagitty	O
.	O
net	O
)	O
[	O
17	O
].	O

Variables	O
BMI	O
,	O
season	O
of	O
conception	O
,	O
education	O
level	O
and	O
origin	O
were	O
identified	O
and	O
included	O
in	O
the	O
final	O
models	O
.	O

Tobacco	O
use	O
and	O
vitamin	O
D	O
supplement	O
use	O
were	O
also	O
investigated	O
as	O
potential	O
confounders	O
but	O
did	O
not	O
show	O
any	O
confounding	O
effect	O
and	O
were	O
thus	B
not	O
included	O
in	O
the	O
final	O
models	O
.	O

In	O
the	O
multivariable	O
analysis	O
with	O
change	O
in	O
25OHD	O
as	O
the	O
independent	O
variable	O
,	O
T1	O
25OHD	O
was	O
also	O
included	O
as	O
a	O
confounder	O
.	O

Correlation	O
between	O
continuous	O
T1	O
25OHD	O
and	O
continuous	O
change	O
in	O
25OHD	O
was	O
low	O
(	O
r	O
=	O
−	O
0	O
.	O
22	O
,	O
p	O
<	O
0	O
.	O
001	O
)	O
and	O
it	O
was	O
therefore	O
considered	O
acceptable	O
to	O
include	O
both	O
variables	O
in	O
the	O
same	O
model	O
.	O

Multivariable	O
logistic	O
regression	O
analysis	O
of	O
the	O
outcome	O
pregnancy	O
loss	O
was	O
also	O
performed	O
with	O
25OHD	O
at	O
T1	O
(	O
continuous	O
and	O
categorical	O
)	O
as	O
independent	O
variable	O
.	O

These	O
models	O
were	O
adjusted	O
for	O
BMI	O
,	O
season	O
of	O
conception	O
,	O
education	O
level	O
,	O
origin	O
and	O
gestational	O
age	O
at	O
registration	O
to	O
antenatal	O
care	O
(	O
based	O
on	O
last	O
menstrual	O
period	O
).	O

Unadjusted	O
logistic	O
regression	O
analysis	O
was	O
used	O
to	O
assess	O
the	O
association	O
between	O
T1	O
25OHD	O
(<	O
30	O
nmol	O
/	O
L	O
;	O
no	O
/	O
yes	O
)	O
and	O
IUFD	O
.	O

Here	O
,	O
no	O
confounders	O
were	O
included	O
due	O
to	O
the	O
small	O
number	O
of	O
cases	O
(	O
N	O
=	O
9	O
).	O

Significance	O
was	O
accepted	O
at	O
p	O
<	O
0	O
.	O
05	O
.	O

Computer	O
software	O
IBM	O
SPSS	O
Statistics	O
version	O
22	O
.	O
0	O
was	O
used	O
for	O
all	O
statistical	O
analyses	O
.	O

Results	O
In	O
total	O
,	O
2052	O
women	O
were	O
included	O
in	O
this	O
study	O
,	O
2046	O
with	O
a	O
blood	O
sample	O
at	O
T1	O
and	O
1816	O
at	O
T3	O
(	O
Fig	O
.	O
1	O
).	O

In	O
total	O
,	O
1810	O
women	O
had	O
samples	O
collected	O
both	O
in	O
T1	O
and	O
T3	O
.	O

Characteristics	O
of	O
the	O
women	O
and	O
the	O
live	O
born	O
infants	O
are	O
shown	O
in	O
Table	O
1	O
.	O

Mean	O
infant	O
birth	O
weight	O
was	O
3542	O
(	O
538	O
)	O
grams	O
and	O
mean	O
gestational	O
age	O
at	O
delivery	O
was	O
280	O
(	O
12	O
.	O
4	O
)	O
days	O
.	O

Mean	O
(	O
SD	O
)	O
maternal	O
25OHD	O
at	O
T1	O
was	O
64	O
(	O
24	O
.	O
4	O
)	O
nmol	O
/	O
L	O
and	O
75	O
(	O
34	O
.	O
4	O
)	O
nmol	O
/	O
L	O
at	O
T3	O
.	O

At	O
T1	O
,	O
10	O
%	O
had	O
25OHD	O
concentrations	O
<	O
30	O
nmol	O
/	O
L	O
and	O
9	O
%	O
at	O
T3	O
(	O
Table	O
2	O
).	O

Caption	O
(	O
FIG	O
):	O
FIG	O
.	O

1	O
Flow	O
chart	O
of	O
the	O
study	O
inclusion	O
Caption	O
(	O
TABLE	O
-	O
WRAP	O
):	O
TABLE	O
1	O
Characteristics	O
of	O
the	O
pregnant	O
women	O
and	O
their	O
infants	O
at	O
birthMeanSDBirth	O
weight	O
(	O
grams	O
)	O
a3542537	O
.	O
7Birth	O
length	O
(	O
cm	O
)	O
a502	O
.	O
3Gestational	O
age	O
at	O
delivery	O
(	O
days	O
)	O
28012	O
.	O
4Gestational	O
age	O
T1	O
(	O
days	O
)	O
7613	O
.	O
8Gestational	O
age	O
T3	O
(	O
days	O
)	O
23412	O
.	O
9Maternal	O
s	O
-	O
25OHD	O
T1	O
(	O
nmol	O
/	O
L	O
)	O
6424	O
.	O
4Maternal	O
s	O
-	O
25OHD	O
T3	O
(	O
nmol	O
/	O
L	O
)	O
7534	O
.	O
4N	O
(%)	O
Male	O
gender	O
of	O
infanta976	O
(	O
49	O
.	O
8	O
)	O
Small	O
for	O
gestational	O
age	O
(	O
weight	O
or	O
length	O
)	O
93	O
(	O
4	O
.	O
5	O
)	O
Low	O
birth	O
weight	O
(<	O
2500	O
g	O
)	O
58	O
(	O
2	O
.	O
8	O
)	O
Preterm	O
delivery	O
(<	O
37	O
weeks	O
)	O
78	O
(	O
3	O
.	O
8	O
)	O
Spontaneous	O
preterm	O
delivery	O
(<	O
37	O
weeks	O
)	O
55	O
(	O
2	O
.	O
7	O
)	O
Pregnancy	O
loss97	O
(	O
4	O
.	O
7	O
)	O
Intrauterine	O
fetal	O
death	O
(≥	O
22	O
weeks	O
)	O
9	O
(	O
0	O
.	O
5	O
)	O
T1	O
first	O
trimester	O
,	O
T3	O
third	O
trimester	O
,	O
25OHD	O
25	O
-	O
hydroxyvitamin	O
D	O
aLive	O
born	O
infants	O
only	O
Caption	O
(	O
TABLE	O
-	O
WRAP	O
):	O
TABLE	O
2	O
The	O
pregnant	O
women	O
’	O
s	O
vitamin	O
D	O
status	O
in	O
the	O
first	O
(	O
T1	O
)	O
and	O
third	O
(	O
T3	O
)	O
trimester	O
of	O
pregnancy	O
,	O
and	O
their	O
characteristics	O
(	O
mean	O
or	O
percent	O
)	O
grouped	O
by	O
25OHD	O
concentration	O
in	O
(	O
T1	O
)	O
T1	O
25OHD	O
(	O
nmol	O
/	O
L	O
)<	O
3030	O
–	O
49	O
.	O
950	O
–	O
74	O
.	O
975	O
–	O
99	O
.	O
9	O
≥	O
100N198291788565125	O
%	O
10	O
.	O
114	O
.	O
840	O
.	O
128	O
.	O
76	O
.	O
4BMI	O
T1	O
(	O
kg	O
/	O
m2	O
)	O
25	O
.	O
124	O
.	O
924	O
.	O
423	O
.	O
924	O
.	O
4Age	O
T1	O
(	O
years	O
)	O
29	O
.	O
430	O
.	O
931	O
.	O
632	O
.	O
032	O
.	O
4Born	O
in	O
Sweden	O
(%)	O
14	O
.	O
154	O
.	O
683	O
.	O
387	O
.	O
893	O
.	O
5Tobacco	O
use	O
T1	O
(%)	O
6	O
.	O
84	O
.	O
64	O
.	O
04	O
.	O
61	O
.	O
6Nulliparous	O
T1	O
(%)	O
34	O
.	O
842	O
.	O
042	O
.	O
643	O
.	O
142	O
.	O
7Vitamin	O
D	O
supplement	O
use	O
T1	O
(%)	O
10	O
.	O
628	O
.	O
245	O
.	O
256	O
.	O
662	O
.	O
9University	O
level	O
education	O
(%)	O
32	O
.	O
354	O
.	O
961	O
.	O
367	O
.	O
366	O
.	O
1Small	O
for	O
gestational	O
age	O
(%)	O
5	O
.	O
74	O
.	O
25	O
.	O
34	O
.	O
14	O
.	O
0Preterm	O
delivery	O
(%)	O
4	O
.	O
15	O
.	O
23	O
.	O
83	O
.	O
91	O
.	O
6Low	O
birth	O
weight	O
(%)	O
3	O
.	O
04	O
.	O
53	O
.	O
12	O
.	O
11	O
.	O
6Pregnancy	O
loss	O
(%)	O
6	O
.	O
35	O
.	O
64	O
.	O
55	O
.	O
10T3	O
25OHD	O
(	O
nmol	O
/	O
L	O
)<	O
3030	O
–	O
49	O
.	O
950	O
–	O
74	O
.	O
975	O
–	O
99	O
.	O
9	O
≥	O
100N163330473409443	O
%	O
9	O
.	O
018	O
.	O
226	O
.	O
022	O
.	O
524	O
.	O
4Small	O
for	O
gestational	O
age	O
(%)	O
7	O
.	O
55	O
.	O
54	O
.	O
74	O
.	O
62	O
.	O
3Preterm	O
delivery	O
(%)	O
4	O
.	O
31	O
.	O
23	O
.	O
62	O
.	O
21	O
.	O
6Low	O
birth	O
weight	O
(%)	O
4	O
.	O
30	O
.	O
32	O
.	O
71	O
.	O
21	O
.	O
4	O
T1	O
first	O
trimester	O
,	O
T3	O
third	O
trimester	O
,	O
25OHD	O
25	O
-	O
hydroxyvitamin	O
D	O
Birth	O
size	O
and	O
preterm	O
delivery	O
In	O
total	O
,	O
93	O
(	O
4	O
.	O
5	O
%)	O
infants	O
were	O
born	O
SGA	O
.	O

Of	O
the	O
SGA	O
deliveries	O
,	O
37	O
were	O
SGA	O
by	O
weight	O
and	O
56	O
by	O
length	O
.	O

Also	O
,	O
58	O
(	O
2	O
.	O
8	O
%)	O
infants	O
had	O
LBW	O
,	O
while	O
78	O
(	O
3	O
.	O
8	O
%)	O
infants	O
were	O
delivered	O
preterm	O
(	O
Table1	O
).	O

Of	O
those	O
who	O
delivered	O
preterm	O
,	O
10	O
delivered	O
before	O
gestational	O
week	O
31	O
and	O
thus	O
before	O
the	O
T3	O
blood	O
sample	O
could	O
be	O
drawn	O
.	O

Among	O
these	O
women	O
,	O
one	O
(	O
10	O
%)	O
had	O
25OHD	O
concentration	O
<	O
30	O
nmol	O
/	O
L	O
in	O
T1	O
.	O

There	O
were	O
no	O
associations	O
between	O
the	O
predictor	O
T1	O
25OHD	O
and	O
the	O
outcomes	O
SGA	O
,	O
LBW	O
and	O
preterm	O
delivery	O
(	O
Table	O
3	O
).	O

Women	O
with	O
T3	O
25OHD	O
≥	O
100	O
nmol	O
/	O
L	O
had	O
a	O
lower	O
OR	O
for	O
SGA	O
(	O
OR	O
=	O
0	O
.	O
32	O
,	O
p	O
=	O
0	O
.	O
031	O
)	O
compared	O
to	O
those	O
with	O
vitamin	O
D	O
deficiency	O
(<	O
30	O
nmol	O
/	O
L	O
).	O

Women	O
with	O
T3	O
25OHD	O
concentrations	O
≥	O
100	O
nmol	O
/	O
L	O
and	O
30	O
–	O
50	O
nmol	O
/	O
L	O
had	O
lower	O
OR	O
for	O
LBW	O
(	O
OR	O
=	O
0	O
.	O
22	O
,	O
p	O
=	O
0	O
.	O
046	O
and	O
OR	O
=	O
0	O
.	O
07	O
,	O
p	O
=	O
0	O
.	O
017	O
,	O
respectively	O
),	O
compared	O
to	O
vitamin	O
D	O
deficiency	O
.	O

However	O
,	O
T3	O
25OHD	O
was	O
not	O
significantly	O
associated	O
with	O
preterm	O
delivery	O
.	O

The	O
results	O
were	O
not	O
meaningfully	O
affected	O
by	O
additional	O
adjustment	O
for	O
tobacco	O
use	O
or	O
vitamin	O
D	O
supplementation	O
or	O
by	O
excluding	O
cases	O
of	O
preeclampsia	O
(	O
data	O
not	O
shown	O
).	O

Caption	O
(	O
TABLE	O
-	O
WRAP	O
):	O
TABLE	O
3	O
Association	O
between	O
vitamin	O
D	O
status	O
in	O
pregnancy	O
with	O
birth	O
size	O
and	O
pregnancy	O
loss	O
(	O
adjusted	O
logistic	O
regression	O
analysis	O
)	O
Small	O
for	O
gestational	O
ageaPreterm	O
delivery	O
(<	O
37	O
weeks	O
)	O
bLow	O
birth	O
weight	O
(<	O
2500	O
g	O
)	O
cPregnancy	O
lossdORCI	O
95	O
%	O
ORCI	O
95	O
%	O
ORCI	O
95	O
%	O
ORCI	O
95	O
%	O
T1	O
25OHDe	O
Continuous	O
nmol	O
/	O
L1	O
.	O
0030	O
.	O
99	O
–	O
1	O
.	O
010	O
.	O
9960	O
.	O
99	O
–	O
1	O
.	O
010	O
.	O
9990	O
.	O
99	O
–	O
1	O
.	O
010	O
.	O
989	O
*	O
0	O
.	O
98	O
–	O
1	O
.	O
00	O
<	O
30	O
(	O
ref	O
)	O
1	O
.	O
01	O
.	O
01	O
.	O
01	O
.	O
0	O
30	O
–	O
49	O
.	O
91	O
.	O
0780	O
.	O
44	O
–	O
2	O
.	O
661	O
.	O
6470	O
.	O
63	O
–	O
4	O
.	O
332	O
.	O
5490	O
.	O
88	O
–	O
7	O
.	O
381	O
.	O
0300	O
.	O
44	O
–	O
2	O
.	O
41	O
50	O
–	O
74	O
.	O
91	O
.	O
6320	O
.	O
69	O
–	O
3	O
.	O
851	O
.	O
2600	O
.	O
47	O
–	O
3	O
.	O
362	O
.	O
2870	O
.	O
77	O
–	O
6	O
.	O
830	O
.	O
6880	O
.	O
29	O
–	O
1	O
.	O
62	O
75	O
–	O
99	O
-	O
91	O
.	O
2920	O
.	O
51	O
–	O
3	O
.	O
271	O
.	O
3320	O
.	O
48	O
–	O
3	O
.	O
731	O
.	O
6650	O
.	O
51	O
–	O
5	O
.	O
490	O
.	O
8090	O
.	O
33	O
–	O
1	O
.	O
96	O
≥	O
1001	O
.	O
2940	O
.	O
38	O
–	O
4	O
.	O
420	O
.	O
5020	O
.	O
09	O
–	O
2	O
.	O
721	O
.	O
2550	O
.	O
22	O
–	O
7	O
.	O
270	O
.	O
000fT3	O
25OHDe	O
<	O
30	O
(	O
ref	O
)	O
1	O
.	O
01	O
.	O
01	O
.	O
0	O
30	O
–	O
49	O
.	O
90	O
.	O
7710	O
.	O
34	O
–	O
1	O
.	O
750	O
.	O
3020	O
.	O
08	O
–	O
1	O
.	O
140	O
.	O
071	O
*	O
0	O
.	O
01	O
–	O
0	O
.	O
63	O
50	O
–	O
74	O
.	O
90	O
.	O
6230	O
.	O
27	O
–	O
1	O
.	O
450	O
.	O
9330	O
.	O
31	O
–	O
2	O
.	O
790	O
.	O
5840	O
.	O
17	O
–	O
1	O
.	O
98	O
75	O
–	O
99	O
-	O
90	O
.	O
6570	O
.	O
27	O
–	O
1	O
.	O
610	O
.	O
6140	O
.	O
18	O
–	O
2	O
.	O
140	O
.	O
2370	O
.	O
06	O
–	O
1	O
.	O
01	O
≥	O
1000	O
.	O
318	O
*	O
0	O
.	O
11	O
–	O
0	O
.	O
900	O
.	O
4460	O
.	O
11	O
–	O
1	O
.	O
760	O
.	O
215	O
*	O
0	O
.	O
05	O
–	O
0	O
.	O
97Δ25OHDg	O
Large	O
increase	O
(≥	O
30	O
nmol	O
/	O
L	O
)	O
(	O
ref	O
)	O
1	O
.	O
01	O
.	O
01	O
.	O
0	O
Small	O
increase	O
(	O
0	O
–	O
30	O
nmol	O
/	O
L	O
)	O
2	O
.	O
564	O
*	O
1	O
.	O
16	O
–	O
5	O
.	O
672	O
.	O
905	O
*	O
1	O
.	O
01	O
–	O
8	O
.	O
343	O
.	O
1220	O
.	O
97	O
–	O
10	O
.	O
09	O
Decrease	O
(<	O
0	O
nmol	O
/	O
L	O
)	O
3	O
.	O
679	O
**	O
1	O
.	O
60	O
–	O
8	O
.	O
442	O
.	O
8940	O
.	O
95	O
–	O
8	O
.	O
854	O
.	O
722	O
*	O
1	O
.	O
37	O
–	O
16	O
.	O
28	O
T1	O
first	O
trimester	O
,	O
T3	O
third	O
trimester	O
,	O
25OHD	O
25	O
-	O
hydroxyvitamin	O
D	O
*	O
p	O
<	O
0	O
.	O
05	O
**	O
p	O
<	O
0	O
.	O
01	O
aModels	O
include	O
92	O
(	O
T1	O
)	O
and	O
80	O
(	O
T3	O
and	O
Δ25OHD	O
)	O
cases	O
of	O
small	O
for	O
gestational	O
age	O
bModels	O
include	O
77	O
(	O
T1	O
)	O
and	O
43	O
(	O
T3	O
and	O
Δ25OHD	O
)	O
cases	O
of	O
preterm	O
delivery	O
cModels	O
include	O
57	O
(	O
T1	O
)	O
and	O
31	O
(	O
T3	O
and	O
Δ25OHD	O
)	O
cases	O
of	O
low	O
birth	O
weight	O
dModels	O
include	O
96	O
cases	O
of	O
pregnancy	O
loss	O
eAdjusted	O
for	O
education	O
,	O
origin	O
,	O
season	O
of	O
conception	O
and	O
BMI	O
at	O
T1	O
.	O

Pregnancy	O
loss	O
models	O
are	O
also	O
adjusted	O
for	O
gestational	O
age	O
at	O
registration	O
for	O
antenatal	O
care	O
fNo	O
case	O
of	O
pregnancy	O
loss	O
in	O
category	O
gAdjusted	O
for	O
education	O
,	O
origin	O
,	O
season	O
of	O
conception	O
,	O
BMI	O
at	O
T1	O
and	O
25OHD	O
at	O
T1	O
Vitamin	O
D	O
status	O
trajectory	O
between	O
T1	O
and	O
T3	O
was	O
inversely	O
related	O
to	O
SGA	O
,	O
preterm	O
and	O
LBW	O
(	O
Table3	O
).	O

Compared	O
to	O
women	O
with	O
a	O
large	O
increase	O
in	O
25OHD	O
(≥	O
30	O
nmol	O
/	O
L	O
),	O
women	O
with	O
a	O
decrease	O
in	O
25OHD	O
had	O
significantly	O
higher	O
OR	O
of	O
having	O
a	O
child	O
born	O
SGA	O
(	O
OR	O
=	O
3	O
.	O
7	O
,	O
p	O
=	O
0	O
.	O
002	O
),	O
with	O
LBW	O
(	O
OR	O
=	O
4	O
.	O
7	O
,	O
p	O
=	O
0	O
.	O
014	O
)	O
as	O
well	O
as	O
a	O
trend	O
toward	O
higher	O
odds	O
of	O
preterm	O
delivery	O
(	O
OR	O
=	O
2	O
.	O
9	O
,	O
p	O
=	O
0	O
.	O
061	O
).	O

Women	O
with	O
a	O
small	O
increase	O
in	O
25OHD	O
(	O
0	O
–	O
30	O
nmol	O
/	O
L	O
)	O
had	O
significantly	O
higher	O
OR	O
of	O
SGA	O
(	O
OR	O
=	O
2	O
.	O
6	O
,	O
p	O
=	O
0	O
.	O
019	O
)	O
and	O
preterm	O
delivery	O
(	O
OR	O
=	O
2	O
.	O
9	O
,	O
p	O
=	O
0	O
.	O
047	O
)	O
as	O
well	O
as	O
a	O
trend	O
toward	O
significance	O
for	O
LBW	O
(	O
OR	O
=	O
3	O
.	O
1	O
,	O
p	O
=	O
0	O
.	O
056	O
),	O
compared	O
to	O
women	O
with	O
a	O
large	O
increase	O
.	O

Neither	O
of	O
these	O
results	O
changed	O
after	O
adjustment	O
for	O
tobacco	O
use	O
and	O
vitamin	O
D	O
supplementation	O
at	O
T3	O
or	O
after	O
excluding	O
cases	O
of	O
preeclampsia	O
.	O

Pregnancy	O
loss	O
The	O
total	O
rate	O
of	O
pregnancy	O
loss	O
was	O
4	O
.	O
7	O
%	O
and	O
the	O
rate	O
of	O
late	O
pregnancy	O
loss	O
(	O
gestational	O
week	O
≥	O
14	O
+	O
0	O
)	O
was	O
1	O
.	O
5	O
%	O
(	O
Table1	O
).	O

There	O
were	O
nine	O
cases	O
of	O
IUFD	O
at	O
gestational	O
week	O
≥	O
22	O
+	O
0	O
.	O

Overall	O
,	O
lower	O
T1	O
25OHD	O
(	O
as	O
a	O
continuous	O
but	O
not	O
categorical	O
variable	O
)	O
was	O
associated	O
with	O
pregnancy	O
loss	O
(	O
Table3	O
).	O

In	O
unadjusted	O
analysis	O
,	O
T1	O
25OHD	O
was	O
associated	O
with	O
IUFD	O
and	O
women	O
with	O
25OHD	O
<	O
30	O
nmol	O
/	O
L	O
at	O
T1	O
had	O
more	O
than	O
fourfold	O
higher	O
odds	O
of	O
IUFD	O
(	O
OR	O
=	O
4	O
.	O
52	O
,	O
p	O
=	O
0	O
.	O
034	O
).	O

Discussion	O
We	O
found	O
that	O
higher	O
vitamin	O
D	O
status	O
among	O
women	O
in	O
late	O
,	O
but	O
not	O
early	O
,	O
pregnancy	O
was	O
associated	O
with	O
lower	O
probability	O
of	O
SGA	O
and	O
LBW	O
.	O

Vitamin	O
D	O
status	O
trajectory	O
during	O
pregnancy	O
was	O
inversely	O
associated	O
with	O
SGA	O
,	O
LBW	O
and	O
preterm	O
delivery	O
.	O

Women	O
with	O
an	O
increase	O
in	O
25OHD	O
≥	O
30	O
nmol	O
/	O
L	O
from	O
T1	O
to	O
T3	O
had	O
the	O
lowest	O
odds	O
of	O
SGA	O
,	O
LBW	O
and	O
preterm	O
delivery	O
.	O

We	O
also	O
found	O
that	O
lower	O
vitamin	O
D	O
status	O
in	O
early	O
pregnancy	O
was	O
related	O
to	O
pregnancy	O
loss	O
.	O

Previous	O
findings	O
from	O
the	O
GraviD	O
study	O
show	O
lower	O
odds	O
of	O
preeclampsia	O
among	O
women	O
with	O
a	O
large	O
increase	O
(≥	O
30	O
nmol	O
/	O
L	O
)	O
in	O
25OHD	O
[	O
3	O
].	O

As	B
SGA	O
,	O
LBW	O
and	O
preterm	O
delivery	O
are	O
related	O
to	O
preeclampsia	O
;	O
these	O
results	O
are	O
consistent	O
with	O
the	O
current	O
findings	O
.	O

However	O
,	O
excluding	O
preeclampsia	O
cases	O
from	O
the	O
analysis	O
did	O
not	O
change	O
the	O
results	O
.	O

Thus	B
,	O
preeclampsia	O
does	O
not	O
seem	O
to	O
mediate	O
the	O
associations	O
between	O
vitamin	O
D	O
status	O
trajectory	O
and	O
neonatal	O
birth	O
size	O
or	O
preterm	O
birth	O
.	O

We	O
have	O
previously	O
shown	O
that	O
the	O
determinants	O
of	O
season	O
-	O
corrected	O
change	O
in	O
25OHD	O
during	O
pregnancy	O
include	O
origin	O
,	O
sun	O
-	O
exposure	O
and	O
dietary	O
as	O
well	O
as	O
supplementary	O
vitamin	O
D	O
intake	O
[	O
18	O
].	O

Supplements	O
containing	O
vitamin	O
D	O
were	O
used	O
by	O
43	O
%	O
in	O
T1	O
and	O
39	O
%	O
in	O
T3	O
-	O
mainly	O
multivitamins	O
[	O
19	O
].	O

As	B
the	O
results	O
between	O
change	O
in	O
25OHD	O
and	O
neonatal	O
birth	O
size	O
and	O
preterm	O
delivery	O
remained	O
after	O
adjustment	O
for	O
season	O
of	O
conception	O
,	O
origin	O
and	O
vitamin	O
D	O
supplementation	O
,	O
vitamin	O
D	O
status	O
trajectory	O
can	O
be	O
suspected	B
to	O
play	O
a	O
role	O
in	O
healthy	O
pregnancy	O
.	O

Vitamin	O
D	O
has	O
been	O
shown	O
to	O
facilitate	O
the	O
transport	O
of	O
nutrients	O
across	O
the	O
placenta	O
[	O
20	O
,	O
21	O
],	O
which	O
could	O
contribute	O
to	O
fetal	O
growth	O
[	O
22	O
].	O

Vitamin	O
D	O
status	O
could	O
also	O
facilitate	O
fetal	O
development	O
by	O
regulating	O
placental	O
inflammation	O
[	O
23	O
].	O

It	O
is	O
also	O
possible	O
that	O
the	O
associations	O
between	O
fetal	O
growth	O
and	O
maternal	O
vitamin	O
D	O
status	O
are	O
due	O
to	O
residual	O
confounding	O
or	O
reverse	O
causation	O
.	O

Whether	O
vitamin	O
D	O
metabolism	O
is	O
altered	O
in	O
placental	O
dysfunction	O
in	O
unclear	O
and	O
warrants	O
further	O
investigation	O
.	O

Our	O
results	O
indicates	O
that	O
25OHD	O
at	O
T3	O
but	O
not	O
at	O
T1	O
is	O
associated	O
with	O
SGA	O
and	O
LBW	O
,	O
despite	O
better	O
statistical	O
power	O
at	O
T1	O
due	O
to	O
more	O
25OHD	O
samples	O
and	O
subsequently	O
more	O
cases	O
of	O
SGA	O
,	O
LBW	O
and	O
preterm	O
birth	O
.	O

This	O
finding	O
is	O
partly	O
consistent	O
with	O
previous	O
studies	O
where	O
25OHD	O
concentrations	O
of	O
25	O
–	O
30	O
nmol	O
/	O
L	O
were	O
associated	O
with	O
higher	O
probability	O
of	O
SGA	O
[	O
5	O
–	O
7	O
].	O

The	O
study	O
by	O
Burris	O
et	O
al	O
.	O

[	O
6	O
]	O
sampled	O
women	O
in	O
gestational	O
week	O
26	O
–	O
28	O
,	O
and	O
found	O
a	O
higher	O
OR	O
for	O
SGA	O
than	O
the	O
two	O
studies	O
that	O
sampled	O
women	O
in	O
T1	O
.	O

This	O
could	O
be	O
interpreted	B
as	I
support	O
of	O
our	O
finding	O
that	O
late	O
rather	O
than	O
early	O
pregnancy	O
vitamin	O
D	O
status	O
is	O
the	O
stronger	O
predictor	O
of	O
fetal	O
growth	O
restriction	O
.	O

Our	O
results	O
also	O
concur	O
with	O
findings	O
by	O
Morley	O
et	O
al	O
.	O

that	O
late	O
but	O
not	O
early	O
pregnancy	O
25OHD	O
was	O
related	O
to	O
gestational	O
length	O
and	O
neonatal	O
birth	O
size	O
[	O
8	O
].	O

Our	O
results	O
could	O
also	O
indicate	O
that	O
it	O
takes	O
time	O
for	O
changes	O
in	O
vitamin	O
D	O
metabolism	O
to	O
manifest	O
as	O
changes	O
in	O
circulating	O
25OHD	O
.	O

We	O
did	O
not	O
see	O
a	O
U	O
-	O
shaped	O
association	O
between	O
early	O
pregnancy	O
vitamin	O
D	O
status	O
and	O
SGA	O
,	O
as	O
previously	O
indicated	O
[	O
9	O
].	O

We	O
found	O
the	O
lowest	O
odds	O
of	O
SGA	O
among	O
women	O
with	O
the	O
highest	O
T3	O
25OHD	O
concentration	O
,	O
≥	O
100	O
nmol	O
/	O
L	O
.	O

A	O
total	O
of	O
25	O
%	O
of	O
the	O
women	O
had	O
25OHD	O
concentrations	O
≥	O
100	O
nmol	O
/	O
L	O
at	O
T3	O
.	O

Sampling	O
was	O
evenly	O
distributed	O
across	O
the	O
seasons	O
and	O
time	O
of	O
year	O
cannot	O
explain	O
the	O
high	O
proportion	O
with	O
high	O
25OHD	O
concentrations	O
.	O

Also	O
,	O
vitamin	O
D	O
supplements	O
were	O
used	O
by	O
almost	O
half	O
of	O
the	O
women	O
but	O
most	O
(	O
88	O
%)	O
used	O
multivitamins	O
containing	O
5	O
–	O
10	O
μg	O
of	O
vitamin	O
D3	O
.	O

Supplementation	O
can	O
therefore	B
only	O
partly	O
explain	B
the	O
large	O
proportion	O
with	O
high	O
vitamin	O
D	O
status	O
,	O
and	O
other	O
likely	B
contributors	O
are	O
pregnancy	O
associated	O
endocrine	O
changes	O
and	O
possibly	O
lifestyle	O
factors	O
.	O

To	B
our	I
knowledge	I
,	O
ours	O
is	O
one	O
of	O
the	O
first	O
studies	O
to	O
find	O
associations	O
between	O
vitamin	O
D	O
status	O
and	O
pregnancy	O
loss	O
.	O

The	O
25OHD	O
concentration	O
has	O
been	O
shown	O
to	O
have	O
immunological	O
effects	O
in	O
women	O
with	O
a	O
history	O
of	O
recurrent	O
pregnancy	O
loss	O
[	O
12	O
].	O

Two	O
previous	O
studies	O
have	O
investigated	O
but	O
not	O
found	O
any	O
association	O
between	O
25OHD	O
and	O
miscarriage	O
[	O
5	O
,	O
13	O
].	O

In	O
those	O
studies	O
,	O
25OHD	O
was	O
used	O
as	O
a	O
categorical	O
variable	O
.	O

One	O
earlier	O
study	O
,	O
from	O
Denmark	O
,	O
found	O
that	O
lower	O
vitamin	O
D	O
status	O
in	O
early	O
pregnancy	O
was	O
associated	O
with	O
pregnancy	O
loss	O
in	O
the	O
first	O
trimester	O
[	O
24	O
].	O

We	O
found	O
that	O
pregnancy	O
loss	O
was	O
associated	O
with	O
lower	O
25OHD	O
when	O
expressed	O
on	O
a	O
continuous	O
but	O
not	O
categorical	O
scale	O
.	O

As	B
most	O
women	O
with	O
high	O
vitamin	O
D	O
status	O
were	O
born	O
in	O
Sweden	O
and	O
thus	B
more	O
likely	B
to	O
be	O
familiar	O
with	O
the	O
Swedish	O
health	O
-	O
care	O
system	O
,	O
it	O
is	O
possible	O
that	O
they	O
registered	O
earlier	O
for	O
antenatal	O
care	O
and	O
were	O
more	O
likely	B
to	O
report	O
pregnancy	O
loss	O
.	O

However	O
,	O
the	O
models	O
were	O
adjusted	O
for	O
gestational	O
age	O
at	O
registration	O
for	O
antenatal	O
care	O
.	O

Despite	O
few	O
cases	O
of	O
IUFD	O
in	O
the	O
GraviD	O
cohort	O
,	O
our	O
results	O
suggest	O
that	O
vitamin	O
D	O
deficiency	O
in	O
early	O
pregnancy	O
may	O
be	O
linked	O
to	O
IUFD	O
.	O

These	O
results	O
need	O
confirmation	O
,	O
preferably	B
by	O
adjusted	O
statistical	O
analysis	O
as	B
confounding	O
can	O
be	O
expected	O
,	O
which	O
was	O
not	O
possible	O
in	O
our	O
present	O
study	O
due	O
to	O
few	O
cases	O
.	O

Strengths	O
of	O
this	O
study	O
are	O
that	O
the	O
GraviD	O
cohort	O
is	O
representative	O
of	O
the	O
general	O
pregnant	O
population	O
in	O
terms	O
of	O
origin	O
,	O
education	O
,	O
parity	O
,	O
BMI	O
and	O
tobacco	O
use	O
[	O
25	O
],	O
which	O
increases	O
the	O
external	O
validity	O
of	O
the	O
findings	O
.	O

Also	O
,	O
gestational	O
age	O
at	O
delivery	O
was	O
estimated	O
by	O
routine	O
ultrasound	O
,	O
which	O
is	O
considered	O
more	O
accurate	O
than	O
dating	O
by	O
last	O
menstrual	O
period	O
[	O
26	O
].	O

A	O
limitation	O
of	O
this	O
study	O
is	O
that	O
information	O
on	O
pregnancy	O
loss	O
,	O
except	O
IUFD	O
,	O
was	O
self	O
-	O
reported	O
.	O

The	O
information	O
on	O
pregnancy	O
loss	O
is	O
likely	B
correct	O
,	O
albeit	O
without	O
conclusive	O
information	O
on	O
the	O
time	O
of	O
fetal	O
demise	O
.	O

Survival	O
analysis	O
could	O
therefore	B
not	O
be	O
performed	O
,	O
as	B
time	O
to	O
event	O
data	O
were	O
missing	O
.	O

In	O
addition	O
,	O
vitamin	O
D	O
status	O
among	O
women	O
who	O
terminated	O
the	O
pregnancy	O
was	O
not	O
assessed	O
.	O

Data	O
on	O
SGA	O
,	O
LBW	O
and	O
preterm	O
delivery	O
were	O
collected	O
from	O
obstetrics	O
charts	O
based	O
on	O
standardized	O
measures	O
.	O

Since	O
there	O
were	O
few	O
cases	O
of	O
SGA	O
based	O
on	O
birth	O
weight	O
alone	O
,	O
the	O
definition	O
of	O
SGA	O
used	O
in	O
this	O
study	O
was	O
based	O
on	O
birth	O
weight	O
and	O
/	O
or	O
length	O
.	O

Among	O
the	O
SGA	O
cases	O
defined	O
by	O
length	O
only	O
,	O
most	O
were	O
close	O
to	O
also	O
meeting	O
the	O
SGA	O
definition	O
for	O
birth	O
weight	O
.	O

Therefore	B
,	O
the	O
definition	O
used	O
in	O
this	O
study	O
is	O
likely	B
to	O
be	O
relevant	O
.	O

Another	O
limitation	O
is	O
that	O
data	O
on	O
physical	O
activity	O
during	O
pregnancy	O
was	O
only	O
available	O
for	O
a	O
subset	O
of	O
the	O
women	O
and	O
was	O
therefore	B
not	O
used	O
.	O

While	O
the	O
GraviD	O
study	O
indicates	O
an	O
association	O
between	O
T3	O
25OHD	O
and	O
consequences	O
of	O
placental	O
insufficiency	O
,	O
change	O
in	O
25OHD	O
during	O
pregnancy	O
might	O
be	O
a	O
stronger	O
predictor	O
of	O
placental	O
dysfunction	O
,	O
as	B
it	O
is	O
associated	O
with	O
SGA	O
,	O
LBW	O
and	O
preterm	O
delivery	O
.	O

The	O
lowest	O
odds	O
of	O
SGA	O
and	O
LBW	O
are	O
found	O
among	O
women	O
with	O
the	O
largest	O
increments	O
in	O
25OHD	O
(≥	O
30	O
nmol	O
/	O
L	O
).	O

Interestingly	O
,	O
vitamin	O
D	O
status	O
at	O
T1	O
-	O
around	O
the	O
time	O
the	O
maternal	O
blood	O
flow	O
of	O
the	O
placenta	O
is	O
fully	O
developed	O
-	O
is	O
only	O
related	O
to	O
pregnancy	O
loss	O
.	O

Conclusion	O
In	O
conclusion	O
,	O
lower	O
early	O
pregnancy	O
25OHD	O
was	O
associated	O
with	O
pregnancy	O
loss	O
.	O

High	O
vitamin	O
D	O
status	O
in	O
late	O
,	O
but	O
not	O
early	O
,	O
pregnancy	O
was	O
associated	O
with	O
lower	O
odds	O
of	O
SGA	O
and	O
LBW	O
.	O

Change	O
in	O
25OHD	O
during	O
pregnancy	O
was	O
associated	O
with	O
SGA	O
,	O
LBW	O
and	O
preterm	O
delivery	O
,	O
with	O
the	O
lowest	O
odds	O
for	O
women	O
with	O
an	O
increment	O
in	O
25OHD	O
≥	O
30	O
nmol	O
/	O
L	O
.	O

Both	O
higher	O
late	O
pregnancy	O
vitamin	O
D	O
status	O
and	O
gestational	O
vitamin	O
D	O
status	O
trajectory	O
can	O
be	O
suspected	B
to	O
play	O
a	O
role	O
in	O
healthy	O
pregnancy	O
.	O

PubMed	O
Central	O
:	O

Major	O
Maternal	O
Dietary	O
Patterns	O
during	O
Early	O
Pregnancy	O
and	O
Their	O
Association	O
with	O
Neonatal	O
Anthropometric	O
Measurement	O
Abstract	O
Background	O
Anthropometric	O
measurements	O
of	O
newborn	O
infant	O
are	O
widely	O
assessed	O
as	O
determinants	O
of	O
maternal	O
nutrition	O
.	O

Although	O
earlier	O
studies	O
have	O
mostly	O
examined	O
the	O
effects	O
of	O
particular	O
nutrients	O
or	O
foods	O
during	O
gestational	O
period	O
on	O
neonatal	O
anthropometric	O
measurements	O
,	O
there	O
are	O
few	O
studies	O
regarding	O
the	O
association	O
of	O
dietary	O
patterns	O
and	O
mentioned	O
measurements	O
.	O

So	O
,	O
the	O
purpose	O
of	O
the	O
current	O
study	O
was	O
to	O
investigate	O
the	O
association	O
between	O
major	O
maternal	O
dietary	O
patterns	O
and	O
neonatal	O
anthropometric	O
measurements	O
including	O
body	O
weight	O
,	O
head	O
circumference	O
,	O
and	O
height	O
.	O

Methods	O
The	O
current	O
prospective	O
observational	O
study	O
is	O
based	O
on	O
the	O
data	O
collected	O
from	O
812	O
pregnant	O
women	O
.	O

Dietary	O
data	O
was	O
collected	O
using	O
a	O
validated	O
semiquantitative	O
food	O
frequency	O
questionnaire	O
.	O

Results	O
Three	O
identified	O
major	O
dietary	O
patterns	O
according	O
to	O
the	O
results	O
obtained	O
from	O
the	O
factor	O
loading	O
matrix	O
were	O
(	O
i	O
)	O
“	O
western	O
dietary	O
pattern	O
”;	O
(	O
ii	O
)	O
“	O
traditional	O
dietary	O
pattern	O
”;	O
(	O
iii	O
)	O
“	O
healthy	O
dietary	O
pattern	O
”.	O

Overall	O
,	O
this	O
study	O
demonstrated	O
a	O
positive	O
significant	O
association	O
between	O
high	O
adherences	O
to	O
western	O
dietary	O
pattern	O
and	O
chance	O
of	O
having	O
low	O
birth	O
weight	O
infant	O
.	O

However	O
,	O
such	O
associations	O
were	O
not	O
seen	O
in	O
women	O
taking	O
healthy	O
and	O
traditional	O
dietary	O
patterns	O
.	O

Conclusion	O
We	O
found	O
that	O
healthier	O
maternal	O
dietary	O
patterns	O
during	O
early	O
pregnancy	O
might	O
be	O
associated	O
with	O
lower	O
risk	O
of	O
low	O
birth	O
weight	O
.	O

Further	O
studies	O
are	O
required	O
to	O
confirm	O
these	O
findings	O
.	O

1	O
.	O

Introduction	O
Anthropometric	O
measurements	O
,	O
including	O
body	O
weight	O
,	O
head	O
circumference	O
,	O
and	O
height	O
of	O
newborn	O
infants	O
,	O
are	O
widely	O
assessed	O
as	O
determinants	O
of	O
impaired	O
fetal	O
growth	O
,	O
intrauterine	O
environment	O
,	O
and	O
maternal	O
nutrition	O
[	O
1	O
].	O

Restricted	O
fetal	O
growth	O
is	O
one	O
of	O
the	O
most	B
important	O
global	O
public	O
health	O
problems	O
which	O
provides	O
a	O
foundation	O
for	O
developing	O
chronic	O
diseases	O
throughout	O
their	O
life	O
[	O
2	O
].	O

Low	O
birth	O
weight	O
infants	O
are	O
susceptible	O
to	O
higher	O
risk	O
of	O
developing	O
iron	O
deficiency	O
anemia	O
leading	O
to	O
impaired	O
development	O
and	O
altered	O
longer	O
term	O
neurodevelopment	O
[	O
3	O
].	O

Also	O
,	O
impaired	O
fetal	O
growth	O
,	O
in	O
particular	O
in	O
head	O
circumference	O
,	O
is	O
associated	O
with	O
nonoptimal	O
neurodevelopmental	O
outcome	O
[	O
4	O
].	O

There	O
are	O
also	O
several	O
evidences	O
regarding	O
the	O
association	O
between	O
the	O
impaired	O
growth	O
indices	O
at	O
birth	O
and	O
increased	O
risk	O
of	O
developing	O
some	O
chronic	O
disorders	O
such	O
as	O
obesity	O
,	O
diabetes	O
[	O
5	O
],	O
cardiovascular	O
diseases	O
[	O
5	O
],	O
endothelial	O
dysfunction	O
[	O
6	O
],	O
nonalcoholic	O
fatty	O
liver	O
disease	O
[	O
7	O
],	O
and	O
chronic	O
kidney	O
disease	O
[	O
8	O
].	O

In	O
addition	O
to	O
genetic	O
factors	O
[	O
9	O
],	O
placenta	O
structural	O
[	O
10	O
]	O
and	O
environmental	O
factors	O
affect	O
fetal	O
growth	O
in	O
utero	O
[	O
9	O
],	O
and	O
maternal	O
nutritional	O
status	O
could	O
impact	O
on	O
fetal	O
growth	O
and	O
development	O
[	O
11	O
].	O

There	O
is	O
increasing	O
evidence	O
that	O
nutrients	O
[	O
12	O
]	O
and	O
some	O
foods	O
[	O
13	O
,	O
14	O
]	O
play	O
an	O
important	O
role	O
in	O
the	O
fetal	O
growth	O
.	O

Earlier	O
studies	O
have	O
also	O
shown	O
that	O
high	O
-	O
quality	O
diet	O
in	O
the	O
first	O
trimester	O
of	O
pregnancy	O
is	O
positively	O
associated	O
with	O
birth	O
size	O
including	O
birth	O
weight	O
and	O
birth	O
length	O
[	O
15	O
].	O

However	O
,	O
due	O
to	O
a	O
wide	O
range	O
of	O
nutrient	O
interactions	O
,	O
maternal	O
dietary	O
patterns	O
should	O
be	O
explored	O
to	O
achieve	O
the	O
association	O
between	O
maternal	O
nutrition	O
and	O
fetal	O
growth	O
.	O

It	O
is	O
noteworthy	O
that	O
there	O
are	O
few	O
studies	O
assessing	O
the	O
birth	O
anthropometric	O
measurements	O
along	O
the	O
maternal	O
dietary	O
patterns	O
[	O
16	O
].	O

Dietary	O
patterns	O
are	O
different	O
based	O
on	O
cultural	O
,	O
geographical	O
,	O
and	O
regional	O
influence	O
in	O
each	O
area	O
and	O
can	O
have	O
effects	O
on	O
health	O
outcomes	O
[	O
17	O
,	O
18	O
].	O

Limited	O
data	O
are	O
available	O
regarding	O
the	O
association	O
of	O
maternal	O
dietary	O
patterns	O
and	O
neonatal	O
anthropometric	O
measurements	O
in	O
Middle	O
Eastern	O
countries	O
,	O
where	O
mentioned	O
factors	O
are	O
different	O
from	O
western	O
population	O
[	O
19	O
].	O

So	O
,	O
the	O
purpose	O
of	O
the	O
current	O
study	O
was	O
to	O
investigate	O
the	O
association	O
between	O
major	O
maternal	O
dietary	O
patterns	O
during	O
the	O
first	O
-	O
trimester	O
period	O
and	O
neonatal	O
anthropometric	O
measurements	O
including	O
body	O
weight	O
,	O
head	O
circumference	O
,	O
and	O
height	O
.	O

Such	O
findings	O
will	O
be	O
used	O
to	O
implement	O
informative	O
interventional	O
programs	O
to	O
control	O
impaired	O
fetal	O
growth	O
and	O
develop	O
practical	O
policies	O
to	O
improve	O
the	O
diet	O
quality	O
among	O
pregnant	O
women	O
.	O

2	O
.	O

Methods	O
2	O
.	O
1	O
.	O

Study	O
Design	O
and	O
Participants	O
The	O
current	O
prospective	O
observational	O
study	O
was	O
conducted	O
among	O
pregnant	O
women	O
during	O
the	O
first	O
trimester	O
,	O
who	O
were	O
being	O
attended	O
at	O
health	O
centers	O
across	O
Isfahan	O
city	O
in	O
the	O
central	O
part	O
of	O
Iran	O
during	O
2015	O
-	O
2016	O
.	O

A	O
random	O
sample	O
of	O
812	O
pregnant	O
women	O
was	O
selected	O
from	O
20	O
various	O
health	O
centers	O
by	O
the	O
multistage	O
cluster	O
random	O
sampling	O
method	O
.	O

Eligible	O
criteria	O
included	O
singleton	O
pregnant	O
women	O
during	O
the	O
first	O
trimester	O
without	O
any	O
medical	O
condition	O
,	O
use	O
of	O
medications	O
,	O
and	O
without	O
following	O
a	O
specific	O
diet	O
.	O

Exclusion	O
criteria	O
were	O
avoiding	O
of	O
follow	O
-	O
up	O
during	O
the	O
study	O
and	O
current	O
-	O
smoker	O
women	O
.	O

Also	O
we	O
exclude	O
twin	O
pregnancies	O
.	O

Informed	O
consent	O
was	O
obtained	O
from	O
all	O
participants	O
.	O

This	O
study	O
was	O
approved	O
by	O
the	O
research	O
council	O
(	O
research	O
project	O
number	O
:	O
193053	O
)	O
and	O
ethics	O
committee	O
(	O
research	O
ethics	O
number	O
:	O
IR	O
.	O
MUI	O
.	O
REC193053	O
).	O

2	O
.	O
2	O
.	O

Data	O
Collection	O
2	O
.	O
2	O
.	O
1	O
.	O

Assessment	O
of	O
Dietary	O
Intake	O
Pregnant	O
women	O
in	O
these	O
analyses	O
completed	O
validated	O
117	O
-	O
item	O
semiquantitative	O
food	O
frequency	O
questionnaire	O
(	O
FFQ	O
)	O
in	O
the	O
first	O
visit	O
,	O
at	O
8	O
–	O
16	O
weeks	O
.	O

The	O
validity	O
and	O
reliability	O
of	O
FFQ	O
had	O
been	O
previously	O
evaluated	O
[	O
20	O
].	O

We	O
inquired	O
about	O
the	O
consumption	O
of	O
each	O
food	O
item	O
,	O
based	O
on	O
commonly	O
used	O
units	O
or	O
portion	O
sizes	O
,	O
over	O
the	O
preceding	O
12	O
months	O
on	O
a	O
daily	O
,	O
weekly	O
,	O
or	O
monthly	O
basis	O
.	O

Participants	O
were	O
asked	O
to	O
report	O
their	O
dietary	O
intakes	O
of	O
foods	O
based	O
on	O
nine	O
multiple	O
choice	O
frequency	O
response	O
categories	O
varying	O
from	O
“	O
never	O
or	O
less	O
than	O
once	O
a	O
month	O
”	O
to	O
“	O
12	O
or	O
more	O
times	O
per	O
day	O
”.	O

Portion	O
sizes	O
of	O
consumed	O
foods	O
were	O
converted	O
to	O
grams	O
from	O
household	O
measures	O
.	O

Supplements	O
were	O
also	O
included	O
to	O
assess	O
total	O
nutrient	O
intake	O
.	O

Then	O
nutrient	O
and	O
energy	O
intakes	O
were	O
computed	O
by	O
using	O
NUTRITIONIST	O
IV	O
software	O
(	O
version	O
7	O
.	O
0	O
;	O
N	O
-	O
Squared	O
Computing	O
,	O
Salem	O
,	O
OR	O
),	O
which	O
was	O
designed	O
for	O
Iranian	O
foods	O
.	O

All	O
nutrient	O
values	O
were	O
energy	O
-	O
adjusted	O
using	O
the	O
residuals	O
method	O
.	O

2	O
.	O
2	O
.	O
2	O
.	O

Determination	O
of	O
Dietary	O
Patterns	O
We	O
applied	O
principal	O
component	O
analysis	O
in	O
order	O
to	O
find	O
major	O
dietary	O
patterns	O
.	O

Food	O
items	O
similar	O
in	O
nutrient	O
profile	O
were	O
combined	O
into	O
33	O
predefined	O
food	O
groups	O
(	O
Table	O
1	O
).	O

When	O
the	O
item	O
was	O
unique	O
in	O
the	O
nutrient	O
profile	O
,	O
it	O
was	O
not	O
combined	O
(	O
e	O
.	O
g	O
.,	O
salt	O
).	O

The	O
factors	O
were	O
rotated	O
by	O
varimax	O
rotation	O
function	O
.	O

Correlated	O
variables	O
are	O
aggregated	O
by	O
factor	O
analysis	O
.	O

The	O
obtained	O
factors	O
are	O
linear	O
combinations	O
of	O
the	O
included	O
variables	O
,	O
explaining	O
as	O
much	O
variation	O
in	O
the	O
original	O
variables	O
as	O
possible	O
.	O

Three	O
factors	O
were	O
retained	O
,	O
based	O
on	O
the	O
screen	O
plot	O
,	O
an	O
eigenvalue	O
of	O
more	O
than	O
1	O
.	O
9	O
,	O
and	O
the	O
interpretability	O
of	O
the	O
derived	O
factors	O
and	O
of	O
the	O
earlier	O
literature	O
.	O

Based	B
on	I
our	O
interpretation	B
of	O
the	O
data	O
and	O
of	O
the	O
earlier	O
literature	O
,	O
these	O
3	O
factors	O
were	O
labeled	O
as	O
the	O
healthy	O
,	O
western	O
,	O
and	O
traditional	O
patterns	O
.	O

The	O
individual	O
scores	O
for	O
the	O
3	O
patterns	O
show	O
the	O
values	O
estimated	O
for	O
each	O
individual	O
based	O
on	O
their	O
consumption	O
of	O
foods	O
and	O
the	O
factor	O
loadings	O
of	O
the	O
foods	O
.	O

2	O
.	O
2	O
.	O
3	O
.	O

Assessment	O
of	O
Other	O
Variables	O
For	O
the	O
infants	O
,	O
birth	O
date	O
,	O
gestational	O
age	O
,	O
and	O
anthropometric	O
measurements	O
including	O
body	O
weight	O
,	O
head	O
circumference	O
,	O
and	O
height	O
were	O
recorded	O
at	O
birth	O
.	O

Neonatal	O
anthropometric	O
measurements	O
were	O
categorized	O
according	O
to	O
WHO	O
standards	O
and	O
as	O
follows	O
:	O
low	O
birth	O
weight	O
(	O
LBW	O
);	O
a	O
birth	O
weight	O
less	O
than	O
2500	O
g	O
,	O
normal	O
birth	O
weight	O
;	O
a	O
birth	O
weight	O
more	O
than	O
2500	O
g	O
and	O
less	O
than	O
3900	O
,	O
low	O
height	O
;	O
a	O
height	O
less	O
than	O
47	O
cm	O
,	O
normal	O
height	O
;	O
a	O
height	O
more	O
than	O
47	O
cm	O
and	O
less	O
than	O
55	O
cm	O
,	O
low	O
head	O
circumference	O
;	O
a	O
head	O
circumference	O
less	O
than	O
33	O
cm	O
,	O
normal	O
head	O
circumference	O
;	O
a	O
head	O
circumference	O
more	O
than	O
33	O
cm	O
and	O
less	O
than	O
37	O
cm	O
[	O
21	O
].	O

We	O
also	O
obtained	O
anthropometric	O
data	O
(	O
height	O
and	O
weight	O
),	O
demographic	O
data	O
(	O
occupation	O
and	O
education	O
),	O
and	O
clinical	O
data	O
(	O
delivery	O
status	O
,	O
IUGR	O
and	O
history	O
of	O
preterm	O
birth	O
,	O
abortion	O
,	O
delivery	O
status	O
,	O
and	O
stillbirth	O
)	O
of	O
the	O
pregnant	O
women	O
.	O

To	O
assess	O
participants	O
'	O
information	O
regarding	O
age	O
and	O
gender	O
,	O
marital	O
status	O
,	O
and	O
educational	O
level	O
,	O
we	O
used	O
a	O
standard	O
self	O
-	O
reported	O
questionnaire	O
.	O

Subjects	O
'	O
weight	O
was	O
measured	O
using	O
a	O
balanced	O
digital	O
scale	O
to	O
the	O
nearest	O
100	O
g	O
,	O
in	O
light	O
clothing	O
and	O
barefoot	O
.	O

Height	O
was	O
measured	O
with	O
a	O
tape	O
measure	O
while	O
the	O
subjects	O
were	O
in	O
a	O
standing	O
position	O
.	O

BMI	O
,	O
defined	O
as	O
weight	O
in	O
kilograms	O
divided	O
by	O
height	O
in	O
meters	O
squared	O
,	O
was	O
calculated	O
.	O

General	O
Practice	O
Physical	O
Activity	O
Questionnaire	O
(	O
GPPAQ	O
)	O
was	O
used	O
to	O
assess	O
the	O
physical	O
activity	O
of	O
participants	O
[	O
22	O
].	O

According	O
to	O
GPPAQ	O
,	O
participants	O
were	O
categorized	O
into	O
4	O
levels	O
of	O
physical	O
activity	O
based	O
on	O
hours	O
/	O
week	O
.	O

2	O
.	O
3	O
.	O

Statistical	O
Analysis	O
As	O
was	O
mentioned	O
,	O
principal	O
component	O
analysis	O
was	O
used	O
to	O
identify	O
major	O
dietary	O
patterns	O
based	O
on	O
the	O
33	O
food	O
groups	O
.	O

Three	O
factors	O
were	O
considered	O
major	O
dietary	O
patterns	O
.	O

Factor	O
scores	O
of	O
dietary	O
patterns	O
were	O
calculated	O
by	O
summing	O
intakes	O
of	O
foods	O
weighed	O
by	O
their	O
factor	O
loading	O
for	O
each	O
participant	O
.	O

Participants	O
were	O
categorized	O
by	O
quintiles	O
of	O
dietary	O
pattern	O
scores	O
.	O

Continuous	O
variables	O
were	O
evaluated	O
across	O
quintile	O
categories	O
of	O
dietary	O
pattern	O
scores	O
by	O
one	O
-	O
way	O
analysis	O
of	O
variance	O
.	O

Chi	O
-	O
square	O
test	O
was	O
used	O
to	O
examine	O
significant	O
differences	O
in	O
the	O
distribution	O
of	O
study	O
participants	O
in	O
terms	O
of	O
categorical	O
variables	O
across	O
different	O
quintile	O
categories	O
of	O
dietary	O
pattern	O
scores	O
.	O

To	O
investigate	O
the	O
association	O
between	O
dietary	O
patterns	O
and	O
neonatal	O
anthropometric	O
measurements	O
,	O
we	O
used	O
multivariable	O
logistic	O
regression	O
models	O
controlled	O
for	O
energy	O
intake	O
,	O
age	O
,	O
and	O
BMI	O
.	O

Further	O
adjustments	O
were	O
made	O
for	O
physical	O
activity	O
and	O
social	O
-	O
economic	O
levels	O
in	O
model	O
2	O
,	O
and	O
additionally	O
adjustment	O
for	O
delivery	O
status	O
,	O
IUGR	O
,	O
preterm	O
delivery	O
,	O
history	O
of	O
abortion	O
,	O
and	O
stillbirth	O
were	O
made	O
in	O
model	O
3	O
.	O

All	O
statistical	O
tests	O
were	O
two	O
-	O
sided	O
,	O
and	O
P	O
<	O
0	O
.	O
05	O
was	O
considered	O
as	O
statistically	O
significant	O
.	O

SPSS	O
16	O
.	O
0	O
(	O
SPSS	O
,	O
Inc	O
.,	O
Chicago	O
,	O
IL	O
,	O
USA	O
)	O
was	O
used	O
for	O
all	O
statistical	O
analyses	O
.	O

3	O
.	O

Results	O
3	O
.	O
1	O
.	O

Identified	O
Major	O
Dietary	O
Patterns	O
Three	O
major	O
dietary	O
patterns	O
were	O
identified	O
according	O
to	O
the	O
results	O
obtained	O
from	O
the	O
factor	O
loading	O
matrix	O
(	O
Table	O
2	O
):	O
(	O
i	O
)	O
“	O
western	O
dietary	O
pattern	O
”	O
which	O
was	O
greatly	O
loaded	O
by	O
processed	O
meats	O
,	O
fruit	O
,	O
fruit	O
juice	O
,	O
citrus	O
,	O
nuts	O
,	O
fish	O
,	O
desserts	O
and	O
sweets	O
,	O
sugar	O
,	O
saturated	O
fat	O
,	O
sweat	O
fruit	O
,	O
potato	O
,	O
legumes	O
,	O
coffee	O
,	O
egg	O
,	O
pizza	O
,	O
high	O
fat	O
dairy	O
,	O
whole	O
grain	O
,	O
and	O
soft	O
drink	O
;	O
(	O
ii	O
)	O
“	O
traditional	O
dietary	O
pattern	O
”	O
which	O
was	O
high	O
in	O
refined	O
grains	O
,	O
colored	O
vegetables	O
,	O
olive	O
,	O
sugar	O
,	O
salt	O
,	O
spices	O
,	O
unsaturated	O
fat	O
,	O
garlic	O
,	O
onion	O
,	O
and	O
tea	O
;	O
(	O
iii	O
)	O
“	O
healthy	O
dietary	O
pattern	O
”	O
which	O
was	O
high	O
in	O
green	O
vegetables	O
,	O
leafy	O
vegetable	O
,	O
colored	O
vegetables	O
,	O
fruit	O
,	O
low	O
-	O
fat	O
dairy	O
,	O
poultry	O
,	O
bulky	O
vegetables	O
,	O
red	O
meat	O
,	O
citrus	O
,	O
nuts	O
,	O
fish	O
,	O
evil	O
,	O
marinades	O
,	O
sweat	O
fruit	O
,	O
egg	O
,	O
and	O
unsaturated	O
fat	O
.	O

3	O
.	O
2	O
.	O

General	O
Characteristics	O
and	O
Dietary	O
Intakes	O
of	O
Study	O
Participants	O
According	O
to	O
inclusion	O
and	O
exclusion	O
criteria	O
,	O
812	O
subjects	O
with	O
mean	O
(	O
SD	O
)	O
maternal	O
age	O
of	O
29	O
.	O
4	O
(	O
4	O
.	O
85	O
)	O
remained	O
for	O
the	O
current	O
analysis	O
.	O

Energy	O
and	O
nutrients	O
intake	O
of	O
the	O
study	O
participants	O
across	O
different	O
categories	O
of	O
healthy	O
,	O
western	O
,	O
and	O
traditional	O
dietary	O
patterns	O
were	O
reported	O
in	O
Tables3	O
,	O
4	O
,	O
and5	O
,	O
respectively	O
.	O

In	O
all	O
dietary	O
patterns	O
,	O
the	O
most	O
of	O
energy	O
and	O
nutrients	O
intake	O
were	O
different	O
in	O
all	O
levels	O
of	O
dietary	O
patterns	O
adherence	O
.	O

The	O
overall	O
characteristics	O
of	O
the	O
study	O
population	O
across	O
different	O
categories	O
of	O
dietary	O
patterns	O
are	O
presented	O
inTable	O
6	O
.	O

Women	O
in	O
the	O
highest	O
quartile	O
of	O
healthy	O
dietary	O
pattern	O
were	O
more	O
likely	B
to	O
be	O
employed	O
and	O
graduated	O
and	O
have	O
employed	O
husband	O
,	O
history	O
of	O
IUGR	O
,	O
and	O
less	O
history	O
of	O
early	O
delivery	O
compared	O
with	O
those	O
in	O
the	O
lowest	O
quartile	O
.	O

In	O
addition	O
,	O
regarding	O
the	O
distribution	O
of	O
the	O
women	O
across	O
categories	O
of	O
western	O
dietary	O
pattern	O
,	O
it	O
was	O
found	O
that	O
those	O
with	O
the	O
highest	O
adherence	O
had	O
significantly	O
higher	O
social	O
-	O
economic	O
level	O
,	O
employed	O
husband	O
,	O
history	O
of	O
cesarean	O
,	O
and	O
less	O
IUGR	O
and	O
stillbirth	O
history	O
.	O

Furthermore	O
,	O
women	O
with	O
highest	O
quartile	O
of	O
traditional	O
dietary	O
pattern	O
had	O
significantly	O
higher	O
social	O
-	O
economic	O
level	O
,	O
education	O
,	O
and	O
husband	O
'	O
s	O
education	O
compared	O
with	O
those	O
in	O
the	O
lowest	O
quartile	O
.	O

Data	O
inTable	O
7represent	O
the	O
crude	O
and	O
adjusted	O
odds	O
ratio	O
(	O
OR	O
)	O
and	O
95	O
%	O
confidence	O
interval	O
(	O
CI	O
)	O
for	O
ORs	O
from	O
the	O
multivariate	O
analysis	O
,	O
where	O
neonatal	O
anthropometric	O
measurements	O
are	O
the	O
dependent	O
variables	O
and	O
major	O
maternal	O
dietary	O
patterns	O
the	O
independent	O
variables	O
.	O

In	O
all	O
fitted	O
models	O
,	O
the	O
low	O
level	O
of	O
each	O
dietary	O
pattern	O
(	O
quartile	O
1	O
)	O
was	O
defined	O
as	O
the	O
reference	O
category	O
.	O

The	O
comparison	O
of	O
neonatal	O
height	O
in	O
different	O
categories	O
of	O
maternal	O
dietary	O
patterns	O
showed	O
maternal	O
dietary	O
patterns	O
were	O
not	O
related	O
to	O
neonatal	O
height	O
in	O
all	O
crude	O
and	O
adjusted	O
models	O
.	O

Women	O
in	O
the	O
highest	O
quartile	O
of	O
adherence	O
to	O
traditional	O
dietary	O
pattern	O
were	O
20	O
%	O
less	O
likely	B
to	O
have	O
short	O
height	O
infant	O
compared	O
with	O
those	O
in	O
the	O
lowest	O
quartile	O
[	O
OR	O
0	O
.	O
80	O
,	O
95	O
%	O
(	O
CI	O
)	O
(	O
0	O
.	O
34	O
-	O
1	O
.	O
85	O
),	O
P	O
<	O
0	O
.	O
93	O
]	O
in	O
the	O
final	O
adjusted	O
model	O
.	O

Also	O
,	O
there	O
were	O
positive	O
nonsignificant	O
relationships	O
between	O
adherence	O
to	O
western	O
[	O
OR	O
1	O
.	O
31	O
,	O
95	O
%	O
(	O
CI	O
)	O
(	O
0	O
.	O
68	O
-	O
2	O
.	O
51	O
),	O
P	O
=	O
0	O
.	O
28	O
]	O
and	O
healthy	O
[	O
OR	O
1	O
.	O
02	O
,	O
95	O
%	O
(	O
CI	O
)	O
(	O
0	O
.	O
39	O
-	O
2	O
.	O
63	O
),	O
P	O
=	O
0	O
.	O
40	O
]	O
dietary	O
pattern	O
of	O
mothers	O
with	O
having	O
short	O
height	O
infant	O
in	O
the	O
final	O
adjusted	O
model	O
.	O

Finding	O
about	O
neonatal	O
weight	O
showed	O
that	O
those	O
in	O
the	O
top	O
quartile	O
of	O
adherence	O
to	O
western	O
dietary	O
pattern	O
had	O
marginally	O
significant	O
chance	B
of	O
having	O
low	O
weight	O
infant	O
compared	O
with	O
those	O
in	O
the	O
bottom	O
quartile	O
in	O
the	O
crude	O
model	O
[	O
OR	O
1	O
.	O
84	O
,	O
95	O
%	O
(	O
CI	O
)	O
(	O
0	O
.	O
94	O
-	O
3	O
.	O
60	O
),	O
P	O
=	O
0	O
.	O
05	O
].	O

The	O
same	O
results	O
were	O
obtained	O
after	O
adjusting	O
for	O
potential	O
confounding	O
variables	O
in	O
model	O
1	O
[	O
OR	O
2	O
.	O
05	O
,	O
95	O
%	O
(	O
CI	O
)	O
(	O
1	O
.	O
01	O
-	O
4	O
.	O
15	O
),	O
P	O
=	O
0	O
.	O
05	O
]	O
and	O
model	O
2	O
[	O
OR	O
2	O
.	O
04	O
,	O
95	O
%	O
(	O
CI	O
)	O
(	O
0	O
.	O
97	O
-	O
4	O
.	O
32	O
),	O
P	O
=	O
0	O
.	O
06	O
].	O

After	O
adjusting	O
for	O
obstetrical	O
factors	O
(	O
model	O
3	O
),	O
there	O
was	O
a	O
positive	O
significant	O
relationship	O
between	O
adherence	O
to	O
western	O
dietary	O
pattern	O
[	O
OR	O
5	O
.	O
51	O
,	O
95	O
%	O
(	O
CI	O
)	O
(	O
1	O
.	O
82	O
-	O
16	O
.	O
66	O
),	O
P	O
=	O
0	O
.	O
001	O
]	O
with	O
having	O
low	O
birth	O
weight	O
infant	O
.	O

In	O
addition	O
,	O
lower	O
marginal	O
significant	O
chance	B
of	O
having	O
low	O
weight	O
infant	O
was	O
found	O
among	O
women	O
who	O
were	O
in	O
the	O
top	O
adherence	O
of	O
traditional	O
dietary	O
pattern	O
[	O
OR	O
0	O
.	O
76	O
,	O
95	O
%	O
(	O
CI	O
)	O
(	O
0	O
.	O
32	O
-	O
1	O
.	O
77	O
),	O
P	O
=	O
0	O
.	O
05	O
]	O
in	O
the	O
crude	O
model	O
.	O

Although	O
this	O
association	O
became	O
significant	O
even	O
after	O
taking	O
potential	O
confounders	O
into	O
account	O
in	O
model	O
1	O
[	O
OR	O
0	O
.	O
80	O
,	O
95	O
%	O
(	O
CI	O
)	O
(	O
0	O
.	O
34	O
-	O
1	O
.	O
93	O
),	O
P	O
<	O
0	O
.	O
01	O
],	O
such	O
association	O
was	O
not	O
seen	O
in	O
models	O
2	O
and	O
3	O
.	O

However	O
,	O
maternal	O
adherence	O
to	O
healthy	O
dietary	O
pattern	O
was	O
not	O
related	O
to	O
birth	O
weight	O
of	O
infants	O
in	O
all	O
crude	O
and	O
adjusted	O
models	O
.	O

We	O
found	O
no	O
significant	O
association	O
either	O
between	O
maternal	O
western	O
dietary	O
pattern	O
and	O
head	O
circumference	O
of	O
infant	O
or	O
between	O
healthy	O
or	O
traditional	O
dietary	O
pattern	O
and	O
mentioned	O
measure	O
.	O

In	O
final	O
adjusted	O
model	O
,	O
women	O
with	O
a	O
higher	O
adherence	O
to	O
western	O
dietary	O
pattern	O
had	O
4	O
.	O
88	O
times	O
larger	O
odds	O
for	O
having	O
an	O
infant	O
with	O
low	O
birth	O
head	O
circumference	O
than	O
those	O
with	O
a	O
lower	O
adherence	O
level	O
(	O
OR	O
:	O
4	O
.	O
88	O
;	O
95	O
%	O
CI	O
:	O
0	O
.	O
79	O
-	O
30	O
.	O
19	O
P	O
=	O
0	O
.	O
35	O
).	O

Same	O
result	O
was	O
obtained	O
about	O
healthy	O
dietary	O
pattern	O
[	O
OR	O
3	O
.	O
70	O
,	O
95	O
%	O
(	O
CI	O
)	O
(	O
0	O
.	O
72	O
-	O
17	O
.	O
86	O
),	O
P	O
=	O
0	O
.	O
52	O
].	O

Furthermore	O
,	O
lower	O
risk	O
of	O
low	O
birth	O
head	O
circumference	O
was	O
nonsignificantly	O
associated	O
with	O
a	O
traditional	O
dietary	O
pattern	O
[	O
OR	O
0	O
.	O
58	O
,	O
95	O
%	O
(	O
CI	O
)	O
(	O
0	O
.	O
13	O
-	O
2	O
.	O
51	O
),	O
P	O
=	O
0	O
.	O
41	O
].	O

4	O
.	O

Discussion	O
Current	O
study	O
on	O
812	O
subjects	O
is	O
one	O
of	O
the	O
largest	O
studies	O
evaluating	O
the	O
association	O
between	O
major	O
maternal	O
dietary	O
patterns	O
during	O
the	O
first	O
-	O
trimester	O
period	O
of	O
pregnancy	O
and	O
neonatal	O
anthropometric	O
measurements	O
.	O

This	O
study	O
demonstrated	O
a	O
significant	O
association	O
between	O
high	O
adherences	O
to	O
western	O
dietary	O
pattern	O
and	O
chance	O
of	O
having	O
low	O
birth	O
weight	O
infant	O
.	O

However	O
,	O
such	O
associations	O
were	O
not	O
seen	O
with	O
healthy	O
and	O
traditional	O
dietary	O
pattern	O
.	O

Earlier	O
studies	O
have	O
mostly	O
examined	O
the	O
effects	O
of	O
particular	O
nutrients	O
or	O
foods	O
during	O
gestational	O
period	O
on	O
neonatal	O
anthropometric	O
measurements	O
[	O
13	O
]	O
and	O
few	O
data	O
are	O
available	O
linking	O
habitual	O
diet	O
to	O
neonatal	O
anthropometric	O
measurements	O
.	O

Western	O
dietary	O
pattern	O
as	O
an	O
unhealthy	O
food	O
choice	O
is	O
unable	O
to	O
fulfill	O
the	O
increased	O
key	O
micronutrients	O
requirements	O
for	O
normal	O
fetal	O
growth	O
during	O
pregnancy	O
and	O
results	O
in	O
such	O
adverse	O
effects	O
on	O
the	O
fetus	O
[	O
23	O
].	O

Earlier	O
studies	O
have	O
also	O
shown	O
that	O
high	O
-	O
quality	O
diet	O
assessed	O
by	O
using	O
the	O
Alternate	O
Healthy	O
Eating	O
Index	O
(	O
AHEI	O
)	O
in	O
the	O
first	O
trimester	O
of	O
pregnancy	O
is	O
positively	O
associated	O
with	O
birth	O
size	O
including	O
birth	O
weight	O
and	O
birth	O
length	O
[	O
15	O
].	O

Other	O
publication	O
has	O
also	O
reported	O
a	O
protective	O
effect	O
of	O
adherence	O
to	O
Mediterranean	O
diet	O
during	O
pregnancy	O
and	O
risk	O
of	O
delivering	O
a	O
fetal	O
growth	O
–	O
restricted	O
infant	O
for	O
weight	O
in	O
Atlantic	O
area	O
[	O
16	O
].	O

In	O
a	O
population	O
-	O
based	O
prospective	O
study	O
,	O
it	O
has	O
been	O
shown	O
that	O
women	O
in	O
the	O
“	O
wheat	O
products	O
”	O
pattern	O
had	O
higher	O
odds	O
of	O
having	O
infants	O
with	O
the	O
low	O
birth	O
weight	O
and	O
head	O
circumference	O
compared	O
with	O
women	O
in	O
the	O
“	O
rice	O
,	O
fish	O
,	O
and	O
vegetables	O
”	O
pattern	O
[	O
24	O
].	O

Also	O
,	O
some	O
maternal	O
dietary	O
patterns	O
characterized	O
by	O
high	O
intakes	O
of	O
vegetable	O
,	O
fruit	O
,	O
white	O
rice	O
[	O
25	O
],	O
Vitamin	O
C	O
,	O
milk	O
,	O
and	O
fat	O
[	O
26	O
]	O
are	O
associated	O
with	O
larger	O
birth	O
size	O
of	O
infant	O
.	O

In	O
contrast	O
maternal	O
intakes	O
of	O
carbohydrate	O
were	O
negatively	O
associated	O
with	O
infant	O
length	O
and	O
abdominal	O
circumference	O
[	O
26	O
].	O

Present	O
study	O
showed	O
that	O
the	O
women	O
with	O
prior	O
problematic	O
pregnancies	O
or	O
higher	O
socioeconomic	O
status	O
or	O
education	O
level	O
were	O
more	O
prone	B
to	O
have	O
a	O
healthy	O
dietary	O
pattern	O
.	O

These	O
results	O
were	O
in	O
line	O
with	O
Northstone	O
et	O
al	O
.	O

study	O
which	O
showed	O
that	O
“	O
health	O
conscious	O
”	O
dietary	O
patterns	O
were	O
negatively	O
associated	O
with	O
decreasing	O
educational	O
level	O
,	O
age	O
,	O
and	O
socioeconomic	O
status	O
[	O
21	O
].	O

Also	O
,	O
dietary	O
surveys	O
during	O
pregnancy	O
have	O
suggested	O
the	O
poor	O
diet	O
quality	O
and	O
quantity	O
of	O
low	O
socioeconomic	O
groups	O
[	O
27	O
].	O

It	O
can	B
be	I
concluded	I
that	O
women	O
with	O
low	O
socioeconomic	O
status	O
need	O
specific	O
dietary	O
intervention	O
programs	O
due	B
to	I
increase	O
in	O
nutritional	O
demands	O
during	O
pregnancy	O
.	O

As	O
was	O
mentioned	O
,	O
we	O
did	O
not	O
see	O
any	O
associations	O
of	O
healthy	O
and	O
traditional	O
dietary	O
patterns	O
with	O
consumption	O
of	O
red	O
meats	O
in	O
the	O
healthy	O
dietary	O
pattern	O
and	O
refined	O
grain	O
,	O
salt	O
,	O
and	O
sugar	O
in	O
the	O
traditional	O
dietary	O
pattern	O
.	O

Mentioned	O
foods	O
as	O
an	O
unhealthy	O
food	O
might	O
have	O
been	O
given	O
an	O
adverse	O
score	O
in	O
the	O
healthy	O
and	O
traditional	O
dietary	O
patterns	O
in	O
the	O
current	O
study	O
.	O

This	O
might	O
be	O
a	O
reason	B
why	O
we	O
failed	O
to	O
report	O
a	O
significant	O
positive	O
association	O
between	O
high	O
adherence	O
to	O
healthy	O
dietary	O
pattern	O
and	O
neonatal	O
anthropometric	O
measurements	O
.	O

It	O
should	O
be	O
mentioned	O
that	O
refined	O
grains	O
are	O
major	O
source	O
of	O
carbohydrate	O
intake	O
in	O
Iranian	O
diet	O
,	O
which	O
has	O
been	O
shown	O
to	O
be	O
associated	O
with	O
higher	O
risk	O
of	O
some	O
chronic	O
disorders	O
.	O

Iranian	O
usual	O
diet	O
also	O
contains	O
high	O
amounts	O
of	O
salt	O
,	O
which	O
means	O
that	O
salt	O
intake	O
among	O
them	O
is	O
almost	O
twofold	O
the	O
recommended	O
levels	O
.	O

In	O
addition	O
,	O
fruits	O
,	O
vegetables	O
,	O
and	O
low	O
-	O
fat	O
dairy	O
intake	O
among	O
them	O
is	O
low	O
;	O
however	O
,	O
legumes	O
intake	O
is	O
good	O
in	O
the	O
mentioned	O
population	O
[	O
28	O
].	O

Therefore	B
,	O
understanding	O
the	O
differences	O
between	O
healthy	O
,	O
western	O
,	O
and	O
traditional	O
dietary	O
patterns	O
and	O
usual	O
Iranian	O
dietary	O
pattern	O
might	O
help	O
interpreting	O
the	O
importance	O
of	O
the	O
findings	O
we	O
reached	O
.	O

Also	O
,	O
postpregnancy	O
dietary	O
habits	O
and	O
choices	O
may	O
be	O
different	O
compared	O
with	O
prepregnancy	O
.	O

The	O
majority	O
of	O
pregnant	O
women	O
are	O
encouraged	O
to	O
healthier	O
dietary	O
changes	O
.	O

We	O
cannot	O
overlook	O
that	O
the	O
long	O
time	O
adherence	O
to	O
a	O
specific	O
diet	O
affects	O
health	O
outcomes	O
.	O

Another	O
point	O
that	O
needs	O
to	O
be	O
considered	O
is	O
the	O
measurements	O
error	O
in	O
nutritional	O
assessment	O
;	O
this	O
may	O
increase	O
the	O
likelihood	O
of	O
misclassification	O
,	O
contributing	O
to	O
the	O
discrepancy	O
among	O
our	O
results	O
.	O

Detailed	O
information	O
about	O
food	O
preparation	O
and	O
brands	O
is	O
also	O
lacking	O
in	O
this	O
instrument	O
.	O

Another	O
potential	O
drawback	O
should	O
be	O
also	O
considered	O
.	O

Lack	O
of	O
funding	O
to	O
obtain	O
fetal	O
weights	O
estimated	O
via	O
serial	O
ultrasound	O
is	O
an	O
issue	O
in	O
the	O
analyses	O
.	O

It	O
has	O
been	O
suggested	O
that	O
intrauterine	O
growth	O
patterns	O
improved	O
prediction	O
of	O
childhood	O
anthropometry	O
,	O
above	O
and	O
beyond	O
birth	O
weight	O
alone	O
.	O

Moreover	O
,	O
up	O
to	O
70	O
%	O
of	O
small	O
-	O
for	O
-	O
gestational	O
-	O
age	O
(	O
SGA	O
)	O
infants	O
are	O
constitutionally	O
small	O
(“	O
small	O
but	O
healthy	O
”),	O
which	O
make	O
SGA	O
birth	O
a	O
poor	O
surrogate	O
for	O
intrauterine	O
growth	O
restriction	O
[	O
29	O
].	O

In	O
this	O
regard	O
,	O
intrauterine	O
growth	O
should	O
be	O
identified	O
on	O
the	O
basis	O
of	O
measures	O
of	O
fetal	O
growth	O
patterns	O
,	O
rather	O
than	O
birth	O
weight	O
[	O
30	O
].	O

In	O
addition	O
,	O
residual	O
confounding	O
due	O
to	O
genetic	O
backgrounds	O
could	O
not	O
be	O
excluded	O
,	O
although	O
we	O
controlled	O
some	O
important	O
potential	O
confounding	O
factors	O
.	O

Therefore	B
,	O
these	O
potential	O
limitations	O
should	O
be	O
considered	O
in	O
the	O
interpretation	O
of	O
our	O
results	O
.	O

However	O
,	O
the	O
main	O
strengths	O
of	O
the	O
current	O
study	O
include	O
its	O
multidisciplinary	O
scope	O
including	O
epidemiology	O
,	O
statistics	O
,	O
pediatrics	O
,	O
maternity	O
,	O
and	O
nutrition	O
.	O

Another	O
positive	O
point	O
is	O
that	O
few	O
studies	O
have	O
collected	O
data	O
on	O
maternal	O
dietary	O
patterns	O
and	O
neonatal	O
anthropometric	O
measurements	O
.	O

In	O
summary	O
,	O
evaluations	O
carried	O
out	O
in	O
the	O
present	O
study	O
indicate	O
that	O
during	O
early	O
pregnancy	O
mothers	O
of	O
low	O
birth	O
weight	O
infant	O
had	O
a	O
different	O
dietary	O
pattern	O
and	O
more	O
adhered	O
to	O
the	O
western	O
dietary	O
pattern	O
compared	O
to	O
mothers	O
of	O
normal	O
weight	O
birth	O
infant	O
.	O

Therefore	B
,	O
intrauterine	O
growth	O
conditions	O
might	O
be	O
improved	O
through	O
the	O
adoption	O
of	O
certain	O
dietary	O
patterns	O
during	O
pregnancy	O
.	O

Larger	O
studies	O
are	O
needed	O
to	O
determine	O
whether	O
maternal	O
dietary	O
patterns	O
lead	O
to	O
significant	O
modifications	O
in	O
neonatal	O
anthropometric	O
measurements	O
.	O

PubMed	O
Central	O
:	O

Vitamin	O
D	O
levels	O
in	O
an	O
Australian	O
and	O
New	O
Zealand	O
cohort	O
and	O
the	O
association	O
with	O
pregnancy	O
outcome	O
Abstract	O
Background	O
Pregnant	O
women	O
are	O
at	O
increased	O
susceptibility	O
to	O
vitamin	O
D	O
deficiency	O
.	O

Hence	O
,	O
there	O
is	O
continuing	O
interest	O
in	O
determining	O
how	O
vitamin	O
D	O
influences	O
pregnancy	O
health	O
.	O

We	O
aimed	O
to	O
compare	O
vitamin	O
D	O
status	O
in	O
two	O
distinct	O
populations	O
of	O
pregnant	O
women	O
in	O
Australia	O
and	O
New	O
Zealand	O
and	O
to	O
investigate	O
the	O
relationship	O
between	O
vitamin	O
D	O
status	O
and	O
pregnancy	O
outcome	O
.	O

This	O
included	O
evaluating	O
possible	O
effect	O
measure	O
modifications	O
according	O
to	O
fetal	O
sex	O
.	O

Methods	O
Serum	O
25	O
-	O
hydroxy	O
vitamin	O
D	O
(	O
25	O
(	O
OH	O
)	O
D	O
)	O
was	O
measured	O
at	O
15	O
±	O
1	O
weeks	O
’	O
gestation	O
in	O
2800	O
women	O
from	O
Adelaide	O
and	O
Auckland	O
who	O
participated	O
in	O
the	O
multi	O
-	O
centre	O
,	O
prospective	O
cohort	O
SCreening	O
fOr	O
Pregnancy	O
Endpoints	O
(	O
SCOPE	O
)	O
study	O
.	O

Results	O
Mean	O
serum	O
25	O
(	O
OH	O
)	O
D	O
in	O
all	O
women	O
was	O
68	O
.	O
1	O
±	O
27	O
.	O
1	O
nmol	O
/	O
L	O
and	O
28	O
%	O
(	O
n	O
=	O
772	O
)	O
were	O
considered	O
vitamin	O
D	O
deficient	O
(<	O
50	O
nmol	O
/	O
L	O
).	O

Serum	O
25	O
(	O
OH	O
)	O
D	O
was	O
lower	O
in	O
the	O
women	O
recruited	O
in	O
Adelaide	O
when	O
compared	O
to	O
the	O
women	O
recruited	O
in	O
Auckland	O
and	O
remained	O
lower	O
after	O
adjusting	O
for	O
covariates	O
including	O
maternal	O
body	O
mass	O
index	O
and	O
socioeconomic	O
index	O
(	O
Adelaide	O
:	O
58	O
.	O
4	O
±	O
50	O
.	O
3	O
vs	O
.	O
Auckland	O
:	O
70	O
.	O
2	O
±	O
54	O
.	O
5	O
nmol	O
/	O
L	O
,	O
P	O
<	O
0	O
.	O
001	O
).	O

A	O
53	O
%	O
decreased	O
risk	O
for	O
gestational	O
diabetes	O
mellitus	O
(	O
GDM	O
)	O
was	O
observed	O
with	O
high	O
(>	O
81	O
nmol	O
/	O
L	O
)	O
“	O
standardised	O
”	O
vitamin	O
D	O
status	O
when	O
compared	O
to	O
moderate	O
-	O
high	O
(	O
63	O
–	O
81	O
nmol	O
/	O
L	O
,	O
aRR	O
,	O
0	O
.	O
47	O
;	O
95	O
%	O
CI	O
:	O
0	O
.	O
23	O
,	O
0	O
.	O
96	O
).	O

Marginal	O
sex	O
-	O
specific	O
differences	O
occurred	O
between	O
vitamin	O
D	O
status	O
and	O
GDM	O
:	O
women	O
carrying	O
a	O
female	O
fetus	O
had	O
a	O
56	O
%	O
decreased	O
risk	O
for	O
GDM	O
in	O
those	O
with	O
low	O
-	O
moderate	O
levels	O
of	O
standardised	O
vitamin	O
D	O
(	O
44	O
–	O
63	O
nmol	O
/	O
L	O
)	O
compared	O
to	O
moderate	O
-	O
high	O
levels	O
(	O
aRR	O
:	O
0	O
.	O
44	O
;	O
95	O
%	O
CI	O
:	O
0	O
.	O
20	O
,	O
0	O
.	O
97	O
),	O
whilst	O
in	O
women	O
carrying	O
a	O
male	O
fetus	O
,	O
a	O
55	O
%	O
decreased	O
risk	O
of	O
GDM	O
was	O
found	O
with	O
high	O
standardised	O
vitamin	O
D	O
when	O
compared	O
to	O
moderately	O
-	O
high	O
vitamin	O
D	O
,	O
but	O
this	O
was	O
not	O
statistically	O
significant	O
(	O
aRR	O
:	O
0	O
.	O
45	O
;	O
95	O
%	O
CI	O
:	O
0	O
.	O
15	O
,	O
1	O
.	O
38	O
).	O

Conclusions	O
High	O
serum	O
25	O
(	O
OH	O
)	O
D	O
at	O
15	O
±	O
1	O
weeks	O
’	O
gestation	O
was	O
shown	O
to	O
be	O
protective	O
against	O
the	O
development	O
of	O
GDM	O
.	O

A	O
possible	O
association	O
between	O
fetal	O
sex	O
,	O
vitamin	O
D	O
status	O
and	O
GDM	O
provides	O
further	O
questions	O
and	O
encourages	O
continual	O
research	O
and	O
discussion	O
into	O
the	O
role	O
of	O
vitamin	O
D	O
in	O
pregnancy	O
,	O
particularly	O
in	O
vitamin	O
D	O
replete	O
populations	O
.	O

Electronic	O
supplementary	O
material	O
The	O
online	O
version	O
of	O
this	O
article	O
(	O
10	O
.	O
1186	O
/	O
s12884	O
-	O
018	O
-	O
1887	O
-	O
x	O
)	O
contains	O
supplementary	O
material	O
,	O
which	O
is	O
available	O
to	O
authorized	O
users	O
.	O

Background	O
With	O
an	O
increasing	O
prevalence	O
of	O
vitamin	O
D	O
deficiency	O
and	O
insufficiency	O
reported	O
both	O
in	O
Australia	O
and	O
New	O
Zealand	O
,	O
as	O
well	O
as	O
worldwide	O
[	O
1	O
],	O
there	O
is	O
continuing	O
interest	O
in	O
determining	O
how	O
vitamin	O
D	O
deficiency	O
may	O
influence	O
health	O
in	O
pregnancy	O
.	O

Evidence	O
suggests	O
that	O
vitamin	O
D	O
deficiency	O
is	O
associated	O
with	O
a	O
number	O
of	O
pregnancy	O
complications	O
including	O
preeclampsia	O
(	O
PE	O
),	O
gestational	O
diabetes	O
mellitus	O
(	O
GDM	O
)	O
and	O
spontaneous	O
preterm	O
birth	O
(	O
sPTB	O
)	O
[	O
2	O
–	O
4	O
].	O

However	O
,	O
inconsistencies	O
between	O
studies	O
reflect	O
uncertainty	O
about	O
the	O
true	O
effect	O
of	O
vitamin	O
D	O
deficiency	O
on	O
pregnancy	O
outcome	O
[	O
5	O
,	O
6	O
].	O

This	O
may	O
be	O
explained	O
,	O
in	O
part	O
,	O
by	O
inadequate	O
control	O
of	O
related	O
risk	O
factors	O
and	O
confounders	O
in	O
statistical	O
analyses	O
,	O
variations	O
between	O
assays	O
that	O
measure	O
vitamin	O
D	O
and	O
significant	O
heterogeneity	O
between	O
studied	O
populations	O
[	O
6	O
].	O

Vitamin	O
D	O
status	O
is	O
determined	O
by	O
measuring	O
circulating	O
serum	O
levels	O
of	O
25	O
-	O
hydroxy	O
vitamin	O
D2	O
+	O
3	O
(	O
25	O
(	O
OH	O
)	O
D	O
).	O

In	O
Australia	O
and	O
New	O
Zealand	O
,	O
the	O
deficiency	O
cut	O
-	O
offs	O
are	O
based	O
on	O
the	O
role	O
of	O
vitamin	O
D	O
in	O
bone	O
health	O
where	O
serum	O
25	O
(	O
OH	O
)	O
D	O
≥	O
50	O
nmol	O
/	O
L	O
at	O
the	O
end	O
of	O
winter	O
is	O
required	O
for	O
optimal	O
musculoskeletal	O
health	O
[	O
1	O
].	O

Furthermore	O
,	O
it	O
has	O
been	O
established	O
that	O
serum	O
25	O
(	O
OH	O
)	O
D	O
≥	O
50	O
nmol	O
/	O
L	O
is	O
recommended	O
during	O
pregnancy	O
and	O
lactation	O
[	O
7	O
].	O

The	O
incidence	O
of	O
vitamin	O
D	O
deficiency	O
(˂	O
50	O
nmol	O
/	O
L	O
)	O
is	O
frequent	O
among	O
pregnant	O
women	O
even	O
in	O
areas	O
such	O
as	O
Australia	O
and	O
the	O
North	O
Island	O
of	O
New	O
Zealand	O
where	O
sunlight	O
exposure	O
is	O
high	O
.	O

Studies	O
focused	O
on	O
high	O
-	O
risk	O
populations	O
,	O
for	O
example	O
,	O
veiled	O
,	O
dark	O
-	O
skinned	O
or	O
obese	O
women	O
in	O
Australia	O
and	O
New	O
Zealand	O
,	O
report	O
between	O
50	O
and	O
94	O
%	O
of	O
women	O
to	O
be	O
vitamin	O
D	O
deficient	O
[	O
8	O
–	O
10	O
].	O

Reports	O
from	O
lower	O
-	O
risk	O
groups	O
have	O
indicated	O
that	O
vitamin	O
D	O
deficiency	O
occurs	O
in	O
25	O
–	O
55	O
%	O
of	O
pregnant	O
women	O
[	O
11	O
–	O
13	O
].	O

There	O
are	O
numerous	O
studies	O
which	O
have	O
shown	O
that	O
vitamin	O
D	O
deficiency	O
is	O
associated	O
with	O
adverse	O
pregnancy	O
outcomes	O
(	O
Most	O
recent	O
:	O
[	O
14	O
–	O
17	O
]),	O
particularly	O
in	O
populations	O
that	O
reside	O
at	O
higher	O
latitudes	O
.	O

However	O
,	O
studies	O
in	O
women	O
from	O
Australia	O
and	O
New	O
Zealand	O
are	O
less	O
consistent	O
.	O

Previous	O
studies	O
on	O
pregnant	O
Australian	O
and	O
New	O
Zealand	O
women	O
have	O
reported	O
that	O
while	O
circulating	O
25	O
(	O
OH	O
)	O
D	O
was	O
significantly	O
lower	O
in	O
women	O
with	O
PE	O
,	O
sPTB	O
,	O
GDM	O
and	O
those	O
who	O
delivered	O
a	O
small	O
-	O
for	O
gestational	O
age	O
(	O
SGA	O
)	O
infant	O
,	O
no	O
association	O
between	O
vitamin	O
D	O
deficiency	O
and	O
these	O
pregnancy	O
complications	O
was	O
found	O
after	O
adjusting	O
for	O
covariates	O
[	O
18	O
–	O
20	O
].	O

Differences	O
in	O
ethnicity	O
[	O
21	O
],	O
solar	O
exposure	O
and	O
geographical	O
location	O
,	O
as	O
well	O
as	O
genetics	O
[	O
22	O
]	O
and	O
supplementation	O
[	O
23	O
–	O
25	O
],	O
are	O
known	O
to	O
affect	O
25	O
(	O
OH	O
)	O
D	O
status	O
and	O
therefore	B
influence	O
study	O
outcomes	O
.	O

Furthermore	O
,	O
the	O
gestation	O
at	O
which	O
vitamin	O
D	O
was	O
measured	O
is	O
also	O
important	O
.	O

In	O
the	O
case	O
of	O
preterm	O
delivery	O
,	O
vitamin	O
D	O
status	O
measured	O
closer	O
to	O
the	O
delivery	O
date	O
was	O
more	O
significantly	O
associated	O
with	O
preterm	O
delivery	O
than	O
earlier	O
measures	O
[	O
26	O
].	O

However	O
,	O
measuring	O
circulating	O
25	O
(	O
OH	O
)	O
D	O
in	O
early	O
pregnancy	O
is	O
common	O
and	O
potentially	O
clinically	O
useful	O
as	O
this	O
is	O
prior	O
to	O
when	O
many	O
of	O
the	O
pregnancy	O
complications	O
that	O
affect	O
late	O
gestation	O
manifest	O
.	O

Using	O
a	O
robust	O
,	O
validated	O
chemiluminescent	O
-	O
based	O
assay	O
to	O
measure	O
serum	O
25	O
(	O
OH	O
)	O
D	O
[	O
27	O
],	O
we	O
aimed	O
to	O
investigate	O
the	O
differences	O
between	O
vitamin	O
D	O
status	O
in	O
early	O
pregnancy	O
in	O
two	O
distinct	O
populations	O
of	O
nulliparous	O
women	O
from	O
Australia	O
and	O
New	O
Zealand	O
.	O

We	O
also	O
aimed	O
to	O
examine	O
the	O
relationship	O
between	O
serum	O
25	O
(	O
OH	O
)	O
D	O
at	O
15	O
±	O
1	O
weeks	O
’	O
gestation	O
and	O
the	O
risk	O
of	O
an	O
adverse	O
pregnancy	O
outcome	O
and	O
included	O
determining	O
the	O
effect	O
modification	O
of	O
fetal	O
sex	O
on	O
the	O
association	O
between	O
maternal	O
vitamin	O
D	O
status	O
and	O
pregnancy	O
outcome	O
.	O

Methods	O
Study	O
population	O
This	O
study	O
utilised	O
data	O
collected	O
from	O
the	O
multi	O
-	O
centre	O
,	O
prospective	O
cohort	O
Screening	O
for	O
Pregnancy	O
Endpoints	O
(	O
SCOPE	O
)	O
study	O
[	O
28	O
].	O

Nulliparous	O
women	O
carrying	O
a	O
singleton	O
pregnancy	O
were	O
recruited	O
between	O
November	O
2004	O
and	O
September	O
2008	O
in	O
Adelaide	O
(	O
Australia	O
)	O
and	O
Auckland	O
(	O
New	O
Zealand	O
).	O

Ethics	O
approval	O
was	O
obtained	O
from	O
Central	O
Northern	O
Adelaide	O
Health	O
Service	O
Ethics	O
of	O
Human	O
Research	O
Committee	O
on	O
2	O
September	O
2005	O
(	O
ethics	O
number	O
REC	O
1714	O
/	O
5	O
/	O
2008	O
)	O
and	O
Northern	O
Region	O
Ethics	O
Committee	O
,	O
in	O
Auckland	O
on	O
23	O
April	O
2003	O
(	O
ethics	O
number	O
AKX	O
/	O
02	O
/	O
00	O
/	O
364	O
).	O

All	O
participants	O
provided	O
written	O
informed	O
consent	O
.	O

At	O
15	O
±	O
1	O
weeks	O
’	O
gestation	O
,	O
women	O
were	O
interviewed	O
by	O
a	O
research	O
midwife	O
and	O
asked	O
questions	O
on	O
maternal	O
demographics	O
and	O
lifestyle	O
and	O
had	O
physical	O
measurements	O
taken	O
,	O
including	O
height	O
and	O
weight	O
.	O

Records	O
included	O
ethnicity	O
,	O
age	O
,	O
body	O
mass	O
index	O
(	O
BMI	O
),	O
socioeconomic	O
index	O
(	O
SEI	O
)	O
and	O
multivitamin	O
use	O
[	O
29	O
].	O

BMI	O
was	O
calculated	O
as	O
weight	O
(	O
kg	O
)/	O
height2	O
(	O
m2	O
).	O

Obesity	O
was	O
defined	O
as	O
BMI	O
≥	O
30	O
kg	O
/	O
m2	O
,	O
overweight	O
as	O
BMI	O
≥	O
25	O
and	O
<	O
30	O
kg	O
/	O
m2	O
,	O
normal	O
weight	O
as	O
BMI	O
>	O
20	O
and	O
<	O
25	O
kg	O
/	O
m2and	O
underweight	O
as	O
BMI	O
≤	O
20	O
kg	O
/	O
m2	O
.	O

SEI	O
was	O
calculated	O
using	O
the	O
New	O
Zealand	O
SEI	O
of	O
occupational	O
status	O
,	O
deriving	O
a	O
number	O
between	O
10	O
and	O
90	O
based	O
on	O
the	O
woman	O
’	O
s	O
occupation	O
;	O
a	O
higher	O
number	O
indicates	O
higher	O
socioeconomic	O
status	O
[	O
30	O
].	O

This	O
population	O
of	O
women	O
was	O
predominantly	O
Caucasian	O
and	O
thus	O
maternal	O
ethnicity	O
was	O
categorised	O
into	O
2	O
main	O
groups	O
;	O
Caucasian	O
and	O
non	O
-	O
Caucasian	O
.	O

Uncomplicated	O
pregnancies	O
were	O
defined	O
as	O
those	O
without	O
any	O
pregnancy	O
disorder	O
who	O
delivered	O
an	O
appropriate	O
weight	O
for	O
gestational	O
age	O
infant	O
at	O
term	O
(≥	O
37	O
weeks	O
gestation	O
)	O
[	O
31	O
].	O

Pregnancy	O
complications	O
studied	O
included	O
PE	O
,	O
gestational	O
hypertension	O
(	O
GH	O
),	O
GDM	O
,	O
sPTB	O
and	O
SGA	O
and	O
have	O
been	O
previously	O
defined	O
[	O
28	O
,	O
29	O
,	O
31	O
,	O
32	O
].	O

Measurement	O
of	O
serum	O
25	O
(	O
OH	O
)	O
D	O
Non	O
-	O
fasting	O
whole	O
peripheral	O
blood	O
samples	O
were	O
collected	O
into	O
non	O
-	O
heparinised	O
tubes	O
at	O
15	O
±	O
1	O
weeks	O
’	O
gestation	O
.	O

Serum	O
was	O
processed	O
within	O
4	O
h	O
of	O
collection	O
and	O
stored	O
at	O
−	O
80	O
°	O
C	O
until	O
required	O
.	O

Unlike	O
the	O
previously	O
published	O
data	O
on	O
vitamin	O
D	O
in	O
the	O
Auckland	O
cohort	O
[	O
20	O
],	O
serum	O
25	O
(	O
OH	O
)	O
D	O
was	O
measured	O
using	O
the	O
IDS	O
-	O
iSYS	O
chemiluminescent	O
-	O
based	O
assay	O
(	O
Abacus	O
,	O
ALS	O
)	O
as	O
per	O
the	O
manufacturer	O
’	O
s	O
instructions	O
.	O

Average	O
intra	O
-	O
and	O
inter	O
-	O
assay	O
coefficient	O
of	O
variation	O
(	O
CV	O
)	O
were	O
5	O
.	O
4	O
and	O
8	O
.	O
8	O
%,	O
respectively	O
.	O

Both	O
serum	O
25	O
(	O
OH	O
)	O
D3and	O
25	O
(	O
OH	O
)	O
D2were	O
measured	O
independently	O
and	O
combined	O
to	O
provide	O
a	O
total	O
25	O
(	O
OH	O
)	O
D	O
in	O
nmol	O
/	O
L	O
[	O
27	O
].	O

Statistical	O
analyses	O
Statistical	O
analyses	O
were	O
performed	O
in	O
R	O
(	O
v3	O
.	O
1	O
.	O
1	O
)	O
[	O
33	O
].	O

Data	O
were	O
checked	O
for	O
normality	O
using	O
a	O
Shapiro	O
-	O
Wilks	O
test	O
and	O
differences	O
between	O
women	O
recruited	O
in	O
Adelaide	O
compared	O
to	O
Auckland	O
were	O
tabulated	O
and	O
compared	O
using	O
a	O
Welch	O
’	O
s	O
t	O
-	O
test	O
(	O
continuous	O
variables	O
)	O
or	O
Fisher	O
’	O
s	O
exact	O
test	O
(	O
categorical	O
variables	O
).	O

Given	O
that	O
the	O
month	O
in	O
which	O
the	O
serum	O
was	O
sampled	O
heavily	O
influences	O
vitamin	O
D	O
status	O
,	O
“	O
standardised	O
”	O
serum	O
25	O
(	O
OH	O
)	O
D	O
concentrations	O
were	O
calculated	O
as	O
previously	O
described	O
[	O
34	O
]	O
in	O
order	O
to	O
normalise	O
against	O
seasonal	O
variation	O
.	O

Briefly	O
,	O
vitamin	O
D	O
concentrations	O
were	O
standardized	O
by	O
taking	O
the	O
difference	O
of	O
25	O
(	O
OH	O
)	O
D	O
concentration	O
to	O
the	O
average	O
25	O
(	O
OH	O
)	O
D	O
concentration	O
of	O
the	O
corresponding	O
month	O
.	O

This	O
25	O
(	O
OH	O
)	O
D	O
concentration	O
was	O
then	O
added	O
to	O
the	O
overall	O
population	O
mean	O
25	O
(	O
OH	O
)	O
D	O
concentration	O
:	O
68	O
.	O
09	O
nmol	O
/	O
L	O
.	O

Quartiles	O
,	O
based	O
on	O
the	O
distribution	O
amongst	O
the	O
population	O
of	O
women	O
studied	O
,	O
in	O
the	O
standardised	O
concentrations	O
were	O
then	O
used	O
to	O
create	O
cut	O
-	O
points	O
and	O
designated	O
‘	O
low	O
’	O
(<	O
44	O
nmol	O
/	O
L	O
),	O
‘	O
low	O
-	O
moderate	O
’	O
(	O
44	O
–	O
63	O
nmol	O
/	O
L	O
),	O
‘	O
moderate	O
-	O
high	O
’	O
(	O
63	O
–	O
81	O
nmol	O
/	O
L	O
)	O
and	O
‘	O
high	O
’	O
(>	O
81	O
nmol	O
/	O
L	O
)	O
categories	O
of	O
serum	O
25	O
(	O
OH	O
)	O
D	O
.	O
Generalised	O
linear	O
models	O
(	O
Poisson	O
with	O
log	O
link	O
and	O
robust	O
variance	O
estimates	O
)	O
were	O
used	O
to	O
calculate	O
the	O
risk	O
ratios	O
for	O
pregnancy	O
complications	O
by	O
standardised	O
serum	O
25	O
(	O
OH	O
)	O
D	O
concentrations	O
calculated	O
among	O
the	O
women	O
who	O
had	O
an	O
uncomplicated	O
pregnancy	O
.	O

Potential	O
confounders	O
for	O
vitamin	O
D	O
status	O
were	O
assessed	O
using	O
linear	O
modelling	O
.	O

Maternal	O
age	O
,	O
BMI	O
,	O
SEI	O
,	O
alcohol	O
consumption	O
at	O
15	O
±	O
1	O
weeks	O
’	O
gestation	O
(	O
never	O
/	O
former	O
vs	O
.	O
current	O
),	O
recreational	O
walking	O
(	O
1	O
–	O
3	O
times	O
/	O
week	O
and	O
≥	O
4	O
times	O
/	O
week	O
vs	O
.	O
never	O
),	O
ethnicity	O
(	O
Caucasian	O
vs	O
.	O
non	O
-	O
Caucasian	O
)	O
and	O
recruitment	O
site	O
(	O
Adelaide	O
vs	O
.	O
Auckland	O
)	O
were	O
significantly	O
associated	O
with	O
serum	O
25	O
(	O
OH	O
)	O
D	O
and	O
along	O
with	O
smoking	O
status	O
at	O
15	O
±	O
1	O
weeks	O
’	O
gestation	O
(	O
never	O
/	O
former	O
vs	O
.	O
current	O
)	O
included	O
as	O
main	O
effects	O
within	O
the	O
generalised	O
linear	O
models	O
.	O

These	O
analyses	O
were	O
also	O
repeated	O
but	O
using	O
the	O
current	O
definitions	O
of	O
vitamin	O
D	O
deficiency	O
:	O
<	O
25	O
,	O
25	O
–	O
50	O
,	O
50	O
–	O
75	O
and	O
>	O
75	O
nmol	O
/	O
L	O
in	O
the	O
non	O
-	O
standardised	O
data	O
[	O
7	O
].	O

We	O
also	O
stratified	O
based	O
on	O
fetal	O
sex	O
to	O
evaluate	O
possible	O
effect	O
measure	O
modifications	O
according	O
to	O
whether	O
the	O
mother	O
was	O
carry	O
a	O
male	O
or	O
female	O
fetus	O
.	O

Results	O
Population	O
characteristics	O
Of	O
3229	O
women	O
recruited	O
as	O
part	O
of	O
SCOPE	O
at	O
the	O
Adelaide	O
and	O
Auckland	O
centres	O
,	O
serum	O
samples	O
at	O
15	O
±	O
1	O
weeks	O
’	O
gestation	O
to	O
measure	O
25	O
(	O
OH	O
)	O
D	O
were	O
available	O
for	O
2800	O
(	O
87	O
%)	O
women	O
of	O
whom	O
,	O
1156	O
(	O
41	O
%)	O
were	O
recruited	O
in	O
Adelaide	O
and	O
1644	O
(	O
59	O
%)	O
were	O
recruited	O
in	O
Auckland	O
.	O

Maternal	O
characteristics	O
are	O
shown	O
in	O
Table	O
1	O
.	O

Compared	O
to	O
women	O
who	O
were	O
recruited	O
at	O
the	O
Adelaide	O
site	O
,	O
women	O
recruited	O
in	O
Auckland	O
were	O
older	O
,	O
had	O
a	O
lower	O
BMI	O
,	O
less	O
likely	B
to	O
smoke	O
or	O
drink	O
alcohol	O
during	O
pregnancy	O
and	O
more	O
likely	B
to	O
eat	O
fruit	O
and	O
undertake	O
recreational	O
walks	O
.	O

Mean	O
±	O
SD	O
SEI	O
of	O
the	O
Auckland	O
women	O
was	O
also	O
higher	O
compared	O
to	O
that	O
in	O
women	O
recruited	O
in	O
Adelaide	O
(	O
Auckland	O
:	O
48	O
.	O
0	O
±	O
14	O
.	O
8	O
vs	O
.	O
Adelaide	O
:	O
27	O
.	O
7	O
±	O
10	O
.	O
5	O
,	O
P	O
<	O
0	O
.	O
001	O
).	O

Given	O
that	O
all	O
these	O
factors	O
significantly	O
influenced	O
serum	O
25	O
(	O
OH	O
)	O
D	O
in	O
the	O
linear	O
regression	O
model	O
,	O
it	O
was	O
unsurprising	O
that	O
vitamin	O
D	O
status	O
of	O
the	O
women	O
was	O
significantly	O
different	O
between	O
the	O
two	O
recruitment	O
sites	O
.	O

However	O
,	O
after	O
adjusting	O
for	O
maternal	O
age	O
,	O
BMI	O
,	O
SEI	O
,	O
smoking	O
status	O
and	O
alcohol	O
consumption	O
at	O
15	O
±	O
1	O
weeks	O
’	O
gestation	O
,	O
ethnicity	O
,	O
recreational	O
walking	O
and	O
season	O
,	O
the	O
women	O
recruited	O
in	O
Adelaide	O
still	O
had	O
significantly	O
lower	O
serum	O
25	O
(	O
OH	O
)	O
D	O
when	O
compared	O
with	O
those	O
in	O
Auckland	O
(	O
Adelaide	O
:	O
58	O
.	O
4	O
±	O
50	O
.	O
3	O
vs	O
.	O
Auckland	O
:	O
70	O
.	O
2	O
±	O
54	O
.	O
5	O
nmol	O
/	O
L	O
,	O
P	O
<	O
0	O
.	O
001	O
)	O
indicating	O
the	O
influence	O
of	O
other	O
confounders	O
not	O
measured	O
as	O
part	O
of	O
the	O
study	O
on	O
vitamin	O
D	O
status	O
.	O

Caption	O
(	O
TABLE	O
-	O
WRAP	O
):	O
TABLE	O
1	O
Participant	O
characteristics	O
and	O
comparison	O
of	O
characteristics	O
between	O
women	O
recruited	O
at	O
the	O
Adelaide	O
and	O
Auckland	O
SCOPE	O
centresAll	O
women	O
(	O
n	O
=	O
2800	O
)	O
Adelaide	O
(	O
n	O
=	O
1156	O
)	O
Auckland	O
(	O
n	O
=	O
1644	O
)	O
P	O
value	O
*	O
Age	O
yrs	O
,	O
mean	O
(	O
SD	O
)	O
28	O
(	O
6	O
)	O
23	O
.	O
73	O
(	O
5	O
.	O
11	O
)	O
30	O
.	O
44	O
(	O
4	O
.	O
82	O
)<	O
0	O
.	O
0001BMI	O
kg	O
/	O
m2	O
,	O
mean	O
(	O
SD	O
)	O
25	O
.	O
8	O
(	O
5	O
.	O
44	O
)	O
27	O
.	O
04	O
(	O
6	O
.	O
56	O
)	O
24	O
.	O
88	O
(	O
4	O
.	O
26	O
)<	O
0	O
.	O
0001Ethnicity	O
<	O
0	O
.	O
0001	O
Caucasian2449	O
(	O
87	O
)	O
1060	O
(	O
92	O
)	O
1389	O
(	O
84	O
)	O
Non	O
Caucasian351	O
(	O
13	O
)	O
96	O
(	O
8	O
)	O
255	O
(	O
16	O
)	O
Smoking	O
status	O
,	O
n	O
(%)<	O
0	O
.	O
0001	O
No2152	O
(	O
77	O
)	O
704	O
(	O
61	O
)	O
1448	O
(	O
88	O
)	O
Quit	O
during	O
pregnancy306	O
(	O
11	O
)	O
175	O
(	O
15	O
)	O
131	O
(	O
8	O
)	O
Smoking342	O
(	O
12	O
)	O
277	O
(	O
24	O
)	O
65	O
(	O
4	O
)	O
Alcohol	O
Consumption	O
,	O
n	O
(%)<	O
0	O
.	O
0001	O
No1480	O
(	O
53	O
)	O
708	O
(	O
61	O
)	O
772	O
(	O
47	O
)	O
Stopped	O
during	O
pregnancy1185	O
(	O
42	O
)	O
397	O
(	O
34	O
)	O
788	O
(	O
48	O
)	O
Consuming	O
alcohol135	O
(	O
5	O
)	O
51	O
(	O
4	O
)	O
84	O
(	O
5	O
)	O
Fruit	O
Intake	O
,	O
n	O
(%)<	O
0	O
.	O
0001	O
≥	O
1x	O
per	O
day2032	O
(	O
73	O
)	O
586	O
(	O
51	O
)	O
1446	O
(	O
88	O
)	O
3	O
-	O
6x	O
per	O
week405	O
(	O
14	O
)	O
272	O
(	O
24	O
)	O
133	O
(	O
8	O
)	O
1	O
-	O
2x	O
per	O
week223	O
(	O
8	O
)	O
181	O
(	O
16	O
)	O
42	O
(	O
3	O
)	O
1	O
-	O
3x	O
per	O
month	O
or	O
less140	O
(	O
5	O
)	O
117	O
(	O
10	O
)	O
23	O
(	O
1	O
)	O
Recreational	O
Walking	O
<	O
0	O
.	O
0001	O
Never428	O
(	O
15	O
)	O
265	O
(	O
23	O
)	O
163	O
(	O
10	O
)	O
1	O
-	O
3	O
times	O
/	O
week1773	O
(	O
63	O
)	O
668	O
(	O
58	O
)	O
1105	O
(	O
68	O
)	O
≥	O
4	O
times	O
/	O
week590	O
(	O
22	O
)	O
221	O
(	O
19	O
)	O
369	O
(	O
23	O
)	O
Time	O
watching	O
TV	O
<	O
0	O
.	O
0001	O
<	O
5	O
hours	O
per	O
day2404	O
(	O
86	O
)	O
901	O
(	O
78	O
)	O
1503	O
(	O
92	O
)	O
≥	O
5	O
hours	O
per	O
day387	O
(	O
14	O
)	O
253	O
(	O
22	O
)	O
134	O
(	O
8	O
)	O
Season	O
serum	O
was	O
sampled0	O
.	O
3213	O
Summer636	O
(	O
23	O
)	O
278	O
(	O
24	O
)	O
358	O
(	O
22	O
)	O
Autumn705	O
(	O
25	O
)	O
273	O
(	O
24	O
)	O
432	O
(	O
26	O
)	O
Winter727	O
(	O
26	O
)	O
300	O
(	O
26	O
)	O
427	O
(	O
26	O
)	O
Spring732	O
(	O
26	O
)	O
305	O
(	O
26	O
)	O
427	O
(	O
26	O
)	O
Serum	O
25	O
(	O
OH	O
)	O
D	O
nmol	O
/	O
L	O
,	O
mean	O
(	O
SD	O
)	O
68	O
.	O
09	O
(	O
27	O
.	O
14	O
)	O
60	O
.	O
06	O
(	O
23	O
.	O
68	O
)	O
73	O
.	O
74	O
(	O
27	O
.	O
99	O
)<	O
0	O
.	O
0001Vitamin	O
D	O
Status	O
<	O
0	O
.	O
0001	O
<	O
25	O
nmol	O
/	O
L99	O
(	O
4	O
)	O
48	O
(	O
4	O
)	O
51	O
(	O
3	O
)	O
25	O
-	O
50	O
nmol	O
/	O
L673	O
(	O
24	O
)	O
375	O
(	O
32	O
)	O
298	O
(	O
18	O
)	O
50	O
-	O
75	O
nmol	O
/	O
L928	O
(	O
33	O
)	O
422	O
(	O
37	O
)	O
506	O
(	O
31	O
)	O
>	O
75	O
nmol	O
/	O
L1098	O
(	O
39	O
)	O
311	O
(	O
27	O
)	O
787	O
(	O
48	O
)	O
*	O
P	O
values	O
for	O
continuous	O
variables	O
were	O
determined	O
using	O
a	O
Welch	O
’	O
s	O
t	O
-	O
test	O
and	O
categorical	O
variables	O
a	O
Fisher	O
’	O
s	O
exact	O
test	O
comparing	O
Adelaide	O
and	O
Auckland	O
women	O
Standardising	O
serum	O
25	O
(	O
OH	O
)	O
D	O
based	O
on	O
seasonal	O
variation	O
As	O
expected	O
,	O
there	O
was	O
a	O
seasonal	O
influence	O
on	O
serum	O
25	O
(	O
OH	O
)	O
D	O
and	O
thus	B
,	O
“	O
standardised	O
”	O
vitamin	O
D	O
concentrations	O
were	O
calculated	O
to	O
account	O
for	O
the	O
month	O
of	O
serum	O
collection	O
.	O

Average	O
hours	O
of	O
sunlight	O
per	O
day	O
in	O
Adelaide	O
from	O
September	O
2005	O
to	O
September	O
2008	O
were	O
obtained	O
from	O
the	O
Australian	O
Government	O
Bureau	O
of	O
Meteorology	O
and	O
compared	O
against	O
serum	O
vitamin	O
D	O
measured	O
in	O
the	O
women	O
recruited	O
in	O
Adelaide	O
(	O
Fig	O
.	O

1a	O
;	O
black	O
line	O
/	O
left	O
axis	O
serum	O
25	O
(	O
OH	O
)	O
D	O
and	O
grey	O
line	O
/	O
right	O
axis	O
average	O
hours	O
of	O
sunlight	O
).	O

The	O
means	O
for	O
serum	O
25	O
(	O
OH	O
)	O
D	O
by	O
month	O
of	O
sampling	O
were	O
also	O
separated	O
for	O
women	O
recruited	O
in	O
Adelaide	O
and	O
women	O
recruited	O
in	O
Auckland	O
(	O
Fig	O
.	O
1b	O
).	O

Caption	O
(	O
FIG	O
):	O
FIG	O
.	O

1	O
Seasonal	O
variation	O
in	O
serum	O
25	O
(	O
OH	O
)	O
D	O
.	O
a	O
.	O

Comparison	O
of	O
serum	O
25	O
(	O
OH	O
)	O
D	O
levels	O
based	O
on	O
month	O
of	O
sampling	O
in	O
the	O
women	O
recruited	O
in	O
Adelaide	O
(	O
black	O
line	O
&	O
left	O
axis	O
)	O
and	O
average	O
hours	O
of	O
sunlight	O
per	O
day	O
in	O
Adelaide	O
(	O
grey	O
line	O
&	O
right	O
axis	O
).	O

Seasonal	O
variation	O
in	O
vitamin	O
D	O
followed	O
a	O
similar	O
pattern	O
to	O
hours	O
of	O
sunlight	O
although	O
was	O
slightly	O
shifted	O
.	O

b	O
.	O

Seasonal	O
variation	O
of	O
serum	O
25	O
(	O
OH	O
)	O
D	O
based	O
on	O
month	O
of	O
sampling	O
between	O
women	O
recruited	O
in	O
Adelaide	O
compared	O
to	O
Auckland	O
.	O

Data	O
are	O
mean	O
±	O
SD	O
Serum	O
25	O
(	O
OH	O
)	O
D	O
and	O
pregnancy	O
outcome	O
Of	O
the	O
2800	O
women	O
present	O
in	O
this	O
study	O
,	O
1217	O
(	O
43	O
%)	O
women	O
went	O
on	O
to	O
develop	O
a	O
pregnancy	O
complication	O
and	O
included	O
5	O
.	O
8	O
%	O
(	O
n	O
=	O
161	O
)	O
who	O
developed	O
PE	O
,	O
7	O
.	O
6	O
%	O
(	O
n	O
=	O
213	O
)	O
who	O
developed	O
GH	O
,	O
3	O
.	O
3	O
%	O
(	O
n	O
=	O
92	O
)	O
who	O
developed	O
GDM	O
,	O
5	O
%	O
(	O
n	O
=	O
139	O
)	O
who	O
spontaneously	O
delivered	O
preterm	O
and	O
10	O
.	O
6	O
%	O
(	O
n	O
=	O
298	O
)	O
who	O
delivered	O
an	O
SGA	O
infant	O
.	O

The	O
association	O
between	O
“	O
standardised	O
”	O
25	O
(	O
OH	O
)	O
D	O
with	O
pregnancy	O
complications	O
is	O
presented	O
in	O
Table	O
2	O
.	O

Using	O
moderate	O
-	O
high	O
as	O
a	O
reference	O
(	O
standardised	O
vitamin	O
D	O
63	O
–	O
81	O
nmol	O
/	O
L	O
),	O
there	O
was	O
no	O
appreciable	O
effect	O
of	O
having	O
a	O
low	O
,	O
low	O
-	O
moderate	O
or	O
high	O
vitamin	O
D	O
with	O
the	O
risk	O
of	O
developing	O
any	O
pregnancy	O
complication	O
after	O
adjusting	O
for	O
confounders	O
.	O

However	O
,	O
when	O
each	O
pregnancy	O
complication	O
was	O
analysed	O
separately	O
,	O
a	O
53	O
%	O
decreased	O
risk	O
for	O
GDM	O
was	O
observed	O
with	O
high	O
vitamin	O
D	O
status	O
when	O
compared	O
to	O
moderate	O
-	O
high	O
status	O
(	O
aRR	O
:	O
0	O
.	O
47	O
;	O
95	O
%	O
CI	O
:	O
0	O
.	O
23	O
,	O
0	O
.	O
96	O
).	O

When	O
women	O
were	O
categorised	O
based	O
on	O
clinical	O
definitions	O
of	O
vitamin	O
D	O
deficiency	O
and	O
serum	O
25	O
(	O
OH	O
)	O
D	O
between	O
50	O
and	O
75	O
nmol	O
/	O
L	O
used	O
as	O
the	O
reference	O
,	O
no	O
significant	O
relationship	O
between	O
vitamin	O
D	O
status	O
and	O
adverse	O
pregnancy	O
outcome	O
was	O
found	O
(	O
Table2	O
).	O

Although	O
,	O
the	O
point	O
estimates	O
indicated	O
a	O
marginal	O
increased	O
risk	O
for	O
developing	O
any	O
pregnancy	O
complication	O
with	O
severe	O
(<	O
25	O
nmol	O
/	O
L	O
)	O
vitamin	O
D	O
deficiency	O
compared	O
to	O
those	O
who	O
had	O
levels	O
between	O
50	O
and	O
75	O
nmol	O
/	O
L	O
(	O
aRR	O
:	O
1	O
.	O
10	O
;	O
95	O
%	O
CI	O
:	O
0	O
.	O
89	O
,	O
1	O
.	O
36	O
).	O

Caption	O
(	O
TABLE	O
-	O
WRAP	O
):	O
TABLE	O
2	O
Adjusted	O
relative	O
risks	O
(	O
aRR	O
)	O
of	O
pregnancy	O
complications	O
from	O
any	O
complication	O
,	O
preeclampsia	O
(	O
PE	O
),	O
gestational	O
hypertension	O
(	O
GH	O
),	O
gestational	O
diabetes	O
mellitus	O
(	O
GDM	O
),	O
spontaneous	O
preterm	O
birth	O
(	O
sPTB	O
)	O
and	O
small	O
-	O
for	O
-	O
gestational	O
age	O
(	O
SGA	O
)	O
according	O
to	O
vitamin	O
D	O
status	O
categorised	O
based	O
on	O
standardised	O
quartiles	O
and	O
clinical	O
definitions	O
of	O
vitamin	O
D	O
statusPregnancy	O
ComplicationsAll	O
womenAny	O
ComplicationPEGHGDMsPTBSGA	O
n	O
(%)	O
n	O
(%)	O
aRR	O
*(	O
95	O
%	O
CI	O
)	O
n	O
(%)	O
aRR	O
*(	O
95	O
%	O
CI	O
)	O
n	O
(%)	O
aRR	O
*(	O
95	O
%	O
CI	O
)	O
n	O
(%)	O
aRR	O
*(	O
95	O
%	O
CI	O
)	O
n	O
(%)	O
aRR	O
*(	O
95	O
%	O
CI	O
)	O
n	O
(%)	O
aRR	O
*(	O
95	O
%	O
CI	O
)	O
Standardised	O
Quartiles	O
**	O
Low711	O
(	O
25	O
)	O
328	O
(	O
46	O
)	O
0	O
.	O
95	O
(	O
0	O
.	O
85	O
,	O
1	O
.	O
07	O
)	O
46	O
(	O
6	O
)	O
1	O
.	O
02	O
(	O
0	O
.	O
66	O
,	O
1	O
.	O
57	O
))	O
57	O
(	O
8	O
)	O
0	O
.	O
97	O
(	O
0	O
.	O
67	O
,	O
1	O
.	O
42	O
)	O
28	O
(	O
4	O
)	O
0	O
.	O
79	O
(	O
0	O
.	O
47	O
,	O
1	O
.	O
30	O
)	O
36	O
(	O
5	O
)	O
0	O
.	O
83	O
(	O
0	O
.	O
54	O
,	O
1	O
.	O
29	O
)	O
84	O
(	O
12	O
)	O
1	O
.	O
02	O
(	O
0	O
.	O
75	O
,	O
1	O
.	O
39	O
)	O
Low	O
-	O
Moderate755	O
(	O
27	O
)	O
318	O
(	O
42	O
)	O
1	O
.	O
00	O
(	O
0	O
.	O
90	O
,	O
1	O
.	O
12	O
)	O
42	O
(	O
6	O
)	O
1	O
.	O
07	O
(	O
0	O
.	O
69	O
,	O
1	O
.	O
64	O
)	O
65	O
(	O
9	O
)	O
1	O
.	O
06	O
(	O
0	O
.	O
74	O
,	O
1	O
.	O
52	O
)	O
25	O
(	O
3	O
)	O
0	O
.	O
67	O
(	O
0	O
.	O
39	O
,	O
1	O
.	O
16	O
)	O
33	O
(	O
4	O
)	O
0	O
.	O
87	O
(	O
0	O
.	O
56	O
,	O
1	O
.	O
3572	O
(	O
10	O
)	O
0	O
.	O
98	O
(	O
0	O
.	O
73	O
,	O
1	O
.	O
32	O
)	O
Moderate	O
-	O
High702	O
(	O
25	O
)	O
309	O
(	O
44	O
)	O
1	O
.	O
0	O
†	O
37	O
(	O
5	O
)	O
1	O
.	O
0	O
†	O
50	O
(	O
7	O
)	O
1	O
.	O
0	O
†	O
28	O
(	O
4	O
)	O
1	O
.	O
0	O
†	O
39	O
(	O
6	O
)	O
1	O
.	O
0	O
†	O
81	O
(	O
12	O
)	O
1	O
.	O
0	O
†	O
High630	O
(	O
23	O
)	O
258	O
(	O
41	O
)	O
0	O
.	O
93	O
(	O
0	O
.	O
82	O
,	O
1	O
.	O
06	O
)†	O
35	O
(	O
6	O
)	O
1	O
.	O
24	O
(	O
0	O
.	O
78	O
,	O
1	O
.	O
96	O
)	O
40	O
(	O
6	O
)	O
0	O
.	O
87	O
(	O
0	O
.	O
58	O
,	O
1	O
.	O
30	O
)	O
10	O
(	O
2	O
)	O
0	O
.	O
47	O
(	O
0	O
.	O
23	O
,	O
0	O
.	O
96	O
)	O
30	O
(	O
5	O
)	O
0	O
.	O
77	O
(	O
0	O
.	O
48	O
,	O
1	O
.	O
25	O
)	O
60	O
(	O
10	O
)	O
0	O
.	O
80	O
(	O
0	O
.	O
57	O
,	O
1	O
.	O
11	O
)	O
Vitamin	O
D	O
Status	O
<	O
25	O
nmol	O
/	O
L99	O
(	O
4	O
)	O
51	O
(	O
52	O
)	O
1	O
.	O
10	O
(	O
0	O
.	O
89	O
,	O
1	O
.	O
36	O
)	O
8	O
(	O
8	O
)	O
1	O
.	O
44	O
(	O
0	O
.	O
68	O
,	O
3	O
.	O
03	O
))	O
6	O
(	O
6	O
)	O
0	O
.	O
70	O
(	O
0	O
.	O
32	O
,	O
1	O
.	O
52	O
)	O
5	O
(	O
5	O
)	O
0	O
.	O
98	O
(	O
0	O
.	O
38	O
,	O
2	O
.	O
52	O
)	O
7	O
(	O
7	O
)	O
1	O
.	O
44	O
(	O
0	O
.	O
68	O
,	O
3	O
.	O
04	O
)	O
13	O
(	O
13	O
)	O
1	O
.	O
15	O
(	O
0	O
.	O
66	O
,	O
2	O
.	O
01	O
)	O
25	O
-	O
50	O
nmol	O
/	O
L673	O
(	O
24	O
)	O
301	O
(	O
45	O
)	O
0	O
.	O
93	O
(	O
0	O
.	O
83	O
,	O
1	O
.	O
03	O
)	O
45	O
(	O
7	O
)	O
1	O
.	O
18	O
(	O
0	O
.	O
80	O
,	O
1	O
.	O
75	O
)	O
59	O
(	O
9	O
)	O
0	O
.	O
97	O
(	O
0	O
.	O
71	O
,	O
1	O
.	O
34	O
)	O
26	O
(	O
4	O
)	O
0	O
.	O
89	O
(	O
0	O
.	O
54	O
,	O
1	O
.	O
47	O
)	O
29	O
(	O
4	O
)	O
0	O
.	O
75	O
(	O
0	O
.	O
48	O
,	O
1	O
.	O
16	O
)	O
74	O
(	O
11	O
)	O
0	O
.	O
93	O
(	O
0	O
.	O
69	O
,	O
1	O
.	O
24	O
)	O
>	O
50	O
-	O
75	O
nmol	O
/	O
L928	O
(	O
33	O
)	O
428	O
(	O
46	O
)	O
1	O
.	O
0	O
†	O
48	O
(	O
5	O
)	O
1	O
.	O
0	O
†	O
80	O
(	O
9	O
)	O
1	O
.	O
0	O
†	O
35	O
(	O
4	O
)	O
1	O
.	O
0	O
†	O
52	O
(	O
6	O
)	O
1	O
.	O
0	O
†	O
107	O
(	O
12	O
)	O
1	O
.	O
0	O
†	O
>	O
75	O
nmol	O
/	O
L1098	O
(	O
39	O
)	O
435	O
(	O
40	O
)	O
0	O
.	O
95	O
(	O
0	O
.	O
86	O
,	O
1	O
.	O
04	O
)	O
60	O
(	O
5	O
)	O
1	O
.	O
28	O
(	O
0	O
.	O
87	O
,	O
1	O
.	O
87	O
)	O
67	O
(	O
6	O
)	O
0	O
.	O
82	O
(	O
0	O
.	O
59	O
,	O
1	O
.	O
12	O
)†	O
26	O
(	O
2	O
)	O
0	O
.	O
78	O
(	O
0	O
.	O
48	O
,	O
1	O
.	O
28	O
)	O
51	O
(	O
5	O
)	O
0	O
.	O
86	O
(	O
0	O
.	O
59	O
,	O
1	O
.	O
26	O
)	O
104	O
(	O
9	O
)	O
0	O
.	O
86	O
(	O
0	O
.	O
67	O
,	O
1	O
.	O
12	O
)	O
*	O
Relative	O
risks	O
compared	O
to	O
all	O
women	O
were	O
adjusted	O
for	O
age	O
,	O
maternal	O
body	O
mass	O
index	O
,	O
ethnicity	O
(	O
non	O
Caucasian	O
vs	O
.	O
Caucasian	O
),	O
smoking	O
status	O
at	O
15	O
±	O
1	O
weeks	O
’	O
gestation	O
(	O
no	O
vs	O
.	O
yes	O
),	O
alcohol	O
consumption	O
at	O
15	O
±	O
1	O
weeks	O
’	O
(	O
no	O
vs	O
yes	O
),	O
recreational	O
walking	O
(	O
1	O
-	O
3	O
×/	O
week	O
and	O
≥	O
4	O
×/	O
week	O
vs	O
.	O
never	O
)	O
and	O
recruitment	O
site	O
(	O
Auckland	O
vs	O
.	O
Adelaide	O
)	O
**	O
Serum	O
25	O
(	O
OH	O
)	O
D	O
was	O
standardised	O
for	O
month	O
that	O
serum	O
was	O
sampled	O
based	O
as	O
previously	O
described	O
[	O
34	O
]	O
†	O
Reference	O
category	O
Serum	O
25	O
(	O
OH	O
)	O
D	O
,	O
pregnancy	O
outcome	O
and	O
fetal	O
sex	O
As	O
there	O
is	O
evidence	O
to	O
suggest	O
that	O
vitamin	O
D	O
metabolism	O
within	O
the	O
placenta	O
may	O
differ	O
with	O
respect	O
to	O
fetal	O
sex	O
[	O
35	O
]	O
thus	B
,	O
we	O
assessed	O
the	O
effect	O
of	O
“	O
standardised	O
”	O
vitamin	O
D	O
status	O
on	O
pregnancy	O
outcome	O
stratified	O
by	O
fetal	O
sex	O
(	O
Table	O
3	O
).	O

Although	O
not	O
statistically	O
significant	O
,	O
point	O
estimates	O
for	O
women	O
carrying	O
a	O
male	O
fetus	O
indicated	O
decreased	O
risk	O
of	O
having	O
any	O
pregnancy	O
complication	O
with	O
high	O
serum	O
25	O
(	O
OH	O
)	O
D	O
compared	O
to	O
moderately	O
-	O
high	O
(	O
aRR	O
:	O
0	O
.	O
86	O
;	O
9	O
%%	O
CI	O
:	O
0	O
.	O
71	O
,	O
1	O
.	O
04	O
).	O

This	O
was	O
largely	O
driven	O
by	O
a	O
55	O
%	O
decreased	O
risk	O
of	O
GDM	O
in	O
women	O
with	O
a	O
male	O
fetus	O
with	O
high	O
standardised	O
serum	O
25	O
(	O
OH	O
)	O
D	O
when	O
compared	O
to	O
those	O
carrying	O
a	O
male	O
fetus	O
with	O
moderate	O
-	O
high	O
serum	O
25	O
(	O
OH	O
)	O
D	O
(	O
aRR	O
:	O
0	O
.	O
45	O
;	O
95	O
%	O
CI	O
:	O
0	O
.	O
15	O
,	O
1	O
.	O
38	O
).	O

Conversely	O
,	O
if	O
a	O
woman	O
was	O
carrying	O
a	O
female	O
fetus	O
,	O
there	O
was	O
generally	B
no	O
effect	O
of	O
having	O
low	O
,	O
low	O
-	O
moderate	O
or	O
high	O
standardised	O
serum	O
25	O
(	O
OH	O
)	O
D	O
on	O
developing	O
any	O
pregnancy	O
complication	O
compared	O
to	O
moderate	O
-	O
high	O
levels	O
(	O
Table3	O
).	O

Although	O
,	O
a	O
56	O
%	O
decreased	O
risk	O
for	O
GDM	O
was	O
observed	O
in	O
those	O
with	O
low	O
-	O
moderate	O
levels	O
of	O
standardised	O
vitamin	O
D	O
when	O
compared	O
to	O
moderate	O
-	O
high	O
levels	O
for	O
women	O
carrying	O
a	O
female	O
fetus	O
(	O
aRR	O
:	O
0	O
.	O
44	O
;	O
95	O
%	O
CI	O
:	O
0	O
.	O
20	O
,	O
0	O
.	O
97	O
).	O

Similar	O
results	O
were	O
observed	O
when	O
vitamin	O
D	O
status	O
was	O
based	O
on	O
clinical	O
definitions	O
of	O
deficiency	O
(	O
Additional	O
file1	O
:	O
Table	O
S1	O
).	O

Caption	O
(	O
TABLE	O
-	O
WRAP	O
):	O
TABLE	O
3	O
Adjusted	O
relative	O
risks	O
(	O
aRR	O
)	O
of	O
pregnancy	O
complications	O
from	O
any	O
complication	O
,	O
preeclampsia	O
(	O
PE	O
),	O
gestational	O
hypertension	O
(	O
GH	O
),	O
gestational	O
diabetes	O
mellitus	O
(	O
GDM	O
),	O
spontaeous	O
preterm	O
birth	O
(	O
sPTB	O
)	O
and	O
small	O
-	O
for	O
-	O
gestational	O
age	O
(	O
SGA	O
)	O
according	O
to	O
vitamin	O
D	O
status	O
and	O
stratified	O
by	O
fetal	O
sexPregnancy	O
ComplicationsAll	O
womenAny	O
ComplicationPEGHGDMsPTBSGA	O
n	O
(%)	O
n	O
(%)	O
aRR	O
*	O
(	O
95	O
%	O
CI	O
)	O
n	O
(%)	O
aRR	O
*	O
(	O
95	O
%	O
CI	O
)	O
n	O
(%)	O
aRR	O
*	O
(	O
95	O
%	O
CI	O
)	O
n	O
(%)	O
aRR	O
*	O
(	O
95	O
%	O
CI	O
)	O
n	O
(%)	O
aRR	O
*	O
(	O
95	O
%	O
CI	O
)	O
n	O
(%)	O
aRR	O
*	O
(	O
95	O
%	O
CI	O
)	O
Standardised	O
Quartiles	O
**	O
Males	O
Low367	O
(	O
26	O
)	O
173	O
(	O
47	O
)	O
1	O
.	O
00	O
(	O
0	O
.	O
85	O
,	O
1	O
.	O
18	O
)	O
24	O
(	O
7	O
)	O
1	O
.	O
24	O
(	O
0	O
.	O
65	O
,	O
2	O
.	O
34	O
)	O
31	O
(	O
8	O
)	O
1	O
.	O
11	O
(	O
0	O
.	O
64	O
,	O
1	O
.	O
94	O
)	O
18	O
(	O
5	O
)	O
1	O
.	O
25	O
(	O
0	O
.	O
58	O
,	O
2	O
.	O
68	O
)	O
22	O
(	O
6	O
)	O
1	O
.	O
09	O
(	O
0	O
.	O
60	O
,	O
1	O
.	O
98	O
)	O
43	O
(	O
12	O
)	O
1	O
.	O
14	O
(	O
0	O
.	O
73	O
,	O
1	O
.	O
79	O
)	O
Low	O
-	O
Moderate364	O
(	O
26	O
)	O
163	O
(	O
45	O
)	O
1	O
.	O
01	O
(	O
0	O
.	O
86	O
,	O
1	O
.	O
19	O
))	O
20	O
(	O
5	O
)	O
1	O
.	O
11	O
(	O
0	O
.	O
58	O
,	O
2	O
.	O
12	O
)	O
32	O
(	O
9	O
)	O
1	O
.	O
25	O
(	O
0	O
.	O
73	O
,	O
2	O
.	O
13	O
)	O
13	O
(	O
4	O
)	O
1	O
.	O
06	O
(	O
0	O
.	O
48	O
,	O
2	O
.	O
38	O
)	O
18	O
(	O
5	O
)	O
0	O
.	O
93	O
(	O
0	O
.	O
49	O
,	O
1	O
.	O
76	O
)	O
45	O
(	O
12	O
)	O
1	O
.	O
23	O
(	O
0	O
.	O
80	O
,	O
1	O
.	O
88	O
)	O
Moderate	O
-	O
High359	O
(	O
25	O
)	O
152	O
(	O
42	O
)	O
1	O
.	O
0	O
†	O
16	O
(	O
4	O
)	O
1	O
.	O
0	O
†	O
23	O
(	O
6	O
)	O
1	O
.	O
0	O
†	O
11	O
(	O
3	O
)	O
1	O
.	O
0	O
†	O
18	O
(	O
5	O
)	O
1	O
.	O
0	O
†	O
35	O
(	O
10	O
)	O
1	O
.	O
0	O
†	O
High325	O
(	O
23	O
)	O
111	O
(	O
34	O
)	O
0	O
.	O
86	O
(	O
0	O
.	O
71	O
,	O
1	O
.	O
04	O
)	O
15	O
(	O
5	O
)	O
1	O
.	O
18	O
(	O
0	O
.	O
59	O
,	O
2	O
.	O
36	O
)	O
17	O
(	O
5	O
)	O
0	O
.	O
90	O
(	O
0	O
.	O
50	O
,	O
1	O
.	O
62	O
)	O
4	O
(	O
1	O
)	O
0	O
.	O
45	O
(	O
0	O
.	O
15	O
,	O
1	O
.	O
38	O
)	O
15	O
(	O
5	O
)	O
0	O
.	O
97	O
(	O
0	O
.	O
50	O
,	O
1	O
.	O
88	O
)	O
26	O
(	O
8	O
)	O
0	O
.	O
77	O
(	O
0	O
.	O
47	O
,	O
1	O
.	O
26	O
)	O
Females	O
Low380	O
(	O
28	O
)	O
169	O
(	O
44	O
)	O
0	O
.	O
91	O
(	O
0	O
.	O
77	O
,	O
1	O
.	O
06	O
)	O
23	O
(	O
6	O
)	O
0	O
.	O
85	O
(	O
0	O
.	O
47	O
,	O
1	O
.	O
55	O
)	O
30	O
(	O
8	O
)	O
0	O
.	O
87	O
(	O
0	O
.	O
52	O
,	O
1	O
.	O
45	O
)	O
13	O
(	O
3	O
)	O
0	O
.	O
51	O
(	O
0	O
.	O
25	O
,	O
1	O
.	O
04	O
)	O
14	O
(	O
4	O
)	O
0	O
.	O
61	O
(	O
0	O
.	O
31	O
,	O
1	O
.	O
18	O
)	O
45	O
(	O
12	O
)	O
0	O
.	O
88	O
(	O
0	O
.	O
58	O
,	O
1	O
.	O
35	O
)	O
Low	O
-	O
Moderate353	O
(	O
26	O
)	O
168	O
(	O
48	O
)	O
0	O
.	O
99	O
(	O
0	O
.	O
85	O
,	O
1	O
.	O
15	O
)	O
24	O
(	O
7	O
)	O
1	O
.	O
03	O
(	O
0	O
.	O
57	O
,	O
1	O
.	O
85	O
)	O
31	O
(	O
9	O
)	O
0	O
.	O
92	O
(	O
0	O
.	O
57	O
,	O
1	O
.	O
50	O
)	O
9	O
(	O
3	O
)	O
0	O
.	O
44	O
(	O
0	O
.	O
20	O
,	O
0	O
.	O
97	O
)	O
18	O
(	O
5	O
)	O
0	O
.	O
79	O
(	O
0	O
.	O
43	O
,	O
1	O
.	O
45	O
)	O
33	O
(	O
9	O
)	O
0	O
.	O
74	O
(	O
0	O
.	O
48	O
,	O
1	O
.	O
13	O
)	O
Moderate	O
-	O
High334	O
(	O
24	O
)	O
149	O
(	O
45	O
)	O
1	O
.	O
0	O
†	O
19	O
(	O
6	O
)	O
1	O
.	O
0	O
†	O
28	O
(	O
8	O
)	O
1	O
.	O
0	O
†	O
17	O
(	O
5	O
)	O
1	O
.	O
0	O
†	O
21	O
(	O
6	O
)	O
1	O
.	O
0	O
†	O
31	O
(	O
9	O
)	O
1	O
.	O
0	O
†	O
High314	O
(	O
23	O
)	O
128	O
(	O
41	O
)	O
1	O
.	O
00	O
(	O
0	O
.	O
84	O
,	O
1	O
.	O
19	O
)	O
19	O
(	O
6	O
)	O
1	O
.	O
29	O
(	O
0	O
.	O
70	O
,	O
2	O
.	O
35	O
)	O
20	O
(	O
6	O
)	O
0	O
.	O
85	O
(	O
0	O
.	O
49	O
,	O
1	O
.	O
46	O
)	O
6	O
(	O
2	O
)	O
0	O
.	O
48	O
(	O
0	O
.	O
19	O
,	O
1	O
.	O
23	O
)	O
12	O
(	O
4	O
)	O
0	O
.	O
60	O
(	O
0	O
.	O
30	O
,	O
1	O
.	O
21	O
)	O
29	O
(	O
9	O
)	O
0	O
.	O
82	O
(	O
0	O
.	O
53	O
,	O
1	O
.	O
28	O
)	O
*	O
Relative	O
risks	O
compared	O
to	O
all	O
women	O
were	O
adjusted	O
for	O
age	O
,	O
maternal	O
body	O
mass	O
index	O
,	O
ethnicity	O
(	O
non	O
Caucasian	O
vs	O
.	O
Caucasian	O
),	O
smoking	O
status	O
at	O
15	O
±	O
1	O
weeks	O
’	O
gestation	O
(	O
no	O
vs	O
.	O
yes	O
),	O
alcohol	O
consumption	O
at	O
15	O
±	O
1	O
weeks	O
’	O
(	O
no	O
vs	O
yes	O
),	O
recreational	O
walking	O
(	O
1	O
-	O
3	O
×/	O
week	O
and	O
≥	O
4	O
×/	O
week	O
vs	O
.	O
never	O
)	O
and	O
recruitment	O
site	O
(	O
Auckland	O
vs	O
.	O
Adelaide	O
)	O
**	O
Serum	O
25	O
(	O
OH	O
)	O
D	O
was	O
standardised	O
for	O
month	O
that	O
serum	O
was	O
sampled	O
based	O
as	O
previously	O
described	O
[	O
34	O
]	O
†	O
Reference	O
category	O
Discussion	O
This	O
study	O
adds	O
to	O
the	O
current	O
body	O
of	O
literature	O
on	O
vitamin	O
D	O
status	O
in	O
a	O
population	O
of	O
pregnant	O
Australian	O
and	O
New	O
Zealand	O
women	O
and	O
provides	O
insight	O
into	O
normal	O
circulating	O
levels	O
of	O
25	O
(	O
OH	O
)	O
D	O
in	O
early	O
pregnancy	O
.	O

It	O
is	O
the	O
largest	O
prospective	O
cohort	O
study	O
to	O
assess	O
vitamin	O
D	O
status	O
within	O
the	O
international	O
SCOPE	O
cohort	O
,	O
comparing	O
and	O
combining	O
two	O
distinct	O
populations	O
of	O
pregnant	O
women	O
living	O
at	O
similar	O
latitude	O
and	O
provides	O
a	O
greater	O
understanding	O
of	O
vitamin	O
D	O
deficiency	O
and	O
the	O
risk	O
of	O
adverse	O
pregnancy	O
outcomes	O
.	O

We	O
found	O
,	O
despite	O
being	O
at	O
similar	O
latitudes	O
,	O
circulating	O
25	O
(	O
OH	O
)	O
D	O
was	O
different	O
between	O
women	O
recruited	O
in	O
Adelaide	O
compared	O
to	O
women	O
recruited	O
in	O
Auckland	O
.	O

This	O
was	O
independent	O
of	O
diet	O
and	O
lifestyles	O
factors	O
including	O
BMI	O
and	O
SEI	O
and	O
highlights	O
the	O
difficulty	O
in	O
understanding	O
the	O
role	O
of	O
vitamin	O
D	O
in	O
pregnancy	O
in	O
human	O
cohort	O
studies	O
.	O

However	O
,	O
there	O
was	O
a	O
protective	O
association	O
of	O
having	O
high	O
vitamin	O
D	O
at	O
15	O
±	O
1	O
weeks	O
’	O
gestation	O
and	O
GDM	O
once	O
standardised	O
based	O
on	O
month	O
serum	O
was	O
sampled	O
.	O

Furthermore	O
,	O
there	O
may	O
be	O
possible	O
fetal	O
sex	O
specific	O
differences	O
in	O
vitamin	O
D	O
status	O
worth	O
considering	O
in	O
future	O
studies	O
.	O

Despite	O
the	O
similar	O
latitudes	O
of	O
Adelaide	O
and	O
Auckland	O
(	O
Adelaide	O
:	O
34	O
.	O
93	O
°	O
S	O
and	O
Auckland	O
36	O
.	O
85	O
°	O
S	O
),	O
serum	O
25	O
(	O
OH	O
)	O
D	O
was	O
lower	O
in	O
the	O
women	O
recruited	O
in	O
Adelaide	O
.	O

Given	O
the	O
significant	O
number	O
of	O
characteristic	O
and	O
lifestyle	O
differences	O
between	O
the	O
two	O
populations	O
,	O
this	O
is	O
not	O
overly	O
surprising	O
.	O

Previous	O
studies	O
have	O
shown	O
a	O
positive	O
association	O
between	O
socioeconomic	O
status	O
and	O
vitamin	O
D	O
in	O
both	O
pregnant	O
and	O
non	O
-	O
pregnant	O
women	O
[	O
36	O
,	O
37	O
].	O

The	O
lower	O
SEI	O
of	O
the	O
Adelaide	O
women	O
could	O
therefore	B
make	O
them	O
more	O
susceptible	O
to	O
lower	O
circulating	O
25	O
(	O
OH	O
)	O
D	O
because	O
of	O
factors	O
relating	O
to	O
disadvantage	O
.	O

Furthermore	O
,	O
increased	O
BMI	O
is	O
known	O
to	O
be	O
associated	O
with	O
reduced	O
serum	O
25	O
(	O
OH	O
)	O
D	O
[	O
38	O
–	O
40	O
]	O
as	B
adipose	O
tissue	O
is	O
thought	O
to	O
sequester	O
25	O
(	O
OH	O
)	O
D	O
[	O
41	O
].	O

However	O
,	O
after	O
adjusting	O
for	O
factors	O
shown	O
to	O
be	O
associated	O
with	O
vitamin	O
D	O
status	O
including	O
BMI	O
and	O
recreational	O
walking	O
,	O
serum	O
25	O
(	O
OH	O
)	O
D	O
remained	O
significantly	O
lower	O
in	O
the	O
women	O
recruited	O
in	O
Adelaide	O
suggesting	O
the	O
influence	O
of	O
other	O
factors	O
not	O
measured	O
as	O
part	O
of	O
SCOPE	O
for	O
example	O
,	O
hours	O
spent	O
outside	O
in	O
the	O
sun	O
.	O

As	O
indicated	O
by	O
the	O
seasonal	O
variation	O
in	O
serum	O
25	O
(	O
OH	O
)	O
D	O
,	O
amongst	O
women	O
recruited	O
in	O
Adelaide	O
,	O
vitamin	O
D	O
status	O
declined	O
significantly	O
from	O
February	O
to	O
April	O
whilst	O
in	O
the	O
women	O
recruited	O
in	O
Auckland	O
,	O
serum	O
25	O
(	O
OH	O
)	O
D	O
in	O
March	O
and	O
April	O
remained	O
elevated	O
before	O
declining	O
.	O

Vitamin	O
D	O
deficiency	O
has	O
previously	O
been	O
associated	O
with	O
insulin	O
resistance	O
and	O
type	O
2	O
diabetes	O
given	O
its	O
role	O
in	O
supporting	O
insulin	O
secretion	O
and	O
pancreatic	O
β	O
-	O
cell	O
function	O
[	O
42	O
].	O

Furthermore	O
,	O
inverse	O
relationships	O
between	O
serum	O
25	O
(	O
OH	O
)	O
D	O
and	O
both	O
fasting	O
glucose	O
and	O
fasting	O
insulin	O
have	O
been	O
shown	O
during	O
pregnancy	O
indicating	O
poorer	O
glycaemic	O
control	O
[	O
19	O
,	O
43	O
].	O

Therefore	B
,	O
the	O
protective	O
role	O
of	O
high	O
25	O
(	O
OH	O
)	O
D	O
15	O
±	O
1	O
weeks	O
’	O
gestation	O
against	O
GDM	O
,	O
as	O
seen	O
with	O
a	O
decreased	O
risk	O
of	O
GDM	O
in	O
women	O
within	O
the	O
‘	O
high	O
’	O
quartile	O
of	O
standardised	O
vitamin	O
D	O
compared	O
to	O
moderate	O
-	O
high	O
,	O
is	O
consistent	O
with	O
knowledge	O
about	O
vitamin	O
D	O
and	O
diabetes	O
.	O

This	O
is	O
also	O
consistent	O
with	O
another	O
study	O
that	O
observed	O
an	O
increased	O
risk	O
of	O
GDM	O
with	O
vitamin	O
D	O
deficiency	O
in	O
early	O
pregnancy	O
(	O
aOR	O
:	O
3	O
.	O
40	O
;	O
95	O
%	O
CI	O
:	O
2	O
.	O
03	O
–	O
4	O
.	O
98	O
[	O
17	O
])	O
and	O
offers	O
potential	O
physiological	O
connections	O
between	O
vitamin	O
D	O
status	O
and	O
the	O
progression	O
of	O
insulin	O
resistance	O
in	O
pregnant	O
women	O
.	O

Furthermore	O
,	O
studies	O
have	O
shown	O
that	O
vitamin	O
D	O
supports	O
early	O
placental	O
development	O
[	O
44	O
,	O
45	O
]	O
in	O
which	O
,	O
abnormal	O
placentation	O
can	O
be	O
a	O
characteristic	O
of	O
a	O
number	O
of	O
pregnancy	O
complications	O
including	O
GDM	O
,	O
PE	O
,	O
sPTB	O
and	O
SGA	O
[	O
46	O
].	O

The	O
placenta	O
expresses	O
all	O
the	O
necessary	O
components	O
to	O
convert	O
25	O
(	O
OH	O
)	O
D	O
to	O
the	O
active	O
form	O
and	O
thus	O
utilise	O
active	O
vitamin	O
D	O
either	O
locally	O
or	O
in	O
a	O
paracrine	O
manner	O
[	O
45	O
,	O
47	O
].	O

Vitamin	O
D	O
metabolism	O
in	O
the	O
placenta	O
has	O
been	O
shown	O
to	O
be	O
influenced	O
by	O
testosterone	O
production	O
and	O
thus	B
varies	O
by	O
fetal	O
sex	O
[	O
35	O
].	O

Furthermore	O
,	O
sex	O
specific	O
differences	O
in	O
pregnancy	O
outcome	O
have	O
also	O
been	O
reported	O
whereby	O
the	O
risk	O
of	O
sPTB	O
,	O
PE	O
and	O
GDM	O
are	O
all	O
higher	O
in	O
pregnancies	O
with	O
a	O
male	O
fetus	O
[	O
48	O
–	O
50	O
].	O

In	O
this	O
study	O
,	O
we	O
observed	O
marginal	O
sex	O
-	O
specific	O
differences	O
between	O
early	O
pregnancy	O
vitamin	O
D	O
status	O
and	O
pregnancy	O
outcome	O
where	O
by	O
high	O
vitamin	O
D	O
status	O
and	O
carrying	O
a	O
male	O
fetus	O
was	O
moderately	O
associated	O
with	O
decreasing	O
the	O
risk	O
of	O
having	O
any	O
pregnancy	O
complication	O
.	O

Conversely	O
,	O
high	O
vitamin	O
D	O
status	O
and	O
carrying	O
a	O
female	O
fetus	O
was	O
not	O
associated	O
with	O
changing	O
the	O
risk	O
of	O
having	O
any	O
pregnancy	O
complication	O
.	O

Indeed	O
,	O
for	O
the	O
risk	O
of	O
GDM	O
an	O
opposite	O
effect	O
of	O
vitamin	O
D	O
status	O
in	O
early	O
pregnancy	O
was	O
observed	O
depending	O
on	O
fetal	O
sex	O
.	O

This	O
is	O
similar	O
to	O
that	O
which	O
has	O
previously	O
been	O
shown	O
in	O
the	O
relationship	O
between	O
vitamin	O
D	O
status	O
at	O
≤	O
26	O
weeks	O
’	O
gestation	O
and	O
placental	O
pathology	O
in	O
pregnancy	O
[	O
51	O
]	O
suggesting	O
that	O
male	O
and	O
female	O
fetuses	O
respond	O
differently	O
to	O
maternal	O
vitamin	O
D	O
status	O
.	O

Lack	O
of	O
statistically	O
significant	O
associations	O
with	O
other	O
pregnancy	O
complications	O
may	O
reflect	O
the	O
fact	O
that	O
this	O
was	O
a	O
largely	O
vitamin	O
D	O
-	O
replete	O
population	O
(>	O
72	O
%	O
with	O
serum	O
25	O
(	O
OH	O
)	O
D	O
>	O
50	O
nmol	O
/	O
L	O
)	O
likely	B
due	O
to	O
their	O
residence	O
latitude	O
as	O
low	O
serum	O
25	O
(	O
OH	O
)	O
D	O
was	O
found	O
in	O
the	O
SCOPE	O
Ireland	O
cohort	O
[	O
52	O
].	O

Indeed	O
many	O
of	O
the	O
studies	O
that	O
have	O
assessed	O
the	O
association	O
between	O
vitamin	O
D	O
status	O
and	O
adverse	O
pregnancy	O
outcome	O
that	O
have	O
reported	O
statistically	O
significant	O
differences	O
have	O
been	O
in	O
populations	O
with	O
higher	O
rates	O
of	O
vitamin	O
D	O
deficiency	O
[	O
2	O
,	O
4	O
].	O

High	O
dose	O
(>	O
2000	O
IU	O
)	O
vitamin	O
D	O
supplementation	O
is	O
associated	O
with	O
decreasing	O
risk	O
of	O
pregnancy	O
complications	O
[	O
23	O
–	O
25	O
].	O

However	O
,	O
routine	O
vitamin	O
D	O
supplementation	O
did	O
not	O
occur	O
during	O
the	O
time	O
period	O
the	O
women	O
in	O
the	O
current	O
study	O
were	O
recruited	O
.	O

Furthermore	O
,	O
multivitamin	O
supplements	O
available	O
during	O
the	O
study	O
period	O
contained	O
very	O
little	O
(	O
maximum	O
50	O
IU	O
),	O
if	O
any	O
,	O
vitamin	O
D	O
and	O
thus	B
are	O
an	O
unlikely	B
source	O
of	O
variation	O
within	O
the	O
population	O
.	O

Inconsistencies	O
in	O
the	O
literature	O
may	O
also	O
reflect	O
other	O
causative	O
factors	O
in	O
which	O
vitamin	O
D	O
is	O
a	O
mediator	O
.	O

For	O
example	O
,	O
active	O
vitamin	O
D	O
(	O
1	O
,	O
25	O
-	O
dihydroxyvitamin	O
D3	O
)	O
is	O
the	O
principal	O
hormone	O
that	O
regulates	O
calcium	O
absorption	O
within	O
the	O
intestine	O
[	O
53	O
]	O
and	O
is	O
integral	O
to	O
maintaining	O
calcium	O
homeostasis	O
.	O

During	O
gestation	O
,	O
fetal	O
demand	O
for	O
calcium	O
increases	O
and	O
it	O
is	O
imperative	O
that	O
maternal	O
vitamin	O
D	O
status	O
remain	O
adequate	O
to	O
support	O
increased	O
calcium	O
absorption	O
from	O
the	O
gut	O
[	O
54	O
].	O

Therefore	B
,	O
vitamin	O
D	O
status	O
may	O
be	O
important	O
in	O
populations	O
where	O
dietary	O
calcium	O
intake	O
is	O
low	O
which	O
is	O
unlikely	B
in	O
the	O
population	O
of	O
women	O
studied	O
here	O
.	O

Conclusions	O
In	O
conclusion	O
,	O
once	O
standardised	O
against	O
month	O
of	O
sampling	O
,	O
we	O
demonstrate	O
a	O
protective	O
effect	O
of	O
high	O
vitamin	O
D	O
with	O
GDM	O
.	O

However	O
,	O
differences	O
in	O
vitamin	O
D	O
status	O
between	O
the	O
women	O
recruited	O
in	O
Adelaide	O
and	O
those	O
recruited	O
in	O
Auckland	O
reflect	O
obvious	O
difficulties	O
in	O
studying	O
how	O
vitamin	O
D	O
may	O
support	O
healthy	O
pregnancies	O
.	O

A	O
possible	O
connection	O
between	O
fetal	O
sex	O
,	O
vitamin	O
D	O
status	O
and	O
pregnancy	O
complications	O
reveals	O
further	O
questions	O
and	O
encourages	O
continual	O
research	O
and	O
discussion	O
into	O
the	O
role	O
of	O
vitamin	O
D	O
in	O
pregnancy	O
,	O
particularly	O
in	O
vitamin	O
D	O
replete	O
populations	O
.	O

Additional	O
file	O
Caption	O
(	O
MEDIA	O
):	O
ADDITIONAL	O
FILE	O
1	O
:	O
Table	O
S1	O
.	O

Adjusted	O
relative	O
risks	O
(	O
aRR	O
)	O
of	O
pregnancy	O
complications	O
from	O
any	O
complication	O
,	O
preeclampsia	O
(	O
PE	O
),	O
gestational	O
hypertension	O
(	O
GH	O
),	O
gestational	O
diabetes	O
mellitus	O
(	O
GDM	O
),	O
spontaeous	O
preterm	O
birth	O
(	O
sPTB	O
)	O
and	O
small	O
-	O
for	O
-	O
gestational	O
age	O
(	O
SGA	O
)	O
according	O
to	O
vitamin	O
D	O
status	O
and	O
stratified	O
by	O
fetal	O
sex	O
.	O

(	O
DOCX	O
15	O
kb	O
)	O
PubMed	O
Central	O
:	O

